var images_info;if (!images_info) images_info =[]; images_info["73"]={"73000":{"type":"graphic_table","displayName":"Types of shock in children","title":"Hemodynamic profiles of the types of shock in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemodynamic profiles of the types of shock in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Physiologic variable</td> <td class=\"subtitle1\">Preload</td> <td class=\"subtitle1\">Pump function</td> <td class=\"subtitle1\">Afterload</td> <td class=\"subtitle1\">Tissue perfusion</td> <td class=\"subtitle1\">Tissue perfusion</td> </tr> <tr> <td class=\"subtitle2\">Clinical measurement</td> <td class=\"subtitle2\">Clinical signs* or central venous pressure (if measured)</td> <td class=\"subtitle2\">Cardiac output or index<sup>&#182;</sup></td> <td class=\"subtitle2\">Systemic vascular resistance</td> <td class=\"subtitle2\">Capillary refill time<sup>&#916;</sup></td> <td class=\"subtitle2\">Mixed venous oxygen saturation<sup>&#9674;</sup></td> </tr> <tr class=\"centered\"> <td>Hypovolemic</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8593;</td> <td>&#8593;</td> <td>Low</td> </tr> <tr class=\"centered\"> <td>Cardiogenic</td> <td>&#8593;</td> <td>&#8595;</td> <td>&#8593;</td> <td>&#8593;</td> <td>Low</td> </tr> <tr class=\"centered\"> <td>Distributive</td> <td>&#8595; or &#8596;</td> <td>&#8593;</td> <td>&#8595;</td> <td>&#8595; (initial)</td> <td>High</td> </tr> <tr class=\"centered\"> <td>Obstructive</td> <td>&#8593;</td> <td>&#8595;</td> <td>&#8593;</td> <td>&#8593;</td> <td>Low</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Clinical signs of decreased preload include tachycardia, tachypnea, decreased or absent peripheral pulses; normal or weak central pulses; capillary refill time &gt;2 seconds; skin that is pale, mottled, cold or diaphoretic; dusky or pale extremities, altered mental status, decreased urine output, and flat jugular veins. Clinical signs of increased preload include jugular venous distension, pulmonary edema, and hepatomegaly. These patients are also typically tachycardic and poorly perfused. Refer to topics on evaluation of shock in children.<br />&para; Cardiac index (cardiac output per body surface area) is typically what is measured during clinical care.<br />&Delta; In patients with shock, capillary refill time &gt;2 seconds is associated with low mixed venous oxygen saturation while flash capillary refill suggests increased mixed venous oxygen saturation.<br /><span class=\"lozenge\">&loz;</span> A low mixed oxygen saturation is &lt;70 percent when measured through a triple lumen catheter and &lt;65 percent when measured through a pulmonary artery catheter.</div><div id=\"graphicVersion\">Graphic 73000 Version 5.0</div></div></div>"},"73002":{"type":"graphic_table","displayName":"Khorana score","title":"Khorana score for estimating venous thromboembolism risk in patients with cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Khorana score for estimating venous thromboembolism risk in patients with cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"5\">Khorana score</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Risk factor</td> <td class=\"subtitle2\" colspan=\"3\">Points</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\">Site of primary tumor</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">Very high risk (stomach, pancreas)</td> <td class=\"sublist_other_centered\" colspan=\"3\">2</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">High risk (lung, lymphoma, gynecologic, bladder, testicular)</td> <td class=\"sublist_other_centered\" colspan=\"3\">1</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\">All other sites</td> <td class=\"sublist_other_centered\" colspan=\"3\">0</td> </tr> <tr> <td colspan=\"2\">Prechemotherapy platelet count &#8805;350,000/microL</td> <td class=\"centered\" colspan=\"3\">1</td> </tr> <tr> <td colspan=\"2\">Hemoglobin level &#60;10 g/dL or use of ESAs</td> <td class=\"centered\" colspan=\"3\">1</td> </tr> <tr> <td colspan=\"2\">Prechemotherapy WBC &#62;11,000/microL</td> <td class=\"centered\" colspan=\"3\">1</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">BMI &#8805;35 kg/m<sup>2</sup></td> <td class=\"centered\" colspan=\"3\">1</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"5\">Incidence of VTE based on Khorana score</td> </tr> <tr> <td><strong>Khorana score points</strong></td> <td> <p>Derivation cohort<sup>[1]</sup></p> VTE risk after 2.5 months</td> <td> <p>Validation cohort<sup>[1]</sup></p> VTE risk after 2.5 months</td> <td> <p>Independent cohort<sup>[2]</sup></p> VTE risk after six months</td> <td> <p>Patients in phase I trials<sup>[3]</sup></p> VTE risk after two months</td> </tr> <tr> <td><strong>0 (low)</strong></td> <td>0.8 percent</td> <td>0.3 percent</td> <td>1.5 percent</td> <td>1.5 percent</td> </tr> <tr> <td><strong>1 to 2 (intermediate)</strong></td> <td>1.8 percent</td> <td>2 percent</td> <td>3.8 percent (1 point); 9.6 percent (2 points)</td> <td>4.8 percent</td> </tr> <tr> <td><strong>&#8805;3 (high)</strong></td> <td>7.1 percent</td> <td>6.7 percent</td> <td>17.7 percent</td> <td>12.9 percent</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The Khorana score was developed from a cohort of 2701 patients with cancer receiving a first course of chemotherapy to predict the cumulative incidence of VTE at 2.5 months<SUP>[1]</SUP>. The score was validated in a cohort of 1365 patients, most of whom (91 percent) had an ECOG performance status of 0 or 1. The score was tested independently in 819 patients with newly diagnosed cancer or cancer progression who had not received chemotherapy within the preceding three months to predict the cumulative incidence of VTE at six months<SUP innerHtml>[2]</SUP>, and in 1415 patients enrolled in phase I clinical trials followed for a median of two months<SUP>[3]</SUP>.</div><div class=\"graphic_footnotes\">ESAs: erythropoiesis-stimulating agents; WBC: white blood cell; BMI: body mass index; VTE: venous thromboembolism; ECOG: Eastern Cooperative Oncology Group.</div><div class=\"graphic_reference\">References: <br /><OL>&#xD;&#xA;<LI>Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111:4902.</LI>&#xD;&#xA;<LI>Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116:5377.</LI>&#xD;&#xA;<LI>Mandala M, Clerici M, Corradino I, et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. Ann Oncol 2012; 23:1416.</LI></OL></div><div id=\"graphicVersion\">Graphic 73002 Version 5.0</div></div></div>"},"73003":{"type":"graphic_figure","displayName":"ST segment resolution and mortality","title":"Mortality after thrombolytic therapy is lower with complete ST segment resolution","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mortality after thrombolytic therapy is lower with complete ST segment resolution</div><div class=\"cntnt\"><img style=\"width:450px; height:316px;\" src=\"images/CARD/73003_ST_segment_resolution_morta.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In four studies of thrombolytic therapy for an acute myocardial infarction, the degree of ST segment resolution at 180 min after administration of therapy was associated with 35-day mortality. All studies found statistically significant mortality differences between the three groups of ST resolution.</div><div class=\"graphic_footnotes\">GUSTO-III: Global Use of Strategies to Open Occluded Coronary Arteries study; HIT-4: Hirudin for Improvement of Thrombolysis (HIT)-4 study; INJECT: International Joint Efficacy Comparison of Thrombolytics study; ISAM: Intravenous Streptokinase in Acute Myocardial Infarction.</div><div class=\"graphic_reference\">Data from de Lemos JA, Braunwald E. J Am Coll Cardiol 2001; 38:1283.</div><div id=\"graphicVersion\">Graphic 73003 Version 2.0</div></div></div>"},"73005":{"type":"graphic_picture","displayName":"Normal esophagus OCT","title":"Normal esophagus (optical coherence tomography)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal esophagus (optical coherence tomography)</div><div class=\"cntnt\"><img style=\"width:450px; height:225px;\" src=\"images/GAST/73005_Normal_esophagus_OCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Endoscopic view with optical coherence tomography (OCT) catheter probe placed adjacent to mucosa. (B,C,D) OCT image showing normal histological layers of epithelium (ep), lamina propria (lp), muscularis mucosa (mm), submucosa (sm), and muscularis propria (mp).</div><div class=\"graphic_reference\">Courtesy of Shai Friedland, MD and Jacques Van Dam, MD, PhD.</div><div id=\"graphicVersion\">Graphic 73005 Version 2.0</div></div></div>"},"73007":{"type":"graphic_table","displayName":"Rx strep NVE I","title":"Treatment regimens for native valve endocarditis due to penicillin-susceptible viridans streptococci and <EM innerHtml>Streptococcus gallolyticus </EM><EM>(</EM><EM innerHtml>bovis) </EM>(MIC ≤0.12 mcg/mL)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment regimens for native valve endocarditis due to penicillin-susceptible viridans streptococci and <EM innerHtml>Streptococcus gallolyticus </EM><EM>(</EM><EM innerHtml>bovis) </EM>(MIC ≤0.12 mcg/mL)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">American Heart Association (AHA)</td> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;European Society of Cardiology (ESC)</td> <td class=\"subtitle1\" rowspan=\"2\">British Society for Antimicrobial Chemotherapy (BSAC)</td> </tr> <tr> <td class=\"subtitle2\">Adult</td> <td class=\"subtitle2\">Pediatric</td> </tr> <tr> <td class=\"subtitle2_left\">4-week regimens<sup>&#182;</sup>:</td> <td class=\"subtitle2_left\">4-week regimens:</td> <td class=\"subtitle2_left\">&nbsp;4-week regimens<sup>&#916;</sup>:</td> <td class=\"subtitle2_left\">4- to 6-week regimens:</td> </tr> <tr> <td> <p>Aqueous penicillin G 12 to 18 million units per 24 hours IV either continuously or in&nbsp;four or&nbsp;six divided doses</p> <p><strong>or <strong>(if penicillin is unavailable)</strong></strong></p> <p>Ampicillin 2 g IV every 4 hours </p> <p><strong>or</strong></p> <p>Ceftriaxone 2 g per 24 hours IV or IM in&nbsp;one dose</p> <p><strong>Beta-lactam-intolerant patients:</strong></p> <p><strong></strong>Vancomycin<sup>&#9674;</sup> 30 mg/kg per 24 hours IV in&nbsp;two divided doses</p> </td> <td> <p>Aqueous penicillin G 200,000 to 300,000 units/kg per 24 hours IV in&nbsp;six divided doses (maximum dose: 24 million units per 24 hours)</p> <p><strong>or (if penicillin is unavailable)</strong></p> <p>Ampicillin 200 to 300 mg/kg per 24 hours IV divided in four&nbsp;or six divided doses (maximum dose: 12 g per 24 hours)</p> <p><strong>or</strong></p> <p>Ceftriaxone 100 mg/kg per 24 hours IV<sup>​&#167;</sup>&nbsp;in two divided doses or 80 mg/kg in one daily dose (maximum dose:&nbsp;4 g per 24 hours; if dose is &#62;2 g per 24 hours, use divided dosing every 12 hours)</p> <p><strong><strong>Beta-lactam-intolerant patients:</strong></strong></p> <p>Vancomycin<sup>&#9674;</sup> 40 mg/kg per 24 hours IV in&nbsp;two or&nbsp;three divided doses (maximum dose: 2 g per 24 hours)</p> </td> <td>Aqueous penicillin G<sup>&#182;</sup> 12 to 18 million units per 24 hours IV in&nbsp;four or six divided doses or continuous infusion <p><strong>or</strong></p> <p>Amoxicillin 100 to 200 mg/kg per 24 hours IV in&nbsp;four to six&nbsp;divided doses</p> <p><strong>or</strong></p> <p>Ampicillin 12 g per 24 hours (or 100 to 200 mg/kg per 24 hours) IV in six divided doses</p> <p><strong>or</strong></p> <p>Ceftriaxone<sup>&#182;&#165;</sup> 2 g per 24 hours IV or IM in&nbsp;one dose</p> <p><strong>or</strong></p> <p>Vancomycin<sup>&#9674;</sup> 30 mg/kg per 24 hours IV in&nbsp;two divided doses</p> </td> <td> <p>Benzylpenicillin<sup>&#135;</sup> 1.2 g every 4 hours IV</p> <p><strong>or</strong></p> <p>Ceftriaxone 2 g per 24 hours IV/IM</p> </td> </tr> <tr> <td class=\"subtitle2_left\">2-week regimens<sup>&#134;</sup>:</td> <td class=\"subtitle2_left\">2-week regimens<sup>&#134;</sup>:</td> <td class=\"subtitle2_left\">2-week regimens<sup>&#916;&#134;</sup>:</td> <td class=\"subtitle2_left\">2-week regimens<sup>&#134;</sup>:</td> </tr> <tr> <td> <p><strong>Either</strong></p> <p>Aqueous penicillin G 12 to 18 million units per 24 hours IV either continuously or in&nbsp;six divided doses</p> <p><strong>or</strong></p> <p>Ceftriaxone 2 g per 24 hours IV or IM in&nbsp;one dose</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>**</sup> 3 mg/kg per 24 hours IV or IM in&nbsp;one dose (preferred) or in&nbsp;three divided doses</p> </td> <td> <p>Not recommended for children due to lack of data</p> </td> <td> <p><strong>Either</strong></p> <p>Aqueous penicillin G 12 to 18 million units per 24 hours IV in&nbsp;four to six divided doses or continuous infusion</p> <p><strong>or</strong></p> <p>Amoxicillin 100 to 200 mg/kg per 24 hours IV in&nbsp;four to six&nbsp;divided doses</p> <p><strong>or</strong></p> <p>Ampicillin 12 g (or 100 to 200 mg/kg) per 24 hours IV in six divided doses</p> <p><strong>or</strong></p> <p>Ceftriaxone<sup>&#182;&#165;</sup> 2 g per 24 hours IV or IM in&nbsp;one dose</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>**,&#182;&#182;</sup> 3 mg/kg per 24 hours IV or IM in&nbsp;one dose</p> </td> <td> <p><strong>Either</strong></p> <p>Benzylpenicillin<sup>&#135; </sup>1.2 g every 4 hours IV</p> <p><strong>or</strong></p> <p>Ceftriaxone 2 g per 24 hours IV or IM</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>**</sup> 1 mg/kg every 12 hours IV</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses above are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the individual Lexicomp drug monographs for renal dose adjustments.<br />​Wherever intramuscular administration is provided as an alternative, intravenous route is preferred, particularly in infants and children.</div><div class=\"graphic_footnotes\">MIC: minimum inhibitory concentration; IV: intravenously; IM: intramuscularly.<br />* AHA adult guidelines use MIC ≤0.12 mcg/mL; AHA pediatric guidelines use MIC ≤0.1 mcg/mL. ESC and BSAC guidelines use MIC ≤0.125 mcg/mL.<br />¶&nbsp;Preferred in most patients &gt;65 years or with impairment of 8th nerve or renal function.<br />Δ&nbsp;Pediatric doses (should not exceed adult doses): Penicillin G 200,000 units/kg per 24 hours IV in&nbsp;four to&nbsp;six divided doses; amoxicillin 300 mg/kg per 24 hours IV in&nbsp;four to&nbsp;six divided doses; ceftriaxone 100mg/kg per dose IV or IM daily; vancomycin 40 mg/kg per 24 hours IV in&nbsp;two or&nbsp;three divided doses; gentamicin 3 mg/kg per 24 hours IV or IM in a single daily dose or in&nbsp;three divided doses.<br />◊&nbsp;Vancomycin therapy only recommended for patients allergic to penicillin and cephalosporins; vancomycin dose adjusted for trough concentration of 10 to 15 mcg/mL. Penicillin desensitization can be attempted in stable patients.&nbsp;<br />§ In infants and children, intravenous antibiotics are recommended rather than intramuscular agents.<br />¥&nbsp;Preferred for outpatient therapy.<br />‡&nbsp;Amoxicillin 2 g every&nbsp;four to&nbsp;six hours IV may be used in place of benzylpenicillin 1.2 to 2.4 g every&nbsp;four hours.&nbsp;<br />† For noncomplicated infective endocarditis. Not intended for patients with known cardiac or extracardiac abscess or for creatinine clearance &lt;20 mL/min, impaired 8th nerve function, or infection due to <EM>Abiotrophia</EM>, <EM innerHtml>Granulicatella </EM>spp, or <EM>Gemella</EM> spp.<br />**&nbsp;Renal function and gentamicin serum concentrations should be monitored at least once per week. Gentamicin dose adjusted for peak serum concentrations 3 to 4 mcg/mL, trough &lt;1 mcg/mL when&nbsp;two to three&nbsp;divided doses used; when given in a single daily dose, pre-dose (trough) concentrations should be &lt;1 mcg/mL. Per ESC guidelines, post-dose (peak, one hour after injection) serum concentrations should be approximately 10 to 12 mcg/mL (per AHA guidelines, there is no role for measuring peak gentamicin concentration following single daily dosing).<br />¶¶&nbsp;Netilmicin (4 to 5 mg/kg/day IV in&nbsp;one dose) is an alternative.</div><div class=\"graphic_reference\">Data from:<br /><br /><OL>&#xD;&#xA;<LI>Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</LI>&#xD;&#xA;<LI>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</LI>&#xD;&#xA;<LI>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</LI>&#xD;&#xA;<LI>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269.</LI></OL></div><div id=\"graphicVersion\">Graphic 73007 Version 13.0</div></div></div>"},"73010":{"type":"graphic_figure","displayName":"Maternal complications of diabetic nephropathy in pregnancy","title":"Maternal complications in pregnancies complicated by diabetic nephropathy (2001 to 2012)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Maternal complications in pregnancies complicated by diabetic nephropathy (2001 to 2012)</div><div class=\"cntnt\"><img style=\"width:415px; height:344px;\" src=\"images/OBGYN/73010_Maternal_complicate_nephrop.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">References: <br /><ol>&#xD;&#xA;    <li>Ekbom P, Damm P, Feldt-Rasmussen B, et al. Pregnancy outcome in type 1 diabetic women with microalbuminuria. Diabetes Care 2001; 24:1739.</li>&#xD;&#xA;    <li>Young EC, Pires ML, Marques LP, et al. Effects of pregnancy on the onset and progression of diabetic nephropathy and of diabetic nephropathy on pregnancy outcomes. Diabetes Metab Syndr 2011; 5:137.</li>&#xD;&#xA;    <li>Carr DB, Koontz GL, Gardella C, et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens 2006; 19:513.</li>&#xD;&#xA;    <li>Yogev Y, Chen R, Ben-Haroush A, et al. Maternal overweight and pregnancy outcome in women with Type-1 diabetes mellitus and different degrees of nephropathy. J Matern Fetal Neonatal Med 2010; 23:999.</li>&#xD;&#xA;    <li>Nielsen LR, Damm P, Mathiesen ER. Improved pregnancy outcome in type 1 diabetic women with microalbuminuria or diabetic nephropathy: effect of intensified antihypertensive therapy? Diabetes Care 2009; 32:38.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 73010 Version 3.0</div></div></div>"},"73011":{"type":"graphic_figure","displayName":"Posterior vaginal wall prolapse 1","title":"Repair of posterior vaginal wall prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of posterior vaginal wall prolapse</div><div class=\"cntnt\"><img style=\"width:372px; height:492px;\" src=\"images/OBGYN/73011_Tx_post_vaginal_wall_def_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A triangular shaped incision is made in the perineal body.</div><div class=\"graphic_reference\">Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &#169;2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 73011 Version 2.0</div></div></div>"},"73012":{"type":"graphic_figure","displayName":"Neurochemical targets","title":"Medications that improve narcolepsy target specific neurochemical systems","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Medications that improve narcolepsy target specific neurochemical systems</div><div class=\"cntnt\"><img style=\"width:494px; height:407px;\" src=\"images/PULM/73012_Neurochemical_targets.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Narcolepsy is caused by a loss of the orexin-producing neurons in the lateral hypothalamus. Normally, the orexin neuropeptides excite neurons that promote wakefulness and suppress REM sleep including monoaminergic areas such as the locus coeruleus, raphe nuclei, ventral tegmental area, periaqueductal grey, and tuberomammillary nucleus as well as cholinergic areas such as the basal forebrain and pedunculopontine and laterodorsal tegmental nuclei (PPT/LDT). Most medications that improve sleepiness do so by enhancing dopamine signaling, and most cataplexy-suppressing medications increase norepinephrine and/or serotonin signaling.</div><div id=\"graphicVersion\">Graphic 73012 Version 1.0</div></div></div>"},"73013":{"type":"graphic_diagnosticimage","displayName":"TEE short axis view LV","title":"Short axis view of the left ventricle on transesophageal echocardiogram (TEE)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Short axis view of the left ventricle on transesophageal echocardiogram (TEE)</div><div class=\"cntnt\"><img style=\"width:284px; height:356px;\" src=\"images/CARD/73013_TEE_short_axis_view_LV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Horizontal (0º) imaging plane with advancement of the probe into the stomach with slight anteflexion allows for imaging of the left ventricle (LV) in the short axis.<br />(A) The anterior (ANT), lateral (LAT) and posterior (POST) walls and the interventricular septum (SEPT) are well seen.<br />(B) Rotation into the vertical (90º) imaging plane allows for evaluation of the ANT and&nbsp;inferior&nbsp;(INF) walls of the LV. The papillary muscles and chordae tendinae may also be seen.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 73013 Version 3.0</div></div></div>"},"73014":{"type":"graphic_diagnosticimage","displayName":"Stage I lateral condyle fracture 1","title":"Stage I lateral condyle elbow fracture","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Stage I lateral condyle elbow fracture</div><div class=\"cntnt\"><img style=\"width:515px; height:273px;\" src=\"images/EM/73014_StageILCfx1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Injury film of a seven-year-old with an undisclosed fracture of the lateral condyle (arrows). Attention was drawn to the location of the fracture because of extensive soft tissue swelling on the lateral aspect (arrowheads).<br />(B) Because of the extensive soft tissue injury, there was little intrinsic stability, allowing the fracture to become displaced at seven days (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Sawyer JR, Beaty JH. Lateral Condylar and Capitellar Fractures of the Distal Humerus. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 73014 Version 15.0</div></div></div>"},"73016":{"type":"graphic_table","displayName":"Guidelines after polypectomy I","title":"Surveillance recommendations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surveillance recommendations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Patients with small rectal hyperplastic polyps should be considered to have normal colonoscopies, and therefore the interval before the subsequent colonoscopy should be 10 years; an exception is patients with a hyperplastic polyposis syndrome; they are at increased risk for adenomas and colorectal cancer and need to be identified for more intensive follow-up evaluation</td> </tr> <tr> <td>2. Patients with only 1 or 2 small (&#60;1 cm) tubular adenomas with only low-grade dysplasia should have their next follow-up colonoscopy in 5 to 10 years; the precise timing within this interval should be based on other clinical factors (such as prior colonoscopy findings, family history, and the preferences of the patient and judgment of the physician)</td> </tr> <tr> <td>3. Patients with 3 to 10 adenomas, or any adenoma &#8805;1 cm, or any adenoma with villous features, or high-grade dysplasia should have their next follow-up colonoscopy in 3 years providing that piecemeal removal has not been performed and the adenoma(s) are removed completely; if the follow-up colonoscopy is normal or shows only 1 or 2 small tubular adenomas with low-grade dysplasia, then the interval for the subsequent examination should be 5 years</td> </tr> <tr> <td>4. Patients who have more than 10 adenomas at 1 examination should be examined at a shorter (&#60;3 year) interval, established by clinical judgment, and the clinician should consider the possibility of an underlying familial syndrome</td> </tr> <tr> <td>5. Patients with sessile adenomas that are removed piecemeal should be considered for follow-up evaluation at short intervals (2 to 6 months) to verify complete removal; once complete removal has been established, subsequent surveillance needs to be individualized based on the endoscopist's judgment; completeness of removal should be based on both endoscopic and pathologic assessments</td> </tr> <tr> <td>6. More intensive surveillance is indicated when the family history may indicate HNPCC</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130:1872. Copyright &#169; 2006 American Gastroenterological Association.</div><div id=\"graphicVersion\">Graphic 73016 Version 4.0</div></div></div>"},"73017":{"type":"graphic_table","displayName":"Carb counting PI","title":"Carbohydrate counting: Getting started","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Carbohydrate counting: Getting started</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Step 1: Know the goal\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Eating about the same amount of carbohydrate at meals and snacks each day will help to keep blood glucose levels from getting too high or too low.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Focus on keeping the amount of carbohydrate intake moderate to keep your blood glucose levels from going too high. Remember, it is not healthy to cut out all carbohydrate foods; the body, especially your brain, needs some every day.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Step 2: Monitoring intake and blood glucose\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Keeping a daily food and blood glucose record will help inform what affects blood glucose levels.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Measuring or weighing foods is helpful in the beginning to learn what common food portions look like.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Step 3: Methods of counting carbohydrate\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   To count carbohydrates, there are two methods. Patients may also blend the two methods.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   <strong>Read food labels:</strong> Look at the grams of total carbohydrate on the label. Remember, the nutrition information on food labels is for the standard serving size. If the portion is larger or smaller, it is necessary to adjust the carbohydrate information.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   <strong>Use the exchange system:</strong> Estimation of carbohydrate content can be broken down into food groups that are standardized for carbohydrate content according to particular portions. For example, one serving from the Bread/Starch, Fruit, or Milk group each contains between 12 and 15 grams of carbohydrate. Most vegetables do not contain a significant number of carbohydrates and do not need to be counted, although there are exceptions (eg, corn, potatoes).\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">12.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=48929&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Carb_counting_PI.htm</title></head></div><div id=\"graphicVersion\">Graphic 73017 Version 2.0</div></div></div>"},"73019":{"type":"graphic_figure","displayName":"Wheezing frequency and causes","title":"Spectrum and frequency of causes of wheezing","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Spectrum and frequency of causes of wheezing</div><div class=\"cntnt\"><img style=\"width:462px; height:368px;\" src=\"images/PULM/73019_Wheezing_frequency_and_caus.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spectrum and frequency of causes of wheeze in patients referred to a pulmonary clinic.</div><div class=\"graphic_footnotes\">PNDS: postnasal drip syndrome.</div><div id=\"graphicVersion\">Graphic 73019 Version 3.0</div></div></div>"},"73021":{"type":"graphic_picture","displayName":"Inflamed tophaceous gout","title":"Inflamed tophaceous gout","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflamed tophaceous gout</div><div class=\"cntnt\"><img style=\"width:383px; height:266px;\" src=\"images/RHEUM/73021_Inflamedtophaceousgout.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three inflamed tophi over the proximal interphalangeal joints in a patient with tophaceous gout. Several of the lesions ruptured spontaneously over the next three days, exuding a pasty material composed of urate crystals and inflammatory cells but no organisms. The inflammation largely subsided over one week after the administration of a nonsteroidal antiinflammatory drug.</div><div class=\"graphic_reference\">Courtesy of Michael A Becker, MD.</div><div id=\"graphicVersion\">Graphic 73021 Version 2.0</div></div></div>"},"73022":{"type":"graphic_figure","displayName":"Cross-sectional anatomy of the adrenal gland","title":"Cross-sectional anatomy of the adrenal gland","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cross-sectional anatomy of the adrenal gland</div><div class=\"cntnt\"><img style=\"width:450px; height:271px;\" src=\"images/SURG/73022_Cross-sectional-anatomy-of-the-adrenal-glands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adrenal glands showing cortex and medulla.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73022 Version 2.0</div></div></div>"},"73023":{"type":"graphic_table","displayName":"Duke criteria for IE I","title":"Modified Duke criteria for diagnosis of infective endocarditis - Table A","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Duke criteria for diagnosis of infective endocarditis - Table A</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Definite IE is established in the presence of any of the following:</td> </tr> <tr> <td class=\"subtitle2_single\">Pathologic criteria</td> </tr> <tr> <td class=\"indent1\">Pathologic lesions: vegetation or intracardiac abscess demonstrating active endocarditis on histology <strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Microorganism: demonstrated by culture or histology of a vegetation or intracardiac abscess</td> </tr> <tr> <td class=\"subtitle2_single\">Clinical criteria</td> </tr> <tr> <td class=\"sublist2_start\">Using specific definitions listed in <strong>Table B:</strong></td> </tr> <tr> <td class=\"sublist2\">2 major clinical criteria <strong>OR</strong></td> </tr> <tr> <td class=\"sublist2\">1 major and 3 minor clinical criteria <strong>OR</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">5 minor clinical criteria</td> </tr> <tr> <td class=\"subtitle1_single\">Possible IE*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Presence of 1 major and 1 minor&nbsp;clinical criteria&nbsp;<strong>OR</strong> presence of 3 minor clinical criteria</td> </tr> <tr> <td class=\"subtitle1_single\">Rejected IE</td> </tr> <tr> <td class=\"indent1\">A firm alternate diagnosis is made <strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Resolution of clinical manifestations occurs after &#8804;4 days of antibiotic therapy <strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">No pathologic evidence of infective endocarditis is found at surgery or autopsy after antibiotic therapy for four days or less</td> </tr> <tr> <td class=\"indent1\">Clinical criteria for possible or definite IE not met</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IE: infective endocarditis.<br />* The category of possible IE represents a modification from the previous published Duke criteria.</div><div class=\"graphic_reference\">Reproduced with permission from: Li JS, Sexton DJ, Mick N, et al. Clin Infect Dis 2000; 30:633. Copyright &copy; 2000 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 73023 Version 6.0</div></div></div>"},"73024":{"type":"graphic_table","displayName":"Risk factors for yersiniosis","title":"Risk factors associated with development or severity of yersiniosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors associated with development or severity of yersiniosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Risk Factor</td>\n<td class=\"subtitle1\">Attributable risk</td>\n</tr>\n<tr>\n<td>Consumption of undercooked or raw pork products</td>\n<td>++++</td>\n</tr>\n<tr>\n<td>Exposure to untreated surface water</td>\n<td>++</td>\n</tr>\n<tr>\n<td>Minority infants (United States)</td>\n<td>++</td>\n</tr>\n<tr>\n<td>Blood transfusion</td>\n<td>+</td>\n</tr>\n<tr>\n<td>Derangements of iron-metabolism (cirrhosis, hemochromatosis, aplastic anemia, thalassemia, iron-overload)</td>\n<td>++</td>\n</tr>\n<tr>\n<td>Other conditions (malignancy, diabetes, malnutrition, gastrointestinal illness)</td>\n<td>+</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 73024 Version 2.0</div></div></div>"},"73027":{"type":"graphic_figure","displayName":"Vascular anatomy lacunes","title":"Vascular anatomy of lacunar strokes","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Vascular anatomy of lacunar strokes</div><div class=\"cntnt\"><img style=\"width:469px; height:506px;\" src=\"images/NEURO/73027_Vascular_anatomy_lacunes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomic location of lentriculostriate, thalamoperforant and paramedian pontine branches.</div><div class=\"graphic_reference\">Reproduced from Kistler, JP, et al, Cerebrovascular diseases, Harrison's Principles of Internal Medicine, 13th ed, McGraw-Hill, New York 1994. Copyright 1994 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 73027 Version 1.0</div></div></div>"},"73028":{"type":"graphic_diagnosticimage","displayName":"Bronchiectasis CT I","title":"Bronchiectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchiectasis</div><div class=\"cntnt\"><img style=\"width:360px; height:282px;\" src=\"images/PULM/73028_Bronchiectasis_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-resolution computerized tomography (HRCT) shows numerous ring shadows representing dilated airways in the right lung, many of which are partially filled with secretions (arrow).</div><div class=\"graphic_reference\">Courtesy of Alan Barker, MD.</div><div id=\"graphicVersion\">Graphic 73028 Version 3.0</div></div></div>"},"73030":{"type":"graphic_table","displayName":"Treatment of hypercalcemia","title":"Treatment of hypercalcemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of hypercalcemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Mode of action</td> <td class=\"subtitle1\">Onset of action</td> <td class=\"subtitle1\">Duration of action</td> </tr> <tr> <td>Isotonic saline hydration</td> <td> <p>Restoration of intravascular volume</p> Increases urinary calcium excretion</td> <td>Hours</td> <td>During infusion</td> </tr> <tr> <td>Calcitonin</td> <td> <p>Inhibits bone resorption via interference with osteoclast function</p> Promotes urinary calcium excretion</td> <td>4 to 6 hours</td> <td>48 hours</td> </tr> <tr> <td>Bisphosphonates</td> <td>Inhibit bone resorption via interference with osteoclast recruitment and function</td> <td>24 to 72 hours</td> <td>2 to 4&nbsp;weeks</td> </tr> <tr> <td>Loop diuretics*</td> <td>Increase urinary calcium excretion via inhibition of calcium reabsorption in the loop of Henle</td> <td>Hours</td> <td>During therapy</td> </tr> <tr> <td>Glucocorticoids</td> <td> <p>Decrease intestinal calcium absorption</p> Decrease 1,25-dihydroxyvitamin D production by activated mononuclear cells in patients with granulomatous diseases or lymphoma</td> <td>2 to 5 days</td> <td>Days to weeks</td> </tr> <tr> <td>Denosumab</td> <td>Inhibits bone resorption via inhibition of RANKL</td> <td>4 to 10 days</td> <td>4 to 15 weeks</td> </tr> <tr> <td>Calcimimetics</td> <td>Calcium-sensing receptor agonist, reduces PTH (parathyroid carcinoma, secondary hyperparathyroidism in CKD)</td> <td>2 to 3 days</td> <td>During therapy</td> </tr> <tr> <td>Dialysis</td> <td>Low or no calcium dialysate</td> <td>Hours</td> <td>During treatment</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RANKL: receptor activator of nuclear factor kappa-B ligand; PTH: parathyroid hormone;&nbsp;CKD: chronic kidney disease.<br />* Loop diuretics should not be used routinely. However, in patients with renal insufficiency or heart failure, judicious use of loop diuretics may be required to prevent fluid overload during saline hydration.</div><div class=\"graphic_reference\">Data from: Shane E, Dinaz I. Hypercalcemia: Pathogenesis, clinical manifestations, differential diagnosis, and management. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (Sixth Edition). American Society of Bone and Mineral Research 2006; 179.</div><div id=\"graphicVersion\">Graphic 73030 Version 7.0</div></div></div>"},"73032":{"type":"graphic_picture","displayName":"Crohn disease of vulva","title":"Crohn disease of vulva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crohn disease of vulva</div><div class=\"cntnt\"><img style=\"width:256px; height:399px;\" src=\"images/OBGYN/73032_Crohns_disease_of_vulva.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Ridley CM, Neill SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright © 1999 Blackwell Science.</div><div id=\"graphicVersion\">Graphic 73032 Version 3.0</div></div></div>"},"73033":{"type":"graphic_figure","displayName":"Long acting beta agonist in EIB","title":"Long acting beta agonist in EIB","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Long acting beta agonist in EIB</div><div class=\"cntnt\"><img style=\"width:438px; height:246px;\" src=\"images/PULM/73033_Long_acting_Beta_agonist_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of a single dose of the long-acting beta agonist salmeterol versus placebo in exercise induced bronchoconstriction. Salmeterol, but not placebo, protected against a decline in FEV1 with exercise. This effect was seen at both one (left panel) and nine (right panel) hours.</div><div class=\"graphic_footnotes\">EIB: exercise induced bronchoconstriction; FEV1: forced expiratory volume in one second.</div><div class=\"graphic_reference\">Redrawn from Green CP, Price JF, Arch Dis Child 1992; 67:1014.</div><div id=\"graphicVersion\">Graphic 73033 Version 2.0</div></div></div>"},"73034":{"type":"graphic_diagnosticimage","displayName":"Small cell ca bone met MRI","title":"Bone metastasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone metastasis</div><div class=\"cntnt\"><img style=\"width:289px; height:432px;\" src=\"images/PULM/73034_Small_cell_ca_bone_met_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI of a 58-year-old woman with back pain showing a hyperintense mass on T1 (shown) and T2 images involving the T8 vertebral body consistent with neoplastic involvement. Supraclavicular node biopsy confirmed small cell carcinoma.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 73034 Version 3.0</div></div></div>"},"73035":{"type":"graphic_picture","displayName":"p50 subunit of NF kB CD14 cells","title":"p50 subunit of nuclear factor-kappa B (NF-kB) in CD14 cells","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">p50 subunit of nuclear factor-kappa B (NF-kB) in CD14 cells</div><div class=\"cntnt\"><img style=\"width:432px; height:285px;\" src=\"images/RHEUM/73035_p50_subunit_of_NF_kB_CD14_c.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sublining tissue from a patient with rheumatoid arthritis studied by double immunohistochemistry. Brown-stained nuclei contain the p50 subunit of nuclear factor-kappa B (NF-kB); blue staining designates CD14-positive cells. Most CD14-positive cells contain the p50 subunit of NF-kB.</div><div class=\"graphic_reference\">Courtesy of Ellen M Gravallese, MD.</div><div id=\"graphicVersion\">Graphic 73035 Version 2.0</div></div></div>"},"73036":{"type":"graphic_figure","displayName":"WHO weight for length girls 0 to 24 months","title":"Weight-for-length percentiles, girls 0 to 24 months, WHO growth standards","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Weight-for-length percentiles, girls 0 to 24 months, WHO growth standards</div><div class=\"cntnt\"><img style=\"width:563px; height:508px;\" src=\"images/PEDS/73036_WHO_wt_leng_girl_0_24_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">WHO: World Health Organization.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.</div><div id=\"graphicVersion\">Graphic 73036 Version 6.0</div></div></div>"},"73037":{"type":"graphic_algorithm","displayName":"Algorithm for management of blunt aortic injury in adults","title":"Algorithm for management of blunt aortic injury in adults","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of blunt aortic injury in adults</div><div class=\"cntnt\"><img style=\"width:396px; height:837px;\" src=\"images/EM/73037_Bluntaorticinjdxalgo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; TEE: transesophageal echocardiogram.<br />* TEE can be performed in the operating room to evaluate the aorta as a source of hemodynamic instability.<br />¶ Multidetector CT is preferred, but TEE may be useful for patients with equivocal findings on CT, or if there is concern for proximal aortic injury or valvular abnormalities. However, the availability of TEE is variable.<br />Δ Aortography may be an option where high-quality computed tomography (at least 32 slice) is not available.<br /><FONT class=lozenge>◊</FONT> Some minimal injuries (Grade I) may be observed with serial imaging in patients who remain hemodynamically stable. Repair may be delayed in patients with severe head injury or other life-threatening injuries who do not have signs suggestive of imminent aortic rupture.</div><div id=\"graphicVersion\">Graphic 73037 Version 6.0</div></div></div>"},"73038":{"type":"graphic_figure","displayName":"Two finger technique","title":"Chest compression for infant resuscitation: Two finger technique","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Chest compression for infant resuscitation: Two finger technique</div><div class=\"cntnt\"><img style=\"width:452px; height:528px;\" src=\"images/EM/73038_Two_finger_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest compressions for infants (under one year) may be performed with two fingers placed on the sternum just below the nipples. This picture shows the site of compressions. When compressions are performed the two fingers used should be perpendicular to the chest and straight.</div><div id=\"graphicVersion\">Graphic 73038 Version 5.0</div></div></div>"},"73040":{"type":"graphic_table","displayName":"Differential diagnosis of tall (peaked) T waves","title":"Differential diagnosis of tall (peaked) T waves","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of tall (peaked) T waves</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Ischemic causes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hyperacute phase of myocardial infarction</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute transient transmural ischemia (Prinzmetal's angina)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chronic (evolving) phase of myocardial infarction (tall positive T waves reciprocal to primary deep T wave inversions)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Nonischemic causes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Normal variants (\"early repolarization\" patterns)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hyperkalemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute hemopericardium</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cerebrovascular hemorrhage (more commonly T wave inversions)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Left ventricular hypertrophy</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Right precordial leads, usually in conjunction with left precordial ST depressions and T wave inversions</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Left precordial leads, particularly in association with \"diastolic\" volume overload conditions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Left bundle branch block (right precordial leads)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute pericarditis (occasionally)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 73040 Version 2.0</div></div></div>"},"73043":{"type":"graphic_picture","displayName":"Elliot type forceps","title":"Elliott type forceps","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Elliott type forceps</div><div class=\"cntnt\"><img style=\"width:468px; height:244px;\" src=\"images/OBGYN/73043_Elliot_type_forceps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Elliot type forceps have overlapping shanks with blades that are short and have a roundish cephalic curve.</div><div class=\"graphic_reference\">Reproduced with permission from: Aron Schuftan, MD. Copyright &#169; Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 73043 Version 3.0</div></div></div>"},"73044":{"type":"graphic_table","displayName":"Chang staging medulloblastoma","title":"Modified Chang system for staging of medulloblastoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Chang system for staging of medulloblastoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_left\">Extent\nof tumor</td>\n\n    </tr>\n\n    <tr>\n\n      <td>T1</td>\n\n      <td>Tumor less than 3 cm in diameter</td>\n\n    </tr>\n\n    <tr>\n\n      <td>T2 </td>\n\n      <td>Tumor greater than 3\ncm in diameter</td>\n\n    </tr>\n\n    <tr>\n\n      <td> T3a</td>\n\n      <td>Tumor greater than 3 cm in diameter with extension into\nthe aqueduct of Sylvius and/or the foramen of Luschka</td>\n\n    </tr>\n\n    <tr>\n\n      <td>T3b</td>\n\n      <td>Tumor greater than 3 cm in diameter with unequivocal\nextension into the brain stem</td>\n\n    </tr>\n\n    <tr>\n\n      <td>T4</td>\n\n      <td>Tumor greater than 3 cm in diameter with extension up\npast the aqueduct of Sylvius and/or down past the foramen magnum</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">No consideration\nis given to the number of structures invaded or the presence of\nhydrocephalus.</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">T3b can be\ndefined by intraoperative demonstration of tumor extension into the\nbrain stem in the absence of radiographic evidence.</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_left\">Degree\nof metastasis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>M0 </td>\n\n      <td>No evidence of gross subarachnoid or hematogenous\nmetastasis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>M1</td>\n\n      <td>Microscopic tumor cells found in the cerebrospinal fluid</td>\n\n    </tr>\n\n    <tr>\n\n      <td>M2</td>\n\n      <td>Gross nodular seeding demonstrated in the\ncerebellar/cerebral subarachnoid space or in the third or lateral\nventricles</td>\n\n    </tr>\n\n    <tr>\n\n      <td>M3</td>\n\n      <td>Gross nodular seeding in the spinal subarachnoid space</td>\n\n    </tr>\n\n    <tr>\n\n      <td>M4</td>\n\n      <td>Metastasis outside the cerebrospinal axis</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">From Chang, CH, Housepain, EM, Herbert, C, Radiology 1969; 93:1351, and Cohen, ME, Duffner, PK (Eds). Brain Tumors in Children, 2d ed, McGraw-Hill, New York, 1994, p. 187.</div><div id=\"graphicVersion\">Graphic 73044 Version 1.0</div></div></div>"},"73045":{"type":"graphic_table","displayName":"Weight loss surgery comparison PI","title":"Comparison of weight loss surgeries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of weight loss surgeries</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"4\" width=\"17.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Gastric band</td> <td class=\"subtitle1\">Gastric balloon</td> <td class=\"subtitle1\">Roux-en-Y gastric bypass</td> <td class=\"subtitle1\">Gastric sleeve</td> </tr> <tr> <td><strong>How high must my BMI be?</strong></td> <td colspan=\"4\">&#62;40 or<br /> &#62;35 with a disease related to obesity* or<br /> &#62;30 with certain diseases related to obesity<sup>&#182;</sup></td> </tr> <tr> <td><strong>How quickly will I lose weight?</strong></td> <td>Gradually</td> <td>Gradually</td> <td>Usually quickly</td> <td>Less quickly</td> </tr> <tr> <td><strong>Can it be done through a scope?</strong></td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td><strong>Will my intestines be re-routed?</strong></td> <td>No</td> <td>No</td> <td>Yes</td> <td>No</td> </tr> <tr> <td><strong>Will a device stay in my body?</strong></td> <td>Yes</td> <td>Yes, for 6 months</td> <td>No</td> <td>No</td> </tr> <tr> <td><strong>Will I be able to return to my normal activities after surgery?</strong></td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td><strong>How often will I have follow-up visits?</strong></td> <td>Every 2 to 3 months in the first year, then annually</td> <td>Every 2 months for 6 months, then as needed</td> <td>Every 3 to 4 months in the first year, then annually</td> <td>Every 3 to 4 months in the first year, then annually</td> </tr> <tr> <td><strong>Will I need regular follow-up with a nutritionist?</strong></td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td><strong>About what percentage of my extra weight can I expect to lose after 1 year?</strong></td> <td>50 to 60</td> <td>20 to 30</td> <td>60 to 75</td> <td>60 to 65</td> </tr> <tr> <td><strong>About what percentage of my extra weight can I expect to lose after 2 to 3 years?</strong></td> <td>45 to 75</td> <td>Unknown</td> <td>50 to 75</td> <td>66</td> </tr> <tr> <td><strong>Should I expect my other medical problems to improve?</strong>*</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td><strong>Will I have trouble absorbing nutrients and medicines?</strong></td> <td>No</td> <td>Occasionally</td> <td>Some</td> <td>Minimal if any</td> </tr> <tr> <td><strong>Will it be possible to adjust the size of my stomach or how much I can eat?</strong></td> <td>Yes</td> <td>No</td> <td>No</td> <td>No</td> </tr> <tr> <td><strong>What are the chances I will need more surgery?</strong></td> <td>Higher</td> <td>Unknown</td> <td>Lower</td> <td>Unknown</td> </tr> <tr> <td><strong>Will it affect my heartburn symptoms?</strong></td> <td>May make symptoms worse</td> <td>May make symptoms worse while the balloon is in</td> <td>Will most likely help symptoms</td> <td>May make symptoms worse</td> </tr> <tr> <td><strong>Other concerns</strong></td> <td>Requires frequent needle adjustments</td> <td>Only meant to stay in for 6 months; long-term outcomes are unknown</td> <td>Patients may develop dumping syndrome<sup>&#916;</sup></td> <td>Long-term outcomes are unknown</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Related diseases include diabetes, high blood pressure, sleep apnea, and high cholesterol.<br />¶ These include diseases such as difficult-to-control type II diabetes or metabolic syndrome (also called \"insulin resistance syndrome\" or \"syndrome X\").<br />Δ Dumping syndrome causes nausea, shaking, sweating, diarrhea, and other symptoms soon after eating.</div><div id=\"graphicVersion\">Graphic 73045 Version 13.0</div></div></div>"},"73046":{"type":"graphic_figure","displayName":"Tubuloglomerular feedback","title":"Tubuloglomerular feedback","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tubuloglomerular feedback</div><div class=\"cntnt\"><img style=\"width:420px; height:251px;\" src=\"images/NEPH/73046_Tubuloglomerularfeedback.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship of single nephron glomerular filtration rate (GFR) to distal nephron (macula densa) perfusion rate in dogs. As the perfusion rate increases (via insertion of a micropipette into the late proximal tubule), there is a progressive reduction in GFR to a minimum of about one-half the basal level.</div><div class=\"graphic_reference\">Data from Navar LG. Renal autoregulation: perspectives from whole kidney and single nephron studies.&nbsp;Am J Physiol 1978; 234:F357.</div><div id=\"graphicVersion\">Graphic 73046 Version 2.0</div></div></div>"},"73047":{"type":"graphic_diagnosticimage","displayName":"Open book fracture pubic symphysis diastasis","title":"Open book fracture: Pubic symphysis diastasis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Open book fracture: Pubic symphysis diastasis</div><div class=\"cntnt\"><img style=\"width:468px; height:376px;\" src=\"images/EM/73047_Openbookfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anterior-posterior (AP) radiograph of the pelvis reveals significant diastasis at the symphysis pubis of this trauma patient. Such fractures can cause significant hemorrhage. Emergent treatment consists of closing the fracture and stabilizing the pelvis by applying a pelvic binder or tying a sheet tightly around the lower pelvis.</div><div id=\"graphicVersion\">Graphic 73047 Version 3.0</div></div></div>"},"73050":{"type":"graphic_figure","displayName":"Survival LGG age","title":"Survival with low-grade glioma as a function of age at diagnosis","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Survival with low-grade glioma as a function of age at diagnosis</div><div class=\"cntnt\"><img style=\"width:500px; height:323px;\" src=\"images/ONC/73050_Survival_LGG_age.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Claus, EB, Black, PM. CANCER 2006; 106:1358.</div><div id=\"graphicVersion\">Graphic 73050 Version 1.0</div></div></div>"},"73051":{"type":"graphic_waveform","displayName":"ECG Mobitz type I AV block","title":"Electrocardiogram (ECG) showing Mobitz type I (Wenckebach) atrioventricular (AV) block","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing Mobitz type I (Wenckebach) atrioventricular (AV) block</div><div class=\"cntnt\"><img style=\"width:431px; height:151px;\" src=\"images/CARD/73051_Mobitz_type_I_AV_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single lead electrocardiogram (ECG) showing Mobitz type I (Wenckebach) second degree AV block with 5:4 conduction. The characteristics of this arrhythmia include: a progressively increasing PR interval until a P wave is not conducted (arrow); a progressive decrease in the increment in the PR interval; a progressive decrease in the RR interval; and the RR interval that includes the dropped beat (0.96 sec) is less than twice the RR interval between conducted beats (0.53 to 0.57 sec).</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 73051 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"73054":{"type":"graphic_diagnosticimage","displayName":"Resection arthroplasty in SSc","title":"Postoperative radiograph following resection arthroplasty in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postoperative radiograph following resection arthroplasty in scleroderma</div><div class=\"cntnt\"><img style=\"width:407px; height:250px;\" src=\"images/RHEUM/73054_Resection_arthroplasty_in_S.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postoperative radiograph following metacarpal head resections with proximal interphalangeal fusions. Preoperatively, this patient with scleroderma had severe metacarpophalangeal hyperextension deformity combined with fixed proximal interphalangeal joint flexion.</div><div class=\"graphic_reference\">Reproduced with permission from: Nalebuff EA. Surgery in patients with systemic sclerosis of the hand. Clin Orthop Rel Res 1999; 91:366. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73054 Version 9.0</div></div></div>"},"73055":{"type":"graphic_picture","displayName":"DM in graft-versus-host","title":"Dermatomyositis-like changes in graft-versus-host disease","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Dermatomyositis-like changes in graft-versus-host disease</div><div class=\"cntnt\"><img style=\"width:505px; height:384px;\" src=\"images/RHEUM/73055_DM_in_graft_versus_host_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Perimysial perifascicular atrophy.<br> (C, D) Muscle infarction.</div><div class=\"graphic_reference\">Allen, JA, Greenberg, SA, Amato, AA. Dermatomyositis-like muscle pathology in patients with chronic graft-versus-host disease. Muscle &amp; Nerve 2009; 40:643. Copyright &#169; 2009. This material was reproduced with permission of John Wiley &amp; Sons.</div><div id=\"graphicVersion\">Graphic 73055 Version 2.0</div></div></div>"},"73056":{"type":"graphic_table","displayName":"Features of hyperlactatemia","title":"Clinical features of hyperlactatemia/lactic acidosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of hyperlactatemia/lactic acidosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Nausea</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vomiting</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Abdominal pain</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sudden weight loss</td>\n\n    </tr>\n\n    <tr>\n\n      <td>\"Extreme fatigue\"</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Exertional dyspnea</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hyperventilation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Liver failure</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Arrhythmias</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 73056 Version 2.0</div></div></div>"},"73058":{"type":"graphic_table","displayName":"Treatment of Erysipelothrix","title":"Antibiotic therapy for <em>Erysipelothrix rhusiopathiae </em>infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic therapy for <em>Erysipelothrix rhusiopathiae </em>infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of infection</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Adult dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Localized cutaneous infection</td> </tr> <tr> <td class=\"indent1\">Preferred</td> <td>Penicillin V</td> <td>500 mg every 6 hours orally</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Alternatives</td> <td>Cephalexin</td> <td>500 mg every 6 hours orally</td> </tr> <tr> <td>Ciprofloxacin*</td> <td>250 mg every 12 hours orally</td> </tr> <tr> <td>Clindamycin</td> <td>300 mg every 8 hours orally</td> </tr> <tr class=\"divider_bottom\"> <td>Erythromycin<sup>&#182;</sup></td> <td>500 mg every 6 hours orally</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Diffuse cutaneous infection OR systemic infection (bacteremia)</td> </tr> <tr> <td class=\"indent1\">Preferred</td> <td>Penicillin G</td> <td>2 to 4 million units every 4 hours IV</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Alternatives</td> <td>Ceftriaxone</td> <td>2 g every 24 hours IV</td> </tr> <tr> <td>Imipenem</td> <td>500 mg every 6 hours IV</td> </tr> <tr> <td>Ciprofloxacin<sup>&#916;</sup></td> <td>400 mg every 12 hours IV</td> </tr> <tr> <td>Daptomycin</td> <td>6 mg/kg every 24 hours IV</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The duration of therapy for localized or diffuse cutaneous infection is seven days. The duration of therapy for systemic infection (bacteremia) is at least four weeks; 14 days of intravenous therapy followed by two to four weeks of oral therapy has also been successful.</div><div class=\"graphic_footnotes\">IV: intravenously.<br />* Other fluoroquinolones may be substituted.<br />¶ Other macrolides may be substituted.<br />Δ Other intravenous fluoroquinolones may be substituted.</div><div id=\"graphicVersion\">Graphic 73058 Version 8.0</div></div></div>"},"73059":{"type":"graphic_diagnosticimage","displayName":"Absent end-diastolic flow in the umbilical artery","title":"Doppler frequency shift waveforms depicting absent end-diastolic flow velocity in the umbilical artery","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Doppler frequency shift waveforms depicting absent end-diastolic flow velocity in the umbilical artery</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/OBGYN/73059_AbsentdiastolicflowUA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Absence of end-diastolic flow velocities (AEDV) is depicted here (vertical arrows). As noted in the text, this is an ominous sign associated with adverse perinatal outcome. The upper portion of the image shows color Doppler guided interrogation of the umbilical artery. The lower portion shows spectral Doppler waveforms from the umbilical artery.</div><div class=\"graphic_reference\">Courtesy of Dev Maulik, MD, PhD.</div><div id=\"graphicVersion\">Graphic 73059 Version 5.0</div></div></div>"},"73060":{"type":"graphic_figure","displayName":"Role of sFlt in preeclampsia","title":"Hypothesis for the role of sFlt1 in preeclampsia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypothesis for the role of sFlt1 in preeclampsia</div><div class=\"cntnt\"><img style=\"width:333px; height:326px;\" src=\"images/OBGYN/73060_Role_of_sFlt_in_preeclampsi.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73060 Version 1.0</div></div></div>"},"73062":{"type":"graphic_diagnosticimage","displayName":"Combined proximal forearm fracture","title":"Olecranon fracture associated with a displaced radial neck fracture","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Olecranon fracture associated with a displaced radial neck fracture</div><div class=\"cntnt\"><img style=\"width:541px; height:382px;\" src=\"images/EM/73062_Combined_prox_fore_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteroposterior (A) and lateral (B) views of the left elbow in a 13-year-old boy who fell off a fence.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 73062 Version 4.0</div></div></div>"},"73063":{"type":"graphic_figure","displayName":"Autonomic nerve supply to the pancreas","title":"Autonomic nerve supply to the pancreas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autonomic nerve supply to the pancreas</div><div class=\"cntnt\"><img style=\"width:414px; height:440px;\" src=\"images/SURG/73063_Auton_nerv_sup_pan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram of the autonomic nerve supply to the pancreas.</div><div class=\"graphic_reference\">Originally published in Skandalakis JE, Gray SW, Rowe JS Jr, et al. Anatomical complications of pancreatic surgery. Contemp Surg 1979; 15:17. Redrawn in Mulholland MW, Maier RV, et al. Greenfield's Surgery: Scientific Principles and Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Reproduced with permission. Copyright &#169; 1979.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 73063 Version 2.0</div></div></div>"},"73064":{"type":"graphic_figure","displayName":"Endotracheal tube adapter","title":"Bag-valve-mask to transtracheal catheter connector","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Bag-valve-mask to transtracheal catheter connector</div><div class=\"cntnt\"><img style=\"width:482px; height:544px;\" src=\"images/EM/73064_ETT_adapter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transtracheal catheter may be connected to a self-inflating bag-valve ventilation device by cutting standard intravenous tubing as pictured. The luer lock end is then connected to the catheter and the cut end is attached to an adapter that has been removed from a 2.5 mm internal diameter endotracheal tube.</div><div id=\"graphicVersion\">Graphic 73064 Version 3.0</div></div></div>"},"73065":{"type":"graphic_picture","displayName":"HSG with air bubble artifact","title":"Hysterosalpingogram showing a filling defect in the left cornual area","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram showing a filling defect in the left cornual area</div><div class=\"cntnt\"><img style=\"width:468px; height:408px;\" src=\"images/OBGYN/73065_HSG_with_air_bubble_artifac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">It proved to be a superimposed gas bubble from the bowel over the uterine shadow.</div><div class=\"graphic_reference\">Reproduced with permission from: Baramki TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright © 2005 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 73065 Version 2.0</div></div></div>"},"73066":{"type":"graphic_figure","displayName":"Double aortic arch","title":"Double aortic arch","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Double aortic arch</div><div class=\"cntnt\"><img style=\"width:579px; height:374px;\" src=\"images/PEDS/73066_Double_aortic_arch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Double aortic arch, viewed from anterior. The right arch is usually the larger of the two arches. A ligamentum arteriosum connects the left arch to the pulmonary artery. <br />(B) A computer reconstructed image of a magnetic resonance angiogram viewed from postero-superior. The star is in the center of the vascular ring, where the trachea and esophagus are encircled (not shown in this projection).</div><div class=\"graphic_footnotes\">DAo: descending aorta; RAA: right aortic arch; LAA: left aortic arch. </div><div class=\"graphic_reference\">Figure A) Reproduced with permission from: Fyler D, Nadas AS. Nadas' Pediatric Cardiology, 1st ed, Hanley and Belfus, Philadelphia 1992. Copyright ©1992 Elsevier.<br />Figure B) Courtesy of Laureen M Sena, MD.</div><div id=\"graphicVersion\">Graphic 73066 Version 2.0</div></div></div>"},"73067":{"type":"graphic_table","displayName":"Fragile X syndrome genotype phenotype correlations","title":"Fragile X syndrome genotype-phenotype correlations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fragile X syndrome genotype-phenotype correlations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Mutation type</td> <td class=\"subtitle1\" rowspan=\"2\">Number of CGG trinucleotide repeats</td> <td class=\"subtitle1\" rowspan=\"2\">Methylation status of <em>FMR1</em></td> <td class=\"subtitle1\" colspan=\"2\">Clinical status</td> </tr> <tr> <td class=\"subtitle2\">Male</td> <td class=\"subtitle2\">Female</td> </tr> <tr> <td>Premutation</td> <td>Approximately 55 to 200</td> <td>Unmethylated</td> <td>At risk for FXTAS*</td> <td>At risk for POI and FXTAS</td> </tr> <tr> <td>Methylated full mutation</td> <td>&#62;200</td> <td>Completely methylated</td> <td>100% with intellectual disability</td> <td>Approximately 50% with intellectual disability, approximately 50% normal intellect</td> </tr> <tr> <td>Repeat size mosaicism</td> <td>Varies between premutation and full mutation in different cell lines</td> <td>Partial: Unmethylated in the premutation cell line; methylated in the full mutation cell line</td> <td>Nearly 100% affected with ID; may be higher functioning<sup>&#182;</sup> than males with full mutation</td> <td>Highly variable: Ranges from normal intellect to affected</td> </tr> <tr> <td>Methylation mosaicism</td> <td>&#62;200</td> <td>Partial: Mixture of methylated and unmethylated cell lines</td> <td>Nearly 100% affected with ID; may be higher functioning<sup>&#182;</sup> than males with full mutation</td> <td>Highly variable: Ranges from normal intellect to affected</td> </tr> <tr> <td>Unmethylated full mutation</td> <td>&#62;200</td> <td>Unmethylated</td> <td>Nearly all have ID but often have high functioning ID to low-normal intellect</td> <td>Highly variable: Ranges from normal intellect to affected</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CGG: cytosine-guanine-guanine; <EM>FMR1</EM>: fragile X mental retardation 1 gene; FXTAS: fragile X-associated tremor/ataxia syndrome; POI: premature ovarian insufficiency; ID: intellectual disability; IQ: intelligence quotient.<br />* Both males and females with premutations and manifestations of some symptoms of fragile X syndrome have been reported<SUP>[1]</SUP>.<br />¶ <EM>FMR1</EM> mutations are complex alterations involving nonclassic gene-disrupting alterations (trinucleotide repeat expansion) and abnormal gene methylation. This complexity at the gene level affects production of the FMR1 protein and may result in an atypical presentation in which affected individuals occasionally have an IQ above 70, the traditional demarcation denoting mental retardation.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Riddle JE, Cheema A, Sobesky WE, et al. Phenotypic involvement in females with the FMR1 gene mutation. Am J Ment Retard. 1998; 102:590.</LI></OL>Reproduced with permission from: Saul RA, Tarleton JC. FMR1-Related Disorders (August 2008). In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright © University of Washington, Seattle. 1997-2010. Available at: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene∂=fragilex (Accessed on December 22, 2009).</div><div id=\"graphicVersion\">Graphic 73067 Version 15.0</div></div></div>"},"73068":{"type":"graphic_table","displayName":"Presports exam counseling","title":"Anticipatory guidance for preparticipation examination for children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anticipatory guidance for preparticipation examination for children and adolescents</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>A medical history and physical examination can identify undiagnosed or incompletely rehabilitated injury or define underlying conditions that require treatment or may exclude a child from certain activities or sports.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Discuss injurious practices such as use of anabolic steroids, ergogenic aids, and dangerous methods of weight loss and weight gain.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Discuss with parents characteristics of physical, cognitive, and social preparation, as well as proper training.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Assure that children and parents have reasonable expectations of a training program.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Identify significant musculoskeletal abnormalities or weaknesses that may require additional training to reach the desired level of fitness and ability without sustaining injury. Anatomical malalignments that commonly occur in growing children may be justification for temporary limitations on sports participation and training. Any deficits in strength and flexibility of major muscle groups and range of motion, stability, and symmetry of major joints ought to be corrected before participating in vigorous sports training. Likewise, any abnormalities related to previous injuries ought to be corrected prior to sport-specific training.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Review nutritional factors that may affect growth and development, as well as performance. A diet that provides adequate calories and a proper balance of nutrients is critical because nutritional needs are increased by growth, as well as training. Dietary practices that compromise physical development, growth, or performance should be discouraged.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Inquire about a child's physical activity habits. Encourage youth to participate in a variety of physical activities and training methods rather than \"specializing\" in one sport or one training method. Specialization can hinder the development of the whole individual.</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 73068 Version 1.0</div></div></div>"},"73070":{"type":"graphic_figure","displayName":"Asthma attacks during pregnancy","title":"Frequency distribution of acute attacks during pregnancy","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Frequency distribution of acute attacks during pregnancy</div><div class=\"cntnt\"><img style=\"width:540px; height:287px;\" src=\"images/PULM/73070_Asthma_attacks_during_pregn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Asthma attacks during pregnancy were seen most frequently between weeks 17 and 24 of gestation.</div><div class=\"graphic_reference\">Data from Stenius-Aarniala, BSM, Hedman, J, Teramo, KS, Thorax 1996; 51:411.</div><div id=\"graphicVersion\">Graphic 73070 Version 1.0</div></div></div>"},"73071":{"type":"graphic_figure","displayName":"Nifedipine in AR","title":"Nifedipine delays progression of aortic regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nifedipine delays progression of aortic regurgitation</div><div class=\"cntnt\"><img style=\"width:425px; height:250px;\" src=\"images/CARD/73071_NifedipineinAR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative incidence of aortic valve replacement in patients with asymptomatic aortic regurgitation treated with digoxin or nifedipine. The rate of progression to valve replacement was significantly lower in the nifedipine group at all times after the first year (p = 0.001).</div><div class=\"graphic_reference\">Data from Scognamiglio R, Rahimtoola SH, Fasolli G, et al, N Engl J Med 1994; 331:689.</div><div id=\"graphicVersion\">Graphic 73071 Version 2.0</div></div></div>"},"73073":{"type":"graphic_figure","displayName":"Medullary syndrome","title":"Medullary syndrome","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Medullary syndrome</div><div class=\"cntnt\"><img style=\"width:560px; height:698px;\" src=\"images/NEURO/73073_Medullary_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Kistler, JP, et al, Cerebrovascular Diseases, Harrison's Principles of Internal Medicine, 13th ed. McGraw-Hill, New York 1994. Copyright 1994 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 73073 Version 1.0</div></div></div>"},"73075":{"type":"graphic_figure","displayName":"Sequential changes during fetal hypoxia","title":"Progression of fetal growth restriction","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Progression of fetal growth restriction</div><div class=\"cntnt\"><img style=\"width:480px; height:317px;\" src=\"images/OBGYN/73075_Sequent_changes_fetal_edt.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73075 Version 4.0</div></div></div>"},"73076":{"type":"graphic_figure","displayName":"Hemorrhoids PI","title":"Hemorrhoids","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemorrhoids</div><div class=\"cntnt\"><img style=\"width:367px; height:316px;\" src=\"images/PI/73076_Hemorrhoids_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemorrhoids that are hidden inside the rectum are called &quot;internal&quot; hemorrhoids. You cannot see them, but they can cause symptoms. Hemorrhoids that you can see or feel are called &quot;external&quot; hemorrhoids.</div><div id=\"graphicVersion\">Graphic 73076 Version 2.0</div></div></div>"},"73078":{"type":"graphic_picture","displayName":"Mycosis fungoides plaque","title":"Mycosis fungoides - plaque stage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mycosis fungoides - plaque stage</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/HEME/73078_Mycosis_fungoides_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous plaque with an annular configuration is present on the chest in this patient with plaque-stage mycosis fungoides.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73078 Version 5.0</div></div></div>"},"73079":{"type":"graphic_table","displayName":"Platelet P2Y12 receptor blocker loading doses in acute STEMI","title":"Platelet P2Y12 receptor blocker loading doses in acute STEMI","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Platelet P2Y12 receptor blocker loading doses in acute STEMI</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Reperfusion</td> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">Preferred drug (loading dose)</td> </tr> <tr> <td rowspan=\"4\">Yes</td> <td rowspan=\"2\">PCI</td> <td rowspan=\"2\">ALL</td> <td>Ticagrelor loading dose 180 mg or prasugrel loading dose 60 mg, in patients without contraindications*. Both are preferred to clopidogrel.</td> </tr> <tr> <td>Clopidogrel loading dose 300-600 mg (600 mg is preferred), in patients for whom ticagrelor or prasugrel is not chosen</td> </tr> <tr> <td rowspan=\"2\">Fibrinolysis</td> <td>&#60;75</td> <td>Clopidogrel 300 mg</td> </tr> <tr> <td>&#8805;75</td> <td>Clopidogrel 75 mg</td> </tr> <tr class=\"divider_top\"> <td>No</td> <td>--</td> <td>ALL</td> <td>Ticagrelor 180 mg </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Absolute contraindications to prasugrel include a history of stroke or transient ischemic attack (T.I.A.) or active pathological bleeding. Weight &lt;60 kg and age &#8805;75 years are relative contraindications.</div><div id=\"graphicVersion\">Graphic 73079 Version 13.0</div></div></div>"},"73080":{"type":"graphic_figure","displayName":"Time to recovery from first unipolar major depressive episode","title":"Time to recovery in patients and nonclinical individuals with unipolar major depression","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Time to recovery in patients and nonclinical individuals with unipolar major depression</div><div class=\"cntnt\"><img style=\"width:468px; height:314px;\" src=\"images/PSYCH/73080_Timerecov1stmajdepr4.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Time to recovery from the first prospectively observed episode of major depression in patients (squares, N = 359) and nonclinical individuals (triangles, N = 216) with major depressive disorder.</div><div class=\"graphic_reference\">Reproduced with permission from: Coryell W, HS Akiskal, AC Leon, et al. The time course of nonchronic major depressive disorder. Uniformity across episodes and samples. National Institute of Mental Health Collaborative Program on the Psychobiology of Depression--Clinical Studies. Arch Gen Psychiatry 1994; 51:405. Copyright © 1994 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 73080 Version 9.0</div></div></div>"},"73081":{"type":"graphic_picture","displayName":"H pylori immunostain","title":"Helicobacter pylori in gastric crypts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Helicobacter pylori in gastric crypts</div><div class=\"cntnt\"><img style=\"width:396px; height:294px;\" src=\"images/GAST/73081_H_pylori_immunostain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 600x magnification of a Helicobacter pylori immunostain with the luminal organisms shown in brown.</div><div class=\"graphic_reference\">Courtesy of Pamela J Jensen, MD.</div><div id=\"graphicVersion\">Graphic 73081 Version 1.0</div></div></div>"},"73083":{"type":"graphic_figure","displayName":"Hysterosc microins in tube","title":"Hysteroscopic sterilization microinsert: Placement and tissue infiltration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysteroscopic sterilization microinsert: Placement and tissue infiltration</div><div class=\"cntnt\"><img style=\"width:299px; height:576px;\" src=\"images/OBGYN/73083_Hysterosc_microins_in_tube.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Essure. Copyright &#169;2009 Conceptus, Inc.</div><div id=\"graphicVersion\">Graphic 73083 Version 1.0</div></div></div>"},"73084":{"type":"graphic_figure","displayName":"Genesis beta thalassemia","title":"Genesis of a beta(0) thalassemia","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Genesis of a beta(0) thalassemia</div><div class=\"cntnt\"><img style=\"width:507px; height:228px;\" src=\"images/HEME/73084_Genesis_beta_thalassemia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this patient with beta(0) thalassemia, mutation of a single base in the 39th codon (C&#8594;U), changed its triplet code from CAG (glycine) to UAG (stop), resulting in the production of a stop codon, preventing further extension of the growing beta chain.</div><div class=\"graphic_reference\">Reproduced with permission from: Takeshita, K, Forget, BG, Scarpa, A Benz, EJ, Jr. Intranuclear defects in Beta-globin mRNA accumulation due to a premature translation termination codon. Blood 1984; 64:13. Copyright &#169; 1984 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 73084 Version 1.0</div></div></div>"},"73085":{"type":"graphic_picture","displayName":"Foreign bodies ear","title":"Foreign bodies in the ear canal and on the tympanic membrane","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Foreign bodies in the ear canal and on the tympanic membrane</div><div class=\"cntnt\"><img style=\"width:499px; height:251px;\" src=\"images/PEDS/73085_Foreign_bodies_ear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) A pearl in the ear canal (a foreign body - not a squamous pearl). Panel B) Sand on the tympanic membrane after swimming in the ocean.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 73085 Version 1.0</div></div></div>"},"73087":{"type":"graphic_picture","displayName":"M mode phono mitral stenosis","title":"M-mode echocardiogram of mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram of mitral stenosis</div><div class=\"cntnt\"><img style=\"width:278px; height:355px;\" src=\"images/CARD/73087_Mmodephonomitralstenosi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal mitral valve, the anterior (aML), and posterior leaflets (pML) are seen in panel A; the e-f slope is normal. The valve thickness, as demonstrated between the arrows, is not increased. Panel B is the M-mode echocardiogram of a severely stenotic mitral valve; the e-f slope is reduced, atrial contraction (a wave) is dimunitive, and the valve thickness is increased (between arrows). The simultaneous phonocardiogram demonstrates a short interval (0.9 sec) between the second sound and opening snap (OS) and a presystolic low-frequency murmur resulting from atrial contraction.</div><div id=\"graphicVersion\">Graphic 73087 Version 5.0</div></div></div>"},"73088":{"type":"graphic_figure","displayName":"Nonsmall cell lung ca survival by TNM gp","title":"Overall survival by TNM grouping, non-small cell lung cancer","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Overall survival by TNM grouping, non-small cell lung cancer</div><div class=\"cntnt\"><img style=\"width:607px; height:491px;\" src=\"images/ONC/73088_OS_SEER_TNM_lung_CA_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overall survival, expressed as median survival time (MST) and five-year survival, using the seventh edition of TNM staging system by (A) clinical stage and (B) pathologic stage.</div><div class=\"graphic_footnotes\">TNM: tumor, node, and metastasis.</div><div class=\"graphic_reference\">Reproduced with permission from: Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2:706. Copyright © 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73088 Version 15.0</div></div></div>"},"73090":{"type":"graphic_picture","displayName":"Heliotrope eruption in DM","title":"Heliotrope euption in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heliotrope euption in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/RHEUM/73090_Heliotrope_rash_in_DM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A reddish-purple eruption on the upper eyelid (the heliotrope eruption), accompanied by swelling of the eyelid in a patient with dermatomyositis (DM). This is the most specific cutaneous eruption in DM, although it is only present in a minority of patients.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 73090 Version 4.0</div></div></div>"},"73092":{"type":"graphic_table","displayName":"Level of care guidelines for patients with eating disorders","title":"Level of care guidelines for patients with eating disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Level of care guidelines for patients with eating disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Level 1: Outpatient</td> <td class=\"subtitle1\">Level 2: Intensive outpatient</td> <td class=\"subtitle1\">Level 3: Partial hospitalization (full-day outpatient care)*</td> <td class=\"subtitle1\">Level 4: Residential treatment center</td> <td class=\"subtitle1\">Level 5: Inpatient hospitalization</td> </tr> <tr class=\"divider_bottom\"> <td>Medical status</td> <td colspan=\"3\">Medically stable to the extent that more extensive medical monitoring, as defined in levels 4 and 5, is not required</td> <td>Medically stable to the extent that intravenous fluids, nasogastric tube feedings, or multiple daily laboratory tests are not needed.</td> <td> <p>For adults: Heart rate &#60;40 bpm; blood pressure &#60;90/60 mmHg; glucose &#60;60 mg/dl; potassium &#60;3 mEq/L; electrolyte imbalance; temperature &#60;97.0&#176;F; dehydration; hepatic, renal, or cardiovascular organ compromise requiring acute treatment; poorly controlled diabetes</p> <p>For children and adolescents: Heart rate near 40 bpm, orthostatic blood pressure changes (&#62;20 bpm increase in heart rate or &#62;10 mmHg to 20 mmHg drop), blood pressure &#60;80/50 mmHg, hypokalemia<sup>&#182;</sup>, hypophosphatemia, or hypomagnesemia</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Suicidality<sup>&#916;</sup></td> <td colspan=\"4\">If suicidality is present, inpatient monitoring and treatment may be needed depending on the estimated level of risk</td> <td>Specific plan with high lethality or intent; admission may also be indicated in patient with suicidal ideas or after a suicide attempt or aborted attempt, depending on the presence or absence of other factors modulating suicide risk</td> </tr> <tr class=\"divider_bottom\"> <td>Weight as percentage of healthy body weight<sup>&#9674;</sup></td> <td>Generally &#62;85 percent</td> <td>Generally &#62;80 percent</td> <td>Generally &#62;80 percent</td> <td>Generally &#60;85 percent</td> <td>Generally &#60;70 percent; acute weight decline with food refusal even if not &#60;70 percent of healthy body weight</td> </tr> <tr class=\"divider_bottom\"> <td>Motivation to recover, including cooperativeness, insight, and ability to control obsessive thoughts</td> <td>Fair-to-good motivation</td> <td>Fair motivation</td> <td>Partial motivation; cooperative; patient preoccupied with intrusive, repetitive thoughts<sup>&#167;</sup> &#62;3 hours/day</td> <td>Poor-to-fair motivation; patient preoccupied with intrusive repetitive thoughts<sup>&#167;</sup> 4 to 6 hours a day; patient cooperative with highly structured treatment</td> <td>Very poor to poor motivation; patient preoccupied with intrusive repetitive thoughts<sup>&#167;</sup>; patient uncooperative with treatment or cooperative only in highly structured environment</td> </tr> <tr class=\"divider_bottom\"> <td>Co-occurring disorders (substance use, depression, anxiety)</td> <td colspan=\"4\">Presence of comorbid condition may influence choice of level of care</td> <td>Any existing psychiatric disorder that would require hospitalization</td> </tr> <tr class=\"divider_bottom\"> <td>Structure needed for eating/gaining weight</td> <td>Self-sufficient</td> <td>Self-sufficient</td> <td>Needs some structure to gain weight</td> <td>Needs supervision at all meals or will restrict eating</td> <td>Needs supervision during and after all meals or nasogastric/special feeding modality</td> </tr> <tr class=\"divider_bottom\"> <td>Ability to control compulsive exercising</td> <td>Can manage compulsive exercising through self-control</td> <td colspan=\"4\">Some degree of external structure beyond self-control required to prevent patient from compulsive exercising; rarely a sole indication for increasing the level of care</td> </tr> <tr class=\"divider_bottom\"> <td>Purging behavior (laxatives and diuretics)</td> <td colspan=\"3\">Can greatly reduce incidents of purging in an unstructured setting; no significant medical complications, such as electrocardiographic or other abnormalities, suggesting the need for hospitalization</td> <td>Can ask for and use support from others or use cognitive and behavioral skills to inhibit purging</td> <td>Needs supervision during and after all meals and in bathrooms; unable to control multiple daily episodes of purging that are severe, persistent, and disabling, despite appropriate trials of outpatient care, even if routine laboratory test results reveal no obvious metabolic abnormalities</td> </tr> <tr class=\"divider_bottom\"> <td>Environmental stress</td> <td colspan=\"2\">Others able to provide adequate emotional and practical support and structure</td> <td>Others able to provide at least limited support and structure</td> <td colspan=\"2\">Severe family conflict or problems or absence of family so patient is unable to receive structured treatment in home; patient lives alone without adequate support system</td> </tr> <tr> <td>Geographic availability of treatment program</td> <td colspan=\"3\">Patient lives near treatment setting</td> <td colspan=\"2\">Treatment program is too distant for patient to participate from home</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In general, a given level of care should be considered for patients who meet one or more criteria under a particular level. These guidelines are not absolutes, however, and their application requires physician judgment.</div><div class=\"graphic_footnotes\">* This level of care is most effective if administered for at least 8 hours/day, 5 days/week; less intensive care is demonstrably less effective (101).<br />&para; If the patient is dehydrated, whole-body potassium values may be low even if the serum potassium value is in the normal range; determine concurrent urine specific gravity to assess dehydration.<br />&Delta; Determining suicide risk is a complex clinical judgment, as is determining the most appropriate treatment setting for patients at risk for suicide. Relevant factors to consider are the patient's concurrent medical conditions, psychosis, substance abuse, other psychiatric symptoms or syndromes, psychosocial supports, past suicidal behaviors, and treatment adherence and the quality of existing physician-patient relationships. These factors are described in greater detail in the APA's <em>Practice Guideline for the Assessment and Treatment of Patients With Suicidal Behaviors</em> (84).<br /><span class=\"lozenge\">&loz;</span> Although this table lists percentages of expected healthy body weight in relation to suggested levels of care, these are only approximations and do not correspond to percentages based on standardized values for the population as a whole. For any given individual, differences in body build, body composition, and other physiological variables may result in considerable differences as to what constitutes a healthy body weight in relation to \"norms.\" For example, for some patients, a healthy body weight may be 110 percent of the standardized value for the population, whereas for other individuals it may be 98 percent. Each individual's physiological differences must be assessed and appreciated. For children, also consider the rate of weight loss. Finally, weight level per se should never be used as the sole criterion for discharge from inpatient care. Many patients require inpatient admission at higher weights and should not be automatically discharged just because they have achieved a certain weight level unless all other factors are appropriately considered. See text for further discussion regarding weight.<br />&sect; Individuals may experience these thoughts as consistent with their own deeply held beliefs (in which case they seem to be ego-syntonic and \"overvalued\") or as unwanted and ego-alien repetitive thoughts, consistent with classic obsessive-compulsive disorder phenomenology.</div><div class=\"graphic_reference\">Reproduced with permission, and adapted, from Practice guideline for the treatment of patients with eating disorders, Third Edition. Am J Psychiatry 2006; 163 Suppl 1:1. Copyright &copy; 2006 American Psychiatric Association.</div><div id=\"graphicVersion\">Graphic 73092 Version 4.0</div></div></div>"},"73093":{"type":"graphic_figure","displayName":"Pulse demand device and SpO2","title":"Variability in oxygen saturation between oxygen conserving devices and continuous flow oxygen","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Variability in oxygen saturation between oxygen conserving devices and continuous flow oxygen</div><div class=\"cntnt\"><img style=\"width:608px; height:381px;\" src=\"images/PULM/73093_Pls_dmnd_dvc_spO2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Differences in resting and exercise pulse oxygen saturation (SpO<sub>2</sub>) between four oxygen conserving devices (D1 through D4) set at \"2,\" continuous oxygen via nasal cannula at 2 L/min, and room air. On room air, the subjects had a mean SpO<sub>2</sub> at rest of 94 percent, which increased by varying amounts with continuous oxygen and the four conserving devices. With exercise, the mean room air SpO<sub>2</sub> decreased to just below 92 percent. Continuous flow oxygen increased the SpO<sub>2</sub> to almost 98 percent, but the response to the conserving devices ranged from 93 to 95 percent. The variability between responses to continuous flow oxygen and the oxygen conserving devices emphasizes the need to evaluate the SpO<sub>2</sub> response to the particular oxygen conserving device at rest and with exertion.</div><div class=\"graphic_reference\">Data from: Palwai A, Skowronski M, Coreno A, et al. Critical comparisons of the clinical performance of oxygen-conserving devices. Am J Respir Crit Care Med 2010; 181:1061.</div><div id=\"graphicVersion\">Graphic 73093 Version 6.0</div></div></div>"},"73094":{"type":"graphic_table","displayName":"Extrapulmonary signs in ILD","title":"Extrapulmonary findings in the interstitial lung diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Extrapulmonary findings in the interstitial lung diseases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Physical findings</td> <td class=\"subtitle1\">Associated conditions</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Systemic arterial hypertension</strong></td> <td>Systemic rheumatic disease, neurofibromatosis, anti-GBM antibody syndrome, systemic vasculitis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skin</td> </tr> <tr> <td class=\"indent1\">Discoid lupus</td> <td>IPF, SLE, drug-induced SLE</td> </tr> <tr> <td class=\"indent1\">Maculopapular rash</td> <td>Drug-induced, amyloidosis, systemic rheumatic disease, Gaucher's disease</td> </tr> <tr> <td class=\"indent1\">Heliotrope rash; Gottron papules; poikiloderma</td> <td>Dermatomyositis</td> </tr> <tr> <td class=\"indent1\">Mechanic's hands</td> <td>Antisynthetase syndrome</td> </tr> <tr> <td class=\"indent1\">Palmar papules, ulcerating lesions</td> <td>Amyopathic dermatomyositis</td> </tr> <tr> <td class=\"indent1\">Telangiectasia, sclerodactyly, hyperpigmentation/hypopigmentation, digital ulcers or pitting</td> <td>Systemic sclerosis (scleroderma)</td> </tr> <tr> <td class=\"indent1\">Raynaud phenomenon</td> <td>Systemic rheumatic disease&nbsp;(scleroderma, SLE, mixed systemic rheumatic disease)</td> </tr> <tr> <td class=\"indent1\">Cafe-au-lait spots, neurofibromas</td> <td>Neurofibromatosis</td> </tr> <tr> <td class=\"indent1\">Cutaneous vasculitis (eg, palpable purpura)</td> <td>Systemic vasculitides; systemic rheumatic disease</td> </tr> <tr> <td class=\"indent1\">Reticulated or mottled skin hyperpigmentation, nail dystropy, mucosal leukoplakia</td> <td>Dyskeratosis congenita</td> </tr> <tr> <td class=\"indent1\">Albinism</td> <td>Hermansky-Pudlak syndrome</td> </tr> <tr> <td class=\"indent1\">Calcinosis</td> <td>Dermatomyositis-polymyositis; scleroderma</td> </tr> <tr> <td class=\"indent1\">Subcutaneous nodules</td> <td>Rheumatoid arthritis, neurofibromatosis, ANCA-associated vasculitis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Erythema nodosum (deep, painful nodules predominantly on anterior surfaces lower extremities)</td> <td>Sarcoidosis; systemic rheumatic disease; Beh&#231;et syndrome; inflammatory bowel disease; histoplasmosis, coccidioidomycosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Eyes</td> </tr> <tr> <td class=\"indent1\">Uveitis</td> <td>Sarcoidosis (eg, mutton-fat keratic precipitates), Beh&#231;et syndrome (eg, panuveitis, hypopyon), ankylosing spondylitis (eg, acute anterior uveitis)</td> </tr> <tr> <td class=\"indent1\">Scleritis</td> <td>ANCA-associated vasculitis, SLE, systemic sclerosis (scleroderma), sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Keratoconjunctivitis sicca</td> <td>Lymphocytic interstitial pneumonia (in Sj&#246;gren syndrome)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cherry red macula, macular halo</td> <td>Neiman-Pick disease</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Hematologic and reticuloendothelial system</td> </tr> <tr> <td class=\"indent1\">Peripheral lymphadenopathy</td> <td>Sarcoidosis, lymphangitic carcinomatosis, lymphocytic interstitial pneumonia, lymphoma, LAM-TSC</td> </tr> <tr> <td class=\"indent1\">Hepatosplenomegaly</td> <td>Sarcoidosis, pulmonary Langerhans cell histiocytosis, systemic rheumatic disease, amyloidosis, lymphocytic interstitial pneumonia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Anemia, thrombocytopenia, hypocellular marrow</td> <td>Dyskeratosis congenita</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Heart</td> </tr> <tr> <td class=\"indent1\">Pericarditis, pericardial effusion</td> <td>Radiation pneumonitis, systemic rheumatic disease, LAM-TSC</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cardiomyopathy</td> <td>ANCA-associated vasculitis, sarcoidosis, SLE</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Musculoskeletal/neurologic</td> </tr> <tr> <td class=\"indent1\">Muscle weakness</td> <td>Systemic rheumatic disease, drugs (eg, statins), sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Nervous system abnormalities</td> <td>Pulmonary Langerhans cell histiocytosis, Neiman-Pick disease, neurofibromatosis, sarcoidosis, SLE, systemic vasculitis, TSC</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Arthritis</td> <td>ANCA-associated vasculitis, Rheumatoid arthritis, SLE, sarcoidosis (predominantly periarthritis of ankles and knees)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Gastrointestinal/renal</td> </tr> <tr> <td class=\"indent1\">Glomerulonephritis</td> <td>Anti-GBM antibody syndrome, ANCA-associated vasculitis, sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Nephrotic syndrome</td> <td>Amyloid, drug-induced, sarcoidosis, SLE</td> </tr> <tr> <td class=\"indent1\">Renal mass (eg, angiomyolipoma)</td> <td>TSC, LAM</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gastrointestinal symptoms (eg, diarrhea, abdominal pain, hematochezia)</td> <td>Pneumonitis related to inflammatory bowel disease</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other</td> </tr> <tr> <td class=\"indent1\">Salivary or lacrimal gland enlargement</td> <td>Sarcoidosis, lymphocytic interstitial pneumonia (in Sj&#246;gren syndrome), IgG4-related disease</td> </tr> <tr> <td class=\"indent1\">Pleural abnormalities</td> <td>Systemic rheumatic disease, LAM-TSC (chylous effusion), abestosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GBM: glomerular basement membrane; IPF: idiopathic pulmonary fibrosis; SLE: systemic lupus erythematosus; ANCA: antineutrophil cytoplasmic antibodies;&nbsp;LAM: lymphangioleiomyomatosis; TSC: tuberous sclerosis complex; IgG4: immunoglobulin G4.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Schwarz MI, King TE Jr, Cherniack RM. General principles and diagnostic approach to the interstitial lung diseases. In: Murray JF, Nadel JA, (Eds), Textbook of Respiratory Medicine, 2nd ed, Philadelphia, WB Saunders Co, 1994, pp. 1803-1826.</li>&#xD;&#xA;    <li>Cosgrove GP, Schwarz MI. Approach to the evaluation and diagnosis of interstitial lung diseases. In: Interstitial Lung Disease, 5th ed, Shelton, CT, Peoples Medical Publishing House, 2011, pp. 3-33.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 73094 Version 6.0</div></div></div>"},"73097":{"type":"graphic_table","displayName":"Sonohysterography indications and contraindications","title":"Indications and contraindications to saline infusion sonohysterography","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications and contraindications to saline infusion sonohysterography</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Indications</td> </tr> <tr> <td>Abnormal uterine bleeding</td> </tr> <tr> <td>Uterine cavity abnormalities that are suspected or noted on transvaginal sonography&nbsp;(eg, leiomyomas, polyps, synechiae)</td> </tr> <tr> <td>Congenital abnormalities of the uterine cavity</td> </tr> <tr> <td>Infertility</td> </tr> <tr> <td>Recurrent pregnancy loss</td> </tr> <tr> <td class=\"subtitle1_single\">Contraindications</td> </tr> <tr> <td>Pregnancy</td> </tr> <tr> <td>Pelvic infection</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73097 Version 2.0</div></div></div>"},"73098":{"type":"graphic_table","displayName":"HCV and blood test results","title":"Risk of HCV transmission based upon donor test results","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of HCV transmission based upon donor test results</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">HCV 2.0 EIA* result</td> <td class=\"subtitle1\">Supplemental test (RIBA)<sup>&#182;</sup> result</td> <td class=\"subtitle1\">Probability of HCV transmission, percent</td> </tr> <tr> <td>Positive</td> <td>Positive</td> <td>70</td> </tr> <tr> <td>Positive</td> <td>Not done</td> <td>40</td> </tr> <tr> <td>Positive</td> <td>Indeterminate</td> <td>5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Enzyme immunoassay.<br />¶ Recombinant immunoblot assay.</div><div class=\"graphic_reference\">Source: American Association of Blood Banks, HCV Lookback Information, September, 1998.</div><div id=\"graphicVersion\">Graphic 73098 Version 2.0</div></div></div>"},"73099":{"type":"graphic_table","displayName":"MGUS characteristics","title":"Characteristics of patients with monoclonal gammopathy of undetermined significance (MGUS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of patients with monoclonal gammopathy of undetermined significance (MGUS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Characteristic</td> <td class=\"subtitle1\">Screening study*</td> <td class=\"subtitle1\">Clinically diagnosed MGUS<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Heavy chain type (percent)</td> </tr> <tr> <td class=\"sublist1\">IgG</td> <td class=\"sublist_other\">69</td> <td class=\"sublist_other\">70</td> </tr> <tr> <td class=\"sublist1\">IgM</td> <td class=\"sublist_other\">17</td> <td class=\"sublist_other\">15</td> </tr> <tr> <td class=\"sublist1\">IgA</td> <td class=\"sublist_other\">11</td> <td class=\"sublist_other\">12</td> </tr> <tr> <td class=\"sublist1\">Biclonal</td> <td class=\"sublist_other\">3</td> <td class=\"sublist_other\">3</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Light chain type (percent)</td> </tr> <tr> <td class=\"sublist1\">Kappa</td> <td class=\"sublist_other\">62</td> <td class=\"sublist_other\">61</td> </tr> <tr> <td class=\"sublist1\">Lambda</td> <td class=\"sublist_other\">38</td> <td class=\"sublist_other\">39</td> </tr> <tr> <td>Reduction in uninvolved immunoglobulins (percent)</td> <td>28</td> <td>38</td> </tr> <tr> <td>Monoclonal urinary light chain detected (percent)</td> <td>22</td> <td>31</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Olmsted County prevalence study of 694 patients with MGUS diagnosed in a population-based screening study. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354:1362.<br />¶&nbsp;Southeastern Minnesota study of 1384 patients with clinically diagnosed MGUS. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564.</div><div id=\"graphicVersion\">Graphic 73099 Version 2.0</div></div></div>"},"73100":{"type":"graphic_table","displayName":"Toronto Side Effects Scale","title":"Toronto Side Effects Scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Toronto Side Effects Scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"19%\"></colgroup><colgroup span=\"5\" width=\"8%\"></colgroup><colgroup width=\"1%\"></colgroup><colgroup span=\"5\" width=\"8%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"7\"><strong>Patient name:</strong></td> <td colspan=\"5\"><strong>Date:</strong></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"12\"> <p>Within the last two weeks, have you had any of the symptoms listed below?</p> <p>How much trouble did each symptom cause you?</p> For each symptom, mark how often (frequency) and how bothersome (severity) it is in the boxes below.</td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">Symptom</td> <td class=\"subtitle1\" colspan=\"5\">Frequency</td> <td class=\"highlight_gray_text\" rowspan=\"35\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"6\">Severity</td> </tr> <tr> <td class=\"subtitle2\">Never<br /> 1</td> <td class=\"subtitle2\">Sometimes<br /> 2</td> <td class=\"subtitle2\">About half the time<br /> 3</td> <td class=\"subtitle2\">Often<br /> 4</td> <td class=\"subtitle2\">Every day<br /> 5</td> <td class=\"subtitle2\">No trouble<br /> 1</td> <td class=\"subtitle2\">Some trouble<br /> 2</td> <td class=\"subtitle2\">Moderate trouble<br /> 3</td> <td class=\"subtitle2\">More trouble<br /> 4</td> <td class=\"subtitle2\">Extreme trouble<br /> 5</td> </tr> <tr> <td>Nervousness</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Agitation</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Tremor</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Twitching/myoclonus (muscle contraction)</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Abdominal pain</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Dyspepsia (upset stomach)</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Nausea</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Diarrhea</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Constipation</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Decreased appetite</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Increased appetite</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Weakness or fatigue</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Dizziness</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Postural hypotension (dizzy when getting up)</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Drowsiness/daytime somnolence</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Increased sleep</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Decreased sleep</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Sweating</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Flushing</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Edema (fluid retention)</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Headache</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Blurred vision</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Dry mouth</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Anorgasmia/no orgasm</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Increased libido</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Decreased libido</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Other, specify:</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Weight gain</td> <td class=\"centered\">None</td> <td class=\"centered\">&#8804;2 lb</td> <td class=\"centered\">&#8804;4 lb</td> <td class=\"centered\">&#8804;6 lb</td> <td class=\"centered\">&#8804;7 lb</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr class=\"divider_bottom\"> <td>Weight loss</td> <td class=\"centered\">None</td> <td class=\"centered\">&#8804;2 lb</td> <td class=\"centered\">&#8804;4 lb</td> <td class=\"centered\">&#8804;6 lb</td> <td class=\"centered\">&#8804;7 lb</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Men only</td> <td class=\"subtitle2_left\" colspan=\"5\">Men only</td> </tr> <tr> <td>Premature ejaculation</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Delayed ejaculation</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td>Erectile dysfunction</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li><strong>Patient instructions:</strong> Circle the number for frequency and the number for severity that best describes the side effect.</li>&#xD;&#xA;    <li><strong>Physician instructions:</strong> An \"intensity\" score is derived by multiplying frequency score by severity score. Use the intensity score to track the progress of your patient's side effects.</li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">Reproduced with permission from: Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: A study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2002; 47:174. Copyright &copy; 2002 Canadian Psychiatric Association.</div><div id=\"graphicVersion\">Graphic 73100 Version 2.0</div></div></div>"},"73101":{"type":"graphic_diagnosticimage","displayName":"Intraluminal retained surgical sponge","title":"Intraluminal retained surgical sponge","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Intraluminal retained surgical sponge</div><div class=\"cntnt\"><img style=\"width:454px; height:576px;\" src=\"images/SURG/73101_Intralum_retain_surg_sponge.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper gastrointestinal contrast-enhanced study shows dilated small-bowel loop caused by presence of intraluminal foreign body (arrows).</div><div class=\"graphic_reference\">From: Manzella A, Filho PB, Albuquerque E, et al. Imaging of gossypibomas: pictorial review. AJR Am J Roentgenol 2009; 193(6 Suppl):S94. Reprinted with permission from the American Journal of Roentgenology. Copyright © 2009 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 73101 Version 10.0</div></div></div>"},"73102":{"type":"graphic_picture","displayName":"Pathology of internal carotid artery dissection","title":"Pathology of internal carotid artery dissection","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Pathology of internal carotid artery dissection</div><div class=\"cntnt\"><img style=\"width:582px; height:308px;\" src=\"images/NEURO/73102_Path_int_carotid_art_dissec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Elastica van Gieson stain of specimens from a 61-year-old man with internal carotid artery dissection and fibromuscular dysplasia.<br> (A) Postmortem exposition of intramural hematoma of the right internal carotid artery above the bifurcation (arrow).<br> (B) Cross-section of the dissected artery shows subintimal and intramedial hematoma (small arrows).<br> (C) Longitudinal section with zipper-like separation within the arterial wall (large arrow) corresponding to the false lumen and myxoid degeneration of the media (small arrows).</div><div class=\"graphic_footnotes\">Asterisk: true lumen; Scale bar: 0.25 mm.</div><div class=\"graphic_reference\">Reproduced with permission from: Besselmann M, Vennemann B, Lowens S, et al. Internal carotid artery dissection. Neurology 2000; 54:442. Copyright © 2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73102 Version 4.0</div></div></div>"},"73103":{"type":"graphic_figure","displayName":"Finger flexion","title":"Finger flexion","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Finger flexion</div><div class=\"cntnt\"><img style=\"width:534px; height:338px;\" src=\"images/EM/73103_Finger_flexion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the muscles and tendons involved in flexion of the distal and middle interphalangeal joints.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company, General Anatomy. Copyright &#169;2008 Anatomical Chart Company.</div><div id=\"graphicVersion\">Graphic 73103 Version 1.0</div></div></div>"},"73104":{"type":"graphic_table","displayName":"Causes of acromegaly","title":"Causes of acromegaly","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acromegaly</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary GH excess</td> </tr> <tr> <td>GH-cell adenoma</td> </tr> <tr> <td>Mixed GH-cell and PRL-cell adenoma</td> </tr> <tr> <td>Mammosomatotroph-cell adenoma</td> </tr> <tr> <td>Plurihormonal adenoma</td> </tr> <tr> <td>GH-cell carcinoma</td> </tr> <tr> <td class=\"subtitle2_single\">Familial syndromes</td> </tr> <tr> <td class=\"indent1\">Multiple endocrine neoplasia type 1&nbsp;(GH-cell adenoma)</td> </tr> <tr> <td class=\"indent1\">Familial acromegaly</td> </tr> <tr> <td class=\"indent1\">McCune-Albright syndrome (rarely adenoma)</td> </tr> <tr> <td class=\"indent1\">Carney's syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">GH excess (ectopic or iatrogenic)</td> </tr> <tr> <td>Pancreatic islet-cell tumor</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td>Iatrogenic</td> </tr> <tr> <td class=\"subtitle1_single\">GHRH excess</td> </tr> <tr> <td class=\"subtitle2_single\">Central ectopic (&#60;1 percent)</td> </tr> <tr> <td class=\"indent1\">Hypothalamic hamartoma, choristoma, ganglioneuroma</td> </tr> <tr> <td class=\"subtitle2_single\">Peripheral ectopic (1 percent)</td> </tr> <tr> <td class=\"indent1\">Bronchial carcinoid, pancreatic islet-cell tumor, small cell lung cancer, adrenal adenoma, medullary thyroid carcinoma, pheochromocytoma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GH: growth hormone; GHRH: growth hormone-releasing hormone; PRL: prolactin.</div><div class=\"graphic_reference\">Adapted from: Melmed S. Acromegaly. N Engl J Med 1990; 322:966.</div><div id=\"graphicVersion\">Graphic 73104 Version 9.0</div></div></div>"},"73105":{"type":"graphic_figure","displayName":"Cherney incision","title":"Cherney incision","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Cherney incision</div><div class=\"cntnt\"><img style=\"width:533px; height:620px;\" src=\"images/SURG/73105_Cherney_incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Transverse incision of rectus sheath. (B) Lower sheath is separated from rectus muscles. Tendons are exposed and incised 0.5 cm above periosteum of symphysis. (C) Tendons are sutured to lower rectus sheath above symphysis with permanent suture material. (D) Sheath is closed in a continuous manner.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 73105 Version 3.0</div></div></div>"},"73106":{"type":"graphic_table","displayName":"Disorders causing visual hallucinations","title":"Disorders causing visual hallucinations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders causing visual hallucinations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">Classification and characteristic features</td> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Triggers</td> <td class=\"subtitle1\">Duration</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\">Insight</td> <td class=\"subtitle1\">Associated symptoms</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Retinal pathology</strong></td> <td> <p>Simple</p> Intrinsic motion is common; eg, flashing lights</td> <td>Monocular or binocular, depending on underlying pathology</td> <td>Valsalva if due to posterior vitreous detachment</td> <td>Seconds</td> <td>Variable</td> <td>Intact</td> <td>Possible vision loss per abnormal funduscopic examination</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Vision loss, release hallucinations</strong></td> <td> <p>Simple or complex</p> Can be stationary, have intrinsic motion, or move en bloc</td> <td>Monocular or binocular, full field or hemifield depending on underlying pathology</td> <td>Sensory deprivation, decreased arousal</td> <td>Variable</td> <td>Frequent, at least weekly, up to multiple times in one day</td> <td>Often intact</td> <td>Related to underlying condition</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Migraine</strong></td> <td> <p>Usually simple and geometric in form; eg, fortification spectra, scintillating scotoma</p> Spread or movement across the visual field over minutes is characteristic</td> <td> <p>Binocular, usually hemifield</p> Often start centrally and move to periphery</td> <td>Migraine triggers (eg, lack of sleep, red wine, menses)</td> <td>Several minutes to an hour</td> <td>Variable, usually less often than weekly</td> <td>Intact</td> <td>Migraine headache, often with nausea, vomiting, photophobia</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Seizures</strong></td> <td> <p>Simple more common than complex</p> <p>Typically circular and colored</p> Movement across the field is rapid (seconds)</td> <td>Binocular, hemifield</td> <td>Usually occur without trigger</td> <td>Seconds to 1-2 minutes</td> <td>Variable</td> <td>Usually intact</td> <td>Other ictal phenomena (eg, automatisms, deja vu, convulsions), postictal headache common</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Dementia with Lewy bodies, Parkinson disease</strong></td> <td>Simple or complex</td> <td>Binocular, full field</td> <td>Usually no trigger</td> <td>Variable, usually minutes</td> <td>Variable, can be daily</td> <td>Variable, perhaps related to cognitive status</td> <td>Dementia, Parkinsonism</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Alcohol withdrawal</strong></td> <td>Complex, often associated with auditory and tactile hallucinations</td> <td>Binocular, full field</td> <td>Abstinence</td> <td>Persistent</td> <td>Persist during withdrawal</td> <td>Often impaired</td> <td>Autonomic disturbances, confusion, agitation</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Peduncular hallucinosis</strong></td> <td>Complex, often associated with auditory and tactile hallucinations</td> <td>Binocular, full field</td> <td>More common in evening hours</td> <td>Variable may persist</td> <td>Variable</td> <td>Maybe impaired</td> <td>Sleep disturbances, other brainstem or diencephalic signs</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Narcolepsy</strong></td> <td>Complex, often associated with auditory and tactile hallucinations</td> <td>Binocular, full field</td> <td>Usually on falling to or on awakening from sleep</td> <td>Variable, seconds to minutes</td> <td>Often nightly</td> <td>Usually intact</td> <td>Cataplexy, excessive daytime sleepiness, sleep paralysis</td> </tr> <tr> <td><strong>Psychiatric illness</strong></td> <td>Complex, often associated with auditory and tactile hallucinations</td> <td>Binocular, full field</td> <td>No trigger</td> <td>Variable</td> <td>Frequent</td> <td>Usually absent</td> <td>Disordered thoughts, delusions</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73106 Version 3.0</div></div></div>"},"73107":{"type":"graphic_table","displayName":"DTaP DT Tdap Td vaccines","title":"Composition of and indications for diphtheria, tetanus, and pertussis vaccines for infants, children, and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Composition of and indications for diphtheria, tetanus, and pertussis vaccines for infants, children, and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vaccine</td> <td class=\"subtitle1\">Diphtheria toxoid<br /> (Lf units)</td> <td class=\"subtitle1\">Tetanus toxoid<br /> (Lf units)</td> <td class=\"subtitle1\">Pertussis antigens</td> <td class=\"subtitle1\">Approved doses and age groups</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Vaccines for children 6 weeks through 6 years</td> </tr> <tr> <td class=\"indent1\"><strong>DT</strong></td> <td class=\"centered\">6.7</td> <td class=\"centered\">5</td> <td>None</td> <td>All 5 doses if there is a contraindication or precaution to pertussis vaccine (6 weeks through 6 years)</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><strong>DTaP</strong></td> </tr> <tr> <td class=\"indent2\">Daptacel</td> <td class=\"centered\">15</td> <td class=\"centered\">5</td> <td> <p>PT (10 mcg)</p> <p>FHA (5 mcg)</p> <p>PERT (3 mcg)</p> FIM (5 mcg)</td> <td>All 5 doses (6 weeks through 6 years)</td> </tr> <tr> <td class=\"indent2\">Infanrix</td> <td class=\"centered\">25</td> <td class=\"centered\">10</td> <td> <p>PT (25 mcg)</p> <p>FHA (25 mcg)</p> PERT (8 mcg)</td> <td>All 5 doses (6 weeks through 6 years)</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><strong>DTaP combination vaccines</strong></td> </tr> <tr> <td class=\"indent2\">Kinrix (DTaP + IPV)</td> <td class=\"centered\">25</td> <td class=\"centered\">10</td> <td> <p>PT (25 mcg)</p> <p>FHA (25 mcg)</p> PERT (8 mcg)</td> <td>Fifth dose of DTaP, fourth dose of IPV (4 through 6 years) in children who have received 4 doses of Infanrix and/or Pediarix</td> </tr> <tr> <td class=\"indent2\">Pediarix (DTap + IPV + HBV)</td> <td class=\"centered\">25</td> <td class=\"centered\">10</td> <td> <p>PT (25 mcg)</p> <p>FHA (25 mcg)</p> PERT (8 mcg)</td> <td>First 3 doses (6 weeks through 6 years)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Pentacel (DTaP + IPV + Hib)</td> <td class=\"centered\">15</td> <td class=\"centered\">5</td> <td> <p>PT (20 mcg)</p> <p>FHA (20 mcg)</p> <p>PERT (3 mcg)</p> FIM (5 mcg)</td> <td>First 4 doses (6 weeks through 4 years)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Quadracel (DTaP + IPV)&nbsp;</td> <td class=\"centered\">15&nbsp;</td> <td class=\"centered\">&nbsp;5</td> <td> <p>PT (20 mcg)</p> <p>FHA (20 mcg)</p> <p>PERT (3 mcg)</p> <p>FIM (5 mcg)</p> </td> <td>Fifth dose of DTaP, fourth dose of IPV (4 through 6 years) in children who have received 4 doses of Daptacel or Pentacel</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Vaccines for children &#8805;7 years, adolescents, and adults</td> </tr> <tr> <td class=\"indent1\"><strong>Td</strong></td> <td class=\"centered\">2</td> <td class=\"centered\">2 to 5</td> <td>None</td> <td>Booster dose (&#8805;7 years)</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\"><strong>Tdap</strong></td> </tr> <tr> <td class=\"indent2\">Adacel</td> <td class=\"centered\">2</td> <td class=\"centered\">5</td> <td> <p>PT (2.5 mcg)</p> <p>FHA (5 mcg)</p> <p>PERT (3 mcg)</p> FIM (5 mcg)</td> <td>Booster dose (10 through 64 years)*</td> </tr> <tr> <td class=\"indent2\">Boostrix</td> <td class=\"centered\">2.5</td> <td class=\"centered\">5</td> <td> <p>PT (8 mcg)</p> <p>FHA (8 mcg)</p> PERT (2.5 mcg)</td> <td>&#8805;10 years</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Lf: limit of flocculation; DT: diphtheria and tetanus toxoids; DTaP: diphtheria toxoid, tetanus toxoid, acellular pertussis vaccine; PT: inactivated pertussis toxin (toxoid); FHA: filamentous hemagglutinin; PERT: pertactin (an outer membrane 69-kd protein); FIM: fimbrial proteins types 2 and 3; IPV: inactivated polio vaccine; HBV: hepatitis B vaccine; Hib: <EM>Haemophilus influenzae </EM>type b vaccine; Td: tetanus, reduced diphtheria; Tdap: tetanus, reduced diphtheria, acellular pertussis.<br />* The Advisory Committee on Immunization Practices recommends off-label use of Tdap vaccine for children age 7 to 10 years who are not fully vaccinated against pertussis (Centers for Disease Control and Prevention [CDC]. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis [Tdap] vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13).</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.</LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Pertussis (whooping cough). In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP>, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.609.</LI>&#xD;&#xA;<LI>Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older--Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2012; 61:468.</LI>&#xD;&#xA;<LI>Adacel (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed) prescribing information, 2014. https://www.vaccineshoppe.com/image.cfm?image_type=product_pdf&amp;pi=400-10 (Accessed on April 08, 2014).</LI>&#xD;&#xA;<LI>Liang J, Wallace G, Mootrey G. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated&nbsp; poliovirus vaccine&nbsp;and guidance for use as a booster dose. MMWR Morb Mortal Wkly Rep 2015; 64:948.</LI></OL></div><div id=\"graphicVersion\">Graphic 73107 Version 15.0</div></div></div>"},"73109":{"type":"graphic_figure","displayName":"Ventilator delivery B agonist","title":"Bronchodilator administration via mechanical ventilator","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchodilator administration via mechanical ventilator</div><div class=\"cntnt\"><img style=\"width:350px; height:248px;\" src=\"images/PULM/73109_Ventilator_delivery_B_agoni.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Continuous beta agonist nebulization set-up for ventilator delivery.</div><div class=\"graphic_footnotes\">O2: oxygen.</div><div class=\"graphic_reference\">Courtesy of Murphy S. Presented at American Academy of Allergy and Immunology 1991. With permission.</div><div id=\"graphicVersion\">Graphic 73109 Version 3.0</div></div></div>"},"73111":{"type":"graphic_algorithm","displayName":"Treatment of neonatal RDS","title":"Treatment of neonatal respiratory distress syndrome for preterm infants","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatment of neonatal respiratory distress syndrome for preterm infants</div><div class=\"cntnt\"><img style=\"width:333px; height:507px;\" src=\"images/PEDS/73111_Prevent_treat_neonatal_RDS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm for management of neonatal respiratory distress syndrome&nbsp;for preterm infants.&nbsp;Note that criteria for initial surfactant therapy, subsequent doses of surfactant, and need for intubation and ventilatory support vary between institutions.</div><div class=\"graphic_footnotes\">CPAP: continuous positive airway pressure; IPPV: intermittent positive pressure ventilation; FiO<sub>2</sub>: fraction of inspired oxygen; ABG: arterial blood gas.</div><div id=\"graphicVersion\">Graphic 73111 Version 6.0</div></div></div>"},"73112":{"type":"graphic_algorithm","displayName":"Failed airway algorithm","title":"Failed airway algorithm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Failed airway algorithm</div><div class=\"cntnt\"><img style=\"width:424px; height:458px;\" src=\"images/EM/73112_Failedairwayalgo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ETT: endotracheal tube.<br />* Placement of an extra-glottic device is contraindicated in the setting of severe hypopharyngeal pathology, such as epiglottitis. Should a surgical airway be needed in these circumstances, one attempt at tracheal intubation using a video laryngoscope or direct laryngoscopy may be performed, provided preparations for a surgical airway occur simultaneously.<br />¶ In children under 8 years of age an uncuffed or cuffed endotracheal tube may be placed. In neonates, uncuffed endotracheal tubes should be placed.</div><div class=\"graphic_reference\">Reproduced with permission from: The Difficult Airway Course®: Emergency and Brown III CA, Walls RM. The Emergency Airway Algorithms. In: The Walls Manual of Emergency Airway Management, 5th ed, Brown III CA, Sakles JC, Mick NW (Eds), Wolters Kluwer, Philadelphia 2018. Copyright © 2018 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 73112 Version 20.0</div></div></div>"},"73114":{"type":"graphic_figure","displayName":"Mobilizing vagina and rectum","title":"Repair of a small rectovaginal fistula through a transvaginal approach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of a small rectovaginal fistula through a transvaginal approach</div><div class=\"cntnt\"><img style=\"width:354px; height:445px;\" src=\"images/OBGYN/73114_Mobilizing_vagina_and_rectu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The posterior vaginal wall is sharply mobilized off of the anterior rectal wall.</div><div id=\"graphicVersion\">Graphic 73114 Version 1.0</div></div></div>"},"73115":{"type":"graphic_figure","displayName":"MCL pathogenesis","title":"Overview of mechanisms in the pathogenesis of mantle cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Overview of mechanisms in the pathogenesis of mantle cell lymphoma</div><div class=\"cntnt\"><img style=\"width:518px; height:721px;\" src=\"images/HEME/73115_MCL_pathogenesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Most cases of mantle cell lymphoma (MCL) are postulated to derive from naïve pre-germinal center B cells of the mantle zone. In the vast majority of cases, expression of the cyclin D1 gene, located at 11q13, drives cell cycle progression from G1 to S phase. A minority of cases do not demonstrate cyclin D1, but are thought to overexpress other cell cycle mediators, such as cyclin D2 and cyclin D3. In addition to cyclin D1 expression, MCL tumors demonstrate a decreased response to DNA damage and enhanced cell survival (impaired apoptosis).</div><div class=\"graphic_footnotes\">ATM: ataxia telangiectasia mutated gene; cdk: cyclin dependent kinase; CHK: cell cycle checkpoint kinase.</div><div id=\"graphicVersion\">Graphic 73115 Version 2.0</div></div></div>"},"73119":{"type":"graphic_picture","displayName":"Chancre","title":"Chancre","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chancre</div><div class=\"cntnt\"><img style=\"width:320px; height:352px;\" src=\"images/OBGYN/73119_Chancre.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from&#160;Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 73119 Version 2.0</div></div></div>"},"73120":{"type":"graphic_diagnosticimage","displayName":"Clear cell carc MRI A","title":"Magnetic resonance images (MRI) of clear cell carcinoma of the kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance images (MRI) of clear cell carcinoma of the kidney</div><div class=\"cntnt\"><img style=\"width:432px; height:365px;\" src=\"images/ONC/73120_Clear_cell_carc_MRI_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal T2-weighted single-shot fast spin echo image shows a heterogeneous mass in the right kidney.</div><div class=\"graphic_reference\">Courtesy of Ivan Pedrosa, MD.</div><div id=\"graphicVersion\">Graphic 73120 Version 2.0</div></div></div>"},"73121":{"type":"graphic_figure","displayName":"Air exchange lungs PI","title":"How air is exchanged in the lungs","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">How air is exchanged in the lungs</div><div class=\"cntnt\"><img style=\"width:460px; height:443px;\" src=\"images/PI/73121_Air_exchange_lungs_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts how oxygen (02) and carbon dioxide (CO2) pass between the alveloi (inside the lung) and the capillaries (the blood stream).</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Co. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73121 Version 2.0</div></div></div>"},"73122":{"type":"graphic_figure","displayName":"Etiology of epididymitis","title":"Etiology of epididymitis","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Etiology of epididymitis</div><div class=\"cntnt\"><img style=\"width:555px; height:366px;\" src=\"images/PEDS/73122_Etiology_of_epididymitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple etiologies of epididymitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Sheldon, CA. The pediatric genitourinary examination. Inguinal, urethral, and genital diseases. Pediatr Clin North Am 2001; 48:1339. Copyright &#169; 2001 Elsevier.</div><div id=\"graphicVersion\">Graphic 73122 Version 1.0</div></div></div>"},"73125":{"type":"graphic_figure","displayName":"Angiographic variables associated with reocclusion","title":"Angiographic variables associated with reocclusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angiographic variables associated with reocclusion</div><div class=\"cntnt\"><img style=\"width:443px; height:271px;\" src=\"images/CARD/73125_Angio_variable_and_reocclus.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The TIMI 4 trial performed angiography 90 minutes after successful thrombolysis and found that factors associated with a higher rate of infarct-related coronary artery reocclusion were lesion ulceration (p = 0.009), presence of collateral (p = 0.03), lesion eccentricity (p = 0.06), and lesions with thrombus (p = 0.06).</div><div class=\"graphic_reference\">Data from Gibson CM, Cannon CP, Piana RN, et al. J Am Coll Cardiol 1995; 25:582.</div><div id=\"graphicVersion\">Graphic 73125 Version 3.0</div></div></div>"},"73126":{"type":"graphic_table","displayName":"RSV prophylaxis and CHD","title":"Respiratory syncytial virus immunoprophylaxis for infants and young children with congenital heart disease*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Respiratory syncytial virus immunoprophylaxis for infants and young children with congenital heart disease*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Most likely to benefit from immunoprophylaxis:</td> </tr> <tr> <td class=\"indent1\">Infants &#60;12 months of age with acyanotic heart disease who are receiving medication to control heart failure and will require cardiac surgery</td> </tr> <tr> <td class=\"indent1\">Infants &#60;12 months of age with moderate to severe pulmonary hypertension</td> </tr> <tr> <td class=\"subtitle1_single\">May benefit from immunoprophylaxis:</td> </tr> <tr> <td class=\"indent1\">Infants &#60;12 months of age with cyanotic heart disease</td> </tr> <tr> <td class=\"indent1\">Children younger than 2 years who undergo cardiac transplantation during RSV season</td> </tr> <tr> <td class=\"subtitle1_single\">Not indicated:</td> </tr> <tr> <td class=\"indent1\">Children &#8805;12 months (with the exception of those &#60;2 years undergoing cardiac transplantation during RSV season)</td> </tr> <tr> <td class=\"sublist2_start\">Infants &#60;12 months with hemodynamically insignificant heart disease:</td> </tr> <tr> <td class=\"sublist2\">Secundum atrial septal defect</td> </tr> <tr> <td class=\"sublist2\">Small ventricular septal defect</td> </tr> <tr> <td class=\"sublist2\">Pulmonic stenosis</td> </tr> <tr> <td class=\"sublist2\">Uncomplicated aortic stenosis</td> </tr> <tr> <td class=\"sublist2\">Mild coarctation of the aorta</td> </tr> <tr> <td class=\"sublist2\">Patent ductus arteriosus</td> </tr> <tr> <td class=\"indent1\">Infants &#60;12 months of age with lesions adequately corrected by surgery unless they continue to require medication</td> </tr> <tr> <td class=\"indent1\">Infants &#60;12 months of age with mild cardiomyopathy who are not receiving medical therapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RSV: respiratory syncytial virus.<br />* Palivizumab is the only RSV immunoprophylactic agent approved for infants with congenital heart disease. Decisions regarding RSV immunoprophylaxis for infants with congenital heart disease should be made in consultation with the infant's cardiologist.</div><div class=\"graphic_reference\">Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134:415.</div><div id=\"graphicVersion\">Graphic 73126 Version 5.0</div></div></div>"},"73127":{"type":"graphic_table","displayName":"Sunscreens","title":"Sunscreens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sunscreens</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Sunscreen</td> <td class=\"subtitle1\">Range of protection</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Organic</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">PABA derivatives</td> </tr> <tr> <td class=\"indent2\">PABA (para-aminobenzoic acid)</td> <td>UVB</td> </tr> <tr> <td class=\"indent2\">Padimate O (octyl dimethyl PABA)</td> <td>UVB</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Cinnamates</td> </tr> <tr> <td class=\"indent2\">Octinoxate (octyl methoxycinnamate)</td> <td>UVB</td> </tr> <tr> <td class=\"indent2\">Cinoxate</td> <td>UVB</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Salicylates</td> </tr> <tr> <td class=\"indent2\">Octisalate (octyl salicylate)</td> <td>UVB</td> </tr> <tr> <td class=\"indent2\">Homosalate</td> <td>UVB</td> </tr> <tr> <td class=\"indent2\">Trolamine salicylate</td> <td>UVB</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Benzophenones</td> </tr> <tr> <td class=\"indent2\">Oxybenzone (benzophenone-3)</td> <td>UVB, UVA2</td> </tr> <tr> <td class=\"indent2\">Sulisobenzone (benzophenone-4)</td> <td>UVB, UVA2</td> </tr> <tr> <td class=\"indent2\">Dioxybenzone (benzophenone-8)</td> <td>UVB, UVA2</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Others</td> </tr> <tr> <td class=\"indent2\">Octocrylene</td> <td>UVB</td> </tr> <tr> <td class=\"indent2\">Ensulizole (phenylbenzimidazole sulfonic acid)</td> <td>UVB</td> </tr> <tr> <td class=\"indent2\">Avobenzone (butyl methoxydibenzoyl methane, Parsol 1789)</td> <td>UVA1</td> </tr> <tr> <td class=\"indent2\">Ecamsule (terephthalylidene dicamphor sulfonic acid, Mexoryl SX)*</td> <td>UVB, UVA2</td> </tr> <tr> <td class=\"indent2\">Drometrizole trisiloxane (Mexoryl XL)<sup>&#182;</sup></td> <td>UVB, UVA2</td> </tr> <tr> <td class=\"indent2\">Meradimate (menthyl anthranilate)</td> <td>UVA2</td> </tr> <tr> <td class=\"indent2\">Bemotrizinol (bis-ethylhexyloxyphenol methoxyphenol triazine, Tinosorb S)<sup>&#182;</sup></td> <td>UVB, UVA2</td> </tr> <tr> <td class=\"indent2\">Bisoctrizole (methylene bis-benzotriazolyl tetramethylbutylphenol, Tinosorb M)<sup>&#182;</sup></td> <td>UVB, UVA2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Inorganic</td> </tr> <tr> <td class=\"indent1\">Titanium dioxide</td> <td>UVB, UVA2, UVA1</td> </tr> <tr> <td class=\"indent1\">Zinc oxide</td> <td>UVB, UVA2, UVA1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UVB: ultraviolet B; UVA: ultraviolet A.<br />* Available in the United States since 2006 in combination with avobenzone and octocrylene.<br />¶&nbsp;Available in Europe but not in the United States.</div><div class=\"graphic_reference\">Adapted with permission from: Sunscreens: An Update. The Medical Letter 2008; 50:70. Copyright &copy; 2008 The Medical Letter.</div><div id=\"graphicVersion\">Graphic 73127 Version 8.0</div></div></div>"},"73128":{"type":"graphic_diagnosticimage","displayName":"Congen pulm airways malform CXR II","title":"Congenital pulmonary airways malformation (Type I) in a newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital pulmonary airways malformation (Type I) in a newborn</div><div class=\"cntnt\"><img style=\"width:360px; height:347px;\" src=\"images/PULM/73128_Adenomatoid_malform_CXR_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After insertion of a left chest tube, liquid is drained out of a large left lung cyst, which doesn't collapse but fills with air.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 73128 Version 3.0</div></div></div>"},"73129":{"type":"graphic_figure","displayName":"Biphasic positive pressure","title":"Biphasic intermittent positive airway pressure ventilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biphasic intermittent positive airway pressure ventilation</div><div class=\"cntnt\"><img style=\"width:376px; height:293px;\" src=\"images/PULM/73129_Biphasic_positive_pressure.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Seymour, CW, Frazer M, Reilly, PM, Fuchs, BD. Airway pressure release and biphasic intermittent positive airway pressure ventilation: are they ready for prime time? J Trauma 2007; 62:1298.</div><div id=\"graphicVersion\">Graphic 73129 Version 1.0</div></div></div>"},"73131":{"type":"graphic_picture","displayName":"Angioedema lip and tongue PI","title":"Angioedema of the lips and tongue","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Angioedema of the lips and tongue</div><div class=\"cntnt\"><img style=\"width:584px; height:221px;\" src=\"images/PI/73131_Angioedema_lip_tongue_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angioedema <FONT color=black>causes swelling or&nbsp;puffiness, often in the face. These photos show angioedema</FONT> of the lips (A) and one side of the tongue (B).</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73131 Version 6.0</div></div></div>"},"73132":{"type":"graphic_picture","displayName":"Bacteroides fragilis in pleural fluid","title":"<em>Bacteroides fragilis</em> in pleural fluid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Bacteroides fragilis</em> in pleural fluid</div><div class=\"cntnt\"><img style=\"width:360px; height:316px;\" src=\"images/ID/73132_Bacteroidesfragilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of purulent pleural fluid (x1000) shows inflammatory cells and thin, hard-to-see gram-negative bacilli. The obligate anaerobe <EM>Bacteroides fragilis </EM>grew from this specimen.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 73132 Version 4.0</div></div></div>"},"73138":{"type":"graphic_diagnosticimage","displayName":"Elliptical lymph nodes on thyroid ultrasound","title":"Elliptical lymph nodes on thyroid ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elliptical lymph nodes on thyroid ultrasound</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/ENDO/73138_Elliptical_lymph_nodes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A longitudinal image of the left side of the neck that shows several thin, elliptical lymph nodes. One of them (+ --- +) is 1.25&nbsp;x 0.25 cm. A 14.0 MHz transducer was used to achieve high resolution.</div><div id=\"graphicVersion\">Graphic 73138 Version 4.0</div></div></div>"},"73139":{"type":"graphic_algorithm","displayName":"Approach to patients with PBC or PSC and features of AIH","title":"Approach to patients with PBC or PSC and features of AIH","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Approach to patients with PBC or PSC and features of AIH</div><div class=\"cntnt\"><img style=\"width:457px; height:498px;\" src=\"images/GAST/73139_Appr_patients_PBC_PSC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PBC: primary biliary cholangitis; PSC: primary sclerosing cholangitis; UDCA: ursodeoxycholic acid; AIH: autoimmune hepatitis; EASL: European Association for the Study of the Liver; ULN: upper limit of normal. <br />* Essentially based on the recommendations in the EASL guidelines.<br /><FONT class=bullet>•</FONT> There are no established definitions of the required degree of elevation of serum transaminases or IgG levels. ALT at least 5x, ULN and IgG at least 2x ULN, as previously suggested as criteria for AIH, may serve as guidelines.<br />Δ Immunosuppressive treatment is not evidence-based. It can be suggested that initial treatment is given according to guidelines for AIH.<br /><FONT class=lozenge>◊</FONT> The American Association for the Study of Liver Diseases guidelines recommend against UDCA in patients with PSC, whereas the EASL guidelines acknowledge that UDCA is widely used in PSC, although the long-term efficacy remains unproven.</div><div class=\"graphic_reference\">Reproduced from: Boberg KM, Chapman RW, Hirschfield GM. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54:374. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 73139 Version 4.0</div></div></div>"},"73140":{"type":"graphic_picture","displayName":"Abscess associated with hand infection","title":"Abscess associated with hand infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abscess associated with hand infection</div><div class=\"cntnt\"><img style=\"width:360px; height:540px;\" src=\"images/SURG/73140_Abscess_assoc_hand_infect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph demonstrates a dorsal subcutaneous abscess. Note that the abscess is pointing, meaning that the skin is starting to thin from the pressure of the fluid underneath, which indicates impending rupture of the abscess.</div><div id=\"graphicVersion\">Graphic 73140 Version 2.0</div></div></div>"},"73143":{"type":"graphic_figure","displayName":"Nephropathy and control","title":"Strict glycemic control prevents moderately increased albuminuria (formerly called microalbuminuria) in patients with type 1 diabetes mellitus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strict glycemic control prevents moderately increased albuminuria (formerly called microalbuminuria) in patients with type 1 diabetes mellitus</div><div class=\"cntnt\"><img style=\"width:382px; height:238px;\" src=\"images/ENDO/73143_Nephropathy_and_control.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative incidence of moderately increased albuminuria (formerly called microalbuminuria) in patients with type 1 diabetes treated with either conventional or intensive insulin therapy for up to nine years. There was an increasing benefit of intensive therapy over time (p&lt;0.04).</div><div class=\"graphic_reference\">Data from: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.</div><div id=\"graphicVersion\">Graphic 73143 Version 7.0</div></div></div>"},"73144":{"type":"graphic_picture","displayName":"Assisted knee flexion PI","title":"Assisted knee flexion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Assisted knee flexion</div><div class=\"cntnt\"><img style=\"width:432px; height:343px;\" src=\"images/PI/73144_Assisted_knee_flexion_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sit on the floor with the legs extended in front of the body. Place the hands behind the injured thigh, bend the knee and pull it towards the chest, keeping the back straight. Hold for 5 seconds then straighten leg. Repeat 10 to 15 times (one set). Perform a total of 3 sets.</div><div id=\"graphicVersion\">Graphic 73144 Version 2.0</div></div></div>"},"73146":{"type":"graphic_figure","displayName":"Excessive sebum in acne PI","title":"Excessive sebum production in acne","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Excessive sebum production in acne</div><div class=\"cntnt\"><img style=\"width:472px; height:330px;\" src=\"images/PI/73146_Excessive_sebum_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">How acne develops. Excessive sebum production.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright © 2008 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 73146 Version 5.0</div></div></div>"},"73147":{"type":"graphic_table","displayName":"BAL connective tissue disease","title":"Bronchoalveolar lavage cytology in connective tissue disease with and without associated interstitial lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bronchoalveolar lavage cytology in connective tissue disease with and without associated interstitial lung disease</div><div class=\"cntnt\"><table cellspacing=\"0\"> <tbody><tr><td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">With ILD</td> <td class=\"subtitle1\">Without ILD</td> </tr> <tr>\n<td>Progressive systemic sclerosis</td> <td>Neutrophils,\neosinophils</td> <td>Neutrophils, eosinophils</td> </tr>\n<tr> <td>Rheumatoid arthritis</td> <td>Neutrophils,\nlymphocytes</td> <td>Lymphocytes (CD4+, T5/9)</td> </tr>\n<tr> <td>Primary Sj&ouml;gren's syndrome</td> <td>Neutrophils,\nlymphocytes (CD8+)</td> <td>Lymphocytes (CD4+)</td> </tr>\n<tr> <td>Systemic lupus erythematosus</td> <td>Neutrophils,\nlymphocytes</td> <td>Lymphocytes</td> </tr> <tr>\n<td>Dermatopolymyositis</td> <td>Neutrophils</td>\n<td>Neutrophils</td> </tr> <tr> <td>Mixed\nconnective tissue disease </td> <td>Neutrophils</td>\n<td>Neutrophils</td> </tr> <tr> <td>Secondary\nSj&ouml;gren's syndrome</td> <td>Neutrophils,\nlymphocytes (CD8+)</td> <td>Neutrophils, lymphocytes (CD8+)</td>\n</tr> </tbody></table></div><div class=\"graphic_lgnd\">Presence of interstitial lung disease&nbsp;(ILD) is judged by clinical and radiographic findings.</div><div class=\"graphic_reference\">Redrawn from Wallaert B, Rossi GA, Sibille Y, Eur Respir J 1990; 3:942.</div><div id=\"graphicVersion\">Graphic 73147 Version 2.0</div></div></div>"},"73148":{"type":"graphic_figure","displayName":"Metabolic disorders and PCO2","title":"Effect of metabolic disorders on arterial PCO<sub>2</sub>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of metabolic disorders on arterial PCO<sub>2</sub></div><div class=\"cntnt\"><img style=\"width:448px; height:293px;\" src=\"images/PULM/73148_Metabolic_disorders_and_PCO.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between arterial plasma [HCO<sub>3</sub>] and PaCO<sub>2</sub> in six healthy subjects prior to (normal) and during 14 episodes of steady-state metabolic alkalosis and seven episodes of metabolic acidosis. The solid black line is the mean regression line, and the two thin lines show 95 percent confidence interval. The linear regression is: PaCO<sub>2</sub> = 0.7 [HCO<sub>3</sub>] + 20 &plusmn; 2 (SEM); L = 0.95.</div><div class=\"graphic_footnotes\">PaCO<sub>2</sub>: arterial carbon dioxide tension; HCO<sub>3</sub>: bicarbonate; SEM: standard error of the mean.</div><div class=\"graphic_reference\">Redrawn from: Javaheri S, Kazemi H. Am Rev Respir Dis 1987; 136:1011.</div><div id=\"graphicVersion\">Graphic 73148 Version 2.0</div></div></div>"},"73151":{"type":"graphic_table","displayName":"Differential diagnosis of pulmonary infiltrate","title":"Common radiographic appearances of pulmonary disorders in HIV patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common radiographic appearances of pulmonary disorders in HIV patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Chest radiograph or CT abnormality</td> <td class=\"subtitle1\">Etiology by rate of disease progression</td> <td class=\"subtitle1\">Etiology by rate of disease progression</td> </tr> <tr> <td class=\"subtitle2\">Acute &#60;24 hours*</td> <td class=\"subtitle2\">Chronic</td> </tr> <tr> <td>Consolidation</td> <td>Any organism (especially bacteria)</td> <td> <p>Fungi</p> <p><em>Nocardia </em>spp, <em>Actinomyces</em> spp</p> <p>Mycobacteria</p> <p>Bronchoalveolar cancer</p> <p>Bronchiolitis obliterans organizing pneumonia</p> </td> </tr> <tr> <td>Diffuse interstitial infiltrate</td> <td> <p><em>Pneumocystis jirovecii</em></p> <p>Bacteria (especially <em>Haemophilus influenzae</em>)</p> <p>Virus (Influenza, CMV)</p> <p>Pulmonary edema</p> <p>Acute respiratory distress syndrome</p> </td> <td> <p>Mycobacteria</p> <p>Drug toxicity</p> <p>Lymphocytic interstitial pneumonia</p> <p>Metastatic disease</p> <p>Pulmonary alveolar proteinosis</p> </td> </tr> <tr> <td>Nodular infiltrate</td> <td> <p>Bacteria</p> <p>&nbsp;</p> </td> <td> <p><em>Nocardia</em> spp, <em>Actinomyces </em>spp</p> <p>Fungi</p> <p>Kaposi's sarcoma</p> <p>Other tumors (especially lung cancer)</p> <p>Castleman's Disease</p> </td> </tr> <tr> <td>Adenopathy</td> <td>&nbsp;</td> <td> <p>Lymphoma</p> <p>Kaposi's sarcoma</p> <p>Castleman's Disease</p> <p>Lung cancer</p> <p>Tuberculosis</p> </td> </tr> <tr> <td>Pleural effusion</td> <td> <p>Bacteria (parapneumonic)</p> <p>Tuberculosis</p> <p>Empyema</p> </td> <td> <p>Lymphoma (especially non-Hodgkin's lymphoma and primary effusion lymphoma)</p> <p>Kaposi's sarcoma</p> </td> </tr> <tr> <td>Pneumothorax</td> <td><em>P. jirovecii</em></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; CMV: cytomegalovirus.<br />* Some infections that are typically chronic may appear acutely with immune recovery/reconstitution.</div><div id=\"graphicVersion\">Graphic 73151 Version 4.0</div></div></div>"},"73154":{"type":"graphic_table","displayName":"Vulnerable elders surv 13 scale","title":"The Vulnerable Elders Survey (VES) 13 scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Vulnerable Elders Survey (VES) 13 scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Domain </td> <td class=\"subtitle1\">Score </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Age </td> </tr> <tr> <td class=\"indent1\">75-85 </td> <td>1</td> </tr> <tr> <td class=\"indent1\">&#62;85 </td> <td>3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Self-rated health </td> </tr> <tr> <td class=\"indent1\">Good, very good, and excellent </td> <td>0</td> </tr> <tr> <td class=\"indent1\">Fair and poor </td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Activities of daily living (ADLs)/instrumental ADLs (IADLs) </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Needs assistance with </td> </tr> <tr> <td class=\"indent2\">Bathing or showering </td> <td>1</td> </tr> <tr> <td class=\"indent2\">Shopping </td> <td>1</td> </tr> <tr> <td class=\"indent2\">Money management </td> <td>1</td> </tr> <tr> <td class=\"indent2\">Transfer </td> <td>1</td> </tr> <tr> <td class=\"indent2\">Light housework </td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Difficulty in special activities </td> </tr> <tr> <td class=\"indent1\">Kneeling, bending, and stooping </td> <td>1</td> </tr> <tr> <td class=\"indent1\">Performance of housework (example: scrubbing the floor) </td> <td>1</td> </tr> <tr> <td class=\"indent1\">Reaching out and lifting upper extremities above the shoulder </td> <td>1</td> </tr> <tr> <td class=\"indent1\">Lifting and carrying 10 pounds </td> <td>1</td> </tr> <tr> <td class=\"indent1\">Walking 0.25 miles</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Writing or handling and grasping small objects </td> <td>1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Score ≥3: Vulnerable elderly</div><div class=\"graphic_reference\">Data from: Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001; 49:1691.</div><div id=\"graphicVersion\">Graphic 73154 Version 3.0</div></div></div>"},"73155":{"type":"graphic_diagnosticimage","displayName":"M mode dilated cardiomyopathy","title":"Dilated cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dilated cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:400px; height:283px;\" src=\"images/CARD/73155_M_mode_dilated_cardiomyopat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">M-mode scan of the heart is obtained by moving the transducer from a cephalad to caudal direction, recording the aortic root, mitral valve and mitral valve annulus, and the left ventricular chamber. In this patient with a severe dilated cardiomyopathy, there is significant enlargement of the left atrium and left ventricle. In addition, the septum and posterior left ventricular wall are thinned and hypokinetic.</div><div id=\"graphicVersion\">Graphic 73155 Version 3.0</div></div></div>"},"73156":{"type":"graphic_figure","displayName":"Obesity all-cause mortality","title":"All-cause mortality versus BMI for each sex in the range 15 to 50 kg/m<sup>2</sup> (excluding the first five years of follow-up)","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">All-cause mortality versus BMI for each sex in the range 15 to 50 kg/m<sup>2</sup> (excluding the first five years of follow-up)</div><div class=\"cntnt\"><img style=\"width:580px; height:697px;\" src=\"images/ENDO/73156_Obesity_all-cause_mortality.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relative risks at age 35 to 89 years, adjusted for age at risk, smoking, and study, were multiplied by a common factor (ie, floated) to make the weighted average match the PSC mortality rate at ages 35 to 79 years. Floated mortality rates shown above each square and numbers of deaths below. Area of square is inversely proportional to the variance of the log risk. Boundaries of BMI groups are indicated by tick marks. 95% CIs for floated rates reflect uncertainty in the log risk for each single rate. Dotted vertical line indicates 25 kg/m<SUP>2</SUP> (boundary between upper and lower BMI ranges in this report). Above 25 kg/m<SUP>2</SUP>, mortality was, on average, approximately 30 percent higher for every 5 kg/m<SUP>2</SUP> higher BMI.</div><div class=\"graphic_footnotes\">BMI: body mass index; PSC: Prospective Studies Collaboration.</div><div class=\"graphic_reference\">Reproduced with permission from: Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373:1083. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 73156 Version 5.0</div></div></div>"},"73157":{"type":"graphic_table","displayName":"Secondary hyperpara","title":"Causes of secondary hyperparathyroidism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of secondary hyperparathyroidism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Renal failure</td> </tr> <tr> <td class=\"sublist1\">Impaired calcitriol production</td> </tr> <tr> <td class=\"sublist1\">Hyperphosphatemia</td> </tr> <tr> <td class=\"sublist1\">Hypocalcemia</td> </tr> <tr> <td>Decreased calcium intake</td> </tr> <tr> <td class=\"sublist1_start\">Calcium malabsorption</td> </tr> <tr> <td class=\"sublist1\">Vitamin D deficiency</td> </tr> <tr> <td class=\"sublist1\">Bariatric surgery</td> </tr> <tr> <td class=\"sublist1\">Celiac disease</td> </tr> <tr> <td class=\"sublist1\">Pancreatic disease (fat malabsorption)</td> </tr> <tr> <td class=\"sublist1_start\">Renal calcium loss</td> </tr> <tr> <td class=\"sublist1\">Idiopathic hypercalciuria</td> </tr> <tr> <td class=\"sublist1\">Loop diuretics</td> </tr> <tr> <td class=\"sublist1_start\">Inhibition of bone resorption</td> </tr> <tr> <td class=\"sublist1\">Bisphosphonates</td> </tr> <tr> <td class=\"sublist1\">Denosumab</td> </tr> <tr> <td class=\"sublist1\">Hungry bone syndrome</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Prince RL. Secondary and tertiary hyperparathyroidism. In: Primer on the metabolic bone diseases and disorders of mineral metabolism,&nbsp;6th, Favus MJ (Ed), ASBMR, 2006. p. 191.</div><div id=\"graphicVersion\">Graphic 73157 Version 4.0</div></div></div>"},"73158":{"type":"graphic_picture","displayName":"Gastric well-differentiated neuroendocrine tumor Endosc","title":"Type 1 gastric neuroendocrine tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Type&nbsp;1 gastric neuroendocrine tumor</div><div class=\"cntnt\"><img style=\"width:389px; height:313px;\" src=\"images/GAST/73158_GastriccarcinoidsEndosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic picture of the gastric corpus in a patient with pernicious anemia demonstrates multiple polypoid masses that were shown to be well-differentiated neuroendocrine tumors (type 1).</div><div class=\"graphic_reference\">From Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of Tumor Pathology (electronic fascicle), Third series, Fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 73158 Version 4.0</div></div></div>"},"73159":{"type":"graphic_algorithm","displayName":"Algorithm VT versus SVT (Brugada algorithm)","title":"Brugada algorithm for the diagnosis of ventricular tachycardia or supraventricular tachycardia in a patient with wide QRS complex tachycardia","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Brugada algorithm for the diagnosis of ventricular tachycardia or supraventricular tachycardia in a patient with wide QRS complex tachycardia</div><div class=\"cntnt\"><img style=\"width:493px; height:447px;\" src=\"images/CARD/73159_AlgorithmIVTversusSVT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brugada algorithm for distinguishing VT from SVT.</div><div class=\"graphic_footnotes\">VT: ventricular tachycardia; SVT: supraventricular tachycardia.</div><div class=\"graphic_reference\">Adapted from: Brugada P, Brugada J, Mont L, et al. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation 1991; 83:1649.</div><div id=\"graphicVersion\">Graphic 73159 Version 4.0</div></div></div>"},"73160":{"type":"graphic_picture","displayName":"Proplatelet processes EM","title":"Megakaryocyte proplatelet processes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Megakaryocyte proplatelet processes</div><div class=\"cntnt\"><img style=\"width:368px; height:252px;\" src=\"images/HEME/73160_Proplatelet_processes_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scanning electron micrograph (x3000) shows the luminal view of the confluence of two bone marrow sinusoids with two proplatelet processes protruding through the lining endothelial cells. One of the processes has intermittent constrictions (arrows), indicating potential sites for platelet formation. Other cells depicted include lymphocytes and erythrocytes.</div><div class=\"graphic_reference\">Reproduced with permission from: Becker, RP, Bruyn, PPH. The transmural passage of blood cells into myeloid sinusoids and the entry of platelets into the sinusoidal circulation; A scanning electron microscopic investigation. Am J Anat 1975; 145:183. Copyright &#169; 1975 John Wiley &amp;Sons, Inc.</div><div id=\"graphicVersion\">Graphic 73160 Version 1.0</div></div></div>"},"73161":{"type":"graphic_picture","displayName":"Healing fifth metacarpal neck fracture ","title":"Healing fifth metacarpal neck fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Healing fifth metacarpal neck fracture</div><div class=\"cntnt\"><img style=\"width:352px; height:262px;\" src=\"images/RHEUM/73161_Metacarpal_neck_fx_healing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior view shows a healing fifth metacarpal neck fracture. Callous formation can be see along the radial side of the distal metacarpal (arrow).</div><div class=\"graphic_reference\">Courtesy of Kevin Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 73161 Version 2.0</div></div></div>"},"73162":{"type":"graphic_picture","displayName":"Open dislocation fifth PIP finger with tuft fracture","title":"Open dislocation of the proximal interphalangeal joint of the fifth finger with a tuft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Open dislocation of the proximal interphalangeal joint of the fifth finger with a tuft fracture</div><div class=\"cntnt\"><img style=\"width:404px; height:590px;\" src=\"images/EM/73162_Open_disloc_fifth_PIP_fing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A 15-year-old male sustained on open dislocation of the proximal interphalangeal joint of the fifth finger while attempting to catch a football.<br> (B) X-ray confirmed suspected open dislocation of proximal interphalangeal (PIP) joint. A tuft fracture was noted at the distal end of the proximal phalanx.<br> (C) Post-reduction film confirmed normal alignment of the PIP joint.</div><div class=\"graphic_reference\">Courtesy of Samir Joshi, MD.</div><div id=\"graphicVersion\">Graphic 73162 Version 1.0</div></div></div>"},"73164":{"type":"graphic_form","displayName":"Hamilton Rating Scale - page 3","title":"Hamilton Rating Scale for Depression, page 3","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Hamilton Rating Scale for Depression, page 3</div><div class=\"cntnt\"><img style=\"width:588px; height:760px;\" src=\"images/PSYCH/73164_Hamilton_p3.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Hamilton, M. A rating scale for depression. J Neurosurg Psychiatry 1960; 23:56.</div><div id=\"graphicVersion\">Graphic 73164 Version 2.0</div></div></div>"},"73165":{"type":"graphic_figure","displayName":"Obstructive defect on spirometry in a nine-year-old child","title":"Obstructive defect on spirometry in a nine-year-old child","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Obstructive defect on spirometry in a nine-year-old child</div><div class=\"cntnt\"><img style=\"width:495px; height:597px;\" src=\"images/ALLRG/73165_Obstr_defect_spiromet_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the reduced FEV<sub>1</sub>/FVC and FEV<sub>1</sub> (red boxes) and the scooped curve shape of the green expiratory flow loop (red arrow, above x-axis), consistent with an obstructive defect. The airflow obstruction is reversible.<br />After treatment with a bronchodilator, there is significant improvement (&gt;10%) in FEV<sub>1</sub> and the FEV<sub>1</sub>/FVC ratio also increases (orange boxes). The expiratory flow volume loop (above x-axis) shown in blue is now nearly normal.</div><div class=\"graphic_footnotes\">R<sub>x</sub>: treatment (with bronchodilator); FEV<sub>1</sub>: forced expiratory volume in the first second; FVC: forced vital capacity; % Pred: percent predicted.<br />* Prebronchodilator.<br />&para; Postbronchodilator.</div><div id=\"graphicVersion\">Graphic 73165 Version 5.0</div></div></div>"},"73166":{"type":"graphic_picture","displayName":"Anterior rhinoscopy","title":"Anterior rhinoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior rhinoscopy</div><div class=\"cntnt\"><img style=\"width:396px; height:347px;\" src=\"images/PC/73166_Anterior_rhinoscopy_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal nasal examination by anterior rhinoscopy.</div><div id=\"graphicVersion\">Graphic 73166 Version 1.0</div></div></div>"},"73168":{"type":"graphic_table","displayName":"WHO nervous system tumors","title":"WHO classification of tumors of the nervous system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO classification of tumors of the nervous system</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Tumors of neuroepithelial tissue</td> </tr> <tr> <td class=\"subtitle2_single\">Astrocytic tumors</td> </tr> <tr> <td class=\"indent1\">Pilocytic astrocytoma</td> </tr> <tr> <td class=\"indent1\">Subependymal giant cell astrocytoma</td> </tr> <tr> <td class=\"indent1\">Pleomorphic xanthoastrocytoma</td> </tr> <tr> <td class=\"indent1\">Diffuse astrocytoma</td> </tr> <tr> <td class=\"indent1\">Anaplastic astrocytoma</td> </tr> <tr> <td class=\"indent1\">Glioblastoma</td> </tr> <tr> <td class=\"indent1\">Gliomatosis cerebri</td> </tr> <tr> <td class=\"subtitle2_single\">Oligodendroglial tumors</td> </tr> <tr> <td class=\"indent1\">Oligodendroglioma</td> </tr> <tr> <td class=\"indent1\">Anaplastic oligodendroglioma</td> </tr> <tr> <td class=\"subtitle2_single\">Oligoastrocytic tumors</td> </tr> <tr> <td class=\"indent1\">Oligoastrocytoma</td> </tr> <tr> <td class=\"indent1\">Anaplastic oligoastrocytoma</td> </tr> <tr> <td class=\"subtitle2_single\">Ependymal tumors</td> </tr> <tr> <td class=\"indent1\">Subependymoma</td> </tr> <tr> <td class=\"indent1\">Myxopapillary ependymoma</td> </tr> <tr> <td class=\"indent1\">Ependymoma</td> </tr> <tr> <td class=\"indent1\">Anaplastic ependymoma</td> </tr> <tr> <td class=\"subtitle2_single\">Choroid plexus tumors</td> </tr> <tr> <td class=\"indent1\">Choroid plexus papilloma</td> </tr> <tr> <td class=\"indent1\">Atypical choroid plexus papilloma</td> </tr> <tr> <td class=\"indent1\">Choroid plexus carcinoma</td> </tr> <tr> <td class=\"subtitle2_single\">Other neuroepithelial tumors</td> </tr> <tr> <td class=\"indent1\">Astroblastoma</td> </tr> <tr> <td class=\"indent1\">Chordoid glioma of the third ventricle</td> </tr> <tr> <td class=\"indent1\">Angiocentric glioma</td> </tr> <tr> <td class=\"subtitle2_single\">Neuronal and mixed neuronal-glial tumors</td> </tr> <tr> <td class=\"indent1\">Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)</td> </tr> <tr> <td class=\"indent1\">Desmoplastic infantile astrocytoma/ganglioglioma</td> </tr> <tr> <td class=\"indent1\">Dysembryoplastic neuroepithelial tumor</td> </tr> <tr> <td class=\"indent1\">Gangliocytoma</td> </tr> <tr> <td class=\"indent1\">Ganglioglioma</td> </tr> <tr> <td class=\"indent1\">Anaplastic ganglioglioma</td> </tr> <tr> <td class=\"indent1\">Central neurocytoma</td> </tr> <tr> <td class=\"indent1\">Extraventricular neurocytoma</td> </tr> <tr> <td class=\"indent1\">Cerebellar liponeurocytoma</td> </tr> <tr> <td class=\"indent1\">Papillary glioneuronal tumor</td> </tr> <tr> <td class=\"indent1\">Rosette-forming glioneuronal tumor of the fourth ventricle</td> </tr> <tr> <td class=\"indent1\">Paraganglioma</td> </tr> <tr> <td class=\"subtitle2_single\">Tumors of the pineal region</td> </tr> <tr> <td class=\"indent1\">Pineocytoma</td> </tr> <tr> <td class=\"indent1\">Pineal parenchymal tumor of intermediate differentiation</td> </tr> <tr> <td class=\"indent1\">Pineoblastoma</td> </tr> <tr> <td class=\"indent1\">Papillary tumor of the pineal region</td> </tr> <tr> <td class=\"subtitle2_single\">Embryonal tumors</td> </tr> <tr> <td class=\"indent1\">Medulloblastoma</td> </tr> <tr> <td class=\"indent1\">CNS primitive neuroectodermal tumor (PNET)</td> </tr> <tr> <td class=\"indent1\">Atypical teratoid/rhabdoid tumor</td> </tr> <tr> <td class=\"subtitle1_single\">Tumors of cranial and paraspinal nerves</td> </tr> <tr> <td>Schwannoma (neurilemoma, neurinoma)</td> </tr> <tr> <td>Neurofibroma</td> </tr> <tr> <td>Perineurioma</td> </tr> <tr> <td>Malignant peripheral nerve sheath tumor</td> </tr> <tr> <td class=\"subtitle1_single\">Tumors of the meninges</td> </tr> <tr> <td class=\"subtitle2_single\">Tumors of meningothelial cells</td> </tr> <tr> <td class=\"indent1\">Meningioma</td> </tr> <tr> <td class=\"subtitle2_single\">Mesenchymal tumors</td> </tr> <tr> <td class=\"indent1\"><em>Adipose tissue:</em> Lipoma, angiolipoma, hibernoma, liposarcoma</td> </tr> <tr> <td class=\"indent1\"><em>Fibrous tissue:</em> Solitary fibrous tumor, fibrosarcoma, malignant fibrous histiocytoma</td> </tr> <tr> <td class=\"indent1\"><em>Smooth muscle:</em> Leiomyoma, leiomyosarcoma</td> </tr> <tr> <td class=\"indent1\"><em>Skeletal muscle:</em> Rhabdomyoma, rhabdomyosarcoma</td> </tr> <tr> <td class=\"indent1\"><em>Cartilage:</em> Chondroma, chondrosarcoma</td> </tr> <tr> <td class=\"indent1\"><em>Bone:</em> Osteoma, osteosarcoma, osteochondroma</td> </tr> <tr> <td class=\"indent1\"><em>Vasculature:</em> Hemangioma, epithelioid haemangioendothelioma, hemangiopericytoma, anaplastic hemangiopericytoma, angiosarcoma, Kaposi sarcoma</td> </tr> <tr> <td class=\"indent1\">Ewing sarcoma - PNET</td> </tr> <tr> <td class=\"subtitle2_single\">Primary melanocytic lesions</td> </tr> <tr> <td class=\"indent1\">Diffuse melanocytosis</td> </tr> <tr> <td class=\"indent1\">Melanocytoma</td> </tr> <tr> <td class=\"indent1\">Malignant melanoma, meningeal melanomatosis</td> </tr> <tr> <td class=\"subtitle2_single\">Other neoplasms related to the meninges</td> </tr> <tr> <td class=\"indent1\">Hemangioblastoma</td> </tr> <tr> <td class=\"subtitle1_single\">Lymphomas and hematopoietic neoplasms</td> </tr> <tr> <td>Malignant lymphomas</td> </tr> <tr> <td>Plasmacytoma</td> </tr> <tr> <td>Granulocytic sarcoma</td> </tr> <tr> <td class=\"subtitle1_single\">Germ cell tumors</td> </tr> <tr> <td>Germinoma</td> </tr> <tr> <td>Embryonal carcinoma</td> </tr> <tr> <td>Yolk sac tumor</td> </tr> <tr> <td>Choriocarcinoma</td> </tr> <tr> <td>Teratoma</td> </tr> <tr> <td>Mixed germ cell tumor</td> </tr> <tr> <td class=\"subtitle1_single\">Tumors of the sellar region</td> </tr> <tr> <td>Craniopharyngioma</td> </tr> <tr> <td>Granular cell tumor</td> </tr> <tr> <td>Pituicytoma</td> </tr> <tr> <td>Spindle cell oncocytoma of the adenohypophysis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Nervous System. IARC Press, Lyon 2007. Copyright &copy; 2007 IARC Press.</div><div id=\"graphicVersion\">Graphic 73168 Version 13.0</div></div></div>"},"73169":{"type":"graphic_figure","displayName":"LV pressure volume loop","title":"Left ventricular pressure versus volume relationship","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular pressure versus volume relationship</div><div class=\"cntnt\"><img style=\"width:202px; height:160px;\" src=\"images/CARD/73169_LV_pressure_volume_loop.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normally contracting left ventricle ejects blood under pressure and the relationship between left ventricular pressure generation and ejection can be expressed in a plot of developed pressure versus volume. In the idealized pressure-volume loop, the left ventricular end-diastolic pressure is represented by point A. Isovolumic contraction at the beginning of systole is represented by line AB. As the developed left ventricular pressure exceeds that of the aorta, the aortic valve opens at point B. This leads to left ventricular ejection of blood (line BC). The volume of blood ejected (point B minus point C) represents the forward effective stroke volume of this contraction. At end-ejection, the aortic valve closes at point C followed by isovolumic relaxation (line CD). The mitral valve then opens at point D with left ventricular diastolic filling represented by line DA. The shaded area enclosed by the PV loop (ABCD) represents the external left ventricular stroke work, which can be represented mathematically as &#8747;PdV.</div><div id=\"graphicVersion\">Graphic 73169 Version 1.0</div></div></div>"},"73171":{"type":"graphic_figure","displayName":"Motor nerve conduction study","title":"Motor nerve conduction study","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Motor nerve conduction study</div><div class=\"cntnt\"><img style=\"width:477px; height:542px;\" src=\"images/NEURO/73171_Motor_nerve_conduction_study.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stimulation at different proximal sites along the ulnar nerve while recording from the abductor digiti minimi muscle allows the conduction velocity (CV) of the motor neurons to be calculated.</div><div class=\"graphic_reference\">Courtesy of Shahram Khoshbin, MD.</div><div id=\"graphicVersion\">Graphic 73171 Version 4.0</div></div></div>"},"73172":{"type":"graphic_figure","displayName":"Lumpectomy mastectomy PI","title":"Lumpectomy and mastectomy to treat breast cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lumpectomy and mastectomy to treat breast cancer</div><div class=\"cntnt\"><img style=\"width:448px; height:615px;\" src=\"images/PI/73172_Lumpectomy_mast_PI_edit2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Women who have a mastectomy have the whole affected breast removed. Women who have a lumpectomy have the tumor and a small part of the surrounding healthy tissue removed. In most cases, women who have a lumpectomy must also have radiation therapy after their surgery. Women who have a mastectomy can usually decide if and when to have their breast reconstructed. The type of reconstruction shown here is just one way surgeons can reconstruct a breast.</div><div id=\"graphicVersion\">Graphic 73172 Version 8.0</div></div></div>"},"73173":{"type":"graphic_picture","displayName":"En coup de sabre - two examples","title":"Two examples of en coup de sabre","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two examples of en coup de sabre</div><div class=\"cntnt\"><img style=\"width:290px; height:334px;\" src=\"images/DERM/73173_En_coup_de_sabre_two_ex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depressed linear plaques are present on the foreheads of these patients.</div><div id=\"graphicVersion\">Graphic 73173 Version 2.0</div></div></div>"},"73174":{"type":"graphic_picture","displayName":"Riedels thyroiditis Light","title":"Riedel's thyroiditis: Microscopic section of thyroid parenchyma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Riedel's thyroiditis: Microscopic section of thyroid parenchyma</div><div class=\"cntnt\"><img style=\"width:378px; height:258px;\" src=\"images/ENDO/73174_Riedels_thyroiditis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic section (hematoxylin and eosin, magnification x 100) of the thyroid gland from a patient with Riedel's thyroiditis demonstrates replacement of the thyroid parenchyma by dense collagenous fibrous tissue mixed with lymphocytes, plasma cells, and eosinophilis.</div><div class=\"graphic_reference\">Courtesy of Stephanie L Lee, MD, PhD.</div><div id=\"graphicVersion\">Graphic 73174 Version 2.0</div></div></div>"},"73175":{"type":"graphic_table","displayName":"Food intolerances IBD","title":"Foods and beverages that may worsen gastrointestinal symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Foods and beverages that may worsen gastrointestinal symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Milk, milk-containing products, and lactose-free milk products, including ice cream, cream cheese, cheese, cottage cheese, yogurt, pudding, whipped cream, cream, cheesecake, chocolate, pastries, crackers, pretzels, cookies, crackers, cakes, and pies</td> </tr> <tr> <td>Caffeine-containing products, including coffee, tea, and sodas</td> </tr> <tr> <td>Alcohol products</td> </tr> <tr> <td>Fruits and fruit juices</td> </tr> <tr> <td>Spices, seasonings, and spicy marinades</td> </tr> <tr> <td>Diet beverages, diet foods, diet candies, diet gum, sugar-free products</td> </tr> <tr> <td>Fried foods, fatty foods, fast foods, and Chinese food</td> </tr> <tr> <td>Condiments including ketchup, mustard, mayonnaise, and relish</td> </tr> <tr> <td>Wholegrain or multigrain breads; sourdough breads, bagels, and yeast-containing products</td> </tr> <tr> <td>Salads, particularly added components including bacon bits, croutons, onions, and peppers</td> </tr> <tr> <td>Salad dressings that contain mayonnaise, cheese, and spices</td> </tr> <tr> <td>Vegetables including cabbage, broccoli, and cauliflower</td> </tr> <tr> <td>Legumes: beans, lentils, chili</td> </tr> <tr> <td>Red meats including steak, hamburger, sausage, bacon, and prime rib</td> </tr> <tr> <td>Gravies, spaghetti sauce, soups, stews, and stuffing</td> </tr> <tr> <td>Popcorn, peanuts, corn</td> </tr> <tr> <td>Artificial colorings, flavorings, and sweeteners</td> </tr> <tr> <td>Foods and beverages containing sorbitol, fructose, or high fructose corn syrup</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The foods and drinks listed above may worsen gastrointestinal symptoms (diarrhea, cramps, abdominal pain, nausea, gas, bloating, heartburn, etc) in some patients with both irritable bowel syndrome and inflammatory bowel disease. These symptoms can begin as soon as 5 to 15 minutes after eating or as many as 12 to 48 hours later.</div><div class=\"graphic_reference\">Data from: MacDermott RP. Treatment of irritable bowel syndrome in outpatients with inflammatory bowel disease using a food and beverage intolerance, food and beverage avoidance diet. Inflamm Bowel Dis 2007; 13:91.</div><div id=\"graphicVersion\">Graphic 73175 Version 2.0</div></div></div>"},"73177":{"type":"graphic_picture","displayName":"Dysgerminoma","title":"Dysgerminoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dysgerminoma</div><div class=\"cntnt\"><img style=\"width:383px; height:267px;\" src=\"images/OBGYN/73177_Dysgerminoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross specimen of an ovarian dysgerminoma.</div><div class=\"graphic_reference\">Reproduced with permssion from Berek JS, Hacker NF. Practical Gynecologic Oncology, 3rd ed. Lippincott Williams &amp;Wilkins, Philadelphia, 2000, p. 225.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 73177 Version 2.0</div></div></div>"},"73178":{"type":"graphic_picture","displayName":"Amplatzer ductal occluder device","title":"Amplatzer ductal occluder device","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amplatzer ductal occluder device</div><div class=\"cntnt\"><img style=\"width:327px; height:308px;\" src=\"images/CARD/73178_Amplatzerductaloccluder.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Kevin Hill, MD.</div><div id=\"graphicVersion\">Graphic 73178 Version 4.0</div></div></div>"},"73179":{"type":"graphic_movie","displayName":"Pericardial effusion subcostal echocardiogram","title":"Pericardial effusion","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericardial effusion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/73179_subperefconv.mp4\" style=\"width:360px;height:272px\"></div><img style=\"width:259px; height:220px;\" src=\"images/CARD/73179_subperef.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcostal view from a 2-D echocardiogram shows a large serofibrinous pericardial effusion. Echos are seen within the effusion, suggesting the presence of fibrous stands.</div><div class=\"graphic_reference\">Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.</div><div id=\"graphicVersion\">Graphic 73179 Version 2.0</div></div></div>"},"73182":{"type":"graphic_table","displayName":"Xenografts","title":"Xenografts","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Xenografts</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Source animal</td> <td class=\"subtitle1\">Tissue type</td> <td class=\"subtitle1\">Product</td> <td class=\"subtitle1\">Manufacturer</td> <td class=\"subtitle1\">Crosslinking</td> <td class=\"subtitle1\">Sterilization</td> <td class=\"subtitle1\">Host response</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Porcine</td> <td>Dermis</td> <td>DermMatrix</td> <td>Brennan Medical</td> <td>No</td> <td>Irradiation</td> <td>Replacement*</td> </tr> <tr> <td>Dermis</td> <td>Fortiva&nbsp;</td> <td>RTI Surgical</td> <td>No</td> <td>Irradiation</td> <td>Replacement</td> </tr> <tr> <td>Small intestine submucosa</td> <td>Biodesign</td> <td>Cook</td> <td>No</td> <td>Ethylene oxide</td> <td>Replacement</td> </tr> <tr> <td>Small intestine submucosa</td> <td>Fortagen</td> <td>Organogenesis</td> <td>EDC</td> <td>Not available</td> <td>Mixed<sup>&#182;</sup></td> </tr> <tr> <td>Dermis</td> <td>Strattice</td> <td>LifeCell</td> <td>No</td> <td>Irradiation<sup>&#916;</sup></td> <td>Replacement<sup>*</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Bladder</td> <td>Matristem</td> <td>ACell</td> <td>No</td> <td>Irradiation</td> <td>Replacement</td> </tr> <tr> <td rowspan=\"4\">Bovine</td> <td>Dermis</td> <td>Xenform</td> <td>Boston Scientific</td> <td>No</td> <td>Ethylene oxide</td> <td>Replacement*</td> </tr> <tr> <td>Pericardium</td> <td>Peri-Guard</td> <td>Synovis</td> <td>GLUT</td> <td>Propylene oxide</td> <td>Encapsulation*</td> </tr> <tr> <td>Pericardium</td> <td>Veritas</td> <td>Baxter</td> <td>No</td> <td>Irradiation<sup>&#916;</sup></td> <td>Replacement*</td> </tr> <tr> <td>Pericardium</td> <td>UroPatch</td> <td>YAMA</td> <td>GLUT</td> <td>Not available</td> <td>Encapsulation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EDC: 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide hydrochloride; GLUT: glutaraldehyde.<br />* Unpublished company communication.<br />¶ Hypothesized based on chemical crosslinking and manufacturer's recommendation of preimplantation perforations, but no histologic studies available to confirm in vivo response.<br />Δ Gamma external beam radiation.</div><div id=\"graphicVersion\">Graphic 73182 Version 5.0</div></div></div>"},"73183":{"type":"graphic_table","displayName":"Energy conservation methods","title":"Ways to conserve energy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ways to conserve energy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Planning and organizing</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Alternate tasks that take lots of energy with those that take less.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Plan activities daily as well as weekly to better alternate tasks.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Delegate as much as possible. It helps you get tasks done and it makes those who want to help feel useful.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Eliminate steps or tasks that are not essential by combining chores or errands.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Arrange your household so that most activities can be done on one floor.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Organize ahead of time so you don't have to rush.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Pacing</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Balance activities so you alternate resting and doing.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stop to rest before you get tired even if it means stopping in the middle of a task.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Try to avoid spurts of activity; this can drain energy.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pace activities on good days as well as bad days.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Develop a routine to prevent overdoing.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Positioning</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sit to do things whenever possible.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use\nassistive devices: walkers, scooters, canes, handrails, crutches, grab\nbars. Assistive devices and adaptive equipment can save energy by\nallowing you to do things without having to bend or reach.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Avoid heavy lifting (such as children, pots and pans, and laundry).</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use carts or wagons to move things from room to room and place to place.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Wear a fanny pack, carpenter's belt, or jacket or sweater with pockets to carry things.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Prioritizing</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Focus on things you enjoy doing.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Be realistic with yourself.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">When you're too tired to eat</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">When just the thought of cooking or eating a meal makes you tired, try these hints to save energy:</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Let others help prepare or bring food. Family or friends usually like to help!</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Shop at less busy times.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Meal preparation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Assemble all ingredients before starting.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use mixes or pre-packaged foods.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use cookware you can serve from.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Use small, lightweight appliances and labor saving devices.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Buy utensils that fit comfortably in the hand.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Store frequently used items at chest level to minimize bending and reaching.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Line ovens and drip pans with foil for easier cleanup.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Let dishes air dry or use a dishwasher.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Childcare</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Plan activities or outings at a place that will allow you to sit or lie down.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Take advantage of daycare programs.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Teach children to make a game out of household chores.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Work</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Plan work around your best times of the day.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Organize work centers so that equipment is within easy reach.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Create short cuts.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Take rest breaks.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Work part time if possible.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Leisure</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Plan activities that allow you to sit or lie down.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Plan social events at peak energy times.</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 73183 Version 1.0</div></div></div>"},"73184":{"type":"graphic_diagnosticimage","displayName":"Post fossa ependymoma MRI T2","title":"Posterior fossa ependymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior fossa ependymoma</div><div class=\"cntnt\"><img style=\"width:317px; height:319px;\" src=\"images/ONC/73184_Post_fossa_ependymoma_MRI_T.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A T2 image demonstrating the ependymoma in the posterior fossa.</div><div class=\"graphic_reference\">Courtesy of Mark Kieran, MD.</div><div id=\"graphicVersion\">Graphic 73184 Version 4.0</div></div></div>"},"73185":{"type":"graphic_picture","displayName":"Contact dermatitis impetiginized","title":"Allergic contact dermatitis with secondary bacterial infection","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis with secondary bacterial infection</div><div class=\"cntnt\"><img style=\"width:540px; height:359px;\" src=\"images/DERM/73185_Contact_derm_impetig_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Impetigized allergic contact dermatitis in a 58-year-old man: pustules and honey-colored crusts cover an erythematous and edematous skin.</div><div class=\"graphic_reference\">Reproduced with permisison from: the Dermatology Online Atlas, <a href=\"http://www.dermis.net/\" target=\"_blank\">www.dermis.net</a>. Copyright &#169; 2011. All rights reserved.</div><div id=\"graphicVersion\">Graphic 73185 Version 1.0</div></div></div>"},"73187":{"type":"graphic_picture","displayName":"Neuroblastoma in marrow","title":"Neuroblastoma cells within the bone marrow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neuroblastoma cells within the bone marrow</div><div class=\"cntnt\"><img style=\"width:433px; height:288px;\" src=\"images/HEME/73187_Neuroblastoma_in_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with metastatic neuroblastoma shows a clump of cells forming a rosette. Note the indistinct borders between cells in this clump of tumor cells.</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD and William C Moloney, MD.</div><div id=\"graphicVersion\">Graphic 73187 Version 2.0</div></div></div>"},"73189":{"type":"graphic_table","displayName":"Severity malnutrition FTT","title":"Systems for assessing the severity of malnutrition in underweight children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systems for assessing the severity of malnutrition in underweight children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Method</td> <td class=\"subtitle1\">Normal</td> <td class=\"subtitle1\">Mild</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe</td> </tr> <tr> <td>Weight for age<sup>[1]</sup></td> <td>Percent of median &#8805;90%</td> <td>Percent of median 75 to 89%</td> <td>Percent of median 60 to 74%</td> <td>Percent of median &#60;60%</td> </tr> <tr> <td>Weight for height<sup>[2]</sup></td> <td>Percent of median &#8805;90%</td> <td>Percent of median 80 to 89%</td> <td>Percent of median 70 to 79%</td> <td>Percent of median &#60;70%</td> </tr> <tr> <td>Height for age<sup>[3]</sup></td> <td>Percent of median &#8805;95%</td> <td>Percent of median 90 to 94%</td> <td>Percent of median 85 to 89%</td> <td>Percent of median &#60;85%</td> </tr> <tr> <td>Weight/height for age<sup>[4]</sup></td> <td>Percent of median &#8805;90%</td> <td>Percent of median 85 to 89%</td> <td>Percent of median 75 to 84%</td> <td>Percent of median &#60;75%</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br> <ol> <li>Gomez F. Mortality in third degree malnutrition. J Trop Peds 1956; 2:77. </li> <li>Waterlow JC. Classification and definition of protein-calorie malnutrition. Br Med J 1972; 3:566. This method assesses acute undernutrition. </li> <li>Waterflow JC. Some aspects of childhood malnutrition as a public health problem. Br Med J 1974; 4:88. This method assesses chronic undernutrition. </li> <li>McLaren DS, Read WW. Weight/length classification of nutritional status. Lancet 1975; 2:219. </li> </ol></div><div id=\"graphicVersion\">Graphic 73189 Version 4.0</div></div></div>"},"73191":{"type":"graphic_picture","displayName":"Keloid injection","title":"Intralesional injection at the edge of a keloid on the chest","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intralesional injection at the edge of a keloid on the chest</div><div class=\"cntnt\"><img style=\"width:385px; height:261px;\" src=\"images/DERM/73191_Keloid_injection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The slightly hypopigmented scar just below the injection site is a successfully treated keloid.</div><div class=\"graphic_reference\">Reproduced with permission from Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 73191 Version 3.0</div></div></div>"},"73193":{"type":"graphic_figure","displayName":"Combitube insertion","title":"Mallinckrodt esophageal tracheal airway double lumen (Combitube) insertion","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Mallinckrodt esophageal tracheal airway double lumen (Combitube) insertion</div><div class=\"cntnt\"><img style=\"width:465px; height:605px;\" src=\"images/EM/73193_Combitube_insertion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lubricate and insert the Combitube until the double black line is located in between the teeth. <br />(B) Inflate the blue pharyngeal cuff and white pilot balloons. <br />(C) Attach bag-valve-mask to the blue connector and assess for lung sounds and chest wall movement. Pass a gastric tube through the white distal connector and confirm suction of gastric contents. <br />(D) If&nbsp;breath sounds and chest wall movement are absent or decreased, the distal balloon may be in the trachea. Place &nbsp;the bag-valve-mask on the connector for the white distal balloon and ventilate.</div><div class=\"graphic_reference\">Image used by permission from: Nellcor Puritan Bennett LLC, Boulder, Colorado, doing business as Covidien. Illustration originally published in: King BR, Hagberg CA. Management of the difficult airway. In: The Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds). Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73193 Version 2.0</div></div></div>"},"73197":{"type":"graphic_diagnosticimage","displayName":"MRI transverse myelitis and MS","title":"Spinal cord MRI demonstrating transverse myelitis in a 37-year-old man with multiple sclerosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spinal cord MRI demonstrating transverse myelitis in a 37-year-old man with multiple sclerosis</div><div class=\"cntnt\"><img style=\"width:430px; height:519px;\" src=\"images/NEURO/73197_37_yo_MS_spinal_cord_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted sagittal (A) and axial (B) images show a focus of hyperintensity in the posterior columns of the cervical spinal cord at the C2 level. Post-gadolinium T1-weighted sagittal (C) and axial (D) images demonstrate enhancement consistent with an active plaque.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 73197 Version 7.0</div></div></div>"},"73199":{"type":"graphic_picture","displayName":"Jaundice newborn","title":"Jaundice newborn","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Jaundice newborn</div><div class=\"cntnt\"><img style=\"width:520px; height:412px;\" src=\"images/PEDS/73199_Jaundice_newborn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Physiologic jaundice. B) Pressing the color from the skin allows better recognition of the yellow of jaundice. Infant with bilirubin level of 13 mg/dL. C) Infant with no appreciable jaundice at chest level.</div><div class=\"graphic_reference\">A) Reproduced with permission from: O'Doherty N. Atlas of the Newborn, JB Lippincott,&nbsp;Philadelphia 1979. Copyright © 1979 Lippincott Williams &amp; Wilkins.<BR>B and C) Reproduced with permission from: Fletcher M. Physical Diagnosis in Neonatology, Lippincott-Raven Publishers, Philadelphia 1998. Copyright © 1998 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73199 Version 2.0</div></div></div>"},"73200":{"type":"graphic_figure","displayName":"Veins of leg and foot","title":"Veins of leg and foot","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">Veins of leg and foot</div><div class=\"cntnt\"><img style=\"width:569px; height:702px;\" src=\"images/EM/73200_Veinsoflegandfoot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The main superficial veins are the great and small saphenous veins, which drain into the deep veins as they ascend the limb by means of perforating veins so that muscular compression can propel blood toward the heart against the pull of gravity. Note that the distal great saphenous vein is accompanied by the saphenous nerve, and the small saphenous vein is accompanied by the sural nerve and its medial root (medial sural cutaneous nerve).</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinically oriented anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 73200 Version 10.0</div></div></div>"},"73201":{"type":"graphic_picture","displayName":"Epidermolysis bullosa simplex - feet","title":"Epidermolysis bullosa simplex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epidermolysis bullosa simplex</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/73201_Epid_bullosa_simplex_feet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erosions and bullae are present on the foot of this child with epidermolysis bullosa simplex.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73201 Version 4.0</div></div></div>"},"73202":{"type":"graphic_picture","displayName":"Dermoscopy melanoma 3","title":"Dermoscopic image of thick melanoma","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of thick melanoma</div><div class=\"cntnt\"><img style=\"width:540px; height:292px;\" src=\"images/DERM/73202_Dermoscopy_melanoma_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Melanoma 3.8 mm. Atypical network (solid arrow), negative network (solid square), and atypical globules (dashed square) are observed.</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 73202 Version 2.0</div></div></div>"},"73203":{"type":"graphic_diagnosticimage","displayName":"Common hepatic duct mass seen on cholangiography","title":"Common hepatic duct mass seen on cholangiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Common hepatic duct mass seen on cholangiography</div><div class=\"cntnt\"><img style=\"width:440px; height:468px;\" src=\"images/GAST/73203_Com_hep_duct_mass_cholan_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangiogram showing a filling defect at the bifurcation of the common hepatic duct due to a tumor.</div><div id=\"graphicVersion\">Graphic 73203 Version 2.0</div></div></div>"},"73205":{"type":"graphic_figure","displayName":"Volvulus in hiatus hernia","title":"Volvulus in hiatus hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Volvulus in hiatus hernia</div><div class=\"cntnt\"><img style=\"width:383px; height:379px;\" src=\"images/GAST/73205_Volvulus_hiatal_hernia_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paraesophageal hernias are associated with abnormal laxity of structures normally preventing displacement of the stomach, the gastrosplenic and gastrocolic ligaments. As the hernia enlarges, the greater curvature of the stomach rolls up into the thorax. Because the stomach is fixed at the gastroesophageal junction, the herniated stomach tends to rotate around its longitudinal axis, resulting in an organoaxial volvulus (top panels); infrequently, rotation occurs around the transverse axis resulting in a mesenteroaxial volvulus (bottom panels).</div><div class=\"graphic_reference\">Adapted from: Peridikis G, Hinder RA. Paraesophageal hiatal hernia. In: Hernia, Nyhus LM, Condon RE (Eds), JB Lippincott, Philadelphia 1995. p.544.</div><div id=\"graphicVersion\">Graphic 73205 Version 4.0</div></div></div>"},"73206":{"type":"graphic_figure","displayName":"Varicocele","title":"Varicocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Varicocele</div><div class=\"cntnt\"><img style=\"width:341px; height:368px;\" src=\"images/PEDS/73206_Varicocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A varicocele is a collection of dilated and tortuous veins in the pampiniform plexus surrounding the spermatic cord. On physical examination, the spermatic cord has a \"bag of worms\" appearance that increases with standing or the Valsalva maneuver.</div><div id=\"graphicVersion\">Graphic 73206 Version 3.0</div></div></div>"},"73208":{"type":"graphic_diagnosticimage","displayName":"Bronchogenic carcinoma CT IV","title":"Bilateral mediastinal lymph node enlargement in lung cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral mediastinal lymph node enlargement in lung cancer</div><div class=\"cntnt\"><img style=\"width:394px; height:261px;\" src=\"images/PULM/73208_Bronchogenic_carcinoma_CT3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral left upper lobe bronchogenic carcinoma with amorphous central calcification. Aortopulmonary window (long arrow), contralateral pretracheal, and retrocaval lymph nodes (short arrow), indicating N3 disease.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 73208 Version 2.0</div></div></div>"},"73209":{"type":"graphic_picture","displayName":"Keratinization lung CA Light","title":"Keratinization in lung cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keratinization in lung cancer</div><div class=\"cntnt\"><img style=\"width:318px; height:353px;\" src=\"images/PULM/73209_Keratinization_lung_CA_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low magnification photomicrograph showing marked keratinization (K) in a squamous cell carcinoma of the lung.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 73209 Version 2.0</div></div></div>"},"73210":{"type":"graphic_picture","displayName":"Negative margins in thymoma","title":"Predominantly lymphocytic, invasive thymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Predominantly lymphocytic, invasive thymoma</div><div class=\"cntnt\"><img style=\"width:360px; height:234px;\" src=\"images/PULM/73210_Negative_margins_in_thymoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This thymoma is predominantly composed of lymphocytes with scattered epithelial cells; it invades the surrounding mediastinal fat tissue but does not reach the inked surgical margin. (Hematoxylin and eosin, magnification 25x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 73210 Version 1.0</div></div></div>"},"73211":{"type":"graphic_table","displayName":"Thymic carcinoma classification","title":"Classification of thymic carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of thymic carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Suster &#38; Rosai (Cancer 1991; 67:1025).</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Low-grade histology</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Well differentiated squamous cell carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Basaloid carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Well differentiated mucoepidermoid carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">High-grade histology</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Lymphoepithelioma-like carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Small cell neuro-endocrine carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Undifferentiated/anaplastic carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Clear cell carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Sarcomatoid carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">WHO, Rosai, J. (Histological Typing of Tumors of the Thymus, 2nd ed, Springer, Berlin, 1999).</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Epidermoid keratinizing (squamous cell) carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Epidermoid non-keratinizing carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lymphoepithelioma-like carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sarcomatoid carcinoma (Carcinosarcoma)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Clear cell carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Basaloid carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mucoepidermoid carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Papillary carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Undifferentiated carcinoma</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 73211 Version 1.0</div></div></div>"},"73213":{"type":"graphic_table","displayName":"Dix Hallpike findings in central vs peripheral vertigo","title":"Dix-Hallpike maneuver for positional nystagmus: Findings in central versus peripheral vertigo","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dix-Hallpike maneuver for positional nystagmus: Findings in central versus peripheral vertigo</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Peripheral disorder</td> <td class=\"subtitle1\">Central disorder</td> </tr> <tr> <td><strong>Latent period before onset of positional nystagmus</strong></td> <td>2 to 20 seconds</td> <td>None</td> </tr> <tr> <td><strong>Duration of nystagmus</strong></td> <td>Less than 1 minute</td> <td>Greater than 1 minute</td> </tr> <tr> <td><strong>Fatigability</strong></td> <td>Fatiguing with repetition</td> <td>Nonfatiguing</td> </tr> <tr> <td><strong>Direction of nystagmus</strong></td> <td>Only one type, may change direction with gaze</td> <td>May change direction with a given head position</td> </tr> <tr> <td><strong>Intensity of vertigo</strong></td> <td>Severe</td> <td>Less severe, sometimes none</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73213 Version 6.0</div></div></div>"},"73214":{"type":"graphic_diagnosticimage","displayName":"EBCT in pericardial disease","title":"Electron beam computed tomograms in pericardial disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron beam computed tomograms in pericardial disease</div><div class=\"cntnt\"><img style=\"width:322px; height:627px;\" src=\"images/CARD/73214_EBCT_pericardial_dis_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple electron beam computed tomograms (EBCT) in pericardial disorders.<br> Panel A shows four images from a patient with thickening and diffuse calcification of the pericardium. The patient presented with clinical evidence of constrictive pericarditis.<br> Panel B is from a patient with a calcified pericardial cyst who presented with right ventricular outflow tract (RVOFT) obstruction. The remainder of the pericardium was normal.<br> Panel C is from a patient with a pericardial thickening (without calcification) and a pericardial effusion who clinically presented with effusive constrictive pericarditis.</div><div id=\"graphicVersion\">Graphic 73214 Version 4.0</div></div></div>"},"73215":{"type":"graphic_table","displayName":"Hirschsprung disease-associated syndromes","title":"Monogenic syndromes associated with Hirschsprung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monogenic syndromes associated with Hirschsprung disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"50%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Features</td> <td class=\"subtitle1\">Mode of inheritance</td> <td class=\"subtitle1\">Chromosomal locus/gene symbol</td> <td class=\"subtitle1\">Percent of individuals with this disorder who have&nbsp;Hirschsprung disease</td> </tr> <tr class=\"divider_bottom\"> <td>Bardet-Biedl syndrome</td> <td>Retinal dystrophy, obesity, intellectual disability, polydactyly, hypogenitalism, renal abnormalities</td> <td>AR</td> <td>At least 11 loci/genes</td> <td>2 to 10 percent*</td> </tr> <tr class=\"divider_bottom\"> <td>Cartilage-hair hypoplasia</td> <td>Short-limbed dwarfism, sparse hair, immune defects</td> <td>AR</td> <td>9p21-p12/RMRP</td> <td>7 to 9 percent</td> </tr> <tr class=\"divider_bottom\"> <td>Congenital central hypoventilation syndrome</td> <td>Hypoxia, reduced ventilatory drive, neuroblastoma</td> <td>Variable</td> <td> <p>4p12/PHOX2B</p> <p>10q11.2/RET</p> <p>5p13.1-p12/GDNF</p> <p>20q13.2-q13.3/EDN3</p> 11p13/BDNF</td> <td>20 percent</td> </tr> <tr class=\"divider_bottom\"> <td>Familial dysautonomia (Riley-Day syndrome)</td> <td>Sensory and autonomic dysfunction (including abnormal sweat, tear, and saliva production)</td> <td>AR</td> <td>9q31/IKBKAP</td> <td>Unknown</td> </tr> <tr class=\"divider_bottom\"> <td>Fryns syndrome</td> <td>Distal digital hypoplasia, diaphragmatic hernia, CHD, craniofacial, intellectual disability</td> <td>AR</td> <td>Unknown</td> <td>Unknown</td> </tr> <tr class=\"divider_bottom\"> <td>Goldberg-Shprintzen syndrome</td> <td>Craniofacial, microcephaly, intellectual disability, PMG</td> <td>AR</td> <td> <p>10q22.1/KIAA1279</p> Others?</td> <td>Common</td> </tr> <tr class=\"divider_bottom\"> <td>Intestinal neuronal dysplasia</td> <td>Abnormal intestinal innervation with giant ganglia</td> <td>Unknown</td> <td>Unknown</td> <td>&#8804;20 percent*</td> </tr> <tr class=\"divider_bottom\"> <td>L1 syndrome</td> <td>Intellectual disability, hydrocephalus, ACC, adducted thumbs</td> <td>XLR</td> <td>Xq28/L1CAM</td> <td>Rare</td> </tr> <tr class=\"divider_bottom\"> <td>MEN 2A/FMTC</td> <td>MTC, pheochromocytoma, hyperparathyroidism<sup>&#182;</sup></td> <td>AD</td> <td>10q11.2/RET</td> <td>&#8804;1 percent</td> </tr> <tr class=\"divider_bottom\"> <td>MEN 2B</td> <td>MTC, pheochromocytoma, mucosal and intestinal neuromas, skeletal abnormalities, corneal changes</td> <td>AD</td> <td>10q11.2/RET</td> <td>Rare</td> </tr> <tr class=\"divider_bottom\"> <td>Mowat-Wilson syndrome</td> <td>Intellectual disability, microcephaly, craniofacial, CHD, ACC, epilepsy, short stature</td> <td>AD</td> <td>2q22/ZFHX1B</td> <td>41 to 71 percent</td> </tr> <tr class=\"divider_bottom\"> <td>Neurofibromatosis 1</td> <td>Caf&#233;-au-lait macules, neurofibromas, Lisch nodules</td> <td>AD</td> <td> <p>17q11.2/NF1</p> 5p13.1-p12/GDNF?</td> <td>Unknown</td> </tr> <tr class=\"divider_bottom\"> <td>Smith-Lemli-Opitz syndrome</td> <td>Intellectual disability, hypospadias, 2/3 syndactyly, CHD, craniofacial</td> <td>AR</td> <td>11q12-q13/DHCR7</td> <td>Unknown</td> </tr> <tr> <td rowspan=\"2\">Waardenburg syndrome type 4 (Waardenburg-Shah syndrome)</td> <td rowspan=\"2\">Pigmentary abnormalities, deafness </td> <td>AR (usually)</td> <td> <p>13q22/EDNRB</p> 20q13.2-q13.3/EDN3</td> <td>Common</td> </tr> <tr> <td>AD</td> <td>22q13/SOX10</td> <td>Almost 100 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CHD: congenital heart disease; PMG: polymicrogyria; AD: autosomal dominant; AR: autosomal recessive; XLR: X-linked recessive; MTC: medullary thyroid carcinoma; DHCR7: 7-dehydrocholesterol reductase; ACC: agenesis of the corpus callosum; ZFHX1B: zinc finger homeobox protein 1b; RMRP: RNAse mitochondrial RNA processing; BDNF: brain-derived neurotrophic factor; L1CAM: neural cell adhesion molecule L1; NF1: neurofibromin; MEN: multiple endocrine neoplasia.<br />* Limited data are available.<br />¶ In FMTC, affected individuals do not have pheochromocytoma or hyperparathyroidism.</div><div class=\"graphic_reference\">Parisi, MA (updated December 2006). Hirschsprung Disease Overview. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright &copy; University of Washington, Seattle. 1997-2010. Available at http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=hirschsprung-ov. Accessed May 31, 2010.</div><div id=\"graphicVersion\">Graphic 73215 Version 8.0</div></div></div>"},"73216":{"type":"graphic_table","displayName":"Safe food handling practices","title":"Tips for safe food handling to avoid microbial food-borne illness (food poisoning)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for safe food handling to avoid microbial food-borne illness (food poisoning)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Purchase</td> </tr> <tr> <td>Do not buy precooked food that is stored adjacent to raw food, even if stored on ice.</td> </tr> <tr> <td>Do not buy canned goods that are dented, cracked, or have a bulging lid.</td> </tr> <tr> <td class=\"subtitle1_single\">Storage</td> </tr> <tr> <td>Make sure meat and poultry products are refrigerated when purchased.</td> </tr> <tr> <td>Use plastic bags to keep drippings from packages of meat and fish from contact with other foods.</td> </tr> <tr> <td>Store perishable items in the refrigerator within one hour of purchase.</td> </tr> <tr> <td>Maintain home refrigerator temperature between 32 and 40&#176;F (0 and 4&#176;C) and freezer temperature at &#8804;0&#176;F (-18&#176;C).</td> </tr> <tr> <td>Freeze meat and poultry that will not be cooked within 48 hours.</td> </tr> <tr> <td>Freeze tuna, bluefish, and mahi-mahi that will not be cooked within 24 hours; other fish can be stored in the refrigerator for 48 hours.</td> </tr> <tr> <td>Do not store eggs on the refrigerator door (warmest part of the refrigerator).</td> </tr> <tr> <td>Refrigerate cooked foods within two hours of preparation.</td> </tr> <tr> <td>Divide leftovers into small portions and store in shallow containers.</td> </tr> <tr> <td>Reheat leftovers to 165&#176;F (74&#176;C).</td> </tr> <tr> <td class=\"subtitle1_single\">Preparation</td> </tr> <tr> <td>Wash hands with soap and water before food preparation and after handling raw meat, poultry, fish, and uncooked eggs.</td> </tr> <tr> <td>Thaw frozen meats and fish in the refrigerator or microwave, not at room temperature.</td> </tr> <tr> <td>Marinate foods in the refrigerator, not at room temperature.</td> </tr> <tr> <td>Avoid contact of cooked foods with contaminated utensils, plates, or food preparation surfaces.</td> </tr> <tr> <td>Wash utensils, plates, and cutting surfaces with soap and water after contact with raw meat, poultry, fish, or eggs.</td> </tr> <tr> <td>Avoid contact of juices from uncooked meat, poultry, or fish with cooked foods or foods that will be eaten raw.</td> </tr> <tr> <td>Thoroughly wash all fresh fruits and vegetables.</td> </tr> <tr> <td>Avoid recipes using raw eggs.</td> </tr> <tr> <td class=\"subtitle1_single\">Cooking</td> </tr> <tr> <td> <p>Use a meat thermometer to monitor internal cooking temperatures:</p> <ul> <li>Cook fresh beef, veal, and lamb (eg, steaks, roasts, or chops) to an internal temperature of 145&#176;F (63&#176;C) and rest for 3 minutes </li> <li>Cook ground beef, pork, veal, and lamb to 160&#176;F (71&#176;C) </li> <li>Cook ground poultry to 165&#176;F (74&#176;C) </li> <li>Cook poultry to 165&#176;F (74&#176;C) </li> <li>Cook fresh pork (eg, roasts, chops, raw ham) to 145&#176;F (63&#176;C) and rest for 3 minutes </li> <li>Cook precooked ham to 140&#176;F (60&#176;C) </li> <li>Cook fin fish until 145&#176;F (63&#176;C) or until flesh is opaque and separates easily with a fork </li> <li>Cook shrimp, lobster, and crabs until flesh is pearly and opaque </li> <li>Cook unshucked clams, oysters, and mussels until shells open during cooking; discard the ones that do not open </li> <li>Cook shucked oysters, clams, and mussels until they are opaque and firm </li> <li>Cook scallops until flesh is milky white or opaque and firm </li> </ul> </td> </tr> <tr> <td>Cook eggs until the yolk and white are firm.</td> </tr> <tr> <td>Boil marinade from raw meat or fish before using it on cooked food.</td> </tr> <tr> <td class=\"subtitle1_single\">Serving</td> </tr> <tr> <td>Serve cooked products on clean plates with clean utensils.</td> </tr> <tr> <td>Keep hot foods at 140&#176;F (60&#176;C) and cold foods below 40&#176;F (4&#176;C).</td> </tr> <tr> <td>Never leave foods at room temperature longer than two hours (one hour if the ambient temperature is &#62;90&#176;F (32&#176;C)).</td> </tr> <tr> <td>Use coolers and ice packs to transport perishable foods away from home.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">United States Department of Agriculture. Food Safety. Safe minimum cooking temperatures. Available at: <A spellcheck=true href=\"http://www.foodsafety.gov/keep/charts/mintemp.html\" target=_blank>www.foodsafety.gov/keep/charts/mintemp.html</A> (Accessed on January 11, 2016).</div><div id=\"graphicVersion\">Graphic 73216 Version 7.0</div></div></div>"},"73219":{"type":"graphic_table","displayName":"ACC AHA HRS pacing syncope","title":"ACC/AHA/HRS guideline summary: Permanent pacing in hypersensitive carotid sinus syndrome and neurocardiogenic syncope","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA/HRS guideline summary: Permanent pacing in hypersensitive carotid sinus syndrome and neurocardiogenic syncope</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Class I - There is evidence and/or general agreement that permanent pacing is indicated in patients with hypersensitive carotid sinus syndrome or neurocardiogenic syncope in the following setting: </td> </tr> <tr> <td class=\"indent1\">&#8226; Recurrent syncope caused by spontaneously occurring carotid sinus stimulation and carotid sinus pressure that induces ventricular asystole of more than 3 seconds. (Level of Evidence: C) </td> </tr> <tr> <td class=\"subtitle1_single\">Class IIa - The weight of evidence or opinion is in favor of the usefulness of permanent pacing in patients with hypersensitive carotid sinus syndrome or neurocardiogenic syncope in the following setting: </td> </tr> <tr> <td class=\"indent1\">&#8226; Syncope without clear, provocative events and with a hypersensitive cardioinhibitory response of 3 seconds or longer. (Level of Evidence: C) </td> </tr> <tr> <td class=\"subtitle1_single\">Class IIb - The evidence or opinion is less well established that permanent pacing in hypersensitive carotid sinus syndrome and neurocardiogenic syncope&nbsp;is beneficial in the following setting: </td> </tr> <tr> <td class=\"indent1\">&#8226; Significantly symptomatic neurocardiogenic syncope associated with bradycardia documented spontaneously or at the time of tilt-table testing. (Level of Evidence: B) </td> </tr> <tr> <td class=\"subtitle1_single\">Class III - There is evidence and/or general agreement that permanent pacing is not indicated in patients with hypersensitive carotid sinus syndrome or neurocardiogenic syncope in the following settings:</td> </tr> <tr> <td class=\"indent1\">&#8226; A hypersensitive cardioinhibitory response to carotid sinus stimulation without symptoms or with vague symptoms. (Level of Evidence: C)</td> </tr> <tr> <td class=\"indent1\">&#8226; Situational vasovagal syncope in which avoidance behavior is effective and preferred. (Level of Evidence: C)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.</div><div id=\"graphicVersion\">Graphic 73219 Version 2.0</div></div></div>"},"73221":{"type":"graphic_figure","displayName":"Pain stages SCD","title":"The stages of pain in sickle cell disease","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">The stages of pain in sickle cell disease</div><div class=\"cntnt\"><img style=\"width:506px; height:381px;\" src=\"images/HEME/73221_Pain_stages_SCD.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Ballas, SK. The sickle cell painful crisis in adults: phases and objective signs. Hemoglobin 1995; 19:323.</div><div id=\"graphicVersion\">Graphic 73221 Version 1.0</div></div></div>"},"73222":{"type":"graphic_picture","displayName":"Tumor vessels seen with white light","title":"White light imaging of tumor vessels in cholangiocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">White light imaging of tumor vessels in cholangiocarcinoma</div><div class=\"cntnt\"><img style=\"width:384px; height:375px;\" src=\"images/GAST/73222_Tumor_vessel_white_light_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangioscopy showing tumor vessels in a patient with cholangiocarcinoma.</div><div id=\"graphicVersion\">Graphic 73222 Version 2.0</div></div></div>"},"73223":{"type":"graphic_picture","displayName":"Perioral dermatitis in a male","title":"Perioral dermatitis","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Perioral dermatitis</div><div class=\"cntnt\"><img style=\"width:455px; height:583px;\" src=\"images/DERM/73223_Perioral_dermatitis_male.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules are present around the mouth.</div><div id=\"graphicVersion\">Graphic 73223 Version 1.0</div></div></div>"},"73224":{"type":"graphic_picture","displayName":"Sunburn back","title":"Sunburn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sunburn</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/73224_Sunburn_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythema in sun-exposed areas is present in this patient with a sunburn on the back. Areas covered by clothing are not affected.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73224 Version 1.0</div></div></div>"},"73225":{"type":"graphic_table","displayName":"Causes of pediatric hypertensive emergencies ","title":"Causes of pediatric hypertensive emergencies by age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of pediatric hypertensive emergencies by age</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Infancy </td> <td class=\"subtitle1\">Childhood </td> <td class=\"subtitle1\">Adolescence </td> </tr> <tr> <td> <p>Renal vascular disease*</p> <p>Congenital renal anomaly*</p> <p>Bronchopulmonary dysplasia*</p> <p>Coarctation of the aorta*</p> <p>Volume overload</p> <p>Increased intracranial pressure</p> <p>Renal parenchymal disease</p> <p>Renal vein thrombosis</p> <p>Congenital adrenal hyperplasia</p> <p>Tumor (eg, neuroblastoma)</p> </td> <td> <p>Renal parenchymal disease*</p> <p>Renovascular disease*</p> <p>Coarctation of the aorta</p> <p>Pheochromocytoma</p> <p>Increased intracranial pressure</p> <p>Drug induced/toxicologic</p> </td> <td> <p>Primary hypertension*</p> <p>Non-adherence to medication*</p> <p>Renal parenchymal disease*</p> <p>Increased intracranial pressure</p> <p>Renovascular disease</p> <p>Preeclampsia/Eclampsia</p> <p>Drug induced/toxicologic</p> <p>Pheochromocytoma</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Common causes of hypertensive emergency.</div><div class=\"graphic_reference\">Adapted from: Constantine, E. Hypertension. In: Textbook of Pediatric Emergency Medicine, 6th ed, Fleisher GR, Ludwig S, Henretig, FM (Ed), Lippincott, Williams &amp; Wilkins, Philadelphia, 2010, p.315.</div><div id=\"graphicVersion\">Graphic 73225 Version 5.0</div></div></div>"},"73226":{"type":"graphic_figure","displayName":"CRITOE mnemonic for elbow ossification","title":"Ossification centers of the elbow","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Ossification centers of the elbow</div><div class=\"cntnt\"><img style=\"width:544px; height:514px;\" src=\"images/EM/73226_CRITOE_mnmnc_elbw_osfct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The six ossification centers in the pediatric elbow are shown numbered in the order of appearance with age range for appearance by sex: Capitellum, radial head,internal (medial) epicondyle, trochlea, olecranon, external (lateral) epicondyle (mnemonic: CRITOE). These secondary ossification centers later fuse to create the mature bony elbow. The salmon shaded regions represent unossified cartilage.</div><div id=\"graphicVersion\">Graphic 73226 Version 4.0</div></div></div>"},"73228":{"type":"graphic_diagnosticimage","displayName":"Normal trachea MRI","title":"Normal trachea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal trachea</div><div class=\"cntnt\"><img style=\"width:290px; height:468px;\" src=\"images/PULM/73228_Normal_trachea_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance image of a normal trachea seen on T1-weighted coronal spin echo sequence.</div><div id=\"graphicVersion\">Graphic 73228 Version 2.0</div></div></div>"},"73229":{"type":"graphic_diagnosticimage","displayName":"Postop tracheobronchial changes","title":"Postpneumonectomy changes in tracheobronchial anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postpneumonectomy changes in tracheobronchial anatomy</div><div class=\"cntnt\"><img style=\"width:360px; height:253px;\" src=\"images/PULM/73229_Postop_tracheobronchial_cha.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest CT after right sided pneumonectomy shows stretching and narrowing of the left main bronchus (arrows) consistent with the postpneumonectomy syndrome.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Richard Irwin, MD.</div><div id=\"graphicVersion\">Graphic 73229 Version 3.0</div></div></div>"},"73230":{"type":"graphic_figure","displayName":"PAH reversal in mitral stenosis","title":"Reversibility of pulmonary hypertension in mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reversibility of pulmonary hypertension in mitral stenosis</div><div class=\"cntnt\"><img style=\"width:391px; height:257px;\" src=\"images/CARD/73230_PAH_reversal_in_mitral_sten.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean pulmonary artery (PA) systolic pressure after correction of mitral stenosis with balloon valvuloplasty or surgical commisurotomy. Mean PA pressure fell progressively with both procedures.</div><div class=\"graphic_reference\">Redrawn from Reyes VP, Raju BS, Wynne J, et al. N Engl J Med 1994; 331:961.</div><div id=\"graphicVersion\">Graphic 73230 Version 2.0</div></div></div>"},"73231":{"type":"graphic_figure","displayName":"Post infarct ischemia outcome","title":"Postinfarction angina with hemodynamic abnormalities predicts mortality","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postinfarction angina with hemodynamic abnormalities predicts mortality</div><div class=\"cntnt\"><img style=\"width:349px; height:511px;\" src=\"images/CARD/73231_Post_infarct_ischemia_outco.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 40,848 patients with an acute myocardial infarction entered into GUSTO-I, 20 percent had recurrent ischemia after thrombolytic therapy. The 30-day and&nbsp;one year survivals were significantly lower among patients with recurrent ischemia associated with hemodynamic abnormalities (eg, hypotension) compared to patients without recurrent ischemia or those with recurrent ischemia without hemodynamic abnormalities (p &lt;0.0001).</div><div class=\"graphic_reference\">Redrawn from Betriu A, Califf RM, Bosch X, et al, for the GUSTO-I Investigators. J Am Coll Cardiol 1998; 31:94.</div><div id=\"graphicVersion\">Graphic 73231 Version 2.0</div></div></div>"},"73233":{"type":"graphic_picture","displayName":"Erythema marginatum","title":"Erythema marginatum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Erythema marginatum</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/73233_Erythema_marginatum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple annular and arcuate erythematous lesions are present on the lower legs.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73233 Version 3.0</div></div></div>"},"73236":{"type":"graphic_diagnosticimage","displayName":"Right mainstem intubation","title":"Left lung atelectasis caused by endotracheal tube in the right mainstem bronchus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left lung atelectasis caused by endotracheal tube in the right mainstem bronchus</div><div class=\"cntnt\"><img style=\"width:333px; height:306px;\" src=\"images/PEDS/73236_Right_mainstem_intubation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Portable supine radiograph of a neonate with respiratory distress. This radiograph demonstrates complete opacification of the left hemithorax with associated ipsilateral mediastinal shift. The tip of the endotracheal tube is within the orifice of the right mainstem bronchus, causing complete left lung atelectasis.</div><div id=\"graphicVersion\">Graphic 73236 Version 3.0</div></div></div>"},"73237":{"type":"graphic_table","displayName":"Diff dx disagreements","title":"Differential diagnosis for disagreements between health care providers and families","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis for disagreements between health care providers and families</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Major Reason</td>\r\n            <td class=\"subtitle1\">Etiology</td>\r\n            <td class=\"subtitle1\">Response</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"2\">Misunderstanding</td>\r\n            <td>Not informed</td>\r\n            <td>Give information simply and in small chunks; check in frequently; use visual aids if possible</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Given different information</td>\r\n            <td>Bring providers together and give consistent information</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"4\">Affective reasons</td>\r\n            <td>Stress interferes with understanding</td>\r\n            <td>Support family; give information again</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Denial</td>\r\n            <td>Attend to emotions</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Guilt</td>\r\n            <td>Attend to emotions; ask what patient wants</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Lack of trust</td>\r\n            <td>Acknowledge; negotiate plan</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"4\">Other</td>\r\n            <td>Following patient's wishes</td>\r\n            <td>Ethics consultation</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Secondary gain</td>\r\n            <td>Confirm facts; ethics consultation</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Hope for a miracle</td>\r\n            <td>Religious support</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Weighs patient attributes more than physician prediction</td>\r\n            <td>Explore and try to understand reasoning behind family decisions&nbsp;</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Conflict persists</td>\r\n            <td>&nbsp;</td>\r\n            <td>Second opinion; ethics or palliative care consultation</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 73237 Version 2.0</div></div></div>"},"73238":{"type":"graphic_figure","displayName":"How pregnancy happens PI","title":"How pregnancy happens","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">How pregnancy happens</div><div class=\"cntnt\"><img style=\"width:537px; height:511px;\" src=\"images/PI/73238_How_preg_happens_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To get pregnant (in the traditional way), a woman must have sex with a man around the time she ovulates (releases an egg from the ovary). Then the following steps must occur:<br /><ol>&#xD;&#xA;    <li>The man's sperm must swim up the vagina, into the uterus, and up the tubes that connect the ovaries to the uterus (called the fallopian tubes). </li>&#xD;&#xA;    <li>When the sperm reach the woman's egg, at least one sperm must eat through the outer casing of the egg and make it inside. This is called fertilization. </li>&#xD;&#xA;    <li>The newly fertilized egg must travel down to the uterus. </li>&#xD;&#xA;    <li>The egg must secure itself to the wall of the uterus. This is called implantation. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 73238 Version 4.0</div></div></div>"},"73240":{"type":"graphic_diagnosticimage","displayName":"Stress fracture of the anterior tibial cortex","title":"Stress fracture of the anterior tibial cortex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stress fracture of the anterior tibial cortex</div><div class=\"cntnt\"><img style=\"width:242px; height:432px;\" src=\"images/EM/73240_Dreaded_anterior_black_line.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The so-called \"dreaded anterior black line\"&nbsp;associated with&nbsp;this tibial stress fracture is clearly visible (arrow). Also note the thickened cortex around the fracture line.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 73240 Version 3.0</div></div></div>"},"73242":{"type":"graphic_diagnosticimage","displayName":"GB cholesterolosis US","title":"Cholesterolosis and multiple cholesterol gallbladder polyps","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholesterolosis and multiple cholesterol gallbladder polyps</div><div class=\"cntnt\"><img style=\"width:360px; height:363px;\" src=\"images/GAST/73242_GB_cholesterolosis_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound imaging demonstrating cholesterol polyps and thickening of the gallbladder wall. Note that the polyps appear much denser than the surrounding liver tissue.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP.</div><div id=\"graphicVersion\">Graphic 73242 Version 2.0</div></div></div>"},"73247":{"type":"graphic_figure","displayName":"Pramipexole vs levodopa complications","title":"Pramipexole versus levodopa complications","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Pramipexole versus levodopa complications</div><div class=\"cntnt\"><img style=\"width:544px; height:358px;\" src=\"images/NEURO/73247_Pramipexole_vs_Levodopa_com.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative probability of reaching the first dopaminergic complication (A) and the individual complications wearing off (B), dyskinesias (C), and freezing (D) by treatment assignment. First dopaminergic complication is defined as the first occurrence of wearing off, dyskinesias, or on-off fluctuations. Initial treatment with pramipexole is associated with a reduction in dyskinesias and wearing off compared with levodopa, but the latter results in a reduction in freezing.</div><div class=\"graphic_reference\">Data from: Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61:1044.</div><div id=\"graphicVersion\">Graphic 73247 Version 3.0</div></div></div>"},"73248":{"type":"graphic_picture","displayName":"Clue cells","title":"Clue cells","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clue cells</div><div class=\"cntnt\"><img style=\"width:366px; height:252px;\" src=\"images/PC/73248_Clue_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of clue cells observed in a patient with bacterial vaginosis. Note the obliteration of each epithelial cell margin by adherent G. vaginalis.</div><div class=\"graphic_reference\">Courtesy of Jack D Sobel, MD.</div><div id=\"graphicVersion\">Graphic 73248 Version 1.0</div></div></div>"},"73252":{"type":"graphic_picture","displayName":"Types of pessaries","title":"Commonly used vaginal pessaries","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Commonly used vaginal pessaries</div><div class=\"cntnt\"><img style=\"width:396px; height:279px;\" src=\"images/OBGYN/73252_Types_of_pessaries.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Smith; (B) Hodge; (C) Hodge with support; (D) Gehrung; (E) Risser; (F) Ring with diaphragm; (G) Ring; (H) Cube; (I) Shaatz; (J) Rigid Gellhorn; (K) Flexible Gellhorn; (L) Incontinence ring; (M) Inflatoball; (N) Donut.</div><div class=\"graphic_reference\">Courtesy of Milex Products, Inc., Chicago, IL.</div><div id=\"graphicVersion\">Graphic 73252 Version 2.0</div></div></div>"},"73254":{"type":"graphic_table","displayName":"Fecal leukocyte testing","title":"Value of fecal leukocyte examination in distinguishing viral gastroenteritis from other causes of acute gastroenteritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Value of fecal leukocyte examination in distinguishing viral gastroenteritis from other causes of acute gastroenteritis</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Cause</td>\r\n                    <td class=\"subtitle1\">Type</td>\r\n                    <td class=\"subtitle1\">Frequency, percent</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Viruses</td>\r\n                    <td>PMN, if any</td>\r\n                    <td>0 to 10</td>\r\n                </tr>\r\n                <tr>\r\n                    <td><em>Vibrio cholerae</em>, EHEC, ETEC, EPEC, <em>Giardia lamblia</em></td>\r\n                    <td>PMN, if any</td>\r\n                    <td>0 to 10</td>\r\n                </tr>\r\n                <tr>\r\n                    <td><em>Shigella</em>, <em>Salmonella</em> (not typhi), <em>Campylobacter jejuni</em>, <em>Clostridium difficile</em></td>\r\n                    <td>PMN</td>\r\n                    <td>90 to 100</td>\r\n                </tr>\r\n                <tr>\r\n                    <td><em>Yersinia enterocolitica</em>, <em>Vibrio parahaemolyticus</em></td>\r\n                    <td>PMN</td>\r\n                    <td>Variable</td>\r\n                </tr>\r\n                <tr>\r\n                    <td><em>Salmonella typhi</em></td>\r\n                    <td>MN</td>\r\n                    <td>100</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Amoebic dysentery</td>\r\n                    <td>MN</td>\r\n                    <td>100</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Ulcerative colitis</td>\r\n                    <td>EO</td>\r\n                    <td>100</td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=52360&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_footnotes\">PMN: polymorphonuclear leukocytes; EHEC:&nbsp;enterohemorrhagic <EM>Escherichia coli</EM>; ETEC: enterotoxigenic <EM>E. coli</EM>; EPEC: enteropathogenic<EM> E. coli</EM>; MN: mononuclear leukocytes; EO: eosinophilic leukocytes.</div><div id=\"graphicVersion\">Graphic 73254 Version 3.0</div></div></div>"},"73256":{"type":"graphic_table","displayName":"OI radiographic features","title":"Radiographic findings of osteogenesis imperfecta (OI) by type","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiographic findings of osteogenesis imperfecta (OI) by type</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Severity</td> <td class=\"subtitle1\">Skull</td> <td class=\"subtitle1\">Back</td> <td class=\"subtitle1\">Extremities</td> <td class=\"subtitle1\">Other</td> </tr> <tr> <td class=\"centered\">I</td> <td>Mild</td> <td>Wormian bones</td> <td>Codfish vertebrae (adults)</td> <td>Thin cortices</td> <td>Osteopenia</td> </tr> <tr> <td class=\"centered\">II</td> <td>Perinatal lethal</td> <td>Undermineralization; plaques of calcification</td> <td>Platyspondyly</td> <td>Severely deformed; broad, crumpled, bent femurs</td> <td>Small beaded ribs are pathognomonic of IIA; pectus excavatum (IIB)</td> </tr> <tr> <td class=\"centered\">III</td> <td>Severe</td> <td>Wormian bones; frontal bossing; micrognathia</td> <td>Codfish vertebrae; kyphoscoliosis; platyspondyly</td> <td>Flared metaphyses (\"popcorn-like\" appearance [childhood]), bowing, thin cortices</td> <td>Thin ribs, severe osteoporosis by DEXA</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Moderate/mild</td> <td>&#177; Wormian bones</td> <td>Codfish vertebrae</td> <td>Thin cortices</td> <td>Protrusio acetabuli</td> </tr> <tr> <td class=\"centered\">V</td> <td>Moderate</td> <td>Relative macrocephaly; wormian bones</td> <td>Mild to moderate scoliosis</td> <td>Hypertrophic callus, usually of the femurs; mineralization of the interosseous membrane in the forearm; radio-opaque metaphyseal bands adjacent to growth-plates</td> <td>Severe osteoporosis by DEXA</td> </tr> <tr> <td class=\"centered\">VI</td> <td>Moderate</td> <td>Wormian bones</td> <td>Compression fractures; scoliosis</td> <td>Similar to OI type IV; bulbous metaphyses</td> <td>Severe osteoporosis by DEXA; coxa vara; protusio acetabuli</td> </tr> <tr> <td class=\"centered\">VII</td> <td>Moderate/severe/lethal</td> <td>Often small head circumference; wormian bones</td> <td>Severe scoliosis</td> <td>Could be similar to OI type IV; severely undertubulated long bones</td> <td>Rhizomelic shortening; osteopenia; coxa vara</td> </tr> <tr> <td class=\"centered\">VIII</td> <td>Lethal/severe</td> <td>Open sutures; normal to small head circumference</td> <td>Severe scoliosis; could be similar to OI type II/III</td> <td>Undertubulated long bones; popcorn calcifications</td> <td>Severe osteoporosis by DEXA; thin ribs; barrel-shaped chest; rhizomelia</td> </tr> <tr> <td class=\"centered\">IX</td> <td>Lethal/severe/moderate</td> <td>Wormian bones</td> <td>Kyphoscoliosis; may not have compression fractures; range of skeletal features similar to OI type II/III/IV</td> <td>Bowed limbs</td> <td>Pectus carinatum; pectus excavatum; moderate to severe osteoporosis by DEXA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DEXA: dual-energy x-ray absorptiometry (bone density scan).</div><div class=\"graphic_reference\">Modified and updated from: Steiner RD, Pepin MG, Byers PH. Osteogenesis Imperfecta. GeneReviews at GeneTests: Medical Genetics Information Resource, January 2005.</div><div id=\"graphicVersion\">Graphic 73256 Version 9.0</div></div></div>"},"73257":{"type":"graphic_picture","displayName":"Anterior drawer test","title":"Anterior drawer test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior drawer test</div><div class=\"cntnt\"><img style=\"width:349px; height:292px;\" src=\"images/PC/73257_Anterior_drawer_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior drawer test is used to assess the integrity of the anterior cruciate ligament. With the knee flexed to 90 degrees, the foot is stabilized by sitting on it. The proximal tibia is grasped firmly with both hands, and the tibia is forcibly pulled anteriorly, noting any pain, laxity, or abnormal movement compared with the opposite side.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 73257 Version 2.0</div></div></div>"},"73259":{"type":"graphic_movie","displayName":"Alligator forceps extraction","title":"Alligator forceps removal of a metallic FB","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alligator forceps removal of a metallic FB</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/73259_alligatorfbeconv.mp4\" style=\"width:352px;height:256px\"></div><img style=\"width:254px; height:176px;\" src=\"images/CARD/73259_alligatorfbe.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 73259 Version 2.0</div></div></div>"},"73261":{"type":"graphic_figure","displayName":"Time course embolic stroke","title":"Time course of embolic stroke","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Time course of embolic stroke</div><div class=\"cntnt\"><img style=\"width:422px; height:275px;\" src=\"images/NEURO/73261_Time_course_embolic_stroke.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Embolic stroke occurs suddenly, with symptoms maximal at onset. This patient had multiple embolic events with different clinical symptoms (initially weakness, followed by paresthesias).</div><div id=\"graphicVersion\">Graphic 73261 Version 1.0</div></div></div>"},"73262":{"type":"graphic_figure","displayName":"Occiput posterior position","title":"Occiput posterior position","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Occiput posterior position</div><div class=\"cntnt\"><img style=\"width:492px; height:368px;\" src=\"images/OBGYN/73262_Occiput_posterior_position.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73262 Version 3.0</div></div></div>"},"73263":{"type":"graphic_picture","displayName":"Necrolytic migratory erythema","title":"Necrolytic migratory erythema (Glucagonoma syndrome)","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Necrolytic migratory erythema (Glucagonoma syndrome)</div><div class=\"cntnt\"><img style=\"width:551px; height:314px;\" src=\"images/ONC/73263_Necrolytic_migratory_erythe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammatory dermatosis with angular cheilitis, and inflammatory, scaly, and erosive plaques around the nose, mouth, and medial aspects of the eyes (left panel). The right panel depicts polycyclic erosions in the anogenital region with necrotic flaccid epidermis still covering part of these erosions.</div><div class=\"graphic_reference\">Reproduced with permission from Color Atlas and Synopsis of Clinical Dermatology, 3rd edition, Fitzpatrick, et al (Eds), McGraw-Hill, New York 1997. Copyright &#169; 1997 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 73263 Version 2.0</div></div></div>"},"73264":{"type":"graphic_movie","displayName":"Membranous VSD with LV to RA shunt","title":"Membranous VSD with LV to RA shunt","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Membranous VSD with LV to RA shunt</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/73264_MembVSDLVRAshuntmovie.mp4\" style=\"width:496px;height:400px\"></div><img style=\"width:504px; height:417px;\" src=\"images/CARD/73264_MembVSDLVRAshuntposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This movie clip obtained from a subcostal coronal imaging plane shows the relationship between the jet of flow (orange) from the LVOT to the RA and the tricuspid valve. There is also a small jet of flow across the atrial septum from left to right, consistent with a coexistent patent foramen ovale.</div><div class=\"graphic_footnotes\">LA: left atrium; RA: right atrium; LV: left ventricle; RV: right ventricle; IVS: intraventricular septum; LVOT: left ventricular outflow tract; TV: tricuspid valve; arrow: VSD.</div><div id=\"graphicVersion\">Graphic 73264 Version 4.0</div></div></div>"},"73265":{"type":"graphic_figure","displayName":"Different sizes of worker ants found in mature fire ant colonies","title":"Different sizes of worker ants found in mature fire ant colonies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Different sizes of worker ants found in mature fire ant colonies</div><div class=\"cntnt\"><img style=\"width:432px; height:286px;\" src=\"images/ALLRG/73265_Mature_fire_ant_colonies_si.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A wide spectrum of different sized ants&nbsp;is found in mature fire ant colonies, with the majority of workers being the smallest in size. A queen is shown on the right. Ten millimeters (mm) is approximately three-eighths of an inch.</div><div class=\"graphic_reference\">Reproduced with permission from: Vinson SB, Sorensen AA. Imported fire ants: Life history and impact. Texas Department of Agriculture 1986. Copyright © 1986 Texas Department of Agriculture.</div><div id=\"graphicVersion\">Graphic 73265 Version 3.0</div></div></div>"},"73266":{"type":"graphic_table","displayName":"Causes subclin hypothyroid","title":"Causes of subclinical hypothyroidism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of subclinical hypothyroidism</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n    <td>Chronic autoimmune thyroiditis (risk factors: family history of autoimmune thyroid disease, personal or family history of associated autoimmune disorders, Down syndrome, Turner's syndrome)</td>\n  </tr>\n  <tr>\n    <td>Persistent TSH increase in subacute thyroiditis, postpartum thyroiditis, painless thyroiditis</td>\n  </tr>\n  <tr>\n    <td>Thyroid injury: partial thyroidectomy or other neck surgery, radioactive iodine therapy, external radiotherapy of the head and neck</td>\n  </tr>\n  <tr>\n    <td>Drugs impairing thyroid function: iodine and iodine-containing medications (amiodarone, radiographic contrast agents), lithium carbonate, cytokines (especially interferon &#945;), aminoglutetimide, ethionamide, sulfonamides, and sulfonylureas</td>\n  </tr>\n  <tr>\n    <td>Inadequate replacement therapy for overt hypothyroidism (inadequate dosage, noncompliance, drug interactions [iron, calcium carbonate, cholestyramine, dietary soy, fiber, etc.], increased T<sub>4</sub> clearance [phenytoin, carbamazepine, phenobarbital, etc.], malabsorption)</td>\n  </tr>\n  <tr>\n    <td>Thyroid infiltration (amyloidosis, sarcoidosis, hemochromatosis, Riedel's thyroiditis, cystinosis, AIDS, primary thyroid lymphoma)</td>\n  </tr>\n  <tr>\n    <td>Central hypothyroidism with impaired TSH bioactivity</td>\n  </tr>\n  <tr>\n    <td>Toxic substances, industrial and environmental agents</td>\n  </tr>\n  <tr>\n    <td>TSH receptor gene mutations; G&#945; gene mutations</td>\n  </tr>\n\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews 2008; 29:76. http://edrv.endojournals.org. Copyright &#169; 2008 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 73266 Version 6.0</div></div></div>"},"73267":{"type":"graphic_picture","displayName":"Familial polyposis Gross","title":"Multiple colorectal polyps in patients with familial adenomatous polyposis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple colorectal polyps in patients with familial adenomatous polyposis</div><div class=\"cntnt\"><img style=\"width:384px; height:280px;\" src=\"images/GAST/73267_Familial_polyposis_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross specimen of the colon from a patient with familial adenomatous polyposis shows innumerable small polyps.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 73267 Version 3.0</div></div></div>"},"73269":{"type":"graphic_picture","displayName":"Examination for malrotation of metacarpals","title":"Examination for malrotation of metacarpals","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examination for malrotation of metacarpals</div><div class=\"cntnt\"><img style=\"width:429px; height:323px;\" src=\"images/EM/73269_Exam_for_metacarpal_malrot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MCP and PIP joints are flexed to 90 degrees in this photograph of two normal hands. Axial lines drawn through the middle and distal phalanges of the second through fifth digits are nearly parallel and converge near the wrist.</div><div class=\"graphic_footnotes\">MCP: metacarpophalangeal; PIP: proximal interphalangeal.</div><div class=\"graphic_reference\">Courtesy of Kevin Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 73269 Version 7.0</div></div></div>"},"73270":{"type":"graphic_figure","displayName":"Pleur evac","title":"Pleur-evac","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleur-evac</div><div class=\"cntnt\"><img style=\"width:348px; height:540px;\" src=\"images/SURG/73270_Pleur_evac.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Teleflex Medical Incorporated. Copyright &#169; 2010.</div><div id=\"graphicVersion\">Graphic 73270 Version 1.0</div></div></div>"},"73271":{"type":"graphic_picture","displayName":"Sarcoidosis resembling lichen nitidus","title":"Cutaneous sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous sarcoidosis</div><div class=\"cntnt\"><img style=\"width:293px; height:432px;\" src=\"images/DERM/73271_Sarc_lichen_nitidus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flat-topped, round or polygonal papules are present on the neck. In addition, there are multiple 1 to 3 mm round, shiny, skin colored papules in groups at the base of the neck, resembling lichen nitidus.</div><div id=\"graphicVersion\">Graphic 73271 Version 2.0</div></div></div>"},"73272":{"type":"graphic_table","displayName":"Physical findings in obese children","title":"Findings of note on physical examination in children with obesity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Findings of note on physical examination in children with obesity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Exam finding</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Clinical concern raised</td> </tr> <tr> <td> <p>Short stature</p> OR unexplained decrease in height velocity</td> <td> <p>Height &#60;50th percentile with weight &#62;95th percentile* (if not explained by familial short stature)</p> Growth velocity &#60;5 cm/year in a prepubertal child, or declining across over two or more height percentile curves on a standard chart (eg, decreasing from the 90th to the 50th percentile)</td> <td>Endocrine or genetic condition (eg, Cushing syndrome)</td> </tr> <tr> <td>Hypertension</td> <td>Hypertension if systolic or diastolic blood pressure &#62;95th percentile for age, gender, and height on &#8805;3 occasions</td> <td>Essential hypertension, renal disease, or Cushing syndrome</td> </tr> <tr> <td>Acanthosis nigricans</td> <td>Hyperpigmented, thickened, velvety skin in body folds and creases, particularly neck</td> <td>Increased risk of insulin resistance</td> </tr> <tr> <td>Excessive acne, hirsutism</td> <td>Hirsutism: excessive growth of hair in atypical areas, such as face and neck</td> <td>Polycystic ovary syndrome (PCOS)</td> </tr> <tr> <td>Violaceous striae</td> <td>Linear lesions, red, pink, or purple in color, particularly on abdomen</td> <td>Cushing syndrome</td> </tr> <tr> <td>Papilledema, cranial nerve VI paralysis</td> <td>Optic disc swelling on funduscopic exam, caused by increased intracranial pressure</td> <td>Pseudotumor cerebri (idiopathic intracranial hypertension)</td> </tr> <tr> <td>Tonsillar hypertrophy</td> <td>Tonsils occupy more than 50 percent of the lateral dimension of oropharynx</td> <td>Obstructive sleep apnea</td> </tr> <tr> <td>Goiter</td> <td>Enlarged or swollen thyroid gland</td> <td>Hypothyroidism</td> </tr> <tr> <td>Wheezing</td> <td>High-pitched whistling on auscultation</td> <td>Asthma</td> </tr> <tr> <td>Hepatomegaly, right upper quadrant tenderness</td> <td>Increased liver span</td> <td>Non-alcoholic fatty liver disease, or gallstones</td> </tr> <tr> <td>Micropenis</td> <td>Unusually small penis</td> <td>In most cases the small-appearing penis is actually normal size; the length is buried under suprapubic fat</td> </tr> <tr> <td>Undescended testes</td> <td>Testicle not palpable in scrotum</td> <td>Prader-Willi syndrome</td> </tr> <tr> <td>Abnormal gait, limp, pain in hip or groin, limited range of motion in hip</td> <td>&nbsp;</td> <td>Slipped capital femoral epiphysis (SCFE)</td> </tr> <tr> <td>Bowing of tibia</td> <td>Lower leg angles inward, causing a bowleg appearance</td> <td>Blount disease</td> </tr> <tr> <td>Small hands and feet, or polydactyly</td> <td>&nbsp;</td> <td>Genetic condition (eg, Prader-Willi syndrome or Bardet-Biedl syndrome)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Most children with obesity who have not completed linear growth are relatively tall for their age. Therefore, height &lt;50th percentile is unusual.</div><div id=\"graphicVersion\">Graphic 73272 Version 10.0</div></div></div>"},"73273":{"type":"graphic_diagnosticimage","displayName":"Pouch dilation after gastric banding","title":"Pouch dilation after gastric banding","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Pouch dilation after gastric banding</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/SURG/73273_Pouch_dilation_gast_banding.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This esophagram demonstrates a pouch dilation. The treatment for this is to deflate the band and slowly inflate it again.</div><div id=\"graphicVersion\">Graphic 73273 Version 7.0</div></div></div>"},"73274":{"type":"graphic_table","displayName":"DDx hoarseness child","title":"Differential diagnosis of hoarseness in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of hoarseness in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Congenital </td> </tr> <tr> <td>Subglottic stenosis*</td> </tr> <tr> <td>Laryngotracheal cleft</td> </tr> <tr> <td>Laryngeal web</td> </tr> <tr> <td>Laryngeal cysts</td> </tr> <tr> <td>Neonatal myasthenia gravis</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic </td> </tr> <tr> <td>Vocal fold paralysis*</td> </tr> <tr> <td>Arnold-Chiari malformation</td> </tr> <tr> <td>Hydrocephalus</td> </tr> <tr> <td>Meningomyelocele</td> </tr> <tr> <td>Wilson disease</td> </tr> <tr> <td>Neuritis</td> </tr> <tr> <td>Myasthenia gravis</td> </tr> <tr> <td>Muscular dystrophy</td> </tr> <tr> <td class=\"subtitle1_single\">Tumors </td> </tr> <tr> <td>Respiratory papillomatosis* (laryngeal papillomatosis)</td> </tr> <tr> <td>Hemangiomas*</td> </tr> <tr> <td>Laryngeal carcinoma</td> </tr> <tr> <td>Rhabdomyosarcoma</td> </tr> <tr> <td>Lymphangioma</td> </tr> <tr> <td class=\"subtitle1_single\">Allergy </td> </tr> <tr> <td>Allergic rhinitis*</td> </tr> <tr> <td>Angioedema</td> </tr> <tr> <td>Anaphylaxis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infection </td> </tr> <tr> <td>Laryngitis*</td> </tr> <tr> <td>Laryngotracheitis (Croup)*</td> </tr> <tr> <td>Epiglottitis</td> </tr> <tr> <td>Syphilis</td> </tr> <tr> <td>Meningitis</td> </tr> <tr> <td class=\"subtitle1_single\">Iatrogenic </td> </tr> <tr> <td>Cardiac surgery</td> </tr> <tr> <td>Birth trauma</td> </tr> <tr> <td>Intubation trauma*</td> </tr> <tr> <td class=\"subtitle1_single\">Psychogenic </td> </tr> <tr> <td>Puberphonia*</td> </tr> <tr> <td>Psychogenic stridor*</td> </tr> <tr> <td class=\"subtitle1_single\">Trauma/Irritation</td> </tr> <tr> <td>Vocal fold nodules*</td> </tr> <tr> <td>Vocal fold polyps</td> </tr> <tr> <td>Vocal fold hemorrhage</td> </tr> <tr> <td> <p>L<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">aryngopharyngeal reflux </span><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">(extra-esophageal GERD)</span>*</p> </td> </tr> <tr> <td>Postintubation*</td> </tr> <tr> <td>Foreign body aspiration</td> </tr> <tr> <td>Blunt neck trauma</td> </tr> <tr> <td>Penetrating neck trauma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Endocrine/metabolic </td> </tr> <tr> <td>Hypothyroidism</td> </tr> <tr> <td>Hypocalcemia</td> </tr> <tr> <td>Pregnancy</td> </tr> <tr> <td>Storage disorders</td> </tr> <tr> <td>Gaucher disease</td> </tr> <tr> <td>Farber disease</td> </tr> <tr> <td>Lipoid proteinosis</td> </tr> <tr> <td>Mucolipidosis II</td> </tr> <tr> <td class=\"subtitle1_single\">Genetic </td> </tr> <tr> <td>Cri-du-chat</td> </tr> <tr> <td>Familial dysautonomia</td> </tr> <tr> <td>Down syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Structural/mechanical </td> </tr> <tr> <td>Laryngomalacia*</td> </tr> <tr> <td>Tracheomalacia</td> </tr> <tr> <td>Subglottic stenosis*</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous causes </td> </tr> <tr> <td>Toxic ingestions</td> </tr> <tr> <td>Chemotherapy</td> </tr> <tr> <td>Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Amyloidosis</td> </tr> <tr> <td>Epidermolysis bullosa</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease.<br /><br />* Common causes within each category</div><div id=\"graphicVersion\">Graphic 73274 Version 4.0</div></div></div>"},"73275":{"type":"graphic_picture","displayName":"Subglottic hemangioma","title":"Endoscopic view of subglottic hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic view of subglottic hemangioma</div><div class=\"cntnt\"><img style=\"width:370px; height:367px;\" src=\"images/PEDS/73275_Subglottic_hemangioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the red-blue sessile lesion in the posterolateral subglottis.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 73275 Version 1.0</div></div></div>"},"73278":{"type":"graphic_table","displayName":"Contraindications TTO2","title":"Contraindications to transtracheal oxygen","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications to transtracheal oxygen</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Relative contraindications</td> </tr> <tr> <td class=\"indent1\">PaO<sub>2</sub> &#8804;55 mmHg at oxygen flow rate of 8 L/min or greater</td> </tr> <tr> <td class=\"indent1\">PaCO<sub>2</sub> &#62;50 mmHg</td> </tr> <tr> <td class=\"indent1\">FEV<sub>1</sub> &#60;500 mL or less than 70 percent of baseline</td> </tr> <tr> <td class=\"indent1\">Anatomic abnormality that makes insertion difficult (severe obesity, deviated trachea, previous tracheostomy)</td> </tr> <tr> <td class=\"indent1\">Coagulopathy, or medications that increase bleeding risk</td> </tr> <tr> <td class=\"indent1\">Risk of delayed healing (diabetes mellitus, glucocorticoid dependence, connective tissue disease)</td> </tr> <tr> <td class=\"indent1\">Uncontrolled bronchial hyperreactivity (eg, greater than 12 percent increase in post-bronchodilator spirometry)</td> </tr> <tr> <td class=\"indent1\">Poor mechanical reserve, weak cough</td> </tr> <tr> <td class=\"indent1\">Copious or viscous sputum production</td> </tr> <tr> <td class=\"indent1\">Mild to moderate anxiety</td> </tr> <tr> <td class=\"subtitle1_single\">Absolute contraindications</td> </tr> <tr> <td class=\"indent1\">Inability to practice self-care, including periodic stripping of catheter</td> </tr> <tr> <td class=\"indent1\">Uncompensated (acute) respiratory acidosis</td> </tr> <tr> <td class=\"indent1\">Severe coagulopathy</td> </tr> <tr> <td class=\"indent1\">Pleura herniated over puncture site</td> </tr> <tr> <td class=\"indent1\">Conditions that predispose to upper airway obstruction (subglottic stenosis, bilateral vocal cord paralysis)</td> </tr> <tr> <td class=\"indent1\">Severe anxiety</td> </tr> <tr> <td class=\"indent1\">Poor adherence to medical regimen</td> </tr> <tr> <td class=\"indent1\">Medically unstable</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PaO<sub>2</sub>: arterial tension of oxygen; PaCO<sub>2</sub>: arterial tension of carbon dioxide; FEV<sub>1</sub>: forced expiratory volume in one second.</div><div id=\"graphicVersion\">Graphic 73278 Version 4.0</div></div></div>"},"73280":{"type":"graphic_diagnosticimage","displayName":"Aortogram showing aortic rupture with pseudoaneurysm","title":"Aortogram showing aortic rupture with pseudoaneurysm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortogram showing aortic rupture with pseudoaneurysm</div><div class=\"cntnt\"><img style=\"width:266px; height:374px;\" src=\"images/SURG/73280_Aortic_pseudoaneurysm_angio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The aortogram, obtained following administration of contrast material into the aortic root, demonstrates a focal pseudoaneurysm (arrow) arising from the proximal descending aorta immediately distal to the origin of the left subclavian artery (small arrow). This traumatic tear of the aorta occurred during a motor vehicle accident.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 73280 Version 4.0</div></div></div>"},"73281":{"type":"graphic_table","displayName":"Causes early diastolic sounds","title":"Causes of a high frequency sound in early diastole","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of a high frequency sound in early diastole</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Mitral opening snap</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Organic mitral stenosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Rarely, pure mitral regurgitation</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Tricuspid opening snap</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Organic tricuspid stenosis</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Functional tricuspid stenosis (rare) </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Atrial septal defect</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">\"Tumor plop\"</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Left atrial myxoma</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Right atrial myxoma</td>\n    </tr>\n    <tr>\n\n      <td>Opening clicks of mitral stenosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mitral valve prolapse</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 73281 Version 1.0</div></div></div>"},"73282":{"type":"graphic_table","displayName":"Dietary triggers for migraine headache","title":"Dietary triggers for migraine headache","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary triggers for migraine headache</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Alcohol</td> </tr> <tr> <td>Chocolate</td> </tr> <tr> <td>Aged cheeses</td> </tr> <tr> <td>Monosodium glutamate (MSG)</td> </tr> <tr> <td>Aspartame (NutraSweet)</td> </tr> <tr> <td>Caffeine</td> </tr> <tr> <td>Nuts</td> </tr> <tr> <td>Nitrites, nitrates</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73282 Version 2.0</div></div></div>"},"73283":{"type":"graphic_picture","displayName":"Advanced lipodermatosclerosis","title":"Advanced lipodermatosclerosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Advanced lipodermatosclerosis</div><div class=\"cntnt\"><img style=\"width:248px; height:284px;\" src=\"images/PC/73283_Advanced_lipodermatoscleros.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In advanced cases of lipodermato- sclerosis, fibrosis binds the skin to the underlying tissue. Significant leg edema, erythema, and hyperpigmentation are present.</div><div class=\"graphic_reference\">Courtesy of Patrick C Alguire, MD.</div><div id=\"graphicVersion\">Graphic 73283 Version 2.0</div></div></div>"},"73286":{"type":"graphic_table","displayName":"Classification of gastritides and gastropathies","title":"Classification of gastritides and gastropathies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of gastritides and gastropathies</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Acute forms</td> </tr> <tr> <td class=\"indent1\">Acute hemorrhagic and erosive gastropathy</td> </tr> <tr> <td class=\"indent1\">Acute Helicobacter pylori gastritis</td> </tr> <tr> <td class=\"indent1\">Uncommon acute infectious gastritides</td> </tr> <tr> <td class=\"subtitle1_single\">Common forms</td> </tr> <tr> <td class=\"indent1\">Helicobacter pylori gastritis</td> </tr> <tr> <td class=\"sublist2_start\">Chemical gastropathy</td> </tr> <tr> <td class=\"sublist2\">Aspirin and other nonsteroidal antiinflammatory drugs</td> </tr> <tr> <td class=\"sublist2\">Bile reflux</td> </tr> <tr> <td class=\"sublist2\">Alcohol</td> </tr> <tr> <td class=\"sublist2\">Others (?)</td> </tr> <tr> <td class=\"sublist2_start\">Metaplastic atrophic gastritis</td> </tr> <tr> <td class=\"sublist2\">Autoimmune</td> </tr> <tr> <td class=\"sublist2\">Environmental</td> </tr> <tr> <td class=\"indent1\">Chronic gastritis/gastropathy of indeterminate type</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Uncommon forms</td> </tr> <tr> <td class=\"indent1\">Postantrectomy atrophic gastritis</td> </tr> <tr> <td class=\"indent1\">Eosinophilic gastritis</td> </tr> <tr> <td class=\"sublist2_start\">Infectious gastritis</td> </tr> <tr> <td class=\"sublist2\">Bacterial, other than Helicobacter pylori</td> </tr> <tr> <td class=\"sublist3\">Helicobacter heilmannii</td> </tr> <tr> <td class=\"sublist3\">Phlegmonous</td> </tr> <tr> <td class=\"sublist3\">Mycobacterial</td> </tr> <tr> <td class=\"sublist3\">Syphilitic</td> </tr> <tr> <td class=\"sublist2\">Viral</td> </tr> <tr> <td class=\"sublist2\">Parasitic</td> </tr> <tr> <td class=\"sublist2\">Fungal</td> </tr> <tr> <td class=\"indent1\">Crohn disease</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Isolated granulomatous gastritis</td> </tr> <tr> <td class=\"indent1\">Lymphocytic gastritis</td> </tr> <tr> <td class=\"indent1\">M&#233;n&#233;trier's disease</td> </tr> <tr> <td class=\"indent1\">Focally-enhanced gastritis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73286 Version 6.0</div></div></div>"},"73287":{"type":"graphic_table","displayName":"Conditions associated with elevated chromogranin A","title":"Conditions associated with elevated chromogranin A","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with elevated chromogranin A</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Gastroenteropancreatic neuroendocrine tumors</td> </tr> <tr> <td>Gastrointestinal tract (carcinoid tumors)</td> </tr> <tr> <td>Pancreatic NETs (islet cell tumors*)</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine disease</td> </tr> <tr> <td>Hyperparathyroidism</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Pheochromocytoma</td> </tr> <tr> <td>Pituitary tumors</td> </tr> <tr> <td>Medullary thyroid carcinoma</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal disorders</td> </tr> <tr> <td>Chronic atrophic gastritis</td> </tr> <tr> <td>Chronic hepatitis</td> </tr> <tr> <td>Colon cancer</td> </tr> <tr> <td>Hepatocellular carcinoma</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> <tr> <td>Irritable bowel syndrome</td> </tr> <tr> <td>Liver cirrhosis</td> </tr> <tr> <td>Pancreatic adenocarcinoma</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular disease</td> </tr> <tr> <td>Acute coronary syndrome</td> </tr> <tr> <td>Arterial hypertension</td> </tr> <tr> <td>Cardiac insufficiency/failure</td> </tr> <tr> <td>Essential hypertension</td> </tr> <tr> <td>Giant cell arteritis</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td>Proton pump inhibitors </td> </tr> <tr> <td>Histamine-2 receptor antagonists</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory disease</td> </tr> <tr> <td>Airway obstruction in smokers</td> </tr> <tr> <td>Chronic bronchitis</td> </tr> <tr> <td>Systemic rheumatoid arthritis</td> </tr> <tr> <td>Systemic inflammatory response syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Renal disorders</td> </tr> <tr> <td>Renal insufficiency/failure</td> </tr> <tr> <td class=\"subtitle1_single\">Non-gastrointestinal cancers</td> </tr> <tr> <td>Breast cancer</td> </tr> <tr> <td>Ovarian cancer</td> </tr> <tr> <td>Prostate cancer<sup>&#182;</sup></td> </tr> <tr> <td>Small cell lung cancer</td> </tr> <tr> <td>Neuroblastoma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Eg, gastrinomas, VIPomas, somatostatinomas, glucagonomas, non-functioning pancreatic neuroendocrine tumors.<br />¶&nbsp;Even with a normal prostate specific antigen level.</div><div class=\"graphic_reference\">Modified from Modlin IM, et al. Ann Surg Oncol 2010; 17:2427.</div><div id=\"graphicVersion\">Graphic 73287 Version 5.0</div></div></div>"},"73288":{"type":"graphic_picture","displayName":"Serous cystadenoma Light I","title":"Serous cystadenoma of the pancreas","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Serous cystadenoma of the pancreas</div><div class=\"cntnt\"><img style=\"width:541px; height:279px;\" src=\"images/GAST/73288_Serous_cystadenoma_Light_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low and high power light micrographs of a serous cystadenoma of the pancreas. Left panel: Low power reveals multiple microcystic spaces within the lesion. Right panel: High power shows that the lining of the cystadenoma is comprised of flat cubboidal glycogen-rich cells (arrow).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD and Michael L Steer, MD.</div><div id=\"graphicVersion\">Graphic 73288 Version 1.0</div></div></div>"},"73290":{"type":"graphic_figure","displayName":"Ovarian volume related to age","title":"Ovarian volume related to age","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Ovarian volume related to age</div><div class=\"cntnt\"><img style=\"width:536px; height:374px;\" src=\"images/ENDO/73290_Ovarian_volume_age_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 95% upper confidence limit (mean + 1.96 x SD) shows the upper range into which individual normal ovarian volume measurements will fall. Mean values are indicated by solid green circles. Bars indicate mean + 1.96 x SD.</div><div class=\"graphic_footnotes\">SD: standard deviation.</div><div class=\"graphic_reference\">Reproduced from: Pavlik EJ, DePriest PD, Gallion HH, et al. Ovarian volume related to age. Gynecologic Oncology 2000; 77: 410. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 73290 Version 4.0</div></div></div>"},"73292":{"type":"graphic_table","displayName":"Risk factors for heat illness in children","title":"Medical risk factors for heat illness in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical risk factors for heat illness in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Increased fluid losses</td> </tr> <tr> <td class=\"sublist1_start\">GI or renal losses</td> </tr> <tr> <td class=\"sublist1\">Gastrointestinal illness</td> </tr> <tr> <td class=\"sublist1\">Diabetes mellitus</td> </tr> <tr> <td class=\"sublist1\">Diabetes insipidus</td> </tr> <tr> <td class=\"sublist1\">Dehydration</td> </tr> <tr> <td class=\"sublist1_start\">Insensible losses</td> </tr> <tr> <td class=\"sublist1\">Burns</td> </tr> <tr> <td class=\"sublist1\">Febrile illness</td> </tr> <tr> <td class=\"sublist1_start\">Increased sweating</td> </tr> <tr> <td class=\"sublist1\">Cystic fibrosis</td> </tr> <tr> <td class=\"sublist1\">Congenital heart disease</td> </tr> <tr> <td class=\"subtitle1_single\">Impaired heat dissipation</td> </tr> <tr> <td>Ectodermal dysplasia</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Spinal cord lesions</td> </tr> <tr> <td class=\"subtitle1_single\">Impaired thirst mechanism</td> </tr> <tr> <td>Young children</td> </tr> <tr> <td>Children with developmental delay</td> </tr> <tr> <td class=\"subtitle1_single\">Impaired temperature regulation</td> </tr> <tr> <td>Anorexia nervosa</td> </tr> <tr> <td>Congenital or acquired brain injury with impaired hypothalamic function</td> </tr> <tr> <td class=\"subtitle1_single\">Environmental risk factors</td> </tr> <tr> <td>High heat index </td> </tr> <tr> <td>Poor preparation (lack of heat acclimitization, inadequate prehydration, lack of sleep or rest, or poor fitness)</td> </tr> <tr> <td>Excessive physical exertion</td> </tr> <tr> <td>Insufficient rehydration</td> </tr> <tr> <td>Clothing or equipment that causes excessive heat retention</td> </tr> <tr> <td class=\"subtitle1_single\">Other or multiple mechanisms</td> </tr> <tr> <td>Obesity</td> </tr> <tr> <td>Prescribed medications*</td> </tr> <tr> <td>Drug abuse<sup>&#182;</sup></td> </tr> <tr> <td>Juvenile hyperthyroidism (Grave disease)</td> </tr> <tr> <td>Prepubescent age</td> </tr> <tr> <td>Sickle cell disease and&nbsp;sickle cell trait</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal.<br />* Eg, dextroamphetamine for attention deficit disorder with hyperactivity, anticholinergic agents.<br />¶ Eg, metamphetamine, cocaine.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Ishimine P. Hyperthermia. In: Pediatric Emergency Medicine, Baren JM, Rothrock SG, Brennan JA, Brown L (Eds), Saunders Elsevier, Philadelphia, PA 2008. p.992.</li>&#xD;&#xA;    <li>Policy Statement - Climatic heat stress and exercising children and adolescents. American Academy of Pediatrics. Committee on Sports Medicine and Fitness and Council on School Health. Pediatrics 2011; 128: e741.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 73292 Version 6.0</div></div></div>"},"73293":{"type":"graphic_table","displayName":"Findings in adult male hypogonadism","title":"Signs and symptoms of adult male hypogonadism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms of adult male hypogonadism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Prepubertal onset</td> <td class=\"subtitle1\" colspan=\"2\">Postpubertal onset</td> </tr> <tr> <td class=\"subtitle2\">Primary</td> <td class=\"subtitle2\">Secondary</td> <td class=\"subtitle2\">Primary</td> <td class=\"subtitle2\">Secondary</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Symptoms</td> </tr> <tr> <td class=\"indent1\">Low energy</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Low libido</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Physical findings</td> </tr> <tr> <td class=\"indent1\">Small testes</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&#177;</td> </tr> <tr> <td class=\"indent1\">Small phallus</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Decreased body/facial hair</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> </tr> <tr> <td class=\"indent1\">Decreased muscle mass</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> </tr> <tr> <td class=\"indent1\">Eunuchoid proportions</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Gynecomastia</td> <td class=\"centered\">+</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Symptoms and physical findings in adults who have untreated hypogonadism grouped by whether the hypogonadism is of prepubertal or postpubertal onset and whether it is primary or secondary.</div><div id=\"graphicVersion\">Graphic 73293 Version 3.0</div></div></div>"},"73294":{"type":"graphic_table","displayName":"Manifestations of insulin resis","title":"Clinical manifestations of insulin resistance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of insulin resistance</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Glucose homeostasis</td>\n</tr>\n<tr>\n<td>Variable, including overt diabetes, impaired glucose tolerance, normal, and hypoglycemia</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Cutaneous</td>\n</tr>\n<tr>\n<td>Acanthosis nigricans</td>\n</tr>\n<tr>\n<td>Skin tags</td>\n</tr>\n<tr>\n<td>Alopecia</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Reproductive</td>\n</tr>\n<tr>\n<td>Amenorrhea</td>\n</tr>\n<tr>\n<td>Hirsutism</td>\n</tr>\n<tr>\n<td>Virilization</td>\n</tr>\n<tr>\n<td>Infertility (in women)</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Linear growth</td>\n</tr>\n<tr>\n<td>Variable, including normal, impaired, increased</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Adipose tissue</td>\n</tr>\n<tr>\n<td>Variable, including normal, lipoatrophy, lipohypertrophy, obesity</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Musculoskeletal</td>\n</tr>\n<tr>\n<td>Variable, including normal, cramps, muscle hypertrophy, pseudoacromegaly</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Lipid metabolism</td>\n</tr>\n<tr>\n<td>Normal or hypertriglyceridemia</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Autoimmunity</td>\n</tr>\n<tr>\n<td>Type B syndrome with variety of immune phenotypes</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 73294 Version 1.0</div></div></div>"},"73295":{"type":"graphic_movie","displayName":"Ruptured papillary muscle post MI 2-chamber view","title":"Ruptured papillary muscle","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ruptured papillary muscle</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/73295_2chruppaconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:239px; height:407px;\" src=\"images/CARD/73295_2chruppa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-chamber view from a two-dimensional echocardiogram shows flail anterior mitral valve leaflet due to a ruptured papillary muscle after a myocardial infarction. Part of the papillary muscle is attached to the leaflet.</div><div class=\"graphic_reference\">Courtesy of Neil Weissman, MD.</div><div id=\"graphicVersion\">Graphic 73295 Version 2.0</div></div></div>"},"73299":{"type":"graphic_waveform","displayName":"ECG nonsustained ventricular tachycardia","title":"Nonsustained ventricular tachycardia","html":"<div class=\"graphic normal\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Nonsustained ventricular tachycardia</div><div class=\"cntnt\"><img style=\"width:505px; height:127px;\" src=\"images/CARD/73299_Nonsustained_VT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nonsustained ventricular tachycardia in a patient with underlying atrial fibrillation. The ventricular arrhythmia consists of nine beats at an approximate rate of 170 beats/min.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 73299 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"73301":{"type":"graphic_diagnosticimage","displayName":"EUS five layer pattern","title":"Endoscopic ultrasound (EUS) of normal esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic ultrasound (EUS) of normal esophagus</div><div class=\"cntnt\"><img style=\"width:427px; height:324px;\" src=\"images/GAST/73301_EUS_five_layer_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">EUS examination of the normal esophagus showing the typical five-layer pattern: first hyperechoic layer (interface between lumen and mucosa), second hypoechoic layer (deep mucosa including muscularis mucosa), third hyperechoic layer (submucosa), fourth hypoechoic layer (muscularis propria), and fifth hyperechoic layer (adventitia interface).</div><div class=\"graphic_reference\">Courtesy of Enrique Vazquez-Sequeiros, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 73301 Version 4.0</div></div></div>"},"73307":{"type":"graphic_table","displayName":"Evaluation of acute flaccid paralysis","title":"Evaluation of the patient with acute flaccid paralysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of the patient with acute flaccid paralysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>History and examination</td> </tr> <tr> <td class=\"subtlist1_start\">Blood testing</td> </tr> <tr> <td class=\"sublist1\">Sedimentation rate</td> </tr> <tr> <td class=\"sublist1\">Autoimmune serology for vasculitis</td> </tr> <tr> <td class=\"sublist1\">Lyme titers</td> </tr> <tr> <td class=\"sublist1\">HIV-1 titers</td> </tr> <tr> <td class=\"sublist1\">HTLV-1 titers</td> </tr> <tr> <td class=\"sublist1\">CK level</td> </tr> <tr> <td>Cerebrospinal fluid analysis, including genetic amplification for polio and nonpolio enteroviruses, West Nile virus, varicella zoster virus, and rabies as indicated</td> </tr> <tr> <td>Stool samples for polio and nonpolio enteroviruses</td> </tr> <tr> <td>Pharyngeal swabs for polio and nonpolio enteroviruses</td> </tr> <tr> <td>Respiratory tract culture and toxin testing for diphtheria</td> </tr> <tr> <td>Toxin testing in serum, stool, and wounds for botulism</td> </tr> <tr> <td>Urinary porphobilinogen for porphyria</td> </tr> <tr> <td>Acetylcholine receptor antibodies for myasthenia gravis</td> </tr> <tr> <td>Electrodiagnostic testing (electromyography, nerve conduction studies, and repetitive stimulation studies)</td> </tr> <tr> <td>MRI of the spine</td> </tr> <tr> <td>MRI of the brain if bulbar involvement</td> </tr> <tr> <td>Nerve and muscle biopsy if mononeuritis multiplex and/or vasculitis suspected</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73307 Version 2.0</div></div></div>"},"73308":{"type":"graphic_diagnosticimage","displayName":"Bladder severe hydronephros","title":"Thickened bladder wall and key hole sign with severe hydronephrosis in a 30 4/7 week old fetus with posterior urethral valves. ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thickened bladder wall and key hole sign with severe hydronephrosis in a 30 4/7 week old fetus with posterior urethral valves. </div><div class=\"cntnt\"><img style=\"width:376px; height:296px;\" src=\"images/PEDS/73308_Bladder_severe_hydronephros.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">BL: bladder; RT: right kidney; LT: left kidney.</div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 73308 Version 4.0</div></div></div>"},"73309":{"type":"graphic_figure","displayName":"Burn class depth skin","title":"Burn classification","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Burn classification</div><div class=\"cntnt\"><img style=\"width:534px; height:421px;\" src=\"images/SURG/73309_Burn_class_depth_skin.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73309 Version 1.0</div></div></div>"},"73310":{"type":"graphic_table","displayName":"Concerning symptoms after oropharyngeal trauma","title":"Concerning symptoms after oropharyngeal trauma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Concerning symptoms after oropharyngeal trauma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\t\n\t<tr>\n\t    <td class=\"subtitle1_single\">Symptoms suggesting deep neck infection</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Fever</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Neck pain</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Torticollis</td>\n\t  </tr>\n\t  <tr>\n\t    <td>New onset of drooling or dysphagia</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Increased neck swelling or bleeding from the mouth</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle1_single\">Symptoms suggesting cerebral artery thrombosis</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Altered mental status</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Seizures</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Slurred or confused speech</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Arm or leg weakness</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Clumsy gait or excessive falling</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Visual changes</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Irritability</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Vomiting</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Headache</td>\n\t  </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=12471&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>OP_trauma_symptoms.htm</title></head></div><div id=\"graphicVersion\">Graphic 73310 Version 2.0</div></div></div>"},"73311":{"type":"graphic_algorithm","displayName":"Diagnosis of demyelinating clinical event","title":"Diagnosis of demyelinating clinical event","html":"<div class=\"graphic\"><div style=\"width: 649px\" class=\"figure\"><div class=\"ttl\">Diagnosis of demyelinating clinical event</div><div class=\"cntnt\"><img style=\"width:629px; height:387px;\" src=\"images/PEDS/73311_Dxdemyelinating.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ADEM: acute disseminated encephalomyelitis; CIS: clinically isolated syndrome; ON: optic neuritis; TM: transverse myelitis; NMO: neuromyelitis optica; DIS: dissemination in space; DIT: dissemination in time; MS: multiple sclerosis.</div><div id=\"graphicVersion\">Graphic 73311 Version 5.0</div></div></div>"},"73313":{"type":"graphic_diagnosticimage","displayName":"Multiple fractures","title":"Multiple fractures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple fractures</div><div class=\"cntnt\"><img style=\"width:209px; height:490px;\" src=\"images/EM/73313_Multiple_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 2-month-old with multiple fractures in various stages of healing (acute distal humerus lateral condyle fracture and old segmental fracture of the radius). Multiple fractures, old or in various stages of healing, are highly suggestive of child abuse.</div><div class=\"graphic_reference\">Courtesy of Susan A Scherl, MD.</div><div id=\"graphicVersion\">Graphic 73313 Version 3.0</div></div></div>"},"73314":{"type":"graphic_waveform","displayName":"Intermediate case 12","title":"Intermediate case 12","html":"<div class=\"graphic normal\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Intermediate case 12</div><div class=\"cntnt\"><img style=\"width:533px; height:267px;\" src=\"images/CARD/73314_Intermediate_case_12.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73314 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"73317":{"type":"graphic_figure","displayName":"Incidence pertussis US 1990 to 2011","title":"Incidence pertussis, United States, 1990 to 2011","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Incidence pertussis, United States, 1990 to 2011</div><div class=\"cntnt\"><img style=\"width:528px; height:367px;\" src=\"images/ID/73317_Report_pertusis_case_US_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Centers for Disease Control and Prevention, National Notifiable Diseases Surveillance System, 2011. Available at <a href=\"http://www.cdc.gov/pertussis/surv-reporting.html\" style=\"font-style: italic;\" target=\"_blank\">www.cdc.gov/pertussis/surv-reporting.html</a> (Accessed on January 29, 2013).</div><div id=\"graphicVersion\">Graphic 73317 Version 5.0</div></div></div>"},"73318":{"type":"graphic_picture","displayName":"Vitritis in endophthalmitis","title":"Active vitritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Active vitritis</div><div class=\"cntnt\"><img style=\"width:376px; height:270px;\" src=\"images/ID/73318_Vitritis_in_endophthalmitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Active vitritis in endogenous <EM>Candida</EM> endophthalmitis. Several fluff balls typical of <EM>Candida</EM> infection can be seen with difficulty; the haziness is due to vitreal inflammation.</div><div class=\"graphic_reference\">Courtesy of Carol Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 73318 Version 3.0</div></div></div>"},"73319":{"type":"graphic_picture","displayName":"Dense deposit disease EM","title":"Electron microscopy in dense deposit disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron microscopy in dense deposit disease</div><div class=\"cntnt\"><img style=\"width:396px; height:252px;\" src=\"images/NEPH/73319_Dense_deposit_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in dense deposit disease (DDD) showing dense, ribbon-like appearance of subendothelial and intramembranous material (arrow) and narrowing of the capillary lumen due to proliferation of cells (double arrow).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 73319 Version 3.0</div></div></div>"},"73323":{"type":"graphic_table","displayName":"Classification of thymic tumors","title":"Classification of thymic epithelial tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of thymic epithelial tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Levine and Rosai*</td> <td class=\"subtitle1\">M&#252;ller-Hermelink, et al<sup>&#182;</sup></td> <td class=\"subtitle1\">WHO<sup>&#916;</sup></td> </tr> <tr> <td>Thymoma</td> <td>Thymoma</td> <td>Thymoma</td> </tr> <tr> <td rowspan=\"2\">Encapsulated</td> <td>Medullary type</td> <td>Type A</td> </tr> <tr> <td>Mixed type</td> <td>Type AB</td> </tr> <tr> <td rowspan=\"3\">Malignant type I (invasive)</td> <td>Predominantly cortical</td> <td>Type B1 </td> </tr> <tr> <td>Cortical type</td> <td>Type B2</td> </tr> <tr> <td>Well-differentiated carcinoma</td> <td>Type B3</td> </tr> <tr> <td>Malignant type II</td> <td>Thymic carcinoma</td> <td>Thymic carcinoma (Type C thymoma)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">* Levine GD, Rosai J. Hum Pathol 1978; 9:495.<br />¶&nbsp;Marino M, Müller-Hermelink HK. Virchows Arch A Pathol Anat Histopathol 1985; 407:119.<br />Δ Rosai J. Histological Typing of Tumours of the Thymus, 2nd ed, Springer, Berlin, 1999.</div><div id=\"graphicVersion\">Graphic 73323 Version 3.0</div></div></div>"},"73324":{"type":"graphic_table","displayName":"DCF for advanced gastric cancer","title":"Chemotherapy regimens for advanced esophagogastric cancer: Docetaxel, cisplatin, and fluorouracil (DCF)<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemotherapy regimens for advanced esophagogastric cancer: Docetaxel, cisplatin, and fluorouracil (DCF)<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Docetaxel</td> <td>75 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (NS) to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.</td> <td>Day 1</td> </tr> <tr> <td>Cisplatin</td> <td>75 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS and administer over 60 minutes. Do not administer with aluminum needles or IV sets.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Fluorouracil (FU)</td> <td>750 mg/m<sup>2</sup> per day IV</td> <td>Dilute in 500 to 1000 mL 5% dextrose in water and administer as a continuous infusion over 24 hours. For use in an ambulatory infusion pump. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.</td> <td>Days 1 through 5</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for two hours before and two hours after cisplatin administration. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with dexamethasone prior to docetaxel administration.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Docetaxel and cisplatin are irritants, but can cause significant tissue damage; avoid extravasation.<sup>[2,3]</sup> </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF indicated (incidence of neutropenic fever 29%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Docetaxel should not be given if serum bilirubin is above the ULN, or if the AST and/or ALT &#62;1.5 times the ULN concomitant with alkaline phosphatase &#62;2.5 times the ULN.<sup>[3]</sup> Dose modifications of FU may be needed for patients with hepatic impairment.<sup>[4]</sup> The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown; such patients were excluded from the original trial.<sup>[1]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for known drug interactions</strong></td> <td colspan=\"3\"> <ul> <li>Caution is needed when administering docetaxel with strong CYP3A4 inhibitors. Although specific dose recommendations are not available, the United States Prescribing Information suggests close monitoring for toxicity and consideration of docetaxel dose reduction if coadministration with a strong CYP3A4 inhibitor cannot be avoided.<sup>[3]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential and platelet count prior to each cycle of treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel including creatinine and electrolytes, and liver function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for neurotoxicity, diarrhea, and palmar-plantar erythrodysesthesias prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Patients should not be retreated until neutrophils recover to &#62;1500 cells/microL and platelets recover to &#62;100,000/microL.<sup>[3]</sup> If the platelet count declines to &#60;25,000/microL during therapy, reduce subsequent doses of docetaxel by 20%. After the first episode of ANC &#60;1000 cells/microL lasting &#62;7 days or febrile neutropenia or neutropenic infection despite G-CSF support, reduce docetaxel dose by 20%.<sup>[3,5]</sup> For a second episode, reduce subsequent doses of docetaxel by another 20%. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL.<sup>[2]</sup> For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate rehydration), creatinine clearance should be determined prior to next cycle and cisplatin dose reduced if &#60;60 mL/min. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Reduce cisplatin dose 20% for grade &#8805;2 peripheral neuropathy and discontinue for grade 3 neuropathy.<sup>[2,5]</sup> </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold FU treatment for grade 3 or worse diarrhea and restart at a lower dose after complete resolution. For the first episode of grade 3 diarrhea or grade 3 or 4 stomatitis, reduce FU by 20%; subsequent episodes, reduce docetaxel 20%.<sup>[3]</sup> First episode of grade 4 diarrhea, reduce both docetaxel and FU by 20%; subsequent episodes, discontinue treatment. </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. </li> <li>Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Palmar-plantar erythrodysesthesia</strong></td> <td colspan=\"3\"> <ul> <li>Hold FU for grade 2 or greater palmar-plantar erythrodysesthesia, and reduce subsequent dose by 20%.<sup>[6]</sup> </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Docetaxel should not be given if serum bilirubin is above the ULN, or if the AST and/or ALT &#62;1.5 times the ULN concomitant with alkaline phosphatase &#62;2.5 times the ULN.<sup>[3]</sup> For intracycle increases of AST/ALT &#62;2.5 but &#8804;5 times the ULN, and alkaline phosphatase &#60;2.5 times the ULN <strong>OR</strong> AST/ALT &#62;1.5 to &#8804;5 times the ULN <strong>AND</strong> alkaline phosphatease &#62;2.5 to &#8804;5 times the ULN, reduce docetaxel by 20%.<sup>[3]</sup> Discontinue docetaxel if AST/ALT &#62;5 times the ULN <strong>AND/OR</strong> alkaline phosphatase &#62;5 times the ULN. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; ALT: alanine aminotranferease; AST: aspartate aminotransferase; G-CSF: granulocyte colony-stimulating factor; CBC: complete blood count; ULN: upper limit of normal.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Van Cutsem E, et al. J Clin Oncol 2006; 24:4991.</li>&#xD;&#xA;    <li>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on March 10, 2011).</li>&#xD;&#xA;    <li>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on March 10, 2011).</li>&#xD;&#xA;    <li>Floyd J, et al. Semin Oncol 2006; 33:50.</li>&#xD;&#xA;    <li>Ajani JA, et al. J Clin Oncol 2005; 23:5660.</li>&#xD;&#xA;    <li>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on March 10, 2011).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 73324 Version 31.0</div></div></div>"},"73325":{"type":"graphic_figure","displayName":"Global distribution of B pseudomallei and melioidosis","title":"The global distribution of Burkholderia pseudomallei and melioidosis","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">The global distribution of Burkholderia pseudomallei and melioidosis</div><div class=\"cntnt\"><img style=\"width:602px; height:385px;\" src=\"images/ID/73325_Global_dist_melio_ed2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Global map showing the categories of distribution of melioidosis and Burkholderia pseudomallei. Pink asterisks indicated three documentated temperate outbreaks of melioidosis: France; southeast Queensland, Australia; and southwest Western Australia.</div><div class=\"graphic_reference\">Reproduced from: Currie BJ, Dance DA, Cheng AC. The global distribution of Burkholderia pseudomallei and melioidosis: An update. Trans R Soc Trop Med Hyg 2008; 102 Suppl 1:S1-4. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 73325 Version 3.0</div></div></div>"},"73326":{"type":"graphic_table","displayName":"Inhibitors and inducers of P-glycoprotein drug efflux","title":"Inhibitors and inducers of P-glycoprotein (P-gp) drug efflux pump (P-gp multidrug resistance transporter)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inhibitors and inducers of P-glycoprotein (P-gp) drug efflux pump (P-gp multidrug resistance transporter)</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33.33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Inhibitors of P-gp</td> </tr> <tr> <td class=\"indent1\">Amiodarone</td> <td>Lopinavir-ritonavir</td> </tr> <tr> <td class=\"indent1\">Azithromycin (systemic)</td> <td>Neratinib</td> </tr> <tr> <td class=\"indent1\">Carvedilol</td> <td>Ombitasvir-paritaprevir-ritonavir (Technivie)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Clarithromycin</td> <td>Propafenone</td> </tr> <tr> <td class=\"indent1\">Cobicistat and cobicistat-containing coformulations*</td> <td>Quinidine</td> </tr> <tr> <td class=\"indent1\">Cyclosporine (systemic)</td> <td>Quinine</td> </tr> <tr> <td class=\"indent1\">Daclatasvir</td> <td>Ranolazine</td> </tr> <tr> <td class=\"indent1\">Dronedarone</td> <td>Ritonavir and ritonavir -containing coformulations<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Eliglustat</td> <td>Rolapitant</td> </tr> <tr> <td class=\"indent1\">Erythromycin (systemic)</td> <td>Simeprevir</td> </tr> <tr> <td class=\"indent1\">Flibanserin</td> <td>Tacrolimus (systemic)*</td> </tr> <tr> <td class=\"indent1\">Glecaprevir-pibrentasvir</td> <td>Tamoxifen*</td> </tr> <tr> <td class=\"indent1\">Itraconazole</td> <td>Telaprevir</td> </tr> <tr> <td class=\"indent1\">Ivacaftor</td> <td>Ticagrelor*</td> </tr> <tr> <td class=\"indent1\">Ketoconazole (systemic)</td> <td>Velpatasvir</td> </tr> <tr> <td class=\"indent1\">Lapatinib</td> <td>Vemurafenib</td> </tr> <tr> <td class=\"indent1\">Ledipasvir</td> <td>Verapamil</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Inducers of P-gp</td> </tr> <tr> <td class=\"indent1\">Apalutamide</td> </tr> <tr> <td class=\"indent1\">Fosphenytoin</td> </tr> <tr> <td class=\"indent1\">Phenobarbital*</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> </tr> <tr> <td class=\"indent1\">Rifampin (rifampicin)</td> </tr> <tr> <td class=\"indent1\">St. John's wort</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Inhibitors of the P-gp drug efflux pump (also known as P-gp multidrug resistance transporter) listed above may <STRONG>increase</STRONG> serum concentrations of drugs that are substrates of P-gp, whereas inducers of P-gp drug efflux may <STRONG>decrease</STRONG> serum concentrations of substrates of P-gp.</LI>&#xD;&#xA;<LI>Examples of drugs that are substrates of P-gp efflux pump include: Apixaban, colchicine, cyclosporine, dabigatran, digoxin, rivaroxaban, and tacrolimus.</LI>&#xD;&#xA;<LI>The degree of effect on P-gp substrate serum concentration may be altered by dose and timing of orally administered P-gp inhibitor or inducer.</LI>&#xD;&#xA;<LI>These classifications are based upon US Food &amp; Drug Administration (US FDA) guidance.<SUP>[1,2]</SUP> Other&nbsp;sources may use a different classification system resulting in some agents being classified differently.</LI>&#xD;&#xA;<LI>Specific drug interaction effects may be determined by using Lexi-Interact, the drug interactions program included with UpToDate. Refer to UpToDate clinical topics on specific agents and conditions for further details.</LI></UL></div><div class=\"graphic_footnotes\">* Minor clinical effect or supportive data are limited to in-vitro effects (ie, clinical effect is unknown).<br />¶ The combination of ombitasvir-paritaprevir-ritonavir plus dasabuvir (Viekira Pak) is not a significant inhibitor of P-gp efflux pump<SUP>[3]</SUP>.</div><div class=\"graphic_reference\">Lexicomp Online (Lexi-Interact). Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.<br /><br />References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>US Food &amp; Drug Administration. Clinical drug interaction studies - Study design, data analysis and clinical implications; Guidance for industry (October 24, 2017) available at: <A href=\"https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf\">https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf</A>&nbsp;</LI>&#xD;&#xA;<LI>US Food &amp; Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: <A spellcheck=true href=\"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm\">FDA.gov </A>website.</LI>&#xD;&#xA;<LI>Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol 2015; 63:20.</LI></OL></div><div id=\"graphicVersion\">Graphic 73326 Version 38.0</div></div></div>"},"73327":{"type":"graphic_picture","displayName":"Age related trabecular loss","title":"Age-related loss of trabecular bone","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Age-related loss of trabecular bone</div><div class=\"cntnt\"><img style=\"width:554px; height:201px;\" src=\"images/ENDO/73327_Age_related_trabecular_loss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequential trabecular loss as shown by histologic examination of bone specimens; the vertical trabeculae are shown in yellow, the horizontal in blue-green.<br />(A)&nbsp;Normal 50-year-old man with an almost perfect continuous trabecular network<br />(B)&nbsp;58-year-old man with thinning of the horizontal trabeculae and some loss of continuity.<br />(C) 76-year-old man with continued thinning of the horizontal trabeculae and wider separation of the vertical structures.<br />(D)&nbsp;87-year-old woman with advanced breakdown of the entire network showing unsupported vertical trabeculae.<br />Panels C and D&nbsp;represent the degree of loss of bone mass and microarchitectural deterioration that is generally defined as osteoporosis.</div><div class=\"graphic_reference\">From: Mosekilde LI. Age-related changes in vertebral trabecular bone architecture—assessed by a new method.&nbsp;Bone 1988; 9:247. Reprinted with permission from Pergamon Press.</div><div id=\"graphicVersion\">Graphic 73327 Version 3.0</div></div></div>"},"73328":{"type":"graphic_picture","displayName":"Bleeding Dieulafoy Endosc","title":"Gastric Dieulafoy's lesion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Gastric Dieulafoy's lesion</div><div class=\"cntnt\"><img style=\"width:504px; height:561px;\" src=\"images/GAST/73328_Bleeding_Dieulafoy_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Active bleeding from a gastric Dieulafoy's lesion (A) along the proximal antrum/anterior wall. The bleeding was controlled with combination endoscopic therapy consisting of: Injection therapy with a 10 French Injector-Gold Probe (Microvasive Corp) using 1:10,000 epinephrine (B), followed by bipolar electrocoagulation at 12 Watts x 10 sec/pulse x 4 pulses using firm tamponade pressure (C), then hemoclipping x 1 (Olympus Corp) (D). India ink tatooing (E) was then performed to mark the treatment site in the event of rebleeding and facilitate localization if surgical intervention (such as wedge resection) is required.</div><div class=\"graphic_reference\">Courtesy of Rome Jutabha, MD.</div><div id=\"graphicVersion\">Graphic 73328 Version 1.0</div></div></div>"},"73329":{"type":"graphic_movie","displayName":"Left ventricular hypertrophy parasternal long axis echo","title":"Left ventricular hypertrophy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular hypertrophy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/73329_palaxlvhconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:250px; height:396px;\" src=\"images/CARD/73329_palaxlvh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parasternal long axis view from a 2-D echocardiogram shows marked thickening of the interventricular septum and posterior left ventricular (LV) wall as a result of hypertrophy.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 73329 Version 2.0</div></div></div>"},"73330":{"type":"graphic_diagnosticimage","displayName":"Lung area HC ratio","title":"Lung area to head circumference ratio (LHR) measurement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lung area to head circumference ratio (LHR) measurement</div><div class=\"cntnt\"><img style=\"width:288px; height:286px;\" src=\"images/OBGYN/73330_Lung_area_HC_ratio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In left congenital diaphragmatic hernia, the LHR is calculated by measuring the two-dimensional area of the right lung (in square millimeters) at the level of the atria and dividing by the head circumference (in millimeters).</div><div class=\"graphic_footnotes\">H: heart; FL: fetal liver; SP: spine: LT: left.</div><div class=\"graphic_reference\">Courtesy of Holly L Hedrick, MD.</div><div id=\"graphicVersion\">Graphic 73330 Version 3.0</div></div></div>"},"73332":{"type":"graphic_table","displayName":"Aircraft cabin pressurization","title":"Cabin pressurization in different commercial aircraft","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cabin pressurization in different commercial aircraft</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Aircraft type</td> <td class=\"subtitle1\">Differential pressure, mmHg</td> <td class=\"subtitle1\">Cabin altitude, ft</td> </tr> <tr> <td>B-727</td> <td>445.0586</td> <td>5400</td> </tr> <tr> <td>B-757</td> <td>445.0586</td> <td>5400</td> </tr> <tr> <td>B-767</td> <td>445.0586</td> <td>5400</td> </tr> <tr> <td>B-747</td> <td>460.5839</td> <td>4700</td> </tr> <tr> <td>B-737</td> <td>385.545</td> <td>8000</td> </tr> <tr> <td>DC-9</td> <td>401.5878</td> <td>7300</td> </tr> <tr> <td>A-300</td> <td>426.9458</td> <td>6100</td> </tr> <tr> <td>A-320</td> <td>429.5333</td> <td>6000</td> </tr> <tr> <td>L-1011</td> <td>434.7084</td> <td>5800</td> </tr> <tr> <td>BAC-111</td> <td>388.1325</td> <td>7900</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Cottrell JJ. Altitude exposures during aircraft flight: Flying higher. Chest 1988; 93:81.</div><div id=\"graphicVersion\">Graphic 73332 Version 4.0</div></div></div>"},"73334":{"type":"graphic_table","displayName":"ACR criteria for SLE","title":"ACR criteria for the classification of systemic lupus erythematosus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACR criteria for the classification of systemic lupus erythematosus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Criterion </td> <td class=\"subtitle1\">Definition </td> </tr> <tr> <td>Malar rash</td> <td>Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds</td> </tr> <tr> <td>Discoid rash</td> <td>Erythematosus raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring may occur in older lesions</td> </tr> <tr> <td>Photosensitivity</td> <td>Skin rash as a result of unusual reaction to sunlight, by patient history or&nbsp;clinician observation</td> </tr> <tr> <td>Oral ulcers</td> <td>Oral or nasopharyngeal ulceration, usually painless, observed by a clinician</td> </tr> <tr> <td>Arthritis</td> <td>Nonerosive arthritis involving&nbsp;two or more peripheral joints, characterized by tenderness, swelling, or effusion</td> </tr> <tr> <td rowspan=\"2\">Serositis </td> <td>Pleuritis - Convincing history of pleuritic pain or rub heard by a&nbsp;clinician or evidence of pleural effusion <strong>OR</strong></td> </tr> <tr> <td>Pericarditis - Documented by EKG, rub, or evidence of pericardial effusion</td> </tr> <tr> <td rowspan=\"2\">Renal disorder </td> <td>Persistent proteinuria greater than 0.5 grams per day or greater than 3+ if quantitation not performed <strong>OR</strong></td> </tr> <tr> <td>Cellular casts - May be red cell, hemoglobin, granular, tubular, or mixed</td> </tr> <tr> <td>Neurologic disorder</td> <td>Seizures <strong>OR</strong> psychosis - In the absence of offending drugs or known metabolic derangements (uremia, ketoacidosis, or electrolyte imbalance)</td> </tr> <tr> <td rowspan=\"4\">Hematologic disorder </td> <td>Hemolytic anemia - With reticulocytosis <strong>OR</strong></td> </tr> <tr> <td>Leukopenia - Less than 4000/mm<sup>3</sup> total on two or more occasions <strong>OR </strong></td> </tr> <tr> <td>Lymphopenia - Less than 1500/mm<sup>3</sup> on two or more occasions <strong>OR</strong></td> </tr> <tr> <td>Thrombocytopenia - Less than 100,000/mm<sup>3</sup> in the absence of offending drugs</td> </tr> <tr> <td rowspan=\"3\">Immunologic disorders </td> <td>Anti-DNA - Antibody to native DNA in abnormal titer <strong>OR</strong></td> </tr> <tr> <td>Anti-Sm - Presence of antibody to Sm nuclear antigen <strong>OR</strong></td> </tr> <tr> <td> <p>Positive antiphospholipid antibody on:</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;1. An abnormal serum level of IgG or IgM anticardiolipin antibodies, or</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;A positive test result for lupus anticoagulant using a standard method, or</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;A false-positive test result for at least&nbsp;six months confirmed by Treponema pallidum immobilization or fluorescent treponemal antibody absorption test</p> </td> </tr> <tr> <td>Antinuclear antibody</td> <td>An abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at any point in time and in the absence of drugs known to be associated with \"drug-induced lupus\" syndrome</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACR: American College of Rheumatology; EKG: electrocardiogram; IgG: immunoglobulin G; IgM: immunoglobulin M.</div><div id=\"graphicVersion\">Graphic 73334 Version 5.0</div></div></div>"},"73335":{"type":"graphic_picture","displayName":"Blood smear too thin","title":"Blood smear too thin","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blood smear too thin</div><div class=\"cntnt\"><img style=\"width:412px; height:270px;\" src=\"images/HEME/73335_Blood_smear_too_thin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Suboptimally prepared peripheral blood smear which is too thin. This low power view shows red cells which appear flattened and &quot;brick like&quot; in appearance.</div><div class=\"graphic_reference\">Courtesy of Jackie Mitus, MD.</div><div id=\"graphicVersion\">Graphic 73335 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"73338":{"type":"graphic_table","displayName":"Accuracy US in Dx IBD","title":"Ultrasonography: sensitivity and specifity in the detection of inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ultrasonography: sensitivity and specifity in the detection of inflammatory bowel disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Sensitivity, percent</td> <td class=\"subtitle1\">Specificity, percent</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Study</td> </tr> <tr> <td>84</td> <td>97</td> <td>57</td> <td>Khaw KT, et al 1990</td> </tr> <tr> <td>90</td> <td>94</td> <td>240</td> <td>Bozkurt T, et al 1994</td> </tr> <tr> <td>88</td> <td>93</td> <td>38</td> <td>Faure C, et al 1997</td> </tr> <tr> <td>70</td> <td>93</td> <td>32</td> <td>Pradel JA, et al 1997</td> </tr> <tr> <td>94</td> <td>67</td> <td>118</td> <td>Reimund JM, et al 1999</td> </tr> <tr> <td>76</td> <td>95</td> <td>227*</td> <td>Hollerbach S, et al 1998</td> </tr> <tr> <td>85</td> <td>95</td> <td>487</td> <td>Parente F, et al 2003</td> </tr> <tr> <td>98</td> <td>97</td> <td>84<sup>&#182;</sup></td> <td>Rispo A, et al 2005</td> </tr> <tr> <td>55</td> <td>100</td> <td>28<sup>&#916;</sup></td> <td>Mittal MK, et al 2013</td> </tr> <tr> <td>55</td> <td>100</td> <td>28<sup>&#916;&#9674;</sup>/23<sup>&#916;&#167;</sup></td> <td>Ziech ML, et al 2014</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">IBD: inflammatory bowel disease.</div><div class=\"graphic_footnotes\">* Patients with symptoms suggestive of IBD<br />¶ Patients with suspected or known Crohn disease<br />Δ Pediatric patients<br />◊ With suspected IBD<br />§ With established IBD<br />​</div><div id=\"graphicVersion\">Graphic 73338 Version 2.0</div></div></div>"},"73339":{"type":"graphic_picture","displayName":"Barretts high grade methyl blue","title":"Chromoendoscopy of Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chromoendoscopy of Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:312px; height:327px;\" src=\"images/GAST/73339_Barretts_high_grade_methyl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic image of diffusely-stained, long-segment Barrett's esophagus with an area of heterogenous staining (pink or unstained mucosa) corresponding to high grade dysplasia, which was confirmed by biopsy.</div><div class=\"graphic_reference\">Courtesy of Marcia I Canto, MD, MHS.</div><div id=\"graphicVersion\">Graphic 73339 Version 3.0</div></div></div>"},"73343":{"type":"graphic_picture","displayName":"Bilateral port wine stains in SWS","title":"Bilateral port wine stains in a child with Sturge-Weber syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral port wine stains in a child with Sturge-Weber syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/73343_SWeber_syndr_bilateral_PWS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral port wine stains are present on the face of this patient with Sturge-Weber syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73343 Version 5.0</div></div></div>"},"73344":{"type":"graphic_picture","displayName":"Chronic GVHD buccal mucosa","title":"Oral chronic graft-versus-host disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral chronic graft-versus-host disease</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/73344_Chronic_GVHD_buccal_mucosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reticulated white plaques and erosions are present on the buccal mucosa. The findings resemble oral lichen planus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73344 Version 3.0</div></div></div>"},"73345":{"type":"graphic_table","displayName":"Age-specific counseling to prevent smoking initiation","title":"Counseling about the health effects of smoking in different age groups","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Counseling about the health effects of smoking in different age groups</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Age group</td>\r\n            <td class=\"subtitle1\">Most compelling information</td>\r\n            <td class=\"subtitle1\">Secondary information</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"2\"><strong>Parent</strong></td>\r\n            <td class=\"subtitle2_left\">Effects of secondhand smoke on their children and other household members</td>\r\n            <td class=\"subtitle2_left\">Personal health risks (emphasize those with personal relevance)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <p>Higher rates of asthma, colds, pneumonia, and ear infections, even if parents do not smoke in the house</p>\r\n            <p>Increases rates of heart disease in the long term</p>\r\n            <p>Children are much more likely to become smokers if their parents smoke, even if parents tell children not to start</p>\r\n            </td>\r\n            <td>\r\n            <p>Heart disease: chance of heart attack is 3 to 6 times higher in smokers</p>\r\n            <p>Lung cancer: chance of getting lung cancer is up to 30 times higher in smokers</p>\r\n            <p>Other cancers: smoking increases the risk for at least 10 types of cancer, including kidney, liver, lung, pancreas, stomach, and cervix</p>\r\n            <p>Other lung disease: smoking increases asthma, bronchitis, pneumonia, chronic cough</p>\r\n            <p>Other: smoking increases risk for infertility, premature birth, ulcers, osteoporosis, and diabetes</p>\r\n            </td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td rowspan=\"2\"><strong>School age</strong><br />\r\n            (5 to 11 years)</td>\r\n            <td class=\"subtitle2_left\">Immediate effects of smoking</td>\r\n            <td class=\"subtitle2_left\">Long-term or less concrete consequences</td>\r\n        </tr>\r\n        <tr>\r\n            <td>\r\n            <p>Bad breath and smell</p>\r\n            <p>Yellow teeth</p>\r\n            <p>Harder to keep up in sports</p>\r\n            <p>Even trying smoking just a few times can get your body hooked so that it is harder to stop</p>\r\n            </td>\r\n            <td>\r\n            <p>Cigarettes are expensive. Smokers spend money on cigarettes that they could use for more fun things.</p>\r\n            <p>Tobacco companys use ads to try to trick you into thinking that smoking is cool and safe</p>\r\n            <p>Smoking has long-term effects on health, including several types of cancer, and heart attacks</p>\r\n            <p>It is illegal to buy cigarettes when you are under-age</p>\r\n            </td>\r\n        </tr>\r\n        <tr class=\"divider_top\">\r\n            <td rowspan=\"6\"><strong>Adolescent</strong></td>\r\n            <td class=\"subtitle2_left\">Immediate effects of smoking</td>\r\n            <td class=\"subtitle2_left\">Long-term health consequences</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"5\">\r\n            <p>Cosmetic effects (smell, bad breath, yellow teeth, early wrinkles)</p>\r\n            <p>Reduced endurance and athletic performance</p>\r\n            <p>More hacking coughs, colds and pneumonias</p>\r\n            <p>Smoking does not&nbsp;cause&nbsp;weight loss in teens</p>\r\n            <p>You can get addicted to tobacco after smoking as few as 100 cigarettes</p>\r\n            <p>Cigarette smoking is expensive. The cost of buying one pack a day for a year could buy a used car (as high as $4300 a year in some states).</p>\r\n            <p>When you smoke you are being controlled by the tobacco companies' marketing; when you do not smoke you show smart independent thinking</p>\r\n            </td>\r\n            <td class=\"sublist1_start\">Selected long-term health risks listed under \"parents\" above</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">- Emphasize issues that are common rather than dire</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"sublist1\">- Emphasize issues that are relevant to patient's experience (ie, health problems in a parent or close relative)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Alternative forms of tobacco (snuff, e-cigarettes) are no safer than cigarettes</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Smoking exposes your friends and family to health risks from secondhand smoke</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_lgnd\">This table summarizes the authors' approaches to advising patients about the health risks of smoking in different age groups.</div><div class=\"graphic_reference\">Courtesy of Drs. Marianna Sockrider and JB Rosen.</div><div id=\"graphicVersion\">Graphic 73345 Version 10.0</div></div></div>"},"73346":{"type":"graphic_picture","displayName":"Positioning for puncture of extensor digitorum compartment","title":"Positioning for ultrasound-guided puncture of extensor digitorum compartment","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Positioning for ultrasound-guided puncture of extensor digitorum compartment</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/73346_Pos_punc_exten_digitorum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient and needle positioning for puncture of extensor digitorum compartment.</div><div class=\"graphic_reference\">Reproduced with permission from: Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, Second Edition. ISBN 978-90-313-9206-3; Bohn Stafleu van Loghum, Houten 2012. Copyright &#169; 2012.</div><div id=\"graphicVersion\">Graphic 73346 Version 2.0</div></div></div>"},"73347":{"type":"graphic_figure","displayName":"Anatomy ant segment struct","title":"Anterior anatomy of the eye","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Anterior anatomy of the eye</div><div class=\"cntnt\"><img style=\"width:539px; height:406px;\" src=\"images/EM/73347_Anatomy_ant_segment_struct.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73347 Version 2.0</div></div></div>"},"73350":{"type":"graphic_table","displayName":"Functional recovery after SCI by level","title":"Expected functional recovery following complete spinal cord injury by spinal level","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expected functional recovery following complete spinal cord injury by spinal level</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Spinal level</td> <td class=\"subtitle1\">Activities of daily living</td> <td class=\"subtitle1\">Mobility/locomotion</td> </tr> <tr> <td>C1-C4</td> <td> <p>Feeding possible with balanced forearm orthoses</p> <p>Computer access by tongue, breath, voice controls</p> <p>Weight shifts with power tilt and recline chair</p> Mouth stick use</td> <td>Operate power chair with tongue, chin, or breath controller</td> </tr> <tr> <td>C5</td> <td> <p>Drink from cup, feed with static splints and setup</p> <p>Oral/facial hygiene, writing, typing with equipment</p> <p>Dressing upper body possible</p> Side-to-side weight shifts</td> <td> <p>Propel chair with hand rim projections short distances on smooth surfaces</p> Power chair with hand controller</td> </tr> <tr> <td>C6</td> <td> <p>Feed, dress upper body with setup</p> <p>Dressing lower body possible</p> Forward weight shifts</td> <td> <p>Bed mobility with equipment</p> <p>Level surface transfers with assistance</p> Propel indoors with coated hand rims</td> </tr> <tr> <td>C7</td> <td>Independent feeding, dressing, bathing with adaptive equipment, built-up utensils</td> <td> <p>Independent bed mobility, level surface transfers</p> Wheelchair use outdoors (power chair for school or work)</td> </tr> <tr> <td>C8</td> <td> <p>Independent in feeding, dressing, bathing</p> Bowel and bladder care with setup</td> <td> <p>Propel chair, including curbs and wheelies</p> Wheelchair-to-car transfers</td> </tr> <tr> <td>T1</td> <td>Independent in all self-care</td> <td>Transfer from floor to wheelchair</td> </tr> <tr> <td>T2-L1</td> <td>&nbsp;</td> <td>Stand with braces for exercise</td> </tr> <tr> <td>L2</td> <td>&nbsp;</td> <td> <p>Potential for swing-to gait with long leg braces indoors</p> Use of forearm crutches</td> </tr> <tr> <td>L3</td> <td>&nbsp;</td> <td> <p>Potential for community ambulation</p> Potential for ambulation with short leg braces</td> </tr> <tr> <td>L4-S1</td> <td>&nbsp;</td> <td>Potential for ambulation without assistive devices</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Physical Medicine and Rehabilitation, 2nd ed, Randall Braddom (ED), WB Saunders Company, 2000. Copyright &copy; 2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 73350 Version 3.0</div></div></div>"},"73352":{"type":"graphic_figure","displayName":"Lithotomy position for vaginal birth","title":"Lithotomy position for vaginal birth","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Lithotomy position for vaginal birth</div><div class=\"cntnt\"><img style=\"width:454px; height:235px;\" src=\"images/OBGYN/73352_Lithotomy_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If the woman cannot be placed in lithotomy position because a suitable bed with stirrups is not available, a stack of towels or an upside down bedpan is placed under the mother's hips and back to raise the perineum above the surface of the bed/stretcher. This provides additional room to maneuver when guiding the infant posteriorly to ease his/her shoulder under the symphysis pubis.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright ©2009.</div><div id=\"graphicVersion\">Graphic 73352 Version 2.0</div></div></div>"},"73353":{"type":"graphic_picture","displayName":"Bilateral cryptorchidism","title":"Bilateral cryptorchidism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral cryptorchidism</div><div class=\"cntnt\"><img style=\"width:400px; height:255px;\" src=\"images/PEDS/73353_Bilateral_cryptorchid_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with bilateral cryptorchidism had a 46,XX karyotype and ovotesticular disorder of sex development.</div><div class=\"graphic_reference\">Courtesy of Christopher P Houk, MD and Lynne L Levitsky, MD.</div><div id=\"graphicVersion\">Graphic 73353 Version 2.0</div></div></div>"},"73354":{"type":"graphic_figure","displayName":"Laparoscopic cystectomy b","title":"Laparoscopic ovarian cystectomy","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Laparoscopic ovarian cystectomy</div><div class=\"cntnt\"><img style=\"width:475px; height:345px;\" src=\"images/OBGYN/73354_Laparoscopic_cystectomy_b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cyst wall is grasped and blunt dissection used to separate the cyst wall from the ovarian cortex.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 73354 Version 3.0</div></div></div>"},"73356":{"type":"graphic_picture","displayName":"Seborrheic keratosis 1","title":"Seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/73356_Seborrheic_keratosis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple seborrheic keratoses.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73356 Version 3.0</div></div></div>"},"73357":{"type":"graphic_picture","displayName":"CPR position PI","title":"CPR position","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">CPR position</div><div class=\"cntnt\"><img style=\"width:505px; height:707px;\" src=\"images/PI/73357_CPR_position_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressing on the chest for CPR is called doing &quot;compressions.&quot; To do compressions, make sure the victim is on a flat, solid surface. Then kneel over the victim, stack your hands on top of one another with both palms facing down, and lock your fingers together. Holding your arms straight, press on the center of the victim's chest with the heel of your bottom hand. Use your body weight, rather than the strength of your arms, to press on the chest. Make sure the victim's chest drops down at least 2 inches under your weight with each push. Between compressions, lift all pressure off the victim's chest so that his or her chest goes back to where it was.</div><div id=\"graphicVersion\">Graphic 73357 Version 2.0</div></div></div>"},"73358":{"type":"graphic_picture","displayName":"Posterior shoulder dislocation appearance","title":"External appearance of a posterior shoulder dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">External appearance of a posterior shoulder dislocation</div><div class=\"cntnt\"><img style=\"width:432px; height:422px;\" src=\"images/EM/73358_Shoulder_post_DL_external.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prominence of the coracoid is noted anteriorly. The patient holds the shoulder internally rotated and is unable to externally rotate.</div><div id=\"graphicVersion\">Graphic 73358 Version 3.0</div></div></div>"},"73360":{"type":"graphic_diagnosticimage","displayName":"Peptic esophageal stricture","title":"Peptic esophageal stricture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peptic esophageal stricture</div><div class=\"cntnt\"><img style=\"width:241px; height:379px;\" src=\"images/GAST/73360_Peptic_esophageal_stricture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Esophagram demonstrates 6 cm long distal esophageal peptic stricture with associated nodularity (arrows). Note the granular pattern of the esophagus consistent with esophagitis.</div><div class=\"graphic_reference\">Courtesy of Anita E Spiess, MD and Peter J Kahrilas, MD.</div><div id=\"graphicVersion\">Graphic 73360 Version 2.0</div></div></div>"},"73361":{"type":"graphic_table","displayName":"Transfusion guidelines for the newborn infant","title":"Transfusion guidelines for the newborn infant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Transfusion guidelines for the newborn infant</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p><strong>OVERVIEW</strong></p> <ul class=\"decimal_heading\"> <li>In term and preterm infants, transfusion should be considered if increased oxygen delivery to tissues is needed based upon the clinical status of the patient. </li> <li>Volume of transfusion should be 20 mL/kg PRBC unless the&nbsp;hematocrit is &#62;29%. 20 mL/kg volume may be used if significant phlebotomy losses are anticipated in small infants with&nbsp;hematocrit &#62;29%. </li> <li>For infants receiving erythropoietin, additional considerations should be made regarding the rate of decrease in hemoglobin or hematocrit, the infant's reticulocyte count, the postnatal day of age, the need for supplemental oxygen, and the overall stability of the infant*. </li> <li>Central measurements of hemoglobin or hematocrit are preferred when using hemoglobin or hematocrit target levels as indications for transfusion; alternatively, heelstick measurements may be obtained after warming the heel adequately. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>ACUTE BLOOD LOSS</strong></p> <p class=\"indent1\">Acute red blood cell transfusions should generally only be considered in the setting of acute blood volume loss of &#8805;10% with symptoms of decreased oxygen delivery or when acute blood volume loss is &#62;20%.</p> </td> </tr> <tr> <td> <p><strong>CHRONIC BLOOD LOSS</strong></p> <p class=\"indent1\">Indications for transfusion for infants with chronic blood loss is based on target hematocrit/hemoglobin levels that are dependent on the infant's need for respiratory support and age*. The following are guidelines used at the University of New Mexico that reflect a restrictive blood transfusion approach for infants.</p> <ul class=\"decimal_heading\"> <li>For infants requiring moderate or significant mechanical ventilation, defined as mean air pressure (MAP) &#62;8 cm H<sub>2</sub>O and FiO<sub>2</sub> &#62;0.4 on a conventional ventilator, or MAP &#62;14 and FiO<sub>2</sub> &#62;0.4 on high frequency ventilator, and with a hematocrit &#8804;30% (hemoglobin &#8804;10 g/dL). </li> <li>For infants requiring minimal mechanical ventilation, defined as MAP &#8804;8 cm H<sub>2</sub>O and/or FiO<sub>2</sub> &#8804;0.4 on a conventional ventilator, or MAP &#60;14 and/or FiO<sub>2</sub> &#60;0.4 on high frequency, and with a hematocrit &#8804;25% (hemoglobin &#8804;8 g/dL). </li> <li>For infants on supplemental oxygen who are not requiring mechanical ventilation, transfusions can be considered if the hematocrit is &#8804;20% (hemoglobin &#8804;7 g/dL) and one or more of the following conditions is present: <ul> <li>&#8805;24 hours of tachycardia (heart rate &#62;180 beats per minute) or tachypnea (RR &#62;60 breaths per minute) </li> <li>Doubling of the oxygen requirement from the previous 48 hours </li> <li>Serum lactate &#8805;2.5 mEq/L or an acute metabolic acidosis (pH &#60;7.2) </li> <li>Weight gain &#60;10 g/kg/day over the previous four days while receiving &#8805;120 kcal/kg/day </li> <li>If the infant will undergo major surgery within 72 hours </li> </ul> </li> <li>For infants without any symptoms, transfusions can be considered if the hematocrit is &#8804;18% (hemoglobin &#8804;6 g/dL) associated with an absolute reticulocyte count &#60;100,000 cells/microL (&#60;2%). </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PRBC: packed red blood cells; FiO<SUB>2</SUB>: fraction of inspired oxygen; RR: respiratory rate.<br />* Refer to the UpToDate topic on red blood cell transfusion in the newborn for further details.</div><div class=\"graphic_reference\">Courtesy of Robin Ohls, MD.</div><div id=\"graphicVersion\">Graphic 73361 Version 8.0</div></div></div>"},"73362":{"type":"graphic_figure","displayName":"Osgood Schlatter pathophysiology","title":"Development of the Osgood-Schlatter lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Development of the Osgood-Schlatter lesion</div><div class=\"cntnt\"><img style=\"width:335px; height:504px;\" src=\"images/PEDS/73362_Osgood_Schlatter_pathogen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Normal. B) Involved, with fragmentation of the ossification center. C) Enlargement shows how the ossicle pulls away from the anterior portion of the main tuberosity ossification center. The region of separation then fills in with fibrous and fibrocartilaginous tissue, which usually ossifies only if the tension stress is relieved.</div><div class=\"graphic_reference\">Reproduced with permission from: Ogden, J. Skeletal Injury in the Child, 3rd ed, Springer-Verlag, New York 2000. p.1018.</div><div id=\"graphicVersion\">Graphic 73362 Version 2.0</div></div></div>"},"73364":{"type":"graphic_figure","displayName":"Shedding epithelial cell in acne PI","title":"Shedding of epithelial cells in acne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shedding of epithelial cells in acne</div><div class=\"cntnt\"><img style=\"width:440px; height:428px;\" src=\"images/PI/73364_Shedding_epithelial_cell_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">How acne develops. Increased shedding of epithelial cells.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright © 2008 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 73364 Version 5.0</div></div></div>"},"73365":{"type":"graphic_figure","displayName":"Pulsed nasal O2 delivery","title":"Pulsed nasal delivery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulsed nasal delivery</div><div class=\"cntnt\"><img style=\"width:394px; height:280px;\" src=\"images/PULM/73365_Pulsed_nasal_02_delivery.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect on pulse oxygen saturation (SpO<sub>2</sub>) of decreasing the delay time between the beginning of inhalation and the beginning of an oxygen delivery pulse. As the delay is shortened, there is a progressive improvement in SpO<sub>2</sub>.</div><div class=\"graphic_reference\">Data from: Tiep BL, Christopher KL, Spofford BT, et al. Pulsed nasal and transtracheal oxygen delivery. Chest 1990; 97:364.</div><div id=\"graphicVersion\">Graphic 73365 Version 3.0</div></div></div>"},"73366":{"type":"graphic_diagnosticimage","displayName":"Adult shoulder normal AP","title":"Anteroposterior radiograph of the shoulder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anteroposterior radiograph of the shoulder</div><div class=\"cntnt\"><img style=\"width:288px; height:212px;\" src=\"images/EM/73366_Adult_shoulder_normal_AP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior radiograph of a normal shoulder demonstrates a congruent humeral head and glenoid fossa. The accromion and the acromioclavicular joint are not not well visualized in this example due to overpenetration.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 73366 Version 2.0</div></div></div>"},"73367":{"type":"graphic_table","displayName":"Neurologic symptoms of D-lactic acidosis","title":"Prevalence of neurologic symptoms and signs in 29 patients with D-lactic acidosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of neurologic symptoms and signs in 29 patients with D-lactic acidosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Neurologic manifestation</td>\n<td class=\"subtitle1\">Percent</td>\n</tr>\n<tr>\n<td>Altered mental status*</td>\n<td>100</td>\n</tr>\n<tr>\n<td>Dysarthria (slurred speech)</td>\n<td>65</td>\n</tr>\n<tr>\n<td>Ataxia</td>\n<td>45</td>\n</tr>\n<tr>\n<td>Gait disturbance</td>\n<td>34</td>\n</tr>\n<tr>\n<td>Weakness</td>\n<td>21</td>\n</tr>\n<tr>\n<td>Impaired motor coordination</td>\n<td>21</td>\n</tr>\n<tr>\n<td>Hostile, aggressive, abusive behavior</td>\n<td>17</td>\n</tr>\n<tr>\n<td>Inability to concentrate</td>\n<td>14</td>\n</tr>\n<tr>\n<td>Nystagmus</td>\n<td>14</td>\n</tr>\n<tr>\n<td>Hallucinations</td>\n<td>10</td>\n</tr>\n<tr>\n<td>Delirium, euphoria</td>\n<td>10</td>\n</tr>\n<tr>\n<td>Paranoid ideation</td>\n<td>7</td>\n</tr>\n<tr>\n<td>Irritability</td>\n<td>3</td>\n</tr>\n<tr>\n<td>Excessive hunger</td>\n<td>3</td>\n</tr>\n<tr>\n<td>Headache</td>\n<td>3</td>\n</tr>\n<tr>\n<td>Partial ptosis</td>\n<td>3</td>\n</tr>\n<tr>\n<td>Asterixis</td>\n<td>3</td>\n</tr>\n<tr>\n<td>Blurred vision</td>\n<td>3</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">9.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=38883&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Neurologic_sx_D_lactic_acid.htm</title></head></div><div class=\"graphic_footnotes\">* From mild drowsiness to coma.</div><div class=\"graphic_reference\">Adapted from: Uribarri J, Oh MS, Carroll HJ. D-lactic acidosis. A review of clinical presentation, biochemical features, and pathophysiologic mechanisms. Medicine (Baltimore) 1998; 77:73.</div><div id=\"graphicVersion\">Graphic 73367 Version 4.0</div></div></div>"},"73368":{"type":"graphic_picture","displayName":"Labioplasty wedge resection","title":"Labia minora labioplasty: Wedge resection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Labia minora labioplasty: Wedge resection</div><div class=\"cntnt\"><img style=\"width:432px; height:303px;\" src=\"images/OBGYN/73368_Labioplastywedge.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incision for resection of excess labial tissue using the V-shaped wedge technique.</div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds). Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 73368 Version 9.0</div></div></div>"},"73369":{"type":"graphic_table","displayName":"Selected agents with potential adverse fetal effects","title":"Selected agents with potential adverse fetal effects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected agents with potential adverse fetal effects</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table style=\"border-bottom: medium none;\" cellspacing=\"0\"> <colgroup width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Reproductive toxin</td> <td class=\"subtitle1\">Alleged fetal effects</td> <td class=\"subtitle1\">Timing of exposure</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Drugs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Androgens</td> <td>Masculinization of the developing female fetus can occur from androgens and high doses of some male-derived progestins.</td> <td>First trimester for labial fusion; second and third trimesters for clitoral hypertrophy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers</td> <td> <p>Fetal hypotension resulting in fetal kidney hypoperfusion and anuria, oligohydramnios, pulmonary hypoplasia, cranial bone hypoplasia, fetal growth restriction and demise.</p> Neonatal oliguria, anuria, hypotension, and renal tubular dysgenesis.</td> <td>Second and third trimesters</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">Anticonvulsants</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Carbamazepine </li> </ul> </td> <td>Increases the risk of facial dysmorphology, neural tube defects, cardiovascular defects, and urinary tract defects.</td> <td>First trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Phenytoin </li> </ul> </td> <td>Increases the risk of fetal hydantoin syndrome, consisting of facial dysmorphology, cleft palate, ventricular septal defect, and growth and intellectual disability.</td> <td>18 to 60 days postconception (organogenesis)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Trimethadione and paramethadione </li> </ul> </td> <td>Increases the risk of characteristic facial dysmorphology, intellectual disability, V-shaped eyebrows, low-set ears with anteriorly folded helix, high-arched palate, irregular teeth, CNS anomalies, and severe developmental delay.</td> <td>First trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Valproic acid </li> </ul> </td> <td>Increases the risk of spina bifida, facial dysmorphology, autism, atrial septal defect, cleft palate, hypospadias, polydactyly, craniosynostosis, and limb abnormalities.</td> <td>18 to 60 days postconception (organogenesis)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Antidepressants</td> <td>Publications have implicated some of the SSRIs administered in the last trimester with postnatal neurobehavioral effects that are transient and whose long-term effects have not been determined. First trimester exposures to some SSRIs have been reported to increase the risk of some congenital malformations, predominantly congenital heart disease. The results have not been consistent, but warnings have been issued. However, other developmental toxicities have been associated with SSRIs including spontaneous abortions, low birth weight, prematurity, neonatal serotonin syndrome, neonatal behavioral syndrome (withdrawal), and persistent pulmonary hypertension of the newborn.</td> <td>First and third trimesters</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Antituberculous therapy</td> <td>Isoniazid does not appear to cause birth defects; paraaminosalicylic acid may cause an increased risk of ear and limb defects and hypospadias.</td> <td>First trimester and possibly second trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cyclophosphamide and other chemotherapeutic agents and immunosuppressive agents (eg, cyclosporine, leflunomide)</td> <td>Many chemotherapeutic agents used to treat cancer have a theoretical risk for producing malformations in the fetus when administered to pregnant women, especially because most of these drugs are teratogenic in animals, but the clinical data are not consistent. Many of these drugs have not been shown to be teratogenic, but the numbers of cases in the studies are small. Caution is the byword. Cyclophosphamide causes congenital defects when used during organogenesis, and fetal bone marrow suppression may occur when exposure occurs later in pregnancy.</td> <td>First trimester for malformations; second and third trimesters possibly associated with fetal growth restriction and pancytopenia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diethylstilbestrol</td> <td>Administration during pregnancy produces genital abnormalities, adenosis, and clear cell adenocarcinoma of vagina in adolescents. The last has a risk of 1:1000 to 1:10,000, but the other effects, such as adenosis, can be quite high.</td> <td>First and second trimesters</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ethanol</td> <td>Fetal alcohol syndrome consists of microcephaly, intellectual disability, growth restriction, typical facial dysmorphogenesis, abnormal ears, small palpebral fissures.</td> <td>First trimester for fetal alcohol syndrome or fetal alcohol-related birth defects; second and third trimesters for fetal alcohol neurodevelopmental disorders</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Glucocorticoids</td> <td>High exposures administered systemically have a low risk for cleft palate in some studies, but the epidemiologic studies are not consistent.</td> <td>First trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Insulin shock therapy</td> <td>Microcephaly and intellectual disability.</td> <td>First trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lithium therapy</td> <td>Chronic usage for the treatment of bipolar disorder has an increased risk for Ebstein anomaly and other malformations, but the risk seems to be very low.</td> <td>First trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Minoxidil</td> <td>Promotion of hair growth in the fetus and hirsutism in newborns.</td> <td>First trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Methimazole</td> <td>Aplasia cutis has been reported to be increased in mothers administered this drug during pregnancy.* Other anomalies have been reported and include tracheoesophageal fistulas, patent vitellointestinal duct, choanal atresia, omphalocele, and omphalomesenteric duct anomaly.</td> <td>First trimester; especially weeks 6 to 10</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Methotrexate</td> <td>Pregnancy loss, growth restriction, microcephaly, meningomyelocele, intellectual disability, decreased ossification of the calvarium, hypoplastic supraorbital ridges, small low-set ears, micrognathia, and limb defects.</td> <td>18 to 60 days postconception (organogenesis)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Methylene blue intra-amniotic instillation</td> <td>Fetal intestinal atresia, hemolytic anemia, and jaundice in the neonatal period. This procedure is no longer used to identify one twin.</td> <td>18 to 60 days postconception (organogenesis)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Misoprostol</td> <td>A low incidence of vascular disruptive phenomenon, such as limb-reduction defects and Mobius syndrome, has been reported in pregnancies in which this drug was used to induce an abortion.</td> <td>First and second trimesters</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mycophenolate mofetil</td> <td>First trimester exposure associated with miscarriage, abnormalities of the brain, ears, eyes, distal limbs, heart, esophagus, kidney, and cleft lip/palate.</td> <td>First trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Penicillamine (D-penicillamine)</td> <td>This drug results in the physical effects referred to as \"lathyrism,\" the results of poisoning by the seeds of the genus <em>Lathyrus</em>. It causes collagen disruption, cutis laxa, and hyperflexibility of joints. The condition seems to be reversible, and the risk is low.</td> <td>Timing associated with the occurrence of these anomalies is not clear</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Progestin therapy</td> <td>Very high doses of androgen hormone-derived progestins can produce masculinization. Many drugs with progestational activity do not have masculinizing potential. None of these drugs have the potential for producing nongenital malformations.</td> <td>Third trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Propylthiouracil</td> <td>This drug and other antithyroid medications administered during pregnancy can result in an infant born with a goiter.</td> <td>Throughout gestation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Retinoids</td> <td>Systemic retinoic acid, isotretinoin, and etretinate can cause increased risk of CNS, cardioaortic, ear, and clefting defects such as microtia, anotia, thymic aplasia, other branchial arch and aortic arch abnormalities, and certain congenital heart malformations.</td> <td>First trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Retinoids, topical</td> <td>Topical administration is very unlikely to have teratogenic potential because teratogenic serum levels cannot be attained by topical exposure to retinoids.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Streptomycin</td> <td>Streptomycin and a group of ototoxic drugs can affect the eighth nerve and interfere with hearing; it is a relatively low-risk phenomenon. Children are less sensitive than adults to the ototoxic effects of these drugs. However, deafness in newborns can occur.</td> <td>Throughout gestation</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Reproductive toxin</td> <td class=\"subtitle1\">Alleged fetal effects</td> <td class=\"subtitle1\">Timing of exposure</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Drugs (continued)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sulfa drugs and vitamin K</td> <td>These drugs can produce hemolysis in some subpopulations of fetuses. Sulfa drugs can cross the placenta and bind proteins displacing bilirubin and trigger kernicterus at low bilirubin levels.</td> <td>Second and third trimesters</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tetracycline</td> <td>This drug produces bone and teeth staining; it does not increase the risk of any other malformations.</td> <td>Second and third trimesters</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Thalidomide</td> <td>Multiple defects in the following systems: limbs, other skeleton, craniofacial, major organs (lungs, cardiovascular, gastrointestinal, and genitourinary), and inguinal hernia.</td> <td>22 to 36 days postconception</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trimethoprim</td> <td>Has been linked to an increased incidence of neural tube defects. The risk is not high, but it is biologically plausible because of the drug's effect on lowering folic acid levels, which has resulted in neurologic symptoms in adults taking this drug. It is also associated with cardiovascular defects and possibly oral clefts.</td> <td>First trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vitamin A</td> <td>Although still controversial, the malformations reported with the retinoids have been reported with very high doses of vitamin A (retinol). Doses to produce birth defects would have to be in excess of 25,000 to 50,000 units/day. Other gravida exposed to high doses of vitamin have had normal pregnancies.</td> <td>Possibly during the first trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Warfarin and warfarin derivatives</td> <td>Early exposure during pregnancy can result in nasal hypoplasia, stippling of secondary epiphysis, intrauterine growth restriction. CNS malformations can occur in late pregnancy exposure because of bleeding.</td> <td>First trimester</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Radiation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ionizing radiation</td> <td>Radiation exposure above a threshold of 20 rad (0.2 Gy) can increase the risk for some fetal effects such as microcephaly or growth retardation, but the threshold for intellectual disability is higher.</td> <td>First trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Radioactive isotopes</td> <td>Tissue- and organ-specific damage depends on the radioisotope element and distribution (ie, high doses of Iodine-131 administered to a pregnant woman can cause fetal thyroid hypoplasia after the eighth week of development).</td> <td>After eighth week</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Chemicals</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Carbon monoxide</td> <td>CNS damage has been reported with very high exposures (carbon monoxide poisoning), but the risk seems to be low.*</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lead</td> <td>Very high exposures can cause pregnancy loss; intrauterine teratogenesis is not established at very low exposures below 20 microgram/percent in the serum of pregnant mothers.</td> <td>Potential risk throughout pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gasoline</td> <td>Facial dysmorphology, intellectual disability, embryopathy from exposure due to gasoline addiction.</td> <td>Throughout the pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Methyl mercury</td> <td>Minamata disease consists of cerebral palsy, microcephaly, intellectual disability, blindness, and cerebellum hypoplasia. Other epidemics have occurred from adulteration of wheat with mercury-containing chemicals that are used to prevent grain spoilage. Present environmental levels of mercury are unlikely to represent a teratogenic risk, but reducing or limiting the consumption of carnivorous fish has been suggested to avoid exceeding the maximum permissible exposure recommended by the Environmental Protection Agency, an exposure level far below the level at which the toxic effects of mercury are seen.</td> <td>Throughout the pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Polychlorinated biphenyls</td> <td>Poisoning has occurred from adulteration of food products (\"Cola-colored babies,\" CNS effects, pigmentation of gums, nails, teeth, and groin; hypoplastic deformed nails; intrauterine growth retardation; abnormal skull calcification). The threshold exposure has not been determined, but it is unlikely to be teratogenic at the present environmental exposures.</td> <td>Throughout the pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Toluene</td> <td>Facial dysmorphology, intellectual disability, embryopathy from exposure due to toluene addiction.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Embryonic and fetal infections</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cytomegalovirus infection</td> <td>Retinopathy, CNS calcification, microcephaly, intellectual disability. Occurs in 30 to 50% of primary infections.</td> <td>First six months of pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rubella</td> <td>Deafness, congenital heart disease, microcephaly, cataracts, intellectual disability. Occurs in up to 80% of fetuses with a primary infections.</td> <td>Up to 16 weeks although more significant in the first two months of pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Herpes simplex</td> <td>Fetal infection, liver disease, death.</td> <td>Throughout the pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">HIV</td> <td>Perinatal HIV infection.</td> <td>Throughout the pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Parvovirus infection, B19</td> <td>Stillbirth, hydrops.</td> <td>Up to 20 weeks gestation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Syphilis</td> <td>Maculopapular rash, hepatosplenomegaly, deformed nails, osteochondritis at joints of extremities, congenital neurosyphilis, abnormal epiphyses, chorioretinitis.</td> <td>Throughout the pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Toxoplasmosis</td> <td>Hydrocephaly, microphthalmia, chorioretinitis, intellectual disability.</td> <td>Throughout the pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Varicella zoster</td> <td>Skin and muscle defects; intrauterine growth retardation; limb reduction defects, CNS damage (very low increased risk).</td> <td>First trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Venezuelan equine encephalitis</td> <td>Hydranencephaly; microphthalmia; destructive CNS lesions; luxation of hip.</td> <td>First trimester</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Zika virus</td> <td>Microcephaly, intracranial calcifications, intellectual disability.</td> <td>Up to 20 weeks gestation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Maternal disease states</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Corticosteroid-secreting endocrinopathy</td> <td>Mothers who have Cushing's disease can have infants with hyperadrenocorticism, but anatomic malformations do not seem to be increased.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Iodine deficiency</td> <td>Can result in embryonic goiter and intellectual disability.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Intrauterine problems of constraint and vascular disruption</td> <td>These defects are more common in multiple-birth pregnancies, pregnancies with anatomic defects of the uterus, placental emboli, or amniotic bands. Possible birth defects include club feet, limb-reduction defects, aplasia cutis, cranial asymmetry, external ear malformations, midline closure defects, cleft palate and muscle aplasia, cleft lip, omphalocele, and encephalocele.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Maternal androgen endocrinopathy (adrenal tumors)</td> <td>Masculinization of female fetuses.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Maternal diabetes with poor glycemic control</td> <td>Increases the risk of a wide variety of congenital anomalies; cardiac abnormalities are most common.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Maternal folic acid in reduced amounts</td> <td>An increased incidence of neural tube defects.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Maternal phenylketonuria</td> <td>Abortion, microcephaly, and intellectual disability; very high risk in untreated patients.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Maternal starvation</td> <td>Intrauterine growth restriction, abortion, neural tube defects (Dutch famine experience).</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tobacco smoking</td> <td>Fetal growth restriction and stillbirth. Although the risk of defects is small (approximately twofold), they can involve the heart and great vessels, limbs, skull, genitourinary system, feet, abdominal wall, small bowel, and muscles.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Zinc deficiency*</td> <td>Neural tube defects.*</td> <td>&nbsp;</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; SSRI: selective serotonin reuptake inhibitor; HIV: human immunodeficiency virus.<br />* Controversial.</div><div class=\"graphic_reference\">From: Brent, RL. How does a physician avoid prescribing drugs and medical procedures that have reproductive and developmental risks? Clin Perinatol 2007; 34:233. Copyright © 2007 Elsevier. Original table modified for this publication.</div><div id=\"graphicVersion\">Graphic 73369 Version 13.0</div></div></div>"},"73370":{"type":"graphic_table","displayName":"IHC dermal spindle cell tumors","title":"Summary of immunohistochemical staining of dermatofibrosarcoma protuberans (DFSP) and other spindle cell dermal tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of immunohistochemical staining of dermatofibrosarcoma protuberans (DFSP) and other spindle cell dermal tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"8\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">CD34</td> <td class=\"subtitle1\">XIIIa</td> <td class=\"subtitle1\">S-100</td> <td class=\"subtitle1\">SMA</td> <td class=\"subtitle1\">Desmin</td> <td class=\"subtitle1\">Vimentin</td> <td class=\"subtitle1\">CD44</td> <td class=\"subtitle1\">Hyaluronate</td> </tr> <tr> <td>DFSP</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">+</td> </tr> <tr> <td>Dermatofibroma</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+*</td> <td class=\"centered\">+/&ndash;*</td> </tr> <tr> <td>Nodular fasciitis</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Nerve sheath tumors</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Fibrosarcoma</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Malignant fibrous histiocytoma</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SMA: smooth muscle actin; +: more than 80 percent of cases staining; &ndash;: less than 20 percent of cases staining; +/&ndash;: variable staining.<br />* For dermatofibromas, cells stain intensely with CD44 while the stroma stains faintly for hyaluronate; DFSPs are strongly positive for hyaluronate while CD44 staining is diminished or absent.</div><div class=\"graphic_reference\">Derived from: Haycox CL, et al. J Am Acad Dermatol 1997; 37:438 and Calikoglu E, et al. J Cutan Pathol 2003; 30:185.</div><div id=\"graphicVersion\">Graphic 73370 Version 3.0</div></div></div>"},"73371":{"type":"graphic_table","displayName":"Rand trials marg width melanoma","title":"Randomized trials examining optimal surgical margin width for cutaneous melanoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Randomized trials examining optimal surgical margin width for cutaneous melanoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Study, author; year</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">Median follow-up</td> <td class=\"subtitle1\">Melanoma thickness</td> <td class=\"subtitle1\">Margins</td> <td class=\"subtitle1\">Local recurrence, (%)</td> <td class=\"subtitle1\">Overall survival, (%)</td> </tr> <tr> <td rowspan=\"4\"> <p>World Health Organization</p> <p>Cascinelli N; 1998</p> </td> <td rowspan=\"4\">612</td> <td rowspan=\"4\">12 yrs</td> <td>0 to 1 mm</td> <td>1 cm</td> <td>3/186 (1.6)</td> <td rowspan=\"2\">87</td> </tr> <tr> <td>1.1 to 2 mm</td> <td>1 cm</td> <td>5/119 (4.2)</td> </tr> <tr> <td>0 to 1 mm</td> <td>3 cm</td> <td>1/173 (0.6)</td> <td rowspan=\"2\">85</td> </tr> <tr> <td>1.1 to 2 mm</td> <td>3 cm</td> <td>2/134 (1.5)</td> </tr> <tr> <td rowspan=\"2\"> <p>Swedish</p> <p>Cohn-Cedarmark G; 2000</p> </td> <td rowspan=\"2\">989</td> <td rowspan=\"2\">11 yrs</td> <td rowspan=\"2\">0.8 to 2 mm</td> <td>2 cm</td> <td>3/476 (0.6)</td> <td>79</td> </tr> <tr> <td>5 cm</td> <td>5/513 (1)</td> <td>76</td> </tr> <tr> <td rowspan=\"2\"> <p>French Cooperative Group</p> <p>Khayat D; 2003</p> </td> <td rowspan=\"2\">326</td> <td rowspan=\"2\">16 yrs</td> <td rowspan=\"2\">&#60;2.1 mm</td> <td>2 cm</td> <td>1/181 (0.05)</td> <td>87</td> </tr> <tr> <td>5 cm</td> <td>4/185 (0.2)</td> <td>86</td> </tr> <tr> <td rowspan=\"2\"> <p>Melanoma Intergroup Trial</p> <p>Karakoussis CP; 1996</p> </td> <td rowspan=\"2\">468</td> <td rowspan=\"2\">8 yrs</td> <td rowspan=\"2\">1 to 4 mm</td> <td>2 cm</td> <td>(2.1)</td> <td>80</td> </tr> <tr> <td>4 cm</td> <td>(2.6)</td> <td>84</td> </tr> <tr> <td rowspan=\"2\"> <p>British Trial</p> <p>Thomas JM; 2004</p> </td> <td rowspan=\"2\">900</td> <td rowspan=\"2\">60 mos</td> <td rowspan=\"2\">&#8805;2 mm</td> <td>1 cm</td> <td>15/453 (3.3)</td> <td rowspan=\"2\">No significant difference</td> </tr> <tr> <td>3 cm</td> <td>13/457 (2.8)</td> </tr> <tr> <td rowspan=\"2\"> <p>Europe</p> <p>Gillgren; 2011</p> </td> <td rowspan=\"2\">936</td> <td rowspan=\"2\">6.7 yrs</td> <td rowspan=\"2\">&#62;2 mm</td> <td>2 cm</td> <td>20/465 (4.3)</td> <td rowspan=\"2\">&nbsp;65</td> </tr> <tr> <td>4 cm</td> <td>&nbsp;9/471 (1.9)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73371 Version 3.0</div></div></div>"},"73372":{"type":"graphic_table","displayName":"Elemental iron in multivitamins","title":"Elemental iron content of selected multivitamin preparations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Elemental iron content of selected multivitamin preparations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Preparation</td> <td class=\"subtitle1\">Elemental iron content</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Prenatal Vitamins</td> </tr> <tr> <td class=\"indent1\">NataChew&#174; Prenatal vitamins</td> <td>29 mg</td> </tr> <tr> <td class=\"indent1\">Natalins Rx</td> <td>60 mg</td> </tr> <tr> <td class=\"indent1\">Natalins</td> <td>45 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Children's multivitamins</td> </tr> <tr> <td class=\"indent1\">BugsBunny&#174; with iron</td> <td>18 mg</td> </tr> <tr> <td class=\"indent1\">Centrum, Jr plus iron</td> <td>18 mg</td> </tr> <tr> <td class=\"indent1\">Centrum Kids Complete Rugrats&#174;</td> <td>18 mg</td> </tr> <tr> <td class=\"indent1\">Flintstones&#174; with iron</td> <td>18 mg</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Poly-Vi-Sol with iron</td> </tr> <tr> <td class=\"sublist2\">Tablet</td> <td class=\"sublist_other\">12mg</td> </tr> <tr> <td class=\"sublist2\">Drops</td> <td class=\"sublist_other\">10 mg/mL</td> </tr> <tr> <td class=\"indent1\">Shamu and his Crew&#174; plus iron</td> <td>18 mg</td> </tr> <tr> <td class=\"indent1\">Sunkist&#174; Complete</td> <td>18 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Adult multivitamins</td> </tr> <tr> <td class=\"indent1\">Centrum&#174;</td> <td>18 mg</td> </tr> <tr> <td class=\"indent1\">Centrum&#174;Silver</td> <td>4 mg</td> </tr> <tr> <td class=\"indent1\">Complete for Men&#174;&nbsp;</td> <td>5 mg</td> </tr> <tr> <td class=\"indent1\">Complete for Women&#174;&nbsp;</td> <td>10 mg</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Natural MD</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">For Men:</td> </tr> <tr> <td class=\"sublist3\">Basic life prescription</td> <td class=\"sublist_other\">5 mg</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">For Women:</td> </tr> <tr> <td class=\"sublist3\">Basic life prescription </td> <td class=\"sublist_other\">5 mg</td> </tr> <tr> <td class=\"sublist3\">Standard life prescription</td> <td class=\"sublist_other\">10 mg</td> </tr> <tr> <td class=\"indent1\">One-A-Day&#174; Maximum</td> <td>18 mg</td> </tr> <tr> <td class=\"indent1\">One-A-Day&#174; Women's</td> <td>27 mg</td> </tr> <tr> <td class=\"indent1\">Stresstabs&#174; plus iron</td> <td>18 mg</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73372 Version 2.0</div></div></div>"},"73373":{"type":"graphic_table","displayName":"HTN with VEGF inhib","title":"Recommendations for initial assessment, surveillance, and management of blood pressure in patients receiving VEGF (vascular endothelial growth factor) signaling pathway inhibitors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for initial assessment, surveillance, and management of blood pressure in patients receiving VEGF (vascular endothelial growth factor) signaling pathway inhibitors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pretreatment assessment and screening</td> </tr> <tr> <td class=\"indent1\">1. Standardized blood pressure measurements, preferably on two separate occasions</td> </tr> <tr> <td class=\"indent1\">2. History and physical examination for formal assessment of specific cardiovascular risk factors, more detailed laboratory and/or diagnostic tests may be required to adequately screen for cardiovascular risks (eg, lipid panel, electrocardiogram)</td> </tr> <tr> <td class=\"indent1\">3. Use this information to determine the appropriate intensity of monitoring and target for blood pressure control during therapy</td> </tr> <tr> <td class=\"indent1\">4. Treat preexisting hypertension and address other comorbidities that might, through more attentive management, prolong life and support more aggressive cancer therapy</td> </tr> <tr> <td class=\"subtitle1_single\">Monitoring during treatment</td> </tr> <tr> <td class=\"indent1\">1. Actively monitor blood pressure throughout treatment with more frequent assessments during the first cycle (when the bulk of blood pressure elevation is expected to occur)</td> </tr> <tr> <td class=\"indent1\">2. Monitoring every two to three weeks after the first cycle</td> </tr> <tr> <td class=\"subtitle1_single\">Management</td> </tr> <tr> <td class=\"indent1\">1. Patients who develop hypertension during therapy (&#8805;130 mmHg/80 Hg, or increases in diastolic blood pressure &#8805;20 mm from baseline) should initiate anti-hypertensive therapy, have current therapy titrated to better control blood pressure, or have another agent added. The goal for blood pressure in patients receiving VEGF inhibitors is maximum blood pressure of 130/80. Target should be adjusted lower for patients with preexisting risk factors for adverse consequences of high blood pressure (eg, diabetes, chronic kidney disease).</td> </tr> <tr> <td class=\"indent1\">2. Manage blood pressure elevations aggressively to avoid complications, pay attention to agent selection, dose and scheduling of follow-up visits to control adverse effects of the antihypertensive agent</td> </tr> <tr> <td class=\"indent1\">3. Consultation with a hypertension specialist may be needed if there is difficulty achieving goal blood pressure</td> </tr> <tr> <td class=\"indent1\">4. Consider discontinuation or dose reduction of VEGF inhibitor therapy if diastolic blood pressure is not controlled with anti-hypertensive medication</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102:596.</div><div id=\"graphicVersion\">Graphic 73373 Version 6.0</div></div></div>"},"73374":{"type":"graphic_picture","displayName":"Infant oral health problems","title":"Infant oral health problems","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infant oral health problems</div><div class=\"cntnt\"><img style=\"width:314px; height:329px;\" src=\"images/PEDS/73374_Infantoralhealthproblems.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal 12- to 14-month-old infant's mouth. <br />(B) Infant's mouth with plaque. <br />(C) Decalcification and early cavitation. <br />(D) Remineralized decalcified enamel. <br />(E) Hypoplastic enamel (no decay). <br />(F) Fractured primary teeth.</div><div class=\"graphic_reference\">Reproduced with permission from: Nowak AJ, Warren JJ. Infant oral health and oral habits. Pediatr Clin North Am 2000; 47:1043. Copyright © 2000 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 73374 Version 3.0</div></div></div>"},"73375":{"type":"graphic_picture","displayName":"Multiple uterine leiomyomata","title":"Uterine leiomyomata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterine leiomyomata</div><div class=\"cntnt\"><img style=\"width:382px; height:252px;\" src=\"images/PC/73375_Multiple_uterine_leiomyomat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross intraoperative photograph of multiple uterine leiomyomata.</div><div class=\"graphic_reference\">Courtesy of Mitchel Hoffman, MD.</div><div id=\"graphicVersion\">Graphic 73375 Version 1.0</div></div></div>"},"73376":{"type":"graphic_table","displayName":"Sliding scale 3","title":"Sliding scale 3","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sliding scale 3</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Blood glucose, mg/dL</td> <td class=\"subtitle1\">Lispro insulin, units</td> </tr> <tr> <td>&#60;100</td> <td>0</td> </tr> <tr> <td>101 to 150</td> <td>2</td> </tr> <tr> <td>151 to 200</td> <td>3</td> </tr> <tr> <td>201 to 250</td> <td>4</td> </tr> <tr> <td>251 to 300</td> <td>5</td> </tr> <tr> <td>301 to 400</td> <td>6</td> </tr> <tr> <td>&#62;400</td> <td>8</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73376 Version 2.0</div></div></div>"},"73377":{"type":"graphic_table","displayName":"ICU admission for alcohol withdrawal","title":"Suggested criteria for ICU admission of patients with alcohol withdrawal","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested criteria for ICU admission of patients with alcohol withdrawal</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Age &#62;40</td> </tr> <tr> <td>Cardiac disease (heart failure, arrhythmia, angina, myocardial ischemia, recent myocardial infarction)</td> </tr> <tr> <td>Hemodynamic instability</td> </tr> <tr> <td>Marked acid-base disturbances</td> </tr> <tr> <td>Severe electrolyte&nbsp;abnormalities (hypokalemia, hypophosphatemia, hypomagnesemia, hypocalcemia)</td> </tr> <tr> <td>Respiratory insufficiency (hypoxemia, hypercapnia, severe hypocapnia, pneumonia, asthma, COPD)</td> </tr> <tr> <td>Potentially serious infections (wounds, pneumonia, trauma, urinary tract infection)</td> </tr> <tr> <td>Signs of gastrointestinal pathology (pancreatitis, GI bleeding, hepatic insufficiency, suspected peritonitis)</td> </tr> <tr> <td>Persistent hyperthermia (T &#62;39&#176;C [103&#176;F])</td> </tr> <tr> <td>Evidence of rhabdomyolysis</td> </tr> <tr> <td>Renal insufficiency or increased fluid requirements</td> </tr> <tr> <td>History of prior alcohol withdrawal complications (eg, delirium tremens, alcohol withdrawal seizures)</td> </tr> <tr> <td>Need for frequent or high doses of sedatives or an intravenous infusion to control symptoms</td> </tr> <tr> <td>Withdrawal despite an elevated ethanol concentration</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD:&nbsp;Chronic obstructive pulmonary disease; GI: Gastrointestinal;&nbsp;ICU: Intensive care unit</div><div class=\"graphic_reference\">Adapted from Carlson, RW, Keske, B, Cortez, D, J Crit Illness 1998; 13:311.</div><div id=\"graphicVersion\">Graphic 73377 Version 2.0</div></div></div>"},"73379":{"type":"graphic_algorithm","displayName":"Management of esophageal perforation","title":"Management of esophageal perforation","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Management of esophageal perforation</div><div class=\"cntnt\"><img style=\"width:575px; height:389px;\" src=\"images/GAST/73379_Mgmt_esophageal_perfor_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; NPO: nothing by mouth; NG: nasogastric; IV: intravenous; TPN: total parenteral nutrition; SEMS: self-expandable metallic stents.<br />* Endoscopy should only be performed in centers of expertise.<br />¶ Depending upon the type, location, severity of the esophageal disease, and size of the perforation.</div><div id=\"graphicVersion\">Graphic 73379 Version 4.0</div></div></div>"},"73382":{"type":"graphic_figure","displayName":"Airway changes with hyperextension","title":"Airway changes with hyperextension","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Airway changes with hyperextension</div><div class=\"cntnt\"><img style=\"width:486px; height:210px;\" src=\"images/EM/73382_Airway_in_hyperextension.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During the chin-lift procedure, care must be taken to avoid hyperextending the neck, which may cause airway obstruction (arrow).</div><div id=\"graphicVersion\">Graphic 73382 Version 3.0</div></div></div>"},"73383":{"type":"graphic_table","displayName":"Factors contributing to HF","title":"Factors potentially contributing to worsening heart failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors potentially contributing to worsening heart failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cardiovascular factors</td> </tr> <tr> <td>Superimposed ischemia or infarction</td> </tr> <tr> <td>Uncontrolled hypertension</td> </tr> <tr> <td>Unrecognized primary valvular disease</td> </tr> <tr> <td>Worsening secondary mitral regurgitation</td> </tr> <tr> <td>New onset or uncontrolled atrial fibrillation</td> </tr> <tr> <td>Excessive tachycardia</td> </tr> <tr> <td>Pulmonary embolism</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic factors</td> </tr> <tr> <td>Inappropriate medications</td> </tr> <tr> <td>Superimposed infection</td> </tr> <tr> <td>Anemia</td> </tr> <tr> <td>Uncontrolled diabetes</td> </tr> <tr> <td>Thyroid dysfunction</td> </tr> <tr> <td>Electrolyte disorders</td> </tr> <tr> <td>Pregnancy</td> </tr> <tr> <td class=\"subtitle1_single\">Patient-related factors</td> </tr> <tr> <td>Medication noncompliance</td> </tr> <tr> <td>Dietary indiscretion</td> </tr> <tr> <td>Alcohol consumption</td> </tr> <tr> <td>Substance abuse</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73383 Version 2.0</div></div></div>"},"73384":{"type":"graphic_picture","displayName":"Common melanocytic nevi","title":"Common (banal) acquired melanocytic nevi","html":"<div class=\"graphic\"><div style=\"width: 796px\" class=\"figure\"><div class=\"ttl\">Common (banal) acquired melanocytic nevi</div><div class=\"cntnt\"><img style=\"width:776px; height:262px;\" src=\"images/PEDS/73384_Commn_melanocytic_nevi_edt1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Flat junctional nevus with darker pigmentation in the center than at the periphery.<br />(B) Compound nevus with central elevation.<br />(C) Soft intradermal nevus that is pink in color. All of these lesions are symmetric with a regular outline and uniform pigmentation.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 73384 Version 2.0</div></div></div>"},"73385":{"type":"graphic_diagnosticimage","displayName":"Plain radiograph of an infant with duodenal atresia","title":"Plain radiograph of an infant with duodenal atresia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of an infant with duodenal atresia</div><div class=\"cntnt\"><img style=\"width:318px; height:319px;\" src=\"images/PEDS/73385_Radiograph_duodenal_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the double bubble caused by dilation of the stomach and proximal duodenum; distal gas is absent.</div><div id=\"graphicVersion\">Graphic 73385 Version 3.0</div></div></div>"},"73386":{"type":"graphic_picture","displayName":"Skin biopsy MCTD I","title":"Skin lesion in mixed connective tissue disease (MCTD)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin lesion in mixed connective tissue disease (MCTD)</div><div class=\"cntnt\"><img style=\"width:359px; height:234px;\" src=\"images/RHEUM/73386_Skin_biopsy_MCTD_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy of a skin lesion in mixed connective tissue disease showing an interface dermatitis with prominent dyskeratosis and suprabasilar lymphocytosis similar to the changes seen in subacute cutaneous lupus erythematosus. There&nbsp;are also conspicuous vascular ectasia and areas of vascular dropout, a constellation of findings suggesting that the primary antigenic targets are both the epidermis and the microvasulature.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 73386 Version 2.0</div></div></div>"},"73387":{"type":"graphic_picture","displayName":"Excoriation","title":"Excoriations","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Excoriations</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/73387_Excoriation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear excoriations (secondary to scratching) are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73387 Version 4.0</div></div></div>"},"73388":{"type":"graphic_table","displayName":"MRCP and EUS for choledoch","title":"Advantages and disadvantages associated with MRCP and EUS for the evaluation of choledocholithiasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages associated with MRCP and EUS for the evaluation of choledocholithiasis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n    <td class=\"subtitle1_single\">MRCP</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\">Advantages</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Noninvasive</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Intravenous contrast usually given but not required</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Established technique, widely available</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\">Disadvantages</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Time consuming</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Contraindications such as cardiac pacemaker/defibrillator, intracranial metal clips</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">False-positive studies (eg, intraductal artifacts such as air or blood, image reconstruction artifacts, motion artifacts)</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">False-negative studies (eg, stones in dilated CBD or stones &#60;5 mm in the distal duct may not be visualized well)</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle1_single\">EUS</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\">Advantages</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Very high resolution (0.1 mm) compared with MRCP (1.5 mm)</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Dynamic imaging allowing manipulation and magnification of image for better visualization</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">ERCP can potentially be performed in the same setting for stone removal</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Can be performed at the bedside in critically ill patients</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\">Disadvantages</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">More invasive than MRCP</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Need for sedation</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Risks associated with sedation (eg, cardiopulmonary compromise) and endoscopy (eg, bleeding and perforation)</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Limited availability of equipment and trained endosonographers</td>\n  </tr>\n  <tr>\n    <td class=\"indent1\">Not possible or limited role in altered anatomy (eg, pyloric stenosis, Roux-en-Y bypass)</td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">CBD: common bile duct; ERCP: endoscopic retrograde cholangiopancreatography; EUS: endoscopic ultrasound; MRCP: magnetic endoscopic retrograde cholangiopancreatography.</div><div class=\"graphic_reference\">Courtesy of ML Freeman, MD.</div><div id=\"graphicVersion\">Graphic 73388 Version 1.0</div></div></div>"},"73389":{"type":"graphic_algorithm","displayName":"EUS subepithelial upper GI lesions","title":"Endoscopic ultrasound evaluation of indeterminate subepithelial lesions of the upper gastrointestinal tract","html":"<div class=\"graphic\"><div style=\"width: 990px\" class=\"figure\"><div class=\"ttl\">Endoscopic ultrasound evaluation of indeterminate subepithelial lesions of the upper gastrointestinal tract</div><div class=\"cntnt\"><img style=\"width:970px; height:462px;\" src=\"images/GAST/73389_EUS_evlt_sbpth_lsn_UGI_trct.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EUS: endoscopic ultrasound; GIST: gastrointestinal stromal tumor; FNA: fine-needle aspiration; FNB: fine-needle biopsy.<br />* A normal-appearing five-layered gastrointestinal wall structure is seen interposed between the lesion and the bowel lumen. Extramural lesions may be normal adjacent structures (eg, spleen, aorta, gallbladder) or pathologic structures (eg, splenic artery aneurysm, cyst, tumor). Rarely, the distinction between an intra- and extramural lesion may be difficult if there is invasion of an extramural lesion&nbsp;into the gastrointestinal wall.<br />&para; Options for tissue sampling include EUS-FNA, EUS-FNB, unroofing the lesion followed by forceps biopsy, and endoscopic resection. The choice of approach will depend on the lesion's characteristics (eg, size and location) and the experience of the endoscopist performing the procedure.<br />&Delta; Tissue sampling is not required to confirm the diagnosis.<br /><span class=\"lozenge\">&loz;</span> Tissue sampling should be performed to confirm the diagnosis.<br />&sect; While carcinoid tumors do not originate from the submucosa, they often invade the submucosa and thus may be seen there on EUS.<br />&yen; Visualization of three or five layers in the wall of the lesion suggests a duplication cyst.</div><div id=\"graphicVersion\">Graphic 73389 Version 2.0</div></div></div>"},"73391":{"type":"graphic_table","displayName":"VWD assays","title":"Assays used for diagnosing von Willebrand disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assays used for diagnosing von Willebrand disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> </tbody> <colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Assay name</td> <td class=\"subtitle1\">What it measures</td> <td class=\"subtitle1\">Method</td> </tr> <tr> <td class=\"sublist1_start\">Von Willebrand factor activity</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1\">1 - von Willebrand factor: ristocetin cofactor (VWF:RCo)</td> <td class=\"sublist_other\">Ability of VWF to bind to normal platelets in the presence of ristocetin with consequent agglutination</td> <td class=\"sublist_other\">Quantitate platelet agglutination/aggregation after addition of ristocetin and VWF (patient plasma). Alternative automated VWF:RCo assays (called VWF activity assays) are used in some laboratories. </td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">2 - von Willebrand factor: collagen binding (VWF:CB)</td> <td class=\"sublist_other\">Ability of VWF to bind to collagen</td> <td class=\"sublist_other\">Quantitate binding of VWF (patient plasma) to collagen-coated plates</td> </tr> <tr class=\"divider_bottom\"> <td>Von Willebrand factor antigen (VWF:Ag)</td> <td>VWF protein as measured by immunologic assays; does not imply functional ability</td> <td>Immunologic assay such as ELISA, RIA, or Laurell electroimmunoassay</td> </tr> <tr class=\"divider_bottom\"> <td>Von Willebrand factor multimer analysis</td> <td>Size distribution of VWF multimers</td> <td>Electrophoresis in low concentration agarose gel and visualization by monospecific antibody to VWF</td> </tr> <tr class=\"divider_bottom\"> <td>Ristocetin-induced platelet aggregation (RIPA)</td> <td>Ability of patient's VWF to bind to platelets in the presence of suboptimal concentrations of ristocetin</td> <td>Platelet aggregation using patient's platelet-rich plasma and lower concentrations of ristocetin than VWF:RCo</td> </tr> <tr> <td>VWF activity/antigen ratio (VWF:Act/Ag)</td> <td>Compare functional activity of VWF with its protein concentration</td> <td>Ratio of measured levels of VWF:RCo to VWF:Ag</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">von Willebrand factor (VWF) is a multimeric glycoprotein that promotes platelet adhesion to collagen and platelet aggregation. VWF also acts as a carrier protein for coagulation factor VIII in plasma. Ristocetin is an antibiotic (no longer in clinical use) that induces VWF binding to platelet glycoprotein 1b (GP 1b), which in turn causes platelets to aggregate. Refer to UpToDate for information on how these tests are used and interpreted in the patient evaluation.</div><div class=\"graphic_footnotes\">VWD: von Willebrand disease; VWF: von Willebrand factor; ELISA: enzyme-linked immunosorbent assay; RIA: radioimmunoassay.</div><div class=\"graphic_reference\">Adapted from: The National Heart, Lung, and Blood Institute. The Diagnosis, Evaluation, and Management of Von Willebrand Disease. Bethesda, MD: National Institutes of Health Publication 08-5832, December 2007.</div><div id=\"graphicVersion\">Graphic 73391 Version 2.0</div></div></div>"},"73392":{"type":"graphic_figure","displayName":"EST v TIPS mortality","title":"Mortality with TIPS versus endoscopic sclerotherapy for variceal bleeding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mortality with TIPS versus endoscopic sclerotherapy for variceal bleeding</div><div class=\"cntnt\"><img style=\"width:335px; height:382px;\" src=\"images/GAST/73392_EST_v_TIPS_mortality.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effects of endoscopic sclerotherapy (EST) and transvenous intrahepatic stent shunt (TIPS) on mortality in published clinical trials of secondary prevention of variceal hemorrhage. There was no difference in mortality rate between the two groups.</div><div class=\"graphic_reference\">Data from Jalan, R, et al, Hepatology 1997; 26:1115; Rossle, M, et al, Lancet 1997; 349:1043; Merli, M, et al, Hepatology 1998; 27:48; Cello, JP, et al, Ann Intern Med 1997; 126:858; Cabrera, J, et al, Gastroenterology 1996; 110:832; and Sanyal, AJ, et al, Ann Intern Med 1997; 126:849.</div><div id=\"graphicVersion\">Graphic 73392 Version 2.0</div></div></div>"},"73397":{"type":"graphic_diagnosticimage","displayName":"Scimitar syndrome II","title":"Scimitar syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scimitar syndrome</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PULM/73397_Scimitar_syndrome_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows an abnormal right basal draining vein as well as dilated central pulmonary arteries due to pulmonary arterial hypertension from longstanding left-to-right shunt.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 73397 Version 3.0</div></div></div>"},"73398":{"type":"graphic_picture","displayName":"Dermatosis papulosa face","title":"Dermatosis papulosa nigra","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatosis papulosa nigra</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/73398_Dermatosis_papulosa_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hyperpigmented papules are present on the face of this patient with dermatosis papulosa nigra.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73398 Version 5.0</div></div></div>"},"73400":{"type":"graphic_table","displayName":"Serotonin syndrome - Rapid overview","title":"Serotonin syndrome: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serotonin syndrome: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical and laboratory features</td> </tr> <tr> <td class=\"sublist1_start\">The Hunter Criteria for serotonin syndrome (SS) are fulfilled if the patient has taken a serotonergic agent and has one of the following:</td> </tr> <tr> <td class=\"sublist1\">Spontaneous clonus</td> </tr> <tr> <td class=\"sublist1\">Inducible clonus and agitation or diaphoresis</td> </tr> <tr> <td class=\"sublist1\">Ocular clonus and agitation or diaphoresis</td> </tr> <tr> <td class=\"sublist1\">Tremor and hyperreflexia</td> </tr> <tr> <td class=\"sublist1\">Hypertonia</td> </tr> <tr> <td class=\"sublist1\">Temperature above 38&#176;C and ocular clonus or inducible clonus</td> </tr> <tr> <td>SS is a clinical diagnosis; no laboratory test can confirm the diagnosis. SS can manifest a wide range of clinical symptoms from mild tremor to life-threatening hyperthermia and shock.</td> </tr> <tr> <td>Examination findings can include: hyperthermia, agitation, ocular clonus, tremor, akathisia, deep tendon hyperreflexia, inducible or spontaneous clonus, muscle rigidity, dilated pupils, dry mucus membranes, increased bowel sounds, flushed skin, and diaphoresis. Neuromuscular findings are typically more pronounced in the lower extremities.</td> </tr> <tr> <td class=\"sublist1_start\">The following tests may be helpful in severe cases of SS to narrow the differential and to monitor potential complications:</td> </tr> <tr> <td class=\"sublist1\">Complete blood count, basic electrolytes, creatinine and BUN</td> </tr> <tr> <td class=\"sublist1\">Creatine phosphokinase, hepatic transaminases, coagulation studies</td> </tr> <tr> <td class=\"sublist1\">Blood culture, urinalysis, urine culture</td> </tr> <tr> <td class=\"sublist1\">Chest radiograph</td> </tr> <tr> <td class=\"sublist1\">Head computed tomography, lumbar puncture</td> </tr> <tr> <td class=\"subtitle1_single\">Differential diagnosis</td> </tr> <tr> <td>Neuroleptic malignant syndrome</td> </tr> <tr> <td>Anticholinergic toxicity</td> </tr> <tr> <td>Malignant hyperthermia</td> </tr> <tr> <td>Sympathomimetic toxicity</td> </tr> <tr> <td>Meningitis or encephalitis</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Discontinue serotonergic agents</td> </tr> <tr> <td>Sedate using benzodiazepines (eg, lorazepam 1 to 2 mg IV per dose; 0.02 to 0.04 mg/kg/dose in children): goal is to eliminate agitation, neuromuscular abnormalities (eg, tremor, clonus), and elevations in heart rate and blood pressure; titrate dose to effect</td> </tr> <tr> <td>Provide: oxygen (maintain SpO2 &#8805;94); IV fluids; continuous cardiac monitoring</td> </tr> <tr> <td>Anticipate complications; in severe SS vital signs can fluctuate widely and rapidly</td> </tr> <tr> <td>If benzodiazepines and supportive care fail to improve agitation and abnormal vital signs, give cyproheptadine (12 mg orally or by orogastric tube for initial adult dose; pediatric doses included in main text)</td> </tr> <tr> <td>Treat patients with temperature &#62;41.1&#176;C with immediate sedation, paralysis, and endotracheal intubation; treat hyperthermia with standard measures; avoid antipyretics such as acetaminophen</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73400 Version 10.0</div></div></div>"},"73401":{"type":"graphic_picture","displayName":"Aponeurosis ext oblique","title":"Right groin node dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right groin node dissection</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/73401_Aponeurosis_ext_oblique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The shiny external oblique aponeurosis has been exposed. The caudal end forms the inguinal ligament.</div><div class=\"graphic_reference\">Courtesy of C. William Helm, MD.</div><div id=\"graphicVersion\">Graphic 73401 Version 3.0</div></div></div>"},"73402":{"type":"graphic_diagnosticimage","displayName":"Pelvic congestion syndrome","title":"Left ovarian venogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ovarian venogram</div><div class=\"cntnt\"><img style=\"width:329px; height:478px;\" src=\"images/OBGYN/73402_Pelvic_congestion_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left ovarian venogram on a 44-year-old woman with chronic pelvic congestion syndrome. There is filling of both markedly dilated ovarian veins (arrows) via venous reflux and interconnecting uterine venous plexus.</div><div id=\"graphicVersion\">Graphic 73402 Version 2.0</div></div></div>"},"73403":{"type":"graphic_table","displayName":"Viruses and polyarthralgias","title":"Viruses that cause arthralgia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Viruses that cause arthralgia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Commonly seen</td> </tr> <tr> <td class=\"indent1\">Hepatitis B and C</td> </tr> <tr> <td class=\"indent1\">Rubella and vaccine</td> </tr> <tr> <td class=\"indent1\">Parvovirus</td> </tr> <tr> <td class=\"indent1\">Alphaviruses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dengue virus</td> </tr> <tr> <td class=\"subtitle1_single\">Occasionally seen</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus</td> </tr> <tr> <td class=\"indent1\">Mumps</td> </tr> <tr> <td class=\"indent1\">Hepatitis A</td> </tr> <tr> <td class=\"indent1\">Coxsackie virus</td> </tr> <tr> <td class=\"indent1\">Echovirus</td> </tr> <tr> <td class=\"indent1\">Adenovirus</td> </tr> <tr> <td class=\"indent1\">Varicella-zoster</td> </tr> <tr> <td class=\"indent1\">Herpes simplex</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73403 Version 6.0</div></div></div>"},"73404":{"type":"graphic_table","displayName":"Vaccine schedule age 7 to 18 years PI","title":"Recommended vaccine schedule for children age 7 to 18 years (United States, 2018)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended vaccine schedule for children age 7 to 18 years (United States, 2018)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Vaccine</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td><span style=\"color: black;\"></span>7 <span style=\"color: black;\">through </span><span style=\"color: black;\">18 years</span></td> <td><span style=\"color: black;\">Influenza (flu)</span></td> <td><span style=\"color: black;\">1 dose each year</span></td> <td><span style=\"color: black;\">Children get 1 dose each fall. Children younger than 9 years may need more than 1 dose.</span></td> </tr> <tr> <td rowspan=\"2\"><span style=\"color: black;\">11 through 12 years</span></td> <td><span style=\"color: black;\">Tetanus, diphtheria, pertussis (Tdap booster)</span></td> <td><span style=\"color: black;\">1 dose</span></td> <td><span style=\"color: black;\">This is usually given at age 11 to 12 years, but can be given later, at any age.</span></td> </tr> <tr> <td><span style=\"color: black;\">Human papillomavirus (HPV)</span></td> <td><span style=\"color: black;\">2 doses</span></td> <td><span style=\"color: black;\">This is usually given at age 11 to 12 years, but can be given from age 9 to 26. People younger than 15 usually get 2 doses over 6 months. People 15 and older get 3 doses over 6 months.</span></td> </tr> <tr> <td><span style=\"color: black;\">11 through 18 years</span></td> <td><span style=\"color: black;\">Meningococcal</span></td> <td><span style=\"color: black;\">2 doses</span></td> <td><span style=\"color: black;\">The first dose is usually given at age 11 to 12 years. A booster dose is usually given at age 16.</span></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\"><span style=\"color: black;\">The following vaccines might be given to children with certain conditions</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">7 through 10 years</span></td> <td><span style=\"color: black;\">Meningococcal</span></td> <td><span style=\"color: black;\">1 dose</span></td> <td><span style=\"color: black;\">This is given to children earlier than the recommended age if they have certain medical conditions, or live in or travel to certain places.</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"color: black;\">9 through 10 years </span></td> <td><span style=\"color: black;\">Human papillomavirus&nbsp;(HPV)&nbsp;</span></td> <td><span style=\"color: black;\">2 or 3 doses</span></td> <td><span style=\"color: black;\">This is given to children earlier than the recommended age if they have certain medical conditions. </span></td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\"><span style=\"color: black;\">7 through 18 years</span></td> <td><span style=\"color: black;\">Haemophilus influenza type b (Hib)</span></td> <td><span style=\"color: black;\">1 dose</span></td> <td><span style=\"color: black;\">This is given to children who have certain medical conditions.</span></td> </tr> <tr> <td><span style=\"color: black;\">Pneumococcal </span></td> <td><span style=\"color: black;\">1 or 2 doses&nbsp;</span></td> <td><span style=\"color: black;\">This is given to children who have certain medical conditions.</span></td> </tr> <tr> <td><span style=\"color: black;\">Hepatitis A (HepA)</span></td> <td><span style=\"color: black;\">2 doses</span></td> <td><span style=\"color: black;\">Some children who never got this vaccine might need it.</span></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: If your child didn't get all of his or her scheduled vaccines from age 0 to 6 years, he or she might need to get those vaccines from age 7 to 18.</div><div id=\"graphicVersion\">Graphic 73404 Version 13.0</div></div></div>"},"73407":{"type":"graphic_figure","displayName":"Distribution of live births and infant deaths by gestational age","title":"Distribution of live births and infant deaths by gestational age in 2005 and 2013 in the United States","html":"<div class=\"graphic\"><div style=\"width: 659px\" class=\"figure\"><div class=\"ttl\">Distribution of live births and infant deaths by gestational age in 2005 and 2013 in the United States</div><div class=\"cntnt\"><img style=\"width:639px; height:300px;\" src=\"images/PEDS/73407_Dstrb_lv_bth_infnt_dth_gst_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note: Percent change indicates significant change between 2005 and 2013.</div><div class=\"graphic_reference\">Reproduced from: Matthews TJ, MacDorman MF. Infant mortality statistics from the 2013 period linked birth/infant death data set. Natl Vital Stat Rep 2015; 64:1. Available at: <a href=\"http://www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_09.pdf\" spellcheck=\"true\" target=\"_blank\">www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_09.pdf</a> (Accessed on December 14, 2015).</div><div id=\"graphicVersion\">Graphic 73407 Version 5.0</div></div></div>"},"73408":{"type":"graphic_picture","displayName":"Solitary keratoacanthoma","title":"Keratoacanthoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Keratoacanthoma</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/73408_Sol_keratoacanthoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A dome-shaped nodule with a keratotic core on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73408 Version 4.0</div></div></div>"},"73409":{"type":"graphic_table","displayName":"Dx extrahepatic cholestasis","title":"Differential diagnosis of cholestatic jaundice: Extrahepatic","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of cholestatic jaundice: Extrahepatic</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Cholangiopathies and other disorders involving bile ducts</td> </tr> <tr> <td>Cholelithiasis</td> </tr> <tr> <td>Biliary strictures after invasive procedure</td> </tr> <tr> <td>Cholangiocellular carcinoma</td> </tr> <tr> <td>Primary sclerosing cholangitis</td> </tr> <tr> <td class=\"sublist1_start\">AIDS cholangiopathy</td> </tr> <tr> <td class=\"sublist1\">CMV</td> </tr> <tr> <td class=\"sublist1\"><em>Cryptosporidium sp</em></td> </tr> <tr> <td class=\"sublist1\">HIV</td> </tr> <tr> <td>Choledochal cyst</td> </tr> <tr> <td>Sphincter of Oddi dysfunction</td> </tr> <tr> <td class=\"sublist1_start\">Parasitic infections</td> </tr> <tr> <td class=\"sublist1\"><em>Ascaris lumricoides</em></td> </tr> <tr> <td>Histiocytosis X</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Extrinsic causes</td> </tr> <tr> <td>Pancreatitis (acute and chronic)</td> </tr> <tr> <td>Pancreatic carcinoma</td> </tr> <tr> <td class=\"sublist1_start\">Portal adenopathy</td> </tr> <tr> <td class=\"sublist1\">Metastases</td> </tr> <tr> <td class=\"sublist1\">Tuberculosis</td> </tr> <tr> <td>Periampullary carcinoma</td> </tr> <tr> <td>Periampullary diverticulum</td> </tr> <tr> <td>Mirizzi's syndrome</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">CMV: cytomegalovirus; HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 73409 Version 2.0</div></div></div>"},"73412":{"type":"graphic_table","displayName":"Interventions for Rx of PPH","title":"Potential interventions for treatment of postpartum hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential interventions for treatment of postpartum hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Pharmacologic interventions</td> </tr> <tr> <td class=\"subtitle2_left\">Drug</td> <td class=\"subtitle2_left\">Dosing</td> </tr> <tr> <td class=\"indent1\">Oxytocin</td> <td class=\"indent1\">10 to 40 units in 500 to 1000 mL normal saline infused at a rate sufficient to control atony or 10 units IM</td> </tr> <tr> <td class=\"indent1\">Tranexamic acid</td> <td class=\"indent1\">1 g (10 mL of a 100 mg/mL solution) is infused over 10 to 20 minutes; if bleeding persists after 30 minutes, a second 1 g dose is administered</td> </tr> <tr> <td class=\"indent1\">Ergots</td> <td class=\"indent1\">Methylergonovine 0.2 mg IM every two to four hours or ergometrine 0.5 mg IV or IM or ergonovine 0.25 mg IM or IV every two hours</td> </tr> <tr> <td class=\"indent1\">Carboprost</td> <td class=\"indent1\">0.25 mg IM every 15 to 90 minutes up to eight doses or 500 mcg IM incrementally up to 3 mg or 0.5 mg intramyometrial</td> </tr> <tr> <td class=\"indent1\">Misoprostol</td> <td class=\"indent1\">800 to 1000 mcg rectally</td> </tr> <tr> <td class=\"indent1\">Dinoprostone</td> <td class=\"indent1\">20 mg vaginally or rectally every two hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Recombinant human Factor VIIa</td> <td class=\"indent1\">50 to 100 mcg/kg every two hours</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Surgical interventions</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Repair lacerations</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Curettage</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Uterine compression suture (eg, B-Lynch suture)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Uterine artery ligation</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Utero-ovarian artery ligation or cross clamp</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Pelvic packing</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Uterine tourniquet</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Focal myometrial excision</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Use of fibrin glues and patches to cover areas of oozing and promote clotting</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Placement of figure 8 sutures or other hemostatic sutures directly into the placental bed</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Resuscitative endovascular balloon occlusion of the aorta (REBOA)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Internal iliac artery (hypogastric artery) ligation</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Aortic/iliac artery&nbsp;compression</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Hysterectomy, supracervical</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Hysterectomy, total</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Interventional endovascular procedures</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Selective arterial embolization</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Intermittent aortic balloon occlusion</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Common iliac artery balloon occlusion</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Blood bank</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Packed red blood cells</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Platelets</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Fresh frozen plasma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Cryoprecipitate</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Nonsurgical interventions</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Uterine massage</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Intravenous fluids</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Tamponade</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">Intrauterine tamponade with an intrauterine balloon or alternative device (eg, bladder catheter bulb, Sengstaken-Blakemore tube)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\">Uterine packing (eg, 4 inch gauge packing)</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Consultations</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">General surgery</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Trauma surgery</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Anesthesia team</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Interventional radiology</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Gynecologic oncology</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Urology</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; IM: intramuscular; mcg: micrograms; kg: kilogram.</div><div class=\"graphic_reference\">Data from: Dahlke JD, Mendoz-Figueroa H, Maggio L, et al. Prevention and management of postpartum hemorrhage: a comparison of 4 national guidelines. Am J Obstet Gynecol 2015; 213.e1.</div><div id=\"graphicVersion\">Graphic 73412 Version 8.0</div></div></div>"},"73413":{"type":"graphic_figure","displayName":"DSS resection radiation associated sarcoma","title":"Disease-specific survival after resection for radiation-associated sarcoma (n = 102)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disease-specific survival after resection for radiation-associated sarcoma (n = 102)</div><div class=\"cntnt\"><img style=\"width:430px; height:308px;\" src=\"images/ONC/73413_DSS_rec_radinduced_sarcs.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cha C, Antonescu CR, Quan ML, et al. Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg 2004; 239:903. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73413 Version 9.0</div></div></div>"},"73414":{"type":"graphic_figure","displayName":"Determining BP cuff size","title":"Determining appropriate blood pressure cuff size in children","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Determining appropriate blood pressure cuff size in children</div><div class=\"cntnt\"><img style=\"width:543px; height:505px;\" src=\"images/PEDS/73414_Determining_BP_cuff_size.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The width of the bladder of the blood pressure cuff should be approximately 40 percent of the circumference of the upper arm midway between the olecranon and the acromion. The length of the bladder of the cuff should encircle 80 to 100 percent of the circumference of the upper arm at the same position.</div><div id=\"graphicVersion\">Graphic 73414 Version 3.0</div></div></div>"},"73415":{"type":"graphic_figure","displayName":"Scalp lac hemorrhage","title":"Treatment of scalp laceration","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Treatment of scalp laceration</div><div class=\"cntnt\"><img style=\"width:460px; height:529px;\" src=\"images/EM/73415_Scalp_lac_hemorrhage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A circumferential penrose drain provides temporary control of hemorrhage while staple closure is performed on a large scalp laceration. <br>Inset: Alternatively, Raney clips may be placed along the wound margin for hemorrhage control.</div><div id=\"graphicVersion\">Graphic 73415 Version 2.0</div></div></div>"},"73416":{"type":"graphic_picture","displayName":"Adenocarcinoma of endometrium","title":"Adenocarcinoma of the endometrium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adenocarcinoma of the endometrium</div><div class=\"cntnt\"><img style=\"width:432px; height:483px;\" src=\"images/OBGYN/73416_Adenocarcinoma_of_endometri.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This tumor, which occupies a small uterine cavity, grows primarily as a firm polypoid mass.</div><div class=\"graphic_reference\">Reproduced with permission from: Silverberg SG, Kurman RJ. tumors of the Uterine Corpus and Gestational Trophoblastic Disease. AFIP Atlas of Tumor Pathology, version 2.0, American Registry of Pathology, Washington DC 1995.</div><div id=\"graphicVersion\">Graphic 73416 Version 2.0</div></div></div>"},"73417":{"type":"graphic_figure","displayName":"Trochanteric bursa injection","title":"Trochanteric bursa injection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trochanteric bursa injection</div><div class=\"cntnt\"><img style=\"width:378px; height:327px;\" src=\"images/RHEUM/73417_Trochant_bursa_inject_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trochanteric bursa injection, which may be multiple, not single as shown, may be made up of a standard large joint dose such as 40 mg of triamcinolone acetonide mixed with several mL of xylocaine without epinephrine. After localizing the points of maximum tenderness by deep palpation, a 1.5- to 4-inch needle is used as a probe and the points of maximum tenderness are determined. The injection should be done by redirecting several places within the same coronal plane close to bone. The operator should not wander off the coronal plane of the maximal bony protuberance in order to be absolutely sure of avoiding neurovascular structures.</div><div class=\"graphic_reference\">Reproduced from: Owen DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley WN, Harris ED Jr, Ruddy S, et al (Eds), WB Saunders, Philadelphia, 1993. p.545.</div><div id=\"graphicVersion\">Graphic 73417 Version 4.0</div></div></div>"},"73418":{"type":"graphic_table","displayName":"Inadequate treatment of maternal syphilis","title":"Inadequate or suboptimal treatment of maternal syphilis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inadequate or suboptimal treatment of maternal syphilis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inadequate therapy</td> </tr> <tr> <td>Treatment with a nonpenicillin antibiotic</td> </tr> <tr> <td>Treatment less than four weeks before delivery (including treatment with penicillin)</td> </tr> <tr> <td>Inappropriate dose for stage of disease</td> </tr> <tr> <td class=\"subtitle1_single\">Inadequate documentation of maternal treatment</td> </tr> <tr> <td>Lack of performance of serial non-treponemal* antibody titers after maternal treatment</td> </tr> <tr> <td>Maternal therapy was not documented</td> </tr> <tr> <td class=\"subtitle1_single\">Inadequate response to therapy</td> </tr> <tr> <td>Maternal non-treponemal antibody titers did not decline at least fourfold (two dilutions) after treatment</td> </tr> <tr> <td>Maternal non-treponemal antibody titers suggest reinfection or relapse (ie, fourfold increase)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Non-treponemal test: Rapid plasma reagin (RPR) test or Venereal Disease Research Laboratory (VDRL) test.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. STD Surveillance case definitions.&nbsp;<A href=\"http://www.cdc.gov/std/stats/CaseDefinitions-2014.pdf\">http://www.cdc.gov/std/stats/CaseDefinitions-2014.pdf </A>(Accessed on March 21, 2014).&nbsp;</LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Syphilis. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th, Kimberlin DW.&nbsp; (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.755.</LI>&#xD;&#xA;<LI>Risser WL, Hwang LY. Problems in the current case definitions of congenital syphilis. J Pediatr 1996; 129:499. </LI>&#xD;&#xA;<LI>Workowski KA, Bolan GA. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015; 64:1.</LI></OL></div><div id=\"graphicVersion\">Graphic 73418 Version 6.0</div></div></div>"},"73419":{"type":"graphic_picture","displayName":"Nasal polyposis","title":"Nasal polyposis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasal polyposis</div><div class=\"cntnt\"><img style=\"width:432px; height:389px;\" src=\"images/PC/73419_Nasal_polyposis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73419 Version 1.0</div></div></div>"},"73420":{"type":"graphic_picture","displayName":"Gastric erosion after gastric banding - Case 1","title":"Case 1: Gastric erosion after gastric banding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Case 1: Gastric erosion after gastric banding</div><div class=\"cntnt\"><img style=\"width:393px; height:584px;\" src=\"images/SURG/73420_Gastric_erosion_case_1_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Band erosion through the wall of the stomach is caused by an excessively tight band or injury to the gastric wall during placement. In panel A, the arrow points to the wall of the stomach outside the band in a case of gastric erosion. Panel B shows the endoscopic appearance of band erosion.</div><div id=\"graphicVersion\">Graphic 73420 Version 3.0</div></div></div>"},"73422":{"type":"graphic_picture","displayName":"IgA-dominant Staph-associated GN immunofluorescence microscopy","title":"IgA-dominant Staphylococcus-associated glomerulonephritis on immunofluorescence microscopy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">IgA-dominant Staphylococcus-associated glomerulonephritis on immunofluorescence microscopy</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/NEPH/73422_IgA_dom_PIGN_imm_fluor_micr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The glomerulus shown is from an elderly patient with IgA-dominant Staphylococcus-associated glomerulonephritis. There is coarsely granular global mesangial and segmental glomerular capillary wall staining for IgA.</div><div class=\"graphic_reference\">Provided by Samih H Nasr, MD.</div><div id=\"graphicVersion\">Graphic 73422 Version 2.0</div></div></div>"},"73424":{"type":"graphic_figure","displayName":"Mitochondrial inheritance--pedigree","title":"Example of a pedigree showing mitochondrial inheritance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of a pedigree showing mitochondrial inheritance</div><div class=\"cntnt\"><img style=\"width:373px; height:255px;\" src=\"images/PC/73424_Mitochondrial_inheritance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This pedigree illustrates a mitochondrial inheritance pattern. All children of affected mothers who are homoplasmic for a mitochondrial gene mutation&nbsp;are affected. Affected males do not pass the affected status to their&nbsp;descendants.</div><div id=\"graphicVersion\">Graphic 73424 Version 3.0</div></div></div>"},"73425":{"type":"graphic_figure","displayName":"Tympanograms in diseases","title":"Tympanograms in various diseases","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Tympanograms in various diseases</div><div class=\"cntnt\"><img style=\"width:471px; height:342px;\" src=\"images/PC/73425_Tympanograms_in_diseases.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type A: Normal tympanic membrane (TM) mobility. Type B: Flat tympanogram associated with fluid or perforation (will have large volume). Type C: Negative middle ear pressure such as from a retracted TM. Type AS: Very stiff noncompliant TM associated with TM sclerosis or otosclerosis. Type AD: Hypermobile usually associated with ossicular discontinuity.</div><div id=\"graphicVersion\">Graphic 73425 Version 1.0</div></div></div>"},"73426":{"type":"graphic_picture","displayName":"HP bronchiolitis Light","title":"Cellular bronchiolitis in hypersensitivity pneumonitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cellular bronchiolitis in hypersensitivity pneumonitis</div><div class=\"cntnt\"><img style=\"width:288px; height:189px;\" src=\"images/PULM/73426_HP_bronchiolitis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph shows a cellular bronchiolitis, including peribronchiolar accumulations of giant cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 73426 Version 1.0</div></div></div>"},"73427":{"type":"graphic_table","displayName":"Recommendations routine TBNA","title":"Recommendations for the routine performance of TBNA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for the routine performance of TBNA</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>All patients presenting with mediastinal or hilar adenopathy or both should have 22G and/or 19G TBNA performed as the initial procedure. These results should provide a diagnosis of both malignant and nonmalignant diseases, as well as help in the staging of lung cancers.</td>\n</tr>\n<tr>\n<td>In patients with visible endobronchial disease, 22G TBNA should be performed in case of a necrotic or a hemorragic tumor, or in a patient with a bleeding diathesis.</td>\n</tr>\n<tr>\n<td>All patients with evidence of submucosal and peribronchial disease should have 22G needle cytology sampling.</td>\n</tr>\n<tr>\n<td>TBNA should be the initial diagnostic procedure in all patients with peripheral lesions which extrinsically compress the bronchus but do not invade the lumen.</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from Dasgupta A, Mehta AC, Clin Chest Med 1999; 20:39 and Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 73427 Version 1.0</div></div></div>"},"73428":{"type":"graphic_diagnosticimage","displayName":"Sequestration aortogram I","title":"Intralobar sequestration left lower lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intralobar sequestration left lower lobe</div><div class=\"cntnt\"><img style=\"width:360px; height:391px;\" src=\"images/PULM/73428_Sequestration_aortogram_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An aortogram demonstrates the systemic supply of the left basal sequestration. The splanchnic artery originates from the lower thoracic aorta.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 73428 Version 3.0</div></div></div>"},"73430":{"type":"graphic_figure","displayName":"J-curve diastolic HTN","title":"Lack of true J-shaped curve in diastolic pressure","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Lack of true J-shaped curve in diastolic pressure</div><div class=\"cntnt\"><img style=\"width:514px; height:441px;\" src=\"images/NEPH/73430_JcurvediastolicHTN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Age- and sex-adjusted mortality rates (per 1000 patient-years; bars show the 95% confidence intervals) according to achieved diastolic pressure in active treatment and control groups in a meta-analysis of seven randomized clinical trials of hypertensive patients. The number of events is shown below each bar. Among treated patients, cardiovascular mortality initially falls at achieved diastolic pressures below 106 mmHg and then rises again at low diastolic pressures (upper right panel). However, a similar relationship is seen with noncardiovascular mortality (bottom right panel) and in the control groups (left panels). Thus, the increase in mortality at low systolic pressures probably reflects underlying poor health rather than an adverse effect of antihypertensive therapy.</div><div class=\"graphic_reference\">Data from Boutitie F, Gueyffier F, Pocock S, et al. J-shaped relationship between blood pressure and mortality in hypertensive patients: New insights from a meta-analysis of individual-patient data. Ann Intern Med 2002; 136:438.</div><div id=\"graphicVersion\">Graphic 73430 Version 4.0</div></div></div>"},"73435":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound of ileal atresia with meconium pseudocyst","title":"Prenatal ultrasound image of ileal atresia with meconium pseudocyst","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of ileal atresia with meconium pseudocyst</div><div class=\"cntnt\"><img style=\"width:500px; height:492px;\" src=\"images/OBGYN/73435_Ileal_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sagittal ultrasound at 28 weeks of gestation shows several dilated loops of bowel.<br> (B) Axial image of the fetal abdomen shows a large cystic mass containing echogenic fluid anterior to dilated bowel loops consistent with a meconium pseudocyst.<br> (C) Newborn abdominal radiograph shows a mass containing air in the right midabdomen and dilated bowel loops to the left. Dilated small bowel loops surround the mass.<br> (D) Contrast enema shows a microcolon surrounding the air-filled meconium pseudocyst. At surgery an ileal atresia with perforation into a meconium pseudocyst was identified.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 73435 Version 4.0</div></div></div>"},"73439":{"type":"graphic_picture","displayName":"Undiff nasopharyngeal CA Light","title":"Nasopharyngeal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Nasopharyngeal carcinoma</div><div class=\"cntnt\"><img style=\"width:547px; height:252px;\" src=\"images/ONC/73439_Undiff_nasopharyngeal_CA_Li.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Undifferentiated carcinoma (lymphoepithelioma) of the nasopharynx. Tumor cells (left panel) are large with vesicular nuclei and prominent nucleoli and are dispersed in an intense background of mature lymphocytes. Cytokeratin immunostains highlight many more tumor cells than are apparent in the routine histology (right panel). These are Epstein-Barr virus associated tumors.</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 73439 Version 3.0</div></div></div>"},"73440":{"type":"graphic_table","displayName":"Amino acid levels","title":"Amino acid levels","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Amino acid levels</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Amino acid</td> <td class=\"subtitle1\">High in plasma</td> <td class=\"subtitle1\">Low in plasma</td> <td class=\"subtitle1\">High in urine</td> </tr> <tr> <td>Alanine</td> <td>Disorders of pyruvate metabolism, urea cycle disorders, mitochondrial disorders</td> <td>Untreated maple syrup urine disease</td> <td>Disorders of pyruvate metabolism, urea cycle disorders, mitochondrial disorders</td> </tr> <tr> <td>Alloisoleucine</td> <td>Maple syrup urine disease</td> <td>&ndash;</td> <td>Maple syrup urine disease</td> </tr> <tr> <td>Arginine</td> <td>Argininemia</td> <td>Argininosuccinic aciduria, citrullinemia, ornitine transcarbamylase deficiency, carbamylphosphatase deficiency, inadequate diet</td> <td>Argininemia, cystinuria, lysinuric protein intolerance</td> </tr> <tr> <td>Argininosuccinate</td> <td>Argininosuccinic aciduria</td> <td>&ndash;</td> <td>Argininosuccinic aciduria</td> </tr> <tr> <td>Aspartate</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>Citrulline</td> <td>Citrullinemia, citrin deficiency, argininosuccinic aciduria</td> <td>Ornitine transcarbamylase deficiency, carbamylphosphatase deficiency, inadequate diet</td> <td>Citrullinemia, citrin deficiency, argininosuccinic aciduria</td> </tr> <tr> <td>Cystine</td> <td>&ndash;</td> <td>Molybdenum cofactor deficiency/sulfate oxidase deficiency</td> <td>Cystinuria</td> </tr> <tr> <td>Glutamate</td> <td>Improper sample handling</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>Glutamine</td> <td>Urea cycle disorders/hyperammonemia</td> <td>Improper sample handling</td> <td>&ndash;</td> </tr> <tr> <td>Glycine</td> <td>Glycine encephalopathy, organic acidemias</td> <td>&ndash;</td> <td>Glycine encephalopathy, organic acidemias</td> </tr> <tr> <td>Histidine</td> <td>Histidinemia (benign condition)</td> <td>&ndash;</td> <td>Histidinemia (benign condition)</td> </tr> <tr> <td>Homocystine (free)</td> <td>Homocystinuria, disorders of vitamin B12 transport and synthesis</td> <td>&ndash;</td> <td>Cystathionine beta-synthetase deficiency, disorders of vitamin B12 transport and synthesis</td> </tr> <tr> <td>Isoleucine</td> <td>Maple syrup urine disease, fasting</td> <td>&ndash;</td> <td>Maple syrup urine disease</td> </tr> <tr> <td>Leucine</td> <td>Maple syrup urine disease, fasting</td> <td>&ndash;</td> <td>Maple syrup urine disease</td> </tr> <tr> <td>Lysine</td> <td>Citrin deficiency, hyperlysinemia (benign)</td> <td>&ndash;</td> <td>Cystinuria, lysinuric protein intolerance</td> </tr> <tr> <td>Methionine</td> <td>Homocystinuria, citrin deficiency, liver dysfunction</td> <td>Disorders of vitamin B12 transport and synthesis</td> <td>Cystathionine beta-synthetase deficiency, liver dysfunction</td> </tr> <tr> <td>Ornithine</td> <td>Ornitine aminotransferase deficiency, hyperornithinemia-hyperammonemia-homocitrullinemia (HHH) syndrome</td> <td>&ndash;</td> <td>Cystinuria, lysinuric protein intolerance, ornithine aminotransferase deficiency</td> </tr> <tr> <td>Phenylalanine</td> <td>Phenylketonuria</td> <td>&ndash;</td> <td>Phenylketonuria</td> </tr> <tr> <td>Proline</td> <td>Hyperprolinemia</td> <td>&ndash;</td> <td>Hyperprolinemia</td> </tr> <tr> <td>Serine</td> <td>&ndash;</td> <td>3-phosphoglycerate dehydrogenase deficiency</td> <td>&ndash;</td> </tr> <tr> <td>Threonine</td> <td>Citrin deficiency</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>Tryptophan</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>Tyrosine</td> <td>Tyrosinemia types I and II, hepatic dysfunction</td> <td>Phenylketonuria</td> <td>Tyrosinemia types I and II, hepatic dysfunction</td> </tr> <tr> <td>Valine</td> <td>Maple syrup urine disease, fasting</td> <td>&ndash;</td> <td>Maple syrup urine disease</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>Patterns of abnormalities:</STRONG><br /><UL>&#xD;&#xA;<LI>Argininemia - elevated plasma arginine</LI>&#xD;&#xA;<LI>Argininosuccinic aciduria - elevated plasma citrulline, elevated plasma argininosuccinate, low plasma arginine</LI>&#xD;&#xA;<LI>Carbamyl phosphate synthetase deficiency - low plasma citrulline, ±elevated plasma glutamine (identical pattern to ornithine transcarbamylase deficiency)</LI>&#xD;&#xA;<LI>Citrin deficiency - elevated plasma citrulline, threonine, methionine, lysine, and arginine</LI>&#xD;&#xA;<LI>Citrullinemia - elevated plasma citrulline, low plasma arginine</LI>&#xD;&#xA;<LI>Cystinuria - elevated urine cystine, lysine, arginine, and ornithine</LI>&#xD;&#xA;<LI>Glycine encephalopathy - cerebrospinal fluid (CSF):plasma glycine ratio &gt;0.08</LI>&#xD;&#xA;<LI>HHH syndrome - elevated plasma ornithine</LI>&#xD;&#xA;<LI>Homocystinuria - elevated plasma homocystine* and methionine</LI>&#xD;&#xA;<LI>Hyperprolinemia - elevated plasma proline</LI>&#xD;&#xA;<LI>Lysinuric protein intolerance - elevated urine lysine, arginine, and ornithine</LI>&#xD;&#xA;<LI>Maple syrup urine disease - elevated plasma alloisoleucine, isoleucine, leucine, and valine with perturbation of the normal 1:2:3 ratio of isoleucine:leucine:valine, low plasma alanine</LI>&#xD;&#xA;<LI>Ornithine aminotransferase deficiency - elevated plasma ornithine</LI>&#xD;&#xA;<LI>Ornithine transcarbamylase deficiency - low plasma citrulline, ±elevated plasma glutamine (identical pattern to carbamyl phosphate synthetase deficiency)</LI>&#xD;&#xA;<LI>Phenylketonuria - elevated plasma phenylalanine ± low plasma tyrosine</LI>&#xD;&#xA;<LI>Tyrosinemia types I and II - elevated plasma tyrosine</LI>&#xD;&#xA;<LI>Vitamin B12 (cobalamin) processing disorders - elevated plasma homocystine* with low or normal plasma methionine</LI></UL></div><div class=\"graphic_footnotes\">* Routine plasma amino acid analysis measures free plasma homocystine, not total plasma homocystine. Total plasma homocystine is the preferred test for the diagnosis and management of homocystinuria and disorders of vitamin B12 (cobalamin) transport and synthesis.</div><div class=\"graphic_reference\">Courtesy of V Reid Sutton, MD.</div><div id=\"graphicVersion\">Graphic 73440 Version 6.0</div></div></div>"},"73442":{"type":"graphic_figure","displayName":"DNA replication","title":"DNA replication","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">DNA replication</div><div class=\"cntnt\"><img style=\"width:527px; height:602px;\" src=\"images/PC/73442_DNA_replication.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73442 Version 2.0</div></div></div>"},"73443":{"type":"graphic_figure","displayName":"Late development edema","title":"Late development of interstitial pulmonary edema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Late development of interstitial pulmonary edema</div><div class=\"cntnt\"><img style=\"width:322px; height:504px;\" src=\"images/PULM/73443_Late_development_edema.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The quantity of fluid pouring from the capillaries overwhelms the capacity of the interstitium and the lymphatics, resulting in interstitial edema. Arrows represent lymphatic movement; small circles represent protein.</div><div id=\"graphicVersion\">Graphic 73443 Version 2.0</div></div></div>"},"73444":{"type":"graphic_picture","displayName":"Cutaneous anthrax","title":"Cutaneous anthrax","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Cutaneous anthrax</div><div class=\"cntnt\"><img style=\"width:480px; height:506px;\" src=\"images/ID/73444_Cutaneous_anthrax_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrotic wound with a hemorrhagic rim on the left hand of a patient with cutaneous anthrax.</div><div class=\"graphic_reference\">Reproduced with permission from: Cinquetti G, Banal F, Dupuy A-L, et al. Three related cases of cutaneous anthrax in France. Medicine 2009; 88:371. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73444 Version 8.0</div></div></div>"},"73445":{"type":"graphic_table","displayName":"TBI HBI RAD NV trials","title":"Randomized trials for total body or hemibody irradiation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Randomized trials for total body or hemibody irradiation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Reference </td> <td class=\"subtitle1\">Number of patients </td> <td class=\"subtitle1\">Radiotherapy </td> <td class=\"subtitle1\">Antiemetic </td> <td class=\"subtitle1\">Complete response (percent) </td> <td class=\"subtitle1\">Results </td> </tr> <tr> <td rowspan=\"2\">Tiley<sup>1</sup> </td> <td rowspan=\"2\">20 </td> <td rowspan=\"2\">10.5 Gy (TBI, single fraction) </td> <td>OND (8 mg IV)</td> <td>90*</td> <td rowspan=\"2\">OND better than placebo </td> </tr> <tr> <td>Placebo</td> <td>50*</td> </tr> <tr> <td rowspan=\"2\">Spitzer<sup>2</sup> </td> <td rowspan=\"2\">20 </td> <td rowspan=\"2\">TBI: 13.2 Gy in 11 fractions over 4 days </td> <td>OND (8 mg x 3/day PO)</td> <td>50</td> <td rowspan=\"2\">OND better than placebo </td> </tr> <tr> <td>Placebo</td> <td>0</td> </tr> <tr> <td rowspan=\"2\">Prentice<sup>3</sup> </td> <td rowspan=\"2\">30 </td> <td rowspan=\"2\">7.5 Gy (TBI, single fraction) </td> <td>GRAN (3 mg IV)</td> <td>53</td> <td rowspan=\"2\">GRAN better than MTC + DEX + LOR </td> </tr> <tr> <td>MCP (20 mg IV) + DEX (6 mg/m2 IV) + LOR (2 mg IV)</td> <td>13</td> </tr> <tr> <td rowspan=\"2\">Huang<sup>4</sup> </td> <td rowspan=\"2\">116 </td> <td rowspan=\"2\">7 to 7.7 Gy (TBI, single fraction) </td> <td>OND (8 mg) + DEX (10 mg)</td> <td>84</td> <td rowspan=\"2\">OND + DEX better than MCP + DEX </td> </tr> <tr> <td>MCP (10 mg) + DEX (10 mg)</td> <td>20</td> </tr> <tr> <td rowspan=\"2\">Sykes<sup>5</sup> </td> <td rowspan=\"2\">66 </td> <td rowspan=\"2\">8 to 12.5 Gy (HBI, single fraction) </td> <td>OND (8 mg x 2 PO)</td> <td>94</td> <td rowspan=\"2\">OND better than CLP + DEX </td> </tr> <tr> <td>CLP (25 mg x 3 PO) + DEX (6 mg x 3 PO)</td> <td>34</td> </tr> <tr> <td rowspan=\"2\">Spitzer<sup>6</sup> </td> <td rowspan=\"2\">34 </td> <td rowspan=\"2\">TBI: 13.2 Gy in 11 fractions over 4 days </td> <td>OND (8 mg x 3/day PO)</td> <td>47</td> <td rowspan=\"2\">No difference </td> </tr> <tr> <td>GRAN (2 mg x 1/day PO)</td> <td>61</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TBI: total body irradiation; IV: intravenously; OND: ondansetron; PO: orally; GRAN: granisetron; MCP: metoclopramide; DEX: dexamethasone; LOR: lorazepam; HBI: hemibody irradiation; CLP: chlorpromazine.<br />* All patients received intravenous dexamethasone (8 mg) and phenobarbitone (60 mg/m<SUP>2</SUP>).</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Tiley C, Powles R, Catalano J, et al. Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation. Leuk Lymphoma 1992; 7:317.</LI>&#xD;&#xA;<LI>Spitzer TR, Bryson JC, Cirenza E, et al. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. J Clin Oncol 1994; 12:2432.</LI>&#xD;&#xA;<LI>Prentice HG, Cunningham S, Gandhi L, et al. Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 1995; 15:445.</LI>&#xD;&#xA;<LI>Huang X, Guo N, Fan Y. [Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)]. Zhonghua Zhong Liu Za Zhi 1995; 17:64.</LI>&#xD;&#xA;<LI>Sykes AJ, Kiltie AE, Stewart AL. Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. Support Care Cancer 1997; 5:500.</LI>&#xD;&#xA;<LI>Spitzer TR, Friedman CJ, Bushnell W, et al. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant 2000; 26:203.</LI></OL></div><div id=\"graphicVersion\">Graphic 73445 Version 2.0</div></div></div>"},"73446":{"type":"graphic_table","displayName":"rMPI CP prog","title":"Myocardial perfusion imaging for acute chest pain: Prognostic data","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Myocardial perfusion imaging for acute chest pain: Prognostic data</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Study </td> <td class=\"subtitle1\" rowspan=\"2\">N </td> <td class=\"subtitle1\" rowspan=\"2\">Duration of f/u </td> <td class=\"subtitle1\" rowspan=\"2\">Endpoint </td> <td class=\"subtitle1\" colspan=\"3\">Event rate, percent </td> </tr> <tr> <td class=\"subtitle2\">Normal scan </td> <td class=\"subtitle2\">Equivocal scan </td> <td class=\"subtitle2\">Abnormal scan </td> </tr> <tr> <td>Varetto T, Cantalupi D, Altieri A, Orlandi C. Emergency room technetium-99m sestamibi imaging to rule out acute myocardial ischemic events in patients with nondiagnostic electrocardiograms. J Am Coll Cardiol 1993; 22:1804.</td> <td>64</td> <td>18 m</td> <td>Death, MI, revasc</td> <td>0</td> <td>N/A</td> <td>20</td> </tr> <tr> <td>Hilton TC, Thompson RC, Williams HJ, et al. Technetium-99m sestamibi myocardial perfusion imaging in the emergency room evaluation of chest pain. J Am Coll Cardiol 1994; 23:1016.</td> <td>102</td> <td>3 m</td> <td>Death, MI, revasc</td> <td>1.4</td> <td>13</td> <td>71</td> </tr> <tr> <td rowspan=\"2\">Tatum JL, Jesse RL, Kontos MC, et al. Comprehensive strategy for the evaluation and triage of the chest pain patient. Ann Emerg Med 1997; 29:116. </td> <td rowspan=\"2\">1187 </td> <td rowspan=\"2\">12 m </td> <td>MI</td> <td>0</td> <td rowspan=\"2\">N/A </td> <td>11</td> </tr> <tr> <td>Death</td> <td>0</td> <td>8</td> </tr> <tr> <td rowspan=\"4\">Heller GV, Stowers SA, Hendel RC, et al. Clinical value of acute rest technetium-99m tetrofosmin tomographic myocardial perfusion imaging in patients with acute chest pain and nondiagnostic electrocardiograms. J Am Coll Cardiol 1998; 31:1011. </td> <td rowspan=\"4\">357 </td> <td rowspan=\"4\">In-hospital </td> <td>AMI</td> <td>0.9</td> <td rowspan=\"4\">N/A </td> <td>12</td> </tr> <tr> <td>Cath</td> <td>19</td> <td>33</td> </tr> <tr> <td>CAD</td> <td>7</td> <td>23</td> </tr> <tr> <td>Revasc</td> <td>5</td> <td>16</td> </tr> <tr> <td rowspan=\"2\">Udelson JE, Beshansky JR, Ballin DS, et al. Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial. JAMA 2002; 288:2693. </td> <td rowspan=\"2\">1215 </td> <td rowspan=\"2\">30 d </td> <td>MI</td> <td>0.6</td> <td>0.8</td> <td>10.3</td> </tr> <tr> <td>MI, death, revasc</td> <td>3</td> <td>6.1</td> <td>20.5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MI: myocardial infarction; revasc: revascularization; CAD: coronary artery disease.</div><div class=\"graphic_reference\">Soman P, Udelson JE. Imaging patients with chest pain in the emergency department. In: Nuclear Cardiology: State of the art and future directions, 3rd ed, Mosby, Philadelphia 2005.</div><div id=\"graphicVersion\">Graphic 73446 Version 3.0</div></div></div>"},"73447":{"type":"graphic_picture","displayName":"Eosinophilic esophagitis barium swallow","title":"Eosinophilic esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic esophagitis</div><div class=\"cntnt\"><img style=\"width:288px; height:288px;\" src=\"images/GAST/73447_Eosinophilic_esophagitis_ba.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium swallow in a patient with eosinophilic esopahgitis showing mild segmental ring-like areas of narrowing in the proximal and mid esophagus representing &quot;trachealization&quot; of the esophagus.</div><div class=\"graphic_reference\">Courtesy of Norman Joffe, MD.</div><div id=\"graphicVersion\">Graphic 73447 Version 2.0</div></div></div>"},"73448":{"type":"graphic_table","displayName":"Lymph node staging EUS FNA","title":"Endoscopic ultrasound (EUS)-guided fine needle aspiration biopsy for lymph node staging in patients with esophageal carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endoscopic ultrasound (EUS)-guided fine needle aspiration biopsy for lymph node staging in patients with esophageal carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">&nbsp;</td>\n<td class=\"subtitle1\">N</td>\n<td class=\"subtitle1\">Sensitivity*</td>\n<td class=\"subtitle1\">Specificity*</td>\n<td class=\"subtitle1\">Accuracy*</td>\n</tr>\n<tr>\n<td>Reed, et al, 1999</td>\n<td>19</td>\n<td>72</td>\n<td>97</td>\n<td>86</td>\n</tr>\n<tr>\n<td>Giovannini, et al, 1999</td>\n<td>40</td>\n<td>97</td>\n<td>100</td>\n<td>97</td>\n</tr>\n<tr>\n<td>Vazquez-Sequeiros, et al, 2001</td>\n<td>31</td>\n<td>93</td>\n<td>100</td>\n<td>93</td>\n</tr>\n<tr>\n<td>Catalano, et al, 1999</td>\n<td>4</td>\n<td>100</td>\n<td>100</td>\n<td>100</td>\n</tr>\n<tr>\n<td><strong>OVERALL</strong></td>\n<td><strong>94</strong></td>\n<td><strong>91</strong></td>\n<td><strong>99</strong></td>\n<td><strong>93</strong></td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* Data shown represent percentages.</div><div id=\"graphicVersion\">Graphic 73448 Version 2.0</div></div></div>"},"73450":{"type":"graphic_table","displayName":"Activity of antimicrobial agents against anaerobes","title":"Activity of antimicrobial agents against anaerobes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Activity of antimicrobial agents against anaerobes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nearly always active</td> </tr> <tr> <td class=\"indent1\">Metronidazole</td> <td>Inactive versus microaerophilic streptococci (eg, <em>S. milleri</em>), <em>Cutibacterium </em>(formerly <em>Propionibacterium</em>), and <em>Actinomyces</em> species; bactericidal versus most gram-negative anaerobic strains</td> </tr> <tr> <td class=\"indent1\">Carbapenems</td> <td>Resistant to most <em>Bacteroides</em> beta-lactamases, although a novel beta-lactamase that cleaves carbapenems was found in rare <em>B. fragilis</em> strains<sup>[1]</sup></td> </tr> <tr> <td class=\"indent1\">Beta-lactam plus beta-lactamase inhibitors</td> <td>The addition of a beta-lactamase inhibitor to a beta-lactam dramatically increases activity against anaerobes that produce a beta-lactamase</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Usually active</td> </tr> <tr> <td class=\"indent1\">Clindamycin</td> <td><em>B. fragilis</em> group:&nbsp;19 to 60 percent of strains resistant; some Clostridia other than <em>C. perfringens</em> are resistant<sup>[2]</sup></td> </tr> <tr> <td class=\"indent1\">Cefoxitin</td> <td><em>B. fragilis</em> group:&nbsp;0 to&nbsp;23 percent of strains resistant with considerable institutional variation at least partly reflecting use patterns; poor activity versus Clostridia<sup>[2]</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Variable activity</td> </tr> <tr> <td class=\"indent1\">Penicillin</td> <td>Inactive versus some or most penicillinase-producing anaerobes, including most of the <em>B. fragilis</em> group and many strains of <em>Prevotella melaninogenica</em>, <em>P. intermedia</em>, <em>P. bivia</em>, <em>P. disiens</em>, and some Clostridia</td> </tr> <tr> <td class=\"indent1\">Cephalosporins</td> <td>Less activity in vitro than penicillin G versus most anaerobes and limited published clinical experience to document efficacy other than cefamycins </td> </tr> <tr> <td class=\"indent1\">Tetracycline</td> <td>Inactive versus many anaerobes and most strains of <em>B. fragilis</em>; doxycycline and minocycline are somewhat more active than tetracycline</td> </tr> <tr> <td class=\"indent1\">Vancomycin</td> <td>Active against gram-positive anaerobes; inactive versus gram-negative anaerobes</td> </tr> <tr> <td class=\"indent1\">Macrolides</td> <td>Inactive versus many <em>Fusobacterium</em> spp and some <em>B. fragilis</em> spp</td> </tr> <tr> <td class=\"indent1\">Fluoroquinolones</td> <td>Moxifloxacin is the best in this class for anaerobic infections, but the <em>B. fragilis</em> group shows increasing resistance and moxifloxacin&nbsp;is no longer recommended in the IDSA guidelines for intraabdominal sepsis.</td> </tr> <tr> <td class=\"indent1\">Tigecycline</td> <td>Active against&nbsp;some anaerobes, including strains of <em>B. fragilis</em> that are resistant to beta-lactams, clindamycin, and quinolones<span style=\"font-size: 13px;\">.<sup>[2]</sup></span></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\"> <p>Poor activity</p> </td> </tr> <tr> <td class=\"indent1\">Aminoglycosides</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Monobactams (aztreonam)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IDSA: Infectious Diseases Society of America.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Edwards R, Hawkyard CV, Garvey MT, Greenwood D. Prevalence and degree of expression of the carbapenemase gene (cfiA) among clinical isolates of Bacteroides fragilis in Nottingham, UK. J Antimicrob Chemother 1999; 43:273.</LI>&#xD;&#xA;<LI>Snydman DR, Jacobus NV, McDermott LA, et al. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. Anaerobe 2011; 17:147.</LI></OL></div><div id=\"graphicVersion\">Graphic 73450 Version 12.0</div></div></div>"},"73452":{"type":"graphic_diagnosticimage","displayName":"ICE transseptal","title":"This ultrasound image is an intracardiac echocardiographic illustration of a transseptal catheterization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">This ultrasound image is an intracardiac echocardiographic illustration of a transseptal catheterization</div><div class=\"cntnt\"><img style=\"width:360px; height:411px;\" src=\"images/CARD/73452_ICE_transseptal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;intracardiac echocardiography&nbsp;catheter is in the right atrium and shows&nbsp;a needle tenting the interatrial septum just before puncture occurs. Transseptal&nbsp;puncture enables acesss to the mitral valve from the left atrium for percutaneous mitral balloon valvotomy.</div><div id=\"graphicVersion\">Graphic 73452 Version 3.0</div></div></div>"},"73454":{"type":"graphic_figure","displayName":"Urea cycle disorders","title":"Urea cycle disorders","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Urea cycle disorders</div><div class=\"cntnt\"><img style=\"width:545px; height:453px;\" src=\"images/PEDS/73454_Ureacycledisordersedt1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double-stroked boxes represent the source of nitrogen for urea formation. Precursor amino acids contributing to the nitrogen pool include glutamine, glycine, and alanine.</div><div class=\"graphic_footnotes\">CPS: carbamyl phosphate synthetase; OTC: ornithine transcarbamylase; ASS: argininosuccinate synthetase; ASL: argininosuccinic acid lyase.</div><div id=\"graphicVersion\">Graphic 73454 Version 2.0</div></div></div>"},"73456":{"type":"graphic_diagnosticimage","displayName":"Pancreatic abscess CT","title":"Pancreatic abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic abscess</div><div class=\"cntnt\"><img style=\"width:309px; height:238px;\" src=\"images/GAST/73456_Pancreatic_abscess_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan in a patient with abdominal pain, fever, and jaundice shows air (thin arrow) in the central pancreas, which is necrotic and largely replaced by an acute fluid collection (thick arrows), leaving only a small residual pancreatic head (P).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 73456 Version 3.0</div></div></div>"},"73457":{"type":"graphic_figure","displayName":"Survival in flail MV leaflet","title":"Long-term survival in flail mitral leaflet","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Long-term survival in flail mitral leaflet</div><div class=\"cntnt\"><img style=\"width:530px; height:196px;\" src=\"images/CARD/73457_Survival_in_flail_MV_leafle.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 229 patients with isolated mitral regurgitation due to a flail mitral leaflet, long-term survival was related to NYHA class (left panel) and left ventricular ejection fraction (LVEF) (right panel). Mortality was higher in patients with poor left ventricular function as indicated by more significant clinical heart failure (class III or IV) and lower EF (&lt;60 percent).</div><div class=\"graphic_reference\">Data from Ling LH, Enriquez-Sarano M, Steward JB, et al. N Engl J Med 1996; 335:1417.</div><div id=\"graphicVersion\">Graphic 73457 Version 2.0</div></div></div>"},"73458":{"type":"graphic_picture","displayName":"Subcutaneous paragonimiasis - finger","title":"Subcutaneous paragonimiasis - finger","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Subcutaneous paragonimiasis - finger</div><div class=\"cntnt\"><img style=\"width:504px; height:355px;\" src=\"images/ID/73458_Subcut_paragonimiasis_fing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left fifth finger showing an erythematous swelling on the tip.</div><div class=\"graphic_reference\">Reproduced with permission from: Sim YS, Lee JH, Hong SC, et al. Paragonimus westermani found in the tip of a little finger. Intern Med 2010; 49:1645. Copyright &#169; 2010 Japanese Society of Internal Medicine.</div><div id=\"graphicVersion\">Graphic 73458 Version 1.0</div></div></div>"},"73459":{"type":"graphic_table","displayName":" Requirements for patient and lesion selection","title":"ACCF/AHA/SCAI expert consensus document requirements for patient and lesion selection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACCF/AHA/SCAI expert consensus document requirements for patient and lesion selection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist_other_start\"><strong>Patient risk:</strong> expected clinical risk in case of occlusion caused by procedure</td> </tr> <tr> <td class=\"indent1\"><strong>High patient risk:</strong> Patients with any of the following:<br /> <ul> <li>Decompensated congestive heart failure (Killip Class 3) without evidence for active ischemia, recent CVA, advanced malignancy, known clotting disorders</li> <li>LVEF &#60;25 percent</li> <li>Left main stenosis (&#8805;50 percent diameter) or 3-vessel disease unprotected by prior bypass surgery (&#62;70 percent stenoses in the proximal segment of all major epicardial coronary arteries)</li> <li>Single-target lesion that jeopardizes &#62;50 percent of remaining viable myocardium</li> </ul> </td> </tr> <tr> <td class=\"sublist_other_start\"><strong>Lesion risk:</strong> probability that procedure will cause acute vessel occlusion</td> </tr> <tr> <td class=\"indent1\"><strong>Increased lesion risk:</strong> lesions in open vessels with any of the following characteristics:<br /> <ul> <li>Diffuse disease (&#62;2 cm in length) and excessive tortuosity of proximal segments</li> <li>More than moderate calcification of a stenosis or proximal segment</li> <li>Location in an extremely angulated segment (&#62;90 percent)</li> <li>Inability to protect major side branches</li> <li>Degenerated older vein grafts with friable lesions</li> <li>Substantial thrombus in the vessel or at the lesion site</li> <li>Any other feature that may, in the operator's judgment, impede successful stent deployment</li> </ul> Aggressive measures to open CTOs are also discouraged because of an increased risk of perforation</td> </tr> <tr> <td class=\"sublist_other_start\"><strong>Strategy for surgical backup based on lesion and patient risk:</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li><strong>High-risk patients with high-risk lesions</strong> should not undergo nonemergency PCI at a facility without on-site surgery</li> <li><strong>High-risk patients with non-high-risk lesions:</strong> Nonemergency patients with this profile may undergo PCI, but confirmation that a cardiac surgeon and operating room are immediately available is necessary</li> <li><strong>Non-high-risk patients with high-risk lesions</strong> require no additional precautions</li> <li><strong>Non-high-risk patients with non-high-risk lesions</strong> require no additional precautions. Best scenario for PCI without on-site surgery.</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CTO: chronic total occlusion; CVA: cerebrovascular accident; LVEF: left ventricular ejection fraction; PCI: percutaneous coronary intervention; SCAI: Society for Cardiovascular Angiography and Interventions.</div><div class=\"graphic_reference\">From: Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58:e44. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 73459 Version 1.0</div></div></div>"},"73460":{"type":"graphic_table","displayName":"Differential diagnosis for lateral elbow pain","title":"Differential diagnosis for lateral elbow pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis for lateral elbow pain</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n\r\n   <td>Epicondylitis</td>\r\n\r\n   </tr>\r\n\r\n   <tr>\r\n  \r\n   <td>Loose bodies</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Osteochondral defect (radiocapitellar joint)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Arthritis (posterior osteophytes)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Valgus extension overload</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Radial tunnel syndrome</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Inflammatory arthritis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lateral synovial plica</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cervical radiculopathy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Thoracic outlet syndrome</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Myofascial pain</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 73460 Version 2.0</div></div></div>"},"73463":{"type":"graphic_table","displayName":"Histologic features RB-ILD","title":"Histologic features of respiratory bronchiolitis pattern","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic features of respiratory bronchiolitis pattern</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Key histologic features</td> </tr> <tr> <td>Bronchiolocentric alveolar macrophage accumulation</td> </tr> <tr> <td>Mild bronchiolar fibrosis and chronic inflammation</td> </tr> <tr> <td>Macrophages have dusty brown cytoplasm (may be positive for iron stains)</td> </tr> <tr> <td class=\"subtitle1_single\">Pertinent negative findings</td> </tr> <tr> <td>Lack of diffuse macrophage accumulation</td> </tr> <tr> <td>Lack of interstitial fibrosis and/or honeycomb fibrosis</td> </tr> <tr> <td>Absence of fibroblast foci</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73463 Version 3.0</div></div></div>"},"73464":{"type":"graphic_figure","displayName":"Open cholecystectomy","title":"Open cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Open cholecystectomy</div><div class=\"cntnt\"><img style=\"width:527px; height:684px;\" src=\"images/SURG/73464_Open_cholecystectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the general steps and principles to help guide safe open cholecytectomy. <br> <br> Unequivocal identification of the cystic duct and cystic artery is critical in order to avoid injury to the common duct, right hepatic artery, and aberrant right hepatic branch duct. The “critical view of safety” must be achieved prior to the clipping or ligation of the cystic duct and artery. The critical view of safety is achieved by dissecting the triangle of Calot free of all tissue except for the cystic duct and cystic artery and by exposing the base of the liver bed by freeing the lower part of the gallbladder from the liver.<br> <br> While most surgeons perform laparoscopic cholecystectomy “from the bottom of the gallbladder (infundibulum) up,” many surgeons perform open cholecystectomy from the “top of the gallbladder (fundus or dome) down&quot; in order to avoid injury to major structures. The top down approach should always be used if there is uncertainty about the location of the cystic duct and artery in relation to other named structures in the hilum of the liver. If the surgeon has identified the cystic duct and artery with certainty, it should be equally safe to remove the gallbladder from the top down or from the bottom up.<br> <br> An “anomalous” cystic duct or cystic artery should not be divided until the surgeon is absolutely certain that the structure is not a major duct or artery.</div><div id=\"graphicVersion\">Graphic 73464 Version 7.0</div></div></div>"},"73467":{"type":"graphic_picture","displayName":"Small vessel disease in HCM","title":"Small vessel disease in hypertrophic cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small vessel disease in hypertrophic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:382px; height:252px;\" src=\"images/CARD/73467_Small_vessel_disease_in_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with hypertrophic cardiomyopathy often have small vessel disease which may be associated with symptoms of ischemia. The small intramural vessels often demonstrate apparent lumenal narrowing, caused by hypertrophy of the tunica media.</div><div class=\"graphic_reference\">Courtesy of Professor Michael Davies, St. George's Hospital, London.</div><div id=\"graphicVersion\">Graphic 73467 Version 1.0</div></div></div>"},"73468":{"type":"graphic_figure","displayName":"Drug facts PI","title":"The different parts of a medicine label (Drug Facts)","html":"<div class=\"graphic\"><div style=\"width: 846px\" class=\"figure\"><div class=\"ttl\">The different parts of a medicine label (Drug Facts)</div><div class=\"cntnt\"><img style=\"width:826px; height:598px;\" src=\"images/PI/73468_Drug_facts_PI_PR_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a Drug Facts label from a bottle of acetaminophen pills. The gray boxes describe the information found in the different parts of the label.</div><div id=\"graphicVersion\">Graphic 73468 Version 4.0</div></div></div>"},"73470":{"type":"graphic_movie","displayName":"TEE LA thrombus and spontaneous echo contrast 1","title":"Left atrial thrombus and spontaneous echo contrast seen on TEE","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial thrombus and spontaneous echo contrast seen on TEE</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/73470_teelatt1conv.mp4\" style=\"width:312px;height:224px\"></div><img style=\"width:260px; height:206px;\" src=\"images/CARD/73470_teelatt1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows a large thrombus adherent to the left atrial wall. Spontaneous echo contrast can be seen within the left atrium.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 73470 Version 3.0</div></div></div>"},"73474":{"type":"graphic_table","displayName":"NCI CTCAE v5 palmar-plantar erythrodysesthesia syndrome","title":"NCI CTCAE v5.0 palmar-plantar erythrodysesthesia syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 palmar-plantar erythrodysesthesia syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Palmar-plantar erythrodysesthesia syndrome</td> <td>Minimal skin changes or dermatitis (eg, erythema, edema, or hyperkeratosis) without pain</td> <td>Skin changes (eg, peeling, blisters, bleeding, edema, or hyperkeratosis) with pain, limiting instrumental ADL*</td> <td>Severe skin changes (eg, peeling, blisters, bleeding, edema, or hyperkeratosis) with pain, limiting self-care ADL*</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Palmar-plantar erythrodysesthesia syndrome is characterized by redness, marked discomfort, swelling, and tingling in the palms of the hands or the soles of the feet. Palmar-plantar erythrodysesthesia syndrome is also called hand-foot syndrome. Refer to UpToDate topics on the cutaneous side effects of conventional and molecularly targeted chemotherapy agents for discussion of palmar-plantar dysesthesia syndrome, hand-foot syndrome, and hand-foot skin reaction.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ADL: activities of daily living.<br />* Instrumental ADLs include preparing meals, shopping, using the telephone, managing money. Self-care ADLs include bathing, dressing/undressing, using the toilet, taking medications, and not bedridden.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <A spellcheck=true href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=_blank>https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</A> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 73474 Version 8.0</div></div></div>"},"73475":{"type":"graphic_figure","displayName":"Survival of dialysis patients after ICDs","title":"Survival of dialysis patients after ICDs","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Survival of dialysis patients after ICDs</div><div class=\"cntnt\"><img style=\"width:620px; height:268px;\" src=\"images/NEPH/73475_Survival_after_ICDs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Period prevalent ESRD patients, 1999 to 2008.</div><div class=\"graphic_footnotes\">n: number of patients; ICD: implantable cardioverter-defibrillator; CRT-D: cardiac resynchronization therapy with defibrillator.</div><div class=\"graphic_reference\">Modified by Charles A Herzog, MD. From: US Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010. Full report available at: <a href=\"http://www.usrds.org/adr.htm\" target=\"_blank\">http://www.usrds.org/adr.htm</a>.</div><div id=\"graphicVersion\">Graphic 73475 Version 4.0</div></div></div>"},"73476":{"type":"graphic_picture","displayName":"Pancreatic stone removal","title":"Removal of a stone fragment from the pancreatic duct","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Removal of a stone fragment from the pancreatic duct</div><div class=\"cntnt\"><img style=\"width:384px; height:373px;\" src=\"images/GAST/73476_Pancreatic_stone_removal_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic imaging showing a fragment of a pancreatic duct stone being removed following pancreatoscopy with lithotripsy.</div><div id=\"graphicVersion\">Graphic 73476 Version 1.0</div></div></div>"},"73477":{"type":"graphic_picture","displayName":"Drug packet - Cut-away view","title":"Drug packet: Cut-away view","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Drug packet: Cut-away view</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/EM/73477_Drug_packet_layers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a cut-away view of a drug packet revealing a hard wax exterior shell, latex wrapping beneath the wax, and a core of compact drug.</div><div class=\"graphic_reference\">Courtesy of Robert Hoffman, MD.</div><div id=\"graphicVersion\">Graphic 73477 Version 2.0</div></div></div>"},"73479":{"type":"graphic_picture","displayName":"Cholesterol crystals","title":"Gallbladder bile microscopy","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Gallbladder bile microscopy</div><div class=\"cntnt\"><img style=\"width:468px; height:376px;\" src=\"images/GAST/73479_Cholesterol_crystals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholesterol crystals on microscopy. Note the rhomboid appearance with the notch on one corner.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP.</div><div id=\"graphicVersion\">Graphic 73479 Version 2.0</div></div></div>"},"73480":{"type":"graphic_picture","displayName":"Normal human promyelocyte","title":"Normal human promyelocyte","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal human promyelocyte</div><div class=\"cntnt\"><img style=\"width:396px; height:255px;\" src=\"images/HEME/73480_Normal_human_promyelocyte.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear showing a normal human promyelocyte. Promyelocytes are larger than myeloblasts and myelocytes (&gt;20 micron). The nucleus and nuclear chromatin and nucleoli resemble myeloblasts but the cardinal feature is the presence of many violet granules in the cytoplasm with either a dense or coarse pattern often obscuring other cell landmarks.</div><div class=\"graphic_reference\">Courtesy of Robert L Baehner, MD.</div><div id=\"graphicVersion\">Graphic 73480 Version 1.0</div></div></div>"},"73484":{"type":"graphic_figure","displayName":"Groin hernias","title":"Groin hernias","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Groin hernias</div><div class=\"cntnt\"><img style=\"width:501px; height:602px;\" src=\"images/SURG/73484_Groin_hernia_exam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inguinal hernias typically present above the inguinal ligament and extend below it. Femoral hernias typically present below the inguinal ligament.</div><div id=\"graphicVersion\">Graphic 73484 Version 2.0</div></div></div>"},"73485":{"type":"graphic_table","displayName":"Adult skeletal and dental effective doses","title":"Adult skeletal and dental effective doses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adult skeletal and dental effective doses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Modality</td> <td class=\"subtitle1\">Average effective dose (mSv)</td> <td class=\"subtitle1\">Number of chest x-rays (PA/lateral) with equivalent radiation dose*</td> </tr> <tr> <td>Hand or foot radiograph</td> <td>Conventional radiography</td> <td>0.001</td> <td>0.01</td> </tr> <tr> <td>Knee radiograph</td> <td>Conventional radiography</td> <td>0.005</td> <td>0.05</td> </tr> <tr> <td>Intraoral radiograph (restricted view)</td> <td>Conventional radiography</td> <td>0.005</td> <td>0.05</td> </tr> <tr> <td>Shoulder radiograph</td> <td>Conventional radiography</td> <td>0.01</td> <td>0.1</td> </tr> <tr> <td>Panoramic radiograph (full mouth view)</td> <td>Conventional radiography</td> <td>0.01</td> <td>0.1</td> </tr> <tr> <td>Dental CT</td> <td>Computed tomography</td> <td>0.2</td> <td>2</td> </tr> <tr> <td>Hip radiograph</td> <td>Conventional radiography</td> <td>0.7</td> <td>7</td> </tr> <tr> <td>Bone scan</td> <td>Nuclear medicine</td> <td>6.3</td> <td>63</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* PA and lateral chest radiograph = .1 mSv.</div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Mettler, FA, Huda, W, Yoshizumi, TT, Mahesh, M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008; 248:254. </li> <li>Smith-Bindman, R, Lipson, J, Marcus, R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009; 169:2078. </li> <li>Shrimpton, PC, Hillier, MC, Lewis, MA, Dunn, M. National survey of doses from CT in the UK: 2003. Br J Radiol 2006; 79:968. </li> </ol></div><div id=\"graphicVersion\">Graphic 73485 Version 3.0</div></div></div>"},"73486":{"type":"graphic_diagnosticimage","displayName":"Rib fracture stabilization","title":"Rib fracture stabilization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rib fracture stabilization</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/73486_Ribfxstabilization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph showing internal fixation of multiple left rib fractures.</div><div id=\"graphicVersion\">Graphic 73486 Version 3.0</div></div></div>"},"73487":{"type":"graphic_figure","displayName":"FAST stroke PI","title":"Signs of stroke","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Signs of stroke</div><div class=\"cntnt\"><img style=\"width:525px; height:673px;\" src=\"images/PI/73487_FAST_stroke_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The letters in the word \"fast\" help you remember the signs of stroke. If a person shows any of these signs, call an ambulance right away. In the US and Canada, dial &nbsp;9-1-1. &nbsp;</div><div id=\"graphicVersion\">Graphic 73487 Version 3.0</div></div></div>"},"73488":{"type":"graphic_figure","displayName":"Holoprosencephaly and normal","title":"Holoprosencephaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Holoprosencephaly</div><div class=\"cntnt\"><img style=\"width:430px; height:306px;\" src=\"images/PEDS/73488_Holoprosencephaly_and_norma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Kawamoto HK Jr, Pravin-Kumar KP, Atypical facial clefts. In: Pediatric Plastic Surgery, Bentz M (Ed), Appleton Lange, Stamford, CT 1998. p.184. Copyright &copy; 1998 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 73488 Version 2.0</div></div></div>"},"73489":{"type":"graphic_table","displayName":"Dietary recommendations for school age children to adolescents","title":"Dietary recommendations for school-age children to adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary recommendations for school-age children to adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Food groups and number of servings</td> <td class=\"subtitle1\">Age 9 to 13 years</td> <td class=\"subtitle1\">Age 14 to 18 years</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Milk and milk products</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"><em>Low-fat or fat-free milk or milk products</em></td> <td>3 cups/day</td> <td>3 cups/day</td> </tr> <tr> <td class=\"centered\" colspan=\"2\"> <p>1 cup equivalent =</p> <p>1 cup of milk or yogurt, 1&#189; ounces of a natural cheese, 2 ounces of processed cheese, 1/3 cup of shredded cheese</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Meat and other protein foods</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"><em>Includes beef, chicken, pork, poultry, fish, eggs, peanut butter, and legumes</em></td> <td>5 ounces/day</td> <td>5 to 6 ounces/day</td> </tr> <tr> <td class=\"centered\" colspan=\"2\"> <p>1 ounce equivalent =</p> <p>1 ounce of beef, poultry, or fish, &#188; cup cooked beans, 1 egg, 1 tablespoon peanut butter, &#189; ounce of nuts</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Breads, cereals, and starches</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"><em>Includes whole-grain breads, infant and cooked cereals, rice, pasta, ready to eat cereals. Half of all starches should be whole grains.</em></td> <td>5 to 6 ounces/day</td> <td>6 to 7 ounces/day</td> </tr> <tr> <td class=\"centered\" colspan=\"2\"> <p>1 ounce equivalent =</p> <p>1 slice whole-grain bread, &#189; cup cooked cereal, rice, or pasta, 1 cup dry cereal</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Fruits</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"><em>Includes one source of vitamin C daily (citrus fruits and juices, strawberries) and one source of vitamin A every other day (dark green and yellow fruits, melons)</em></td> <td>1&#189; cups/day</td> <td>1&#189; to 2 cups/day</td> </tr> <tr> <td class=\"centered\" colspan=\"2\"> <p>1 cup equivalent =</p> <p>1 cup of fruit or 100 percent fruit juice*, &#189; cup of dried fruit</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Vegetables</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"><em>Includes one source of vitamin C daily (broccoli and tomatoes) and one source of vitamin A every other day (spinach, sweet potatoes, corn, squash)</em></td> <td>2 to 2&#189; cups/day</td> <td>2&#189; to 3 cups/day</td> </tr> <tr> <td class=\"centered\" colspan=\"2\"> <p>1 cup equivalent =</p> <p>1 cup of raw or cooked vegetables or vegetable juice, 2 cups of raw leafy greens</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Fats and oils</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"><em>Includes margarine, butter, oils</em></td> <td>5 teaspoons/day</td> <td>5 to 6 teaspoons/day</td> </tr> <tr> <td class=\"centered\" colspan=\"2\"> <p>1 teaspoon equivalent =</p> <p>1 teaspoon oil, margarine, butter or mayonnaise, 1 tablespoon salad dressing, sour cream, or light mayonnaise</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\"><em>Desserts, sweets, soft drinks, candy, jams and jelly</em></td> <td colspan=\"2\">Limit to small amount, use sparingly</td> </tr> <tr> <td colspan=\"2\">Discretionary kilocalories<sup>&#182;</sup></td> </tr> <tr> <td>100 kilocalories (approximately 25 g or 6 teaspoons of added sugars)</td> <td>100 kilocalories (approximately 25 g or 6 teaspoons of added sugars)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: For more details, go to <A href=\"http://www.choosemyplate.gov/\" target=_blank>www.choosemyplate.gov</A>.</div><div class=\"graphic_footnotes\">* Children should be encouraged to consume whole fruits. Recommend limiting fruit juice to 8 ounces (240 mL)&nbsp;for children 7 to 18 years of age. <br />¶ Discretionary kilocalories are those that are available for consumption as added sugars and solid fats after essential daily nutrient requirements are met.</div><div class=\"graphic_reference\">Reproduced with permission from: Texas Children's Hospital Pediatric Nutrition Reference Guide 2010, 9<SUP>th</SUP> ed, Bunting KD, Mills J, Phillips S et al (Eds). Copyright © 2010 Texas Children's Hospital. All rights reserved.<br /><br />Additional data from: <br /><OL>&#xD;&#xA;<LI>Vos MB, Kaar JL, Welsh JA, et al. Added sugars and cardiovascular disease risk in children: A scientific statement from the American Heart Association. Circulation 2016.</LI>&#xD;&#xA;<LI>​Heyman MB, Abrams SA, AAP Section on Gastroenterology, Hepatology, and Nutrition, Committee on Nutrition. Fruit juice in infants, children, and adolescents: Current recommendations. Pediatrics 2017; 139:e20170967.</LI></OL></div><div id=\"graphicVersion\">Graphic 73489 Version 13.0</div></div></div>"},"73491":{"type":"graphic_figure","displayName":"Tinnitus PI","title":"Tinnitus (ringing in the ears)","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Tinnitus (ringing in the ears)</div><div class=\"cntnt\"><img style=\"width:535px; height:602px;\" src=\"images/PI/73491_Tinnitus_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the different parts of the ear. Cells in the inner ear are damaged in people with tinnitus.</div><div class=\"graphic_reference\">Illustration by&nbsp;Jenny Wang.</div><div id=\"graphicVersion\">Graphic 73491 Version 5.0</div></div></div>"},"73492":{"type":"graphic_diagnosticimage","displayName":"DAH PA II","title":"Diffuse alveolar hemorrhage due to inhalation of crack cocaine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse alveolar hemorrhage due to inhalation of crack cocaine</div><div class=\"cntnt\"><img style=\"width:378px; height:334px;\" src=\"images/PULM/73492_DAH_PA_II_light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph from a patient with diffuse alveolar hemorrhage due to inhalation of crack cocaine showing patchy upper zone opacities. The radiograph returned to normal in several days without specific treatment.</div><div class=\"graphic_reference\">Courtesy of Marvin I Schwarz, MD.</div><div id=\"graphicVersion\">Graphic 73492 Version 3.0</div></div></div>"},"73494":{"type":"graphic_diagnosticimage","displayName":"Diffuse histoplasmosis PA","title":"Diffuse pulmonary histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse pulmonary histoplasmosis</div><div class=\"cntnt\"><img style=\"width:260px; height:326px;\" src=\"images/ID/73494_Diffuse_histoplasmosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows diffuse reticulonodular infiltrates involving all lung fields in a patient who experienced extensive exposure to <EM>Histoplasma capsulatum</EM> spores during removal of bird droppings from a bell tower. This patient exhibited dyspnea and hypoxia. Diagnosis was based on detection of high concentrations of antigen in urine, bronchoalveolar lavage fluid, and blood. The patient improved rapidly in response to glucocorticoids and amphotericin B.</div><div class=\"graphic_reference\">Courtesy of Joseph Wheat, MD.</div><div id=\"graphicVersion\">Graphic 73494 Version 4.0</div></div></div>"},"73495":{"type":"graphic_movie","displayName":"Left atrial myxoma small four chamber echocardiogram","title":"Left atrial myxoma","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial myxoma</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/73495_4chlamysconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:230px; height:437px;\" src=\"images/CARD/73495_4chlamys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The four chamber view from a 2-D echocardiogram shows a small, sessile left atrial myxoma, adherent to the interatrial septum with a broad base.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 73495 Version 2.0</div></div></div>"},"73497":{"type":"graphic_picture","displayName":"Bilateral tonic pupils","title":"Bilateral tonic pupils","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Bilateral tonic pupils</div><div class=\"cntnt\"><img style=\"width:541px; height:438px;\" src=\"images/NEURO/73497_Bilateral_tonic_pupils.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top panel shows the poor reaction to light in both eyes. The bottom panel shows the much better near reaction in both eyes, with the right pupil constricting a bit more than the left. These photos thus illustrate the characteristic light-near dissociation seen with tonic pupils.</div><div class=\"graphic_reference\">Courtesy of Andrew G Lee, MD and Paul W Brazis, MD.</div><div id=\"graphicVersion\">Graphic 73497 Version 2.0</div></div></div>"},"73498":{"type":"graphic_figure","displayName":"Stroke probability by stenosis","title":"Stroke probability by stenosis","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Stroke probability by stenosis</div><div class=\"cntnt\"><img style=\"width:471px; height:390px;\" src=\"images/NEURO/73498_Stroke_probability_by_steno.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Product-limit estimate of the cumulative probability of an ischemic stroke in the territory of the stenotic artery versus years after randomization, according to percent stenosis (&#8805;70 percent stenosis shown as red solid line, &lt;70 percent stenosis as blue dashed line); log-rank test P 0.0010.</div><div class=\"graphic_reference\">Reproduced with permission from Kasner, SE, Chimowitz, MI, Lynn, MJ, et al. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006; 113:555. Copyright &#169;2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73498 Version 1.0</div></div></div>"},"73499":{"type":"graphic_diagnosticimage","displayName":"CT imaging findings","title":"CT scan showing typical findings of a presenting patient with malignant peritoneal mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan showing typical findings of a presenting patient with malignant peritoneal mesothelioma</div><div class=\"cntnt\"><img style=\"width:301px; height:592px;\" src=\"images/ONC/73499_CT_imaging_findings.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows medial displacement of the liver and Panel C shows compression of the rectosigmoid in the pelvis. Panel B shows diffuse ascites and shortened mesentery due to malignant infiltration of tissues.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Dr. H Richard Alexander, Jr., as published for the National Institutes of Health.</div><div id=\"graphicVersion\">Graphic 73499 Version 3.0</div></div></div>"},"73501":{"type":"graphic_diagnosticimage","displayName":"C difficile colitis child","title":"Contrast-enhanced computed tomography in 2 1/2-year-old with <em>Clostridium difficile</em> colitis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Contrast-enhanced computed tomography in 2 1/2-year-old with <em>Clostridium difficile</em> colitis</div><div class=\"cntnt\"><img style=\"width:576px; height:444px;\" src=\"images/PEDS/73501_C_difficile_colitis_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 2 1/2-year-old boy with an ill-defined congenital arthrogryposis syndrome and developmental delay developed diarrhea. Over a three-week period, his illness progressed to include 6 to 12 stools per day, abdominal tenderness, mild abdominal distension, fever to 39.4°C, and fecal occult blood. The dose of a proton pump inhibitor for gastroesophageal reflux had been increased within two weeks prior to onset, and he had received courses of cefdinir and azithromycin for minor respiratory infections. At admission, polymorphonuclear neutrophil count was 6670/microL, and band count was 14,330/microL. Hemoglobin was 10.5 g/dL. Albumin and globulin were both low at 2.4 g/dL and 2.2 g/dL, respectively. Fecal <EM>C. difficile</EM> toxin A/B enzyme immunoassay was positive. Computed tomography (above) demonstrated findings consistent with severe <EM>C. difficile</EM> disease, including colonic wall thickening (panels A, B, C), dilated colon (panel C), and accordion sign (panels A, C). He was admitted to the intensive care unit and treated with oral vancomycin and intravenous metronidazole for two weeks, with gradual resolution of symptoms. He had two subsequent, progressively milder, toxin-positive relapses, which were treated with tapering courses of vancomycin.</div><div class=\"graphic_reference\">Radiographs courtesy of Brian Green, MD, University of Missouri Health Care.</div><div id=\"graphicVersion\">Graphic 73501 Version 5.0</div></div></div>"},"73502":{"type":"graphic_figure","displayName":"Virilization cross section view","title":"Virilization (cross-sectional view)","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Virilization (cross-sectional view)</div><div class=\"cntnt\"><img style=\"width:525px; height:236px;\" src=\"images/PEDS/73502_Virilization_cross_section.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal and abnormal differentiation of the urogenital sinus and external genitalia. Diagrams of normal female and male anatomy flank a series of schematic representations of different degrees of virilization of females, graded using the scale developed by Prader for patients with congenital adrenal hyperplasia. Note the uterus persists in virilized females even when the external genitalia have a completely masculine appearance (Prader grade 5).</div><div class=\"graphic_reference\">Reproduced with permission from: White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21:245. http://edrv.endojournals.org/. Copyright &#169; 2000 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 73502 Version 6.0</div></div></div>"},"73503":{"type":"graphic_diagnosticimage","displayName":"Simple cyst","title":"Simple cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Simple cyst</div><div class=\"cntnt\"><img style=\"width:355px; height:283px;\" src=\"images/SURG/73503_Simple_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound image with color of palpable breast mass: simple cyst.</div><div id=\"graphicVersion\">Graphic 73503 Version 2.0</div></div></div>"},"73504":{"type":"graphic_table","displayName":"Two by two table","title":"The two-by-two table","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The two-by-two table</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Disease present, gold standard</td>\n\n      <td class=\"subtitle1\">Disease absent, gold standard</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Test result positive</td>\n\n      <td>True positives</td>\n\n      <td>False positives</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Test result negative</td>\n\n      <td>False negatives</td>\n\n      <td>True negatives</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Sensitivity: true positives/(true positives + false negatives); Specificity: true negatives/(false positives + true negatives).</div><div id=\"graphicVersion\">Graphic 73504 Version 1.0</div></div></div>"},"73505":{"type":"graphic_figure","displayName":"UGT gene locus","title":"Genetic lesions in bilirubin-UGT deficiency syndromes","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Genetic lesions in bilirubin-UGT deficiency syndromes</div><div class=\"cntnt\"><img style=\"width:509px; height:293px;\" src=\"images/GAST/73505_UGT_gene_locus.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Organization of the UGT1A gene. The organization of the UGT1A locus is depicted in the top panel. Four common exons (exons 2, 3, 4, and 5) are used in several UGT isoforms expressed from this locus. Upstream from these exons are a series of &quot;unique&quot; exons, only one of which is used in a given isoform. Each unique exon is preceded by a separate promoter (arrows). Splicing of exon 1A1 to the common region exons (2 to 5) generates the mRNA for bilurubin UGT (also termed UGT1A1). Genetic lesions in any of the five exons constituting the bilirubin UGT mRNA can abolish (Crigler-Najjar type I) or reduce (Crigler-Najjar type II) bilirubin-UGT activity. In the case of Crigler-Najjar I the genetic lesions may result in a premature stop codon or a single amino acid substitution. The sequence abnormalities can be located in the region encoding the signal peptide or other domains of the enzyme, or even in the introns at the splice donor or splice acceptor sites. Crigler-Najjar type II is caused by point mutations that result in substitution of a single amino acid. In contrast to Crigler-Najjar syndrome types I or II, Gilbert's syndrome is caused by a promoter abnormality. Normally, the TATAA element within the promoter upstream to exon 1A1 consists of A(TA)6TAA. In Gilbert's syndrome, two additional nucleotide residues (TA) are present in this element. Alleles containing the Gilbert-type promoter are termed UGT1A1*28. In addition, Japanese investigators have reported sequence abnormalities in the coding region of the gene that cause mild elevations of serum bilirubin concentrations, consistent with Gilbert's syndrome.</div><div id=\"graphicVersion\">Graphic 73505 Version 1.0</div></div></div>"},"73506":{"type":"graphic_picture","displayName":"Biologic control of imported fire ant","title":"Biologic control of imported fire ant ","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Biologic control of imported fire ant </div><div class=\"cntnt\"><img style=\"width:468px; height:343px;\" src=\"images/ALLRG/73506_Decapitating_fly_attacking.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a <EM>Pseudacteon tricuspis</EM> decapitating fly preparing to attack an imported fire ant&nbsp;worker. Decapitating flies have been proposed as a means of biologic control of imported fire ants.</div><div class=\"graphic_reference\">Reproduced with permission from: Williams DF, deShazo RD. Biological control of fire ants: an update on new techniques. Ann Allergy Asthma Immunol 2004; 93:15. Copyright © 2004 American Academy of Allergy, Asthma, and Immunology.</div><div id=\"graphicVersion\">Graphic 73506 Version 5.0</div></div></div>"},"73509":{"type":"graphic_algorithm","displayName":"Crash airway algorithm","title":"The crash airway algorithm©","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The crash airway algorithm&copy;</div><div class=\"cntnt\"><img style=\"width:398px; height:608px;\" src=\"images/EM/73509_Crashairwayalgo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IVP: intravenous push.</div><div class=\"graphic_reference\">Reproduced with permission from: The Difficult Airway Course®: Emergency and Brown III CA, Walls RM. The Emergency Airway Algorithms. In: The Walls Manual of Emergency Airway Management, 5th ed, Brown III CA, Sakles JC, Mick NW (Eds), Wolters Kluwer, Philadelphia 2018. Copyright © 2018 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 73509 Version 15.0</div></div></div>"},"73510":{"type":"graphic_algorithm","displayName":"Algorithm gallbladder polyps","title":"A suggested algorithm for managing gallbladder polyps found on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">A suggested algorithm for managing gallbladder polyps found on ultrasound</div><div class=\"cntnt\"><img style=\"width:571px; height:377px;\" src=\"images/GAST/73510_Algorithm_gallbladder_polyp.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* An extended cholecystectomy includes lymph node dissection and partial hepatic resection in the gallbladder bed.<br />&para; Symptoms: Biliary type pain, common duct obstruction, cholangitis, or recurrent pancreatitis. Dyspepsia is not an indication for surgery.</div><div id=\"graphicVersion\">Graphic 73510 Version 5.0</div></div></div>"},"73512":{"type":"graphic_table","displayName":"Classes of ERCP complications","title":"Classification of site, timing, and severity of complications related to endoscopic retrograde cholangiopancreatography (ERCP)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of site, timing, and severity of complications related to endoscopic retrograde cholangiopancreatography (ERCP)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Site</td> </tr> <tr> <td>Focal</td> <td>Occurring at the point of endoscopic contact</td> </tr> <tr> <td>Nonspecific</td> <td>Occurring in organs not traversed or treated</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Timing</td> </tr> <tr> <td>Immediate</td> <td>Occurring during ERCP</td> </tr> <tr> <td>Early</td> <td>Evident within the recovery period</td> </tr> <tr> <td rowspan=\"2\">Delayed</td> <td>Focal (occurring within 30 days)</td> </tr> <tr> <td>Nonspecific (first symptom presenting within 3 days)</td> </tr> <tr> <td>Late</td> <td>Evident after months or years</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Criteria for severity</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Length of stay</td> </tr> <tr> <td class=\"indent1\">Mild</td> <td>&#8804;3 nights</td> </tr> <tr> <td class=\"indent1\">Moderate</td> <td>4 to 10 nights</td> </tr> <tr> <td class=\"indent1\">Severe</td> <td>&#62;10 nights, ICU admission, or surgery</td> </tr> <tr> <td class=\"indent1\">Fatal</td> <td>Death attributable to the procedure within 30 days (or longer if under continued in-patient treatment for the complication)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other indices of severity</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Need for blood transfusion</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Additional interventions (endoscopic or radiologic)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Total length of stay</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Permanent residual disability</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Cotton PB, Gastrointest Endosc 1994; 40:514 and Aliperti G, et al, Gastrointest Endosc Clin N Am 1996; 6:379.</div><div id=\"graphicVersion\">Graphic 73512 Version 3.0</div></div></div>"},"73513":{"type":"graphic_table","displayName":"Core components rehab B","title":"Core components of cardiac rehabilitation/secondary prevention programs: Blood pressure management, lipid management, diabetes management, tobacco cessation, psychosocial management, physical activity counseling, and exercise training","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Core components of cardiac rehabilitation/secondary prevention programs: Blood pressure management, lipid management, diabetes management, tobacco cessation, psychosocial management, physical activity counseling, and exercise training</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Blood pressure management </td> </tr> <tr> <td class=\"subtitle2_left\">Evaluation </td> </tr> <tr> <td class=\"indent1\">Measure seated resting blood pressure on &#8805;two visits. </td> </tr> <tr> <td class=\"indent1\">Measure blood pressure in both arms at program entry. </td> </tr> <tr> <td class=\"indent1\">To rule out orthostatic hypotension, measure lying, seated, and standing blood pressure at program entry and after adjustments in antihypertensive drug therapy. </td> </tr> <tr> <td class=\"indent1\">Assess current treatment and compliance. </td> </tr> <tr> <td class=\"indent1\">Assess use of nonprescription drugs that may adversely affect blood pressure. </td> </tr> <tr> <td class=\"subtitle2_left\">Interventions </td> </tr> <tr> <td class=\"indent1\">Provide and/or monitor drug therapy in concert with primary healthcare provider as follows: </td> </tr> <tr> <td class=\"sublist2_start\">If blood pressure is 120 to 139 mmHg systolic or 80 to 89 mmHg diastolic: </td> </tr> <tr> <td class=\"sublist2\">&#8226; Provide lifestyle modifications, including regular physical activity/exercise; weight management; moderate sodium restriction and increased consumption of fresh fruits, vegetables, and low-fat dairy products; alcohol moderation; and smoking cessation. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Provide drug therapy for patients with chronic kidney disease, heart failure, or diabetes if blood pressure is &#8805;130 / &#8805;80 mmHg after lifestyle modification. </td> </tr> <tr> <td class=\"sublist2_start\">If blood pressure is &#8805;140 mmHg systolic or &#8805;90 mmHg diastolic: </td> </tr> <tr> <td class=\"sublist2\">&#8226; Provide lifestyle modification and drug therapy. </td> </tr> <tr> <td class=\"subtitle2_left\">Expected outcomes </td> </tr> <tr> <td class=\"indent1\">Short-term: Continue to assess and modify intervention until normalization of blood pressure in prehypertensive patients; &#60;140 mmHg systolic and &#60;90 mmHg diastolic in hypertensive patients; &#60;130 mmHg systolic and &#60;80 mmHg diastolic in hypertensive patients with diabetes, heart failure, or chronic kidney disease. </td> </tr> <tr> <td class=\"indent1\">Long-term: Maintain blood pressure at goal levels. </td> </tr> <tr> <td class=\"subtitle1_single\">Lipid management </td> </tr> <tr> <td class=\"subtitle2_left\">Evaluation </td> </tr> <tr> <td class=\"indent1\">Obtain fasting measures of total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides. In those patients with abnormal levels, obtain a detailed history to determine whether diet, drug, and/or other conditions that may affect lipid levels can be altered. </td> </tr> <tr> <td class=\"indent1\">Assess current treatment and compliance. </td> </tr> <tr> <td class=\"indent1\">Repeat lipid profiles at&nbsp;four to six&nbsp;weeks after hospitalization and at two months after initiation or change in lipid-lowering medications. </td> </tr> <tr> <td class=\"indent1\">Assess creatine kinase levels and liver function in patients taking lipid-lowering medications as recommended by NCEP. </td> </tr> <tr> <td class=\"subtitle2_left\">Interventions </td> </tr> <tr> <td class=\"indent1\">Provide nutritional counseling consistent with the Therapeutic Lifestyle Change diet, such as the recommendation to add plant stanol/sterols and viscous fiber and the encouragement to consume more omega-3 fatty acids, as well as weight management counseling, as needed, in all patients. Add or intensify drug treatment in those with low-density lipoprotein &#62;100 mg/dL; consider adding drug treatment in those with low-density lipoprotein &#62;70 mg/dL. </td> </tr> <tr> <td class=\"indent1\">Provide interventions directed toward management of triglycerides to attain non-high-density lipoprotein cholesterol &#60;130 mg/dL. These include nutritional counseling and weight management, exercise, smoking cessation, alcohol moderation, and drug therapy as per NCEP and AHA/ACC. </td> </tr> <tr> <td class=\"indent1\">Provide and/or monitor drug treatment in concert with primary healthcare provider.</td> </tr> <tr> <td class=\"subtitle2_left\">Expected outcomes</td> </tr> <tr> <td class=\"indent1\">Short-term: Continue to assess and modify intervention until low-density lipoprotein is &#60;100 mg/dL (further reduction to a goal &#60;70 mg/dL is considered reasonable) and non-high-density lipoprotein cholesterol &#60;130 mg/dL (further reduction to a goal of &#60;100 mg/dL is considered reasonable).</td> </tr> <tr> <td class=\"indent1\">Long-term: Low-density lipoprotein cholesterol &#60;100 mg/dL (further reduction to a goal &#60;70 mg/dL is considered reasonable). Non-high-density lipoprotein cholesterol &#60;130 mg/dL (further reduction to a goal of &#60;100 mg/dL is considered reasonable). </td> </tr> <tr> <td class=\"subtitle1_single\">Diabetes management </td> </tr> <tr> <td class=\"subtitle2_left\">Evaluation </td> </tr> <tr> <td class=\"sublist2_start\">From medical record review: </td> </tr> <tr> <td class=\"sublist2\">&#8226; Confirm presence or absence of diabetes in all patients. </td> </tr> <tr> <td class=\"sublist2\">&#8226; If a patient is known to be diabetic, identify history of complications such as findings related to heart disease; vascular disease; problems with eyes, kidneys, or feet; or autonomic or peripheral neuropathy. </td> </tr> <tr> <td class=\"sublist2_start\">From initial patient interview: </td> </tr> <tr> <td class=\"sublist2\">&#8226; Obtain history of signs/symptoms related to above complications and/or reports of episodes of hypoglycemia or hyperglycemia. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Identify physician managing diabetic condition and prescribed treatment regimen, including: </td> </tr> <tr> <td class=\"sublist3\">- Medications and extent of compliance. </td> </tr> <tr> <td class=\"sublist3\">- Diet and extent of compliance. </td> </tr> <tr> <td class=\"sublist3\">- Blood sugar monitoring method and extent of compliance. </td> </tr> <tr> <td class=\"sublist2_start\">Before starting exercise: </td> </tr> <tr> <td class=\"sublist2\">&#8226; Obtain latest fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c). </td> </tr> <tr> <td class=\"sublist2\">&#8226; Consider stratifying patient to high-risk category because of the greater likelihood of exercise-induced complications. </td> </tr> <tr> <td class=\"subtitle2_left\">Interventions </td> </tr> <tr> <td class=\"indent1\">Educate patient and staff to be alert for signs/symptoms of hypoglycemia or hyperglycemia and provide appropriate assessment and interventions as per the American Diabetes Association. </td> </tr> <tr> <td class=\"sublist2_start\">In those taking insulin or insulin secretogogues: </td> </tr> <tr> <td class=\"sublist2\">&#8226; Avoid exercise at peak insulin times. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Advise that insulin be injected in abdomen, not muscle to be exercised. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Test blood sugar levels pre- and post-exercise at each session: if blood sugar value is &#60;100 mg/dL, delay exercise and provide patient 15 g of carbohydrate; retest in 15 minutes; proceed if blood sugar value is &#62;100 mg/dL; if blood sugar value is &#62;300 mg/dL, patient may exercise if he or she feels well, is adequately hydrated, and blood and/or urine ketones are negative; otherwise, contact patient's physician for further treatment. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Encourage adequate hydration to avoid effects of fluid shifts on blood sugar levels. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Caution patient that blood sugar may continue to drop for 24 to 48 hours after exercise. </td> </tr> <tr> <td class=\"indent1\">In those treated with diet, metformin, alpha glucosidase inhibitors, and/or thiozolidinediones, without insulin or insulin secretogogues, test blood sugar levels prior to exercise for first 6 to 10 sessions to assess glycemic control; exercise is generally unlikely to cause hypoglycemia. </td> </tr> <tr> <td class=\"sublist2_start\">Education recommendations: </td> </tr> <tr> <td class=\"sublist2\">&#8226; Teach and practice self-monitoring skills for use during unsupervised exercise. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Refer to registered dietitian for medical nutrition therapy. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Consider referral to certified diabetic educator for skill training, medication instruction, and support groups. </td> </tr> <tr> <td class=\"subtitle2_left\">Expected outcomes </td> </tr> <tr> <td class=\"sublist2_start\">Short-term: </td> </tr> <tr> <td class=\"sublist2\">&#8226; Communicate with primary physician or endocrinologist about signs/symptoms and medication adjustments. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Confirm patient's ability to recognize signs/symptoms, self-monitor blood sugar status, and self-manage activities. </td> </tr> <tr> <td class=\"sublist2_start\">Long-term: </td> </tr> <tr> <td class=\"sublist2\">&#8226; Attain FPG levels of 90 to 130 mg/dL and HbA1c &#60;7 percent. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Minimize complications and reduce episodes of hypoglycemia or hyperglycemia at rest and/or with exercise. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Maintain blood pressure at &#60;130 / &#60;80 mmHg. </td> </tr> <tr> <td class=\"subtitle1_single\">Tobacco cessation </td> </tr> <tr> <td class=\"subtitle2_left\">Evaluation </td> </tr> <tr> <td class=\"sublist2_start\">Initial encounter: </td> </tr> <tr> <td class=\"sublist2\">&#8226; Ask the patient about his or her smoking status and use of other tobacco products. Document status as never smoked, former smoker, current smoker (includes those who have quit in the last 12 months because of the high probability of relapse). Specify both amount of smoking (cigarettes per day) and duration of smoking (number of years). Quantify use and type of other tobacco products. Question exposure to second-hand smoke at home and at work. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Determine readiness to change by asking every smoker/tobacco user if he or she is now ready to quit. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Assess for psychosocial factors that may impede success. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Ongoing contact: Update status at each visit during first&nbsp;two weeks of cessation, periodically thereafter. </td> </tr> <tr> <td class=\"subtitle2_left\">Interventions </td> </tr> <tr> <td class=\"indent1\">When readiness to change is not expressed, provide a brief motivational message containing the \"5 Rs\": Relevance, Risks, Rewards, Roadblocks, and Repetition. </td> </tr> <tr> <td class=\"indent1\">When readiness to change is confirmed, continue with the \"5 As\": Ask, Advise, Assess, Assist, and Arrange. Assist the smoker/tobacco user to set a quit date, and select appropriate treatment strategies (preparation): </td> </tr> <tr> <td class=\"sublist2_start\"><em>Minimal (brief)</em>: </td> </tr> <tr> <td class=\"sublist2\">&#8226; Individual education and counseling by program staff supplemented by self-teaching materials. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Social support provided by physician, program staff, family and/or domestic partner; identify other smokers in the house; discuss how to engage them in the patient's cessation efforts. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Relapse prevention: problem solving, anticipated threats, practice scenarios. </td> </tr> <tr> <td class=\"sublist2_start\"><em>Optimal (intense)</em>: </td> </tr> <tr> <td class=\"sublist2\">&#8226; Longer individual counseling or group involvement. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Pharmacological support (in concert with primary physician): nicotine replacement therapy, bupropion hydrochloride. </td> </tr> <tr> <td class=\"sublist2\">&#8226; Supplemental strategies if desired (eg, acupuncture, hypnosis). </td> </tr> <tr> <td class=\"indent1\">If patient has recently quit, emphasize relapse prevention skills. </td> </tr> <tr> <td class=\"indent1\">Urge avoidance of exposure to second-hand smoke at work and home. </td> </tr> <tr> <td class=\"subtitle2_left\">Expected outcomes </td> </tr> <tr> <td class=\"indent1\">Note: Patients who continue to smoke upon enrollment are subsequently more likely to drop out of cardiac rehabilitation/secondary prevention programs. </td> </tr> <tr> <td class=\"indent1\">Short-term: Patient will demonstrate readiness to change by initially expressing decision to quit and selecting a quit date. Subsequently, patient will quit smoking and all tobacco use and adhere to pharmacological therapy (if prescribed) while practicing relapse prevention strategies; patient will resume cessation plan as quickly as possible when temporary relapse occurs. </td> </tr> <tr> <td class=\"indent1\">Long-term: Complete abstinence from smoking and use of all tobacco products for at least 12 months (maintenance) from quit date. No exposure to environmental tobacco smoke at work and home. </td> </tr> <tr> <td class=\"subtitle1_single\">Psychosocial management </td> </tr> <tr> <td class=\"subtitle2_left\">Evaluation </td> </tr> <tr> <td class=\"indent1\">Identify psychological distress as indicated by clinically significant levels of depression, anxiety, anger or hostility, social isolation, marital/family distress, sexual dysfunction/adjustment, and substance abuse (alcohol or other psychotropic agents), using interview and/or standardized measurement tools. </td> </tr> <tr> <td class=\"indent1\">Identify use of psychotropic medications. </td> </tr> <tr> <td class=\"subtitle2_left\">Interventions </td> </tr> <tr> <td class=\"indent1\">Offer individual and/or small group education and counseling on adjustment to heart disease, stress management, and health-related lifestyle change. When possible, include family members, domestic partners, and/or significant others in such sessions. </td> </tr> <tr> <td class=\"indent1\">Develop supportive rehabilitation environment and community resources to enhance the patient's and the family's level of social support. </td> </tr> <tr> <td class=\"indent1\">Teach and support self-help strategies. </td> </tr> <tr> <td class=\"indent1\">In concert with primary healthcare provider, refer patients experiencing clinically significant psychosocial distress to appropriate mental health specialists for further evaluation and treatment. </td> </tr> <tr> <td class=\"subtitle2_left\">Expected outcomes </td> </tr> <tr> <td class=\"indent1\">Emotional well-being is indicated by the absence of clinically significant psychological distress, social isolation, or drug dependency. </td> </tr> <tr> <td class=\"indent1\">Patient demonstrates responsibility for health-related behavior change, relaxation, and other stress management skills; ability to obtain effective social support; compliance with psychotropic medications if prescribed; and reduction or elimination of alcohol, tobacco, caffeine, or other nonprescription psychoactive drugs. </td> </tr> <tr> <td class=\"indent1\">Arrange for ongoing management if important psychosocial issues are present. </td> </tr> <tr> <td class=\"subtitle1_single\">Physical activity counseling </td> </tr> <tr> <td class=\"subtitle2_left\">Evaluation </td> </tr> <tr> <td class=\"indent1\">Assess current physical activity level (eg, questionnaire, pedometer) and determine domestic, occupational, and recreational needs. </td> </tr> <tr> <td class=\"indent1\">Evaluate activities relevant to age, gender, and daily life, such as driving, sexual activity, sports, gardening, and household tasks. </td> </tr> <tr> <td class=\"indent1\">Assess readiness to change behavior, self-confidence, barriers to increased physical activity, and social support in making positive changes. </td> </tr> <tr> <td class=\"subtitle2_left\">Interventions </td> </tr> <tr> <td class=\"indent1\">Provide advice, support, and counseling about physical activity needs on initial evaluation and in follow-up. Target exercise program to meet individual needs (see Exercise Training section of table). Provide educational materials as part of counseling efforts. Consider exercise tolerance or simulated work testing for patients with heavy labor jobs. </td> </tr> <tr> <td class=\"indent1\">Consistently encourage patients to accumulate 30 to 60 minutes per day of moderate-intensity physical activity on &#8805;5 (preferably most) days of the week. Explore daily schedules to suggest how to incorporate increased activity into usual routine (eg, parking farther away from entrances, walking &#8805;2 flights of stairs, and walking during lunch break). </td> </tr> <tr> <td class=\"indent1\">Advise low-impact aerobic activity to minimize risk of musculoskeletal injury. Recommend gradual increases in the volume of physical activity over time. </td> </tr> <tr> <td class=\"indent1\">Caution patients to avoid performing unaccustomed vigorous physical activity (eg, racquet sports and manual snow removal). Reassess the patient's ability to perform such activities as exercise training program progresses. </td> </tr> <tr> <td class=\"subtitle2_left\">Expected outcomes </td> </tr> <tr> <td class=\"indent1\">Patient shows increased participation in domestic, occupational, and recreational activities. </td> </tr> <tr> <td class=\"indent1\">Patient shows improved psychosocial well-being, reduction in stress, facilitation of functional independence, prevention of disability, and enhancement of opportunities for independent self-care to achieve recommended goals. </td> </tr> <tr> <td class=\"indent1\">Patient shows improved aerobic fitness and body composition and lessens coronary risk factors (particularly for the sedentary patient who has adopted a lifestyle approach to regular physical activity). </td> </tr> <tr> <td class=\"subtitle1_single\">Exercise training </td> </tr> <tr> <td class=\"subtitle2_left\">Evaluation </td> </tr> <tr> <td class=\"indent1\">Symptom-limited exercise testing prior to participation in an exercise-based cardiac rehabilitation program is strongly recommended. The evaluation may be repeated as changes in clinical condition warrant. Test parameters should include assessment of heart rate and rhythm, signs, symptoms, ST-segment changes, hemodynamics, perceived exertion, and exercise capacity. </td> </tr> <tr> <td class=\"indent1\">On the basis of patient assessment and the exercise test if performed, risk stratify the patient to determine the level of supervision and monitoring required during exercise training. Use risk stratification schema as recommended by the AHA and the AACVPR. </td> </tr> <tr> <td class=\"subtitle2_left\">Interventions </td> </tr> <tr> <td class=\"sublist2_start\">Develop an individualized exercise prescription for aerobic and resistance training that is based on evaluation findings, risk stratification, comorbidities (eg, peripheral arterial disease and musculoskeletal conditions), and patient and program goals. The exercise regimen should be reviewed by the program medical director or referring physician, modified if necessary, and approved. Exercise prescription should specify frequency (F), intensity (I), duration (D), modalities (M), and progression (P). </td> </tr> <tr> <td class=\"sublist2\">&#8226; For aerobic exercise: F=3-5 days/wk; I=50-80 percent of exercise capacity; D=20-60 minutes; and M=walking, treadmill, cycling, rowing, stair climbing, arm/leg ergometry, and others using continuous or interval training as appropriate. </td> </tr> <tr> <td class=\"sublist2\">&#8226; For resistance exercise: F=2-3 days/wk; I=10-15 repetitions per set to moderate fatigue; D=1-3 sets of 8-10 different upper and lower body exercises; and M=calisthenics, elastic bands, cuff/hand weights, dumbbells, free weights, wall pulleys, or weight machines. </td> </tr> <tr> <td class=\"indent1\">Include warm-up, cool-down, and flexibility exercises in each exercise session. </td> </tr> <tr> <td class=\"indent1\">Provide progressive updates to the exercise prescription and modify further if clinical status changes. </td> </tr> <tr> <td class=\"indent1\">Supplement the formal exercise regimen with activity guidelines as outlined in the Physical Activity Counseling section of this table. </td> </tr> <tr> <td class=\"subtitle2_left\">Expected outcomes </td> </tr> <tr> <td class=\"indent1\">Patient understands safety issues during exercise, including warning signs/symptoms. </td> </tr> <tr> <td class=\"indent1\">Patient achieves increased cardiorespiratory fitness and enhanced flexibility, muscular endurance, and strength. </td> </tr> <tr> <td class=\"indent1\">Patient achieves reduced symptoms, attenuated physiologic responses to physical challenges, and improved psychosocial well-being. </td> </tr> <tr> <td class=\"indent1\">Patient achieves reduced global cardiovascular risk and mortality resulting from an overall program of cardiac rehabilitation/secondary prevention that includes exercise training. </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Balady GJ, Williams MA, Ades PA, et al. Circulation 2007;115:2675. Copyright 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73513 Version 3.0</div></div></div>"},"73515":{"type":"graphic_table","displayName":"Seizures versus syncope","title":"Differentiation of generalized tonic-clonic seizures from pseudoseizures and syncope","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differentiation of generalized tonic-clonic seizures from pseudoseizures and syncope</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Characteristic </td> <td class=\"subtitle1\">Generalized seizure tonic-clonic </td> <td class=\"subtitle1\">Pseudoseizure </td> <td class=\"subtitle1\">Syncope </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Circumstances </td> </tr> <tr> <td class=\"indent1\">Situation </td> <td>Awake or sleep</td> <td>Awake</td> <td>Usually upright; any position if cardiogenic</td> </tr> <tr> <td class=\"indent1\">Precipitating factors </td> <td>Sleep loss, alcohol withdrawal, flashing lights</td> <td>Emotion</td> <td>Emotion, injury, heat, crowds; none if cardiogenic</td> </tr> <tr> <td class=\"indent1\">Presence of others </td> <td>Variable</td> <td>Usual</td> <td>Variable</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Motor phenomena </td> </tr> <tr> <td class=\"indent1\">Vocalization </td> <td>At onset, if any</td> <td>During course</td> <td>None</td> </tr> <tr> <td class=\"indent1\">Location of motor component (if present) </td> <td>Proximal limb</td> <td>Proximal limb</td> <td>None</td> </tr> <tr> <td class=\"indent1\">Generalized motor </td> <td>Tonic, then clonic</td> <td>Tonic; flailing; struggling or thrashing, or both</td> <td>Usually atonic; if syncope lasts &#62;20 seconds: tonic, then clonic</td> </tr> <tr> <td class=\"indent1\">Tonic posture </td> <td>Partial flexion or straight</td> <td>Opisthotonic</td> <td>-</td> </tr> <tr> <td class=\"indent1\">Head movements </td> <td>To one side or none</td> <td>Side to side</td> <td>-</td> </tr> <tr> <td class=\"indent1\">Clonus/limb jerks </td> <td>Bilaterally synchronous</td> <td>Asynchronous</td> <td>Bilaterally synchronous</td> </tr> <tr> <td class=\"indent1\">Purposeful movements </td> <td>Absent</td> <td>Occasional, including avoidance</td> <td>Absent</td> </tr> <tr> <td class=\"indent1\">Biting </td> <td>Tongue, inside mouth</td> <td>Lips, arms, other people</td> <td>Tongue biting rare</td> </tr> <tr> <td class=\"indent1\">Babinski's sign </td> <td>Present</td> <td>Absent</td> <td>Absent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Autonomic features </td> </tr> <tr> <td class=\"indent1\">Micturition </td> <td>Frequent</td> <td>Rare</td> <td>Occasional</td> </tr> <tr> <td class=\"indent1\">Eyes </td> <td>Open</td> <td>Closed</td> <td>Open</td> </tr> <tr> <td class=\"indent1\">Pupils </td> <td>Dilated or hippus during attacks</td> <td>Normal</td> <td>Dilated</td> </tr> <tr> <td class=\"indent1\">Colour </td> <td>Cyanotic or grey</td> <td>Rubor or normal</td> <td>Pale</td> </tr> <tr> <td class=\"indent1\">Pulse </td> <td>Rapid, strong</td> <td>Normal</td> <td>Slow if vasovagal, weak if vasodepressor; that of arrhythmias if cardiogenic</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Timing </td> </tr> <tr> <td class=\"indent1\">Usual duration </td> <td>1 to 5 min</td> <td>5 to 60 min</td> <td>1 to 2 min</td> </tr> <tr> <td class=\"indent1\">Onset </td> <td>Sudden</td> <td>Gradual</td> <td>Gradual; possibly sudden if cardiogenic</td> </tr> <tr> <td class=\"indent1\">Sequence of symptoms </td> <td>Stereotyped</td> <td>Variable</td> <td>Stereotyped</td> </tr> <tr> <td class=\"indent1\">Termination </td> <td>Spontaneous</td> <td>Spontaneous or induced by supraorbital pressure, suggestion</td> <td>Rapid</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Sequelae </td> </tr> <tr> <td class=\"indent1\">Injury </td> <td>Frequent, mild; scalp, face, common</td> <td>Rare, but multiple bruises possible; scalp, face, rare</td> <td>If sudden onset</td> </tr> <tr> <td class=\"indent1\">Postictal </td> <td>Tired, confused, sleepy</td> <td>Alert, emotional outburst</td> <td>Regains consciousness in 2 to 3 min; alert but tired</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Blume WT. Diagnosis and management of epilepsy. CMAJ 2003; 168:441. Copyright © 2003 Canadian Medical Association.</div><div id=\"graphicVersion\">Graphic 73515 Version 2.0</div></div></div>"},"73518":{"type":"graphic_figure","displayName":"Percutaneous transtracheal ventilation anatomy","title":"Anatomic landmarks for needle cricothyroidotomy","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Anatomic landmarks for needle cricothyroidotomy</div><div class=\"cntnt\"><img style=\"width:516px; height:438px;\" src=\"images/EM/73518_PTVanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Cartilaginous skeleton of the extrathoracic airway. With older children and adolescents, the laryngeal prominence at the superior border of the thyroid cartilage can usually be palpated. The thyroid cartilage is followed inferiorly to locate the cricothyroid membrane.<br />(B) With infants and younger children, the laryngeal prominence is not developed. The rings of the tracheal cartilage are followed superiorly to locate the prominence of the cricoid cartilage. The cricothyroid membrane is just superior to the cricoid cartilage. <br />(C) A midline approach will avoid the normal position of the cricothyroid artery.</div><div class=\"graphic_reference\">Reproduced with permission from: Mittal MK, Baren JM. Percutaneous Transtracheal Ventilation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 73518 Version 12.0</div></div></div>"},"73519":{"type":"graphic_figure","displayName":"Pregnancy and pituitary size","title":"Pregnancy increases pituitary volume","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Pregnancy increases pituitary volume</div><div class=\"cntnt\"><img style=\"width:512px; height:271px;\" src=\"images/ENDO/73519_Pregnancy_and_pituitary_ed.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pituitary volume, as assessed by magnetic resonance imaging (MRI), in the nonpregnant state and during pregnancy in 19- to 23-year-old normal women. There is a progressive increase in pituitary volume during pregnancy.</div><div class=\"graphic_reference\">Data from: Gonzales JG, Elizondo G, Saldivar D, et al. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging.&nbsp;Am J Med 1988; 85:217.</div><div id=\"graphicVersion\">Graphic 73519 Version 5.0</div></div></div>"},"73521":{"type":"graphic_algorithm","displayName":"Possible mechanisms of ulcerogenesis in H pylori infection","title":"Possible mechanisms of ulcerogenesis in Helicobacter pylori infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Possible mechanisms of ulcerogenesis in Helicobacter pylori infection</div><div class=\"cntnt\"><img style=\"width:429px; height:440px;\" src=\"images/GAST/73521_Ulcerogenesis_with_H_pylori.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">H. pylori: Helicobacter pylori.</div><div class=\"graphic_reference\">Reproduced with permission from: Peura DA. Ulcerogenesis: Integrating the roles of Helicobacter pylori and acid secretion in duodenal ulcer. Am J Gastroenterol 1997; 92(4 Suppl):8S.&nbsp;&nbsp;</div><div id=\"graphicVersion\">Graphic 73521 Version 4.0</div></div></div>"},"73522":{"type":"graphic_figure","displayName":"Uterine size by age and parity","title":"The comparative size of prepubertal, adult nonparous, and multiparous uteri (frontal and sagittal sections)","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">The comparative size of prepubertal, adult nonparous, and multiparous uteri (frontal and sagittal sections)</div><div class=\"cntnt\"><img style=\"width:468px; height:303px;\" src=\"images/OBGYN/73522_Uterine_size_by_age_and_par.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &#169; 1980 McGraw Hill. p.22.</div><div id=\"graphicVersion\">Graphic 73522 Version 2.0</div></div></div>"},"73523":{"type":"graphic_picture","displayName":"Benign lichenoid keratosis","title":"Benign lichenoid keratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Benign lichenoid keratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/73523_Benign_lichenoid_keratosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This erythematous, scaly macule was a benign lichenoid keratosis. Benign lichenoid keratoses share clinical features with actinic keratoses, squamous cell carcinoma in situ, and superficial basal cell carcinoma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73523 Version 3.0</div></div></div>"},"73524":{"type":"graphic_figure","displayName":"Connection between osteocytes and blood vessels","title":"Connection between osteocytes and blood vessels","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Connection between osteocytes and blood vessels</div><div class=\"cntnt\"><img style=\"width:588px; height:427px;\" src=\"images/ENDO/73524_Conn_betw_osteocy_bl_vessel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The connection between osteocytes and blood vessels.<br> (A) Low (upper panel) and high (lower panel) magnifications of electron microscopy images demonstrating reliefs of the osteocytes and their canalicular network following acid-etching of murine bone sections (Courtesy of Lynda Bonewald from the University of Missouri and Kansas City Dental School). Please note multiple attachments of the osteocyte processes to the vessels depicted in the center of these images.<br> (B) Cartoon depicting the same connections.</div><div class=\"graphic_reference\">Reproduced with permission from: Manolagas SC. From estrogen-centric to aging and oxidative stress: A revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010; 31:266. Copyright &#169; 2010 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 73524 Version 2.0</div></div></div>"},"73525":{"type":"graphic_picture","displayName":"Blastocystis microscopy","title":"<EM>Blastocystis </EM>microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Blastocystis </EM>microscopy</div><div class=\"cntnt\"><img style=\"width:390px; height:584px;\" src=\"images/ID/73525_Blastocystis_microscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) <em>Blastocystis</em> spp cyst-like forms stained in trichrome. The nuclei in the peripheral cytoplasmic rim are visible, staining purple.<br />(C, D) <em>Blastocystis</em> spp cyst-like forms in a wet mount stained in iodine.<br />(E) <em>Blastocystis</em> spp cyst-like form in a wet mount, unstained.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Blastocystis hominis. Available at: <A href=\"http://www.cdc.gov/dpdx/blastocystis/index.html\">http://www.cdc.gov/dpdx/blastocystis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 73525 Version 6.0</div></div></div>"},"73527":{"type":"graphic_picture","displayName":"Nail pitting in alopecia areata","title":"Nail pitting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nail pitting</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/73527_Nail_pits_aa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous pits are present in this nail from a patient with alopecia areata.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73527 Version 6.0</div></div></div>"},"73528":{"type":"graphic_figure","displayName":"Defects in leukocyte-adhesion deficiency disorders","title":"Defects in leukocyte-adhesion deficiency disorders","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Defects in leukocyte-adhesion deficiency disorders</div><div class=\"cntnt\"><img style=\"width:554px; height:413px;\" src=\"images/ALLRG/73528_Defectsinleukocyteadhesiondeficiencydisorders.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on leukocyte-adhesion deficiency and leukocyte-endothelial interactions for details.</div><div class=\"graphic_footnotes\">LAD: leukocyte-adhesion deficiency; IL-1 beta: interleukin-1 beta; ICAM-1, -2: intracellular adhesion molecule-1 and -2; PECAM-1: platelet-endothelial cell adhesion molecule-1.</div><div id=\"graphicVersion\">Graphic 73528 Version 7.0</div></div></div>"},"73530":{"type":"graphic_table","displayName":"Transudative pleural effusions","title":"Causes of transudative pleural effusions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of transudative pleural effusions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Causes of transudative effusions</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Processes that <em>always</em> cause a transudative effusion</td> </tr> <tr> <td class=\"indent1\">Atelectasis</td> <td>Caused by increased intrapleural negative pressure</td> </tr> <tr> <td class=\"indent1\">Cerebrospinal fluid leak into pleural space</td> <td>Thoracic spinal surgery or trauma and ventriculopleural shunts</td> </tr> <tr> <td class=\"indent1\">Heart failure</td> <td>Acute diuresis can result in borderline exudative features</td> </tr> <tr> <td class=\"indent1\">Hepatic hydrothorax</td> <td>Rare without clinical ascites</td> </tr> <tr> <td class=\"indent1\">Hypoalbuminemia</td> <td>Edema&nbsp;liquid rarely isolated to pleural space</td> </tr> <tr> <td class=\"indent1\">Iatrogenic</td> <td>Misplaced intravenous catheter into the pleural space; post Fontan procedure</td> </tr> <tr> <td class=\"indent1\">Nephrotic syndrome</td> <td>Usually subpulmonic and bilateral</td> </tr> <tr> <td class=\"indent1\">Peritoneal dialysis</td> <td>Acute massive effusion develops within 48 hours of initiating dialysis</td> </tr> <tr> <td class=\"indent1\">Urinothorax</td> <td>Caused by ipsilateral obstructive uropathy or by iatrogenic or traumatic GU injury</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Processes that <em>may</em> cause a transudative effusion, but <em>usually</em> cause an exudative effusion</td> </tr> <tr> <td class=\"indent1\">Amyloidosis</td> <td>Often exudative due to disruption of pleural surfaces</td> </tr> <tr> <td class=\"indent1\">Chylothorax</td> <td>Most are exudative effusions&nbsp;</td> </tr> <tr> <td class=\"indent1\">Constrictive pericarditis</td> <td>Bilateral effusions</td> </tr> <tr> <td class=\"indent1\">Hypothyroid pleural effusion</td> <td>From hypothyroid heart disease or hypothyroidism per se</td> </tr> <tr> <td class=\"indent1\">Malignancy</td> <td>Usually exudative, but 3 to 10 percent transudative possibly due to early lymphatic obstruction, obstructive atelectasis, or concomitant disease (eg, heart failure)</td> </tr> <tr> <td class=\"indent1\">Pulmonary embolism</td> <td>Most are exudative effusions</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> <td>Stage II and III disease</td> </tr> <tr> <td class=\"indent1\">Superior vena caval obstruction</td> <td>May be due to acute systemic venous hypertension or acute blockage of thoracic lymph flow</td> </tr> <tr> <td class=\"indent1\">Trapped lung</td> <td>A result of remote or chronic inflammation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GU: genitourinary.</div><div id=\"graphicVersion\">Graphic 73530 Version 7.0</div></div></div>"},"73531":{"type":"graphic_table","displayName":"Rheumatic and systemic causes of musculoskeletal chest wall pain","title":"Rheumatic and systemic diseases associated with musculoskeletal chest wall pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rheumatic and systemic diseases associated with musculoskeletal chest wall pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Clinical characteristics</td> </tr> <tr> <td> <p>Fibromyalgia</p> </td> <td> <p>Widespread pain with multiple tender points, including over the chest wall; fatigue, sleep disturbance, cognitive dysfunction, and may have symptoms of depression and anxiety.</p> </td> </tr> <tr> <td>Rheumatoid arthritis</td> <td>Up to one-fifth with sternoclavicular joint involvement; typically without costochondral involvement; usually symmetric, inflammatory polyarthritis,&nbsp;affecting hands, wrists, feet, and other peripheral&nbsp;joints; extra-articular manifestations may occur.&nbsp;</td> </tr> <tr> <td>Ankylosing spondylitis</td> <td>Thoracic spine and chest wall pain from costovertebral, costotransverse, and thoracic apophyseal joint inflammation is common; usually low back pain and stiffness, buttock pain, and sacroiliitis; some have peripheral arthritis, enthesitis, dactylitis, and uveitis.</td> </tr> <tr> <td>Psoriatic arthritis</td> <td>Uncommon to rare anterior chest wall symptoms despite imaging evidence&nbsp;of manubriosternal and sternoclavicular joint disease in 10 to 25%; spondyloarthritis and inflammatory polyarthritis, nail diseases, enthesitis, and dactylitis may occur.</td> </tr> <tr> <td>Sternocostoclavicular hyperostosis (SAPHO syndrome)</td> <td>Arthritis of the anterior chest wall in the majority of patients, with sterile osteomyelitis; hyperostosis; palmoplantar pustulosis, acne, peripheral, and/or axial arthritis.</td> </tr> <tr> <td> <p>Systemic lupus erythematosus</p> </td> <td> <p>Tenderness in muscles and joints of the chest wall that can mimic pleuritic pain; patients have multisystem autoimmune disease with arthritis, cutaneous manifestations, pleurisy, pericarditis, neurologic changes, and/or&nbsp;cytopenias; antinuclear antibodies.</p> </td> </tr> <tr> <td>Infectious arthritis</td> <td>Most often affects the sternoclavicular joint, when present, but joints of chest wall and ribs are infrequent sites of bacterial arthritis.</td> </tr> <tr> <td>Relapsing polychondritis</td> <td>Up to 25% have inflammation of costochondral and manubriosternal regions, rarely with destructive changes; cartilage inflammation involves ears, nasal cartilage, respiratory tract; synovitis, ocular inflammation, inner ear dysfunction may occur.</td> </tr> <tr> <td class=\"sublist1_start\">Other systemic conditions</td> <td class=\"sublist1_start\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Osteoporosis, osteomalacia</td> <td class=\"sublist1\">Low bone mass increases the risk of fracture, including fracture of the ribs; risk factors for osteoporosis include advanced age, glucocorticoids, chronic kidney injury, and others; osteomalacia may be associated with bone pain, muscle weakness, elevated alkaline phosphatase and parathyroid hormone with decreased calcium and vitamin D.</td> </tr> <tr> <td class=\"sublist1\">Tumors (benign, malignant, metastatic and primary)</td> <td class=\"sublist1\">Primary neoplasms (eg, sarcoma or multiple myeloma) or secondary neoplasms (eg, lung or breast cancer) may very infrequently involve the ribs or soft tissues of the chest wall.</td> </tr> <tr> <td class=\"sublist1\">Sickle cell disease</td> <td class=\"sublist1\">Rib infarct, with resultant local pain,&nbsp;is a rare cause of acute chest pain syndrome in patients with sickle cell crisis.&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">SAPHO: synovitis, acne, pustulosis, hyperostosis, and osteitis.</div><div id=\"graphicVersion\">Graphic 73531 Version 4.0</div></div></div>"},"73533":{"type":"graphic_table","displayName":"Dissociative Experiences Scale - Revised","title":"Dissociative Experiences Scale - Revised","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dissociative Experiences Scale - Revised</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"3\"><strong>Name:</strong></td> <td colspan=\"3\"><strong>Date:</strong></td> <td colspan=\"3\"><strong>Age:</strong></td> <td colspan=\"2\"><strong>Sex:</strong></td> </tr> <tr> <td colspan=\"11\"><em>Directions:</em> This questionnaire consists of twenty-eight questions about experiences that you may have in your daily life. We are interested in how often you have these experiences. It is important, however, that your answers show how often these experiences happen to you when you are not under the influence of alcohol or drugs. To answer the questions, please determine to what degree the experience described in the question applies to you and circle the number to show what percentage of the time you have the experience.</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>1.</strong> Some people have the experience of driving a car and suddenly realizing that they don't remember what has happened during all or part of the trip. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>2.</strong> Some people find that sometimes they are listening to someone talk and they suddenly realize that they did not hear all or part of what was said. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>3.</strong> Some people have the experience of finding themselves in a place and having no idea how they got there. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>4.</strong> Some people have the experience of finding themselves dressed in clothes that they don't remember putting on. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>5.</strong> Some people have the experience of finding new things among their belongings that they do not remember buying. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>6.</strong> Some people sometimes find that they are approached by people that they do not know who call them by another name or insist that they have met them before. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>7.</strong> Some people sometimes have the experience of feeling as though they are standing next to themselves or watching themselves do something as if they were looking at another person. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>8.</strong> Some people are told that they sometimes do not recognize friends or family members. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>9.</strong> Some people find that they have no memory for some important events in their lives (for example, a wedding or graduation). Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>10.</strong> Some people have the experience of being accused of lying when they do not think that they have lied. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>11.</strong> Some people have the experience of looking in a mirror and not recognizing themselves. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>12.</strong> Some people sometimes have the experience of feeling that other people, objects, and the world around them are not real. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>13.</strong> Some people sometimes have the experience of feeling that their body does not belong to them. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>14.</strong> Some people have the experience of sometimes remembering a past event so vividly that they feel as if they were reliving that event. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>15.</strong> Some people have the experience of not being sure whether things that they remember happening really did happen or whether they just dreamed them. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>16.</strong> Some people have the experience of being in a familiar place but finding it strange and unfamiliar. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>17.</strong> Some people find that when they are watching television or a movie they become so absorbed in the story that they are unaware of other events happening around them. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>18.</strong> Some people sometimes find that they become so involved in a fantasy or daydream that it feels as though it were really happening to them. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>19.</strong> Some people find that they are sometimes able to ignore pain. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>20.</strong> Some people find that they sometimes sit staring off into space, thinking of nothing, and are not aware of the passage of time. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>21.</strong> Some people sometimes find that when they are alone they talk out loud to themselves. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>22.</strong> Some people find that in one situation they may act so differently compared with another situation that they feel almost as if they were different people. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>23.</strong> Some people sometimes find that in certain situations they are able to do things with amazing ease and spontaneity that would usually be difficult for them (for example, sports, work, social situations, etc.). Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>24.</strong> Some people sometimes find that they cannot remember whether they have done something or have just thought about doing that thing (for example, not knowing whether they have just mailed a letter or have just thought about mailing it). Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>25.</strong> Some people find evidence that they have done things that they do not remember doing. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>26.</strong> Some people sometimes find writings, drawings, or notes among their belongings that they must have done but cannot remember doing. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>27.</strong> Some people find that they sometimes hear voices inside their head that tell them to do things or comment on things that they are doing. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> <tr class=\"divider_top\"> <td colspan=\"11\"><strong>28.</strong> Some people sometimes feels as if they are looking at the world through a fog so that people or objects appear far away or unclear. Circle a number to show what percentage of the time this happens to you.</td> </tr> <tr> <td class=\"centered\">0%<br /> (never)</td> <td class=\"centered\">10</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">50</td> <td class=\"centered\">60</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100%<br /> (always)</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">22.0000000000000</mso:Specialty>\r\n<mso:Publishable_Version msdt:dt=\"string\">0</mso:Publishable_Version>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=85445&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Dissociative_Experiences_Scale.htm</title></head></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced with permission from: Dalenberg C, Carlson E. New versions of the Dissociative Experiences Scale: The DES-R (Revised) and the DES-B (Brief). Paper presented at Annual Meeting of the International Society, November 2010. Copyright © 2010 Constance Dalenberg, Ph.D.</div><div id=\"graphicVersion\">Graphic 73533 Version 1.0</div></div></div>"},"73534":{"type":"graphic_table","displayName":"Medications and other substances associated with easy bruising","title":"Classes of medications and other substances associated with easy bruising","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classes of medications and other substances associated with easy bruising</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td class=\"subtitle2_single\">Frequently seen causes</td> </tr> <tr> <td class=\"indent1\">Anticoagulants (eg, heparin, warfarin)</td> </tr> <tr> <td class=\"indent1\">Nonsteroidal antiinflammatory drugs (eg, ibuprofen, naproxen)</td> </tr> <tr> <td class=\"indent1\">Antiplatelet medications (eg, aspirin, clopidogrel)</td> </tr> <tr> <td class=\"indent1\">Corticosteroids (eg, prednisone, hydrocortisone)</td> </tr> <tr> <td class=\"indent1\">Antineoplastics &ndash; Multiple agents, primarily manifesting via decreased platelet production; also&nbsp;Bruton tyrosine kinase inhibitors, which may affect platelet function</td> </tr> <tr> <td class=\"subtitle2_single\">Other</td> </tr> <tr> <td class=\"indent1\">Antibiotics &ndash; Most broad-spectrum antibiotics, especially with long-term use</td> </tr> <tr> <td class=\"indent1\">Antidepressants &ndash; SSRIs and SSNRIs*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Quinidine</td> </tr> <tr> <td class=\"subtitle1_single\">Other agents</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Alcohol</td> </tr> <tr> <td class=\"subtitle1_single\">Herbs and supplements</td> </tr> <tr> <td class=\"indent1\">Fish oil</td> </tr> <tr> <td class=\"indent1\">Garlic</td> </tr> <tr> <td class=\"indent1\">Gingko</td> </tr> <tr> <td class=\"indent1\">Vitamin E</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SSRIs: Selective serotonin reuptake inhibitors; SSNRIs: selective&nbsp;serotonin norepinephrine reuptake inhibitors.<br />* Have been associated with bruising in observational reports but not randomized trials. Please refer to the UpToDate topic on easy bruising for a full discussion.</div><div id=\"graphicVersion\">Graphic 73534 Version 5.0</div></div></div>"},"73535":{"type":"graphic_picture","displayName":"HCV cirrhosis Light","title":"Cirrhosis in HCV","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cirrhosis in HCV</div><div class=\"cntnt\"><img style=\"width:432px; height:256px;\" src=\"images/GAST/73535_HCV_cirrhosis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a liver biopsy stained with Masson trichrome from a patient with chronic hepatitis C virus (HCV) infection. Areas of hepatic fibrosis and nodule formation are seen in blue.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 73535 Version 1.0</div></div></div>"},"73540":{"type":"graphic_figure","displayName":"Breech6","title":"Beginning delivery of the head","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Beginning delivery of the head</div><div class=\"cntnt\"><img style=\"width:448px; height:334px;\" src=\"images/OBGYN/73540_Breech6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following delivery of the arms, the fetus is slightly elevated. The fetal face and airway may be visible over the perineum. Excessive elevation of the trunk is avoided.</div><div class=\"graphic_reference\">Reproduced with permission from: Gabbe, SG, Niebyl, JR, Simpson, JL (Eds). Obstetrics: Normal and Problem Pregnancies, 4th ed, Churchill Livingstone New York 2003. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 73540 Version 1.0</div></div></div>"},"73541":{"type":"graphic_picture","displayName":"Colonic angiodysplasia Endosc","title":"Colon angiodysplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colon angiodysplasia</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/GAST/73541_Colonic_angiodysplasia_Endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of T Edward Bynum, MD.</div><div id=\"graphicVersion\">Graphic 73541 Version 1.0</div></div></div>"},"73543":{"type":"graphic_figure","displayName":"BCR-ABL FISH in CML","title":"Interphase fluorescence in situ hybridization (FISH) images of normal and t(9;22) positive nuclei","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Interphase fluorescence in situ hybridization (FISH) images of normal and t(9;22) positive nuclei</div><div class=\"cntnt\"><img style=\"width:360px; height:216px;\" src=\"images/HEME/73543_BCR-ABL_FISH_in_CML.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dual-color ABL (green) and BCR (red) probes span their respective breakpoint regions, producing two red and two green signals in a normal nucleus (on the left). In the t(9;22) cell (on the right), the single red and green signals correspond to the normal ABL and BCR genes, respectively, while the two yellow-white fusion signals correspond to the Ph chromosome and the reciprocal balanced translocation product (derivative chromosome 9).</div><div class=\"graphic_reference\">Photo courtesy of Athena Cherry, PhD.</div><div id=\"graphicVersion\">Graphic 73543 Version 1.0</div></div></div>"},"73544":{"type":"graphic_picture","displayName":"Hirsutism in PCOS","title":"Hirsutism in PCOS","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Hirsutism in PCOS</div><div class=\"cntnt\"><img style=\"width:576px; height:413px;\" src=\"images/ENDO/73544_Hirsutism_PCOS.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PCOS: polycystic ovary syndrome.</div><div id=\"graphicVersion\">Graphic 73544 Version 3.0</div></div></div>"},"73545":{"type":"graphic_picture","displayName":"Linear porokeratosis","title":"Linear porokeratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Linear porokeratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/73545_Linear_porokeratosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear erythematous plaques with prominent keratotic rims are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73545 Version 3.0</div></div></div>"},"73546":{"type":"graphic_figure","displayName":"Ligation of mesenteric vessels for right hemicolectomy","title":"Ligation of mesenteric vessels for right hemicolectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ligation of mesenteric vessels for right hemicolectomy</div><div class=\"cntnt\"><img style=\"width:440px; height:477px;\" src=\"images/SURG/73546_Ligation_of_mesenteric_vessels_for_right_hemicolectomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73546 Version 2.0</div></div></div>"},"73547":{"type":"graphic_figure","displayName":"TIMI frame count outcome","title":"Use of TIMI frame count to risk stratify within TIMI flow grades","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Use of TIMI frame count to risk stratify within TIMI flow grades</div><div class=\"cntnt\"><img style=\"width:420px; height:281px;\" src=\"images/CARD/73547_TIMI_frame_count_outcome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">TIMI frame count improves risk stratification after a myocardial infarction. Shown is the risk of adverse outcomes assoicated with TIMI flow grades (p = 0.024) and corrected TIMI frame count (p = 0.015) (TFC). The TFC demonstrates that for patients with TIMI grade 2 or 3 flow, in whom the overall risk of an adverse outcome is 27 and 13 percent, respectively, there are lower- and higher-risk subgroups; in those with TIMI grade 3 flow, a TFC ≤20 is associated with a 7.9 percent incidence of an adverse outcome, whereas the incidence with a TFC &gt;20 to ≤40 is 15.5 percent. In patients with TIMI grade 2 flow, the incidence of an adverse outcome ranges from 18.8 to 42.9 percent with TFC of 40 to &gt;100.</div><div class=\"graphic_reference\">Data from Gibson CM, Murphy SA, Rizzo MJ, et al for the TIMI Study Group. Circulation 1999; 99:1945.</div><div id=\"graphicVersion\">Graphic 73547 Version 2.0</div></div></div>"},"73548":{"type":"graphic_diagnosticimage","displayName":"Stable and unstable intertrochanteric hip fractures","title":"Stable and unstable intertrochanteric hip fractures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stable and unstable intertrochanteric hip fractures</div><div class=\"cntnt\"><img style=\"width:412px; height:361px;\" src=\"images/EM/73548_Hip_fx_intertroch4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Stable intertrochanteric fracture characterized by an intact posteromedial cortex. B) An unstable intertrochanteric fracture characterized by disruption of the posteromedial cortex (note the displaced lesser trochanter).</div><div class=\"graphic_reference\">Reproduced with permission from: Koval KJ, Zuckerman JD. Intertrochanteric fractures. In: Rockwood and Green's Fractures in Adults, 5th ed,&nbsp;Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 73548 Version 10.0</div></div></div>"},"73551":{"type":"graphic_table","displayName":"Infectious causes fever ICU","title":"Infectious causes of fever in the intensive care unit","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious causes of fever in the intensive care unit</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Common causes</td></tr>\n\t\t\t\t\t\t<tr><td>Bacteremia</td></tr>\n\t\t\t\t\t\t<tr><td>Intravascular catheter-related infection</td></tr>\n\t\t\t\t\t\t<tr><td>Surgical site infection</td></tr>\n\t\t\t\t\t\t<tr><td>Ventilator-associated pneumonia</td></tr></tbody></table></td>\n<td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Other causes</td></tr>\n\t\t\t\t\t\t<tr><td>Cellulitis</td></tr>\n\t\t\t\t\t\t<tr><td>Cholangitis</td></tr>\n\t\t\t\t\t\t<tr><td>Diverticulitis</td></tr>\n\t\t\t\t\t\t<tr><td>Empyema</td></tr>\n\t\t\t\t\t\t<tr><td>Endocarditis</td></tr>\n\t\t\t\t\t\t<tr><td>Intra-abdominal abscess</td></tr>\n\t\t\t\t\t\t<tr><td>Meningitis</td></tr>\n\t\t\t\t\t\t<tr><td>Myonecrosis</td></tr>\n\t\t\t\t\t\t<tr><td>Necrotizing fasciitis</td></tr>\n\t\t\t\t\t\t<tr><td>Pseudomembranous colitis</td></tr>\n\t\t\t\t\t\t<tr><td>Septic arthritis</td></tr>\n\t\t\t\t\t\t<tr><td>Sinusitis</td></tr>\n\t\t\t\t\t\t<tr><td>Suppurative thrombophlebitis</td></tr>\n\t\t\t\t\t\t<tr><td>Urinary tract infection</td></tr></tbody></table></td>\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 73551 Version 1.0</div></div></div>"},"73552":{"type":"graphic_diagnosticimage","displayName":"RLL nodule PET","title":"Malignant solitary pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Malignant solitary pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:570px; height:233px;\" src=\"images/PULM/73552_RLL_nodule_PET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal (left) and axial (right) PET scans confirm the solitary nature of the nodule and exclude mediastinal lymph node metastasis.</div><div class=\"graphic_footnotes\">PET: positron emission tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 73552 Version 3.0</div></div></div>"},"73553":{"type":"graphic_diagnosticimage","displayName":"Left subclavian artery GCA","title":"Narrowing of the left subclavian artery in giant cell (temporal) arteritis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Narrowing of the left subclavian artery in giant cell (temporal)&nbsp;arteritis</div><div class=\"cntnt\"><img style=\"width:504px; height:406px;\" src=\"images/RHEUM/73553_Left_subclavian_artery_GCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiogram of the left subclavian artery in GCA, showing several areas of severe vascular narrowing but a proliferation of small blood vessels forming excellent collateral circulation. The long, smooth arterial tapering in large vessel GCA is often not amenable to revascularization interventions such as angioplasty or stent placement. Those types of interventions are rarely necessary.</div><div class=\"graphic_footnotes\">GCA: giant cell (temporal) arteritis.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 73553 Version 6.0</div></div></div>"},"73555":{"type":"graphic_figure","displayName":"Maximum dimensions of abdominal wall defect for CST","title":"Maximum dimensions of abdominal wall defect for CST","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Maximum dimensions of abdominal wall defect for CST</div><div class=\"cntnt\"><img style=\"width:376px; height:381px;\" src=\"images/SURG/73555_Maximum-dimensions-of-abdominal-wall-defect-for-CST.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The maximum size of an abdominal wall defect or hernia that can be reconstructed in the upper, middle, and lower abdominal wall using the component separation technique.</div><div class=\"graphic_reference\">Nguyen VT and Shestak KC. &quot;Separation of anatomic components&quot; Method of abdominal wall reconstruction. Clin Plast Surg 2006; 33:247.</div><div id=\"graphicVersion\">Graphic 73555 Version 6.0</div></div></div>"},"73559":{"type":"graphic_table","displayName":"Nutritional assess children IBD","title":"Nutritional assessment in children with inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nutritional assessment in children with inflammatory bowel disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Global assessment</td> </tr> <tr> <td class=\"indent1\">Measure weight and height, determine percentiles</td> </tr> <tr> <td class=\"indent1\">Calculate BMI and height velocity</td> </tr> <tr> <td class=\"indent1\">Estimate height potential (based on midparental height)</td> </tr> <tr> <td class=\"indent1\">Anthropometrics (mid-arm circumference, mid-arm muscle area)</td> </tr> <tr> <td class=\"indent1\">Pubertal staging (Tanner stage)</td> </tr> <tr> <td class=\"indent1\">Diet history and calorie count</td> </tr> <tr> <td class=\"subtitle1_single\">Assessment for nutrient deficiencies</td> </tr> <tr> <td class=\"indent1\">Hemoglobin, iron, TIBC, ferritin, and folate</td> </tr> <tr> <td class=\"indent1\">Vitamin D</td> </tr> <tr> <td class=\"indent1\">Vitamin A, vitamin E, and prothrombin time</td> </tr> <tr> <td class=\"indent1\">Albumin (or prealbumin)</td> </tr> <tr> <td class=\"indent1\">Vitamin B12</td> </tr> <tr> <td class=\"indent1\">Calcium, phosphorus, and magnesium</td> </tr> <tr> <td class=\"indent1\">Zinc level</td> </tr> <tr> <td class=\"indent1\">Selenium level</td> </tr> <tr> <td class=\"indent1\">Bone density study (DXA scan)</td> </tr> <tr> <td class=\"subtitle1_single\">If growth failure:</td> </tr> <tr> <td class=\"indent1\">IGF-1</td> </tr> <tr> <td class=\"indent1\">Bone age</td> </tr> <tr> <td class=\"indent1\">Thyroid function tests</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index; TIBC: total iron binding capacity; DXA: dual energy x-ray absorptiometry; IGF-1: insulin-like growth factor 1.</div><div id=\"graphicVersion\">Graphic 73559 Version 4.0</div></div></div>"},"73564":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound fetal pelvic kidney","title":"Prenatal ultrasound fetal pelvic kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound fetal pelvic kidney</div><div class=\"cntnt\"><img style=\"width:409px; height:361px;\" src=\"images/OBGYN/73564_Pelvic_kidney.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right pelvic kidney next to the bladder and blood flow to both kidneys on color Doppler seen. The left kidney and bladder locations appear normal.</div><div class=\"graphic_footnotes\">RT: right.</div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 73564 Version 3.0</div></div></div>"},"73565":{"type":"graphic_table","displayName":"Daily weight gain in infants and toddlers","title":"Expected daily weight gain for children younger than three years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expected daily weight gain for children younger than three years</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Expected weight gain, g/day</td> </tr> <tr> <td>0 to 3 months</td> <td>26 to 31</td> </tr> <tr> <td>3 to 6 months</td> <td>17 to 18</td> </tr> <tr> <td>6 to 9 months</td> <td>12 to 13</td> </tr> <tr> <td>9 to 12 months</td> <td>9 </td> </tr> <tr> <td>1 to 3 years</td> <td>7 to 9</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Frank DA. Failure to thrive. In: The Zuckerman Parker Handbook of&nbsp;Developmental and Behavioral&nbsp;Pediatrics for Primary Care, 3<SUP innerHtml>rd</SUP> ed,&nbsp; Augustyn M, Zuckerman B, Caronna EB&nbsp;(Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.204.</div><div id=\"graphicVersion\">Graphic 73565 Version 5.0</div></div></div>"},"73566":{"type":"graphic_picture","displayName":"HSV lip","title":"Herpes simplex virus lesion on the lip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes simplex virus lesion on the lip</div><div class=\"cntnt\"><img style=\"width:350px; height:295px;\" src=\"images/PEDS/73566_HSV_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Martha Ann Keels, DDS, PhD.</div><div id=\"graphicVersion\">Graphic 73566 Version 1.0</div></div></div>"},"73567":{"type":"graphic_table","displayName":"Practical guide CBT IEI","title":"A practical guide for treating symptoms of idiopathic environmental intolerance (IEI) with cognitive behavioral therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A practical guide for treating symptoms of idiopathic environmental intolerance (IEI) with cognitive behavioral therapy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n  <td>Explore beliefs</td>\n  <td>Ask patients what they believe is causing their symptoms.</td>\n </tr>\n <tr>\n  <td>Define goals</td>\n  <td>Define goals, eg, take responsibility for one's health or reduce avoidance behavior.</td>\n </tr>\n <tr>\n  <td>Behavioral analysis</td>\n  <td>Analyze behavior to determine antecedents and consequences (ABC: antecedent, behavior, consequence). Ask about thoughts, behaviors, emotions, and situations that precede, accompany, and follow the symptoms.</td>\n </tr>\n <tr>\n  <td>Diary</td>\n  <td>The patient should use a diary to record symptoms, rate their severity, describe the situation during which a symptom occurred, describe how they felt at the time, and what they were thinking at the time. These entries are reviewed during treatment sessions.</td>\n </tr>\n <tr>\n  <td>Family</td>\n  <td>The spouse or parents should be invited to attend one or more treatment sessions so they understand the treatment approach. Family members should be directed to stop their responses and accommodations to symptoms that are performed out of concern but which ultimately serve to reinforce the illness.</td>\n </tr>\n <tr>\n  <td>Behavior first</td>\n  <td>The focus of treatment is changing cognitions and behaviors. It is easier to first change behaviors, especially for those patients who are less psychiatrically minded or more resistant to psychiatric explanations of their illness.</td>\n </tr>\n <tr>\n  <td>Reduce maladaptive behavior</td>\n  <td>Behavioral change starts with reducing avoidance behavior and other maladaptive behavioral responses to symptoms. This can reduce the frequency and intensity of symptoms, reduce disability, and help facilitate cognitive changes. In addition, clinicians and patients need to decide which adaptive behaviors to increase. These should be clearly specified, realistically attainable, and of value to the patient.</td>\n </tr>\n <tr>\n  <td>Incremental change</td>\n  <td>Behavioral change is approached in a gradual way, with graded increases in desired activities. The difference between current behavior and the desired goals is assessed, and then broken down into manageable steps.</td>\n </tr>\n <tr>\n  <td>Practice</td>\n  <td>The clinician should warn the patient that each increase in previously avoided behavior could cause a transient increase in symptoms. The desired behavior is practiced daily until it is mastered, and then the next goal is undertaken.</td>\n </tr>\n <tr>\n  <td>Relaxation</td>\n  <td>Teach relaxation techniques to increase the patient's ability to bear with symptoms, reduce stress, and develop pleasant bodily sensations.</td>\n </tr>\n <tr>\n  <td>Social skills</td>\n  <td>Provide social skills training.</td>\n </tr>\n <tr>\n  <td>Regulate emotions</td>\n  <td>Teach patients how to regulate their emotions.</td>\n </tr>\n <tr>\n  <td>Cognitive change</td>\n  <td>Cognitive change begins with identifying the patient's thoughts and beliefs about bodily sensations, symptoms, and IEI. The clinician then asks the patient to consider alternative explanations and interpretations of symptoms. Patients record their thoughts about symptoms and practice challenging them by producing and recording more benign explanations.</td>\n </tr>\n <tr>\n  <td>Psychoeducation</td>\n  <td>Provide psychoeducation about IEI.</td>\n </tr>\n <tr>\n  <td>Realistic health concept</td>\n  <td>Help the patient develop a realistic health concept. Challenge faulty assumptions, such as the idea that one must be in perfect health in order to function, or that any bodily sensation is pathologic.</td>\n </tr>\n <tr>\n  <td>Restructure cognitions</td>\n  <td>Aim to restructure cognitions to accept the role of psychiatric factors in IEI.</td>\n </tr>\n <tr>\n  <td>Demonstrate role of psychiatric factors</td>\n  <td>Conduct exercises to demonstrate the role of psychiatric factors in health. Biofeedback experiments can help patients understand how their somatic preoccupation perpetuates their symptoms and disability. As an example, if the patient focuses on a normal bodily sensation such as the heartbeat, this will reveal an increase in its apparent intensity. The value of distraction as a method of symptom control can then be demonstrated. These experiments provide personal evidence the patient can use in reconsidering IEI as the explanation of their symptoms.</td>\n </tr>\n <tr>\n  <td>Well-being</td>\n  <td>Address problems affecting well-being, such as difficulties in relationships and at work, cognitive misattributions, and emotional state.</td>\n </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from:<br> Bornschein, S, Forstl, H, Zilker, T. Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives. J Intern Med 2001; 250:309.<br> Sharpe, M, Peveler, R, Mayou, R. The psychological treatment of patients with functional symptoms: a practical guide. J Psychosom Res 1992; 36:515.</div><div id=\"graphicVersion\">Graphic 73567 Version 1.0</div></div></div>"},"73569":{"type":"graphic_figure","displayName":"Apoptotic program C elegans","title":"Apoptotic program C. elegans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apoptotic program C. elegans</div><div class=\"cntnt\"><img style=\"width:237px; height:238px;\" src=\"images/ALLRG/73569_Apoptotic_program_c_elegans.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73569 Version 2.0</div></div></div>"},"73570":{"type":"graphic_table","displayName":"Management infertility","title":"General principles of management of infertile couples","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General principles of management of infertile couples</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Involve both partners in the evaluation and management of infertility</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Recommend lifestyle modifications to enhance fertility\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Couple - smoking cessation and reduce exposure to potential environmental toxins\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Women - abstinence from alcohol, reduction of excessive caffeine intake, weight modulation to achieve target body mass index (20-25 kg/m2)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Perform infertility evaluation according to established guidelines</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Identify causes of infertility\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Reversible causes - implement medical or surgical therapy to correct the etiology of infertility\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Irreversible causes - utilize assisted reproductive technologies, gamete donation, gestational carrier, adoption to overcome the etiology of infertility\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 73570 Version 1.0</div></div></div>"},"73571":{"type":"graphic_figure","displayName":"Cough method","title":"Techniques for transbronchial penetration: cough method","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Techniques for transbronchial penetration: cough method</div><div class=\"cntnt\"><img style=\"width:258px; height:197px;\" src=\"images/PULM/73571_Cough_method.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram shows the cough method used for tracheobronchial wall penetration in transbronchoscopic needle aspiration. The fiberoptic bronchoscope and needle assembly are held stationary and the patient is asked to cough, which forces the tracheobronchial wall over the needle.</div><div class=\"graphic_reference\">Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research - Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.</div><div id=\"graphicVersion\">Graphic 73571 Version 1.0</div></div></div>"},"73572":{"type":"graphic_table","displayName":"Initial oxygen flow in COPD","title":"Recommended initial oxygen settings to achieve ambient air PaO2 >60 mmHg","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended initial oxygen settings to achieve ambient air PaO2 &gt;60 mmHg</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">PaO2 breathing room air (mmHg)</td>\n<td class=\"subtitle1\">FIO2 (percent)</td>\n<td class=\"subtitle1\">Nasal cannula setting to achieve approximate FIO2 (L/min)</td>\n</tr>\n<tr>\n<td>50</td>\n<td>24</td>\n<td>1</td>\n</tr>\n<tr>\n<td>45</td>\n<td>28</td>\n<td>2</td>\n</tr>\n<tr>\n<td>40</td>\n<td>32</td>\n<td>3</td>\n</tr>\n<tr>\n<td>35</td>\n<td>35</td>\n<td>4</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 73572 Version 1.0</div></div></div>"},"73573":{"type":"graphic_table","displayName":"Major triatomine species of Chagas","title":"The major triatomine species that colonize the domestic and peridomestic environment and play an important role in the epidemiology of Chagas disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The major triatomine species that colonize the domestic and peridomestic environment and play an important role in the epidemiology of Chagas disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vector species</td> <td class=\"subtitle1\">Found in<sup>[2]</sup></td> </tr> <tr> <td><em>Triatoma infestans</em></td> <td>Argentina*, Bolivia*, Brazil<sup>&#182;</sup>, Chile<sup>&#182;</sup>, Paraguay*, southern Peru*, Uruguay<sup>&#182;</sup></td> </tr> <tr> <td><em>Rhodnius prolixus</em></td> <td>Belize<sup>&#916;</sup>, Colombia<sup>&#9674;</sup>, El Salvador<sup>&#916;</sup>, Guatemala<sup>&#916;</sup>, Honduras<sup>&#916;</sup>, southern Mexico<sup>&#167;</sup>, Nicaragua<sup>&#916;</sup>, Venezuela</td> </tr> <tr> <td><em>Triatoma dimidiata</em></td> <td>Belize, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, northern Peru, Venezuela</td> </tr> <tr> <td><em>Panstrongylus megistus</em></td> <td>Argentina, Brazil, Paraguay, Uruguay</td> </tr> <tr> <td><em>Triatoma brasiliensis</em></td> <td>Northeastern Brazil</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* <EM>Trypanosoma cruzi </EM>transmission by <EM>T. infestans </EM>certified as interrupted in&nbsp;8 provinces of Argentina,&nbsp;2 departments of Bolivia,&nbsp;2 departments of Paraguay, and&nbsp;2 departments of Peru<SUP>[2]</SUP>.<br />¶ <EM>T. cruzi </EM>transmission by <EM>T. infestans </EM>certified as interrupted throughout the country<SUP>[2]</SUP>.<br />Δ <EM>T. cruzi </EM>transmission by <EM>R. prolixus </EM>certified as interrupted throughout the country<SUP>[2,3]</SUP>.<br />◊ <EM>T. cruzi </EM>transmission by <EM>R. prolixus </EM>certified as interrupted in 10 municipalities of 4 departments of Colombia<SUP>[2]</SUP>.<br />§ <EM>T. </EM><EM innerHtml>cruzi </EM>transmission by <EM>R. prolixus </EM>certified as interrupted in 2 states of Mexico<SUP>[2]</SUP>.</div><div class=\"graphic_reference\">References:<br /><br /><OL>&#xD;&#xA;<LI>World Health Organization&nbsp;Expert Committee. Control of Chagas disease. World Health Organization, Brasilia,&nbsp;Brazil&nbsp;2002. p.1.</LI>&#xD;&#xA;<LI>Pan American Health Organization. Chagas disease (American trypanosomiasis).&nbsp; Available at: <A href=\"http://www.paho.org/hq/index.php?option=com_content&amp;view=article&amp;id=5856&amp;Itemid=41506&amp;lang=en\">http://www.paho.org/hq/index.php?option=com_content&amp;view=article&amp;id=5856&amp;Itemid=41506&amp;lang=en</A> (Accessed on July 28, 2017).</LI>&#xD;&#xA;<LI>Hashimoto K, Schofield CJ. Elimination of Rhodnius prolixus in Central America. Parasit Vectors 2012; 5:45.</LI></OL></div><div id=\"graphicVersion\">Graphic 73573 Version 5.0</div></div></div>"},"73575":{"type":"graphic_picture","displayName":"Endogenous Candida endophthalmitis","title":"Endogenous <EM>Candida</EM> endophthalmitis","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Endogenous <EM>Candida</EM> endophthalmitis</div><div class=\"cntnt\"><img style=\"width:475px; height:504px;\" src=\"images/ID/73575_Endogen_Cand_endophthalmit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endogenous <EM>Candida </EM>endophthalmitis showing fungal chorioretinal (white) lesions, not obscured by overlying vitritis.</div><div class=\"graphic_reference\">Courtesy of Marlene Durand, MD.</div><div id=\"graphicVersion\">Graphic 73575 Version 3.0</div></div></div>"},"73576":{"type":"graphic_picture","displayName":"Pityriasis alba 2","title":"Pityriasis alba","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pityriasis alba</div><div class=\"cntnt\"><img style=\"width:432px; height:303px;\" src=\"images/DERM/73576_Pityriasisalba2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pityriasis alba. Hypopigmented, slightly scaly macules are present on this child's cheeks.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73576 Version 2.0</div></div></div>"},"73578":{"type":"graphic_waveform","displayName":"ECG in atrial tachycardia","title":"Electrocardiogram in atrial tachycardia suggesting left atrial origin of the arrhythmia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram in atrial tachycardia suggesting left atrial origin of the arrhythmia</div><div class=\"cntnt\"><img style=\"width:323px; height:172px;\" src=\"images/CARD/73578_ECG_in_atrial_tachycardia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Leads aVL and V1 show a regular narrow QRS complex tachycardia with P waves present before each QRS complex. The P waves are abnormal when compared&nbsp;with those during sinus rhythm occurring after the tachycardia breaks (arrow). The P wave morphology&nbsp;- negative in aVL, positive in V1 - suggests a left atrial origin.</div><div id=\"graphicVersion\">Graphic 73578 Version 4.0</div></div></div>"},"73579":{"type":"graphic_picture","displayName":"Petroleum gauze","title":"Petroleum gauze","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Petroleum gauze</div><div class=\"cntnt\"><img style=\"width:468px; height:305px;\" src=\"images/OBGYN/73579_Petroleum_gauze.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 73579 Version 1.0</div></div></div>"},"73581":{"type":"graphic_diagnosticimage","displayName":"CT scan horseshoe kidney","title":"Computed tomographic scan of horseshoe kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomographic scan of horseshoe kidney</div><div class=\"cntnt\"><img style=\"width:400px; height:325px;\" src=\"images/PEDS/73581_CT_scan_horseshoe_kidney.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unenhanced&nbsp;computed tomographic&nbsp;scan of horseshoe kidney with bilateral calculi.</div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 73581 Version 6.0</div></div></div>"},"73583":{"type":"graphic_table","displayName":"Types trace minerals","title":"Macro-, trace-, and ultra-trace minerals in man","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Macro-, trace-, and ultra-trace minerals in man</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Macro-minerals</td> </tr> <tr> <td>Calcium&nbsp;</td> </tr> <tr> <td>Chloride&nbsp;</td> </tr> <tr> <td>Magnesium&nbsp;</td> </tr> <tr> <td>Phosphate&nbsp;</td> </tr> <tr> <td>Potassium&nbsp;</td> </tr> <tr> <td>Sodium</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Trace minerals</td> </tr> <tr> <td>Copper&nbsp;</td> </tr> <tr> <td>Iron</td> </tr> <tr> <td>Fluoride</td> </tr> <tr> <td>Manganese</td> </tr> <tr> <td>Zinc&nbsp;</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Ultra-trace minerals</td> </tr> <tr> <td>Arsenic</td> </tr> <tr> <td>Boron</td> </tr> <tr> <td>Chromium</td> </tr> <tr> <td>Iodine</td> </tr> <tr> <td>Molybdenum</td> </tr> <tr> <td>Nickel&nbsp;</td> </tr> <tr> <td>Selenium</td> </tr> <tr> <td>Silicon</td> </tr> <tr> <td>Vanadium</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73583 Version 2.0</div></div></div>"},"73585":{"type":"graphic_picture","displayName":"Bumble bee","title":"Bumble bee","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bumble bee</div><div class=\"cntnt\"><img style=\"width:432px; height:342px;\" src=\"images/ALLRG/73585_Bumble_bee.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 73585 Version 1.0</div></div></div>"},"73588":{"type":"graphic_table","displayName":"Interpretation of DLCO","title":"Interpretation of diffusing capacity of the lungs for carbon monoxide (DLCO)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretation of diffusing capacity of the lungs for carbon monoxide (DLCO)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Increased DLCO</td> </tr> <tr> <td class=\"indent1\">Altitude</td> </tr> <tr> <td class=\"indent1\">Asthma</td> </tr> <tr> <td class=\"indent1\">Polycythemia</td> </tr> <tr> <td class=\"indent1\">Severe obesity</td> </tr> <tr> <td class=\"indent1\">Pulmonary hemorrhage</td> </tr> <tr> <td class=\"indent1\">Left-to-right intracardiac shunting</td> </tr> <tr> <td class=\"indent1\">Mild left heart failure - increased pulmonary capillary blood volume</td> </tr> <tr> <td class=\"indent1\">Exercise just prior to the test - increased cardiac output</td> </tr> <tr> <td class=\"indent1\">Mueller maneuver</td> </tr> <tr> <td class=\"indent1\">Supine position</td> </tr> <tr> <td class=\"subtitle1_single\">Low DLCO with normal spirometry and normal lung volume</td> </tr> <tr> <td class=\"indent1\">Anemia - mild decrease</td> </tr> <tr> <td class=\"indent1\">Pulmonary vascular disease - mild to severe decrease</td> </tr> <tr> <td class=\"indent1\">Early interstitial lung disease - mild to moderate decrease</td> </tr> <tr> <td class=\"indent1\">Valsalva maneuver</td> </tr> <tr> <td class=\"subtitle1_single\">Low DLCO with obstruction with or without concomitant restriction</td> </tr> <tr> <td class=\"indent1\">Bronchiolitis</td> </tr> <tr> <td class=\"indent1\">Combined pulmonary fibrosis and emphysema (CPFE)</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> </tr> <tr> <td class=\"indent1\">Emphysema</td> </tr> <tr> <td class=\"indent1\">Interstitial lung disease in patient with COPD</td> </tr> <tr> <td class=\"indent1\">Lymphangioleiomyomatosis</td> </tr> <tr> <td class=\"indent1\">Sarcoid</td> </tr> <tr> <td class=\"subtitle1_single\">Low DLCO with restriction</td> </tr> <tr> <td class=\"indent1\">Interstitial lung disease</td> </tr> <tr> <td class=\"indent1\">Pneumonitis</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Carboxyhemoglobin - reduces DLCO</td> </tr> <tr> <td class=\"indent1\">Supplemental oxygen - reduces DLCO</td> </tr> <tr> <td class=\"indent1\">Bronchodilator - increases DLCO</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73588 Version 5.0</div></div></div>"},"73589":{"type":"graphic_figure","displayName":"CABG PI","title":"Coronary artery bypass graft surgery","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Coronary artery bypass graft surgery</div><div class=\"cntnt\"><img style=\"width:533px; height:599px;\" src=\"images/PI/73589_CABG_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During coronary artery bypass surgery, the surgeon removes a piece of blood vessel from the leg, chest, arm, or belly. Then the surgeon uses that piece of blood vessel (called a \"graft\") to reroute blood around the blocked artery. The surgery is called \"bypass surgery\" because it bypasses the blockage. Some people have more than 1 blocked artery bypassed. In this picture, the graft came from a vein in the leg called the \"saphenous vein.\" But grafts can come from other places, too.</div><div id=\"graphicVersion\">Graphic 73589 Version 5.0</div></div></div>"},"73591":{"type":"graphic_picture","displayName":"Granular parakeratosis","title":"Granular parakeratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Granular parakeratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/73591_Granular_parakeratosis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratotic red-brown papules are present in the axilla.</div><div id=\"graphicVersion\">Graphic 73591 Version 1.0</div></div></div>"},"73592":{"type":"graphic_picture","displayName":"Pediculosis corporis 2","title":"Pediculosis corporis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pediculosis corporis</div><div class=\"cntnt\"><img style=\"width:432px; height:399px;\" src=\"images/DERM/73592_Pediculosis_corporis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient presented with widespread hyperpigmentation, lichenification, and excoriations, most severe on his legs. His socks were covered with numerous nits and adult and immature lice.</div><div class=\"graphic_reference\">Copyright © Chris Ha, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 73592 Version 7.0</div></div></div>"},"73593":{"type":"graphic_diagnosticimage","displayName":"Choanal atresia","title":"CT scan of choanal atresia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of choanal atresia</div><div class=\"cntnt\"><img style=\"width:298px; height:546px;\" src=\"images/ALLRG/73593_Choanal_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image A shows bilateral choanal atresia. The bony atresia plate is seen (arrows), as well as retained secretions in the posterior nasal cavity (arrowhead). Image B shows normal anatomy.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Marilene B Wang, MD.</div><div id=\"graphicVersion\">Graphic 73593 Version 4.0</div></div></div>"},"73594":{"type":"graphic_movie","displayName":"Echo MR in MI apical long axis color Doppler echo","title":"Echocardiogram apical long axis post MI mitral regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram apical long axis post MI mitral regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/73594_aplacmrmconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:238px; height:415px;\" src=\"images/CARD/73594_aplacmrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical long axis view from a 2-D echocardiogram with color flow Doppler shows mitral regurgitation with a jet directed toward the posterior left atrial wall. The etiology is papillary muscle dysfunction from a prior inferior wall myocardial infarction.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 73594 Version 3.0</div></div></div>"},"73597":{"type":"graphic_picture","displayName":"Placenta increta","title":"Placenta increta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Placenta increta</div><div class=\"cntnt\"><img style=\"width:298px; height:445px;\" src=\"images/OBGYN/73597_Placentaincreta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Clusters of villi are entirely surrounded by myometrium without intervening decidua. Implantation site trophoblast can be seen scattered throughout the myometrium (arrows).<br />(B) Higher power of panel A.</div><div class=\"graphic_reference\">Courtesy of Miriam D Post, MD.</div><div id=\"graphicVersion\">Graphic 73597 Version 2.0</div></div></div>"},"73599":{"type":"graphic_diagnosticimage","displayName":"Oblique fracture of the proximal phalanx of the great toe ","title":"Oblique fracture of the proximal phalanx of the great toe ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oblique fracture of the proximal phalanx of the great toe </div><div class=\"cntnt\"><img style=\"width:224px; height:504px;\" src=\"images/EM/73599_Oblique_fx_prox_phalanx_grt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the clear break in the cortex at the medial base of the phalanx.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 73599 Version 4.0</div></div></div>"},"73600":{"type":"graphic_table","displayName":"CT EUS and EUS-FNA for esoph cancer staging","title":"Prospective comparison of CT, EUS and EUS FNA for preoperative lymph node staging of esophageal carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prospective comparison of CT, EUS and EUS FNA for preoperative lymph node staging of esophageal carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Sensitivity*</td> <td class=\"subtitle1\">Specificity*</td> </tr> <tr> <td><strong>CT</strong></td> <td class=\"centered\">29 (17 to 44)</td> <td class=\"centered\">89 (72 to 98)</td> </tr> <tr> <td><strong>EUS</strong></td> <td class=\"centered\">71 (56 to 83)</td> <td class=\"centered\">79 (59 to 92)</td> </tr> <tr> <td><strong>EUS FNA</strong></td> <td class=\"centered\">83 (70 to 93)</td> <td class=\"centered\">93 (77 to 99)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; EUS: endoscopic ultrasound; FNA: fine-needle aspiration.<br />* Data shown represent percentages (95% CI).</div><div class=\"graphic_reference\">Data from: Vazquez-Sequeiros E, Clain JE, Norton ID, et al, Gastroenterology 2003; 125:1626.</div><div id=\"graphicVersion\">Graphic 73600 Version 6.0</div></div></div>"},"73602":{"type":"graphic_figure","displayName":"Retinoblastoma formation","title":"The genetics of retinoblastoma formation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The genetics of retinoblastoma formation</div><div class=\"cntnt\"><img style=\"width:411px; height:553px;\" src=\"images/ONC/73602_Retinoblastoma_formation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The <EM>RB1</EM> gene is located on human chromosome 13. In&nbsp;hereditary retinoblastoma, the fertilized egg carries one defective copy of the <EM>RB1</EM> gene, and all retinal cells in this offspring carry only a single functional <EM>RB1</EM> gene copy. If this surviving copy is eliminated in a retinal cell by a&nbsp;nonheritable mutation (the second hit of the Knudson two-hit hypothesis), the cell will lack <EM>RB1</EM> gene function and will proliferate into a tumor. In&nbsp;nonheritable retinoblastoma, the fertilized egg is genetically wild type at the<EM> RB1 </EM>locus. In the retina of this offspring, retinoblastoma development requires two successive&nbsp;nonheritable mutations striking both copies of the<EM> RB1 </EM>gene in the retinal precursor cells. Because only a single&nbsp;nonheritable mutation is needed to eliminate <EM>RB1</EM> function in familial cases, multiple cells in both eyes are affected. In contrast, the two&nbsp;nonheritable mutations required in&nbsp;nonheritable disease are unlikely to affect a single cell lineage, yielding at most one tumor.</div><div id=\"graphicVersion\">Graphic 73602 Version 4.0</div></div></div>"},"73607":{"type":"graphic_picture","displayName":"HSTCL spleen","title":"Hepatosplenic T-cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hepatosplenic T-cell lymphoma</div><div class=\"cntnt\"><img style=\"width:504px; height:380px;\" src=\"images/HEME/73607_HSTCLdilatedsinuses.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Splenectomy specimen shows dilated sinuses, filled with lymphoma cells. Hematoxylin and eosin, 40x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry and Immunochemistry for Hematologic Neoplasms, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 73607 Version 8.0</div></div></div>"},"73611":{"type":"graphic_table","displayName":"Drugs that can induce Brugada-like ECG patterns","title":"Drugs that can induce Brugada-like patterns on the surface electrocardiogram (ECG)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs that can induce Brugada-like patterns on the surface electrocardiogram (ECG)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Antiarrhythmic or antianginal drugs</td> </tr> <tr> <td class=\"sublist2_start\">Cardiac sodium channel blockers (some have been used for drug challenge in patients with Brugada type 2 or 3 ECG pattern)</td> </tr> <tr> <td class=\"sublist2\">Class IC drugs (flecainide, pilsicainide, propafenone)</td> </tr> <tr> <td class=\"sublist2\">Class IA drugs (ajmaline, procainamide, disopyramide, cibenzoline)</td> </tr> <tr> <td class=\"sublist2\">Lithium</td> </tr> <tr> <td class=\"indent1\">Calcium channel blockers</td> </tr> <tr> <td class=\"indent1\">Beta blockers</td> </tr> <tr> <td class=\"indent1\">Nitrates</td> </tr> <tr> <td class=\"indent1\">Nicorandil (a potassium channel opener)</td> </tr> <tr> <td class=\"subtitle1_single\">Psychotropic drugs</td> </tr> <tr> <td class=\"sublist2_start\">Tricyclic antidepressants</td> </tr> <tr> <td class=\"sublist2\">Amitriptyline</td> </tr> <tr> <td class=\"sublist2\">Nortriptyline</td> </tr> <tr> <td class=\"sublist2\">Desipramine</td> </tr> <tr> <td class=\"sublist2\">Clomipramine</td> </tr> <tr> <td class=\"sublist2_start\">Tetracyclic antidepressants</td> </tr> <tr> <td class=\"sublist2\">Maprotiline</td> </tr> <tr> <td class=\"sublist2_start\">Phenothiazines</td> </tr> <tr> <td class=\"sublist2\">Perphenazine</td> </tr> <tr> <td class=\"sublist2\">Cyamemazine</td> </tr> <tr> <td class=\"sublist2_start\">Selective serotonin reuptake inhibitors</td> </tr> <tr> <td class=\"sublist2\">Fluoxetine</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Dimenhydrinate</td> </tr> <tr> <td class=\"indent1\">Cocaine intoxication</td> </tr> <tr> <td class=\"indent1\">Alcohol intoxication</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111:659.</div><div id=\"graphicVersion\">Graphic 73611 Version 5.0</div></div></div>"},"73613":{"type":"graphic_figure","displayName":"Heel pain exercises PI","title":"Exercises that can help with heel pain","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Exercises that can help with heel pain</div><div class=\"cntnt\"><img style=\"width:586px; height:481px;\" src=\"images/PI/73613_Heel_pain_exercises_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73613 Version 1.0</div></div></div>"},"73615":{"type":"graphic_picture","displayName":"Acne excoriee des jeunes filles","title":"Acne excoriée des jeunes filles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acne excori&eacute;e des jeunes filles</div><div class=\"cntnt\"><img style=\"width:432px; height:307px;\" src=\"images/PC/73615_Excoriee_des_jeunes_filles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple excoriations are present on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73615 Version 5.0</div></div></div>"},"73616":{"type":"graphic_picture","displayName":"Pleomorphic calcifications","title":"Pleomorphic calcifications (suspicious)","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Pleomorphic calcifications (suspicious)</div><div class=\"cntnt\"><img style=\"width:478px; height:573px;\" src=\"images/PC/73616_Pleomorphic_calcifications.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three different cases of pleomorphic calcifications seen in a segmental distribution in Panel A; faint, with some linear branching calcifications in Panels B and C.</div><div id=\"graphicVersion\">Graphic 73616 Version 1.0</div></div></div>"},"73618":{"type":"graphic_table","displayName":"Drugs associated with isolated thrombocytopenia","title":"Drugs associated with isolated thrombocytopenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs associated with isolated&nbsp;thrombocytopenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Mechanism(s)</td> </tr> <tr> <td><strong>Abciximab</strong></td> <td>DITP</td> </tr> <tr> <td>Acetaminophen</td> <td>DITP; antibodies&nbsp;react with&nbsp;a drug metabolite, not the&nbsp;unmodified drug</td> </tr> <tr> <td>Alemtuzumab</td> <td>ITP-like syndrome*</td> </tr> <tr> <td>Amiodarone</td> <td>DITP</td> </tr> <tr> <td><strong>Beta-lactam antibiotics (eg, penicillins, cephalosporins)</strong></td> <td>DITP</td> </tr> <tr> <td><strong>Carbamazepine</strong></td> <td>DITP</td> </tr> <tr> <td>Ceftriaxone</td> <td>DITP</td> </tr> <tr> <td>Daptomycin</td> <td>Bone marrow suppression (dose-dependent)</td> </tr> <tr> <td><strong>Eptifibatide</strong></td> <td>DITP</td> </tr> <tr> <td>Ethambutol</td> <td>DITP</td> </tr> <tr> <td>Furosemide</td> <td>DITP</td> </tr> <tr> <td><strong>Gold compounds</strong></td> <td>Bone marrow suppression</td> </tr> <tr> <td>Haloperidol</td> <td>DITP</td> </tr> <tr> <td><strong>Heparin</strong></td> <td>Drug-dependent antibodies that also activate platelets and are associated with thrombosis</td> </tr> <tr> <td>Ibuprofen</td> <td>DITP;&nbsp;in some patients, antibodies react with the unmodified drug; in others, antibodies&nbsp;only react with a drug metabolite</td> </tr> <tr> <td>Irinotecan</td> <td>DITP</td> </tr> <tr> <td>Levofloxacin</td> <td>DITP</td> </tr> <tr> <td><strong>Linezolid</strong></td> <td>Bone marrow suppression (dose-dependent)</td> </tr> <tr> <td><strong>MMR vaccine</strong></td> <td>ITP-like syndrome*</td> </tr> <tr> <td>Mirtazapine</td> <td>DITP</td> </tr> <tr> <td>Naproxen</td> <td>DITP;&nbsp;antibodies react with a drug metabolite, not the unmodified drug</td> </tr> <tr> <td>Oxaliplatin</td> <td>DITP</td> </tr> <tr> <td>Penicillin</td> <td>DITP</td> </tr> <tr> <td><strong>Phenytoin</strong></td> <td>DITP</td> </tr> <tr> <td><strong>Piperacillin</strong></td> <td>DITP</td> </tr> <tr> <td><strong>Quinidine</strong></td> <td>DITP</td> </tr> <tr> <td><strong>Quinine<sup>&#182;</sup></strong></td> <td>DITP</td> </tr> <tr> <td>Ranitidine</td> <td>DITP</td> </tr> <tr> <td><strong>Rifampin</strong></td> <td>DITP</td> </tr> <tr> <td>Simvastatin</td> <td>DITP</td> </tr> <tr> <td><strong>Sulfonamides</strong></td> <td>DITP</td> </tr> <tr> <td>Suramin</td> <td>DITP</td> </tr> <tr> <td><strong>Tirofiban</strong></td> <td>DITP</td> </tr> <tr> <td><strong>Trimethoprim-sulfamethoxazole</strong></td> <td>DITP; antibodies react with the sulfamethoxazole; antibodies to trimethoprim have not been identified</td> </tr> <tr> <td><strong>Valproic acid</strong></td> <td>Bone marrow suppression (dose-dependent)</td> </tr> <tr> <td><strong>Vancomycin<sup>&#916;</sup></strong></td> <td>DITP</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table lists drugs with evidence for a causal association with isolated thrombocytopenia; certain foods and beverages (eg, quinine-containing beverages, certain herbal teas, walnuts) can also cause thrombocytopenia. The drugs listed&nbsp;in this table come from&nbsp;clinical data in published case reports, identification of drug-dependent, platelet-reactive antibodies, or both; it also lists their mechanisms. Criteria for evaluating reports of a drug-induced etiology include: (1)&nbsp;use of the&nbsp;drug preceded development of thrombocytopenia <EM>and</EM> platelet count recovery was sustained and complete following drug discontinuation; (2) no other drugs were used prior to development of thrombocytopenia <EM>or</EM> platelet count remained normal&nbsp;despite continuation&nbsp;or reintroduction of other drugs; (3) other etiologies for thrombocytopenia were eliminated; and (4) re-exposure to the candidate drug caused recurrent thrombocytopenia<EM> o</EM>r drug-dependent antiplatelet antibodies were demonstrated.&nbsp;Drugs in <STRONG>bold</STRONG> have been most commonly implicated in a causal relationship. Drug-dependent antibodies have been shown for all agents associated with DITP. Refer to UpToDate&nbsp;for additional information on&nbsp;drug-induced thrombocytopenia.</div><div class=\"graphic_footnotes\">DITP: drug-induced immune thrombocytopenia (ie, thrombocytopenia caused by drug-dependent antibodies); ITP: immune thrombocytopenia, which is caused by an autoimmune mechanism that no longer requires the presence of the drug; MMR: measles, mumps, and&nbsp;rubella.<br />* A rare adverse reaction to alemtuzumab results in prolonged, severe thrombocytopenia that responds to&nbsp;immunosuppressive therapy.<br />¶&nbsp;Quinine can also cause a thrombotic microangiopathy and/or other cytopenias.<br />Δ In addition to parenteral formulations, vancomycin may be present in orthopedic cement used for joint replacement.</div><div class=\"graphic_reference\">Adapted from Reese JA, Li X, Hauben M, et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood 2010; 116:2127; George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129:886; and Arnold DM, Nazi I, Warkentin TE, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia.&nbsp;Transfusion Med Reviews, 2013; 27:137.</div><div id=\"graphicVersion\">Graphic 73618 Version 16.0</div></div></div>"},"73620":{"type":"graphic_table","displayName":"Rx enterococci UTI","title":"Oral therapy for susceptible enterococcal lower urinary tract infections*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral therapy for susceptible enterococcal lower urinary tract infections*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Adult dose</td> <td class=\"subtitle1\">Pediatric dose</td> </tr> <tr class=\"divider_bottom\"> <td>Nitrofurantoin<sup>&#182;</sup></td> <td>100 mg (macrocrystals/monohydrate delayed release) twice daily for five days</td> <td> <p>Children &#8804;12 years: 5 to 7 mg/kg per day (oral suspension) in four divided doses (maximum 400 mg per day) for five days</p> Children &#62;12 years: Refer to adult dose</td> </tr> <tr class=\"divider_bottom\"> <td>Fosfomycin</td> <td>3 g (single dose)</td> <td> <p>Children &#60;12 years: Insufficient data</p> Children &#8805;12 years: Refer to adult dose</td> </tr> <tr class=\"divider_bottom\"> <td>Amoxicillin<sup>&#916;</sup></td> <td>875 mg twice daily for five days</td> <td>25 to 50 mg/kg per day in three divided doses (maximum 1750 mg per day) for five days</td> </tr> <tr class=\"divider_bottom\"> <td>Amoxicillin-clavulanate</td> <td>875 mg (amoxicillin component) twice daily for five days</td> <td>25 to 45 mg/kg (amoxicillin component<sup>&#9674;</sup>) per day in two divided doses (maximum 1750 mg per day) for five days</td> </tr> <tr> <td>Penicillin V potassium</td> <td>500 mg four times daily for five days</td> <td>25 to 50 mg/kg per day in four divided doses (maximum 2 g per day) for five days</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Doses are for patients with normal renal function.<br />¶ Use of nitrofurantoin is not recommended in the setting of moderate or severe renal impairment. Taking the&nbsp;oral suspension with food is preferred. A higher daily dose of nitrofurantoin oral suspension is suggested in children ≤12 years (relative to adults and children &gt;12 years) due to formulation differences and resultant urinary tract concentrations.<br />Δ Infections due to beta-lactamase-producing enterococci requiring oral therapy may be treated with amoxicillin-clavulanate.<br /><FONT class=lozenge>◊</FONT> Dose shown is for 7:1 ratio preparation of amoxicillin to clavulanate (eg, amoxicillin 200 mg and clavulanate 28.5 mg or amoxicillin 400 mg and clavulanate 57 mg per 5 mL oral suspension or chewable tablet); if a 4:1 ratio preparation is used (eg, amoxicillin 125 mg and clavulanate 31.25 mg or amoxicillin 250 mg and clavulanate 62.5 mg per 5 mL oral suspension), the dose is 20 to 40 mg/kg per day in three divided doses (maximum 1500 mg per day) for five days.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 73620 Version 11.0</div></div></div>"},"73621":{"type":"graphic_movie","displayName":"TEE sinus venosus defect","title":"Sinus venosus defect viewed by transesophageal echocardiogram","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sinus venosus defect viewed by transesophageal echocardiogram</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/73621_sinveteeconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:432px; height:307px;\" src=\"images/CARD/73621_sinveteeedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SVC: superior vena cava; RA: right atrium.</div><div class=\"graphic_reference\">Courtesy of Dr. Brian Soriano.</div><div id=\"graphicVersion\">Graphic 73621 Version 8.0</div></div></div>"},"73622":{"type":"graphic_table","displayName":"Exit site scoring system","title":"Peritoneal catheter exit-site scoring system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Peritoneal catheter exit-site scoring system</div><div class=\"cntnt\"><table style=\"width: 628px; height: 246px;\" cellspacing=\"0\">\n\t\t<tbody>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1\">&nbsp;</td>\n\n\t\t\t\t<td class=\"subtitle1\">0 points</td>\n\n\t\t\t\t<td class=\"subtitle1\">1 point</td>\n\n\t\t\t\t<td class=\"subtitle1\">2 points</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Swelling</td>\n\n\t\t\t\t<td>No</td>\n\n\t\t\t\t<td>Exit only; &#60;0.5 cm</td>\n\n\t\t\t\t<td>&#62;0.5 and/or tunnel</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Crust</td>\n\n\t\t\t\t<td>No</td>\n\n\t\t\t\t<td>&#60;0.5 cm</td>\n\n\t\t\t\t<td>&#62;0.5 cm</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Redness</td>\n\n\t\t\t\t<td>No</td>\n\n\t\t\t\t<td>&#60;0.5 cm</td>\n\n\t\t\t\t<td>&#62;0.5 cm</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Pain</td>\n\n\t\t\t\t<td>No</td>\n\n\t\t\t\t<td>Slight</td>\n\n\t\t\t\t<td>Severe</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Drainage</td>\n\n\t\t\t\t<td>No</td>\n\n\t\t\t\t<td>Serous</td>\n\n\t\t\t\t<td>Purulent</td>\n\t\t\t</tr>\n\t\t</tbody>\n\t</table></div><div class=\"graphic_lgnd\">Infection should be assumed with exit-site score of 4 or greater. Purulent drainage, even if alone, is sufficient to indicate infection. A score of less than 4 may not represent infection.</div><div class=\"graphic_reference\">Reproduced with permission from: Piraino, B, Bailie, GR, Bernardini, J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25:107. Copyright &#169; 2005 Peritoneal Dialysis International.</div><div id=\"graphicVersion\">Graphic 73622 Version 2.0</div></div></div>"},"73624":{"type":"graphic_diagnosticimage","displayName":"CW Doppler AS mild","title":"Mild aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mild aortic stenosis</div><div class=\"cntnt\"><img style=\"width:273px; height:228px;\" src=\"images/CARD/73624_CW_Doppler_AS_mild.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Continuous wave Doppler echocardiogram shows a peak velocity across the aortic valve of 2.7 m/sec or a gradient of 30 mmHg, which is compatible with mild aortic stenosis. No aortic regurgitation is seen.</div><div class=\"graphic_reference\">Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.</div><div id=\"graphicVersion\">Graphic 73624 Version 4.0</div></div></div>"},"73627":{"type":"graphic_table","displayName":"ROMAN mnemonic for difficult bag mask ventilation","title":"ROMAN mnemonic for difficult bag mask ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ROMAN mnemonic for difficult bag mask ventilation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>R</strong>adiation (head and neck)/<strong>R</strong>estriction (poor lung compliance)</td> </tr> <tr> <td><strong>O</strong>besity/<strong>O</strong>bstruction (upper airway)/<strong>O</strong>bstructive sleep apnea</td> </tr> <tr> <td><strong>M</strong>ask seal/<strong>M</strong>allampati/<strong>M</strong>ale</td> </tr> <tr> <td><strong>A</strong>ge over 55 years</td> </tr> <tr> <td><strong>N</strong>o teeth</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Brown III CA, Walls RM. Identification of the difficult and failed airway. In: The Walls Manual of Emergency Airway Management, 5th ed, Brown III CA, Sakles JC, Mick NW (Eds), Wolters Kluwer, Philadelphia 2018.</div><div id=\"graphicVersion\">Graphic 73627 Version 6.0</div></div></div>"},"73628":{"type":"graphic_figure","displayName":"Adrenal androgens and age","title":"Adrenal androgen production declines with age","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Adrenal androgen production declines with age</div><div class=\"cntnt\"><img style=\"width:542px; height:248px;\" src=\"images/ENDO/73628_Adrenal_androgens_and_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urinary 17-ketosteroid excretion and DHEA-S concentrations as a function of age in normal women. There is a progressive decline in both measurements after age 20 years.</div><div class=\"graphic_footnotes\">DHEA-S: dehydroepiandrosterone sulfate.</div><div class=\"graphic_reference\">Data from: Zumoff B, Rosenfield RS, Strain GW, et al. Sex differences in the twenty-four-hour mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone sulfate (DHAS) and the DHA to DHAS ratio in normal adults.&nbsp;J Clin Endocrinol Metab 1980; 51:330.</div><div id=\"graphicVersion\">Graphic 73628 Version 3.0</div></div></div>"},"73629":{"type":"graphic_figure","displayName":"Bone density with raloxifene","title":"Bone mineral density increases with raloxifene in postmenopausal women","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Bone mineral density increases with raloxifene in postmenopausal women</div><div class=\"cntnt\"><img style=\"width:468px; height:404px;\" src=\"images/ENDO/73629_Bone_density_with_raloxifen.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Administration of raloxifene at varying doses (30 mg, black dashed line; 60 mg, green line; 150 mg, blue dotted line) resulted in an increase in bone mineral density compared&nbsp;with placebo (black dotted line) in all sites tested over the two-year follow-up period.</div><div class=\"graphic_reference\">Data from: Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641.</div><div id=\"graphicVersion\">Graphic 73629 Version 3.0</div></div></div>"},"73631":{"type":"graphic_diagnosticimage","displayName":"Echogenic fetal bowel","title":"Echogenic fetal bowel","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Echogenic fetal bowel</div><div class=\"cntnt\"><img style=\"width:606px; height:388px;\" src=\"images/OBGYN/73631_Echogenicbowel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this longitudinal image, arrow points to a very echogenic portion of fetal bowel that is as echodense as fetal bone.</div><div class=\"graphic_reference\">Courtesy of Beryl R Benacerraf, MD.</div><div id=\"graphicVersion\">Graphic 73631 Version 4.0</div></div></div>"},"73634":{"type":"graphic_table","displayName":"Asthma control 5 to 11 yrs","title":"Assessing asthma control in children 5 to 11 years of age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessing asthma control in children 5 to 11 years of age</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">Components of control</td> <td class=\"subtitle1\" colspan=\"3\">Classification of asthma control (children 5 to 11 years of age)</td> </tr> <tr> <td class=\"subtitle2\">Well controlled</td> <td class=\"subtitle2\">Not well controlled</td> <td class=\"subtitle2\">Very poorly controlled</td> </tr> <tr> <td rowspan=\"7\">Impairment</td> <td>Symptoms</td> <td>&#8804;2 days/week, but not more than once on each day</td> <td>&#62;2 days/week or multiple times on &#8804;2 days/week</td> <td>Throughout the day</td> </tr> <tr> <td>Nighttime awakenings</td> <td>&#8804;1 time/month</td> <td>&#8805;2 times/month</td> <td>&#8805;2 times/week</td> </tr> <tr> <td>Interference with normal activity</td> <td>None</td> <td>Some limitation</td> <td>Extremely limited</td> </tr> <tr> <td>Short-acting beta<sub>2</sub>-agonist use for symptom control (not prevention of EIB)</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week</td> <td>Several times per day</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Lung function</td> </tr> <tr> <td class=\"sublist1\">FEV<sub>1</sub> or peak flow</td> <td class=\"sublist_other\">&#62;80% predicted/personal best</td> <td class=\"sublist_other\">60 to 80% predicted/personal best</td> <td class=\"sublist_other\">&#60;60% predicted/personal best</td> </tr> <tr> <td class=\"sublist1\">FEV<sub>1</sub>/FVC</td> <td class=\"sublist_other\">&#62;80%</td> <td class=\"sublist_other\">75 to 80%</td> <td class=\"sublist_other\">&#60;75%</td> </tr> <tr> <td rowspan=\"3\">Risk</td> <td rowspan=\"2\"><strong>Exacerbations requiring oral systemic glucocorticoids</strong></td> <td><strong>0 to 1/year</strong></td> <td colspan=\"2\"><strong>&#8805;2/year (see footnote)</strong></td> </tr> <tr> <td colspan=\"3\"><strong>Consider severity and interval since last exacerbation</strong></td> </tr> <tr> <td>Treatment-related adverse effects</td> <td colspan=\"3\">Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's/caregiver's recall of previous&nbsp;two to four&nbsp;weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had ≥2 exacerbations requiring oral systemic&nbsp;glucocorticoids in the past year may be considered the same as patients who have not well-controlled asthma, even in the absence of impairment levels consistent with not well-controlled asthma.</div><div class=\"graphic_footnotes\">EIB: exercise-induced bronchospasm; FEV<sub>1</sub>: forced expiratory volume in 1 second; FVC: forced vital capacity; ICU: intensive care unit.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 73634 Version 3.0</div></div></div>"},"73635":{"type":"graphic_table","displayName":"Drug and toxin related electrolyte change","title":"Drug- and toxin-induced electrolyte abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug- and toxin-induced electrolyte abnormalities</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hyperkalemia</td> </tr> <tr> <td>Cardiac glycosides</td> </tr> <tr> <td>Fluoride</td> </tr> <tr> <td class=\"subtitle1_single\">Hypokalemia</td> </tr> <tr> <td class=\"sublist1_start\">Beta-adrenergic agonists</td> </tr> <tr> <td class=\"sublist1\">Albuterol</td> </tr> <tr> <td class=\"sublist1\">Theophylline</td> </tr> <tr> <td class=\"sublist1\">Epinephrine</td> </tr> <tr> <td class=\"sublist1\">Methylphenidate</td> </tr> <tr> <td class=\"sublist1\">Caffeine</td> </tr> <tr> <td>Diuretics</td> </tr> <tr> <td>Toluene</td> </tr> <tr> <td>Barium</td> </tr> <tr> <td class=\"subtitle1_single\">Hypocalcemia</td> </tr> <tr> <td>Ethylene glycol</td> </tr> <tr> <td>Oxalate</td> </tr> <tr> <td>Fluoride</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hyperglycemia</td> </tr> <tr> <td class=\"sublist1_start\">Beta-adrenergic agonists</td> </tr> <tr> <td class=\"sublist1\">Albuterol</td> </tr> <tr> <td class=\"sublist1\">Theophylline</td> </tr> <tr> <td class=\"sublist1\">Epinephrine</td> </tr> <tr> <td class=\"sublist1\">Caffeine</td> </tr> <tr> <td>Calcium channel blockers</td> </tr> <tr> <td>Iron</td> </tr> <tr> <td>Vacor (rodenticide)</td> </tr> <tr> <td class=\"subtitle1_single\">Hypoglycemia</td> </tr> <tr> <td>Ackee fruit (unripe)</td> </tr> <tr> <td>Beta blockers</td> </tr> <tr> <td>Insulin</td> </tr> <tr> <td>Oral hypoglycemic agents</td> </tr> <tr> <td>Ethanol</td> </tr> <tr> <td>Quinine</td> </tr> <tr> <td>Salicylate</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73635 Version 6.0</div></div></div>"},"73637":{"type":"graphic_table","displayName":"Treatment of latent tuberculosis in pregnancy","title":"Treatment of latent tuberculosis in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of latent tuberculosis in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\">Duration</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Preferred regimens</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Isoniazid*</td> <td>5 mg/kg (up to 300 mg) orally</td> <td>Daily</td> <td>Nine months</td> </tr> <tr class=\"divider_bottom\"> <td>15 mg/kg (up to 900 mg) orally</td> <td>Twice weekly<sup>&#182;</sup></td> <td>Nine months</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Alternative regimens</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Isoniazid*</td> <td>5 mg/kg (up to 300 mg) orally</td> <td>Daily</td> <td>Six months</td> </tr> <tr> <td>15 mg/kg (up to 900 mg) orally</td> <td>Twice weekly<sup>&#182;</sup></td> <td>Six months</td> </tr> <tr> <td class=\"indent1\">Rifampin</td> <td>600 mg orally</td> <td>Daily</td> <td>Four months</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Pyridoxine (vitamin B6; 25 to 50 mg daily) should be administered to pregnant women receiving isoniazid as well as to infants of breastfeeding mothers receiving isoniazid.<br />¶ Twice-weekly regimens must be administered with directly observed therapy.</div><div id=\"graphicVersion\">Graphic 73637 Version 8.0</div></div></div>"},"73638":{"type":"graphic_movie","displayName":"Laser resection of bronchial carcinoid tumor","title":"Bronchoscopic laser resection","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoscopic laser resection</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/73638_brlasvapconv.mp4\" style=\"width:240px;height:196px\"></div><img style=\"width:197px; height:177px;\" src=\"images/CARD/73638_brlasvap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Video shows vaporization of a smooth walled bronchial carcinoid tumor with a Nd:YAG laser. The Nd:YAG light is invisible, but a red helium-neon aiming beam can be seen.</div><div class=\"graphic_reference\">Courtesy of Henri G Colt, MD, and Praveen Mathur, MD.</div><div id=\"graphicVersion\">Graphic 73638 Version 2.0</div></div></div>"},"73639":{"type":"graphic_movie","displayName":"Dissection of the descending aorta on TEE","title":"Dissection of the descending aorta on transesophageal echocardiography","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dissection of the descending aorta on transesophageal echocardiography</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/73639_teedeaodconv.mp4\" style=\"width:431px;height:322px\"></div><img style=\"width:278px; height:283px;\" src=\"images/CARD/73639_teedeaod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows a large dissection of the descending aorta. Spontaneous echo contrast is seen in the false lumen, resulting from&nbsp;stagnant blood flow.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 73639 Version 4.0</div></div></div>"},"73642":{"type":"graphic_picture","displayName":"Uric acid crystals under polarized light","title":"Uric acid crystals under polarized light","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uric acid crystals under polarized light</div><div class=\"cntnt\"><img style=\"width:360px; height:256px;\" src=\"images/NEPH/73642_Uric_acid_crystals_polarize.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment showing uric acid crystals viewed under polarized light.</div><div class=\"graphic_reference\">Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.</div><div id=\"graphicVersion\">Graphic 73642 Version 2.0</div></div></div>"},"73643":{"type":"graphic_diagnosticimage","displayName":"Bilateral facet dislocation xray","title":"Bilateral facet dislocations (C4/C5)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral facet dislocations (C4/C5)</div><div class=\"cntnt\"><img style=\"width:288px; height:416px;\" src=\"images/EM/73643_Facet_dislocatn_bilat1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral facet dislocations occur when flexion forces extend anteriorly, causing the inferior articulating facets of the upper vertebra to pass over the superior facets of the lower vertebra. Complete spinal cord injury most often results.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD</div><div id=\"graphicVersion\">Graphic 73643 Version 2.0</div></div></div>"},"73644":{"type":"graphic_algorithm","displayName":"Neck stiffness in the well-appearing child","title":"Neck stiffness or torticollis without major trauma, fever, or neurologic abnormality in the well-appearing child","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Neck stiffness or torticollis without major trauma, fever, or neurologic abnormality in the well-appearing child</div><div class=\"cntnt\"><img style=\"width:482px; height:375px;\" src=\"images/EM/73644_Neck_stiff_well_appear_algo.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73644 Version 3.0</div></div></div>"},"73646":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound Doppler renal agenesis","title":"Prenatal ultrasound Doppler bilateral renal agenesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound Doppler bilateral renal agenesis</div><div class=\"cntnt\"><img style=\"width:432px; height:270px;\" src=\"images/OBGYN/73646_Doppler_renal_agenesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 73646 Version 3.0</div></div></div>"},"73647":{"type":"graphic_waveform","displayName":"LA PCWP mitral valve","title":"Left atrial and pulmonary capillary wedge pressures in mitral regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial and pulmonary capillary wedge pressures in mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:405px; height:214px;\" src=\"images/CARD/73647_LA_PCWP_mitral_valve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure tracings in mitral regurgitation. Although the mean pulmonary capillary wedge (PCW) and left atrial (LA) pressures are equivalent, a damped PCW pressure tracing obscures the waveforms, and the tall &quot;v&quot; wave of mitral regurgitation, seen on the LA tracing, is absent on the PCW tracing.</div><div class=\"graphic_reference\">Redrawn from Kern MJ (Ed). Hemodynamic Rounds: Interpretation of Cardiac Pathophysiology from Pressure Waveform Analysis, Wiley-Liss, New York, 1993.</div><div id=\"graphicVersion\">Graphic 73647 Version 4.0</div></div></div>"},"73648":{"type":"graphic_picture","displayName":"Asbestos pleural plaques","title":"Pleural plaques","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural plaques</div><div class=\"cntnt\"><img style=\"width:239px; height:371px;\" src=\"images/PULM/73648_Asbestos_pleural_plaques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross appearance at autopsy of asbestos-associated pleural plaques overlying the lateral thoracic wall.</div><div class=\"graphic_reference\">Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org</div><div id=\"graphicVersion\">Graphic 73648 Version 2.0</div></div></div>"},"73651":{"type":"graphic_picture","displayName":"Café-au-lait macule 1","title":"Café-au-lait macules","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Café-au-lait macules</div><div class=\"cntnt\"><img style=\"width:487px; height:475px;\" src=\"images/DERM/73651_Cafe-au-lait_macule_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple café-au-lait macules were present on this young boy with neurofibromatosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73651 Version 5.0</div></div></div>"},"73652":{"type":"graphic_movie","displayName":"TEE 4 chamber view tricuspid valve vegetation","title":"Transesophageal echocardiogram (TEE) mid-esophageal 4 chamber view showing a tricuspid valve vegetation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram (TEE) mid-esophageal 4 chamber view showing a tricuspid valve vegetation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/73652_tricvegeconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:320px; height:240px;\" src=\"images/CARD/73652_tricvege.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transesophageal echocardiography showing a large vegetation in the tricuspid valve in a patient with subacute bacterial endocarditis.</div><div class=\"graphic_reference\">Courtesy of Roberto Lang, MD.</div><div id=\"graphicVersion\">Graphic 73652 Version 3.0</div></div></div>"},"73654":{"type":"graphic_picture","displayName":"LCDD tubules IF","title":"Light chain deposition disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light chain deposition disease</div><div class=\"cntnt\"><img style=\"width:378px; height:236px;\" src=\"images/NEPH/73654_LCDD_tubules_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy in light chain deposition disease involving the kidney. There is intense staining with anti-kappa light chain antibodies along the tubular basement membranes.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 73654 Version 1.0</div></div></div>"},"73655":{"type":"graphic_figure","displayName":"Age related incidence of epilepsy","title":"Age-related incidence of epilepsy","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Age-related incidence of epilepsy</div><div class=\"cntnt\"><img style=\"width:455px; height:266px;\" src=\"images/NEURO/73655_Age_related_incidence_epile.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Hauser, WA, Annegers, JF, Kurland, LT. The incidence of epilepsy and unprovoked seizures in Rochester, Minnesota, 1935-1984. Epilepsia 1993; 34:453.</div><div id=\"graphicVersion\">Graphic 73655 Version 2.0</div></div></div>"},"73656":{"type":"graphic_figure","displayName":"Cerebellar arteries","title":"Major cerebellar arterial branches","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Major cerebellar arterial branches</div><div class=\"cntnt\"><img style=\"width:547px; height:383px;\" src=\"images/NEURO/73656_Cerebellar_arteries.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The intracranial vertebral and basilar arteries are depicted with their major cerebellar arterial branches, including PICA (posterior inferior and cerebellar artery), AICA (anterior inferior cerebellar artery), and SCA (superior cerebellar artery).</div><div class=\"graphic_reference\">Reproduced with permission from Caplan, LR. Posterior circulation disease. Clinical findings, diagnosis, and management. Blackwell Science, Boston 1996. Copyright &#169;1996 Blackwell Science.</div><div id=\"graphicVersion\">Graphic 73656 Version 1.0</div></div></div>"},"73657":{"type":"graphic_figure","displayName":"Derivation Doppler indices","title":"Doppler indices derived from the maximum frequency shift envelope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Doppler indices derived from the maximum frequency shift envelope</div><div class=\"cntnt\"><img style=\"width:447px; height:320px;\" src=\"images/OBGYN/73657_Derivation_Doppler_indices.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">S: peak systolic frequency shift; D: end diastolic freqency shift; and A: temporal average frequency shift over one cardiac cycle.</div><div class=\"graphic_reference\">With permission from Maulik, D, Yarlagadda, P, Youngblood, JP, Willoughby, L. Componants of variability of umbilical arterial Doppler velocimetry: a prospective analysis. Am J Obstet Gynecol, 1989; 160:1406.</div><div id=\"graphicVersion\">Graphic 73657 Version 1.0</div></div></div>"},"73658":{"type":"graphic_figure","displayName":"Treatment of a leak","title":"Treatment of a surgical leak","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Treatment of a surgical leak</div><div class=\"cntnt\"><img style=\"width:454px; height:442px;\" src=\"images/SURG/73658_Treatment_of_a_leak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The surgical principles in treating a leak include broad spectrum antibiotic coverage, identification and repair of the defect, irrigation and control of contamination, wide external drainage of the contaminated area and gastrostomy tube placement. The drawing depicts a gastrostomy tube that has been placed in the stomach and large drains placed in the area of the leak.</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &#169; 2010 Cine-Med.</div><div id=\"graphicVersion\">Graphic 73658 Version 5.0</div></div></div>"},"73660":{"type":"graphic_picture","displayName":"Dermoid cyst inflamed","title":"Inflamed dermoid cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflamed dermoid cyst</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/73660_Dermoid_cyst_inflamed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous nodule is present on the temple.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73660 Version 4.0</div></div></div>"},"73661":{"type":"graphic_picture","displayName":"Examination of finger DIP joint flexion","title":"Examination of finger DIP joint flexion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examination of finger DIP joint flexion</div><div class=\"cntnt\"><img style=\"width:396px; height:312px;\" src=\"images/EM/73661_Finger_dip_flex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flexion of the distal interphalangeal (DIP) joint is evaluated independently of other finger movements.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 73661 Version 2.0</div></div></div>"},"73663":{"type":"graphic_picture","displayName":"NuvaRing hand squeezing PI","title":"NuvaRing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">NuvaRing</div><div class=\"cntnt\"><img style=\"width:432px; height:302px;\" src=\"images/PI/73663_NuvaRing_hand_squeezing_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ring stays inside the vagina for 3 weeks at a time. It delivers hormones into the body that help prevent pregnancy.</div><div class=\"graphic_reference\">Reproduced with permission from: www.nuvaring.com. Copyright © 2004 Organon USA.</div><div id=\"graphicVersion\">Graphic 73663 Version 3.0</div></div></div>"},"73664":{"type":"graphic_table","displayName":"Brachytherapy esophagus CA selection criteria","title":"Selection criteria for definitive and palliative brachytherapy for esophageal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selection criteria for definitive and palliative brachytherapy for esophageal cancer</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Definitive treatment</td> </tr> <tr> <td class=\"subtitle2_single\">Good candidates</td> </tr> <tr> <td class=\"indent1\">Unifocal thoracic esophageal cancer &#8804;10 cm</td> </tr> <tr> <td class=\"indent1\">No extraesophageal extension</td> </tr> <tr> <td class=\"indent1\">No nodal disease or metastatic disease</td> </tr> <tr> <td class=\"subtitle2_single\">Poor candidates</td> </tr> <tr> <td class=\"indent1\">Tumor &#62;10 cm in length</td> </tr> <tr> <td class=\"indent1\">Extraesophageal extension</td> </tr> <tr> <td class=\"indent1\">Regional lymphadenopathy</td> </tr> <tr> <td class=\"indent1\">Tumor involving GE junction or cardia</td> </tr> <tr> <td class=\"subtitle2_single\">Contraindications</td> </tr> <tr> <td class=\"indent1\">Esophageal fistula</td> </tr> <tr> <td class=\"indent1\">Cervical esophageal location</td> </tr> <tr> <td class=\"indent1\">Stenosis that cannot be bypassed</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Palliative treatment</td> </tr> <tr> <td>Thoracic esophageal lesions with distant metastases</td> </tr> <tr> <td>Unresectable local disease progression</td> </tr> <tr> <td>Recurrence after definitive EBRT</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GE: gastroesophageal; EBRT: external beam radiation therapy.</div><div class=\"graphic_reference\">Adapted from Gaspar LE, Nag S, Herskovic A, et al. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Int J Radiat Oncol Biol Phys 1997; 38:127.</div><div id=\"graphicVersion\">Graphic 73664 Version 5.0</div></div></div>"},"73665":{"type":"graphic_diagnosticimage","displayName":"Cystic hygroma CT III","title":"Cystic hygroma in left axillary region","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic hygroma in left axillary region</div><div class=\"cntnt\"><img style=\"width:396px; height:231px;\" src=\"images/PULM/73665_Cystic_hygroma_CT_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan displays a large cyst in the left axilla.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 73665 Version 3.0</div></div></div>"},"73666":{"type":"graphic_figure","displayName":"M mode echo mitral stenosis","title":"Mitral stenosis on M-mode echocardiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral stenosis on M-mode echocardiography</div><div class=\"cntnt\"><img style=\"width:376px; height:252px;\" src=\"images/CARD/73666_Mmodeechomitralstenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top tracing shows a normal anterior mitral leaflet (AL), showing early opening (E) due to passive left ventricle filling and the late leaflet opening due to atrial contraction (A). The bottom tracing is from a patient with mitral stenosis. In contrast to the normal valve, the stenotic valve is thicker, as indicated by the multiple lines rather than a single one; it never closes during diastole and the slope of closure (E to F slope) is reduced with a velocity of 20 mm/sec; and the posterior leaflet (PL) moves in parallel to the anterior rather than independently. In this patient, the A wave is lost because of atrial fibrillation.</div><div id=\"graphicVersion\">Graphic 73666 Version 2.0</div></div></div>"},"73667":{"type":"graphic_figure","displayName":"Ipratropium vs metaproterenol","title":"Effect of ipratropium bromide versus metaproterenol in patients with COPD without asthma or atopy","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Effect of ipratropium bromide versus metaproterenol in patients with COPD without asthma or atopy</div><div class=\"cntnt\"><img style=\"width:469px; height:302px;\" src=\"images/PULM/73667_Ipratropium_vs_metaproteren.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean percentage changes in FEV<SUB>1</SUB> at serial times after inhalation of ipratropium bromide (40 mcg) or metaproterenol (1500 mcg) on day 90 of the 90 day trial period of daily drug administration. Ipratropium was more potent at the peak of its effect and was longer acting than the adrenergic agent. Similar results were demonstrated on days 1 and 45 (not shown).</div><div class=\"graphic_footnotes\">FEV<SUB>1</SUB>: forced expiratory volume in one second.<BR>* p≤0.05.<BR><FONT class=bullet>•</FONT> p≤0.01.</div><div class=\"graphic_reference\">Redrawn from: Tashkin DP, Ashutosh K, Bleecker ER, et al. Am J Med 1986; 81(Suppl A):81.</div><div id=\"graphicVersion\">Graphic 73667 Version 2.0</div></div></div>"},"73669":{"type":"graphic_diagnosticimage","displayName":"Tension pneumothorax I PA","title":"Chest radiograph of a tension pneumothorax","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of a tension pneumothorax</div><div class=\"cntnt\"><img style=\"width:314px; height:324px;\" src=\"images/PULM/73669_Tension_pneumothorax_I_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tension pneumothorax&nbsp;caused by&nbsp;extensive tuberculosis in the subjacent left lung. Chest radiograph shows a large collection of gas in the left hemithorax with inversion of the left hemidiaphragm and cardiomediastinal shift to the right. The left intercostal spaces are wider than the right ones.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 73669 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"73673":{"type":"graphic_waveform","displayName":"EEG 6 Hz spike and wave","title":"Six-Hz spike-and-wave bursts","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Six-Hz spike-and-wave bursts</div><div class=\"cntnt\"><img style=\"width:500px; height:613px;\" src=\"images/NEURO/73673_6Hz_spike_8_wave.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Six-Hz spike-and-wave bursts (&quot;Phantom spike and wave&quot;; see arrows): three 1 second bursts from one routine EEG recording. (A) This pattern is accentuated in an average referential montage, sensitivity 5 uV/mm. Note the low amplitude, occipitally predominant &quot;phantom&quot; spikes (arrows), and the frequency of approximately 6 per second (B) in a longitudinal bipolar montage (7 uv/mm), this pattern is not as well-appreciated. This is a normal variant.</div><div class=\"graphic_reference\">Courtesy of Drs. Lawrence Hirsch and Hiba Arif.</div><div id=\"graphicVersion\">Graphic 73673 Version 3.0</div></div></div>"},"73674":{"type":"graphic_table","displayName":"Clinical characteristics migraine with brainstem aura","title":"Clinical characteristics of migraine with brainstem aura (basilar-type migraine)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical characteristics of migraine with brainstem aura (basilar-type migraine)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Always present:</td> </tr> <tr> <td>Two or more brainstem-related aura symptoms (ie, dysarthria, vertigo, tinnitus, hypacusis, diplopia, ataxia, decreased level of consciousness)</td> </tr> <tr> <td class=\"subtitle1_single\">May be present:</td> </tr> <tr> <td>Visual aura characterized by positive features (ie, zigzag lines, flickering light) or negative features (ie, scotoma)</td> </tr> <tr> <td>Sensory aura characterized by positive features (ie, pins and needles) or negative features (ie, numbness)</td> </tr> <tr> <td>Aphasic aura</td> </tr> <tr> <td class=\"subtitle1_single\">Temporal characteristics of aura</td> </tr> <tr> <td>Aura symptoms almost always develop gradually over &#8805;5 minutes and/or aura symptoms occur in succession over &#8805;5 minutes</td> </tr> <tr> <td>Duration of individual aura symptom is&nbsp;5 to 60 minutes</td> </tr> <tr> <td>The aura is accompanied, or followed within 60 minutes, by headache</td> </tr> <tr> <td class=\"subtitle1_single\">Patient characteristics</td> </tr> <tr> <td>Onset occurs before age 50 years</td> </tr> <tr> <td>Most patients with migraine with brainstem aura also have attacks of migraine with typical aura (ie,&nbsp;without brainstem-related symptoms)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br />1. Kirchmann M, Thomsen LL, Olesen J. Basilar-type migraine: clinical, epidemiologic, and genetic features. Neurology 2006; 66:880.<br />2. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629.</div><div id=\"graphicVersion\">Graphic 73674 Version 6.0</div></div></div>"},"73675":{"type":"graphic_algorithm","displayName":"Algorithm for management of suspected fetomaternal hemorrhage","title":"Management of spontaneous fetomaternal hemorrhage (FMH)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of spontaneous fetomaternal hemorrhage (FMH)</div><div class=\"cntnt\"><img style=\"width:448px; height:708px;\" src=\"images/OBGYN/73675_Algorithm_for_FMH.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">K-B: Kleihauer Betke; MOM: multiples of the median; MCA: middle cerebral artery.</div><div id=\"graphicVersion\">Graphic 73675 Version 2.0</div></div></div>"},"73676":{"type":"graphic_table","displayName":"Insulin pharmacokinetics","title":"Pharmacokinetics of the most commonly used insulin preparations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacokinetics of the most commonly used insulin preparations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Insulin type</td> <td class=\"subtitle1\">Onset of action</td> <td class=\"subtitle1\">Peak effect</td> <td class=\"subtitle1\">Duration of action</td> </tr> <tr> <td>Lispro, aspart, glulisine</td> <td>5 to 15 minutes</td> <td>45 to 75 minutes</td> <td>Two to four hours</td> </tr> <tr> <td>Regular</td> <td>About 30 minutes</td> <td>Two to four hours</td> <td>Five to eight hours</td> </tr> <tr> <td>NPH</td> <td>About two hours</td> <td>4 to 12 hours</td> <td>18 to 28 hours</td> </tr> <tr> <td>Insulin glargine</td> <td>About two hours</td> <td>No peak</td> <td>20 to &#62;24 hours</td> </tr> <tr> <td>Insulin detemir</td> <td>About two hours</td> <td>Three to nine hours</td> <td>6 to 24 hours*</td> </tr> <tr> <td>NPL</td> <td>About two hours</td> <td>Six hours</td> <td>15 hours</td> </tr> <tr> <td>Insulin degludec</td> <td>About two hours</td> <td>No peak</td> <td>&#62;40 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NPH: neutral protamine hagedorn; NPL: neutral protamine lispro.<br />* Duration of action is dose-dependent. At higher doses (&ge;0.8 units/kg), mean duration of action is longer and less variable (22 to 23 hours).</div><div id=\"graphicVersion\">Graphic 73676 Version 8.0</div></div></div>"},"73677":{"type":"graphic_waveform","displayName":"TDE LV dyssynchrony","title":"Tissue Doppler echocardiography color-coded images and time-velocity curves demonstrating dyssynchrony in a heart failure patient with left bundle branch block","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tissue Doppler echocardiography color-coded images and time-velocity curves demonstrating dyssynchrony in a heart failure patient with left bundle branch block</div><div class=\"cntnt\"><img style=\"width:397px; height:475px;\" src=\"images/CARD/73677_TDE_LV_dyssynchrony.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vertical yellow lines mark the ejection interval and the color-coded curves correspond to the 12 segments. The white arrows indicate the opposing wall delay in time-to-peak velocity from different left ventricular walls.</div><div class=\"graphic_reference\">Courtesy of John Gorcsan III, MD.</div><div id=\"graphicVersion\">Graphic 73677 Version 4.0</div></div></div>"},"73678":{"type":"graphic_picture","displayName":"Fixed drug hyperpigment","title":"Fixed drug eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fixed drug eruption</div><div class=\"cntnt\"><img style=\"width:293px; height:508px;\" src=\"images/DERM/73678_Fixed_drug_hyperpigment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fixed drug eruptions (A) typically resolve with postinflammatory hyperpigmentation (B).</div><div class=\"graphic_reference\">Copyright © Chris Ha, MD, DermAtlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 73678 Version 6.0</div></div></div>"},"73679":{"type":"graphic_picture","displayName":"Scabies axilla 2","title":"Scabies lesions in the axilla of a child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies lesions in the axilla of a child</div><div class=\"cntnt\"><img style=\"width:400px; height:393px;\" src=\"images/DERM/73679_Scabies_axilla_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: George A Datto, III, MD.</div><div id=\"graphicVersion\">Graphic 73679 Version 2.0</div></div></div>"},"73680":{"type":"graphic_figure","displayName":"Forearm dorsal anatomy","title":"Extensor muscles of right forearm","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Extensor muscles of right forearm</div><div class=\"cntnt\"><img style=\"width:602px; height:787px;\" src=\"images/EM/73680_Forearmdorsalanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) In this image, the superficial layer of extensor muscles is shown. The distal extensor tendons have been removed from the dorsum of the hand without disturbing the arteries because they lie on the skeletal plane. The fascia on the posterior aspect of the forearm is thickened to form the extensor retinaculum, which is anchored on its deep aspect to the radius and ulna. (B) Here, the deep layer of extensor muscles is shown. Three outcropping muscles of the thumb* emerge between the extensor carpi radialis brevis and the extensor digitorum: abductor pollicis longus, extensor pollicis brevis, and extensor pollicis longus. The furrow from which the three muscles emerge has been opened proximally to the lateral epicondyle, exposing the supinator muscle. (C) This transverse section of the forearm shows the superficial and deep layers of muscles in the posterior compartment (pink), supplied by the radial nerve, and the anterior compartment (gold), supplied by the ulnar and median nerves.</div><div class=\"graphic_footnotes\">* Outcropping muscles of thumb.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 73680 Version 10.0</div></div></div>"},"73681":{"type":"graphic_table","displayName":"Methamphetamine intoxication in adults - Rapid overview","title":"Methamphetamine intoxication in adults: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methamphetamine intoxication in adults: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-222-1222<a href=\"#\" title=\"Call: 1-800-222-1222\"><img alt=\"\" title=\"Call: 1-800-222-1222\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span>, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">General</td> </tr> <tr> <td>May be abused by nasal, oral, or intravenous route</td> </tr> <tr> <td>Rapid onset of symptoms with long (~24 hours) duration of action</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td>History may be difficult to obtain</td> </tr> <tr> <td>Severe agitation can occur</td> </tr> <tr> <td class=\"sublist1_start\">Sympathomimetic toxidrome frequently present:</td> </tr> <tr> <td class=\"sublist1\">&#8226; CNS stimulation (agitation, delirium or acute psychosis)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Tachycardia</td> </tr> <tr> <td class=\"sublist1\">&#8226; Hypertension</td> </tr> <tr> <td class=\"sublist1\">&#8226; Dilated pupils (mydriasis)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Diaphoresis</td> </tr> <tr> <td>Hyperthermia (variable; may be severe)</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory analysis:</td> </tr> <tr> <td class=\"sublist1_start\">Routine testing in poisoned patients</td> </tr> <tr> <td class=\"sublist1\">&#8226; Fingerstick glucose</td> </tr> <tr> <td class=\"sublist1\">&#8226; ECG to assess for conduction system impairment</td> </tr> <tr> <td class=\"sublist1\">&#8226; Acetaminophen and salicylate levels</td> </tr> <tr> <td class=\"sublist1\">&#8226; Pregnancy test in women of childbearing age</td> </tr> <tr> <td class=\"sublist1_start\">Basic electrolytes, BUN, creatinine</td> </tr> <tr> <td class=\"sublist1\">&#8226; Metabolic acidosis, acute renal failure, and hyperkalemia may be seen in severe toxicity</td> </tr> <tr> <td>Creatinine phosphokinase, serum lactate, aminotransferases, coagulation studies</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"sublist1_start\">Agitation (control with aggressive sedation)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Benzodiazepines are first line therapy; may need large doses</td> </tr> <tr> <td class=\"sublist1\">&#8226; For severe agitation:</td> </tr> <tr> <td class=\"sublist2\">- Lorazepam, 4 mg IV, may repeat every 8-10 minutes, titrate to sedation</td> </tr> <tr> <td class=\"sublist2\">- Diazepam, 5-10 mg IV, may repeat every 8-10 minutes, titrate to sedation</td> </tr> <tr> <td class=\"sublist2\">- If lacks IV access, midazolam 5-10 mg IM, may repeat every 10 minutes, titrate to sedation</td> </tr> <tr> <td class=\"sublist1\">&#8226; Consider other agents (see text) in cases of benzodiazepine failure</td> </tr> <tr> <td>Paralysis and tracheal intubation may be necessary; succinylcholine should <strong>not</strong> be used for rapid sequence intubation</td> </tr> <tr> <td class=\"sublist1_start\">Critical hypertension</td> </tr> <tr> <td class=\"sublist1\">&#8226; Benzodiazepines are first line therapy (see dosing above)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Nitroprusside: start at 0.25-0.5 mcg/kg/minute; titrate to effect</td> </tr> <tr> <td class=\"sublist1\">&#8226; Phentolamine: 2-5 mg IV, may repeat; titrate to effect</td> </tr> <tr> <td class=\"sublist1\">&#8226;&nbsp;Avoid pure&nbsp;beta&nbsp;blockers; we suggest avoiding combined alpha- and beta-blocking medications in acute poisoning&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Hyperthermia</td> </tr> <tr> <td class=\"sublist1\">&#8226; Sedation with benzodiazepines (see dosing above);&nbsp;do<strong>&nbsp;not</strong> give antipyretics</td> </tr> <tr> <td class=\"sublist1\">&#8226; Evaporative cooling measures</td> </tr> <tr> <td class=\"sublist1\">&#8226; Cooling blankets</td> </tr> <tr> <td class=\"sublist1\">&#8226; Neuromuscular paralysis in severe cases</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; ECG: electrocardiogram; IV: intravenous; IM: intramuscularly.</div><div id=\"graphicVersion\">Graphic 73681 Version 10.0</div></div></div>"},"73684":{"type":"graphic_figure","displayName":"Protective mechanisms in edema","title":"Protective mechanisms against pulmonary edema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Protective mechanisms against pulmonary edema</div><div class=\"cntnt\"><img style=\"width:268px; height:400px;\" src=\"images/PULM/73684_Protective_mechanisms_in_ed.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An osmotic gradient favoring fluid reabsorption from the interstitium is maintained by retention of serum proteins within the intravascular space. Fluid which does leak into the interstitium is transported to lymphatics from which it is returned to the circulation. Finally, tight junctions between alveolar epithelial cells prevent leakage of fluid into the alveolar space. Arrows represent lymphatic movement; small circles represent protein.</div><div id=\"graphicVersion\">Graphic 73684 Version 1.0</div></div></div>"},"73685":{"type":"graphic_diagnosticimage","displayName":"Thymoma CT I","title":"Thymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thymoma</div><div class=\"cntnt\"><img style=\"width:400px; height:257px;\" src=\"images/PULM/73685_Thymoma_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed&nbsp;tomography (CT)&nbsp;scan of a thymoma originating from the right lobe of the thymus. A large rounded mass is seen in the retrosternal location, to the right of the midline (arrow).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 73685 Version 3.0</div></div></div>"},"73686":{"type":"graphic_figure","displayName":"Upper airway obstruction","title":"Importance of the degree of upper airway obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Importance of the degree of upper airway obstruction</div><div class=\"cntnt\"><img style=\"width:300px; height:310px;\" src=\"images/PULM/73686_Upper_airway_obstruction.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Volume (as liters [L] from total lung capacity [TLC]) is plotted against inspiratory and expiratory flows. The blue line (C) is the control effort; the number on each curve refers to the orifice diameter in mm. Lesions must narrow the tracheal lumen to less than 8 mm before abnormalities can be detected by spirometry.</div><div class=\"graphic_reference\">Redrawn from Miller RD, Hyatt RE, Mayo Clin Proc 1969; 44:145.</div><div id=\"graphicVersion\">Graphic 73686 Version 3.0</div></div></div>"},"73688":{"type":"graphic_waveform","displayName":"Sinus arrhythmia tutorial","title":"Sinus arrhythmia","html":"<div class=\"graphic normal\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Sinus arrhythmia</div><div class=\"cntnt\"><img style=\"width:526px; height:122px;\" src=\"images/CARD/73688_Sinus_arrhythmia_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus arrhythmia is present when there is a sinus rhythm with variability in the cycle lengths between successive P waves. This rhythm strip reveals a gradual increase and decrease in the heart rate with the respiratory cycle; the heart rate increases with inspiration and decreases with expiration.</div><div id=\"graphicVersion\">Graphic 73688 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"73691":{"type":"graphic_picture","displayName":"Sporo asteroid body","title":"Sporotrichosis - asteroid body","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sporotrichosis - asteroid body</div><div class=\"cntnt\"><img style=\"width:432px; height:339px;\" src=\"images/ID/73691_Sporo_asteroid_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An asteroid body, composed of a pair of budding yeasts of <EM>S. schenckii</EM> surrounded by a layer of Splendore-Hoeppli substance, with radiating projections.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73691 Version 2.0</div></div></div>"},"73696":{"type":"graphic_figure","displayName":"Complete fracture molding","title":"Complete fracture molding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complete fracture molding</div><div class=\"cntnt\"><img style=\"width:444px; height:389px;\" src=\"images/EM/73696_Completefxmolding.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-point molding. A) Three-point molding for dorsally angulated (apex volar) fractures, with the proximal and distal points on the dorsal aspect of the cast and the middle point on the volar aspect just proximal to the fracture site. B) For volar angulated fractures, where the periosteum is intact volarly and disrupted on the dorsal surface, three-point molding is performed with the proximal and distal points on the volar surface of the cast and the middle point just proximal to the fracture site on the dorsal aspect of the cast.</div><div class=\"graphic_reference\">Reproduced with permission from: Schoenecker JG, Bae DS. Fractures of the Distal Radius and Ulna. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 73696 Version 13.0</div></div></div>"},"73698":{"type":"graphic_table","displayName":"Stress dose steroids","title":"Stress dose replacement of steroids","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stress dose replacement of steroids</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Indication</td> </tr> <tr> <td>Any patient who received more than 7.5 mg/day of prednisone for more than&nbsp;five days in the prior year</td> </tr> <tr> <td class=\"subtitle1_single\">Preoperative regimen</td> </tr> <tr> <td>One hour before surgery 100 mg hydrocortisone intravenously</td> </tr> <tr> <td class=\"subtitle1_single\">Postoperative regimen</td> </tr> <tr> <td>Day 1:&nbsp;100 mg hydrocortisone intravenously every&nbsp;eight hours</td> </tr> <tr> <td>Day 2: 100 mg hydrocortisone intravenously every 12 hours</td> </tr> <tr> <td>Day 3: 100 mg hydrocortisone intravenously once in morning</td> </tr> <tr> <td>If patient begins oral feedings at any time: prednisone 20 mg the first day; decrease by 5 mg/day or until chronic dose is reached</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73698 Version 3.0</div></div></div>"},"73699":{"type":"graphic_table","displayName":"Ann Arbor system in lymphoma","title":"Ann Arbor staging classification for Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ann Arbor staging classification for Hodgkin&nbsp;lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\">Stage I </td> <td>Involvement of a single lymph node region (I) or of a single extralymphatic organ or site (IE)*</td> </tr> <tr> <td class=\"subtitle1_left\">Stage II </td> <td>Involvement of two or more lymph node regions or lymphatic structures on the same side of the diaphragm alone (II) or with involvement of limited, contiguous extralymphatic organ or tissue (IIE)</td> </tr> <tr> <td class=\"subtitle1_left\">Stage III </td> <td>Involvement of lymph node regions on both sides of the diaphragm (III), which may include the spleen (IIIS) or limited, contiguous extralymphatic organ or site (IIIE) or both (IIIES)</td> </tr> <tr> <td class=\"subtitle1_left\">Stage IV </td> <td>Diffuse or disseminated foci of involvement of one or more extralymphatic organs or tissues, with or without associated lymphatic involvement</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All cases are subclassified to indicate the absence (A) or presence (B) of the <STRONG>systemic (\"B\") symptoms</STRONG> of significant unexplained fever (&gt;38 degrees C), night sweats, or unexplained weight loss exceeding 10 percent of body weight during the six months prior to diagnosis. Clinical stage refers to the extent of disease determined by diagnostic tests following a single diagnostic biopsy. If a second biopsy of any kind is obtained, even if negative, the term pathologic stage is used.</div><div class=\"graphic_footnotes\">* The designation &quot;E&quot; generally refers to <strong>extranodal contiguous extension</strong> (ie, proximal or contiguous extranodal disease) that can be encompassed within an irradiation field appropriate for nodal disease of the same anatomic extent. A single extralymphatic site as the <strong>only site of disease</strong> should be classified as IE, rather than stage IV.</div><div class=\"graphic_reference\">Adapted from Carbone PP, et al. Cancer Res 1971; 31:1860 and Lister TA, et al. J Clin Oncol 1989; 7:1630.</div><div id=\"graphicVersion\">Graphic 73699 Version 3.0</div></div></div>"},"73700":{"type":"graphic_table","displayName":"CALGB progn groups mesothelioma","title":"Prognostic indices of survival for advanced mesothelioma in CALGB* studies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognostic indices of survival for advanced mesothelioma in CALGB* studies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">CALGB studies</td> </tr> <tr> <td class=\"subtitle2\">Study</td> <td class=\"subtitle2\">Dates</td> <td class=\"subtitle2\">Response, %</td> <td class=\"subtitle2\">MST, months</td> </tr> <tr> <td rowspan=\"2\">#8435 (Mitomycin/cisplatin)</td> <td rowspan=\"2\">6/84-10/86</td> <td>26</td> <td>8.1</td> </tr> <tr> <td>14</td> <td>8.8</td> </tr> <tr> <td>#8638 (Carboplatin)</td> <td>2/87-2/88</td> <td>7</td> <td>7.1</td> </tr> <tr> <td>#8833 (DHAC)</td> <td>6/88-6/89</td> <td>17</td> <td>6.7</td> </tr> <tr> <td rowspan=\"2\">#8933 (Trimetrexate)</td> <td rowspan=\"2\">7/89-8/91</td> <td>12</td> <td>3.9</td> </tr> <tr> <td>12</td> <td>9.8</td> </tr> <tr> <td>#9031 (DHAC/cisplatin)</td> <td>7/90-7/93</td> <td>14</td> <td>6.4</td> </tr> <tr> <td rowspan=\"2\">#9131 (Edatrexate)</td> <td rowspan=\"2\">5/92-9/94</td> <td>25</td> <td>9.6 </td> </tr> <tr> <td>18</td> <td>6.9</td> </tr> <tr> <td>#9234 (Paclitaxel)</td> <td>3/93-9/94</td> <td>9</td> <td>5</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Poor prognostic factors in multivariate analysis</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">Variable</td> <td class=\"subtitle2\" colspan=\"2\">Relative risk</td> </tr> <tr> <td>Pleural disease</td> <td>Present</td> <td colspan=\"2\">2.64</td> </tr> <tr> <td>Lactic dehydrogenase (LDH)</td> <td>&#62;500 IU/L</td> <td colspan=\"2\">1.91</td> </tr> <tr> <td rowspan=\"2\">Poor performance status (PS)</td> <td>PS1</td> <td colspan=\"2\">1.65</td> </tr> <tr> <td>PS2 </td> <td colspan=\"2\">2.71</td> </tr> <tr> <td>Platelet count</td> <td>&#62;400,000/microL</td> <td colspan=\"2\">1.57</td> </tr> <tr> <td>Epithelial histology</td> <td>Absent</td> <td colspan=\"2\">1.33</td> </tr> <tr> <td>Age</td> <td>Each year over 75 yo</td> <td colspan=\"2\">1.34</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"4\">CALGB prognostic groups</td> </tr> <tr> <td class=\"subtitle2\">Group</td> <td class=\"subtitle2\" colspan=\"2\">Characteristics</td> <td class=\"subtitle2\">MST, months</td> </tr> <tr> <td rowspan=\"2\">Group I</td> <td colspan=\"2\">PS, 0; age &#60;49 years</td> <td>12.5</td> </tr> <tr> <td colspan=\"2\">PS, 0; age &#8805;49 years; HGB* &#8805;14.6</td> <td>14.5</td> </tr> <tr> <td>Group II</td> <td colspan=\"2\">PS, 1 or 2; WBC* &#60; 8.7; no chest pain</td> <td>9.5</td> </tr> <tr> <td rowspan=\"3\">Group III</td> <td colspan=\"2\">PS, 0; age &#62;49 years; HGB &#60;14.6</td> <td>9.3</td> </tr> <tr> <td colspan=\"2\">PS, 1 or 2; WBC &#60; 15.6; chest pain; weight loss; HGB &#8805; 12.3</td> <td>9.3</td> </tr> <tr> <td colspan=\"2\">PS, 1 or 2; 9.8 &#8804; WBC &#60; 15.6; chest pain; weight loss; HGB &#8805; 11.2 </td> <td>9.6</td> </tr> <tr> <td>Group IV</td> <td colspan=\"2\">PS, 1 or 2; 8.7 &#8804; WBC &#60;15.6; no chest pain</td> <td>6.6</td> </tr> <tr> <td rowspan=\"3\">Group V</td> <td colspan=\"2\">PS, 1 or 2; WBC &#60;15.6; chest pain; no weight loss; HGB &#60;12.3</td> <td>3.9</td> </tr> <tr> <td colspan=\"2\">PS, 1 or 2; 9.8 &#8804; WBC &#60;15.6; chest pain; weight loss; HGB &#60;11.2</td> <td>4.9</td> </tr> <tr> <td colspan=\"2\">PS, 1 or 2; WBC &#60; 9.8; chest pain; weight loss</td> <td>3.9</td> </tr> <tr> <td>Group VI</td> <td colspan=\"2\">PS, 1 or 2; WBC&nbsp; &#8805; 15.6</td> <td>1.4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CALGB: cancer and leukemia Group B; MST: median survival time; Mos: months; DHAC: dihydro-5-azacytidine; WBC: white blood cell count, X 1000/microL; HGB: hemoglobin (HGB is given in g/percent; WBC, x 1000/microL).</div><div id=\"graphicVersion\">Graphic 73700 Version 2.0</div></div></div>"},"73703":{"type":"graphic_table","displayName":"Drugs implicated in serum sickness/serum sickness-like reactions","title":"Drugs implicated in serum sickness and serum sickness-like reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs implicated in serum sickness and serum sickness-like reactions</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Commonly implicated drugs</td> </tr> <tr> <td class=\"indent1\">Cefaclor</td> </tr> <tr> <td class=\"indent1\">Penicillins</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole</td> </tr> <tr> <td class=\"subtitle1_single\">Uncommonly implicated drugs</td> </tr> <tr> <td class=\"indent1\">Aspirin/salicylates</td> </tr> <tr> <td class=\"indent1\">Barbiturates</td> </tr> <tr> <td class=\"indent1\">Bupropion</td> </tr> <tr> <td class=\"indent1\">Captopril</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> </tr> <tr> <td class=\"indent1\">Cefatrizine</td> </tr> <tr> <td class=\"indent1\">Cefditoren</td> </tr> <tr> <td class=\"indent1\">Cholecystographic dyes</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin</td> </tr> <tr> <td class=\"indent1\">Clarithromycin</td> </tr> <tr> <td class=\"indent1\">Fluoxetine</td> </tr> <tr> <td class=\"indent1\">Furazolidone</td> </tr> <tr> <td class=\"indent1\">Hair straightener</td> </tr> <tr> <td class=\"indent1\">Heparin</td> </tr> <tr> <td class=\"indent1\">Indomethacin</td> </tr> <tr> <td class=\"indent1\">Insulin (in type 1 diabetes)</td> </tr> <tr> <td class=\"indent1\">Iron-dextran</td> </tr> <tr> <td class=\"indent1\">Itraconazole</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Uncommonly implicated drugs (continued)</td> </tr> <tr> <td class=\"indent1\">6-mercaptopurine</td> </tr> <tr> <td class=\"indent1\">Methimazole</td> </tr> <tr> <td class=\"indent1\">Metronidazole</td> </tr> <tr> <td class=\"indent1\">Minocycline</td> </tr> <tr> <td class=\"indent1\">N-acetyl cysteine</td> </tr> <tr> <td class=\"indent1\">Naproxen</td> </tr> <tr> <td class=\"indent1\">Novobiocin</td> </tr> <tr> <td class=\"indent1\">Pamabrom</td> </tr> <tr> <td class=\"indent1\">Penicillamine</td> </tr> <tr> <td class=\"indent1\">Phenylbutazone</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> </tr> <tr> <td class=\"indent1\">Propranolol</td> </tr> <tr> <td class=\"indent1\">Propylthiouracil</td> </tr> <tr> <td class=\"indent1\">Rifampin</td> </tr> <tr> <td class=\"indent1\">Streptomycin</td> </tr> <tr> <td class=\"indent1\">Sulfasalazine</td> </tr> <tr> <td class=\"indent1\">Sulfonamides</td> </tr> <tr> <td class=\"indent1\">Tinidazole</td> </tr> <tr> <td class=\"indent1\">Verapamil</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73703 Version 8.0</div></div></div>"},"73704":{"type":"graphic_figure","displayName":"Plantar anatomy PI","title":"Plantar fasciitis","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Plantar fasciitis</div><div class=\"cntnt\"><img style=\"width:541px; height:535px;\" src=\"images/PI/73704_Plantar_anatomy_patient_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plantar fascia is a tough band of tissue that connects the heel bone to the toes.</div><div id=\"graphicVersion\">Graphic 73704 Version 8.0</div></div></div>"},"73705":{"type":"graphic_picture","displayName":"Amanita phalloides-Death cap","title":"Amanita phalloides (\"Death cap\")","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amanita phalloides (\"Death cap\")</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/EM/73705_Amanita_phalloides.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One of the most toxic mushrooms, this cyclopeptide-containing mushroom is responsible for the majority of human fatalities due to mushroom poisoning because of the life-threatening liver toxicity that it can cause. Note the greenish white cap and large bulbous root. This specimen was mistaken for the edible mushrooms, Caesar's mushroom (<EM>Amanita caesara</EM>) and straw mushroom (<EM>Volvariella volvacea</EM>) and was picked in the Finger Lakes Region of New York State.</div><div class=\"graphic_reference\">Courtesy of William Hollenbaugh.</div><div id=\"graphicVersion\">Graphic 73705 Version 4.0</div></div></div>"},"73706":{"type":"graphic_table","displayName":"Causes of bacterial meningitis","title":"Characteristic features of common causes of bacterial meningitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristic features of common causes of bacterial meningitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Organism</td> <td class=\"subtitle1\">Site of entry</td> <td class=\"subtitle1\">Age range</td> <td class=\"subtitle1\">Predisposing conditions</td> </tr> <tr> <td><em>Neisseria meningitidis</em></td> <td>Nasopharynx</td> <td>All ages</td> <td>Usually none, rarely complement deficiency</td> </tr> <tr> <td><em>Streptococcus pneumoniae</em></td> <td>Nasopharynx, direct extension across skull fracture, or from contiguous or distant foci of infection</td> <td>All ages</td> <td>All conditions that predispose to pneumococcal bacteremia, fracture of cribriform plate, cochlear implants,&nbsp;cerebrospinal fluid&nbsp;otorrhea from basilar skull fracture, defects of the ear ossicle (Mondini defect)</td> </tr> <tr> <td><em>Listeria monocytogenes</em></td> <td>Gastrointestinal tract, placenta</td> <td>Older&nbsp;adults and neonates</td> <td>Defects in cell-mediated immunity (eg, glucocorticoids, transplantation [especially renal transplantation]), pregnancy, liver disease, alcoholism, malignancy</td> </tr> <tr> <td>Coagulase-negative staphylococci</td> <td>Foreign body</td> <td>All ages</td> <td>Surgery and foreign body, especially ventricular drains</td> </tr> <tr> <td><em>Staphylococcus aureus</em></td> <td>Bacteremia, foreign body, skin</td> <td>All ages</td> <td>Endocarditis, surgery and foreign body, especially ventricular drains; cellulitis, decubitus ulcer</td> </tr> <tr> <td>Gram-negative bacilli</td> <td>Various</td> <td>Older adults and neonates</td> <td>Advanced medical illness, neurosurgery, ventricular drains, disseminated strongyloidiasis</td> </tr> <tr> <td><em>Haemophilus influenzae</em></td> <td>Nasopharynx, contiguous spread from local infection</td> <td>Adults; infants and children if not vaccinated</td> <td>Diminished humoral immunity</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73706 Version 8.0</div></div></div>"},"73707":{"type":"graphic_picture","displayName":"Lymphogranuloma venereum","title":"Lymphogranuloma venereum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphogranuloma venereum</div><div class=\"cntnt\"><img style=\"width:253px; height:352px;\" src=\"images/ID/73707_Lymphogranuloma_venereum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A dramatic case of lymphogranuloma venereum shows chronic ulcerating lymph nodes and prominent edema.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 73707 Version 3.0</div></div></div>"},"73711":{"type":"graphic_figure","displayName":"Genetic code","title":"Genetic code","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Genetic code</div><div class=\"cntnt\"><img style=\"width:496px; height:504px;\" src=\"images/PC/73711_Genetic_code.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">amber: stop codon UGA (U replacing T in RNA)<BR>ochre: stop codon UAA (U replacing T in RNA)</div><div id=\"graphicVersion\">Graphic 73711 Version 2.0</div></div></div>"},"73714":{"type":"graphic_diagnosticimage","displayName":"Interstitial pregnancy","title":"Interstitial pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Interstitial pregnancy</div><div class=\"cntnt\"><img style=\"width:354px; height:253px;\" src=\"images/OBGYN/73714_Interstitial_pregnancy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is an interstitial pregnancy with thinning of the myometrium (arrows). The &quot;interstitial line&quot; sign is seen (arrowheads).</div><div class=\"graphic_footnotes\">UT: uterus.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 73714 Version 2.0</div></div></div>"},"73715":{"type":"graphic_diagnosticimage","displayName":"Cryptogenic organizing pneumonia CT III","title":"Cryptogenic organizing pneumonitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryptogenic organizing pneumonitis</div><div class=\"cntnt\"><img style=\"width:337px; height:288px;\" src=\"images/PULM/73715_BOOP_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Forty-eight-year-old woman with an eight-week history of cough, dyspnea with exertion, fatigue, and slight weight loss. High resolution CT scan shows right lower lobe reticular and hazy opacities that are subpleural. This CT pattern is most common in patients with chronic progressive disease and looks similar to that usually seen in idiopathic pulmonary fibrosis. On lung biopsy, this patient had areas of chronic fibrosis in addition to the predominant pattern of organizing pneumonia.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 73715 Version 4.0</div></div></div>"},"73716":{"type":"graphic_picture","displayName":"HP giant cells Light","title":"Giant cells in hypersensitivity pneumonitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Giant cells in hypersensitivity pneumonitis</div><div class=\"cntnt\"><img style=\"width:289px; height:192px;\" src=\"images/PULM/73716_HP_giant_cells_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph shows giant cells (arrows) within an interstitial lymphoplasmacytic infiltrate.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 73716 Version 1.0</div></div></div>"},"73717":{"type":"graphic_diagnosticimage","displayName":"Fluid and debris in postpartum uterus","title":"Fluid and debris in postpartum uterus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fluid and debris in postpartum uterus</div><div class=\"cntnt\"><img style=\"width:343px; height:578px;\" src=\"images/OBGYN/73717_Fluid_debris_uterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Transabdominal sagittal greyscale image and (B) transvaginal color Doppler image from a 35-year-old woman two weeks postpartum with vaginal bleeding. Note the fluid and debris in the uterus. The color Doppler image shows no flow within the debris.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 73717 Version 4.0</div></div></div>"},"73718":{"type":"graphic_table","displayName":"Hearing handicap inventory for the elderly","title":"Hearing handicap inventory for the elderly","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hearing handicap inventory for the elderly</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Item</td> <td class=\"subtitle1\">Yes<br /> (4 pts)</td> <td class=\"subtitle1\">Sometimes<br /> (2 pts)</td> <td class=\"subtitle1\">No<br /> (0 pts)</td> </tr> <tr> <td>Does a hearing problem cause you to feel embarrassed when you meet new people?</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Does a hearing problem cause you to feel frustrated when talking to members of your family?</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Do you have difficulty hearing when someone speaks in a whisper?</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Do you feel handicapped by a hearing problem?</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Does a hearing problem cause you difficulty when visiting friends, relatives, or neighbors?</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Does a hearing problem cause you to attend religious services less often than you would like?</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Does a hearing problem cause you to have arguments with family members?</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Does a hearing problem cause you difficulty when listening to TV or radio?</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Do you feel that any difficulty with your hearing limits or hampers your personal or social life?</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Does a hearing problem cause you difficulty when in a restaurant with relatives or friends?</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"4\"><br /> <p><strong>RAW SCORE</strong> (sum of the points assigned each of the items): ____________</p> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_single\" colspan=\"4\">Interpreting the raw score</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">0 to 8 = 13 percent probability of hearing impairment (no handicap/no referral)</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">10 to 24 = 50 percent probability of hearing impairment (mild-moderate handicap/refer)</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">26 to 40 = 84 percent probability of hearing impairment (severe handicap/refer)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from: Hearing handicap inventory for the elderly by I. Ventry and B. Weinstein. ASHA, 25, 37. Copyright &#169; 1983 by American Speech-Language-Hearing Association.</div><div id=\"graphicVersion\">Graphic 73718 Version 2.0</div></div></div>"},"73719":{"type":"graphic_picture","displayName":"Posterior thigh superficial anatomy","title":"Posterior thigh superficial anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior thigh superficial anatomy</div><div class=\"cntnt\"><img style=\"width:384px; height:453px;\" src=\"images/EM/73719_Postthighsuperficialanat.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 73719 Version 9.0</div></div></div>"},"73722":{"type":"graphic_picture","displayName":"Optic nerve lung metastasis","title":"Optic nerve lung metastasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optic nerve lung metastasis</div><div class=\"cntnt\"><img style=\"width:432px; height:326px;\" src=\"images/NEURO/73722_Optic_nerve_lung_metastasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Don C Bienfang, MD.</div><div id=\"graphicVersion\">Graphic 73722 Version 1.0</div></div></div>"},"73723":{"type":"graphic_picture","displayName":"Blanket phototherapy PI","title":"Baby getting home light therapy for jaundice","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Baby getting home light therapy for jaundice</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PI/73723_Blanket_phototherapy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Wikipedia under the terms of the GNU Free Documentation License, Version 1.2 of any later version published by the Free Software Foundation.</div><div id=\"graphicVersion\">Graphic 73723 Version 4.0</div></div></div>"},"73725":{"type":"graphic_algorithm","displayName":"Oxygen extraction in sepsis","title":"Decreased oxygen extraction in sepsis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Decreased oxygen extraction in sepsis</div><div class=\"cntnt\"><img style=\"width:374px; height:320px;\" src=\"images/PULM/73725_Oxygen_extraction_in_sepsis.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73725 Version 2.0</div></div></div>"},"73729":{"type":"graphic_table","displayName":"Hospice provider rating of symptoms","title":"Hospice provider rating of symptom presence, frequency and severity (n = 348)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hospice provider rating of symptom presence, frequency and severity (n = 348)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Present*<br /> <em>n</em> (percentage)</td> <td class=\"subtitle1\">Frequent<sup>&#182;</sup>, when symptom present<br /> <em>n</em> (percentage)</td> <td class=\"subtitle1\">Severe<sup>&#916;</sup>, when symptom present<br /> <em>n</em> (percentage)</td> </tr> <tr> <td>Lack of energy</td> <td>289 (83)</td> <td>216 (75)</td> <td>132 (46)</td> </tr> <tr> <td>Pain</td> <td>263 (76)</td> <td>90 (34)</td> <td>38 (14)</td> </tr> <tr> <td>Lack of appetite</td> <td>218 (63)</td> <td>119 (55)</td> <td>67 (31)</td> </tr> <tr> <td>Feeling drowsy</td> <td>213 (61)</td> <td>111 (52)</td> <td>45 (21)</td> </tr> <tr> <td>Difficulty concentrating</td> <td>208 (60)</td> <td>120 (58)</td> <td>65 (31)</td> </tr> <tr> <td>Feeling sad</td> <td>177 (51)</td> <td>56 (32)</td> <td>33 (19)</td> </tr> <tr> <td>Shortness of breath</td> <td>167 (48)</td> <td>84 (50)</td> <td>43 (26)</td> </tr> <tr> <td>Agitation</td> <td>166 (48)</td> <td>50 (30)</td> <td>28 (17)</td> </tr> <tr> <td>Worrying</td> <td>151 (43)</td> <td>51 (34)</td> <td>23 (15)</td> </tr> <tr> <td>Cough</td> <td>145 (42)</td> <td>47 (32)</td> <td>16 (11)</td> </tr> <tr> <td>Nervousness</td> <td>145 (42)</td> <td>35 (24)</td> <td>23 (16)</td> </tr> <tr> <td>Constipation</td> <td>135 (39)</td> <td>-</td> <td>25 (18)</td> </tr> <tr> <td>Irritability</td> <td>134 (38)</td> <td>37 (28)</td> <td>17 (13)</td> </tr> <tr> <td>Swelling of arms or legs</td> <td>125 (36)</td> <td>-</td> <td>30 (24)</td> </tr> <tr> <td>Difficulty sleeping</td> <td>122 (35)</td> <td>32 (26)</td> <td>14 (11)</td> </tr> <tr> <td>Weight loss</td> <td>122 (35)</td> <td>-</td> <td>18 (15)</td> </tr> <tr> <td>Dry mouth</td> <td>120 (34)</td> <td>56 (47)</td> <td>21 (17)</td> </tr> <tr> <td>Difficulty swallowing</td> <td>103 (30)</td> <td>52 (50)</td> <td>31 (30)</td> </tr> <tr> <td>Changes in skin</td> <td>90 (26)</td> <td>-</td> <td>31 (34)</td> </tr> <tr> <td>Nausea</td> <td>83 (24)</td> <td>23 (28)</td> <td>12 (14)</td> </tr> <tr> <td>Dizziness</td> <td>71 (20)</td> <td>19 (27)</td> <td>11 (15)</td> </tr> <tr> <td>Problems with urination</td> <td>69 (20)</td> <td>30 (43)</td> <td>22 (32)</td> </tr> <tr> <td>Numbness</td> <td>67 (20)</td> <td>34 (51)</td> <td>19 (28)</td> </tr> <tr> <td>Feeling bloated</td> <td>62 (18)</td> <td>21 (34)</td> <td>12 (19)</td> </tr> <tr> <td>Diarrhea</td> <td>60 (17)</td> <td>13 (22)</td> <td>9 (15)</td> </tr> <tr> <td>Changes in the way food tastes</td> <td>54 (15)</td> <td>-</td> <td>14 (26)</td> </tr> <tr> <td>Vomiting</td> <td>45 (13)</td> <td>7 (16)</td> <td>11 (24)</td> </tr> <tr> <td>Sweats</td> <td>43 (12)</td> <td>13 (30)</td> <td>8 (19)</td> </tr> <tr> <td>Change in self image</td> <td>43 (13)</td> <td>-</td> <td>15 (35)</td> </tr> <tr> <td>Itching</td> <td>37 (11)</td> <td>14 (38)</td> <td>9 (24)</td> </tr> <tr> <td>Hair loss</td> <td>22 (6)</td> <td>-</td> <td>8 (36)</td> </tr> <tr> <td>Mouth sores</td> <td>21 (6)</td> <td>-</td> <td>0 (0)</td> </tr> <tr> <td>Problems with sexual interest or activity</td> <td>12 (3)</td> <td>5 (42)</td> <td>3 (25)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* <strong>Present:</strong> answer other than \"do not have\" or \"do not know\".<br />&para; <strong>Frequent:</strong> \"frequently\" or \"almost constantly\".<br />&Delta; <strong>Severe:</strong> \"severe\" or \"very severe\".<br /></div><div class=\"graphic_reference\">Reproduced from: Kutner JS, Kassner CT, Nowels DE. Symptom Burden at the End of Life: Hospice Providers' Perceptions. J Pain Symptom Manage 2001; 21:473. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 73729 Version 3.0</div></div></div>"},"73730":{"type":"graphic_figure","displayName":"Knee walker","title":"Knee walker","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Knee walker</div><div class=\"cntnt\"><img style=\"width:476px; height:674px;\" src=\"images/SURG/73730_Knee-walker.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73730 Version 2.0</div></div></div>"},"73731":{"type":"graphic_picture","displayName":"FAST perisplenic left flank probe position","title":"FAST: Perisplenic (left flank) probe position","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">FAST: Perisplenic (left flank) probe position</div><div class=\"cntnt\"><img style=\"width:504px; height:334px;\" src=\"images/EM/73731_FAST_splenorenal_left_flank.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows proper probe position for obtaining a view of the&#160;splenorenal interface.</div><div class=\"graphic_reference\">Courtesy of Manoj Pariyadath, MD.</div><div id=\"graphicVersion\">Graphic 73731 Version 2.0</div></div></div>"},"73733":{"type":"graphic_table","displayName":"Amino acid composition GnRHa","title":"Amino acid composition of native GnRH and GnRH agonist analogues","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Amino acid composition of native GnRH and GnRH agonist analogues</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Amino acid position</td> <td class=\"subtitle1\">1</td> <td class=\"subtitle1\">2</td> <td class=\"subtitle1\">3</td> <td class=\"subtitle1\">4</td> <td class=\"subtitle1\">5</td> <td class=\"subtitle1\">6</td> <td class=\"subtitle1\">7</td> <td class=\"subtitle1\">8</td> <td class=\"subtitle1\">9</td> <td class=\"subtitle1\">10</td> </tr> <tr> <td>GnRH </td> <td>pGlu</td> <td>His</td> <td>Trp</td> <td>Ser</td> <td>Tyr</td> <td>Gly</td> <td>Leu</td> <td>Arg</td> <td>Pro</td> <td>Gly-NH2</td> </tr> <tr> <td>Leuprolide</td> <td>pGlu</td> <td>His</td> <td>Trp</td> <td>Ser</td> <td>Tyr</td> <td>D-Leu6</td> <td>Leu</td> <td>Arg</td> <td>N-ethyl Pro</td> <td>&nbsp;</td> </tr> <tr> <td>Nafarelin</td> <td>pGlu</td> <td>His</td> <td>Trp</td> <td>Ser</td> <td>Tyr</td> <td>D-Nal(2)6</td> <td>Leu</td> <td>Arg</td> <td>Pro</td> <td>Gly-NH2</td> </tr> <tr> <td>Goserelin</td> <td>pGlu</td> <td>His</td> <td>Trp</td> <td>Ser</td> <td>Tyr</td> <td>D-Ser(tBu)6</td> <td>Leu</td> <td>Arg</td> <td>Pro</td> <td>Aza-Gly-NH10</td> </tr> <tr> <td>Buserelin</td> <td>pGlu</td> <td>His</td> <td>Trp</td> <td>Ser</td> <td>Tyr</td> <td>D-Ser(tBu)6</td> <td>Leu</td> <td>Arg</td> <td>Pro</td> <td>&nbsp;</td> </tr> <tr> <td>Histrelin</td> <td>pGlu</td> <td>His</td> <td>Trp</td> <td>Ser</td> <td>Tyr</td> <td>Imbzl-D-His6</td> <td>Leu</td> <td>Arg</td> <td>Pro</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All of the agonists have amino acid changes at positions 6 and most have changes at position 10.</div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone agonist.</div><div class=\"graphic_reference\">Courtesy of Robert L Barbieri, MD.</div><div id=\"graphicVersion\">Graphic 73733 Version 2.0</div></div></div>"},"73735":{"type":"graphic_picture","displayName":"Chronic otitis media with effusion","title":"Chronic otitis media with effusion","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Chronic otitis media with effusion</div><div class=\"cntnt\"><img style=\"width:451px; height:405px;\" src=\"images/ID/73735_ChronicOMwitheffusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tympanic membrane in chronic otitis media with effusion. The membrane is not erythematous, but fluid levels (arrows) can be seen.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 73735 Version 3.0</div></div></div>"},"73737":{"type":"graphic_picture","displayName":"Histol lentigo maligna melanoma","title":"Lentigo maligna melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lentigo maligna melanoma</div><div class=\"cntnt\"><img style=\"width:382px; height:270px;\" src=\"images/ONC/73737_Histol_lentigo_maligna_mela.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power light photomicrograph of a lentigo maligna melanoma. Within a background of epidermal atrophy, the neoplastic melanocytes are arrayed along the dermo-epidermal junction in a lentiginous pattern. Small dyshesive nests are also seen along the junction (black arrows).</div><div class=\"graphic_reference\">Courtesy of Vincent Liu, MD, and April Wang Armstrong, MD.</div><div id=\"graphicVersion\">Graphic 73737 Version 2.0</div></div></div>"},"73738":{"type":"graphic_table","displayName":"Causes HTN children","title":"Causes of secondary hypertension in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of secondary hypertension in children and adolescents</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Renal disease</td> </tr> <tr> <td class=\"indent1\">Pyelonephritis</td> </tr> <tr> <td class=\"indent1\">Renal parenchymal disease</td> </tr> <tr> <td class=\"indent1\">Congenital anomalies</td> </tr> <tr> <td class=\"indent1\">Reflux nephropathy</td> </tr> <tr> <td class=\"indent1\">Acute glomerulonephritis</td> </tr> <tr> <td class=\"indent1\">Henoch-Sch&#246;nlein purpura</td> </tr> <tr> <td class=\"indent1\">Renal trauma</td> </tr> <tr> <td class=\"indent1\">Hydronephrosis</td> </tr> <tr> <td class=\"indent1\">Hemolytic uremic syndrome</td> </tr> <tr> <td class=\"indent1\">Renal stones</td> </tr> <tr> <td class=\"indent1\">Nephrotic syndrome</td> </tr> <tr> <td class=\"indent1\">Wilm's tumor</td> </tr> <tr> <td class=\"indent1\">Hypoplastic kidney</td> </tr> <tr> <td class=\"indent1\">Polycystic kidney disease</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine disease</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">Congenital adrenal hyperplasia</td> </tr> <tr> <td class=\"indent1\">Cushing syndrome</td> </tr> <tr> <td class=\"indent1\">Primary aldosteronism</td> </tr> <tr> <td class=\"indent1\">Primary hyperparathyroidism</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Hypercalcemia</td> </tr> <tr> <td class=\"indent1\">Pheochromocytoma</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic causes</td> </tr> <tr> <td class=\"indent1\">Increased intracranial pressure</td> </tr> <tr> <td class=\"indent1\">Guillain-Barr&#233; syndrome</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Psychologic causes</td> </tr> <tr> <td class=\"indent1\">Mental stress</td> </tr> <tr> <td class=\"indent1\">Anxiety</td> </tr> <tr> <td class=\"subtitle1_single\">Pharmacologic causes</td> </tr> <tr> <td class=\"indent1\">Sympathomimetics</td> </tr> <tr> <td class=\"indent1\">Corticosteroids</td> </tr> <tr> <td class=\"indent1\">Stimulants</td> </tr> <tr> <td class=\"indent1\">Oral contraceptives</td> </tr> <tr> <td class=\"indent1\">Anabolic steroids</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> </tr> <tr> <td class=\"indent1\">Phencyclidine (PCP)</td> </tr> <tr> <td class=\"indent1\">Licorice</td> </tr> <tr> <td class=\"indent1\">Nicotine</td> </tr> <tr> <td class=\"indent1\">Caffeine</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular disease</td> </tr> <tr> <td class=\"indent1\">Renal artery abnormalities</td> </tr> <tr> <td class=\"indent1\">Renal vein thrombosis</td> </tr> <tr> <td class=\"indent1\">Coarctation of the aorta</td> </tr> <tr> <td class=\"indent1\">Patent ductus arteriosus</td> </tr> <tr> <td class=\"indent1\">Arteriovenous fistula</td> </tr> <tr> <td class=\"subtitle1_single\">Other causes</td> </tr> <tr> <td class=\"indent1\">Neuroblastoma</td> </tr> <tr> <td class=\"indent1\">Heavy metal poisoning</td> </tr> <tr> <td class=\"indent1\">Acute pain</td> </tr> <tr> <td class=\"indent1\">Collagen vascular diseases</td> </tr> <tr> <td class=\"indent1\">Neurofibromatosis</td> </tr> <tr> <td class=\"indent1\">Tuberous sclerosis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Tunnessen WW, Roberts KB. Hypertension. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.413.</li>&#xD;&#xA;    <li>Pappadis SL, Somers MJ. Hypertension in adolescents: a review of diagnosis and management. Curr Opin Pediatr 2003; 15:370.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 73738 Version 3.0</div></div></div>"},"73740":{"type":"graphic_figure","displayName":"Accessory AV pathways I","title":"AV conduction with a concealed accessory pathway","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AV conduction with a concealed accessory pathway</div><div class=\"cntnt\"><img style=\"width:424px; height:302px;\" src=\"images/CARD/73740_Accessory_AV_pathways_I_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of atrioventricular conduction. The normal pacemaker is in the sinoatrial (SA) node at the junction of the superior vena cava and the right atrium. The SA node activates the right and left atria (shown in green). In the absence of an accessory pathway (AP) or, as in this case, if the AP is concealed, ventricular activation results from the impulse traversing the AV node, the specialized infranodal conducting system (His bundle and bundle and fascicular branches, shown in red), thereby activating the ventricular myocardium (shown in yellow). The ECG shows a normal PR interval and a narrow QRS complex. The inset on the right shows the timing of SA node (SAN), right (RA) and left atrial (LA), His bundle (H), and the beginning of normal ventricular activation (V<sub>N</sub>). All of ventricular activation (shown in yellow) is due to normal AV nodal and infranodal conduction.</div><div id=\"graphicVersion\">Graphic 73740 Version 3.0</div></div></div>"},"73741":{"type":"graphic_algorithm","displayName":"H pylori and gastric CA","title":"Possible mechanisms of Helicobacter pylori-induced gastric carcinogenesis","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Possible mechanisms of Helicobacter pylori-induced gastric carcinogenesis</div><div class=\"cntnt\"><img style=\"width:517px; height:292px;\" src=\"images/GAST/73741_H_pylori_and_gastric_CA.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Blaser, MJ, Parsonnet, J, J Clin Invest 1994; 94:4.</div><div id=\"graphicVersion\">Graphic 73741 Version 2.0</div></div></div>"},"73744":{"type":"graphic_diagnosticimage","displayName":"Bronchogenic carcinoma CT I","title":"Peripheral bronchogenic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral bronchogenic carcinoma</div><div class=\"cntnt\"><img style=\"width:276px; height:239px;\" src=\"images/PULM/73744_Bronchogenic_carcinoma_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows peripheral mass, in the right lung representing a T3 bronchogenic carcinoma, invading and extending through the intercostal space.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 73744 Version 3.0</div></div></div>"},"73745":{"type":"graphic_movie","displayName":"Breech delivery using forceps for aftercoming head","title":"Breech delivery using forceps for aftercoming head","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Breech delivery using forceps for aftercoming head</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/73745_Bredelusingforcepconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:350px; height:360px;\" src=\"images/OBGYN/73745_Breechdelivusingforceps.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Rafik Mansour, MD and the STRATUS Center for Medical Simulation at Brigham and Women's Hospital, Boston, MA.</div><div id=\"graphicVersion\">Graphic 73745 Version 2.0</div></div></div>"},"73746":{"type":"graphic_diagnosticimage","displayName":"Pleural effusion and diaphragm","title":"Pleural effusion and diaphragm on thoracic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural effusion and diaphragm on thoracic ultrasound</div><div class=\"cntnt\"><img style=\"width:432px; height:298px;\" src=\"images/PULM/73746_Pleural_effusion_diaph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical orientation of ultrasound views of a large anechoic pleural effusion on the right. The transducer marker is seen in blue at the top of the image. The effusion is located immediately above the diaphragm, which appears hyperechoic relative to the liver.</div><div id=\"graphicVersion\">Graphic 73746 Version 2.0</div></div></div>"},"73747":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound images of single umbilical artery","title":"Prenatal ultrasound images of single umbilical artery","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound images of single umbilical artery</div><div class=\"cntnt\"><img style=\"width:586px; height:336px;\" src=\"images/OBGYN/73747_US_images_single_umbil_art.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Single umbilical artery. Transverse section of a two-vessel umbilical cord in two different fetuses shows the typical &quot;soda can tab&quot; sign.<br> (Panel B) Single umbilical artery. Longitudinal views of a two-vessel umbilical cord as depicted by two-dimensional ultrasound show the single umbilical artery (sua) and the vein (v). Upper panel, fetus with a coiled umbilical cord. Lower panel, fetus with a straight, non-coiled umbilical cord.<br> (Panel C) Single umbilical artery. Color Doppler ultrasound shows a straight, non-coiled two-vessel umbilical cord (upper panel) and a coiled two-vessel umbilical cord (lower panel).</div><div id=\"graphicVersion\">Graphic 73747 Version 3.0</div></div></div>"},"73749":{"type":"graphic_table","displayName":"Post RT ambul rates scores","title":"Malignant epidural spinal cord compression: scoring system to predict outcomes post-radiotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Malignant epidural spinal cord compression: scoring system to predict outcomes post-radiotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1\">Variable</td>\n\t    <td class=\"subtitle1\">Post-RT ambulatory rate, percent</td>\n\t    <td class=\"subtitle1\">Score</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"3\">Type of primary tumor</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Breast cancer</td>\n\t    <td>81</td>\n\t    <td>8</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Prostate cancer</td>\n\t    <td>68</td>\n\t    <td>7</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Myeloma/lymphoma</td>\n\t    <td>89</td>\n\t    <td>9</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Non-small-cell lung cancer</td>\n\t    <td>54</td>\n\t    <td>5</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Small-cell lung cancer</td>\n\t    <td>64</td>\n\t    <td>6</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Cancer of unknown primary</td>\n\t    <td>45</td>\n\t    <td>5</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Renal cell carcinoma</td>\n\t    <td>62</td>\n\t    <td>6</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Colorectal cancer</td>\n\t    <td>64</td>\n\t    <td>6</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Other tumors</td>\n\t    <td>59</td>\n\t    <td>6</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"3\">Interval from tumor diagnosis to MSCC</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">&#8804;15 mo</td>\n\t    <td>58</td>\n\t    <td>6</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">&#62;15 mo</td>\n\t    <td>78</td>\n\t    <td>8</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"3\">Visceral metastases at the time of RT</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Yes</td>\n\t    <td>54</td>\n\t    <td>5</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">No</td>\n\t    <td>77</td>\n\t    <td>8</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"3\">Motor function before RT</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Ambulatory without aid</td>\n\t    <td>98</td>\n\t    <td>10</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Ambulatory with aid</td>\n\t    <td>89</td>\n\t    <td>9</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Not ambulatory</td>\n\t    <td>28</td>\n\t    <td>3</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Paraplegic</td>\n\t    <td>7</td>\n\t    <td>1</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"3\">Time of developing motor deficits before RT</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">1-7 days</td>\n\t    <td>37</td>\n\t    <td>4</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">8-14 days</td>\n\t    <td>69</td>\n\t    <td>7</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">&#62;14 days</td>\n\t    <td>88</td>\n\t    <td>9</td>\n\t  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">RT: radiotherapy; MSCC: metastatic spinal cord compression.</div><div class=\"graphic_reference\">Reproduced with permission from: Rades D, Rudat V, Veninga T, et al. A score predicting posttreatment ambulatory status in patients irradiated for metastatic spinal cord compression. Int J Rad Oncol Biol Phys 2008; 72:905. Illustration used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 73749 Version 2.0</div></div></div>"},"73750":{"type":"graphic_picture","displayName":"Bladder exstrophy female","title":"Bladder exstrophy (female)","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Bladder exstrophy (female)</div><div class=\"cntnt\"><img style=\"width:477px; height:319px;\" src=\"images/PEDS/73750_Bladder_exstrophy_female.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of&nbsp;Joseph G Borer, MD.</div><div id=\"graphicVersion\">Graphic 73750 Version 4.0</div></div></div>"},"73751":{"type":"graphic_figure","displayName":"Effect of disease prevalence on predictive values","title":"Effect of disease prevalence on predictive values","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of disease prevalence on predictive values</div><div class=\"cntnt\"><img style=\"width:380px; height:256px;\" src=\"images/PEDS/73751_Prevalenceandpredvalue.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Consider a population of 2000 people and a diagnostic test that is 90 percent sensitive and specific. The positive and negative predictive values of the test vary when the prevalence of the disease is varied. <br />Left panel: If the prevalence of the disease is high at 50 percent, the positive and negative predictive values will be similar to the sensitivity and specificity (90 percent, respectively). <br />Right panel: In contrast, if the prevalence of the disease is only 1 percent, the positive predictive value decreases (8 percent) and the negative predictive value increases (99 percent).</div><div id=\"graphicVersion\">Graphic 73751 Version 2.0</div></div></div>"},"73752":{"type":"graphic_diagnosticimage","displayName":"Severe right PIE","title":"Severe right-sided pulmonary interstitial emphysema in a neonate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe right-sided pulmonary interstitial emphysema in a neonate</div><div class=\"cntnt\"><img style=\"width:283px; height:361px;\" src=\"images/PEDS/73752_Severe_right_PIE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note massive hyperinflation of right lung with herniation across midline.</div><div class=\"graphic_reference\">Courtesy of Gerardo Cabrera-Meza, MD.</div><div id=\"graphicVersion\">Graphic 73752 Version 3.0</div></div></div>"},"73753":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of popliteal stent","title":"Ultrasound of popliteal stent-graft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of popliteal stent-graft</div><div class=\"cntnt\"><img style=\"width:432px; height:459px;\" src=\"images/SURG/73753_US_pop_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The stent graft is widely patent by color flow Duplex and the stent struts (bright white) are well-visualized and fully expanded. The aneurysm sac is completely thrombosed without evidence of endoleak.</div><div class=\"graphic_reference\">Courtesy of Dr. Joseph L Mills, Sr.</div><div id=\"graphicVersion\">Graphic 73753 Version 2.0</div></div></div>"},"73754":{"type":"graphic_table","displayName":"Classification of non-5q SMAs","title":"Simplified classification of non-5q spinal muscular atrophies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Simplified classification of non-5q spinal muscular atrophies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease/phenotype, selected distinguishing features</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Gene/locus</td> <td class=\"subtitle1\">OMIM designations</td> <td class=\"subtitle1\">MIM number</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Distal spinal muscular atrophy/distal hereditary motor neuropathy or neuronopathy</td> </tr> <tr> <td class=\"indent1\">SMA with respiratory distress or diaphragmatic SMA</td> <td>AR</td> <td>IGHMBP2</td> <td>SMARD1/HMN6/DSMA1</td> <td>604320</td> </tr> <tr> <td class=\"indent1\">Distal HMN</td> <td>AR</td> <td>SIGMAR1</td> <td>DSMA2/HMNJ</td> <td>605726</td> </tr> <tr> <td class=\"indent1\">Distal SMA</td> <td>AR</td> <td>11q13</td> <td>DSMA3/HMN3/HMN4</td> <td>607088</td> </tr> <tr> <td class=\"indent1\">Lower motor neuron syndrome with childhood onset</td> <td>AR</td> <td>PLEKHG5</td> <td>DSMA4</td> <td>611067</td> </tr> <tr> <td class=\"indent1\">Distal SMA with late adolescent or young adult onset</td> <td>AR</td> <td>DNAJB2 </td> <td>DSMA5</td> <td>614881 </td> </tr> <tr> <td class=\"indent1\">Distal HMN/SMA, juvenile</td> <td>AD</td> <td>7q34-q36</td> <td>HMN1</td> <td>182960</td> </tr> <tr> <td class=\"indent1\">Distal adult HMN, Type IIA</td> <td>AD</td> <td>HSPB8</td> <td>HMN2A</td> <td>158590</td> </tr> <tr> <td class=\"indent1\">Distal HMN, Type IIB</td> <td>AD</td> <td>HSPB1</td> <td>HMN2B</td> <td>608634</td> </tr> <tr> <td class=\"indent1\">Distal HMN, Type IIC</td> <td>AD</td> <td>HSPB3</td> <td>HMN2C</td> <td>613376</td> </tr> <tr> <td class=\"indent1\">Distal SMA with upper-limb predominance, Type VA</td> <td>AD</td> <td>GARS</td> <td>HMN5</td> <td>600794</td> </tr> <tr> <td class=\"indent1\">Charcot-Marie-Tooth disease 2D</td> <td>AD</td> <td>GARS</td> <td>CMT2D</td> <td>601472</td> </tr> <tr> <td class=\"indent1\">Distal SMA with upper-limb predominance, Type VB</td> <td>AD</td> <td>BSCL2</td> <td>HMN5</td> <td>600794</td> </tr> <tr> <td class=\"indent1\">Silver spastic paraplegia syndrome</td> <td>AD</td> <td>BSCL2</td> <td>SPG17</td> <td>270685</td> </tr> <tr> <td class=\"indent1\">Distal HMN with vocal cord paralysis</td> <td>AD</td> <td>2q14</td> <td>HMN7A</td> <td>158580</td> </tr> <tr> <td class=\"indent1\">Distal HMN with vocal cord paralysis</td> <td>AD</td> <td>DCTN1</td> <td>HMN7B</td> <td>607641</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Proximal spinal muscular atrophy (+/- distal involvement)</td> </tr> <tr> <td class=\"indent1\">SMA with late-onset, Finkel type</td> <td>AD</td> <td>VAPB</td> <td>SMAFK</td> <td>608627</td> </tr> <tr> <td class=\"indent1\">SMA, Jokela type</td> <td>AD</td> <td>CHCHD10</td> <td>SMAJ</td> <td>615048 </td> </tr> <tr> <td class=\"indent1\">Congenital SMA with contractures/SMA, congenital, nonprogressive, with lower limb predominance</td> <td>AD</td> <td>TRPV4</td> <td>&nbsp;</td> <td>600175</td> </tr> <tr> <td class=\"indent1\">Scapuloperoneal SMA</td> <td>AD</td> <td>TRPV4</td> <td>SPSMA</td> <td>181405</td> </tr> <tr> <td class=\"indent1\">Charcot-Marie-Tooth, Type 2C</td> <td>AD</td> <td>TRPV4</td> <td>HMSN2C</td> <td>606071</td> </tr> <tr> <td class=\"indent1\">SMA with lower extremity predominance 1&nbsp;(early onset)</td> <td>AD</td> <td>DYNC1H1</td> <td>SMALED1</td> <td>158600</td> </tr> <tr> <td class=\"indent1\">SMA with lower extremity predominance 2&nbsp;(early onset)</td> <td>AD</td> <td>BICD2</td> <td>SMALED2&nbsp;</td> <td>615290</td> </tr> <tr> <td class=\"indent1\">Hereditary motor and sensory neuropathy, Okinawa type</td> <td>AD</td> <td>TFG</td> <td>HMSNO</td> <td>604484</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Other non-5q spinal and bulbar muscular atrophies, SMA plus types</td> </tr> <tr> <td class=\"indent1\">Lethal arthrogryposis with anterior horn cell disease</td> <td>AR</td> <td>GLE1</td> <td>LAAHD</td> <td>611890</td> </tr> <tr> <td class=\"indent1\">Lethal congenital contracture syndrome 1</td> <td>AR</td> <td>GLE1</td> <td>LCCS1</td> <td>253310</td> </tr> <tr> <td class=\"indent1\">Pontocerebellar hypoplasia type 1A</td> <td>AR</td> <td>VRK1</td> <td>PCH1A</td> <td>607596</td> </tr> <tr> <td class=\"indent1\">Pontocerebellar hypoplasia type 1B</td> <td>AR</td> <td>EXOSC3 </td> <td>PCH1B </td> <td>614678</td> </tr> <tr> <td class=\"indent1\">Brown-Vialetto-Van Laere syndrome 1</td> <td>AR</td> <td>SLC52A3</td> <td>BVVLS1</td> <td>211530</td> </tr> <tr> <td class=\"indent1\">Fazio-Londe disease, bulbar palsy</td> <td>AR</td> <td>SLC52A3</td> <td>&nbsp;</td> <td>211500</td> </tr> <tr> <td class=\"indent1\">Brown-Vialetto-Van Laere syndrome 2</td> <td>AR</td> <td>SLC52A2</td> <td>BVVLS2</td> <td>614707</td> </tr> <tr> <td class=\"indent1\">Spinal muscular atrophy with progressive myoclonic epilepsy</td> <td>AR&nbsp;</td> <td>ASAH1</td> <td>SMAPME</td> <td>159950</td> </tr> <tr> <td class=\"indent1\">Spinal and bulbar muscular atrophy (Kennedy disease)</td> <td>XR</td> <td>AR</td> <td>SMAX1/SBMA</td> <td>313200</td> </tr> <tr> <td class=\"indent1\">Infantile SMA with arthrogryposis</td> <td>XR</td> <td>UBA1</td> <td>SMAX2</td> <td>301830</td> </tr> <tr> <td class=\"indent1\">Distal SMA, X-linked</td> <td>XR</td> <td>ATP7A</td> <td>SMAX3</td> <td>300489</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD:&nbsp;autosomal dominant; AR:&nbsp;autosomal recessive; HMN:&nbsp;hereditary motor neuropathy or neuronopathy; DSMA:&nbsp;distal spinal muscular atrophy; SMA:&nbsp;spinal muscular atrophy; XR:&nbsp;X-linked recessive<br /></div><div class=\"graphic_reference\">Modified with permission from: Darras BT. Non-5q spinal muscular atrophies: the alphanumeric soup thickens. Neurology 2011; 77:31. Copyright © 2011 Lippincott Williams &amp; Wilkins.<BR>Additional data from: <A style=\"FONT-STYLE: italic\" href=\"http://www.ncbi.nlm.nih.gov/omim\">Online Inheritance in Man</A></div><div id=\"graphicVersion\">Graphic 73754 Version 10.0</div></div></div>"},"73756":{"type":"graphic_figure","displayName":"Blood supply to the colon and rectum","title":"Blood supply to the colon and rectum","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Blood supply to the colon and rectum</div><div class=\"cntnt\"><img style=\"width:527px; height:540px;\" src=\"images/SURG/73756_Blood_supply_to_the_colon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The blood supply to the colon originates from the SMA and the IMA. The SMA arises approximately 1 cm below the celiac artery and runs inferiorly toward the cecum, terminating as the ileocolic artery. The SMA gives rise to the inferior pancreaticoduodenal artery, several jejunal and ileal branches, the middle colic artery, and the right colic artery. <br />As a general rule, the middle colic artery arises from the proximal SMA and supplies blood to the proximal to midtransverse colon. However, it occasionally provides the predominant blood flow to the splenic flexure. <br />The right colic artery supplies blood to the mid-distal ascending colon. In anatomical studies, the right colic artery arises independently from the SMA in 28 percent of individuals, which is depicted in this figure. More frequently, the right colic artery arises with, or as a branch of, the middle colic, ileocolic, or left colic arteries. The right colic artery is absent in 13 percent of individuals.<SUP>[1]</SUP><br />The ileocolic artery supplies blood to the distal ileum, cecum, and proximal ascending colon.<br />The IMA arises approximately 6 to 7 cm below the SMA. The IMA gives rise to the left colic artery and sigmoid arteries continuing as the superior rectal (hemorrhoidal) artery. It is largely responsible for supplying blood&nbsp;distal to the&nbsp;transverse colon.</div><div class=\"graphic_footnotes\">SMA: superior mesenteric artery; IMA: inferior mesenteric artery.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Bergman RA, Thompson SA, Afifi AK, Saadeh FA. Compendium of Human Anatomic Variation: Text, Atlas, and World Literature, Urban &amp; Schwarzenberg, Baltimore, MD&nbsp;1988.</LI></OL></div><div id=\"graphicVersion\">Graphic 73756 Version 11.0</div></div></div>"},"73757":{"type":"graphic_figure","displayName":"Mitochondrial genome","title":"Mitochondrial genome","html":"<div class=\"graphic\"><div style=\"width: 654px\" class=\"figure\"><div class=\"ttl\">Mitochondrial genome</div><div class=\"cntnt\"><img style=\"width:634px; height:804px;\" src=\"images/PC/73757_Mitochon_genome_PR.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: MITOMAP: A human mitochondrial genome database. Available at: http://mitomap.org/pub/MITOMAP/MitomapFigures/mitomapgenome.pdf. (Accessed December 6, 2011).</div><div id=\"graphicVersion\">Graphic 73757 Version 2.0</div></div></div>"},"73760":{"type":"graphic_figure","displayName":"Fibrosis progression after transplant","title":"Progression of hepatic fibrosis after HCT for thalassemia major, according to iron and HCV status","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Progression of hepatic fibrosis&nbsp;after HCT for thalassemia major, according to&nbsp;iron and HCV status</div><div class=\"cntnt\"><img style=\"width:555px; height:309px;\" src=\"images/HEME/73760_Fibrosis_progression_ex_tha.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the probability of surviving without progression of hepatic fibrosis (percent, y axis) versus time after HCT (months, x axis) in 211 patients with thalassemia major who were not treated with iron chelation or antiviral therapy. Patients were stratified into six groups according to hepatic iron concentration (low: 0.5 to 5.6, medium: 5.7 to 12.7, high &gt;12.7 mg/g dry weight) and HCV status (positive, negative). HCV-negative patients with low or medium hepatic iron levels did not show progression of fibrosis and were grouped together (uppermost curve, red).</div><div class=\"graphic_footnotes\">HCT: hematopoietic cell transplant; HCV: hepatitis C virus.</div><div class=\"graphic_reference\">Data from Angelucci, E, et al. Blood 2002; 100:17.</div><div id=\"graphicVersion\">Graphic 73760 Version 5.0</div></div></div>"},"73762":{"type":"graphic_algorithm","displayName":"Pathogenesis of PBC","title":"Pathogenesis of primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:396px; height:530px;\" src=\"images/GAST/73762_Pathogenesis_of_PBC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The initial requirement is a genetically susceptible host, which may involve an inability to suppress an immunologically mediated attack on bile duct cells once it has begun. Some triggering event is required to set this process in motion; it could be any event that damages bile duct cells and exposes the unique primary biliary cholangitis bile duct cell antigen to the cellular or humoral immune system. Progressive damage to bile duct cells causes cholestasis. This sets up a vicious cycle in which retention of toxic substances, such as bile acids, cause chemical damage to hepatocytes. Cholestasis also causes increased expression of HLA Class I and II antigens on bile duct cells and hepatocytes which make them better targets for activated lymphocytes. The gradual loss of bile ducts causes progressive scarring, cirrhosis, portal hypertension, and eventually, liver failure.</div><div id=\"graphicVersion\">Graphic 73762 Version 4.0</div></div></div>"},"73763":{"type":"graphic_waveform","displayName":"Basic case 8","title":"Basic case 8","html":"<div class=\"graphic normal\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Basic case 8</div><div class=\"cntnt\"><img style=\"width:518px; height:113px;\" src=\"images/CARD/73763_Basic_case_8.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73763 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"73764":{"type":"graphic_table","displayName":"Outbreaks of yersiniosis","title":"Signs, symptoms, and outcome in outbreaks of yersiniosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs, symptoms, and outcome in outbreaks of yersiniosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">New York state*</td>\n\n      <td class=\"subtitle1\">Southern US&#8226; </td>\n\n      <td class=\"subtitle1\"> Washington state&#916; </td>\n\n      <td class=\"subtitle1\">Georgia&#9674;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Time period</td>\n\n      <td>1976</td>\n\n      <td>1982</td>\n\n      <td>1981-82</td>\n\n      <td>1988-89</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Median age, years </td>\n\n      <td>13 </td>\n\n      <td>6</td>\n\n      <td>3</td>\n\n      <td>&#60;1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Number of patients</td>\n\n      <td>38</td>\n\n      <td>172</td>\n\n      <td>50</td>\n\n      <td>15</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Serotype</td>\n\n      <td>O:8</td>\n\n      <td>O13a, 13b</td>\n\n      <td>O:8</td>\n\n      <td>O:3</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"5\" rowspan=\"1\">Percent with:</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Diarrhea</td>\n\n      <td class=\"sublist1\">47</td>\n\n      <td class=\"sublist1\">83</td>\n\n      <td class=\"sublist1\">86</td>\n\n      <td class=\"sublist1\">100</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Bloody diarrhea</td>\n\n      <td class=\"sublist1\"> - </td>\n\n      <td class=\"sublist1\">20</td>\n\n      <td class=\"sublist1\">30</td>\n\n      <td class=\"sublist1\">60</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Abdominal pain</td>\n\n      <td class=\"sublist1\"> 97</td>\n\n      <td class=\"sublist1\">86</td>\n\n      <td class=\"sublist1\">96</td>\n\n      <td class=\"sublist1\">-</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Fever</td>\n\n      <td class=\"sublist1\">100 </td>\n\n      <td class=\"sublist1\">93</td>\n\n      <td class=\"sublist1\">91</td>\n\n      <td class=\"sublist1\">100</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Vomiting</td>\n\n      <td class=\"sublist1\">- </td>\n\n      <td class=\"sublist1\">41</td>\n\n      <td class=\"sublist1\">42</td>\n\n      <td class=\"sublist1\">27</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Sore throat</td>\n\n      <td class=\"sublist1\">- </td>\n\n      <td class=\"sublist1\">22</td>\n\n      <td class=\"sublist1\">2</td>\n\n      <td class=\"sublist1\">-</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"5\" rowspan=\"1\">Outcome, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hospitalization</td>\n\n      <td class=\"sublist1\">95 </td>\n\n      <td class=\"sublist1\">-</td>\n\n      <td class=\"sublist1\">30</td>\n\n      <td class=\"sublist1\">47</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Surgery</td>\n\n      <td class=\"sublist1\">42 </td>\n\n      <td class=\"sublist1\">10 </td>\n\n      <td class=\"sublist1\">6</td>\n\n      <td class=\"sublist1\">0</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Death</td>\n\n      <td class=\"sublist1\">0 </td>\n\n      <td class=\"sublist1\">0</td>\n\n      <td class=\"sublist1\">0 </td>\n\n      <td class=\"sublist1\">0</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Dash indicates data were not collected.<span style=\"font-style:italic\"></div><div class=\"graphic_reference\">* Black, RE, Jackson, RJ, Tsai, T, et al, N Engl J Med 1978; 298:76.<br> &#8226; Tacket, CO, Narain, JP, Sattin, R, et al, JAMA 1984; 251:483.<br> &#916; Tacket, CO, Ballard, J, Harris, N, et al, Am J Epidemiol 1985; 121:705.<br> &#9674; Lee, LA, Gerber, R, Lonsway, DR, et al, N Engl J Med 1990; 322:984.</div><div id=\"graphicVersion\">Graphic 73764 Version 1.0</div></div></div>"},"73765":{"type":"graphic_table","displayName":"Pyrazinamide dosing","title":"Suggested pyrazinamide doses, using whole tablets, for adults weighing 40 to 90 kilograms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested pyrazinamide doses, using whole tablets, for adults weighing 40 to 90 kilograms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Weight (kg)*</td> </tr> <tr> <td class=\"subtitle2\">40 to 55</td> <td class=\"subtitle2\">56 to 75</td> <td class=\"subtitle2\">76 to 90</td> </tr> <tr> <td><strong>Daily, mg (mg/kg)</strong></td> <td>1000 (18.2 to 25)</td> <td>1500 (20 to 26.8)</td> <td>2000<sup>&#182;</sup> (22.2 to 26.3)</td> </tr> <tr> <td><strong>Thrice weekly, mg (mg/kg)</strong></td> <td>1500 (27.3 to 37.5)</td> <td>2500 (33.3 to 44.6)</td> <td>3000<sup>&#182;</sup> (33.3 to 39.5)</td> </tr> <tr> <td><strong>Twice weekly, mg (mg/kg)</strong></td> <td>2000 (36.4 to 50)</td> <td>3000 (40 to 53.6)</td> <td>4000<sup>&#182;</sup> (44.4 to 52.6)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Based on estimated lean body weight.<br />¶ Maximum dose regardless of weight.</div><div class=\"graphic_reference\">Reproduced from: Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63(7):e147-e195, by permission of Oxford University Press on behalf of the Infectious Diseases Society of America. Copyright © 2016 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.idsociety.org/\" target=_blank>www.idsociety.org</A>.</div><div id=\"graphicVersion\">Graphic 73765 Version 10.0</div></div></div>"},"73766":{"type":"graphic_picture","displayName":"Anaplastic astrocytoma Light","title":"Anaplastic astrocytoma histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anaplastic astrocytoma histology</div><div class=\"cntnt\"><img style=\"width:396px; height:258px;\" src=\"images/ONC/73766_Anaplastic_astrocytoma_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypercellular tumor with marked nuclear pleomorphism, mitotic figures, and lack of endothelial vascular proliferation or necrosis. Hematoxylin and eosin; magnified x 200.</div><div class=\"graphic_reference\">Prepared by Mila Blaivas, MD, PhD.</div><div id=\"graphicVersion\">Graphic 73766 Version 1.0</div></div></div>"},"73767":{"type":"graphic_diagnosticimage","displayName":"Triple phase CT HCC diagnosis","title":"Triple phase CT scanning of hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Triple phase CT scanning of hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:504px; height:127px;\" src=\"images/ONC/73767_Triple_phase_CT_HCC_diagnos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT images of a 74-year-old man with cirrhosis and a history of alcohol exposure. Panel A: Unenhanced scan of liver shows exophytic mass (arrow) in segment VII; panel B: Contrast-enhanced scan of the liver during late arterial phase shows the lesion more clearly and multiple additional enhancing masses suspicious for multifocal disease (arrows); panel C: contrast-enhanced scan during venous delayed phase of enhancement shows decrease in the contrast between lesion and adjacent liver.</div><div class=\"graphic_reference\">Szklaruk J, Silverman PM, Charnsangavej C. Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carinoma. Am J Roentgenol 2003; 180:441. Reprinted with permission from the American Journal of Roentgenology.&nbsp;Copyright © 2003 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 73767 Version 10.0</div></div></div>"},"73768":{"type":"graphic_figure","displayName":"Unicornuate uter and xtra hornC","title":"Unicornuate uterus with noncommunicating uterine horn (containing an endometrial cavity) fused to unicornuate uterus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unicornuate uterus with noncommunicating uterine horn (containing an endometrial cavity) fused to unicornuate uterus</div><div class=\"cntnt\"><img style=\"width:382px; height:260px;\" src=\"images/OBGYN/73768_Unicornuateuterandxtra2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 73768 Version 10.0</div></div></div>"},"73769":{"type":"graphic_picture","displayName":"Circumscribed morphea - inflammatory plaque","title":"Circumscribed morphea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circumscribed morphea</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/73769_Circum_morph_inflamm_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An indurated plaque with central hypopigmentation and peripheral erythema is present in this patient with circumscribed morphea.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>.&nbsp;Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73769 Version 3.0</div></div></div>"},"73770":{"type":"graphic_picture","displayName":"Eclipse nevus","title":"Eclipse nevus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eclipse nevus</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/73770_Eclipse_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A compound nevus on the scalp of a child showing a light brown center and a more intensely pigmented rim.</div><div id=\"graphicVersion\">Graphic 73770 Version 3.0</div></div></div>"},"73771":{"type":"graphic_picture","displayName":"C diphtheriae photomicrograph","title":"Photomicrograph of <EM>Corynebacterium diphtheriae</EM>","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Photomicrograph of <EM>Corynebacterium diphtheriae</EM></div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/73771_C_diphth_photomicrograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photomicrograph depicts numerous Gram-positive asporogenous, rod-shaped <EM>Corynebacterium diphtheriae </EM>bacteria.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention Public Health Image Library. Available at:http://phil.cdc.gov/phil/home.asp./u003c/div/u003e/u003cdiv id/u003d\"graphicVersion\">Graphic 73771 Version 3.0</div></div></div>"},"73772":{"type":"graphic_figure","displayName":"Cutaneous larva migrans life cycle","title":"Cutaneous larva migrans life cycle","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Cutaneous larva migrans life cycle</div><div class=\"cntnt\"><img style=\"width:591px; height:453px;\" src=\"images/ID/73772_Cutaneous_Lmigrans_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous larval migrans (also known as creeping eruption) is a zoonotic infection with hookworm species that do not use humans as a definitive host, the most common being <em>Ancylostoma braziliense</em> and <em>Ancylostoma caninum</em>. The normal definitive hosts for these species are dogs and cats. The cycle in the definitive host is very similar to the cycle for the human species. Eggs are passed in the stool <strong>(1)</strong>, and under favorable conditions (moisture, warmth, shade) larvae hatch in one to two days. The released rhabditiform larvae grow in the feces and/or the soil <strong>(2)</strong>, and after 5 to 10 days (and two molts) they become filariform (third-stage) larvae that are infective <strong>(3)</strong>. These infective larvae can survive three to four weeks in favorable environmental conditions. On contact with the animal host <strong>(4)</strong>, the larvae penetrate the skin and are carried through the blood vessels to the heart and then to the lungs. They penetrate into the pulmonary alveoli, ascend the bronchial tree to the pharynx, and are swallowed. The larvae reach the small intestine, where they reside and mature into adults. Adult worms live in the lumen of the small intestine, where they attach to the intestinal wall. Some larvae become arrested in the tissues and serve as source of infection for pups via transmammary (and possibly transplacental) routes <strong>(5)</strong>. Humans may also become infected when filariform larvae penetrate the skin <strong>(6)</strong>. With most species, the larvae cannot mature further in the human host and migrate aimlessly within the epidermis, sometimes as much as several centimeters a day. Some larvae may persist in deeper tissue after finishing their skin migration.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Hookworm. Available at: <a href=\"http://www.cdc.gov/dpdx/hookworm/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/hookworm/index.html</a>.</div><div id=\"graphicVersion\">Graphic 73772 Version 6.0</div></div></div>"},"73773":{"type":"graphic_picture","displayName":"EUS FNA esophageal TB","title":"Esophageal tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal tuberculosis</div><div class=\"cntnt\"><img style=\"width:416px; height:395px;\" src=\"images/GAST/73773_EUS_FNA_esophageal_TB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 47-year-old woman with a remotely positive PPD presented with several months of odynophagia. Panel A: Endoscopy demonstrated an ulcerated area in the proximal esophagus, which on biopsy showed acute and chronic inflammation. Panel B: Endoscopic ultrasonography (EUS) revealed an inhomogenous periesophageal lymph node with a fistula tract to the esophagus. Panel C: Cytology obtained from EUS fine needle aspiration showed multinucleated giant cells with noncaseating granulomatous inflammation. Acid-fast and fungal stains were negative, as were serum fungal titers. Antituberculosis therapy was recommended.</div><div class=\"graphic_reference\">From: Norton ID, Wiersema MJ. Endoscopic ultrasound- guided fine needle aspiration biopsy. In: Endoscopic Ultrasonography. Gress F, Bhattacharya I (Eds), Blackwell Science, Malden, MA 2001. p.136. Reprinted with permission of Blackwell Science, Inc. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 73773 Version 4.0</div></div></div>"},"73775":{"type":"graphic_figure","displayName":"Low sodium diet 1 PI","title":"Low-sodium diet","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Low-sodium diet</div><div class=\"cntnt\"><img style=\"width:578px; height:777px;\" src=\"images/PI/73775_Low_sodium_diet_1_PI.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73775 Version 4.0</div></div></div>"},"73776":{"type":"graphic_form","displayName":"CBT techniques adolescents1","title":"CBT techniques for primary care encounters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CBT techniques for primary care encounters</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Teaching skills to counter distorted thinking:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>1. \"Depression often makes us see small or medium-size problems as huge problems, and that thinking just makes the depression even stronger. So a good trick to keep problems in perspective (and beat depression) is to use the \"Rule of Five\" technique.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   <strong>Rule of Five Technique for battling \"depressogenic\" thinking</strong>\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   When you experience a situation that feels like a problem, you ask yourself if the situation that is bothering you will <em>really</em> matter to you...\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent3\">\r\n  \r\n   &#8226; In 5 decades\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent3\">\r\n  \r\n   &#8226; In 5 years\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent3\">\r\n  \r\n   &#8226; In 5 months\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent3\">\r\n  \r\n   &#8226; In 5 weeks\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent3\">\r\n  \r\n   &#8226; In 5 days\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent3\">\r\n  \r\n   &#8226; In 5 hours\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   If something will not really matter in five years or five decades from now, then it really is not a huge deal, but instead is a small to middle-sized problem. Don't let depression trick you into making small problems into big ones!\"\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>2. \"Depression also sometimes gets in the way of people seeing the good, positive possibilities, or even the neutral aspects of situations. Instead, depression often has us seeing things through \"mud-colored glasses\" where situations are either all good or all bad. So, another useful trick to battle depression is to wipe out \"all-or-none\" thinking and remembering to \"look for the good.\"</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   <strong>Words to AVOID:</strong>\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Always &#8594; Every single time\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Never &#8594; Not even once\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Nobody &#8594; Not even one person\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Everybody &#8594; Every single person\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   <strong>Use these words INSTEAD:</strong>\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Sometimes\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Some\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Pretty good\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   Ok\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Courtesy of Liza Bonin, PhD.</div><div id=\"graphicVersion\">Graphic 73776 Version 2.0</div></div></div>"},"73777":{"type":"graphic_table","displayName":"Genetic causes of congenital diarrhea","title":"Molecular basis of the main forms of congenital diarrheal diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Molecular basis of the main forms of congenital diarrheal diseases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Function</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Defects of digestion, absorption, and transport of nutrients and electrolytes</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Disaccharidase deficiency</td> </tr> <tr> <td class=\"indent2\">Congenital lactase deficiency</td> <td>LCT</td> <td>2q21</td> <td>Lactase-phlorizin hydrolase activity</td> </tr> <tr> <td class=\"indent2\">Sucrase-isomaltase deficiency</td> <td>EC 3.2.1.48</td> <td>3q25-q26</td> <td>Isomaltase-sucrase</td> </tr> <tr> <td class=\"indent2\">Maltase-glucoamylase deficiency</td> <td>MGAM</td> <td>7q34</td> <td>Maltase-glucoamylase activity</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Ion and nutrient transport defects</td> </tr> <tr> <td class=\"indent2\">Glucose-galactose malabsorption</td> <td>SLC5A1 (SGLT1)</td> <td>22q13.1</td> <td>Na<sup>+</sup>/glucose cotransporter</td> </tr> <tr> <td class=\"indent2\">Fructose malabsorption</td> <td>GLUT5</td> <td>1p36</td> <td>Fructose transporter</td> </tr> <tr> <td class=\"indent2\">Fanconi-Bickel syndrome</td> <td>GLUT2</td> <td>3q26</td> <td>Basolateral glucose transporter</td> </tr> <tr> <td class=\"indent2\">Cystic fibrosis</td> <td>CFTR</td> <td>7q31.2</td> <td>cAMP-dependent Cl<sup>&ndash;</sup> channel</td> </tr> <tr> <td class=\"indent2\">Acrodermatitis enteropathica</td> <td>SLC39A4</td> <td>8q24.3</td> <td>Zn<sup>2+</sup> transporter</td> </tr> <tr> <td class=\"indent2\">Congenital chloride diarrhea</td> <td>SLC26A3 (DRA)</td> <td>7q22-q31.1</td> <td>Cl<sup>&ndash;</sup>/base exchanger</td> </tr> <tr> <td class=\"indent2\">Congenital sodium diarrhea</td> <td>SPINT2*</td> <td>19q13.1</td> <td>Serine-protease inhibitor</td> </tr> <tr> <td class=\"indent2\">Familial diarrhea syndrome<sup>[1]</sup></td> <td>GUCY2C</td> <td>12p12.3</td> <td>Intestinal guanylate cyclase C (ligand for bacterial heat-stable enterotoxins)</td> </tr> <tr> <td class=\"indent2\">Lysinuric protein intolerance</td> <td>SLC7A7</td> <td>14q11</td> <td>Hydrolyzes endo-/exopeptidases, amino acid basolateral transport</td> </tr> <tr> <td class=\"indent2\">Congenital bile acid diarrhea</td> <td>SLC10A2 (ABAT)</td> <td>13q33</td> <td>Ileal Na<sup>+</sup>/bile salt transporter</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Pancreatic insufficiency</td> </tr> <tr> <td class=\"indent2\">Enterokinase deficiency</td> <td>PRSS7</td> <td>21q21</td> <td>Proenterokinase</td> </tr> <tr> <td class=\"indent2\">Trypsinogen deficiency</td> <td>PRSS1</td> <td>7q35</td> <td>Trypsinogen synthesis</td> </tr> <tr> <td class=\"indent2\">Pancreatic lipase deficiency</td> <td>PNLIP</td> <td>10q26.1</td> <td>Hydrolyzes triglycerides to fatty acids</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Lipid trafficking</td> </tr> <tr> <td class=\"indent2\">Abetalipoproteinemia</td> <td>MTP</td> <td>4q22</td> <td>Transfer lipids to apolipoprotein B</td> </tr> <tr> <td class=\"indent2\">Hypobetalipoproteinemia</td> <td>APOB</td> <td>2p24</td> <td>Apolipoprotein that forms chylomicrons</td> </tr> <tr> <td class=\"indent2\">Chylomicron retention disease</td> <td>SAR1B</td> <td>5q31.1</td> <td>Intracellular chylomicron trafficking</td> </tr> <tr> <td class=\"indent2\">Diacylglycerol acyltransferase 1&nbsp;deficiency<sup>[2]</sup>&nbsp;</td> <td>DGAT1</td> <td>8q24.3&nbsp;</td> <td><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">Enzyme that catalyzes the final step in triglyceride synthesis </span>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Defects of enterocyte differentiation and polarization</td> </tr> <tr> <td class=\"indent1\">Microvillous inclusion disease</td> <td>MY05B</td> <td>18q21</td> <td>Intracellular protein trafficking</td> </tr> <tr> <td class=\"indent1\">Congenital tufting enteropathy</td> <td>EpCAM</td> <td>2p21</td> <td>Cell-cell interaction</td> </tr> <tr> <td class=\"indent1\">Syndromic diarrhea</td> <td>Unknown</td> <td>Unknown</td> <td>Unknown</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Defects of enteroendocrine cell differentiation</td> </tr> <tr> <td class=\"indent1\">Enteric anendocrinosis</td> <td>NEUROG3</td> <td>10q21.3</td> <td>Enteroendocrine cell fate determination</td> </tr> <tr> <td class=\"indent1\">Enteric dysendocrinosis</td> <td>Unknown</td> <td>Unknown</td> <td>Enteroendocrine cell function</td> </tr> <tr> <td class=\"indent1\">Proprotein convertase 1 deficiency</td> <td>PCSK1</td> <td>5q15-q21</td> <td>Prohormone processing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Defects of modulation of the intestinal immune response</td> </tr> <tr> <td class=\"indent1\">IPEX</td> <td>FOXP3</td> <td>Xp11.23-q13.3</td> <td>Transcription factor</td> </tr> <tr> <td class=\"indent1\">IPEX-like syndrome</td> <td>Unknown</td> <td>Unknown</td> <td>Unknown</td> </tr> <tr> <td class=\"indent1\">Immunodeficiency-associated autoimmune enteropathy</td> <td>Unknown</td> <td>Unknown</td> <td>Unknown</td> </tr> <tr> <td class=\"indent1\">APS-1</td> <td>AIRE</td> <td>21p22.3</td> <td>Regulation gene transcription</td> </tr> <tr> <td class=\"indent1\">Autoimmune enteropathy with colitis-GAGD</td> <td>Unknown</td> <td>Unknown</td> <td>Unknown</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">cAMP: cyclic adenosine monophosphate; EpCAM: epithelial cell adhesion molecule; NEUROG-3: neurogenin-3; IPEX: immune dysregulation polyendocrinopathy, enteropathy, X-linked syndrome; FOXP3: forkhead box P3; APS-1: autoimmune polyglandular syndrome-1; GAGD: generalized autoimmune gut disorder.<br />* This mutation has been associated with the syndromic form of congenital sodium diarrhea.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Fikerstrand T, Arshad J, Haukanes BI, et al. Familial diarrhea syndrome caused by an activating GUCY2C mutation. New Engl J Med 2012; 366:1586.</LI>&#xD;&#xA;<LI>Haas JT, Winter HS, Lim E, et al. DGAT1 mutation is linked to a congenital diarrheal disorder. J Clin Invest 2012; 122:4680.</LI></OL>All other entries in this table were reproduced with permission from: Canani RB, Terrin G, Cardillo G, et al. Congenital Diarrheal Disorders: Improved Understanding of Gene Disorders is Leading to Advances in Intestinal Physiology and Clinical Management. J Pediatr Gastroenterol Nutr 2010; 50:360. Copyright © 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73777 Version 12.0</div></div></div>"},"73778":{"type":"graphic_table","displayName":"Motor sensory social milestones","title":"Average age of attainment of motor, sensory, and social skills in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Average age of attainment of motor, sensory, and social skills in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Skills attained by 4 years of age</td> </tr> <tr> <td>Buttoning and unbuttoning</td> </tr> <tr> <td class=\"subtitle1_single\">Skills attained by 4.5 years of age</td> </tr> <tr> <td>Dressing self (except tying shoelaces)</td> </tr> <tr> <td>Riding a bicycle with training wheels</td> </tr> <tr> <td>Cutting across a page with scissors</td> </tr> <tr> <td>Coloring within the lines</td> </tr> <tr> <td class=\"subtitle1_single\">Skills attained by 5 years of age</td> </tr> <tr> <td>Drawing a square</td> </tr> <tr> <td>Standing on one foot for 15 seconds</td> </tr> <tr> <td class=\"subtitle1_single\">Skills attained by 5.5 years of age</td> </tr> <tr> <td>Tying shoelaces</td> </tr> <tr> <td>Printing first and last name</td> </tr> <tr> <td>Jumping down several steps</td> </tr> <tr> <td>Repetitive finger tapping of thumb and index finger</td> </tr> <tr> <td>Tripod pencil grasp</td> </tr> <tr> <td class=\"subtitle1_single\">Skills attained by 6 years of age</td> </tr> <tr> <td>Riding a bicycle without training wheels</td> </tr> <tr> <td>Ability to spread with a dinner knife</td> </tr> <tr> <td>Rhythmic skipping</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Skills attained by 7 years of age</td> </tr> <tr> <td>Drawing a diagonal line</td> </tr> <tr> <td class=\"subtitle1_single\">Skills attained by 8 years of age</td> </tr> <tr> <td>With his or her eyes closed, can tell you which finger you touched (finger gnosia)</td> </tr> <tr> <td class=\"subtitle1_single\">Skills attained by 8.5 years of age</td> </tr> <tr> <td>Alternating foot-hop in place</td> </tr> <tr> <td class=\"subtitle1_single\">Skills attained by 9 years of age</td> </tr> <tr> <td>Sequential finger tapping at rapid speed</td> </tr> <tr> <td>Drawing two-dimensional cross with same dimensions</td> </tr> <tr> <td class=\"subtitle1_single\">Skills attained by 10 years of age</td> </tr> <tr> <td>Persistent tandem stance for 10 seconds with eyes closed</td> </tr> <tr> <td>Absence of choreiform movements with arms extended</td> </tr> <tr> <td class=\"subtitle1_single\">Skills attained by 11 years of age</td> </tr> <tr> <td>Suppressing mirror movements while doing sequential finger tapping</td> </tr> <tr> <td class=\"subtitle1_single\">Skills attained by 12 years of age</td> </tr> <tr> <td>Drawing three-dimensional cube with all sides angulated</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Blondis TA. Motor disorders and attention-deficit/hyperactivity disorder. Pediatr Clin North Am 1999; 46:899.</div><div id=\"graphicVersion\">Graphic 73778 Version 4.0</div></div></div>"},"73779":{"type":"graphic_picture","displayName":"Perioral dermatitis","title":"Perioral dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perioral dermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:299px;\" src=\"images/PC/73779_Perioral_dermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small acne-like papules and scale are typically present in perioral dermatitis. The skin nearest to the mouth is characteristically spared.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73779 Version 2.0</div></div></div>"},"73781":{"type":"graphic_figure","displayName":"Blood pressure by doctor and nurse","title":"Effect of doctor and nurse measurement of blood pressure during an office visit","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Effect of&nbsp;doctor and nurse measurement of blood pressure during an office visit</div><div class=\"cntnt\"><img style=\"width:452px; height:224px;\" src=\"images/NEPH/73781_BP_by_doctor_and_nurse.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increase in systolic pressure, determined by continuous intra-arterial monitoring, in 30 hypertensive patients as the blood pressure is taken with a sphygmomanometer by an unfamiliar doctor or nurse. A new doctor's visit raised the systolic pressure by a mean of 22 mmHg within the first few minutes, an effect that attenuated within 5 to 10 minutes and that was less pronounced with a nurse's visit. The alerting effect of the new doctor's visit persisted for four daily visits in this study but typically diminished with increasing familiarity. A similar pattern was seen with the diastolic pressure, with the peak increase being 13 mmHg during a doctor's visit.</div><div class=\"graphic_footnotes\">BP: blood pressure.</div><div class=\"graphic_reference\">Data from Mancia G, Parati G, Pomidossi G, et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 1987; 9:209.</div><div id=\"graphicVersion\">Graphic 73781 Version 6.0</div></div></div>"},"73783":{"type":"graphic_diagnosticimage","displayName":"DIP plain radiograph","title":"Desquamative interstitial pneumonitis (DIP)","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Desquamative interstitial pneumonitis (DIP)</div><div class=\"cntnt\"><img style=\"width:462px; height:280px;\" src=\"images/PEDS/73783_DIP_plain_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frontal and lateral chest radiographs in a ten-year old child with DIP show bilateral ground glass abnormality. The child is now known to have mutations in the ABCA3 gene, consistent with a defect in surfactant function.</div><div class=\"graphic_reference\">Courtesy of Leland L Fan, MD and Cynthia Epstein, MD.</div><div id=\"graphicVersion\">Graphic 73783 Version 2.0</div></div></div>"},"73785":{"type":"graphic_picture","displayName":"Normal newborn larynx","title":"Normal newborn larynx","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal newborn larynx</div><div class=\"cntnt\"><img style=\"width:365px; height:286px;\" src=\"images/PEDS/73785_Normal_newborn_larynx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the healthy appearance of the normal structures: epiglottis (E); glottis (G); aryepiglottic folds (AF); vocal folds (vf); and vestibular folds (VF).</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 73785 Version 1.0</div></div></div>"},"73786":{"type":"graphic_picture","displayName":"Traumatic ulcer 2","title":"Traumatic lip ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traumatic lip ulcer</div><div class=\"cntnt\"><img style=\"width:235px; height:240px;\" src=\"images/PEDS/73786_Traumatic_ulcer_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lower lip ulceration from lip chewing in a three-year-old child with Lesch-Nyhan syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Delaney JE, Keels MA. Pediatric oral pathology. Soft tissue and periodontal conditions. Pediatr Clin North Am 2000; 47:1125. Copyright © 2000 W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 73786 Version 3.0</div></div></div>"},"73788":{"type":"graphic_picture","displayName":"Nabothian cyst","title":"Colposcopic view of a Nabothian cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colposcopic view of a Nabothian cyst</div><div class=\"cntnt\"><img style=\"width:384px; height:266px;\" src=\"images/OBGYN/73788_Nabothian_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cyst (the raised area between lines A+B) has a yellow hue and is covered by enlarged capillaries.</div><div class=\"graphic_reference\">Courtesy of Kathryn F McGonigle, MD.</div><div id=\"graphicVersion\">Graphic 73788 Version 1.0</div></div></div>"},"73789":{"type":"graphic_picture","displayName":"Simple endometrial hyperplasia","title":"Simple endometrial hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Simple endometrial hyperplasia</div><div class=\"cntnt\"><img style=\"width:504px; height:375px;\" src=\"images/OBGYN/73789_Simple_hyperplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The endometrial glands in this lesion are irregularly distributed but widely separated by stroma, which is also hyperplastic. The glands are mostly round or tubular, with only a few angularities encountered.</div><div class=\"graphic_reference\">Reproduced with permission from: Silverberg SG, Kurman,RJ. Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. AFIP Atlas of Tumor Pathology, version 2.0, American Registry of Pathology, Washington DC 1995.</div><div id=\"graphicVersion\">Graphic 73789 Version 3.0</div></div></div>"},"73790":{"type":"graphic_picture","displayName":"Heinz body hemolytic anemia","title":"Peripheral smear in Heinz body hemolytic anemia showing Heinz bodies and bite cells","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral smear in Heinz body hemolytic anemia showing Heinz bodies and bite cells</div><div class=\"cntnt\"><img style=\"width:389px; height:270px;\" src=\"images/HEME/73790_Heinz_body_hemolytic_anemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Split screen view of a peripheral smear from a patient with Heinz body hemolytic anemia. Left panel: red cells with characteristic bite-like deformity (arrows). Right panel: Heinz body preparation that reveals the denatured hemoglobin precipitates.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 73790 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"73793":{"type":"graphic_algorithm","displayName":"Insulin titration","title":"Initiation and adjustment of insulin regimens in type 2 diabetes mellitus","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Initiation and adjustment of insulin regimens in type 2 diabetes mellitus</div><div class=\"cntnt\"><img style=\"width:728px; height:578px;\" src=\"images/ENDO/73793_Insulin_titration.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Insulin regimens should be designed taking lifestyle and meal schedule into account. The algorithm can only provide basic guidelines for initiation and adjustment of insulin.</div><div class=\"graphic_footnotes\">A1C: glycated hemoglobin.<br />* Glucose levels updated with data from: American Diabetes Association. Glycemic Targets. Diabetes Care 2016; 39 Suppl 1:S39.<br />¶ The A1C goal should be individualized in accordance with patient age, comorbidities, and life expectancy.<br />Δ Premixed insulins are not recommended during adjustment of doses; however, they can be used conveniently, usually before breakfast and/or dinner if proportion of rapid- and intermediate-acting insulins is similar to the fixed proportions available.</div><div class=\"graphic_reference\">Adapted with permission from: Nathan DM, Buse JB, Davidson MB, et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193. Copyright © 2009 American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 73793 Version 10.0</div></div></div>"},"73795":{"type":"graphic_picture","displayName":"Circinate balanitis 2","title":"Circinate balanitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circinate balanitis</div><div class=\"cntnt\"><img style=\"width:329px; height:432px;\" src=\"images/DERM/73795_Circinate_balanitis_2_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple moist papules are present on the glans penis.</div><div class=\"graphic_reference\">Reproduced with permission from: Keat A. Reactive Arthritis. In: Fitzpatrick's dermatology in general medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw-Hill Professional 2003. Copyright © 2003 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 73795 Version 6.0</div></div></div>"},"73796":{"type":"graphic_movie","displayName":"Toe stand video","title":"Strength exercise video: Toe stand","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Strength exercise video: Toe stand</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PC/73796_Toestandvideo.mp4\" style=\"width:480px;height:336px\"></div><img style=\"width:369px; height:297px;\" src=\"images/PC/73796_ToestandexerciseimgPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise will help make walking easier by strengthening your calves and ankles. For an added challenge, you can modify the exercise to improve your balance.<br> <ol> <li>Stand behind a sturdy chair, feet shoulder-width apart, holding on for balance. Breathe in slowly. </li> <li>Breathe out and slowly stand on tiptoes, as high as possible. </li> <li>Hold position for one second. </li> <li>Breathe in as you slowly lower heels to the floor. </li> <li>Repeat 10 to 15 times. </li> <li>Rest; then repeat 10 to 15 more times. </li> </ol> As you progress, try doing the exercise standing on one leg at a time for a total of 10 to 15 times on each leg.</div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 73796 Version 1.0</div></div></div>"},"73797":{"type":"graphic_table","displayName":"Rapid overview for hypoglycemia in adults","title":"Rapid overview for hypoglycemia in adults, other than significant sulfonylurea overdose","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview for hypoglycemia in adults, other than significant sulfonylurea overdose</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td><strong>Any</strong> patient with acute change in mental status or coma should undergo rapid assessment of blood glucose as a possible cause.</td> </tr> <tr> <td class=\"sublist2_start\">All findings of hypoglycemia are nonspecific, including the following:</td> </tr> <tr> <td class=\"sublist3_start\">&#8226; Autonomic response (tends to occur with blood glucose below 65 mg/dL)</td> </tr> <tr> <td class=\"sublist3\">- Sweating</td> </tr> <tr> <td class=\"sublist3\">- Weakness</td> </tr> <tr> <td class=\"sublist3\">- Tachycardia</td> </tr> <tr> <td class=\"sublist3\">- Palpitations</td> </tr> <tr> <td class=\"sublist3\">- Tremor</td> </tr> <tr> <td class=\"sublist3\">- Nervousness</td> </tr> <tr> <td class=\"sublist3\">- Hunger</td> </tr> <tr> <td class=\"sublist3\">- Paresthesias</td> </tr> <tr> <td class=\"sublist3_start\">&#8226; Neuroglycopenia</td> </tr> <tr> <td class=\"sublist3\">- Irritability</td> </tr> <tr> <td class=\"sublist3\">- Confusion</td> </tr> <tr> <td class=\"sublist3\">- Uncharacteristic behavior</td> </tr> <tr> <td class=\"sublist3\">- Seizure</td> </tr> <tr> <td class=\"sublist3\">- Occasionally, transient focal neurologic deficits</td> </tr> <tr> <td class=\"sublist3\">- Loss of consciousness</td> </tr> <tr> <td class=\"sublist3\">- Visual disturbance</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td class=\"sublist_other_start\"> <ul> <li><strong>Obtain blood glucose</strong> concentration as soon as possible (usually with a meter and strips, if available): </li> </ul> </td> </tr> <tr> <td class=\"indent3\">For symptomatic patient known to have diabetes and with a low glucose value, &#60;70 mg/dL [3.89 mmol/L], administer treatment. If a glucose test cannot be performed, do not delay. Treat <strong>as if</strong> hypoglycemia has been confirmed.</td> </tr> <tr> <td class=\"indent3\">If the glucose is low (&#60;55 mg/dL) and the patient is a not a diabetic, draw blood for glucose, insulin, C-peptide, and an oral hypoglycemic agent screen and then treat,</td> </tr> <tr> <td class=\"sublist_other_start\"> <ul> <li><strong>Do not delay</strong> treatment if symptomatic hypoglycemia is suspected but rapid blood glucose measurement is not available or blood for diagnostic studies cannot be collected. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td> <ul> <li>If the patient is conscious and able to drink and swallow safely (ie, alert enough to do so and with gag reflex intact), administer a rapidly-absorbed carbohydrate (eg, 3 to 4 glucose tablets or a tube of gel with 15 grams, 4 to 6 oz. fruit juice or non-diet soda, or a teaspoon of honey or table sugar).* </li> <li>If the patient has altered mental status, is unable to swallow, or does not respond to oral glucose administration within 15 minutes, give an IV bolus of 12.5 to 25 gm of glucose (25 to 50 mL of 50 percent dextrose). </li> <li>Measure a blood glucose 10 to 15 minutes after the IV bolus. Readminister 12.5 to 25 grams of glucose as needed to maintain the blood glucose above 80 mg/dL. </li> <li>If glucose cannot be given by parenteral or oral routes, give glucagon 1 mg IM or subcutaneously. Response may be transient and should be followed by careful glucose monitoring and oral or intravenous glucose administration. </li> <li>Give additional maintenance glucose by mouth or IV. IV dextrose infusion should ensure delivery of 6 to 9 mg/kg per minute of glucose. Amounts needed vary depending upon the cause and severity of the symptomatic hypoglycemia. Once the patient is able to ingest carbohydrate safely, providing a mixed meal (including carbohydrates, such as a sandwich) is the preferred means of maintaining glucose levels. </li> <li>Measure a blood glucose 10 to 15 minutes after the initial IV bolus and monitor every 30 to 60 minutes thereafter until stable (minimum of&nbsp;four hours). The measurement method should provide rapid turnaround, preferably at the point of care. </li> <li>Admit patients with ingestion of a long-acting hypoglycemic agent, recurrent hypoglycemia during observation, and those unable to eat. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IM: intramuscular; IV: intravenous.<br />* Patients taking an alpha-glucosidase inhibitor (eg, acarbose, miglitol, voglibose) with symptomatic hypoglycemia should only receive pure glucose (dextrose) orally because digestion and absorption of other carbohydrates (eg, table sugar [sucrose]) will be delayed by these medications and will be less effective in raising blood glucose levels.</div><div id=\"graphicVersion\">Graphic 73797 Version 5.0</div></div></div>"},"73799":{"type":"graphic_table","displayName":"Causes portal vein thrombosis","title":"Causes of portal vein thrombosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of portal vein thrombosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Abdominal sepsis</td> </tr> <tr> <td>Abdominal surgery</td> </tr> <tr> <td>Beh&#231;et's syndrome</td> </tr> <tr> <td>Cirrhosis</td> </tr> <tr> <td>Collagen vascular diseases (eg, lupus)</td> </tr> <tr> <td>Compression or invasion of the portal vein by tumor (eg, pancreatic cancer)</td> </tr> <tr> <td>Endoscopic sclerotherapy</td> </tr> <tr> <td>Hepatocellular carcinoma</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> <tr> <td>Inherited thrombophilias</td> </tr> <tr> <td>Myeloproliferative syndromes</td> </tr> <tr> <td>Omphalitis</td> </tr> <tr> <td>Oral contraceptives</td> </tr> <tr> <td>Pancreatic islet cell transplantation</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td>Paroxysmal nocturnal hemoglobinuria</td> </tr> <tr> <td>Pregnancy</td> </tr> <tr> <td>Retroperitoneal fibrosis</td> </tr> <tr> <td>Transjugular intrahepatic portosystemic shunt</td> </tr> <tr> <td>Trauma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73799 Version 5.0</div></div></div>"},"73800":{"type":"graphic_picture","displayName":"Active trachoma follicles","title":"Active trachoma: Follicles and their sequelae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Active trachoma: Follicles and their sequelae</div><div class=\"cntnt\"><img style=\"width:358px; height:442px;\" src=\"images/ID/73800_Active_trachoma_follicles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) World Health Organization (WHO) grade TF (trachomatous inflammation, follicular). To make a diagnosis of WHO grade TF, five or more white or yellow follicles &gt;0.5 mm must be visualized on the upper tarsal conjunctiva. <br />(B) Herbert's pits. Herbert's pits are shallow pits in the cornea that form as a result of follicle rupture. They are pathognomonic for trachoma but are not assessed in the current grading scheme.</div><div id=\"graphicVersion\">Graphic 73800 Version 3.0</div></div></div>"},"73801":{"type":"graphic_table","displayName":"IV antimicrobials for pneumococcal pneumonia","title":"Intravenous antimicrobials for pneumococcal pneumonia in adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intravenous antimicrobials for pneumococcal pneumonia in adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Antimicrobial </td> <td class=\"subtitle1\">Dose </td> <td class=\"subtitle1\">Interval </td> </tr> <tr> <td>Penicillin G</td> <td>2 to 3 million units</td> <td>Every 4 hours</td> </tr> <tr> <td>Ampicillin</td> <td>2 g</td> <td>Every 6 hours</td> </tr> <tr> <td>Ampicillin-sulbactam</td> <td>1.5 to 3 g</td> <td>Every 6 hours</td> </tr> <tr> <td>Cefotaxime</td> <td>1&nbsp;to 2 g</td> <td>Every&nbsp;8 hours</td> </tr> <tr> <td>Ceftriaxone</td> <td>1&nbsp;to 2 g</td> <td>Every 12 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* &nbsp;These doses are intended for patients with normal renal function. For some of these antibiotics, dosing must be adjusted in patients with impaired renal function.</div><div id=\"graphicVersion\">Graphic 73801 Version 2.0</div></div></div>"},"73802":{"type":"graphic_picture","displayName":"Ixodes scapularis","title":"An adult female <EM>Ixodes scapularis</EM> (blacklegged tick)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">An adult female <EM>Ixodes scapularis</EM> (blacklegged tick)</div><div class=\"cntnt\"><img style=\"width:180px; height:179px;\" src=\"images/ID/73802_Ixodes_scapularis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Champman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichiosis, and Anaplasmosis-United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.</div><div id=\"graphicVersion\">Graphic 73802 Version 3.0</div></div></div>"},"73803":{"type":"graphic_table","displayName":"Uterine cancer survival histol","title":"Survival by histology for patients with uterine cancer 1993-1995 FIGO statistics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival by histology for patients with uterine cancer 1993-1995 FIGO statistics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Histology</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients</td> <td class=\"subtitle1\" colspan=\"3\">Overall survival (percent)</td> </tr> <tr> <td class=\"subtitle2\">One year</td> <td class=\"subtitle2\">Two years</td> <td class=\"subtitle2\">Five years</td> </tr> <tr> <td>Endometrioid</td> <td class=\"centered\">4661</td> <td class=\"centered\">94</td> <td class=\"centered\">89</td> <td class=\"centered\">80</td> </tr> <tr> <td>Adenosquamous</td> <td class=\"centered\">418</td> <td class=\"centered\">91</td> <td class=\"centered\">86</td> <td class=\"centered\">79</td> </tr> <tr> <td>Mucinous</td> <td class=\"centered\">67</td> <td class=\"centered\">89</td> <td class=\"centered\">85</td> <td class=\"centered\">73</td> </tr> <tr> <td>Papillary</td> <td class=\"centered\">305</td> <td class=\"centered\">84</td> <td class=\"centered\">71</td> <td class=\"centered\">54</td> </tr> <tr> <td>Clear cell</td> <td class=\"centered\">140</td> <td class=\"centered\">86</td> <td class=\"centered\">76</td> <td class=\"centered\">63</td> </tr> <tr> <td>Squamous</td> <td class=\"centered\">20</td> <td class=\"centered\">90</td> <td class=\"centered\">85</td> <td class=\"centered\">64</td> </tr> <tr> <td>Other</td> <td class=\"centered\">303</td> <td class=\"centered\">88</td> <td class=\"centered\">80</td> <td class=\"centered\">65</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FIGO: International Federation of Gynecology and Obstetrics.</div><div class=\"graphic_reference\">Modified from: J Epidemiol Biostat 2001; 6:64.</div><div id=\"graphicVersion\">Graphic 73803 Version 3.0</div></div></div>"},"73805":{"type":"graphic_picture","displayName":"Mucosal changes in Stevens-Johnson syndrome","title":"Mucosal changes in Stevens-Johnson syndrome/toxic epidermal necrolysis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Mucosal changes in Stevens-Johnson syndrome/toxic epidermal necrolysis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/EM/73805_Mucosal_changes_SJS_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes similar to those observed in SJS/TEN can be observed also in erythema multiforme majus.</div><div class=\"graphic_footnotes\">SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73805 Version 5.0</div></div></div>"},"73806":{"type":"graphic_picture","displayName":"Measles facial eruption","title":"Measles","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Measles</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/73806_Measles_facial_eruption.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous erythematous macules are present on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73806 Version 3.0</div></div></div>"},"73807":{"type":"graphic_figure","displayName":"Unicornuate uter and fuse horn","title":"Unicornuate uterus with uterine horn (not containing an endometrial cavity) fused to unicornuate uterus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unicornuate uterus with uterine horn (not containing an endometrial cavity) fused to unicornuate uterus</div><div class=\"cntnt\"><img style=\"width:358px; height:250px;\" src=\"images/OBGYN/73807_Unicornuateuterandfuseh.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 73807 Version 14.0</div></div></div>"},"73809":{"type":"graphic_table","displayName":"Causes of leukocoria","title":"Causes of leukocoria in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes&nbsp;of leukocoria in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Lens abnormalities</td> </tr> <tr> <td>Cataract (congenital or acquired)</td> </tr> <tr> <td>Posterior lenticonus</td> </tr> <tr> <td class=\"subtitle1_single\">Vitreous hemorrhage</td> </tr> <tr> <td>Ocular trauma (especially penetrating)</td> </tr> <tr> <td class=\"subtitle1_single\">Retinal detachment</td> </tr> <tr> <td>Ocular trauma</td> </tr> <tr> <td>Nonaccidental trauma (abusive head trauma)</td> </tr> <tr> <td>Norrie disease</td> </tr> <tr> <td>Incontinentia pigmenti</td> </tr> <tr> <td>Cutis marmorata telangiectatica</td> </tr> <tr> <td>Turner syndrome</td> </tr> <tr> <td>Walker-Warburg syndrome</td> </tr> <tr> <td>Stickler syndrome</td> </tr> <tr> <td>Familial exudative vitreoretinopathy</td> </tr> <tr> <td>Retinopathy of prematurity</td> </tr> <tr> <td class=\"subtitle1_single\">Other retinal abnormalities</td> </tr> <tr> <td>Coats disease</td> </tr> <tr> <td>Persistent hyperplastic primary vitreous (persistent fetal vasculature)</td> </tr> <tr> <td>Congenital retinoschisis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Optic disc abnormalities</td> </tr> <tr> <td>Colobomata of choroid and optic disc</td> </tr> <tr> <td>Morning glory disc anomaly</td> </tr> <tr> <td>Myelinated nerve fibers</td> </tr> <tr> <td class=\"subtitle1_single\">Intraocular inflammation/infection</td> </tr> <tr> <td>Juvenile idiopathic arthritis</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td>Toxoplasmosis</td> </tr> <tr> <td>Ocular toxocariasis</td> </tr> <tr> <td>Endophthalmitis</td> </tr> <tr> <td class=\"subtitle1_single\">Tumors</td> </tr> <tr> <td>Retinoblastoma</td> </tr> <tr> <td>Leukemia (with ocular involvement)</td> </tr> <tr> <td>Choroidal melanoma</td> </tr> <tr> <td>Metastatic tumors</td> </tr> <tr> <td>Choroidal osteoma</td> </tr> <tr> <td>Medulloepithelioma (\"diktyoma\")</td> </tr> <tr> <td>Combined hamartoma of the retina and the retinal pigment epithelium</td> </tr> <tr> <td>Choroidal hemangioma</td> </tr> <tr> <td>Benign astrocytic hamartomas in tuberous sclerosis</td> </tr> <tr> <td>Glioma of the optic nerve head</td> </tr> </tbody> </table> </td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=51422&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div id=\"graphicVersion\">Graphic 73809 Version 5.0</div></div></div>"},"73810":{"type":"graphic_figure","displayName":"Hand expression PI","title":"Hand method to release breast milk","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Hand method to release breast milk</div><div class=\"cntnt\"><img style=\"width:533px; height:489px;\" src=\"images/PI/73810_Hand_expression_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hold your hand in a c-shape, with your thumb on top. Press your thumb gently on your breast straight back into the chest. Then, roll your thumb and fingers toward the nipple. Breast milk should come out of the nipple. Keep doing this as you move your hand around the whole breast.</div><div id=\"graphicVersion\">Graphic 73810 Version 4.0</div></div></div>"},"73812":{"type":"graphic_picture","displayName":"Histopathology of tendinosis","title":"Histopathology of tendinosis","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Histopathology of tendinosis</div><div class=\"cntnt\"><img style=\"width:544px; height:463px;\" src=\"images/EM/73812_Histopathology_tendinosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal tendon. H&amp;E.<br> (B) Increased tenocytes. H&amp;E, patellar tendinopathy. Note the large increase in tenocyte numbers characteristic of tendinosis. The dense central structure represents a vessel wall.<br> (C) Increased proteoglycan. H&amp;E, patellar tendinopathy. Increased blue-staining material surrounding an area of hypocellularity typical of tendinosis.<br> (D) Vascular hyperplasia. H&amp;E, patellar tendinopathy. Large increase in the presence of microvessels within the tendon substance.<br> (E) Collagen disorganization. H&amp;E, patellar tendinopathy. Focal collagen degeneration.</div><div class=\"graphic_reference\">Scott A, Khan KM, Cook J, Duronio V. Human tendon overuse pathology: Histopathologic and biochemical findings. In: Tendinopathy in Athletes, Woo SL, Arnoczky SP, Renstrom P (Eds). Malden: Wiley-Blackwell, 2007. Copyright &#169; 2007. Reproduced with permission of Wiley-Blackwell.</div><div id=\"graphicVersion\">Graphic 73812 Version 2.0</div></div></div>"},"73813":{"type":"graphic_picture","displayName":"Seborrheic dermatitis diaper area","title":"Infantile seborrheic dermatitis involving the diaper area","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infantile seborrheic dermatitis involving the diaper area</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/73813_Seborr_derm_diaper_area.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, moist, confluent erythematous plaques in a child with infantile seborrheic dermatitis involving the diaper area.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73813 Version 4.0</div></div></div>"},"73814":{"type":"graphic_diagnosticimage","displayName":"Gastrogastric fistula after gastric bypass","title":"Gastrogastric fistula after gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Gastrogastric fistula after gastric bypass</div><div class=\"cntnt\"><img style=\"width:472px; height:577px;\" src=\"images/SURG/73814_Gastrogastric_fistula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These images are obtained from one patient who developed a gastrogastric fistula following a gastric bypass procedure.<br />(A) Arrow points to the gastrogastric fistula after gastric bypass, originating at the gastrojejunostomy.<br />(B) Arrows point to gastric pouch with contrast and air and the gastric remnant with air, indicative of a gastrogastric fistula.</div><div id=\"graphicVersion\">Graphic 73814 Version 6.0</div></div></div>"},"73816":{"type":"graphic_diagnosticimage","displayName":"Fetal gallstones","title":"Fetal gallstones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal gallstones</div><div class=\"cntnt\"><img style=\"width:360px; height:356px;\" src=\"images/OBGYN/73816_Fetal_gallstones.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse view of fetal abdomen at gestational age of 35 weeks shows a multiple echogenic masses consistent with gallstones within the gallbladder.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 73816 Version 2.0</div></div></div>"},"73817":{"type":"graphic_picture","displayName":"Syringoma","title":"Vulvar syringoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar syringoma</div><div class=\"cntnt\"><img style=\"width:350px; height:295px;\" src=\"images/OBGYN/73817_Syringoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 73817 Version 3.0</div></div></div>"},"73818":{"type":"graphic_figure","displayName":"Elbow ossification","title":"Secondary ossification centers of the elbow","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Secondary ossification centers of the elbow</div><div class=\"cntnt\"><img style=\"width:527px; height:437px;\" src=\"images/EM/73818_Elbow_ossification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The appearance of the secondary ossification centers of the elbow proceeds in an orderly fashion, usually occurring approximately one year earlier in girls than in boys.</div><div class=\"graphic_reference\">Reproduced with permission from DeLee, JC, Drez, D (Eds). Orthopaedic sports medicine: Principles and practice, W.B. Saunders, Philadelphia 1994. Copyright © 1994 W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 73818 Version 2.0</div></div></div>"},"73819":{"type":"graphic_table","displayName":"Muscle innervation part A","title":"Function and peripheral and segmental innervation of muscles: part A","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Function and peripheral and segmental innervation of muscles: part A</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Function</td>\n\n      <td class=\"subtitle1\">Muscle</td>\n\n      <td class=\"subtitle1\">Nerve</td>\n\n    </tr>\n\n    <tr><td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Plexus cervicalis: C1-C4</td></tr><tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">&nbsp;</td>\n\n      \n\n      <td class=\"subtitle2_left\">Cervical nerves</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Flexion, extension, rotation and lateral bending of the back</td>\n\n      <td>Colli profundi (+ sternocleidomastoideus + trapezius)</td>\n\n      <td>C1-C4</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td class=\"indent1\">Lifting of upper thorax; inspiration</td>\n\n      <td>Scaleni</td>\n\n      <td>C3-C5</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\"> &nbsp;</td>\n\n      \n\n      <td class=\"subtitle2_left\">Phrenic nerve</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Inspiration</td>\n\n      <td>Diaphragm</td>\n\n      <td>C3-C5</td>\n\n    </tr>\n\n    <tr><td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Plexus brachialis: C5-T1</td></tr><tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">&nbsp;</td>\n\n      \n\n      <td class=\"subtitle2_left\">Anterior thoracic nerve</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Adduction and internal rotation of arm and dorsoventral lowering of shoulder</td>\n\n      <td>Pectoralis major and minor</td>\n\n      <td>C5-T1</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;&nbsp;</td>\n\n      \n\n      <td class=\"subtitle2_left\">Long thoracic nerve</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Fixation of scapula during lifting of arm (anterior movement of shoulder)</td>\n\n      <td>Serratus anterior</td>\n\n      <td>C5-C7</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;&nbsp;</td>\n\n      \n\n      <td class=\"subtitle2_left\">Dorsal scapular nerve</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Elevation and adduction of scapula toward spinal column</td>\n\n      <td><p>Levator scapulae</p>\n\t\t\t<p>Rhomboidei</p></td>\n\n      <td>C4-C5</td>\n\n    </tr>\n\n    \n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;&nbsp;</td>\n\n      \n\n      <td class=\"subtitle2_left\">Suprascapular nerve</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Lifting and outward rotation of arm</td>\n\n      <td>Supraspinatus</td>\n\n      <td>C4-C6</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Outward rotation of arm in shoulder joint</td>\n\n      <td>Infraspinatus</td>\n\n      <td>C4-C6</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;&nbsp;</td>\n\n      \n\n      <td class=\"subtitle2_left\">Dorsal thoracic nerve</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Inward rotation of shoulder joint; adduction from ventral to dorsal; lowering of elevated arm</td>\n\n      <td><p>Latissimus dorsi</p>\n\t\t\t<p>Teres major</p>\n\t\t\t<p>Subscapularis</p></td>\n\n      <td>C5-C8 (from dorsal portion of plexus)</td>\n\n    </tr>\n\n    \n\n    \n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;&nbsp;</td>\n\n      \n\n      <td class=\"subtitle2_left\">Axillary nerve</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Lateral lifting (abduction) of arm up to the horizontal line</td>\n\n      <td>Deltoideus</td>\n\n      <td>C5-C6</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Outward rotation of arm</td>\n\n      <td>Teres minor</td>\n\n      <td>C4-C5</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;&nbsp;</td>\n\n      \n\n      <td class=\"subtitle2_left\">Musculocutaneous nerve</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Flexion of upper and lower arm and supination of lower arm</td>\n\n      <td>Biceps brachii</td>\n\n      <td>C5-C6</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Elevation and adduction of arm</td>\n\n      <td>Coracobrachialis</td>\n\n      <td>C5-C7</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Flexion of lower arm</td>\n\n      <td>Brachialis</td>\n\n      <td>C5-C6</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">&nbsp;&nbsp;</td>\n\n      \n\n      <td class=\"subtitle2_left\">Median nerve</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Flexion and radial deviation of hand</td>\n\n      <td>Flexor carpi radialis</td>\n\n      <td>C6-C7</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Pronation of lower arm</td>\n\n      <td>Pronator teres</td>\n\n      <td>C6-C7</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Flexion of hand</td>\n\n      <td>Palmaris longus</td>\n\n      <td>C7-T1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Flexion of fingers II-V in middle phalanges</td>\n\n      <td>Flexor digitorum superficialis</td>\n\n      <td>C7-T1</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">Flexion of end phalanx of the thumb</td>\n\n      <td>Flexor pollicis longus</td>\n\n      <td>C6-C8</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Flexion of end phalanges of index and middle finger</td>\n\n      <td>Flexor digitorum profundus (radial portion)</td>\n\n      <td>C7-T1</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">3/23/99-Perm requested. 5/18/99-Perm granted for 1 edition. 11/18/99-perm requested for 8.1. 2/23/00-perm granted for 8.2 and 8.3 (put back in gold). \r\n10/16/2000-may not be in gold. 11/29/2000-renewal sent. 12/4/2000-perm granted 9.1-9.3; 11/7/2001 -renewal requested -jm;  11/13/2001 -renewal granted -jm; 5/14/2002 - received invoice for figure 1 - $85.00.  Gave to ajeah -jm\r\n10/4/2002 - renewal requested -jm; 10/9/2002 -renewal granted, no charge.   CD-Rom granted for 1 year, and internet perm expires after 2 years -jm\r\n10/8/2003 perm granted for 2 years\r\n11/14/2005 renewal requested 11/17/2005 granted - they will send invoice 1/10/2006 invoice to susan\r\n10/10/2006 renewal requested 1/9/2007 renewal granted (online perm until 2008) - invoice to come\r\n2/23/2007 - Inovice to Tammy.mt\r\n11/28/2007--renewal requested. EM\r\n1/8/2008--renewal granted, invoice to Tammy. EM\r\n\r\n1/13/2009--Requested renewal (JD).\r\n2/9/2009--Renewal granted via permissions agreement, awaiting formal invoice (JD).\r\n4/8/2009--Formal invoice received, to Catherine for payment (JD).\r\n\r\n The total fee of $&amp;quot;120.00&amp;quot;was originally charged to\r\nMuscle_innervation_part_A\r\nMuscle_innervation_part_B\r\nMuscle_innervation_part_C</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=59937&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Muscle_innervation_part_A.htm</title></head></div><div class=\"graphic_reference\">Data from Duus, P. Topical Diagnosis in Neurology, 2nd ed. Thieme Medical Publishers, New York, 1989.</div><div id=\"graphicVersion\">Graphic 73819 Version 2.0</div></div></div>"},"73820":{"type":"graphic_diagnosticimage","displayName":"Flock workers lung CT - Ground glass opacities","title":"Flock worker's lung CT - Ground glass opacities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flock worker's lung CT - Ground glass opacities</div><div class=\"cntnt\"><img style=\"width:303px; height:272px;\" src=\"images/PULM/73820_Flock_workers_lung_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prone CT of the chest shows ground glass opacification and patchy consolidation.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of David Kern, MD and Robert Crausman, MD.</div><div id=\"graphicVersion\">Graphic 73820 Version 5.0</div></div></div>"},"73822":{"type":"graphic_table","displayName":"GI motility disorders","title":"Gastrointestinal motility disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gastrointestinal motility disorders</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Region</td>\n<td class=\"subtitle1\">With dilatation</td>\n<td class=\"subtitle1\">Without dilatation</td>\n</tr>\n<tr>\n<td>Esophagus</td>\n<td>Achalasia with mega-esophagus</td>\n<td>Achalasia</td>\n</tr>\n<tr>\n<td>Stomach</td>\n<td>Acute gastric dilatation</td>\n<td>Gastroparesis</td>\n</tr>\n<tr>\n<td>Small bowel</td>\n<td>Pseudo-obstruction</td>\n<td>Chronic intestinal dysmotility</td>\n</tr>\n<tr>\n<td>Colon</td>\n<td>Megacolon/pseudo-obstruction</td>\n<td>Slow transit constipation/colonic inertia</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 73822 Version 1.0</div></div></div>"},"73823":{"type":"graphic_picture","displayName":"Localized granuloma annulare on hands","title":"Localized granuloma annulare","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Localized granuloma annulare</div><div class=\"cntnt\"><img style=\"width:576px; height:227px;\" src=\"images/DERM/73823_Localized_granuloma_hands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 66-year-old woman presents with slowly enlarging plaques on the backs of the hands. The largest lesions have been present for six years, while the smaller, more proximal 2 cm diameter annular lesions appeared within the past year. All lesions show persistent blanching erythema in central areas.</div><div id=\"graphicVersion\">Graphic 73823 Version 5.0</div></div></div>"},"73824":{"type":"graphic_figure","displayName":"Normal values for GFR in men and women","title":"Normal values for GFR in men and women","html":"<div class=\"graphic\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">Normal values for GFR in men and women</div><div class=\"cntnt\"><img style=\"width:636px; height:436px;\" src=\"images/NEPH/73824_Normal_GFR_MF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal values for inulin clearance are shown for men (panel A) and women (panel B) of various ages, with the GFR measured as the urinary clearance of inulin. A GFR &lt;60 mL/min/1.73 m<sup>2</sup> is the threshold for the definition of chronic kidney disease. Solid lines represent the mean value of GFR per decade of age, and dashed lines represent the value 1 SD from the mean value of GFR per decade of age.</div><div class=\"graphic_reference\">Reproduced from: Wesson L. Physiology of the Human Kidney, Grune &amp; Stratton, New York 1969. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 73824 Version 1.0</div></div></div>"},"73825":{"type":"graphic_figure","displayName":"IgE trends in CMA","title":"Trend in cow's milk specific-IgE levels over time by final cow's milk allergy status","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Trend in cow's milk specific-IgE levels over time by final cow's milk allergy status</div><div class=\"cntnt\"><img style=\"width:585px; height:311px;\" src=\"images/ALLRG/73825_IgE_trends_in_CMA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scatter plots of all cm-IgE levels recorded, by age, to age 18 years (n = 2498). Panel A) All values in the group with persistent CMA (n = 1651). Panel B) All values in the group with resolved CMA (n = 847). Nonparametric smoothed curves show the trend in cm-IgE levels over time. These curves approximate the mean value at any given age.</div><div class=\"graphic_footnotes\">CMA: cow's milk allergy; cm-IgE: cow's milk specific-IgE.</div><div class=\"graphic_reference\">Reproduced with permission from: Skripak JM, Matsui EC, Mudd K, Wood RA. The natural history of IgE-mediated cow's milk allergy. J Allergy Clin Immunol 2007; 120:1172. Copyright ©2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 73825 Version 3.0</div></div></div>"},"73826":{"type":"graphic_picture","displayName":"Cerebriform connective tissue nevus plantar foot","title":"Cerebriform connective tissue nevus of the plantar foot is classic for Proteus syndrome","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Cerebriform connective tissue nevus of the plantar foot is classic for Proteus syndrome</div><div class=\"cntnt\"><img style=\"width:576px; height:358px;\" src=\"images/ONC/73826_Cere_con_tiss_nev_plan_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: the Dermatology Online Atlas, www.dermis.net. Copyright © 2012. All rights reserved.</div><div id=\"graphicVersion\">Graphic 73826 Version 3.0</div></div></div>"},"73827":{"type":"graphic_waveform","displayName":"ECG torsades de pointes","title":"Single lead electrocardiogram (ECG) showing torsades de pointes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Single lead electrocardiogram (ECG) showing torsades de pointes</div><div class=\"cntnt\"><img style=\"width:420px; height:119px;\" src=\"images/CARD/73827_Torsades_de_pointes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The electrocardiographic rhythm strip shows torsades de pointes, a polymorphic ventricular tachycardia associated with QT prolongation. There is a short, preinitiating RR interval due to a ventricular couplet, which is followed by a long, initiating cycle resulting from the compensatory pause after the couplet.</div><div id=\"graphicVersion\">Graphic 73827 Version 4.0</div></div></div>"},"73829":{"type":"graphic_algorithm","displayName":"Enterovirus dissemination","title":"Pathogenesis of enterovirus infection: replication and dissemination","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of enterovirus infection: replication and dissemination</div><div class=\"cntnt\"><img style=\"width:352px; height:318px;\" src=\"images/ID/73829_Enterovirus_dissemination.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73829 Version 3.0</div></div></div>"},"73832":{"type":"graphic_table","displayName":"PD cath sinus appearance","title":"Grading of pertioneal catheter sinus tract based upon exit site appearance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading of pertioneal catheter sinus tract based upon exit site appearance</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Perfect</td> <td class=\"subtitle1\">Good</td> <td class=\"subtitle1\">Equivocal</td> <td class=\"subtitle1\">Acute infection &#60;4 weeks</td> <td class=\"subtitle1\">Chronic infection &#62;4 weeks</td> <td class=\"subtitle1\">Cuff infection without exit infection</td> </tr> <tr> <td>Epithelium</td> <td>Strong, mature. Covers visible sinus.</td> <td>Strong, mature at rim. Fragile or mucosal deeper.</td> <td>Absent or covers part of sinus.</td> <td>Absent or covers only part of sinus.</td> <td>Absent or covers only part of sinus.</td> <td>Covers most or all of sinus. May be macerated.</td> </tr> <tr> <td>Granulation tissue</td> <td>None.</td> <td>Plain beyond epithelium.</td> <td>Slightly exuberant.</td> <td>Slightly exuberant or \"proud flesh.\"</td> <td>\"Proud flesh\" or slightly exuberant.</td> <td>None or exuberant deep in sinus.</td> </tr> <tr> <td rowspan=\"2\">Drainage</td> <td>None or barely visible.</td> <td rowspan=\"2\">None or barely visible.</td> <td>Purulent or bloody.</td> <td>Purulent or bloody.</td> <td rowspan=\"2\">Purulent or bloody.</td> <td rowspan=\"2\">Purulent, bloody, gluey. May be seen only after pressure on cuff. Clot or dried blood in sinus.</td> </tr> <tr> <td>Clear or thick.</td> <td>Clear or thick.</td> <td>Sometimes clear.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from Twardowski, ZJ, Prowant, BF. Nephrol Dial Transplant 1997; 12:1284. Copyright © 1997 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 73832 Version 3.0</div></div></div>"},"73833":{"type":"graphic_table","displayName":"Encephalitis travel history","title":"Travel history and possible etiologic agent(s) of viral encephalitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Travel history and possible etiologic agent(s) of viral encephalitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Travel</td> <td class=\"subtitle1\">Possible infectious agent(s)</td> </tr> <tr> <td>Africa</td> <td>Rabies virus, West Nile virus, <em>Plasmodium falciparum</em>, Dengue virus, <em>Trypanosoma brucei gambiense</em>, <em>T. brucei rhodesiense</em></td> </tr> <tr> <td>Australia</td> <td>Murray Valley encephalitis virus, Japanese encephalitis virus, Hendra virus</td> </tr> <tr> <td>Central America</td> <td>Rabies virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, St. Louis encephalitis virus, Dengue virus, <em>Rickettsia rickettsii</em>, <em>P. falciparum</em>, <em>Taenia solium</em></td> </tr> <tr> <td>Europe</td> <td>West Nile virus, tick-borne encephalitis virus, <em>Borrelia burgdorferi</em>, <em>Anaplasma phagocytophilum</em></td> </tr> <tr> <td>India, Nepal</td> <td>Rabies virus, Japanese encephalitis virus, <em>P. falciparum</em>, Dengue virus<em> </em></td> </tr> <tr> <td>Middle East</td> <td>West Nile virus, <em>P. falciparum</em></td> </tr> <tr> <td>Russia</td> <td>Tick-borne encephalitis virus</td> </tr> <tr> <td>South America</td> <td>Rabies virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, St. Louis encephalitis virus, Dengue virus, <em>R. rickettsii</em>, <em>Bartonella bacilliformis</em> (Andes mountain), <em>P. falciparum</em>, <em>Taenia solium</em></td> </tr> <tr> <td>Southeast Asia, China, Pacific Rim</td> <td>Japanese encephalitis virus, tickborne encephalitis virus, Nipah virus, <em>P. falciparum</em>, <em>Gnathostoma</em> species, <em>Taenia solium</em>, Dengue virus</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47:303. Copyright © 2008 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 73833 Version 4.0</div></div></div>"},"73834":{"type":"graphic_table","displayName":"ACOVE quality indicators","title":"Quality indicators for appropriate medication use in vulnerable elders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Quality indicators for appropriate medication use in vulnerable elders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indicator title</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Rationale</td> </tr> <tr> <td>Medication list</td> <td>An up-to-date medication list that includes over-the-counter medications should be accessible to all healthcare providers in the medical record.</td> <td>Enables identification of potential drug-related causes of new symptoms, eliminates inappropriate duplications, allows review for drug-drug interactions, and allows streamlining of regimen to improve adherence.</td> </tr> <tr> <td>Annual drug regimen review</td> <td>All vulnerable&nbsp;older adults&nbsp;should have an annual drug regimen review.</td> <td>Allows an opportunity for discontinuing unnecessary medications, or addition of necessary drugs that are not currently prescribed.</td> </tr> <tr> <td>Drug indication</td> <td>All drugs prescribed for vulnerable elders should have a clearly defined indication.</td> <td>Allows discontinuing medications that may have been prescribed for unclear or transient indications.</td> </tr> <tr> <td>Patient education</td> <td>All vulnerable&nbsp;older adults&nbsp;(or caregivers) should receive appropriate education about the use of any prescribed drug.</td> <td>Education may improve adherence and clinical outcomes; also can alert patients or caregivers to potential adverse effects.</td> </tr> <tr> <td>Response to therapy</td> <td>Response to therapy should be documented for all ongoing medical conditions.</td> <td>Documenting response will help clarify whether a drug is meeting the therapeutic goal for which it was prescribed and provides a basis for continuation, modification, or discontinuation.</td> </tr> <tr> <td>Education for warfarin therapy</td> <td>Patients newly prescribed warfarin should receive education about diet, drug interactions, and risk of bleeding, or should be referred to an anticoagulation clinic.</td> <td>Awareness of drugs and dietary substances that interact with warfarin can decrease the risk of bleeding complications.</td> </tr> <tr> <td>Monitoring warfarin therapy</td> <td>When warfarin is prescribed, international normalized ratio (INR) should be determined within four days of initiation of therapy and at least every six weeks therafter.*</td> <td>Older adults are at high risk for drug toxicity, and close monitoring can help maintain the INR within the therapeutic range.</td> </tr> <tr> <td>Monitoring angiotensin-converting enzyme (ACE) inhibitor therapy</td> <td>When ACE inhibitor therapy is prescribed, a serum creatinine and potassium should be monitored within two weeks after initiation of therapy and at least yearly thereafter.</td> <td>Older adults are at increased risk of renal insufficiency and hyperkalemia.</td> </tr> <tr> <td>Monitoring loop diuretic therapy</td> <td>When loop diuretic therapy is prescribed, electrolytes should be checked within two weeks after initiation and at least annually.</td> <td>Risk of hypokalemia due to diuretic therapy.</td> </tr> <tr> <td>Avoid propoxyphene</td> <td>Do not prescribe propoxyphene as an analgesic agent.</td> <td>Propoxyphene is inferior to, or at best equivalent to, acetaminophen or other analgesics with better safety profiles.</td> </tr> <tr> <td>Avoid chronic or high-dose benzodiazepine use</td> <td>If a benzodiazepine is taken for more than one month, there should be documentation of discussion of risks and attempt to taper or discontinue.</td> <td>Benzodiazepines increase the risk of falls, hip fracture, and confusion.</td> </tr> <tr> <td>Avoid drugs with strong anticholinergic properties</td> <td>Do not prescribe drug therapies with a strong anticholinergic effect if alternative therapies are available.</td> <td>These therapies are associated with adverse events such as confusion, urinary retention, constipation, visual disturbance, and hypotension.</td> </tr> <tr> <td>Avoid barbiturates</td> <td>If an older adult does require the therapy for control of seizures, do not use barbiturates.</td> <td>These therapies are potent central nervous system depressants, have a low therapeutic index, are highly addictive, cause drug interactions, and are associated with an increased risk for falls and hip fracture.</td> </tr> <tr> <td>Avoid meperidine as an opioid analgesic</td> <td>When analgesia is required, avoid use of meperidine.</td> <td>This therapy is associated with an increased risk for delirium and may be associated with the development of seizures.</td> </tr> <tr> <td>Avoid chronic use of ketorolac</td> <td>Ketorolac should not be prescribed for more than five days.</td> <td>This therapy is associated with a high risk of GI side effects, including bleeding, and other analgesics are safer in older patients.</td> </tr> <tr> <td>Avoid skeletal muscle relaxants</td> <td>Skeletal muscle relaxants (cyclobenzaprine, methocarbamol, carisoprodol, chlorzoxazone, orphenadrine, tizanidine, metaxalone) should not be prescribed for more than one week.</td> <td>These medications can cause anticholinergic adverse effects, sedation, confusion, and data of efficacy are limited.</td> </tr> <tr> <td>Avoid ticlopidine</td> <td>Clopidogrel should be prescribed rather than ticlopidine for patients who require antiplatelet therapy (eg, recent stroke, myocardial infarction, acute coronary syndrome, percutaneous angioplasty).</td> <td>Ticlopidine may be less effective than clopidogrel and is associated with a higher risk of hematological disorders than clopidogrel.</td> </tr> <tr> <td>Treat iron deficiency anemia with low-dose oral iron therapy</td> <td>Vulnerable&nbsp;older adults&nbsp;with iron deficiency anemia should take no more than one low-dose oral iron tablet daily.</td> <td>Low-dose therapy is equally effective with fewer adverse effects than high-dose oral iron therapy.</td> </tr> <tr> <td>Antipsychotic medication response</td> <td>An assessment of response should be documented within one month for older adults started on an antipsychotic drug.</td> <td>The use of antipsychotic drugs increases mortality in older adults, and behavioral modification is an effective alternative.</td> </tr> <tr> <td>Acetaminophen</td> <td>Older adults prescribed high-dose (&#8805;3 g per day) acetaminophen, or those with liver disease taking acetaminophen chronically, should be advised of the risk of liver toxicity.</td> <td>The risk of liver toxicity is greater with use of acetaminophen.</td> </tr> <tr> <td>NSAIDs and aspirin</td> <td> <p>The risk of GI bleeding should be discussed and documented.</p> Individuals at increased risk for GI bleeding (aged &#62;75 years, peptic ulcer disease, history of GI bleeding, warfarin use, chronic glucocorticoid use) should be treated concomitantly with misoprostol or a proton pump inhibitor when treated with a nonselective NSAID. </td> <td>Risks of GI bleeding are increased in older adults taking NSAIDs or daily aspirin.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal; NSAIDs: nonsteroidal antiinflammatory drugs.<br />* These monitoring frequencies represent minimal indications; many experts would advise daily monitoring initially and monitoring every four weeks once a stable and at-goal therapeutic INR has been achieved.</div><div class=\"graphic_reference\">Data from: Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Amer Geriatr Soc 2007; 55:S373.</div><div id=\"graphicVersion\">Graphic 73834 Version 6.0</div></div></div>"},"73836":{"type":"graphic_algorithm","displayName":"Screening diagnosis congenital hypothyroidism","title":"Algorithm for screening and diagnosis of congenital hypothyroidism","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">Algorithm for screening and diagnosis of congenital hypothyroidism</div><div class=\"cntnt\"><img style=\"width:768px; height:596px;\" src=\"images/PEDS/73836_Scrndgnscngnhypthyrdsm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm shows the pathway for newborn screening using either a primary T4 technique (left-hand pathway), or primary TSH technique (right-hand pathway). &nbsp;A third technique employed by some newborn screening programs is to perform these tests simultaneously for the initial screen; in those programs infants with abnormal results either&nbsp;proceed directly to confirmatory serum testing, or undergo a second screening test before referral. The exact protocol varies by program. </div><div class=\"graphic_footnotes\">FP: filter paper; T3: triiodothyronine; T4: thyroxine; TSH: thyrotropin.<br />* Filter paper blood spot TSH cutoffs are expressed as serum values. To get equivalent whole blood values, divide the serum value by 2. Screening programs in North America typically report serum values, whereas screening programs in Europe often report whole blood values.<br />&para; For newborn screening programs that employ primary thyroxine (T4) screen, samples with T4 values below a certain concentration (usually less than the 10th percentile for the laboratory's samples on the same day), undergo a TSH measurement on the same FP blood spot.<br />&Delta; Prematurity or nonthyroidal illness may cause false-positive results on serum testing and/or the initial screen, with low T4 and normal TSH.<br /><span class=\"lozenge\">&loz;</span> This result usually indicates that the screen was a false-positive, especially if the screening TSH was only mildly elevated. However, one study suggests that infants with these findings are at increased risk for developing subclinical hypothyroidism later in life.<sup>[1]</sup><br />&sect; Rarely, infants with low TSH and low free T4 are ultimately proven to have primary hypothyroidism (rather than central hypothyroidism) because the expected rise in serum TSH is delayed.<br />&yen; Thyroid imaging studies may be useful for infants with borderline results of serum testing, or with goiter, or suspected transient hypothyroidism. Measurement of the urinary iodine concentration may be useful for infants with suspected exposure to excess iodine or iodine deficiency.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​Leonardi D, Polizzotti N, Carta A, et al. Longitudinal study of thyroid function in children with mild hyperthyrotropinemia at neonatal screening for congenital hypothyroidism. J Clin Endocrinol Metab 2008; 93:2679.</li>&#xD;&#xA;    <li>American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics 2006; 117:2290.</li>&#xD;&#xA;    <li>L&eacute;ger J, Olivieri A, Donaldson M, et al. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. J Clin Endocrinol Metab 2014; 99:363.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 73836 Version 9.0</div></div></div>"},"73838":{"type":"graphic_figure","displayName":"Moderate physical activities","title":"Examples of moderate physical activity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examples of moderate physical activity</div><div class=\"cntnt\"><img style=\"width:442px; height:549px;\" src=\"images/PC/73838_Moderate_physical_activt_E1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A moderate amount of physical activity is roughly equivalent to physical activity that uses approximately 150 calories (kcal) of energy per day, or 1000 calories per week. Some activities can be performed at various intensities; the suggested durations correspond to the expected intensity of effort.</div><div id=\"graphicVersion\">Graphic 73838 Version 4.0</div></div></div>"},"73839":{"type":"graphic_picture","displayName":"Tinea versicolor shoulder","title":"Tinea versicolor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tinea versicolor</div><div class=\"cntnt\"><img style=\"width:432px; height:281px;\" src=\"images/PC/73839_Tinea_versicolor_shoulder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tinea versicolor. Hypopigmented macules and patches are scattered on the shoulder and arm of this patient.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73839 Version 2.0</div></div></div>"},"73840":{"type":"graphic_figure","displayName":"Burn costs US","title":"Cost of burn injuries compared by age and type of burn in the US between 1998 and 2008","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Cost of burn injuries compared by age and type of burn in the US between 1998 and 2008</div><div class=\"cntnt\"><img style=\"width:612px; height:369px;\" src=\"images/SURG/73840_Cost_of_burns_US.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Centers for Disease Control. Web-based injury and statistics query and reporting system (WISQARS™) 2009. Available online at: webappa.cdc.gov/sasweb/ncipc/mortrate9.html (Accessed on April 2, 2010).</div><div id=\"graphicVersion\">Graphic 73840 Version 3.0</div></div></div>"},"73841":{"type":"graphic_picture","displayName":"Keratoderma blennorrhagicum","title":"Keratoderma blennorrhagicum in reactive arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keratoderma blennorrhagicum in reactive arthritis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/73841_Keratoderma_blennorrhagicum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple vesicles and pustules are present on the plantar foot of this patient with reactive arthritis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73841 Version 3.0</div></div></div>"},"73842":{"type":"graphic_picture","displayName":"PCFCL chest","title":"Primary cutaneous follicle center lymphoma with localized skin lesions on the chest","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous follicle center lymphoma with localized skin lesions on the chest</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/HEME/73842_PCFCL_chest_PR.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73842 Version 1.0</div></div></div>"},"73843":{"type":"graphic_picture","displayName":"Lichen simplex chronicus ankle","title":"Lichen simplex chronicus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lichen simplex chronicus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/73843_Lichen_simplex_chron_ankle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Areas of thickened and hyperpigmented skin from chronic rubbing on the ankle of a patient with lichen simplex chronicus.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73843 Version 5.0</div></div></div>"},"73845":{"type":"graphic_table","displayName":"Agents opioid constipation","title":"Approved and commonly used drugs for chronic opioid-induced constipation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approved and commonly used drugs for chronic opioid-induced constipation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Mechanism </td> <td class=\"subtitle1\">Use</td> <td class=\"subtitle1\">Problems</td> </tr> <tr class=\"divider_bottom\"> <td>Bulk-forming laxatives (cellulose or psyllium seeds)</td> <td> <p>Increases mass and water content of stool</p> Decreases transit time</td> <td>Should always be considered; may be useful in changing character of the effluent from a functioning stoma</td> <td> <ul> <li>May worsen flatulence and distention </li> <li>Should be avoided in patients who are severely debilitated or suspected of early bowel obstruction </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Osmotic cathartics (magnesium salts, sodium salts, lactulose, sorbitol, polyethylene glycol)</td> <td> <p>Increases water in the bowel</p> <p>Decreases transit time</p> <p>Lactulose/sorbitol attracts water into colon, acidifies contents</p> Polyethylene glycol attracts water into the colon</td> <td> <p>Often used for bowel cleansing before medical procedures</p> <p>Lactulose and sorbitol have a slower onset and are commonly selected for long-term use; dose must be adjusted to effect</p> Polyethylene glycol is not absorbed, has a slower onset, and the powder formulation also is commonly used for long-term therapy; dose must be adjusted to effect</td> <td> <ul> <li>Severe diarrhea and dehydration may occur with overuse </li> <li>Rarely, causes serious electrolyte disorders or volume overload </li> <li>Patients with renal insufficiency or cardiac failure must be carefully monitored if sodium or magnesium salts are used </li> <li>Use of phosphate containing laxatives has been associated with acute phosphate nephropathy (rare); risk factors include chronic kidney disease, frequent use, and advanced age </li> <li>Lactulose or sorbitol may increase flatulence </li> <li>Lactulose should be avoided in patients who are lactose-intolerant </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Surfactants (docusate)</td> <td>Facilitates mixture of fat and stool</td> <td>Usually combined with a contact cathartic as a first-line therapy for opioid-induced constipation</td> <td> <ul> <li>Minimal risks </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Contact cathartics diphenylmethane drugs (bisacodyl)</p> Anthraquinone drugs (cascara, senna)</td> <td> <p>Increases peristalsis</p> Reduces absorption of water and electrolytes from intraluminal contents</td> <td> <p>May be used for acute or chronic therapy</p> Often a first-line approach for long-term management, including prophylaxis when opioid therapy is initiated</td> <td> <ul> <li>Risks associated with short-term use are minimal </li> <li>\"Laxative bowel,\" a condition characterized by dependence on laxatives for bowel function has been reported but is presumably rare </li> <li>Allergies to these substances have been reported </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Opioid antagonists</td> <td>Opioid antagonist</td> <td>Goal is \"bowel withdrawal\" without concurrent systemic withdrawal</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Subcutaneous methylnaltrexone</td> <td>&nbsp;</td> <td>Opioid-induced constipation in refractory cases; does not cause systemic withdrawal symptoms</td> <td> <ul> <li>Methylnaltrexone must be given subcutaneously; dose adjustment needed for renal impairment </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Naloxegol</td> <td>&nbsp;</td> <td>Opioid-induced constipation; does not cause systemic withdrawal symptoms</td> <td> <ul> <li>Naloxegol is metabolized by CYP3A4; numerous significant drug interactions are anticipated </li> <li>Dose adjustment needed for renal impairment&nbsp;&nbsp; </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Oral naloxone</td> <td>&nbsp;</td> <td>Opioid-induced constipation; parenteral formulation has been given orally, but the optimal dose and schedule are unknown</td> <td> <ul> <li>Limited evidence supporting efficacy of oral naloxone, and some patients will absorb sufficient naloxone to develop systemic withdrawal symptoms </li> <li>May cause abdominal cramping </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fixed combination of extended-release oral oxycodone and naloxone (2:1 ratio)</td> <td>&nbsp;</td> <td>Chronic pain requiring around-the-clock opioid treatment and prevention or relief of opioid-induced constipation</td> <td> <ul> <li>Exceeding the maximum daily dose of 80 mg oxycodone/40 mg naloxone can cause systemic withdrawal symptoms </li> <li>Though systemic exposure of oral naloxone is low (&#8804;3%) among patients with normal organ function, bioavailability increases in the setting of hepatic impairment and/or renal impairment </li> <li>Use is contraindicated in moderate to severe hepatic impairment </li> <li>Not recommended for perioperative use </li> </ul> </td> </tr> <tr> <td> <p>Chloride channel activator</p> Lubiprostone</td> <td>Locally acting type 2 chloride channel (ClC-2) activator</td> <td>Treatment of opioid-induced constipation</td> <td> <ul> <li>Can cause nausea and abdominal pain </li> <li>Some patients report dyspnea and/or chest tightness within 0.5-2 hours of taking the drug (mechanism unknown) </li> <li>Not studied in methadone-associated&nbsp;opioid-induced constipation&nbsp;and based upon in vitro data provided in the product label; it may not be effective for that use </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73845 Version 7.0</div></div></div>"},"73846":{"type":"graphic_table","displayName":"Temperature conversion","title":"Fahrenheit and Celsius temperature equivalents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fahrenheit and Celsius temperature equivalents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"24%\"></colgroup><colgroup width=\"1%\"></colgroup><colgroup span=\"2\" width=\"24%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Fahrenheit</td> <td class=\"subtitle1\">Celsius</td> <td class=\"highlight_gray_text\" rowspan=\"31\">&nbsp;</td> <td class=\"subtitle1\">Fahrenheit</td> <td class=\"subtitle1\">Celsius</td> </tr> <tr> <td class=\"centered\">96.0</td> <td class=\"centered\">35.6</td> <td class=\"centered\">102.0</td> <td class=\"centered\">38.9</td> </tr> <tr> <td class=\"centered\">96.2</td> <td class=\"centered\">35.7</td> <td class=\"centered\">102.2</td> <td class=\"centered\">39.0</td> </tr> <tr> <td class=\"centered\">96.4</td> <td class=\"centered\">35.8</td> <td class=\"centered\">102.4</td> <td class=\"centered\">39.1</td> </tr> <tr> <td class=\"centered\">96.6</td> <td class=\"centered\">35.9</td> <td class=\"centered\">102.6</td> <td class=\"centered\">39.2</td> </tr> <tr> <td class=\"centered\">96.8</td> <td class=\"centered\">36.0</td> <td class=\"centered\">102.8</td> <td class=\"centered\">39.3</td> </tr> <tr> <td class=\"centered\">97.0</td> <td class=\"centered\">36.1</td> <td class=\"centered\">103.0</td> <td class=\"centered\">39.4</td> </tr> <tr> <td class=\"centered\">97.2</td> <td class=\"centered\">36.2</td> <td class=\"centered\">103.2</td> <td class=\"centered\">39.6</td> </tr> <tr> <td class=\"centered\">97.4</td> <td class=\"centered\">36.3</td> <td class=\"centered\">103.4</td> <td class=\"centered\">39.7</td> </tr> <tr> <td class=\"centered\">97.6</td> <td class=\"centered\">36.4</td> <td class=\"centered\">103.6</td> <td class=\"centered\">39.8</td> </tr> <tr> <td class=\"centered\">97.8</td> <td class=\"centered\">36.6</td> <td class=\"centered\">103.8</td> <td class=\"centered\">39.9</td> </tr> <tr> <td class=\"centered\">98.0</td> <td class=\"centered\">36.7</td> <td class=\"centered\">104.0</td> <td class=\"centered\">40.0</td> </tr> <tr> <td class=\"centered\">98.2</td> <td class=\"centered\">36.8</td> <td class=\"centered\">104.2</td> <td class=\"centered\">40.1</td> </tr> <tr> <td class=\"centered\">98.4</td> <td class=\"centered\">36.9</td> <td class=\"centered\">104.4</td> <td class=\"centered\">40.2</td> </tr> <tr> <td class=\"centered\">98.6</td> <td class=\"centered\">37.0</td> <td class=\"centered\">104.6</td> <td class=\"centered\">40.3</td> </tr> <tr> <td class=\"centered\">98.8</td> <td class=\"centered\">37.1</td> <td class=\"centered\">104.8</td> <td class=\"centered\">40.4</td> </tr> <tr> <td class=\"centered\">99.0</td> <td class=\"centered\">37.2</td> <td class=\"centered\">105.0</td> <td class=\"centered\">40.6</td> </tr> <tr> <td class=\"centered\">99.2</td> <td class=\"centered\">37.3</td> <td class=\"centered\">105.2</td> <td class=\"centered\">40.7</td> </tr> <tr> <td class=\"centered\">99.4</td> <td class=\"centered\">37.4</td> <td class=\"centered\">105.4</td> <td class=\"centered\">40.8</td> </tr> <tr> <td class=\"centered\">99.6</td> <td class=\"centered\">37.6</td> <td class=\"centered\">105.6</td> <td class=\"centered\">40.9</td> </tr> <tr> <td class=\"centered\">99.8</td> <td class=\"centered\">37.7</td> <td class=\"centered\">105.8</td> <td class=\"centered\">41.0</td> </tr> <tr> <td class=\"centered\">100.0</td> <td class=\"centered\">37.8</td> <td class=\"centered\">106.0</td> <td class=\"centered\">41.1</td> </tr> <tr> <td class=\"centered\">100.2</td> <td class=\"centered\">37.9</td> <td class=\"centered\">106.2</td> <td class=\"centered\">41.2</td> </tr> <tr> <td class=\"centered\">100.4</td> <td class=\"centered\">38.0</td> <td class=\"centered\">106.4</td> <td class=\"centered\">41.3</td> </tr> <tr> <td class=\"centered\">100.6</td> <td class=\"centered\">38.1</td> <td class=\"centered\">106.6</td> <td class=\"centered\">41.4</td> </tr> <tr> <td class=\"centered\">100.8</td> <td class=\"centered\">38.2</td> <td class=\"centered\">106.8</td> <td class=\"centered\">41.6</td> </tr> <tr> <td class=\"centered\">101.0</td> <td class=\"centered\">38.3</td> <td class=\"centered\">107.0</td> <td class=\"centered\">41.7</td> </tr> <tr> <td class=\"centered\">101.2</td> <td class=\"centered\">38.4</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">101.4</td> <td class=\"centered\">38.6</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">101.6</td> <td class=\"centered\">38.7</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">101.8</td> <td class=\"centered\">38.8</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle4\" colspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">To convert from Fahrenheit to Celsius:</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">(Temperature - 32) x (5/9)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">To convert from Celsius to Fahrenheit:</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">((9/5) x Temperature) + 32</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73846 Version 2.0</div></div></div>"},"73849":{"type":"graphic_diagnosticimage","displayName":"Achilles tendon US long","title":"Achilles tendon","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Achilles tendon</div><div class=\"cntnt\"><img style=\"width:504px; height:288px;\" src=\"images/RHEUM/73849_Achilles_tendon_US_long.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal sonographic image of the Achilles tendon and the underlying soft tissues.</div><div class=\"graphic_reference\">Reproduced with permission from Bruyn GA, Schmidt WA. Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist. Bohn Stafleu &amp; Van Loghum, 2006. Copyright &#169;2006 Bohn Stafleu &amp; Van Loghum.</div><div id=\"graphicVersion\">Graphic 73849 Version 2.0</div></div></div>"},"73850":{"type":"graphic_diagnosticimage","displayName":"Hysterosc microinsert ultrasound","title":"Hysteroscopic sterilization microinsert: Pelvic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Hysteroscopic sterilization microinsert: Pelvic ultrasound</div><div class=\"cntnt\"><img style=\"width:480px; height:363px;\" src=\"images/OBGYN/73850_Hysterosc_microinsert_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound showing microinsert in expected location (arrow).</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 73850 Version 3.0</div></div></div>"},"73851":{"type":"graphic_picture","displayName":"Keratoacanthoma centrifugum marginatum","title":"Keratoacanthoma centrifugum marginatum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Keratoacanthoma centrifugum marginatum</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/73851_Keratoacan_centri_margin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large plaque with peripheral hyperkeratosis and central atrophy is present on the extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73851 Version 3.0</div></div></div>"},"73852":{"type":"graphic_diagnosticimage","displayName":"Type III supracondylar fracture","title":"Type III supracondylar fracture","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Type III supracondylar fracture</div><div class=\"cntnt\"><img style=\"width:516px; height:191px;\" src=\"images/EM/73852_TypeIIIsupracondylarfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This 5-year-old girl fell on her fully extended left hand. Her elbow is displaced in the posterior direction similar to an older patient with a dislocated elbow. <br />(B) The radiograph shows a displaced supracondylar fracture.</div><div class=\"graphic_reference\">Reproduced with permission from: Baskin M. Trauma: Extremeties. In: Atlas of pediatric emergency medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 73852 Version 14.0</div></div></div>"},"73853":{"type":"graphic_picture","displayName":"False black widow spider","title":"False black widow spider","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">False black widow spider</div><div class=\"cntnt\"><img style=\"width:432px; height:281px;\" src=\"images/ALLRG/73853_Spider_false_b_widow.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Richard S Vetter, MS.</div><div id=\"graphicVersion\">Graphic 73853 Version 2.0</div></div></div>"},"73854":{"type":"graphic_figure","displayName":"Cut off value","title":"Importance of cut-off value on test performance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Importance of cut-off value on test performance</div><div class=\"cntnt\"><img style=\"width:422px; height:216px;\" src=\"images/OBGYN/73854_Cut_off_value_edt3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As the cut-off value is moved to the left, sensitivity (the true positive rate) increases, but specificity decreases.</div><div class=\"graphic_footnotes\">TN: true negatives; TP: true positives; FN: false negatives; FP: false positives.</div><div id=\"graphicVersion\">Graphic 73854 Version 4.0</div></div></div>"},"73855":{"type":"graphic_picture","displayName":"Bridging septal perforators","title":"Myocardial bridging","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Myocardial bridging</div><div class=\"cntnt\"><img style=\"width:474px; height:305px;\" src=\"images/CARD/73855_Bridging_septal_perforators.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right anterior oblique view shows myocardial bridging during systole of the major septal perforator (arrow).</div><div id=\"graphicVersion\">Graphic 73855 Version 1.0</div></div></div>"},"73856":{"type":"graphic_picture","displayName":"Vibrio species on TCBS agar","title":"<em>Vibrio</em> species on TCBS agar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Vibrio</em> species on TCBS agar</div><div class=\"cntnt\"><img style=\"width:355px; height:240px;\" src=\"images/ID/73856_TCBSagarstoolwithanswer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><em>Vibrio </em>species can be selectively recovered from stool by culture on thiosulfate-citrate-bile salts-sucrose (TCBS) agar. On this medium, <em>Vibrio parahaemolyticus</em> (arrow) usually produces a green colony and <em>Vibrio cholerae</em> (dashed arrow) a yellow colony (indicative of the fermentation of sucrose).</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 73856 Version 3.0</div></div></div>"},"73858":{"type":"graphic_table","displayName":"Systematic review empyema Rx","title":"Summary of the data from a systematic review of primary operative versus nonoperative therapy for pediatric empyema","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of the data from a systematic review of primary operative versus nonoperative therapy for pediatric empyema</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Outcome</td> <td class=\"subtitle1\">Antibiotics and chest tube (N = 3183)</td> <td class=\"subtitle1\">Fibrinolytic therapy* (N = 64)</td> <td class=\"subtitle1\">VATS<sup>&#182;</sup> (N = 176)</td> <td class=\"subtitle1\">Thoracotomy (N = 175)</td> </tr> <tr> <td>Mortality rate (range)</td> <td>3.3 percent (0 to 35 percent)</td> <td>0 percent</td> <td>0 percent</td> <td>0&nbsp;percent</td> </tr> <tr> <td>Failure rate<sup>&#916;</sup> (range)</td> <td>23.6 percent (0 to 67 percent)</td> <td>9.4 percent (6.7 to 14.2 percent)</td> <td>2.8 percent</td> <td>3.1 percent</td> </tr> <tr> <td>Length of stay</td> <td>20 &#177; 8.3 days</td> <td>10.7 &#177; 5.1 days</td> <td>11.2 days</td> <td>10.6 days</td> </tr> <tr> <td>Duration of chest tube</td> <td>10.6 &#177; 3.4 days</td> <td>4 days</td> <td>4 days</td> <td>6.2 days</td> </tr> <tr> <td>Duration of antibiotics</td> <td>21.3 &#177; 7.9 days</td> <td>Not specified</td> <td>13.2 days</td> <td>Not specified</td> </tr> <tr> <td>Complication rate<sup>&#9674;</sup> (range)</td> <td>5.6 percent (0 to 45 percent)</td> <td>12.5 percent (0 to 16.6 percent)</td> <td>5.4 percent</td> <td>5.2 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Fibrinolytic therapy: Treatment with fibrinolytics either at the time of or within 24 hours of tube thoracostomy.<br />¶ VATS: Video-assisted thoracoscopy.<br />Δ Failure: Failure of primary intervention necessitating subsequent operative intervention.<br /><FONT class=lozenge>◊</FONT> Complications typically included pneumothorax, bronchopleural fistula, persistent or recurrent empyema, bleeding, and wound infection.</div><div class=\"graphic_reference\">Adapted from Avansino, JR, Goldman, B, Sawin, RS, Flum, DR. Primary operative versus nonoperative therapy for pediatric empyema: a meta-analysis. Pediatrics 2005; 115:1652.</div><div id=\"graphicVersion\">Graphic 73858 Version 2.0</div></div></div>"},"73862":{"type":"graphic_algorithm","displayName":"Adult cardiac arrest algorithm","title":"Adult cardiac arrest algorithm","html":"<div class=\"graphic\"><div style=\"width: 848px\" class=\"figure\"><div class=\"ttl\">Adult cardiac arrest algorithm</div><div class=\"cntnt\"><img style=\"width:828px; height:742px;\" src=\"images/EM/73862_Adult_cardiac_arrest.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The algorithm presented above has been modified to make it more consistent with the 2015 update to the ACLS Guidelines while we await permission from the AHA to reproduce the latest version.</div><div class=\"graphic_footnotes\">CPR: cardiopulmonary resuscitation; ET: endotracheal tube; EtCO<sub>2</sub>: end tidal carbon dioxide; IO: intraosseous; IV: intravenous; PEA: pulseless electrical activity; VF: ventricular fibrillation; VT: ventricular tachycardia.</div><div class=\"graphic_reference\">Reprinted with permission. Adult Advanced Cardiovascular Life Support: 2010. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. &copy; 2010 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 73862 Version 16.0</div></div></div>"},"73863":{"type":"graphic_table","displayName":"Reconstruction techniques for contractures from burns","title":"Reconstruction techniques for contractures from burns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reconstruction techniques for contractures from burns</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of burn contracture</td> <td class=\"subtitle1\">Condition of adjacent skin and tissue</td> <td class=\"subtitle1\">Reconstruction technique options</td> </tr> <tr> <td>Isolated linear</td> <td>Healthy, unburned, or elastic skin and tissue at both sides of the contracture</td> <td> <p>Z-plasty - if realignment via transposition with moderate elongation needs to be achieved</p> <p>Y-V-plasty - if realignment via advancement of transposing flaps needs to be achieved with introduction of pliable tissue</p> </td> </tr> <tr> <td>Isolated linear</td> <td>Healthy, unburned, or elastic skin and tissue at only one side of the contracture</td> <td>Local fasciocutaneous transposition flap</td> </tr> <tr> <td>Multiple linear</td> <td>Wide contractures or no healthy adjacent skin or tissue on either side of contracture</td> <td> <p>Dermal skin substitute with split thickness skin graft</p> <p>Regional, distant, or free flap</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73863 Version 1.0</div></div></div>"},"73864":{"type":"graphic_table","displayName":"Serologic findings in LGL","title":"Serologic findings in CD3+ large granular lymphocyte leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serologic findings in CD3+ large granular lymphocyte leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Feature</td>\n\n      <td class=\"subtitle1\">Freqeuncy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rheumatoid factor</td>\n\n      <td>60 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Antinuclear antibody</td>\n\n      <td>40 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Polyclonal hypergammaglobulinemia</td>\n\n      <td>10 - 40 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Monoclonal gammopathy</td>\n\n      <td>8 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Circulating immune complexes</td>\n\n      <td>55 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Antineutrophil antibody</td>\n\n      <td>40 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Positive Coombs' test</td>\n\n      <td>15 percent</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced by permission from Cancer Control: Journal of the Moffitt Cancer Center. Lamy, T, Loughran, TP Jr. Large granular lymphocyte leukemia. Cancer Control 1998; 5:25.</div><div id=\"graphicVersion\">Graphic 73864 Version 1.0</div></div></div>"},"73865":{"type":"graphic_figure","displayName":"Venomous vs nonvenomous","title":"Comparison of venomous snakes (pit vipers) and nonvenomous snakes in the United States","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Comparison of venomous snakes (pit vipers) and nonvenomous snakes in the United States</div><div class=\"cntnt\"><img style=\"width:601px; height:493px;\" src=\"images/EM/73865_Venomous_vs_nonvenomous_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Hodge III D. Bites and Stings. In: Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73865 Version 9.0</div></div></div>"},"73867":{"type":"graphic_table","displayName":"Common etiologies of neonatal seizures","title":"Common etiologies of neonatal seizures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common etiologies of neonatal seizures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td>Hypoxic-ischemic encephalopathy</td> </tr> <tr> <td>Ischemic stroke</td> </tr> <tr> <td class=\"indent1\">Arterial</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Venous</td> </tr> <tr> <td>Intracranial hemorrhage</td> </tr> <tr> <td class=\"indent1\">Intraparenchymal</td> </tr> <tr> <td class=\"indent1\">Intraventricular</td> </tr> <tr> <td class=\"indent1\">Subarachnoid</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Subdural</td> </tr> <tr> <td>Central nervous system infection</td> </tr> <tr> <td class=\"indent1\">Meningitis</td> </tr> <tr> <td class=\"indent1\">Encephalitis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Intrauterine (prenatal) infection</td> </tr> <tr> <td>Metabolic disturbance</td> </tr> <tr> <td class=\"indent1\">Hypoglycemia</td> </tr> <tr> <td class=\"indent1\">Hypocalcemia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypomagnesemia</td> </tr> <tr> <td>Neonatal-onset epilepsy</td> </tr> <tr> <td class=\"indent1\">Epileptic encephalopathy/genetic epilepsy syndrome</td> </tr> <tr> <td class=\"indent1\">Congenital brain malformation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Benign familial neonatal epilepsy</td> </tr> <tr> <td>Inborn error of metabolism</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73867 Version 13.0</div></div></div>"},"73868":{"type":"graphic_diagnosticimage","displayName":"MRI right occipital infarct","title":"Right occipital infarction","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Right occipital infarction</div><div class=\"cntnt\"><img style=\"width:504px; height:291px;\" src=\"images/NEURO/73868_MRI_right_occipital_infarct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial FLAIR MRI images showing a right occipital infarction.</div><div class=\"graphic_footnotes\">FLAIR: fluid-attenuated inversion recovery. MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 73868 Version 3.0</div></div></div>"},"73869":{"type":"graphic_picture","displayName":"Lamina propria invasion","title":"Invasion of the lamina propria","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Invasion of the lamina propria</div><div class=\"cntnt\"><img style=\"width:505px; height:230px;\" src=\"images/ONC/73869_Lamina_propria_invasion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A: In early invasive urothelial carcinoma (superficial disease, pT1), foci of invasion are characterized by nests, clusters, or single urothelial cells within lamina propria (10x). B: The invasive nests may induce a desmoplastic stromal response (20x). C: Foci of invasive tumor within the lamina propria may be associated with retraction artifact, mimicking vascular invasion (40x).</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 73869 Version 1.0</div></div></div>"},"73870":{"type":"graphic_diagnosticimage","displayName":"Flow propagation velocity","title":"Example of flow propagation velocity measurement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of flow propagation velocity measurement</div><div class=\"cntnt\"><img style=\"width:416px; height:355px;\" src=\"images/CARD/73870_Flow_prop_vel.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Sherif F Nagueh.</div><div id=\"graphicVersion\">Graphic 73870 Version 3.0</div></div></div>"},"73873":{"type":"graphic_algorithm","displayName":"Diagnosis and management of platelet refractoriness","title":"Diagnosis and management of platelet refractoriness","html":"<div class=\"graphic\"><div style=\"width: 696px\" class=\"figure\"><div class=\"ttl\">Diagnosis and management of platelet refractoriness</div><div class=\"cntnt\"><img style=\"width:676px; height:580px;\" src=\"images/HEME/73873_Dxmanagementplateletrefractoriness.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate for additional details regarding evaluation and management of platelet refractoriness. In the context of this algorithm, \"random platelets\" indicates non-HLA-matched platelets, which may be obtained by apheresis or from donated blood.</div><div class=\"graphic_footnotes\">DIC: Disseminated intravascular coagulation; HLA: Human leukocyte antigen; HPA-1A: Human platelet antigen 1a (previously called PIA1).</div><div id=\"graphicVersion\">Graphic 73873 Version 5.0</div></div></div>"},"73874":{"type":"graphic_picture","displayName":"Mucous membrane pemphigoid gingivitis","title":"Mucous membrane pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Mucous membrane pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/73874_Muc_memb_pemphi_gingi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Desquamative gingivitis with edema and hemorrhage in this patient with mucous membrane pemphigoid.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73874 Version 5.0</div></div></div>"},"73875":{"type":"graphic_picture","displayName":"Immunostaining for CD30 in HL","title":"Immunostaining for CD30 in Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Immunostaining for CD30 in Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:504px; height:756px;\" src=\"images/HEME/73875_ImmunostainingCD30.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunostaining for CD30 demonstrates strong membrane and paranuclear staining, and weaker cytoplasmic staining, of the Hodgkin cells.</div><div class=\"graphic_reference\">Reproduced with permission from: Weiss LM, Warnke RA, Hansmann ML, et al. Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 73875 Version 9.0</div></div></div>"},"73876":{"type":"graphic_diagnosticimage","displayName":"Distal radius measurements AP view","title":"Distal radius measurements: AP view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal radius measurements: AP view</div><div class=\"cntnt\"><img style=\"width:426px; height:377px;\" src=\"images/EM/73876_Distal_radius_measure_AP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three important measurements can be determined, using the AP view, to assess the distal radius. Radial inclination is the angle between one line drawn perpendicular to the long axis of the radius and a second line from the tip of the radial styloid to the central reference point (CRP). Radial height is the distance between two lines drawn perpendicular to the long axis of the radius: one through the distal tip of the radial styloid, the second through the CRP. Ulnar variance is the distance between this second line through the CRP and a line through the distal articular surface of the ulnar head. Measurements are often abnormal when a fracture of the distal radius is present.</div><div class=\"graphic_reference\">Courtesy of Erik L Schroeder, MD.</div><div id=\"graphicVersion\">Graphic 73876 Version 4.0</div></div></div>"},"73877":{"type":"graphic_diagnosticimage","displayName":"Rib stress fracture bone scan","title":"Bone scan of a rib stress fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone scan of a rib stress fracture</div><div class=\"cntnt\"><img style=\"width:360px; height:260px;\" src=\"images/EM/73877_Rib_fracture_bone_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A bone scan of the chest wall is needed to diagnose rib stress fractures radiographically. A fracture is indicated by an area of increased radionuclide uptake (dark area on image above). Imaging is needed only in some cases where there is doubt about the diagnosis or when a definitive diagnosis is required to make decisions about returning to competition. The need for imaging will vary based on the clinician's experience managing rib stress fractures.</div><div class=\"graphic_reference\">Courtesy of Kristine Karlson, MD.</div><div id=\"graphicVersion\">Graphic 73877 Version 3.0</div></div></div>"},"73878":{"type":"graphic_figure","displayName":"Causes of FUO over time","title":"The percentage of patients with fever of unknown origin by cause during four decades","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">The percentage of patients with fever of unknown origin by cause during four decades</div><div class=\"cntnt\"><img style=\"width:572px; height:335px;\" src=\"images/PC/73878_Causes_of_FUO_over_time.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Mourad O, Palda V, Detsky AS. Arch Intern Med 2003; 163:545.</div><div id=\"graphicVersion\">Graphic 73878 Version 3.0</div></div></div>"},"73880":{"type":"graphic_table","displayName":"BTS diving guidelines a","title":"Summary of key points and recommendations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of key points and recommendations</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">The diving environment</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diving is an arduous underwater activity in which environmental conditions affect bodily structure and function.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>For\nevery 10 meters descent in sea water, ambient pressure increases by 100\nkPa, equivalent to 1 atmosphere (1 bar). The volume of a given mass of\ngas changes inversely in proportion to pressure. The gas in bodily\ncavities such as the lungs, sinuses, middle ear and intestine is\ntherefore subject to compression during descent and expansion during\nascent. This may lead to tissue damage.</td>\n\n    </tr>\n\n\n\n\n    <tr>\n\n      <td>Partial pressure of\ngases increases in direct proportion to the increase in ambient\npressure. Greater quantities of inert gas, mainly nitrogen, therefore\ndissolve in tissues at depth and come out of solution on ascent.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>The density of inhaled gas increases with pressure, restricting breathing.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Immersion displaces blood from the periphery into the thorax, reducing lung volume.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Work of breathing\nincreases due to a combination of increased gas density, increased\nhydrostatic pressure, and altered respiratory mechanics.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>The underwater breathing apparatus adds dead space and increases resistance to breathing.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>During diving, carbon dioxide retention may result from the above listed effects on the body.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Potential risks of diving</td>\n\n    </tr>\n\n    <tr>\n\n      <td>General risks: panic, hypothermia, physical trauma, and drowning.</td>\n\n    </tr>\n\n\n    <tr>\n      <td>Equipment/technique\nproblems: hypoxia, hyperoxia, or poisoning by inappropriate gas\nmixtures or contaminant gases may result from equipment malfunction or\npoor dive planning. A\nmalfunctioning respiratory regulator may result in aspiration.</td>\n    </tr>\n    <tr>\n\n      <td>Barotrauma:\nis caused by compression or expansion of gas filled spaces during\ndescent or ascent, respectively. Compression of the lungs during\ndescent may lead to alveolar exudation\nand haemorrhage. Expansion of the lungs during ascent may cause lung\nrupture leading to pneumothorax, pneumomediastinum, and arterial gas\nembolism.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Decompression illness:\nmay occur when gas, which has dissolved in tissues while at depth,\ncomes out of solution as bubbles. Clinical manifestations vary, the\nmost severe being cardiorespiratory and neurological.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Loss of buoyancy control: is a cause of many accidents, usually when it leads to rapid uncontrolled ascent.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>It is also essential to consider comorbidities such as\ndiabetes and epilepsy which may influence capability for diving but are\noutside the scope of this document.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">The physician should bear the following general concepts in mind when assessing respiratory fitness to dive:</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\"> The subject may be required to swim in strong currents.</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> The subject may be required to rescue a companion (dive buddy) in the event of an emergency.</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">The diving environment is associated with a risk of lung rupture.</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\"> The gas breathed by the diver may be very cold.</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Buoyancy\ncontrol is essential and requires training, experience, and use of\nappropriate equipment.</td>\n    </tr>\n    <tr>\n      <td>The following recommendations are therefore made.</td>\n    </tr>\n    <tr>\n\n      <td class=\"subtitle1_single\">Assessment of respiratory fitness to dive</td>\n\n    </tr>\n\n    <tr>\n\n      <td>In the history,\nparticular attention should be paid to current respiratory symptoms,\nprevious history of lung disease including childhood history, previous\ntrauma to the chest, and previous episodes of pneumothorax.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Respiratory system examination should be performed.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Forced expiratory\nvolume in 1 second (FEV1), forced vital capacity (FVC), and peak\nexpiratory flow rate (PEF) should be measured. FEV1 and PEF should\nnormally be greater than 80% of predicted and the FEV1/FVC ratio\ngreater than 70 percent.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Routine chest\nradiography is not considered necessary in asymptomatic subjects with\nno significant respiratory history and normal examination findings.\nHowever, all professional divers, including recreational divers, who\nplan to work as instructors are recommended by the Health and Safety\nExecutive to undergo chest radiography.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chest radiography\nis appropriate if there is a previous history of any significant\nrespiratory illness - for example, pleurisy, pneumonia, recurrent\nrespiratory infections, sarcoidosis, chest surgery or trauma,\npneumothorax - and those with current respiratory symptoms and/or\nabnormal examination findings.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Routine measurement\nof the expiratory flow-volume loop, exercise testing, or bronchial\nprovocation testing are not considered necessary although these tests\nmay be useful in specific cases.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thoracic CT\nscanning, which has greater sensitivity than standard chest radiography\nto detect lung structural abnormality, may be useful in specific areas.</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">2/11/2003 perm requested 2/28/2003 perm granted but checking with Tim to see if PC still wants this 3/11/2003 Still wants. Invoice to ajeah 7/14/2003 emailed them about invoice confusion 1/30/2004 renewal requested 2/3/2004 granted 2/2/2005 renewal requested 2/8/2005 granted - they will send invoice 3/9/2005 invoice to susan 5/11/2006 renewal requested 5/19/2006 granted 3/15/2007 - renewal requested.mt 4/3/2007 - BMJ wants to charge over $500/year for these. Asking JG if he still wants to use them.mt 4/24/2007 - yes, he does. putting request through CCC. they will send invoice; put invoice into 16.2 renewals.mt 5/1/2007 - Invoice to Tammy and to 16.2 renewals.mt 4/25/2008--Asked AB to check with her author (JD). 5/22/2008--Renewal granted via Rightslink (JD). 7/15/2008--$264 CD/ $264 Online 5/30/2009--Renewal granted via Rightslink, awaiting formal invoice (JD). 7/6/2009--Formal invoice received, to Catherine for payment (JD). 5/15/2010--Renewal granted via Rightslink, paid on my AMEX (JD). The total fee of $&amp;quot;420.00&amp;quot;was originally charged to BTS_diving_guidelines_a BTS_diving_guidelines_b Assessment_of_potential_divers</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=63424&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>BTS_diving_guidelines_a.htm</title></head></div><div class=\"graphic_reference\">Reproduced from Thorax, British Thoracic Society guidelines on respiratory aspects of fitness for diving, volume 58, pages 3-13, Copyright © 2003, with permission from&nbsp;BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 73880 Version 9.0</div></div></div>"},"73882":{"type":"graphic_figure","displayName":"Respiratory support system","title":"Respiratory support system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Respiratory support system</div><div class=\"cntnt\"><img style=\"width:382px; height:352px;\" src=\"images/PULM/73882_Respiratory_support_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The VPAP III ST-A (ResMed, Inc) &quot;bilevel&quot; ventilator provides two different adjustable levels of positive airway pressure, a back-up rate, and adjustable alarms. Inspiratory pressure capacity is up to 30 cm H2O.</div><div class=\"graphic_reference\">Copyright &#169; ResMed 2010. Used with permission.</div><div id=\"graphicVersion\">Graphic 73882 Version 1.0</div></div></div>"},"73887":{"type":"graphic_table","displayName":"Frisen scale","title":"Modified Frisén Scale for grading papilledema","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Fris&#233;n Scale for grading papilledema</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n    <td class=\"subtitle1_single\">Stage 0: Normal optic disc or not a disc but no edema/swelling</td>\n  </tr>\n  <tr>\n    <td>A. Prominence of the retinal nerve fiber layer at the nasal, superior and inferior poles in inverse proportion to disc diameter</td>\n  </tr>\n  <tr>\n    <td>B. Radial nerve fiber layer striations, without tortuosity</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle1_single\">Stage I: Minimal</td>\n  </tr>\n  <tr>\n    <td>A. C-shaped halo that is subtle and grayish with a temporal gap; obscures underlying retinal details</td>\n  </tr>\n  <tr>\n    <td>B. Disruption of normal radial NFL arrangement striations</td>\n  </tr>\n  <tr>\n    <td>C. Temporal disc margin normal</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle1_single\">Stage II: Low degree</td>\n  </tr>\n  <tr>\n    <td>A. Circumferential halo</td>\n  </tr>\n  <tr>\n    <td>B. Elevation - nasal border</td>\n  </tr>\n  <tr>\n    <td>C. No major vessel obscuration</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle1_single\">Stage III: Moderate</td>\n  </tr>\n  <tr>\n    <td>A. Obscuration of one or more segments of major blood vessels leaving disc</td>\n  </tr>\n  <tr>\n    <td>B. Circumferential halo</td>\n  </tr>\n  <tr>\n    <td>C. Elevation - all borders</td>\n  </tr>\n  <tr>\n    <td>D. Halo - irregular outer fringe with finger-like extensions</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle1_single\">Stage IV: Marked</td>\n  </tr>\n  <tr>\n    <td>A. Total obscuration on the disc of a segment of a major blood vessel on the disc</td>\n  </tr>\n  <tr>\n    <td>B. Elevation - whole nerve head, including the cup</td>\n  </tr>\n  <tr>\n    <td>C. Border obscuration - complete</td>\n  </tr>\n  <tr>\n    <td>D. Halo - complete</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle1_single\">Stage V: Severe</td>\n\t</tr>\n\t<tr>\n<td>A. Partial obscuration of all vessels on disc and total obscuration of at least one vessel on disc</td>\n  </tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: Fris&#233;n, L. Swelling of the optic nerve head: a staging scheme. J Neurol Neurosurg Psychiatry 1982; 45:13.</div><div id=\"graphicVersion\">Graphic 73887 Version 1.0</div></div></div>"},"73888":{"type":"graphic_waveform","displayName":"Hypokalemia tutorial","title":"Hypokalemia","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Hypokalemia</div><div class=\"cntnt\"><img style=\"width:499px; height:108px;\" src=\"images/CARD/73888_Hypokalemia_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An increase in the amplitude of U waves, which occur at the end of the T wave, are characteristic of hypokalemia.</div><div id=\"graphicVersion\">Graphic 73888 Version 2.0</div></div></div>"},"73889":{"type":"graphic_table","displayName":"Spinal cord sensory levels","title":"Sensory loss in patients with spinal cord disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensory loss in patients with spinal cord disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\" class=\"subtitle1\">Area of sensory loss</td><td class=\"subtitle1\">Level</td>\n\n      \n\n    </tr>\n\n    <tr><td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Cervical spine</td></tr><tr>\n\n      <td class=\"indent1\">Supraclavicular fossa</td>\n\n      <td>C3</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Top of acromioclavicular point</td>\n\n      <td>C4</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Lateral antecubital fossa</td>\n\n      <td>C5</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Thumb</td>\n\n      <td>C6</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Middle finger</td>\n\n      <td>C7</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Little finger</td>\n\n      <td>C8</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Thoracic spine</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Ulnar side of antecubital fossa</td>\n\n      <td>T1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Apex of axilla</td>\n\n      <td>T2</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Fourth intercostal space (nipple line)</td>\n\n      <td>T4</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Tenth intercostal space (umbilicus)</td>\n\n      <td>T10</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Midpoint of inguinal ligament</td>\n\n      <td>T12</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Lumbar spine</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Halfway between T12 and L2</td>\n\n      <td>L1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Mid-anterior thigh</td>\n\n      <td>L2</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Medial femoral condyle</td>\n\n      <td>L3</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Medial malleolus</td>\n\n      <td>L4</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Dorsum of third metatarsophalangeal joint</td>\n\n      <td>L5</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Sacral spine</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Lateral heel</td>\n\n      <td>S1</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Midline popliteal fossa</td>\n\n      <td>S2</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Ischial tuberosity</td>\n\n      <td>S3</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Perianal</td>\n\n      <td>S4-5</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from McGee, S, Evidence-Based Physical Diagnosis, WB Saunders Company, 2001.</div><div id=\"graphicVersion\">Graphic 73889 Version 1.0</div></div></div>"},"73890":{"type":"graphic_table","displayName":"Characteristics of precordial motion","title":"Characteristics of precordial motion with various cardiac abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of precordial motion with various cardiac abnormalities</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Aortic regurgitation</td> </tr> <tr> <td class=\"indent1\">Apex impulse hyperdynamic in mild to moderate AR</td> </tr> <tr> <td class=\"indent1\">Severe AR: LV dilatation results in sustained impulse that is displaced laterally and downward (especially in chronic AR)</td> </tr> <tr> <td class=\"indent1\">Systolic retraction medial to PMI</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Palpable a wave may be present</td> </tr> <tr> <td class=\"subtitle1_single\">Mitral regurgitation</td> </tr> <tr> <td class=\"indent1\">Apical systolic thrill in severe MR</td> </tr> <tr> <td class=\"indent1\">Apex impluse hyperdynamic</td> </tr> <tr> <td class=\"indent1\">Severe and/or chronic MR; impulse is sustained and laterally displaced</td> </tr> <tr> <td class=\"indent1\">Can have late parasternal impulse with severe MR without pulmonary hypertension</td> </tr> <tr> <td class=\"indent1\">Parasternal (RV) heave if significant pulmonary hypertension</td> </tr> <tr> <td class=\"indent1\">S3 visible and palpable if severe MR</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">S4 palpable with acute onset MR</td> </tr> <tr> <td class=\"subtitle1_single\">Congestive cardiomyopathy</td> </tr> <tr> <td class=\"indent1\">Sustained and displaced LV impulse, usually felt over 2 interspaces</td> </tr> <tr> <td class=\"indent1\">Palpable a wave (S4) and S3 common</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Parasternal lift, midsystolic bulge common</td> </tr> <tr> <td class=\"subtitle1_single\">Coronary artery disease</td> </tr> <tr> <td class=\"indent1\">Usually normal at rest unless prior MI</td> </tr> <tr> <td class=\"indent1\">Palpable S4 in left decubitus position</td> </tr> <tr> <td class=\"indent1\">Ectopic LV thrust if dyssynergy or LV aneurysm. May have transient abnormalities (eg, bulge, heave) during acute infarction or attack of angina.</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hypertrophic cardiomyopathy</td> </tr> <tr> <td class=\"indent1\">Systolic thrill superior, medial to apex impulse</td> </tr> <tr> <td class=\"indent1\">Vigorous LV apical impulse, often sustained</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Occasional mid- or late systolic bulge - \"tripple ripple\"</td> </tr> <tr> <td class=\"subtitle1_single\">Atrial septal defect</td> </tr> <tr> <td class=\"indent1\">Hyperdynamic parasternal impulse</td> </tr> <tr> <td class=\"indent1\">PA impulse may be present</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">RV impulse may be sustained if pulmonary hypertension is present and occasionally with large left to right shunt without elevated PA pressure</td> </tr> <tr> <td class=\"subtitle1_single\">Mitral stenosis</td> </tr> <tr> <td class=\"indent1\">Small or impalpable apex impulse but S1 typically palpable</td> </tr> <tr> <td class=\"indent1\">Opening snap palpable medial to apex</td> </tr> <tr> <td class=\"indent1\">Apical diastolic thrill in left decubitus position</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Parasternal lift is common; suggests pulmonary hypertension at rest or with effort</td> </tr> <tr> <td class=\"subtitle1_single\">Valvular aortic stenosis</td> </tr> <tr> <td class=\"indent1\">Systolic thrill - aortic area, 2 LICS. Or occasionally at apex.</td> </tr> <tr> <td class=\"indent1\">Sustained and forceful LV apical impulse</td> </tr> <tr> <td class=\"indent1\">Little lateral (leftward) displacement of apex unless LV dilatation has occurred</td> </tr> <tr> <td class=\"indent1\">Palpable a wave (S4) is common and indicates severe aortic obstruction</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AR: aortic regurgitation; LV: left ventricular; PA: pulmonary artery; RV: right ventricular; MI: myocardial infarction; MR: mitral regurgitation; LICS: left intercostal space.</div><div class=\"graphic_reference\">Adapted from Abrams, J. Examination of the precordium. Primary Cardiol 1982; 8:156.</div><div id=\"graphicVersion\">Graphic 73890 Version 4.0</div></div></div>"},"73891":{"type":"graphic_diagnosticimage","displayName":"Radial head fracture dislocation","title":"Fracture-dislocation of the radial head","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fracture-dislocation of the radial head</div><div class=\"cntnt\"><img style=\"width:239px; height:438px;\" src=\"images/EM/73891_Radial_head_fx_dislocatn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These radiographs show a radial head fracture with posterior ulnar dislocation (MCL rupture and coronoid fracture; Mason Type IV).</div><div class=\"graphic_footnotes\">MCL: medial collateral ligament.</div><div class=\"graphic_reference\">Courtesy of Mark Slabaugh, MD.</div><div id=\"graphicVersion\">Graphic 73891 Version 3.0</div></div></div>"},"73897":{"type":"graphic_figure","displayName":"Saber sheath ratio","title":"Schematic representation of saber sheat trachea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic representation of saber sheat trachea</div><div class=\"cntnt\"><img style=\"width:308px; height:416px;\" src=\"images/PULM/73897_Saber_sheath_ratio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This deformity is characterized by narrowing of the trachea in the coronal plane (c) combined with widening in the sagittal plane (s). A ratio of coronal to sagittal diameter &#8804;0.6 is suggestive of this diagnosis.</div><div id=\"graphicVersion\">Graphic 73897 Version 1.0</div></div></div>"},"73898":{"type":"graphic_diagnosticimage","displayName":"Adult scaphoid fracture plain radiograph","title":"Transverse fracture of the scaphoid on plain radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse fracture of the scaphoid on plain radiograph</div><div class=\"cntnt\"><img style=\"width:288px; height:454px;\" src=\"images/EM/73898_Adult_scaphoid_fracture_xra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior plain radiograph of the wrist shows a linear fracture through the waist of the scaphoid (ie, carpal navicular) bone.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 73898 Version 4.0</div></div></div>"},"73899":{"type":"graphic_diagnosticimage","displayName":"Diffuse metastatic pheo MIBG","title":"Diffuse metastatic pheochromocytoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse metastatic pheochromocytoma</div><div class=\"cntnt\"><img style=\"width:370px; height:276px;\" src=\"images/ENDO/73899_Diffuse_metastic_pheo_MIBG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">123-I MIBG scan from a 41-year-old woman shows diffuse metastatic pheochromocytoma.</div><div class=\"graphic_footnotes\">123-I: iodine-123; MIBG: metaiodobenzylguanidine.</div><div class=\"graphic_reference\">Courtesy of William F Young, Jr, MD.</div><div id=\"graphicVersion\">Graphic 73899 Version 4.0</div></div></div>"},"73902":{"type":"graphic_table","displayName":"Sieving coefficients for drugs","title":"Hemofiltration sieving coefficients for drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemofiltration sieving coefficients for drugs</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody><tr>\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tbody>\n\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1\">&nbsp;</td>\n\t\t\t\t\t\t<td class=\"subtitle1\">SC</td>\n\n\t\t\t\t\t\t<td class=\"subtitle1\">Unbound fraction</td>\n\n\t\t\t\t\n\t\t\t\t\t</tr>\n<tr>\n\t\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"3\">Antimicrobials</td>\n\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Acyclovir</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\n\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Amikacin</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\n\t\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Amphotericin</td>\n\n\t\t\t\t\t\t<td>0.3</td>\n\n\t\t\t\t\t\t<td>0.1</td>\n\n\t\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Ampicillin</td>\n\n\t\t\t\t\t\t<td>0.7</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\n\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Cefoperazone</td>\n\n\t\t\t\t\t\t<td>0.3</td>\n\n\t\t\t\t\t\t<td>0.1</td>\n\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Cefoxitin</td>\n\n\t\t\t\t\t\t<td>0.6</td>\n\n\t\t\t\t\t\t<td>0.5</td>\n\n\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Ceftazidime</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\n\t\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Ciprofloxacin</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\n\t\t\t\t\t\t<td>0.7</td>\n\n\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Ganciclovir</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\n\t\t\t\t\t\t<td>1.0</td>\n\n\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Gentamicin</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\n\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Imipenem</td>\n\n\t\t\t\t\t\t<td>1.0</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\n\t\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Jazobactam</td>\n\n\t\t\t\t\t\t<td>0.7</td>\n\n\t\t\t\t\t\t<td>0.7</td>\n\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Levofloxacin</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\n\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Linezolid</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\n\t\t\t\t\t\t<td>0.7</td>\n\n\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Metronidazole</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Mezlocillin</td>\n\n\t\t\t\t\t\t<td>0.7</td>\n\n\t\t\t\t\t\t<td>0.7</td>\n\n\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Ofloxacin</td>\n\n\t\t\t\t\t\t<td>0.3</td>\n\n\t\t\t\t\t\t<td>0.7</td>\n\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Oxacillin</td>\n\n\t\t\t\t\t\t<td>0.02</td>\n\n\t\t\t\t\t\t<td>0.05</td>\n\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Penicillin</td>\n\n\t\t\t\t\t\t<td>0.7</td>\n\n\t\t\t\t\t\t<td>0.5</td>\n\n\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Piperacillin</td>\n\n\t\t\t\t\t\t<td>0.7</td>\n\n\t\t\t\t\t\t<td>0.7</td>\n\n\t\t\t\t\t\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Sulfamethoxazole</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\n\t\t\t\t\t\t<td>0.6</td>\n\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"indent1\">Vancomycin</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\t\t\t\t\t</tr>\n\t\t\t\t</tbody>\n\t\t\t</table>\n\t\t</td>\n\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tbody>\n\t\t\t\t\n\n\t\t\t\t\t<tr>\n\n\t\t\t\t\t\t<td class=\"subtitle1\">&nbsp;</td>\n\n\t\t\t\t\t\t<td class=\"subtitle1\">SC</td>\n\n\t\t\t\t\t\t<td class=\"subtitle1\">Unbound fraction</td>\n\t\t\t\t\t</tr>\n\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"3\">Other drugs</td>\n\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\n\n\t\t\t\t\t\t<td class=\"indent1\">Cyclosporine</td>\n\n\t\t\t\t\t\t<td>0.6</td>\n\n\t\t\t\t\t\t<td>0.1</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\n\n\t\t\t\t\t\t<td class=\"indent1\">Diazepam</td>\n\n\t\t\t\t\t\t<td>0.02</td>\n\n\t\t\t\t\t\t<td>0.02</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\n\t\t\t\t\t\t<td class=\"indent1\">Digitoxin</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\n\n\t\t\t\t\t\t<td class=\"indent1\">Digoxin</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\n\n\t\t\t\t\t\t<td class=\"indent1\">Famotidine</td>\n\n\t\t\t\t\t\t<td>0.7</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\n\n\t\t\t\t\t\t<td class=\"indent1\">Glutethimide</td>\n\n\t\t\t\t\t\t<td>0.02</td>\n\n\t\t\t\t\t\t<td>0.5</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\n\n\t\t\t\t\t\t<td class=\"indent1\">Lidocaine</td>\n\n\t\t\t\t\t\t<td>0.2</td>\n\n\t\t\t\t\t\t<td>0.4</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\n\n\t\t\t\t\t\t<td class=\"indent1\">Metamizole</td>\n\n\t\t\t\t\t\t<td>0.4</td>\n\n\t\t\t\t\t\t<td>0.4</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\n\t\t\t\t\t\t<td class=\"indent1\">Oxazepam</td>\n\n\t\t\t\t\t\t<td>0.1</td>\n\n\t\t\t\t\t\t<td>0.1</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\n\n\t\t\t\t\t\t<td class=\"indent1\">Phenobarbital</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\n\t\t\t\t\t\t<td>0.6</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\n\t\t\t\t\t\t<td class=\"indent1\">Phenytoin</td>\n\n\t\t\t\t\t\t<td>0.4</td>\n\n\t\t\t\t\t\t<td>0.2</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\n\n\t\t\t\t\t\t<td class=\"indent1\">Procainamide</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\n\n\t\t\t\t\t\t<td class=\"indent1\">Ranitidine</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\n\t\t\t\t\t\t<td>0.8</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t\t<tr>\n\n\t\t\t\t\t\t<td class=\"indent1\">Theophylline</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\n\t\t\t\t\t\t<td>0.9</td>\n\t\t\t\t\t</tr>\n\n\t\t\t\t</tbody>\n\t\t\t</table>\n\t\t</td>\n\t</tr>\n</tbody></table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">9.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=39700&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Sieving_Coefficients_for_Dr.htm</title></head></div><div class=\"graphic_lgnd\">Sieving coefficient (SC) and unbound fraction for some commonly used drugs. There is usually a close correlation between these parameters because only the free or unbound drug is available for removal by hemofiltration.</div><div id=\"graphicVersion\">Graphic 73902 Version 2.0</div></div></div>"},"73903":{"type":"graphic_table","displayName":"Safety of MS drugs in pregnancy","title":"Safety during pregnancy of drugs used to treat multiple sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Safety during pregnancy of drugs used to treat multiple sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Category B - No evidence of human risk in controlled studies</td> </tr> <tr> <td class=\"indent1\">Glatiramer acetate</td> </tr> <tr> <td class=\"indent1\">Oxybutynin</td> </tr> <tr> <td class=\"indent1\">Selective serotonin reuptake inhibitors</td> </tr> <tr> <td class=\"subtitle1_single\">Category C - Risk cannot be ruled out</td> </tr> <tr> <td class=\"indent1\">Alemtuzumab</td> </tr> <tr> <td class=\"indent1\">Dalfampridine</td> </tr> <tr> <td class=\"indent1\">Dimethyl fumarate</td> </tr> <tr> <td class=\"indent1\">Glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Fingolimod</td> </tr> <tr> <td class=\"indent1\">Interferon beta-1a (Avonex, Rebif)</td> </tr> <tr> <td class=\"indent1\">Interferon beta-1b (Betaseron)</td> </tr> <tr> <td class=\"indent1\">Natalizumab</td> </tr> <tr> <td class=\"indent1\">Baclofen</td> </tr> <tr> <td class=\"indent1\">Amantadine</td> </tr> <tr> <td class=\"indent1\">Modafinil</td> </tr> <tr> <td class=\"indent1\">Tizanidine</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> </tr> <tr> <td class=\"subtitle1_single\">Category D - Positive evidence of risk</td> </tr> <tr> <td class=\"indent1\">Azathioprine</td> </tr> <tr> <td class=\"indent1\">Cladribine</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> </tr> <tr> <td class=\"indent1\">Mitoxantrone</td> </tr> <tr> <td class=\"subtitle1_single\">Category X - Contraindicated in pregnancy</td> </tr> <tr> <td class=\"indent1\">Methotrexate</td> </tr> <tr> <td class=\"indent1\">Teriflunomide</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Damek DM, Shuster EA, Mayo Clin Proc 1997; 72:977.</div><div id=\"graphicVersion\">Graphic 73903 Version 8.0</div></div></div>"},"73905":{"type":"graphic_picture","displayName":"Petechiae","title":"Petechiae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Petechiae</div><div class=\"cntnt\"><img style=\"width:347px; height:432px;\" src=\"images/EM/73905_Child_petechiae.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Leslie Raffini, MD.</div><div id=\"graphicVersion\">Graphic 73905 Version 2.0</div></div></div>"},"73906":{"type":"graphic_table","displayName":"Pediatric intubation equipment","title":"Equipment sizing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Equipment sizing</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Age\n   </td>\n   <td  class=\"subtitle1\">\n   Blade size and type\n   </td>\n   <td  class=\"subtitle1\">\n   Uncuffed tube size (mm ID)\n   </td>\n   <td  class=\"subtitle1\">\n   Cuffed tube size (mm ID)\n   </td>\n   <td  class=\"subtitle1\">\n   Stylet size\n   </td>\n   <td  class=\"subtitle1\">\n   Insertion depth (cm)\n   </td>\n   </tr>\n   <tr>\n   <td>Newborn</td>\n   <td>1 straight</td>\n   <td>3-3.5</td>\n   <td>N/A</td>\n   <td>Pediatric</td>\n   <td>9-10</td>\n   </tr>\n   <tr>\n   <td>6 months</td>\n   <td>1 straight</td>\n   <td>3.5-4.0</td>\n   <td>3.0-3.5</td>\n   <td>Pediatric</td>\n   <td>11-12</td>\n   </tr>\n   <tr>\n   <td>1 years</td>\n   <td>1-1.5 straight</td>\n   <td>4.0</td>\n   <td>3.5</td>\n   <td>Pediatric</td>\n   <td>12</td>\n   </tr>\n   <tr>\n   <td>2 years</td>\n   <td>1.5-2 straight</td>\n   <td>4.5</td>\n   <td>4.0</td>\n   <td>Pediatric</td>\n   <td>13-14</td>\n   </tr>\n   <tr>\n   <td>5 years</td>\n   <td>2 straight or curved</td>\n   <td>5.0</td>\n   <td>4.5</td>\n   <td>Pediatric x 2*</td>\n   <td>14-15</td>\n   </tr>\n   <tr>\n   <td>8 years</td>\n   <td>2 straight or curved</td>\n   <td>6.0</td>\n   <td>5.5</td>\n   <td>Adult</td>\n   <td>16-18</td>\n   </tr>\n   <tr>\n   <td>10 years</td>\n   <td>2-3 straight or curved</td>\n   <td>6.5</td>\n   <td>6.0</td>\n   <td>Adult</td>\n   <td>18-20</td>\n   </tr>\n   <tr>\n   <td>12 years</td>\n   <td>2-3 straight or curved</td>\n   <td>7.0</td>\n   <td>6.5</td>\n   <td>Adult</td>\n   <td>20-21</td>\n   </tr>\n   <tr>\n   <td>15 years</td>\n   <td>3 straight or curved</td>\n   <td>7.0</td>\n   <td>6.5</td>\n   <td>Adult</td>\n   <td>20-21</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">mm ID: internal diameter in mm.<br>* Use two pediatric stylets in children of this size to ensure adequate endotracheal tube stiffness.</div><div id=\"graphicVersion\">Graphic 73906 Version 2.0</div></div></div>"},"73907":{"type":"graphic_figure","displayName":"CT treatment of osteoporosis","title":"Calcitonin reduces vertebral fractures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcitonin reduces vertebral fractures</div><div class=\"cntnt\"><img style=\"width:420px; height:248px;\" src=\"images/ENDO/73907_CT_treatment_of_osteoporosi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Change in the&nbsp;SDI (with a higher value reflecting more deformity) in 72 postmenopausal women with osteoporosis treated with calcium alone or with nasal salmon calcitonin. There was less deformity in the calcitonin group (p&lt;0.001).</div><div class=\"graphic_footnotes\">Ca: calcium; CT: calcitonin; SDI: spinal deformity index.</div><div class=\"graphic_reference\">Data from: Rico H, Revilla M, Hernandez ER, et al. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 1995; 56:181.</div><div id=\"graphicVersion\">Graphic 73907 Version 2.0</div></div></div>"},"73908":{"type":"graphic_picture","displayName":"Acetic acid mag Endosc2","title":"Magnification endoscopy in a patient with Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Magnification endoscopy in a patient with Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:453px; height:226px;\" src=\"images/GAST/73908_Acetic_acid_mag_Endosc2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnification endoscopy following instillation of acetic acid in a patient suspected of having short-segment Barrett's esophagus (left panel). The magnified image (right panel) shows a villous pattern, typical for intestinal metaplasia, which was confirmed on biopsy.</div><div class=\"graphic_reference\">Courtesy of Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 73908 Version 3.0</div></div></div>"},"73909":{"type":"graphic_diagnosticimage","displayName":"EGPA (Churg-Strauss) CT","title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</div><div class=\"cntnt\"><img style=\"width:360px; height:282px;\" src=\"images/PULM/73909_Churg_Strauss_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Supine high-resolution CT scan through the right lower and middle lobes in a patient with eosinophilic granulomatosis with polyangiitis (Churg-Strauss) demonstrates a thickened major fissure and thickened septal lines in the subpleural parenchyma. Enlarged pulmonary arteries are also present in this area. The adjacent bronchi are normal in size with some peribronchiolar thickening. Small patchy opacities are present in the pulmonary parenchyma and are believed to correlate with the eosinophilic pneumonitis that is present.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 73909 Version 5.0</div></div></div>"},"73910":{"type":"graphic_table","displayName":"Medications for narcolepsy","title":"Drugs used in the treatment of narcolepsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs used in the treatment of narcolepsy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"19%\"></colgroup><colgroup span=\"3\" width=\"27%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dosage (adult)</td> <td class=\"subtitle1\">Common side effects</td> <td class=\"subtitle1\">Serious side effects</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Excessive daytime sleepiness</td> </tr> <tr> <td class=\"indent1\">Modafinil</td> <td>100 to 400 mg every morning <strong>or</strong> 200 mg twice per day</td> <td>Headache, nervousness, nausea, insomnia</td> <td>Severe rash</td> </tr> <tr> <td class=\"indent1\">Armodafinil</td> <td>150 to 250 mg every morning <strong>or</strong> 125 mg (half of 250 mg tablet) twice per day</td> <td>Headache, nervousness, nausea, insomnia</td> <td>Severe rash</td> </tr> <tr> <td class=\"indent1\">Methylphenidate</td> <td>10 to 30 mg twice per day <strong>or</strong> 20 mg sustained-release every morning with 10 to 20 mg every afternoon</td> <td>Reduced appetite, nausea, headache, insomnia</td> <td>Abuse potential, psychosis, mania, seizures, cardiovascular effects*</td> </tr> <tr> <td class=\"indent1\">Dextroamphetamine</td> <td>5 to 30 mg twice per day <strong>or</strong> 10 mg sustained-release every morning with 10 to 20 mg every afternoon</td> <td>Reduced appetite, nausea, headache, insomnia</td> <td>High abuse potential, psychosis, mania, seizures, cardiovascular effects*</td> </tr> <tr> <td class=\"indent1\">Amphetamine-dextroamphetamine</td> <td>10 to 30 mg twice per day <strong>or</strong> 20 mg sustained-release twice per day</td> <td>Reduced appetite, nausea, headache, insomnia</td> <td>High abuse potential, psychosis, mania, seizures, cardiovascular effects*</td> </tr> <tr> <td class=\"indent1\">Amphetamine sulfate</td> <td>10 to 60 mg per day in two or three divided doses</td> <td>Reduced appetite, nausea, headache, insomnia</td> <td>High abuse potential, psychosis, mania, seizures, cardiovascular effects*</td> </tr> <tr> <td class=\"indent1\">Sodium oxybate (gamma hydroxybutyrate)</td> <td>2.25 to 4.5 grams at bedtime <strong>and</strong> repeated 3 to 4 hours later</td> <td>Morning sedation, nausea, dizziness, urinary incontinence, sleepwalking</td> <td>Abuse potential, confusion, severe sedation, coma<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Cataplexy<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Venlafaxine</td> <td>37.5 to 75 mg twice per day <strong>or</strong> 37.5 to 150 mg extended release every morning</td> <td>Transient nausea, headache, insomnia, increase in blood-pressure when given in higher doses</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Fluoxetine</td> <td>20 to 80 mg every morning</td> <td>Nausea, dry mouth, insomnia</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Clomipramine</td> <td>10 to 150 mg as a single dose every morning or in divided doses</td> <td>Dry mouth, constipation, sweating, dizziness, somnolence, weight gain, orthostatic hypotension</td> <td>Cardiotoxicity, seizures, dangerous in overdose<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Protriptyline</td> <td>5 to 60 mg as a single dose every morning or in divided doses</td> <td>Dry mouth, constipation, sweating, anxiety, disturbed nighttime sleep, orthostatic hypotension</td> <td>Cardiotoxicity, seizures, dangerous in overdose<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Sodium oxybate (gamma hydroxybutyrate)</td> <td>2.25 to 4.5 grams at bedtime <strong>and</strong> repeated 3 to 4 hours later</td> <td>Morning sedation, nausea, dizziness, urinary incontinence, sleepwalking</td> <td>Abuse potential, confusion, severe sedation, coma<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Disrupted nighttime sleep<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Zolpidem</td> <td>5 to 10 mg at bedtime</td> <td>Morning sedation, dizziness</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Sodium oxybate (gamma hydroxybutyrate)</td> <td>2.25 to 4.5 grams at bedtime <strong>and</strong> repeated 3 to 4 hours later</td> <td>Morning sedation, nausea, dizziness, urinary incontinence, sleepwalking</td> <td>Abuse potential, confusion, severe sedation, coma<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Most of the medications listed in this table require gradual dose titration and administration at specific scheduled times to optimize patient response. For details, refer to the topic review and the Lexicomp individual drug monographs.</div><div class=\"graphic_footnotes\">* For additional information refer to topic review of treatment of attention deficit hyperactivity disorder in adults or adolescents, section on adverse effects.<br />&para; Combined use with alcohol, sedatives, or hypnotics is specifically contraindicated in US licensing information.<br />&Delta; Anti-cataplexy medications are also useful for problematic sleep paralysis or hypnagogic hallucinations.<br /><span class=\"lozenge\">&loz;</span> For additional information refer to topic review of tricyclic antidepressants, section on adverse effects.<br />&sect; Some sleep disruption in narcolepsy may be caused by additional sleep disorders that require specific treatment (examples include obstructive sleep apnea or periodic limb movements of sleep).</div><div class=\"graphic_reference\">Adapted and expanded from: Scammell TE. The Neurobiology, diagnosis, and treatment of Narcolepsy. Ann Neurol 2003; 53:154.</div><div id=\"graphicVersion\">Graphic 73910 Version 9.0</div></div></div>"},"73912":{"type":"graphic_picture","displayName":"Circumscribed morphea","title":"Circumscribed morphea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circumscribed morphea</div><div class=\"cntnt\"><img style=\"width:352px; height:315px;\" src=\"images/RHEUM/73912_Circumscribed_morphea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lesions in circumscribed morphea are few and well demarcated. They begin as small violaceous or erythematous skin changes.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 73912 Version 2.0</div></div></div>"},"73913":{"type":"graphic_figure","displayName":"Serum IgG levels in the first five years of life","title":"Serum IgG levels in the first five years of life","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Serum IgG levels in the first five years of life</div><div class=\"cntnt\"><img style=\"width:506px; height:296px;\" src=\"images/RHEUM/73913_Serum_IgG_levels_less_than.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Placental transfer of materal IgG (red line with circles) provides the neonate with a serum level that is usually slightly higher than the mother's at the time of birth. These antibodies are decreased by at least 50% in two to three months after birth. The rate of the infant's IgG production (blue line with squares) becomes greater than the rate of loss of the mother's IgG by approximately four to six months of age. Serum IgG levels increase gradually in the first three years, then plateau at approximately 60% of the adult concentration, while the rate of increase becomes very slow. Normal adult levels are reached in late childhood or early adolescence.</div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; IgA: immunoglobulin A; IgM: immunoglobulin M.</div><div class=\"graphic_reference\">Reproduced with permission from: Bona C, Bonilla F. B Cells and Humoral Immunity. In: Textbook of Immunology, 2nd ed, Harwood Academic Publishers 1996. Page 116, figure 5.10.<br />Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Johansson SG, Berg T. Immunoglobulin levels in healthy children. Acta Paediatr Scand 1967; 56:572.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 73913 Version 5.0</div></div></div>"},"73914":{"type":"graphic_figure","displayName":"Resp change const peri","title":"Respiratory change from a patient with constrictive pericarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Respiratory change from a patient with constrictive pericarditis</div><div class=\"cntnt\"><img style=\"width:381px; height:479px;\" src=\"images/CARD/73914_Resp_change_const_peri.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left ventricular (LV) and right ventricular (RV) tracings from a patient with constrictive pericarditis. There is early rapid filling in diastole and equalization of the diastolic pressures. There also is discordance of the LV and RV systolic pressures with respiration due to enhancement of ventricular interdependence.</div><div class=\"graphic_reference\">Courtesy of Paul Sorajja, MD.</div><div id=\"graphicVersion\">Graphic 73914 Version 1.0</div></div></div>"},"73916":{"type":"graphic_table","displayName":"Diagnostic and staging studies RMS","title":"Diagnostic and staging studies at the time of initial presentation of rhabdomyosarcoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic and staging studies at the time of initial presentation of rhabdomyosarcoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>CT or MRI scan of primary tumor area</td> </tr> <tr> <td>Thin-cut (5 mm section) CT scan of abdomen and retroperitoneum (all tumors below the diaphragm, including genitourinary primaries)</td> </tr> <tr> <td>Bone scan</td> </tr> <tr> <td>CT scan of chest</td> </tr> <tr> <td>Ultrasound (pelvic tumors)</td> </tr> <tr> <td>Bilateral bone marrow aspirate and biopsy</td> </tr> <tr> <td>Lumbar puncture (parameningeal primary)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 73916 Version 5.0</div></div></div>"},"73918":{"type":"graphic_diagnosticimage","displayName":"ICE normal MV","title":"Intracardiac ultrasound examination of a normal mitral valve is shown in diastole and systole","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Intracardiac ultrasound examination of a normal mitral valve is shown in diastole and systole</div><div class=\"cntnt\"><img style=\"width:504px; height:202px;\" src=\"images/CARD/73918_ICE_normal_MV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that individual chordae tendineae are visible and the thin leaflets of the mitral valve.</div><div id=\"graphicVersion\">Graphic 73918 Version 3.0</div></div></div>"},"73919":{"type":"graphic_table","displayName":"DSM undiff somatoform","title":"DSM-IV-TR diagnostic criteria for undifferentiated somatoform disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-IV-TR diagnostic criteria for undifferentiated somatoform disorder</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n  <td>A. One or more physical complaints, eg, fatigue, anorexia, gastrointestinal or urinary complaints.</td>\n </tr>\n <tr>\n  <td class=\"sublist1_start\">B. Either 1 or 2:</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">1. After appropriate investigation, the symptoms cannot be fully explained by a known nonpsychiatric medical condition or the direct effects of a substance (eg, a drug of abuse or a medication).</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">2. When there is a nonpsychiatric medical condition, the physical complaints or resulting social or occupational impairment is in excess of what would be expected from the history, physical examination, or laboratory findings.</td>\n </tr>\n <tr>\n  <td>C. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.</td>\n </tr>\n <tr>\n  <td>D. The duration of the disturbance is at least six months.</td>\n </tr>\n <tr>\n  <td>E. The disturbance is not better accounted for by another mental disorder (eg, another somatoform disorder, sexual dysfunction, mood disorder, anxiety disorder, sleep disorder, or psychotic disorder).</td>\n </tr>\n <tr>\n  <td>F. The symptoms are not intentionally produced or feigned, as in factitious disorder or malingering.</td>\n </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">1/20/2010--Requested permission (JD). 1/26/2010--Permission granted; figure to Terrence, invoice to Jo (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=58503&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>DSM_undiff_somatoform.htm</title></head></div><div class=\"graphic_reference\">Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition (Copyright © 2000). American Psychiatric Association.</div><div id=\"graphicVersion\">Graphic 73919 Version 8.0</div></div></div>"},"73921":{"type":"graphic_picture","displayName":"Water moccasin bite","title":"Water moccasin snake bite","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Water moccasin snake bite</div><div class=\"cntnt\"><img style=\"width:360px; height:287px;\" src=\"images/EM/73921_Water_moccasin_bite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Local edema and inflammation of the hand is obvious in this bite of a water moccasin (Ancistrodon piscivorus).</div><div class=\"graphic_reference\">Courtesy of Carol Venable, MD.</div><div id=\"graphicVersion\">Graphic 73921 Version 2.0</div></div></div>"},"73926":{"type":"graphic_table","displayName":"Risk of a third preterm birth","title":"Risk of preterm birth in a third pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of preterm birth in a third pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Obstetric history</td> <td class=\"subtitle1\">Risk of PTB in&nbsp;third pregnancy&nbsp;(%)</td> </tr> <tr> <td class=\"sublist1_start\">Two prior preterm births</td> <td class=\"sublist_other_start_centered\">42</td> </tr> <tr> <td class=\"sublist1\">Both at 32 to 36 weeks</td> <td class=\"sublist_other_centered\">33</td> </tr> <tr> <td class=\"sublist1\">Both at less than 32 weeks</td> <td class=\"sublist_other_centered\">57</td> </tr> <tr> <td>Term birth followed by PTB</td> <td class=\"centered\">21</td> </tr> <tr> <td>PTB followed by term birth</td> <td class=\"centered\">13</td> </tr> <tr> <td>Two prior term births</td> <td class=\"centered\">5</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These data were derived from women with spontaneous or&nbsp;indicated preterm birth.</div><div class=\"graphic_footnotes\">PTB: preterm birth.</div><div class=\"graphic_reference\">Data from: McManemy J, Cooke E, Amon E, Leet T. Recurrence risk for preterm delivery. Am J Obstet Gynecol 2007; 196:576.</div><div id=\"graphicVersion\">Graphic 73926 Version 7.0</div></div></div>"},"73928":{"type":"graphic_picture","displayName":"Duodenal amyloid Congo red","title":"Amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amyloidosis</div><div class=\"cntnt\"><img style=\"width:242px; height:275px;\" src=\"images/GAST/73928_Duodenal_amyloid_Congo_red.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic biopsy of nodular appearing duodenal mucosa stained with Congo red. Note the positive staining of the lamina propria and blood vessels (arrow).</div><div class=\"graphic_reference\">Courtesy of Michael Camilleri, MD.</div><div id=\"graphicVersion\">Graphic 73928 Version 1.0</div></div></div>"},"73930":{"type":"graphic_picture","displayName":"Encrusted ureteral stent","title":"Encrusted ureteral stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Encrusted ureteral stent</div><div class=\"cntnt\"><img style=\"width:396px; height:311px;\" src=\"images/SURG/73930_Encrusted_ureteral_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Stephen Nakada, MD and Sutchin Patel, MD.</div><div id=\"graphicVersion\">Graphic 73930 Version 3.0</div></div></div>"},"73931":{"type":"graphic_figure","displayName":"Reentry in AF","title":"Two types of reentry in atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two types of reentry in atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:383px; height:344px;\" src=\"images/CARD/73931_Reentry_in_AF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The isochronal activation maps demonstrate two types of reentry in atrial fibrillation. Map A shows random reentry with three simultaneous wavefronts (black arrows) activating most of the recording area. Map B also shows three simultaneous wavefronts, but they are coming from different directions than those in map A. Maps C and D show two consecutive cycles of complete reentry. The wave of activation (black arrow) spreads clockwise in a circular fashion around a line of unexcited tissue.</div><div class=\"graphic_reference\">Reproduced with permission from Holm M, Johansson R, Brandt J, et al. Eur Heart J 1997; 18:290.</div><div id=\"graphicVersion\">Graphic 73931 Version 2.0</div></div></div>"},"73933":{"type":"graphic_picture","displayName":"Central line SC mid needle","title":"Needle insertion for the middle approach to subclavian vein","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Needle insertion for the middle approach to subclavian vein</div><div class=\"cntnt\"><img style=\"width:432px; height:273px;\" src=\"images/EM/73933_Central_line_SC_mid_needle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the middle approach to the subclavian vein, the needle is inserted 2 to 3 cm inferior to the midpoint of the clavicle. The needle is advanced while aiming for a point just deep to the suprasternal notch.</div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 73933 Version 2.0</div></div></div>"},"73934":{"type":"graphic_table","displayName":"Dysphagia child","title":"Causes of dysphagia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of dysphagia in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n    <td class=\"subtitle2_left\">Life-threatening</td>\n    <td><p>Esophageal foreign body</p>\n\t\t<p>Stevens-Johnson syndrome</p>\n\t\t<p>Caustic ingestion</p>\n\t\t<p>Retropharyngeal abscess</p>\n\t\t<p>Epiglottitis</p>\n\t\t<p>Central nervous system infection (eg, meningitis, encephalitis, cerebral abscess)</p>\n\t\t<p>Impairment of swallowing (eg, cerebral palsy, myasthenia gravis, botulism, Miller Fisher syndrome)</p>\n\t\t<p>Tetanus</p>\n\t\t<p>Diphtheria</p>\n\t\t<p>Poliomyelitis</p>\n\t\t<p>Central nervous system tumor</p>\n\t\t<p>Esophageal perforation</p></td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\">Common</td>\n    <td><p>Stomatitis</p>\n\t\t<p>Infectious pharyngitis</p>\n\t\t<p>Peritonsillar abscess</p>\n\t\t<p>Esophagitis</p>\n\t\t<p>Dystonic reaction</p>\n\t\t<p>Oropharyngeal trauma</p></td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2_left\">Other</td>\n    <td><p>Achalasia</p>\n\t\t<p>Rheumatic disease (eg, juvenile systemic sclerosis, dermatomyositis)</p>\n\t\t<p>Myasthenia gravis</p>\n\t\t<p>Crohn's disease</p>\n\t\t<p>Thyroid enlargement (eg, acute suppurative thyroiditis)</p>\n\t\t<p>Esophageal tumor</p>\n\t\t<p>Vascular ring</p>\n\t\t<p>Globus sensation</p></td>\n  </tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 73934 Version 1.0</div></div></div>"},"73935":{"type":"graphic_figure","displayName":"Pelvic arteries nerve roots","title":"Schematic of arteries and nerve roots near bony pelvis","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Schematic of arteries and nerve roots near bony pelvis</div><div class=\"cntnt\"><img style=\"width:604px; height:433px;\" src=\"images/EM/73935_Pelvis_arteries_nerve_rts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Not shown are the veins which run with the arteries and the venous plexus overlying the sacrum. Also notice the relationship of the bladder and the rectum to the bony pelvis.</div><div class=\"graphic_reference\">Reproduced with permission from: Kellam, JF, Mayo, K. Pelvic Ring Disruptions. In: Skeletal Trauma: Basic Science, Management, and Reconstruction, Browner, BD, Jupiter, JB, Levine, AM, Trafton, PG (Eds), Saunders, Philadelphia 2003. p. 1056. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &#169;2003 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 73935 Version 2.0</div></div></div>"},"73937":{"type":"graphic_table","displayName":"Classification tracheomalacia","title":"Classification of adult tracheomalacia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of adult tracheomalacia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Primary or Congenital\n   </td>\n   </tr>\n   <tr>\n   <td>Genetic, such as polychondritis (See also Pediatric table)</td>\n   </tr>\n   <tr>\n   <td>Idiopathic \"Giant Trachea\" or Mounier-Kuhn</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Secondary or Acquired\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Post-traumatic\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Post intubation\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Post tracheostomy\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   External chest trauma\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Post lung transplantation\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Emphysema\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Chronic Infection/Bronchitis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Chronic Inflammation\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Relapsing Polychondritis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Chronic External Compression of the Trachea\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Malignancy\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Benign Tumors\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Cysts\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Abscesses\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Aortic aneurysm\n   </td>\n   </tr>\n   <tr>\n   <td>Vascular Rings, previously undiagnosed in childhood</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 73937 Version 1.0</div></div></div>"},"73938":{"type":"graphic_picture","displayName":"Fractured metallic stent","title":"Fractured metallic stent","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Fractured metallic stent</div><div class=\"cntnt\"><img style=\"width:501px; height:254px;\" src=\"images/PULM/73938_Fractured_metallic_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Images of patients with term stent complications. A) A metallic stent with ulceration and fractures; B) a torn silicone stent. Both stents had to be removed. Stent complications in tracheomalacia are common, probably due to the hyperdynamic environment.</div><div id=\"graphicVersion\">Graphic 73938 Version 3.0</div></div></div>"},"73939":{"type":"graphic_diagnosticimage","displayName":"Metastatic chordoma CT","title":"Metastatic chordoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metastatic chordoma</div><div class=\"cntnt\"><img style=\"width:320px; height:320px;\" src=\"images/PULM/73939_Metastatic_chordoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan showing multiple nodules secondary to metastases from a sacral chordoma. The lesions are round, smooth bordered, and peripherally located.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 73939 Version 3.0</div></div></div>"},"73941":{"type":"graphic_picture","displayName":"Skin biopsy morphea","title":"Stages of morphea on skin biopsy","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Stages of morphea on skin biopsy</div><div class=\"cntnt\"><img style=\"width:497px; height:232px;\" src=\"images/RHEUM/73941_Skin_biopsy_morphea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Skin biopsy from an early stage of morphea showing a mononuclear infiltrate in the interstitium and hyalinization and widening of occasional collagen bundles. <br />Right panel: Burnt out stage of morphea. The dermal collagen bundles are widened with loss of their fibrillar architecture. There is only a sparse plasma cell rich infiltrate in the interstitium.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 73941 Version 3.0</div></div></div>"},"73944":{"type":"graphic_diagnosticimage","displayName":"CT scan jejunal adenoCA","title":"Axial image of a contrast-enhanced CT scan demonstrates a proximal adenocarcinoma of the jejunum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Axial image of a contrast-enhanced CT scan demonstrates a proximal adenocarcinoma of the jejunum</div><div class=\"cntnt\"><img style=\"width:396px; height:341px;\" src=\"images/ONC/73944_CT_scan_jejunal_adenoCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Dr. Michael Overman.</div><div id=\"graphicVersion\">Graphic 73944 Version 3.0</div></div></div>"},"73945":{"type":"graphic_figure","displayName":"IASLC lymph node map","title":"The International Association for the Study of Lung Cancer (IASLC) lymph node map","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">The International Association for the Study of Lung Cancer (IASLC) lymph node map</div><div class=\"cntnt\"><img style=\"width:568px; height:786px;\" src=\"images/ONC/73945_IASLC_lymph_node_map.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The International Association for the Study of Lung Cancer (IASLC) lymph node map, including the proposed grouping of lymph node stations into &quot;zones&quot; for the purposes of prognostic analyses.</div><div class=\"graphic_reference\">Reproduced with permission from: Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4:568. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73945 Version 8.0</div></div></div>"},"73946":{"type":"graphic_picture","displayName":"Physiologic bow-legs","title":"Physiologic bow-legs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Physiologic bow-legs</div><div class=\"cntnt\"><img style=\"width:246px; height:396px;\" src=\"images/PEDS/73946_Physiologicbowlegs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examination of the child with physiologic bowing shows symmetric bowing throughout the tibia and internal tibial torsion, which is often more noticeable with walking.</div><div class=\"graphic_reference\">Reproduced with permission from: Schoenecker PL, Rich MM. The Lower Extremity. In: Lovell and Winter's Pediatric Orthopaedics, 6<SUP>th</SUP> ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 73946 Version 12.0</div></div></div>"},"73947":{"type":"graphic_table","displayName":"Normal visual behavior of infants","title":"Normal visual behavior of infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal visual behavior of infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age, months</td> <td class=\"subtitle1\">Behavior</td> </tr> <tr> <td rowspan=\"3\">0 to 1</td> <td>Turns eyes and head to look at light sources</td> </tr> <tr> <td>Horizontal tracking</td> </tr> <tr> <td>Eye contact at 6 to 8 weeks</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">2 to 3</td> <td>Intense eye contact</td> </tr> <tr> <td>Vertical and circular tracking</td> </tr> <tr> <td>Interested in mobiles</td> </tr> <tr> <td>Interested in \"lip reading\"</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">3 to 6</td> <td>Watches own hands</td> </tr> <tr> <td>Reaches toward, later grasps, hanging objects</td> </tr> <tr> <td>Observes toys falling and rolling away</td> </tr> <tr> <td>Shifts fixation across midline</td> </tr> <tr> <td>Visual sphere of attention widens gradually</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">7 to 10</td> <td>Notices small bread crumbs</td> </tr> <tr> <td>First touches them, then develops pincer grasp</td> </tr> <tr> <td>Interested in pictures</td> </tr> <tr> <td>Recognizes partially hidden objects</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">11 to 12</td> <td>Visual orientation at home</td> </tr> <tr> <td>Looks through window and recognizes people, recognizes pictures, plays hide-and-seek</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">3/28/2001 - perm requested - jm 4/24/2001 - perm granted - gave info to Nan &amp;amp; Chris - jm; 6/25/2001-will be used. ($150.00) 11/7/2001 - renewal requested -jm; 11/13/2001 - Lawley faxed back that we cannot renew, must rerequest. Faxed new request - jm 12/20/2001 -renewal granted (free). Did not say we have to renew.</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=56936&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reproduced with permission from: Hyvarinen L. Assessment of visually impaired infants. Ophthalmol Clin North Am 1994; 7:219. Copyright © 1994 WB Saunders.</div><div id=\"graphicVersion\">Graphic 73947 Version 4.0</div></div></div>"},"73950":{"type":"graphic_picture","displayName":"Pneumatic compression boots","title":"Pneumatic compression boots","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumatic compression boots</div><div class=\"cntnt\"><img style=\"width:389px; height:262px;\" src=\"images/OBGYN/73950_Pneumatic_compression_boots.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Intermittent pneumatic compression devices are applied before draping, and the power units placed well out of the way of the surgeons and assistants.</div><div id=\"graphicVersion\">Graphic 73950 Version 1.0</div></div></div>"},"73951":{"type":"graphic_diagnosticimage","displayName":"Long axis mitral stenosis","title":"Two dimensional echocardiogram of mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two dimensional echocardiogram of mitral stenosis</div><div class=\"cntnt\"><img style=\"width:302px; height:268px;\" src=\"images/CARD/73951_Long_axis_mitral_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The precordial long axis during diastole from a two dimensional echocardiogram of a patient with mitral stenosis shows a very small, flow limiting orifice that is maximally opened (arrow). The flexible portion of the valve leaflet domes (assumes a knee bend appearance) under the continually elevated left atrial (LA) pressure and lowered left ventricular (LV) diastolic pressure. The LA and right ventricle (RV) are large and the LV small.</div><div class=\"graphic_footnotes\">Ao: aorta.</div><div id=\"graphicVersion\">Graphic 73951 Version 2.0</div></div></div>"},"73952":{"type":"graphic_table","displayName":"Identifying asthmatic patients","title":"Approaches for identifying persons with asthma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approaches for identifying persons with asthma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Method</td> <td class=\"subtitle1\">Problems</td> </tr> <tr> <td>Clinical evaluation</td> <td>Nonstandardization of physician criteria for diagnosis; bias toward more severe cases; bias by access to physician</td> </tr> <tr> <td>Questionnaire history of diagnosis</td> <td>Same as above; plus recall bias in subjects</td> </tr> <tr> <td>Questionnaire history of symptoms</td> <td>Possibly influenced by frequency of other symptoms; less specific than physician's diagnosis</td> </tr> <tr> <td>Response to bronchodilator</td> <td>May be influenced by level of FEV<sub>1</sub> correlation with bronchodilator; may lack sensitivity</td> </tr> <tr> <td>Bronchoconstrictor response</td> <td>Influenced by level of FEV<sub>1</sub>; may be nonspecific</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FEV<SUB>1</SUB>: forced expiratory volume in one second.</div><div class=\"graphic_reference\">Adapted from: Weiss ST, Speizer FE. Epidemiology and natural history. In: Bronchial Asthma: Mechanisms and Therapeutics, 3rd ed, Weiss EB, Stein M (Eds), Little, Brown, Boston 1993.</div><div id=\"graphicVersion\">Graphic 73952 Version 2.0</div></div></div>"},"73954":{"type":"graphic_movie","displayName":"Short axis tetralogy of Fallot","title":"Parasternal short axis view of tetralogy of Fallot (TOF)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal short axis view of tetralogy of Fallot (TOF)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/73954_ShortaxistetraFallot.mp4\" style=\"width:432px;height:400px\"></div><img style=\"width:452px; height:350px;\" src=\"images/PEDS/73954_ShortaxistetralogyFallot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This still frame from the accompanying echocardiographic video clip of the parasternal short axis view of a patient with tetralogy of Fallot (TOF) shows the boundaries of the ventricular septal defect (VSD). The VSD extends from the membranous septum, beneath the tricuspid valve, and into the outlet septum. The conal septum (CS) is intact in the suprascristal region and anteriorly deviated, separating the defect from the right ventricular outflow tract (RVOT). The video clip begins with these structures. The ultrasound transducer then sweeps apically through the ventricles, showing no other septal defects present in this patient.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; RV: right ventricle; LVOT: left ventricular outflow tract.</div><div id=\"graphicVersion\">Graphic 73954 Version 1.0</div></div></div>"},"73956":{"type":"graphic_diagnosticimage","displayName":"Lateral foot x-ray with metatarsal shaft fracture","title":"Lateral foot x-ray with metatarsal shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral foot x-ray with metatarsal shaft fracture</div><div class=\"cntnt\"><img style=\"width:432px; height:297px;\" src=\"images/EM/73956_Lateral_metatars_shaft_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrow indicates a fracture of the third metatarsal. However, the lateral view is less useful than the oblique and AP views because of overlapping of the metatarsals.</div><div class=\"graphic_footnotes\">AP: anterior-posterior.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH and James R Clugston, MD, MS.</div><div id=\"graphicVersion\">Graphic 73956 Version 4.0</div></div></div>"},"73958":{"type":"graphic_waveform","displayName":"ECG atrial fibrillation 1","title":"Single-lead electrocardiogram (ECG) showing atrial fibrillation","html":"<div class=\"graphic normal\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:531px; height:90px;\" src=\"images/CARD/73958_Atrialfibrillation1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lead V1 showing coarse AF with moderate ventricular response. The two characteristic findings in AF are present: the very rapid atrial fibrillatory waves (f waves), which are variable in appearance; and the irregularly irregular ventricular response as the R-R interval between beats is unpredictable. Coarse AF may appear similar to atrial flutter. However, the variable height and duration of the f waves differentiate them from atrial flutter (F) waves, which are identical in appearance and occur at a constant rate of about 250 to 350 beats/min.</div><div class=\"graphic_footnotes\">AF: atrial fibrillation.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 73958 Version 6.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"73959":{"type":"graphic_table","displayName":"Snake venom syndromes","title":"Site of action of venom, clinical features, tests, and management","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Site of action of venom, clinical features, tests, and management</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Site of action</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Ancillary testing</td> <td class=\"subtitle1\">Management</td> </tr> <tr class=\"divider_bottom\"> <td>Local tissue</td> <td> <p>Pain</p> <p>Fang marks</p> <p>Swelling</p> <p>Blistering</p> <p>Ecchymoses</p> <p>Tissue necrosis</p> Lymph node swelling and tenderness</td> <td>&nbsp;</td> <td> <p>Antivenom</p> <p>Manage signs of compartment syndrome (Rare)</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Neuromuscular junction</td> <td> <p>Ptosis </p> <p>Diplopia</p> <p>Dysphagia</p> <p>Bulbar palsy: \"drooling\" pooling of secretions in pharynx</p> <p>Dyspnea</p> Limb weakness</td> <td> <p>Positive Tensilon (edrophonium)&nbsp;test&nbsp;indicates paralysis responsive to antivenom and anticholinesterase*</p> <p>Low&nbsp;maximal inspiratory and expiratory forces</p> </td> <td> <p>Antivenom</p> <p>Anticholinesterase (eg, neostigmine)*</p> <p>Maintain and support airway and breathing, as needed </p> </td> </tr> <tr class=\"divider_bottom\"> <td>Coagulopathy</td> <td> <p>Epistaxis </p> <p>Gingival oozing</p> <p>Bleeding from venipuncture site</p> <p>Ecchymoses and bruising</p> Clinically evident bleeding (hemoptysis, hematemesis, hematuria, intracranial hemorrhage)</td> <td> <p>Thrombocytopenia (Complete blood count)</p> <p>Anemia</p> <p>Prolonged INR or&nbsp;aPTT</p> <p>Decreased fibrinogen</p> <p>Increased fibrin degradation products or &nbsp;D-dimer</p> <p>Whole blood clotting test (resource-limited settings)<sup>&#8226;</sup></p> </td> <td> <p>Antivenom primary treatment</p> <p>Blood products (eg, whole blood, fresh frozen plasma, or platelets)&nbsp;only if life-threatening bleeding and, when available,&nbsp;<strong>after</strong> antivenom administration</p> Heparin, aminocaproic acid <strong>not</strong> helpful</td> </tr> <tr> <td>Shock</td> <td> <p>Hypotension</p> <p>Tachycardia</p> <p>Signs of poor perfusion (prolonged capillary refill, decreased urine output, altered mental status)</p> </td> <td> <p>Central pressure monitoring </p> &nbsp;</td> <td> <p>Antivenom</p> <p>Intravenous isotonic fluids (eg, normal saline)&nbsp;and vasoactive infusions to maintain perfusion pressure depending upon whether shock is hypovolemic, cardiogenic, or both</p> </td> </tr> <tr> <td>Rhabdomyolysis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td> <td> <p>Red or brown urine</p> <p>Oliguria&nbsp;&nbsp;&nbsp;&nbsp;</p> </td> <td> <p>Rapid urine dipstick positive for blood with microscopic urinalysis showing no red blood cells</p> <p>Positive urine for myoglobin</p> <p>Increased serum creatine kinase, potassium, creatinine, and/or blood urea nitrogen</p> <p>EKG changes indicating hyperkalemia</p> </td> <td> <p>Intravenous normal saline in volumes sufficient to reestablish urinary output<sup>&#916;</sup></p> <p>Hemodialysis, as needed, for acute kidney injury</p> <p>&nbsp;</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">* Refer to UpToDate topics on snakebites worldwide for specific guidance on performing a Tensilon (edrophonium)&nbsp;test and for recommended dosing of neostigmine in snakebite victims with a positive test. <br />• The whole blood clotting test (WBCT) has also been considered a useful bedside screening test when more formal coagulation testing is not available; failure of the blood to clot in a clean glass tube after 20 minutes has been considered evidence of severe hypofibrinogenemia. The WBCT has low sensitivity but high specificity. Thus, a positive test is a reasonable indication for antivenom administration. However, a negative test does <STRONG>not</STRONG> mean that antivenom should be withheld, especially if there are clinical features of coagulopathy (eg, blood oozing at puncture sites, bleeding gums, or epistaxis).<br /><SUP>Δ </SUP>Antivenom may attenuate rhabdomyolysis but will not reverse it for selected snakes. Refer to UpToDate topics on management of snakebites worldwide.</div><div id=\"graphicVersion\">Graphic 73959 Version 7.0</div></div></div>"},"73961":{"type":"graphic_picture","displayName":"Pilocytic astrocytoma Light","title":"Pilocytic astrocytoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pilocytic astrocytoma</div><div class=\"cntnt\"><img style=\"width:392px; height:259px;\" src=\"images/ONC/73961_Pilocytic_astrocytoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a pilocytic astrocytoma. They differ microscopically from fibrillary astrocytomas in that there is scant intercellular fibrillary matrix.</div><div class=\"graphic_reference\">Courtesy of Thomas Smith, MD, University of Massachusetts.</div><div id=\"graphicVersion\">Graphic 73961 Version 2.0</div></div></div>"},"73962":{"type":"graphic_table","displayName":"Dietary sources of iron PI","title":"Dietary sources of iron","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary sources of iron</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food</td> <td class=\"subtitle1\">Approximate measure</td> <td class=\"subtitle1\">Iron (mg)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">High iron sources</td> </tr> <tr> <td class=\"indent1\">Cream of Wheat (quick or instant)*</td> <td>1/2 cup</td> <td>7.8</td> </tr> <tr> <td class=\"indent1\">Kidney, beef<sup>&#182;</sup></td> <td>2 oz (60 g)</td> <td>5.3</td> </tr> <tr> <td class=\"indent1\">Liver, beef<sup>&#182;</sup></td> <td>2 oz (60 g)</td> <td>5.8</td> </tr> <tr> <td class=\"indent1\">Liver, calf<sup>&#182;</sup></td> <td>2 oz (60 g)</td> <td>9.0</td> </tr> <tr> <td class=\"indent1\">Liver, chicken<sup>&#182;</sup></td> <td>2 oz (60 g)</td> <td>6.0</td> </tr> <tr> <td class=\"indent1\">Liverwurst<sup>&#182;</sup></td> <td>2 oz (60 g)</td> <td>3.6</td> </tr> <tr> <td class=\"indent1\">Prune juice</td> <td>1/2 cup</td> <td>5.1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Spinach</td> <td>1/2 cup</td> <td>3.2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Moderate iron sources</td> </tr> <tr> <td class=\"indent1\">All-Bran cereal</td> <td>1/2 cup</td> <td>2.9</td> </tr> <tr> <td class=\"indent1\">Almonds, dried unblanched</td> <td>1/2 cup</td> <td>3.0</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Dried beans and peas</td> </tr> <tr> <td class=\"sublist2\">Baked beans, no pork</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">1.5</td> </tr> <tr> <td class=\"sublist2\">Blackeye peas, cooked</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">0.8</td> </tr> <tr> <td class=\"sublist2\">Chick peas, dry</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">3.5</td> </tr> <tr> <td class=\"sublist2\">Great northern beans, cooked</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">1.3</td> </tr> <tr> <td class=\"sublist2\">Green peas, cooked</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">1.4</td> </tr> <tr> <td class=\"sublist2\">Lentils, dry</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">3.4</td> </tr> <tr> <td class=\"sublist2\">Lima beans, cooked</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">1.3</td> </tr> <tr> <td class=\"sublist2\">Navy beans, cooked</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">1.3</td> </tr> <tr> <td class=\"sublist2\">Red beans, dry</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">3.5</td> </tr> <tr> <td class=\"sublist2\">Soybeans, cooked</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">1.4</td> </tr> <tr> <td class=\"sublist2\">White beans, dry</td> <td class=\"sublist_other\">1/4 cup</td> <td class=\"sublist_other\">3.9</td> </tr> <tr> <td class=\"indent1\">Beef, cooked</td> <td>2 oz (60 g)</td> <td>2-3<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Ham, cooked</td> <td>2 oz (60 g)</td> <td>1.3</td> </tr> <tr> <td class=\"indent1\">Lamb, cooked</td> <td>2 oz (60 g)</td> <td>1.9</td> </tr> <tr> <td class=\"indent1\">Peaches, dried</td> <td>1/4 cup</td> <td>2.4</td> </tr> <tr> <td class=\"indent1\">Peanuts, roasted without skins</td> <td>3 1/2 oz (100 g)</td> <td>3.2</td> </tr> <tr> <td class=\"indent1\">Pork, cooked</td> <td>2 oz (60 g)</td> <td>2-3<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Prunes, dried</td> <td>2 large</td> <td>1.1</td> </tr> <tr> <td class=\"indent1\">Scallops</td> <td>2 oz (60 g)</td> <td>1.6</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Turkey, cooked</td> <td>2 oz (60 g)</td> <td>1.7</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Approximate iron content of children's favorite foods</td> </tr> <tr> <td class=\"sublist2_start\">Hamburger, small</td> <td class=\"sublist_other_start\">1</td> <td class=\"sublist_other_start\">3.0</td> </tr> <tr> <td class=\"sublist2\">Large</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">5.2</td> </tr> <tr> <td class=\"sublist2\">Big Mac</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">4.3</td> </tr> <tr> <td class=\"sublist2\">Quarter Pounder</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">5.1</td> </tr> <tr> <td class=\"indent1\">Spaghetti with meatballs</td> <td>1 cup</td> <td>3.3</td> </tr> <tr> <td class=\"indent1\">Frankfurter and beans</td> <td>1 cup</td> <td>4.8</td> </tr> <tr> <td class=\"indent1\">Pork and beans</td> <td>1 cup</td> <td>5.9</td> </tr> <tr> <td class=\"indent1\">Raisins<sup>&#167;</sup></td> <td>5/8 cup</td> <td>3.5</td> </tr> <tr> <td class=\"indent1\">Cereals, fortified</td> <td>1 serving</td> <td>4.5-17.8</td> </tr> <tr> <td class=\"indent1\">Nuts<sup>&#167;</sup></td> <td>1 cup</td> <td>5.0-7.0</td> </tr> <tr> <td class=\"indent1\">Seeds, sunflower<sup>&#167;</sup></td> <td>3 1/2 oz (100 g)</td> <td>7.1</td> </tr> <tr> <td class=\"indent1\">Chile con carne</td> <td>1 cup</td> <td>3.6</td> </tr> <tr> <td class=\"indent1\">Beef burrito or tostado</td> <td>1 medium</td> <td>3.4-4.6</td> </tr> <tr> <td class=\"indent1\">Cheese pizza</td> <td>2 slices</td> <td>3.0</td> </tr> <tr> <td class=\"indent1\">Cheese pizza with beef</td> <td>2 slices</td> <td>4.8</td> </tr> <tr> <td class=\"indent1\">White bread</td> <td>1 piece</td> <td>0.7</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Or other fortified cereals which contain 10 mg of iron per ounce or 100 percent RDA per serving.<br />&para; As organ meats are generally high in cholesterol, these iron-rich foods should be eaten in moderation.<br />&Delta; Depending on cut, the greatest amounts of iron are generally found in the chuck, flank, and bottom round cuts of beef.<br /><span class=\"lozenge\">&loz;</span> Depending on cut, the greatest amounts of iron are generally found in the loin, sirloin, tenderloin, and picnic shoulder cuts of pork.<br />&sect; Raisins, nuts, and seeds are not generally recommended for children under age three because of risk of choking.</div><div class=\"graphic_reference\">Data from: Walker WA, Watkins JB (Eds), Nutrition in Pediatrics, 2nd ed, BC Decker, Inc, London 1997.</div><div id=\"graphicVersion\">Graphic 73962 Version 6.0</div></div></div>"},"73963":{"type":"graphic_picture","displayName":"Ant drawer test","title":"Anterior drawer test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior drawer test</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/EM/73963_Ant_drawer_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior drawer test is performed with the patient lying supine and the knee flexed at 90 degrees. The proximal tibia is gripped with both hands and pulled anteriorly, checking for anterior translation. Often the clinician sits on the foot while performing the test to provide stability. It is helpful to compare the degree of translation with the uninjured knee.</div><div class=\"graphic_reference\">Courtesy of Ryan P Friedberg, MD.</div><div id=\"graphicVersion\">Graphic 73963 Version 3.0</div></div></div>"},"73964":{"type":"graphic_diagnosticimage","displayName":"Cholangiocarcinoma MRCP","title":"Distal cholangiocarcinoma as seen on MRCP","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal cholangiocarcinoma as seen on MRCP</div><div class=\"cntnt\"><img style=\"width:249px; height:238px;\" src=\"images/GAST/73964_Cholangiocarcinoma_MRCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This magnetic resonance cholangiopancreatography (MRCP) image, obtained without having to opacify the bile ducts, demonstrates a circumferential narrowing of the distal common bile duct (CBD, arrow) due to a focal distal cholangiocarcinoma. The obstructing tumor is causing dilation of the CBD.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 73964 Version 3.0</div></div></div>"},"73965":{"type":"graphic_picture","displayName":"Acute promyeloctic leukemia","title":"Acute promyelocytic leukemia - hypergranular variant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute promyelocytic leukemia - hypergranular variant</div><div class=\"cntnt\"><img style=\"width:416px; height:288px;\" src=\"images/HEME/73965_AML_FAB_M3_Faggot_cell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with the hypergranular variant of acute promyelocytic leukemia (APL; formerly described in the French-American-British [FAB] classification as the M3 variant of acute myeloid leukemia).&nbsp;The cells in the top center and far left contain numerous intertwining Auer rods (arrows). (Wright-Giemsa stain)</div><div class=\"graphic_reference\">From Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 73965 Version 2.0</div></div></div>"},"73966":{"type":"graphic_table","displayName":"Dx criteria panic disorder","title":"Diagnostic criteria for panic attack and panic disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for panic attack and panic disorder</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"subtitle1_single\">Panic attack (summary of DSM-IV criteria)</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>A discrete period of intense fear or discomfort, in which four (or more) of the following symptoms develop abruptly and reach a peak within ten minutes:</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle2_single\">Cardiopulmonary symptoms</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">Chest pain or discomfort</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">Sensations of shortness of breath or smothering</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">Palpitations, pounding heart, or accelerated heart rate</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle2_single\">Neurological symptoms</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">Trembling or shaking</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">Parasthesias (numbness or tingling sensation)</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">Feeling dizzy, unsteady, light-headed or faint</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle2_single\">Psychiatric symptoms</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">Derealization (feelings of unreality) or depersonalization (being detached from oneself)</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">Fear of losing control or going crazy</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">Fear of dying</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle2_single\">Autonomic symptoms</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">Sweating</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">Chills or hot flushes</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle2_single\">Gastrointestinal symptoms</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">Feeling of choking</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">Nausea or abdominal distress</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle1_single\">Panic disorder (summary of DSM-IV criteria)</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle2_single\">With agoraphobia</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">A. Recurrent, unexpected panic attacks.</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">B. At least one of the attacks has been followed by a month or more of: persistent concern about having additional attacks; worry about the implications of the attack or its consequences; a significant change in behavior related to the attacks.</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">C. The presence of agoraphobia, ie, anxiety about being in places or situations in which escape might be difficult (or embarrassing) or in which help might not be available in the event of having a panic attack.</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle2_single\">Without agoraphobia</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">A. Both A and B above</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"indent1\">B. Absence of agoraphobia</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Primary Care Version (DSM-IV-PC). American Psychiatric Association, Washington, DC 1995.</div><div id=\"graphicVersion\">Graphic 73966 Version 1.0</div></div></div>"},"73968":{"type":"graphic_diagnosticimage","displayName":"Parapneumonic effusion chest xray","title":"Parapneumonic effusion chest radiograph","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parapneumonic effusion chest radiograph</div><div class=\"cntnt\"><img style=\"width:376px; height:366px;\" src=\"images/PULM/73968_Parapneumonic_effusion_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph showing loculated right parapneumonic effusion.</div><div class=\"graphic_reference\">Courtesy of Charlie Strange, MD.</div><div id=\"graphicVersion\">Graphic 73968 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"73969":{"type":"graphic_table","displayName":"Manifestations of OA","title":"Clinical manifestations of osteoarthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of osteoarthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Age of onset</td> </tr> <tr> <td>Usually after age 40</td> </tr> <tr> <td class=\"subtitle1_single\">Commonly affected joints</td> </tr> <tr> <td>Cervical and lumbar spine</td> </tr> <tr> <td>First carpometacarpal joint</td> </tr> <tr> <td>Proximal interphalangeal joint</td> </tr> <tr> <td>Distal interphalangeal joint</td> </tr> <tr> <td>Hip</td> </tr> <tr> <td>Knee</td> </tr> <tr> <td>Subtalar joint</td> </tr> <tr> <td>First metatarsophalangeal joint</td> </tr> <tr> <td class=\"subtitle1_single\">Uncommonly affected joints</td> </tr> <tr> <td>Shoulder</td> </tr> <tr> <td>Wrist</td> </tr> <tr> <td>Elbow</td> </tr> <tr> <td>Metacarpophalangeal joint</td> </tr> <tr> <td class=\"subtitle1_single\">Symptoms</td> </tr> <tr> <td>Pain without significant swelling or other inflammatory characteristics</td> </tr> <tr> <td>Stiffness, if present, worse after effort; may be described as evening stiffness</td> </tr> <tr> <td class=\"subtitle1_single\">Findings on physical examination</td> </tr> <tr> <td>Crepitus</td> </tr> <tr> <td>Bony enlargement</td> </tr> <tr> <td>Decreased range of motion</td> </tr> <tr> <td>Malalignment</td> </tr> <tr> <td>Tenderness to palpation</td> </tr> <tr> <td class=\"subtitle1_single\">Synovial fluid analysis</td> </tr> <tr> <td>Clear fluid</td> </tr> <tr> <td>WBC &#60;2000/mm<sup>3</sup></td> </tr> <tr> <td>Normal viscosity</td> </tr> <tr> <td class=\"subtitle1_single\">Radiographic features</td> </tr> <tr> <td>Joint space narrowing</td> </tr> <tr> <td>Subchondral sclerosis</td> </tr> <tr> <td>Marginal osteophytes</td> </tr> <tr> <td>Subchondral cysts</td> </tr> <tr> <td class=\"subtitle1_single\">Patterns of presentation</td> </tr> <tr> <td>Monoarticular in young adult</td> </tr> <tr> <td>Pauciarticular, large-joint in middle age</td> </tr> <tr> <td>Polyarticular generalized</td> </tr> <tr> <td>Rapidly progressive</td> </tr> <tr> <td>Secondary to trauma, congenital abnormality, or systemic disease</td> </tr> <tr> <td class=\"subtitle1_single\">Prognosis</td> </tr> <tr> <td>Variable, generally slowly progressive</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WBC: white blood cells.</div><div id=\"graphicVersion\">Graphic 73969 Version 5.0</div></div></div>"},"73970":{"type":"graphic_figure","displayName":"Chart for medication management","title":"Chart for medication management","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Chart for medication management</div><div class=\"cntnt\"><img style=\"width:510px; height:516px;\" src=\"images/CARD/73970_Chart_for_Medication_Management.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: DeWalt DA, Malone RM, Bryant ME, et al. A heart failure self-management program for patients of all literacy levels: a randomized, controlled trial. BMC Health Serv Res 2006; 6:30. Copyright &#169; 2006 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 73970 Version 2.0</div></div></div>"},"73971":{"type":"graphic_figure","displayName":"Number of hospital discharges with diabetic ketoacidosis","title":"Number (in thousands) of hospital discharges with diabetic ketoacidosis as first-listed diagnosis, United States, 1988 to 2009","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">Number (in thousands) of hospital discharges with diabetic ketoacidosis as first-listed diagnosis, United States, 1988 to 2009</div><div class=\"cntnt\"><img style=\"width:618px; height:508px;\" src=\"images/ENDO/73971_Numhospdischdiabket.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The number of hospital discharges with diabetic ketoacidosis (DKA) as the first-listed diagnosis increased between 1988 and 2009, with approximately 80,000 discharges in 1988 with DKA as the first-listed diagnosis and approximately 140,000 in 2009.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Diabetes Public Health Resource: Diabetes Data &amp; Trends (Accessed on March 26, 2014).</div><div id=\"graphicVersion\">Graphic 73971 Version 5.0</div></div></div>"},"73973":{"type":"graphic_table","displayName":"Causes of proteinuria children","title":"Causes of proteinuria in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of proteinuria in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Transient proteinuria</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Associated with fever, exercise, seizures and/or hypovolemia</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Orthostatic proteinuria</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Persistent proteinuria</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Glomerular proteinuria</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2_start\">Primary</td>\n\n    </tr>\n    <tr>\n\n      <td class=\"sublist2\">Minimal change disease</td>\n\n    </tr>\n    <tr>\n      <td class=\"sublist2\"> Congenital nephrotic syndrome</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist3\">\"Finnish-type\"</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist3\">Mesangial sclerosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\"> Focal segmental glomerular sclerosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\"> IgA nephropathy (Berger's disease)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\"> Membranoproliferative glomerulonephritis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\"> Membranous nephropathy</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\"> Alport syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2_start\">Secondary</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\"> Acute post-streptococcal glomerulonephritis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\"> Diabetes mellitus</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\"> Systemic lupus erythematosus</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\"> Henoch-Sch&#246;nlein purpura</td>\n    </tr>\n    <tr>\n\n      <td class=\"subtitle2_single\">Tubular proteinuria</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2_start\">Primary</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\"> Cystinosis </td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\"> Dent's syndrome</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\"> Wilson's disease</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\"> Lowe's syndrome</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\"> Polycystic kidney disease</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\"> Mitochondrial disorders</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist2_start\">Secondary</td>\n\n    </tr>\n    <tr>\n      <td class=\"sublist2\"> Heavy metal poisoning</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\"> Acute tubular necrosis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\"> Tubulointerstitial nephritis </td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\"> Secondary to obstructive uropathy</td>\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 73973 Version 1.0</div></div></div>"},"73974":{"type":"graphic_table","displayName":"International neuroblastoma staging system","title":"International neuroblastoma staging system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International neuroblastoma staging system</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td>1</td> <td>Localized tumor with complete gross excision, with or without microscopic residual disease; representative ipsilateral lymph nodes negative for tumor microscopically (nodes attached to and removed with the primary tumor may be positive)</td> </tr> <tr> <td>2A</td> <td>Localized tumor with incomplete gross excision; representative ipsilateral nonadherent lymph nodes negative for tumor microscopically</td> </tr> <tr> <td>2B</td> <td>Localized tumor with or without complete gross excision; with ipsilateral nonadherent lymph nodes positive for tumor. Enlarged contralateral lymph nodes must be negative microscopically.</td> </tr> <tr> <td>3</td> <td>Unresectable unilateral tumor infiltrating across the midline, with or without regional lymph node involvement; or localized unilateral tumor with contralateral regional lymph node involvement; or midline tumor with bilateral extension by infiltration (unresectable) or by lymph node involvement</td> </tr> <tr> <td>4</td> <td>Any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, liver, skin and/or other organs (except as defined for stage 4S)</td> </tr> <tr> <td>4S</td> <td>Localized primary tumor (as defined for stage 1, 2A or 2B), with dissemination limited to skin, liver, and/or bone marrow (limited to infants &#60;1 year of age)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466. Copyright &#169; 1993 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 73974 Version 3.0</div></div></div>"},"73975":{"type":"graphic_picture","displayName":"Herpes simplex labialis","title":"Herpes simplex labialis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Herpes simplex labialis</div><div class=\"cntnt\"><img style=\"width:504px; height:290px;\" src=\"images/PC/73975_Herpes_simplex_labialis_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grouped vesicles are evident on the lower vermilion border.</div><div class=\"graphic_reference\">Reproduced with permission from: Bickley LS, Szilagyi P. Bates' Guide to Physical Examination and History Taking, Eighth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 73975 Version 4.0</div></div></div>"},"73976":{"type":"graphic_picture","displayName":"Vocal fold nodules","title":"Vocal fold nodules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vocal fold nodules</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/PC/73976_Vocal_fold_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note fairly symmetric nodular appearing lesions in the classic location at the junction of the anterior and middle thirds of the vocal folds bilaterally.</div><div id=\"graphicVersion\">Graphic 73976 Version 2.0</div></div></div>"},"73977":{"type":"graphic_figure","displayName":"Number of burns US","title":"Number of burn injuries compared by age and type occurring in the US between 1998 and 2008","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Number of burn injuries compared by age and type occurring in the US between 1998 and 2008</div><div class=\"cntnt\"><img style=\"width:593px; height:353px;\" src=\"images/SURG/73977_Number_of_burns_US.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The number of fire/flame, scald, and contact burns in the United States (US)&nbsp;between 1998 and 2008 are shown by age group. Fire/flame burns are the most common burn injury for all age groups except for children under five years of age. Scald injuries are the most common burns for children under five years of age.</div><div class=\"graphic_reference\">Centers for Disease Control. Web-based injury and statistics query and reporting system (WISQARS™) 2009. Available online at: webappa.cdc.gov/sasweb/ncipc/mortrate9.html (Accessed on April 2, 2010).</div><div id=\"graphicVersion\">Graphic 73977 Version 3.0</div></div></div>"},"73978":{"type":"graphic_picture","displayName":"Port wine stain - V2 child","title":"Port wine stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Port wine stain</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/73978_Port_wine_stain_V2_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A port wine stain, represented by an erythematous patch, is present in the V2 distribution on the face of this child.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 73978 Version 4.0</div></div></div>"},"73979":{"type":"graphic_diagnosticimage","displayName":"Cerebral paragonimiasis","title":"Cerebral paragonimiasis","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Cerebral paragonimiasis</div><div class=\"cntnt\"><img style=\"width:584px; height:201px;\" src=\"images/ID/73979_Cerebral_paragonimiasis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Twenty-four-year-old woman who has had a positive enzyme-linked immunosorbent assay (ELISA)&nbsp;reaction for <EM>Paragonimus</EM>-specific antibody in cerebrospinal fluid (CSF) since her first magnetic resonance (MR)&nbsp;examination.<br />(A) T1-weighted (500/30) axial image from initial MR study shows subacute hemorrhages of high signal intensity (arrows) in occipital lobes bilaterally, presumably due to vascular involvement of <EM>Paragonimus</EM>. No other abnormality was seen on initial study.<br />(B, C) Follow-up MR images obtained two months later, after no specific treatment. Contrast-enhanced T1-weighted image (B) shows multiple, conglomerated, ring-enhancing lesions with surrounding edema in right frontal lobe. On unenhanced T2-weighted (3000/80) image (C), walls of rings appear either isointense (arrow) or hypointense (arrowhead) relative to lesions. Hemorrhages in occipital lobes were markedly absorbed (not shown). <EM>Paragonimus</EM> eggs were found in a lesion of the right frontal lobe during surgery.</div><div class=\"graphic_reference\">Reprinted with permission from: The American Journal of Roentgenology. Cha SH, Chang KH, Cho SY, et al. Cerebral paragonimiasis in early active stage: CT and MR features. AJR Am J Roentgenol 1994; 162:141. Copyright © 1994 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 73979 Version 7.0</div></div></div>"},"73983":{"type":"graphic_figure","displayName":"Position of R paratracheal node","title":"Position of the right paratracheal lymph node","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Position of the right paratracheal lymph node</div><div class=\"cntnt\"><img style=\"width:325px; height:329px;\" src=\"images/PULM/73983_Position_of_R_paratracheal.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Kavuru, MS, Mehta, AC. Applied anatomy of the airways. In: Wang, KP, Mehta, AC (Eds), Flexible Bronchoscopy Blackwell Science Inc, Cambridge, MA 1995.</div><div id=\"graphicVersion\">Graphic 73983 Version 1.0</div></div></div>"},"73984":{"type":"graphic_diagnosticimage","displayName":"Delayed presentation of metatarsal shaft fracture","title":"Delayed presentation of metatarsal shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Delayed presentation of metatarsal shaft fracture</div><div class=\"cntnt\"><img style=\"width:498px; height:478px;\" src=\"images/RHEUM/73984_Delayed_metatarsal_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first metatarsal fracture (arrow) was evident on the initial and follow-up radiographs (panels A and B), but the second metatarsal fracture (arrowhead) only clearly appeared with a follow-up film (panel B).</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH and James R Clugston, MD, MS.</div><div id=\"graphicVersion\">Graphic 73984 Version 3.0</div></div></div>"},"73985":{"type":"graphic_picture","displayName":"Retinal periphlebitis sarcoid","title":"Retinal periphlebitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinal periphlebitis</div><div class=\"cntnt\"><img style=\"width:346px; height:259px;\" src=\"images/RHEUM/73985_Retinal_periphlebitis_sarco.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of the fundus shows periphlebitis in a patient with sarcoidosis.</div><div class=\"graphic_reference\">Courtesy of Michael Tolentino, MD.</div><div id=\"graphicVersion\">Graphic 73985 Version 1.0</div></div></div>"},"73986":{"type":"graphic_picture","displayName":"Histopathology of ARPKD kidney","title":"Histopathology of autosomal recessive polycystic kidney disease (ARPKD)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histopathology of autosomal recessive polycystic kidney disease (ARPKD)</div><div class=\"cntnt\"><img style=\"width:432px; height:289px;\" src=\"images/PEDS/73986_Histopathology_ARPKD_kidney.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic examination of a renal sample from a patient with ARPKD reveals cystic dilatations of the collecting tubules with flattening of the epithelium that runs perpendicular to the renal capsule.</div><div id=\"graphicVersion\">Graphic 73986 Version 2.0</div></div></div>"},"73987":{"type":"graphic_table","displayName":"Diagnostic and therapeutic paracenteses checklist","title":"Diagnostic and therapeutic paracenteses checklist","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic and therapeutic paracenteses checklist</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Supplies needed for diagnostic and therapeutic paracenteses</td> </tr> <tr> <td class=\"indent1\">Signed consent form</td> </tr> <tr> <td class=\"indent1\">Ultrasound machine if needed to localize the entry site</td> </tr> <tr> <td class=\"indent1\">Completed lab slips and labels</td> </tr> <tr> <td class=\"indent1\">Red-top tube</td> </tr> <tr> <td class=\"indent1\">Purple-top (EDTA) tube (or other tube depending on the lab)</td> </tr> <tr> <td class=\"indent1\">Blood culture bottles (2, for aerobic and anaerobic culture)</td> </tr> <tr> <td class=\"indent1\">1- to 2-liter vacuum bottles (for therapeutic paracentesis, enough bottles to remove 8 L of fluid should be available)</td> </tr> <tr> <td class=\"indent1\">Iodine or chlorhexidine skin sterilizer</td> </tr> <tr> <td class=\"indent1\">Alcohol wipes (3)</td> </tr> <tr> <td class=\"indent1\">4x4 sterile gauze sponges (3)</td> </tr> <tr> <td class=\"indent1\">Sterile and nonsterile gloves</td> </tr> <tr> <td class=\"indent1\">25- to 27-gauge 1.5 inch needle, if available (if not, a tuberculin syringe can be used) (1)</td> </tr> <tr> <td class=\"indent1\">18-gauge 1 to 1.5 inch needles (2 or 3)</td> </tr> <tr> <td class=\"indent1\">22-gauge 1.5 inch needle, if available</td> </tr> <tr> <td class=\"indent1\">22-gauge 3.5 inch spinal needle</td> </tr> <tr> <td class=\"indent1\">Sterile syringes (3, 5, 20 mL)</td> </tr> <tr> <td class=\"indent1\">Lidocaine 1 percent</td> </tr> <tr> <td class=\"indent1\">#11 blade scalpel (for therapeutic paracentesis)</td> </tr> <tr> <td class=\"indent1\">Adhesive bandage</td> </tr> <tr> <td class=\"indent1\">Sharp receptacle box</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 73987 Version 5.0</div></div></div>"},"73988":{"type":"graphic_waveform","displayName":"Basic case 11","title":"Basic case 11","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Basic case 11</div><div class=\"cntnt\"><img style=\"width:540px; height:95px;\" src=\"images/CARD/73988_Basic_case_11.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 73988 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"73989":{"type":"graphic_figure","displayName":"Comparison AV nodal blockers","title":"Atenolol plus digoxin is most effective for rate control in AF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atenolol plus digoxin is most effective for rate control in AF</div><div class=\"cntnt\"><img style=\"width:384px; height:529px;\" src=\"images/CARD/73989_Comparison_AV_nodal_blocker.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 12 patients which compared the effect of various atrioventricular nodal drugs on heart rate during atrial fibrillation (AF), digoxin plus atenolol was the most effective therapy for attenuating the circadian rhythmicity of heart rate (upper panel) and the peak heart rate with exercise (bottom panel). The least effective therapies were digoxin or diltiazem administered as single agents.</div><div class=\"graphic_reference\">Data from Farshi R, Kistner D, Sarma JS, et al. J Am Coll Cardiol 1999; 33:304.</div><div id=\"graphicVersion\">Graphic 73989 Version 2.0</div></div></div>"},"73991":{"type":"graphic_picture","displayName":"Upper lip defect resect","title":"Upper lip defect after resection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Upper lip defect after resection</div><div class=\"cntnt\"><img style=\"width:351px; height:270px;\" src=\"images/ONC/73991_Upper_lip_defect_resect.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Neil D Gross, MD.</div><div id=\"graphicVersion\">Graphic 73991 Version 2.0</div></div></div>"},"73992":{"type":"graphic_table","displayName":"Infant feeding guide PI","title":"Infant feeding guide","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infant feeding guide</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Food</td> <td class=\"subtitle1\" colspan=\"5\">Age (months)</td> </tr> <tr> <td class=\"subtitle2\">0-4</td> <td class=\"subtitle2\">4-6</td> <td class=\"subtitle2\">6-8</td> <td class=\"subtitle2\">8-10</td> <td class=\"subtitle2\">10-12</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Breast milk</p> <p>(number of feedings)</p> </td> <td> <p>Frequent feedings</p> <p>(8-12)</p> </td> <td> <p>Frequent feedings</p> <p>(4-6)</p> </td> <td> <p>On demand</p> <p>(3-5)</p> </td> <td>On demand</td> <td>On demand</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Iron-fortified formula</p> <p>(number of feedings)</p> </td> <td> <p>16-32 oz</p> <p>(8-12)</p> </td> <td> <p>24-40 oz</p> <p>(4-6)</p> </td> <td> <p>24-32 oz</p> <p>(3-5)</p> </td> <td> <p>16-32 oz</p> <p>(3-4)</p> </td> <td> <p>16-24 oz</p> <p>(3-4)</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Cereals, bread</td> <td>None</td> <td>None</td> <td> <p>Infant cereal</p> <p>1-4 tbsp twice per day</p> </td> <td> <p>Infant cereals</p> <p>Cream of wheat</p> <p>Other plain hot cereals</p> <p>Toast, bagel, crackers</p> <p>2-3 servings per day*</p> </td> <td> <p>Unsweetened hot or cold cereals</p> <p>Bread</p> <p>Rice</p> <p>Noodles</p> <p>4 servings per day*</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Fruit</td> <td>None</td> <td>None</td> <td> <p>Fresh/cooked pur&#233;ed fruits</p> <p>Mashed bananas</p> <p>Applesauce</p> <p>1/2 cup&nbsp;per day</p> </td> <td> <p>Peeled, soft fruit wedges</p> <p>Bananas, peaches, pears, oranges, apples</p> <p>1-2 servings per day*</p> </td> <td> <p>All fresh fruits, peeled and seeded</p> <p>Canned fruits, packed in water or fruit juice</p> <p>2 servings per day*</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Vegetables</td> <td>None</td> <td>None</td> <td> <p>Strained or mashed vegetables</p> <p>Dark yellow, orange, or green (avoid corn)</p> <p>1/2 cup&nbsp;per day</p> </td> <td> <p>Cooked and mashed fresh or frozen vegetables</p> <p>1-2 servings per day*</p> </td> <td> <p>Cooked vegetable pieces</p> <p>2 servings per day*</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Protein foods</td> <td>None</td> <td>None</td> <td> <p>Pur&#233;ed meats</p> <p>1-2 servings per day*</p> </td> <td> <p>Lean meat, chicken, or fish (strained, chopped, or small tender pieces)</p> <p>Egg yolk</p> <p>Cooked dried beans</p> <p>3-4&nbsp;&nbsp;servings per day*</p> </td> <td> <p>Small tender pieces of meat, chicken, or fish (1-2 oz)</p> <p>Egg yolk</p> <p>Yogurt</p> <p>Cheese</p> <p>Cooked dried beans</p> <p>3-4&nbsp;servings per day*</p> </td> </tr> <tr> <td>Fruit juice</td> <td>None</td> <td>None</td> <td> <p>None</p> </td> <td> <p>None</p> </td> <td> <p>None</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* One serving size is considered to be 1 tablespoon.</div><div class=\"graphic_reference\">Adapted from: Massachusetts WIC program Nutrition Education Task Force.</div><div id=\"graphicVersion\">Graphic 73992 Version 9.0</div></div></div>"},"73993":{"type":"graphic_diagnosticimage","displayName":"Multiple posterior rib fractures","title":"Multiple posterior rib fractures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple posterior rib fractures</div><div class=\"cntnt\"><img style=\"width:340px; height:297px;\" src=\"images/EM/73993_Multiple_posterior_rib_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone scan showing multiple posterior rib fractures. Rib fractures are highly suggestive of child abuse. Inflicted rib fractures usually are non-displaced and involve multiple sequential ribs (corresponding to the abuser's fingers).</div><div class=\"graphic_reference\">Courtesy of Susan A Scherl, MD.</div><div id=\"graphicVersion\">Graphic 73993 Version 4.0</div></div></div>"},"73995":{"type":"graphic_table","displayName":"HPO axis and amenorrhea","title":"Major causes of amenorrhea due to abnormalities in the hypothalamic-pituitary-ovarian axis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of amenorrhea due to abnormalities in the hypothalamic-pituitary-ovarian axis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Abnormality</td> <td class=\"subtitle1\">Causes</td> </tr> <tr> <td rowspan=\"11\">Hypothalamic dysfunction</td> <td>Isolated GnRH deficiency</td> </tr> <tr> <td class=\"sublist1_start\">Functional hypothalamic amenorrhea</td> </tr> <tr> <td class=\"sublist1\">- Weight loss, eating disorders</td> </tr> <tr> <td class=\"sublist1\">- Excessive exercise (including but not exclusively: running, ballet dancing, figure skating, gymnastics)</td> </tr> <tr> <td class=\"sublist1\">- Stress</td> </tr> <tr> <td class=\"sublist1\">- Severe or prolonged illness</td> </tr> <tr> <td>Inflammatory or infiltrative diseases</td> </tr> <tr> <td>Brain tumors - eg, craniopharyngioma</td> </tr> <tr> <td>Cranial irradiation</td> </tr> <tr> <td>Traumatic brain injury</td> </tr> <tr> <td>Other syndromes - Prader-Willi, Laurence-Moon-Biedl, leptin mutations</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Pituitary dysfunction</td> <td>Hyperprolactinemia, including lactotroph adenomas</td> </tr> <tr> <td>Other pituitary tumors - acromegaly, corticotroph adenomas (Cushing's disease)</td> </tr> <tr> <td>Other tumors - meningioma, germinoma, glioma</td> </tr> <tr> <td>Genetic causes of hypopituitarism</td> </tr> <tr> <td>Empty sella syndrome</td> </tr> <tr> <td>Pituitary infarct or apoplexy</td> </tr> <tr> <td rowspan=\"2\">Ovarian dysfunction</td> <td class=\"sublist1_start\">Primary ovarian insufficiency (premature ovarian failure)</td> </tr> <tr> <td class=\"sublist1\">- Turner syndrome, fragile X permutation, chemotherapy and radiotherapy, somatic chromosomal defects, autoimmune, idiopathic</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Other</td> <td>Polycystic ovary syndrome</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Hypothyroidism</td> </tr> <tr> <td>Uncontrolled diabetes mellitus types 1 and 2</td> </tr> <tr> <td>Exogenous androgen use</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HPO: hypothalamic-pituitary-ovarian; GnRH: gonadotropin-releasing hormone.</div><div id=\"graphicVersion\">Graphic 73995 Version 11.0</div></div></div>"},"73998":{"type":"graphic_picture","displayName":"Lymphoplasmacytic node","title":"Lymphoplasmacytic lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphoplasmacytic lymphoma</div><div class=\"cntnt\"><img style=\"width:420px; height:285px;\" src=\"images/HEME/73998_Lymphoplasmacytic_node.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymph node section shows infiltration with cells having the nuclear features of small lymphocytes but with eccentric nuclei and moderately large amounts of cytoplasm.</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 73998 Version 1.0</div></div></div>"}};